Unique_ID Origin_ID Sequence Activity Source Structure Hemolysis Reference Length Stereo FPDB00002 AP00026|||AP00026|||Lactotransferrin precursor|||LFcinB|||DRAMP02840 FKCRRWQWRMKKLGAPSITCVRRAF Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||anti-sepsis||Synergistic AMPs||Anticancer||Anti-E. coli IID-861, activity value is MIC = 2 uM||Anti-K. pneumoniae JCM1662T, activity value is MIC = 3 uM||Anti-P. aeruginosa IFO-3446, activity value is MIC = 3 uM||Anti-S. aureus JCM-2151 or MRSA, activity value is MIC = 2 uM||Anti-L. monocytogenes IDF-1 b, activity value is MIC = 0.3 uM||MRSA||Antibacterial||Anti-Streptomyces scabiei S58, activity value is IC50 = 1.222||Anti-Escherichia coli L361, activity value is MIC = 4 uM||Anti-Salmonella Salford, activity value is MIC = 4 uM||Anti-Escherichia coli O:9, activity value is MIC = 6 uM||Anti-Pseudomonas fluorescens, activity value is MIC = 10 uM||Anti-Listeria monocytogenes, activity value is MIC = 2 uM||Anti-Staphylococcus aureus, activity value is MIC = 6 uM||Anti-Bacillus cereus, activity value is MIC = 6 uM||Anti-ctive against E. coli IID-861, activity value is MIC = 2 uM cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine) Beta||Beta strand (4 strands; 8 residues) E.coli ( MIC = 12.5 ug/ml) "J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.|||Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M.1992 J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol. 1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.|||1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol . 1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.|||9521752 , 8980754|||35213576|||Ref.8980754|||1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012" 25 FPDB00003 AP00028|||Aborycin|||DRAMP00205|||AP00028|||DRAMP00205|||Rp 71955 CLGIGSCNDFAGCGYAVVCFW Antiviral||Anti-HIV||inhibited the HIV-1 aspartyl protease (IC50||35 ug/ml) a||Anti-S.aureus, activity value is MIC = 8 ug/ml||Anti-Methicillin-resistant S.aureus, activity value is MIC = 8 ug/ml||Anti-Methicillin-resistant S.epidermidis, activity value is MIC = 128 ug/ml||Anti-S.aureus Sau 29213, activity value is MIC = 8 ug/ml||Anti-S.aureus Sau 1862, activity value is MIC = 16 ug/ml||Anti-S.aureus Sau 669, activity value is MIC = 32 ug/ml||Anti-S.aureus Sau 991, activity value is MIC = 16 ug/ml||Anti-S.aureus 16339, activity value is MIC = 16 ug/ml||Anti-S.aureus 6917, activity value is MIC = 16 ug/ml||Anti-S.aureus 16162, activity value is MIC = 64 ug/ml||Anti-S.aureus 718306, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus 745524, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus GDQ6P012P, activity value is MIC = 64 ug/ml||Anti-E.faecalis ATCC 29212, activity value is MIC = 8 ug/ml||Anti-E.gallinarum 5F52C, activity value is MIC = 0.5 ug/ml||Anti-B. thuringiensis, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC 19606, activity value is MIC = 128 ug/ml||Antimicrobial||Antiviral ; HIV-1 Streptomyces strains AA3891|||Streptomyces sp. SCSIO ZS0098|||Streptomyces sp. (strain SP9440) (Gram-positive bacteria)|||Streptomyces strains AA3891|||Streptomyces sp. (strain SP9440) (Gram-positive bacteria)|||Actinomycete Sp9440 Beta||Beta strand No hemolysis information or data found in the reference(s) presented in this entry J Antibiot (Tokyo). 1993 Nov;46(11):1756-7. 1993 Nov;46(11):1756-7. doi: 10.7164/antibiotics.46.1756.PubMed.|||30795576|||J Antibiot (Tokyo). 1993 Nov;46(11):1756-1757.Biochemistry. 1994 Jan 11;33(1):42-50.|||1993 Nov;46(11):1756-7. doi: 10.7164/antibiotics.46.1756.|||J Antibiot (Tokyo). 1993 Nov;46(11):1756-1757.Biochemistry. 1994 Jan 11;33(1):42-50.|||8286361 21 FPDB00004 AP00058|||1649|||1653|||1657|||1661|||AP00058|||Maximin 1|||DRAMP01107|||Maximin 1|||AP00058|||AP00058|||DRAMP01107|||Maximin 1 GIGTKILGGVKTALKGALKELASTYAN Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Spermicidal||Anti-HIV||Hemolytic||Anticancer||Anti-E. coli ATCC25922, activity value is MIC = 19.5 ug/ml||Anti-S. aureus ATCC2592, activity value is MIC = 19.5 ug/ml||Anti-B. pyocyaneus CMCCB10104, activity value is MIC = 19.5 ug/ml||Anti-B. megatherium, activity value is MIC = 19.5 ug/ml||Anti-K. pneumoniae, activity value is MIC = 9 ug/ml||Anti-B. dysenterium, activity value is MIC = 2.7 uM||Anti-C. albicans ATCC2002, activity value is MIC = 3 uM||activity value is IC50 = 15.3 ug/ml||activity value is IC50 = 24.3 ug/ml||activity value is IC50 = 20.5 ug/ml||activity value is IC50 = 35.4 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 9 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 4.5 ug/ml||Anti-Bacillus pyocyaneus CMCCB1010, activity value is MIC = 9 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 4.5 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 19.5 ug/ml||Anti-Klebsiella pneumoniae, activity value is MIC = 9 ug/ml||Anti-Staphylococcus aureus ATCC 2592, activity value is MIC = 19.5 ug/ml||Anti-Bacillus pyocyaneus CMCCB 10104, activity value is MIC = 19.5 ug/ml||Anti-Bacillus megatherium, activity value is MIC = 19.5 ug/ml||Anti-Bacillus dysenteriae, activity value is MIC = 2.7 ug/ml||Anti-Candida albicans ATCC 2002, activity value is MIC = 3 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-cancer Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima [Giant fire-bellied toad]|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima Helix "No hemolytic activity (0% hemolysis at 100 µM)|||In Document 3 (Eur. J. Immunol. 2005), the specific hemolytic values of the maximin family and maximin H family antimicrobial peptides in the skin secretions of the large-webbed bell toad (Bombina maxima) are not explicitly mentioned.|||No hemolytic activity (0% hemolysis at 100 µM)|||Maximins show almost no hemolytic activity against red blood cells even at a concentration as high as 50 µg/ml. Maximin H peptides can lyse 90-100% of rabbit red blood cells at a concentration of 50 µg/ml.|||[Ref:11835991]Little hemolytic activity at 50 ug/ml against red blood cells" "Peptides 2002; 23:427-435. PubMed.|||Lai R, Zheng Y-T, Shen J-H, Liu GJ, Liu H, Lee W-H, Tang S-Z., Zhang Y.2002. Peptides 2002; 23:427-435. PubMed.|||Peptides 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Peptides . 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||11835991|||Eur J Immunol. 2005 Apr;35(4):1220-9.||Ref.11835991|||11835991|||Peptides 2002; 23:427-435. doi: 10.1016/s0196-9781(01)00641-6.|||2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||https://pubmed.ncbi.nlm.nih.gov/11835991|||Peptides 2002; 23:427-435. PubMed." 27 L FPDB00005 AP00060|||1650|||1654|||1658|||1662|||AP00060|||Maximin 3|||DRAMP01109|||Maximin 3|||AP00060|||DRAMP01109|||AP00060|||DRAMP01109|||Maximin 3 GIGGKILSGLKTALKGAAKELASTYLH Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Spermicidal||Anti-HIV||Anticancer||Anti-E. coli ATCC25922, activity value is MIC = 0.9 ug/ml||Anti-S. aureus ATCC2592, activity value is MIC = 3.1 ug/ml||Anti-B. pyocyaneus CMCCB10104, activity value is MIC = 1.5 ug/ml||Anti-B. megatherium, activity value is MIC = 0.9 ug/ml||Anti-B. dysenterium, activity value is MIC = 0.9 ug/ml||Anti-K. pneumoniae, activity value is MIC = 3.1 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 15 uM||activity value is IC50 = 11.4 ug/ml||activity value is IC50 = 25.2 ug/ml||activity value is IC50 = 28 ug/ml||activity value is IC50 = 18 ug/ml||Anti-and T24, activity value is IC50 = 11||Anti-Escherichia coli ATCC25922, activity value is MIC = 20 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 2 ug/ml||Anti-Bacillus pyocyaneus CMCCB1010, activity value is MIC = 4 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 2 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 0.9 ug/ml||Anti-Klebsiella pneumoniae, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus ATCC 2592, activity value is MIC = 3.1 ug/ml||Anti-Bacillus pyocyaneus CMCCB 10104, activity value is MIC = 1.5 ug/ml||Anti-Bacillus megatherium, activity value is MIC = 0.9 ug/ml||Anti-Bacillus dysenteriae, activity value is MIC = 0.9 ug/ml||Anti-Candida albicans ATCC 2002, activity value is MIC = 15 ug/ml||Anti-HIV-1, activity value is IC50 = 11.4 ug/ml||activity value is EC50 = 1.5 ug/ml||Anti-Cancer cell lines: C8166, activity value is IC50 = 11.4 ug/ml||Anti-Molt-4, activity value is IC50 = 25.2 ug/ml||Anti-BIU-87, activity value is IC50 = 28 ug/ml||Anti-T24, activity value is IC50 = 18 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-cancer Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima [Giant fire-bellied toad]|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima , Yunnan, China, Asia|||Bombina maxima Helix "No hemolytic activity (0% hemolysis at 100 µM)|||Maximins show almost no hemolytic activity against red blood cells even at a concentration as high as 50 µg/ml. Maximin H peptides can lyse 90-100% of rabbit red blood cells at a concentration of 50 µg/ml.|||[Ref:11835991]Little hemolytic activity at 50 ug/ml against red blood cells|||human RBC: HC50 >250 ug/ml, less hemo.lytic. toxic to cell IC50 11.4 ug/ml, anti-HIV-1 EC50 1.5 ug/ml, cell selectivity index 7.6 (Lai R et al., 2012)." "Peptides 2002; 23:427-435. PubMed.|||Lai R, Zheng Y-T, Shen J-H, Liu GJ, Liu H, Lee W-H, Tang S-Z., Zhang Y.2002. Peptides 2002; 23:427-435. PubMed.|||Peptides 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Peptides . 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||11835991|||Eur J Immunol. 2005 Apr;35(4):1220-9.||Ref.11835991|||11835991|||Peptides 2002; 23:427-435. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||https://pubmed.ncbi.nlm.nih.gov/11835991|||Peptides 2002; 23:427-435. PubMed." 27 L FPDB00006 AP00061|||AP00061|||Maximin 4|||DRAMP01110|||Maximin 4|||AP00061|||DRAMP01110|||AP00061|||DRAMP01110|||Maximin 4 GIGGVLLSAGKAALKGLAKVLAEKYAN Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Spermicidal||Anti-HIV||Anticancer||Anti-E. coli ATCC25922, activity value is MIC = 2.7 uM||Anti-S. aureus ATCC2592, activity value is MIC = 2.7 uM||Anti-B. pyocyaneus CMCCB10104, activity value is MIC = 2.7 uM||Anti-B. megatherium, activity value is MIC = 1.5 uM||Anti-B. dysenterium, activity value is MIC = 2.7 uM||Anti-K. pneumoniae, activity value is MIC = 15 uM||Anti-C. albicans ATCC2002, activity value is MIC = 15 uM||Anti-and P.uticale IFFI2001 . active against cancer cells C8166 and Molt-4, activity value is IC50 = 24||Anti-Escherichia coli ATCC25922, activity value is MIC = 20 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 10 ug/ml||Anti-Bacillus pyocyaneus CMCCB1010, activity value is MIC = 20 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 5 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2.7 ug/ml||Anti-Klebsiella pneumoniae, activity value is MIC = 15 ug/ml||Anti-Staphylococcus aureus ATCC 2592, activity value is MIC = 2.7 ug/ml||Anti-Bacillus pyocyaneus CMCCB 10104, activity value is MIC = 2.7 ug/ml||Anti-Bacillus megatherium, activity value is MIC = 1.5 ug/ml||Anti-Bacillus dysenteriae, activity value is MIC = 2.7 ug/ml||Anti-Candida albicans ATCC 2002, activity value is MIC = 15 ug/ml||Anti-HIV-1, activity value is IC50 = 24.2 ug/ml||activity value is EC50 = 21.9 ug/ml||Anti-Cancer cell lines: C8166, activity value is IC50 = 24.2 ug/ml||Anti-Molt-4, activity value is IC50 = 35.4 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-cancer Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima [Giant fire-bellied toad]|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima Helix "No hemolytic activity (0% hemolysis at 100 µM)|||Maximins show almost no hemolytic activity against red blood cells even at a concentration as high as 50 µg/ml. Maximin H peptides can lyse 90-100% of rabbit red blood cells at a concentration of 50 µg/ml.|||[Ref:11835991]Little hemolytic activity at 50 ug/ml against red blood cells|||toxic to cell IC50 24.2 ug/ml, similar to EC50 against HIV-1 (Lai R et al., 2012)." "Peptides 2002; 23:427-435. PubMed.|||Lai R, Zheng Y-T, Shen J-H, Liu GJ, Liu H, Lee W-H, Tang S-Z., Zhang Y.2002. Peptides 2002; 23:427-435. PubMed.|||Peptides 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Peptides . 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||11835991|||Eur J Immunol. 2005 Apr;35(4):1220-9.||Ref.11835991|||11835991|||Peptides 2002; 23:427-435. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9. Peptides. 2002 Mar;23(3):427-435.|||https://pubmed.ncbi.nlm.nih.gov/11835991|||Peptides 2002; 23:427-435. PubMed." 27 FPDB00007 AP00062|||1652|||1656|||1660|||1664|||AP00062|||Maximin 5|||DRAMP01111|||Maximin 5|||AP00062|||DRAMP01111|||AP00062|||DRAMP01111|||Maximin 5 SIGAKILGGVKTFFKGALKELASTYLQ Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anticancer||Anti-S. aureus ATCC2592, activity value is MIC = 3.6 uM||Anti-B. pyocyaneus CMCCB10104, activity value is MIC = 7.2 uM||Anti-B. megatherium, activity value is MIC = 12 uM||Anti-B. dysenterium, activity value is MIC = 12 uM||Anti-K. pneumoniae, activity value is MIC = 3.6 uM||Anti-C. albicans ATCC2002, activity value is MIC = 1.2 uM||Anti-A. flavus IFFI4015, activity value is MIC = 12 ug/ml||Anti-and P. uticale IFFI2001, activity value is MIC = 12 ug/ml||activity value is IC50 = 34.4 ug/ml||activity value is IC50 > 50 ug/ml||IC50 =>50 ug/ml||IC50=>50 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 3.6 ug/ml||Anti-Bacillus pyocyaneus CMCCB10104, activity value is MIC = 7.2 ug/ml||Anti-Bacillus megatherium, activity value is MIC = 12 ug/ml||Anti-Bacillus dysenteriae, activity value is MIC = 12 ug/ml||Anti-Klebsiella pneumoniae, activity value is MIC = 3.6 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 1.2 ug/ml||Anti-Aspergillus flavus IFFI4015, activity value is MIC = 12 ug/ml||Anti-Penicillium uticale IFFI2001, activity value is MIC = 12 ug/ml||Anti-HIV-1, activity value is MIC = 34.4 ug/ml||Anti-Staphylococcus aureus ATCC 2592, activity value is MIC = 3.6 ug/ml||Anti-Bacillus pyocyaneus CMCCB 10104, activity value is MIC = 7.2 ug/ml||Anti-Aspergillus flavus IFFI 4015, activity value is MIC = 12 ug/ml||Anti-Penicillium uticale IFFI 2001, activity value is MIC = 12 ug/ml||Anti-HIV-1, activity value is IC50 = 34.4 ug/ml||activity value is EC50 = 39.8 ug/ml||Anti-Cancer cell lines: C8166, activity value is IC50 = 34.4 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-cancer Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima [Giant fire-bellied toad]|||Chinese red belly toad, Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima , Yunnan, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||Bombina maxima N/A "No hemolytic activity (0% hemolysis at 100 µM)|||Maximins show almost no hemolytic activity against red blood cells even at a concentration as high as 50 µg/ml. Maximin H peptides can lyse 90-100% of rabbit red blood cells at a concentration of 50 µg/ml.|||[Ref:11835991]Little hemolytic activity at 50 ug/ml against red blood cells|||IC50 34.4 ug/ml, against HIV-1 cell selectivity index 0.88 (Lai R et al., 2012). Updated 2/2012; 12/2015; 11/2024 GW." "Peptides 2002; 23:427-435. PubMed.|||Lai R, Zheng Y-T, Shen J-H, Liu GJ, Liu H, Lee W-H, Tang S-Z., Zhang Y.2002. Peptides 2002; 23:427-435. PubMed.|||Peptides 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Peptides . 2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||11835991|||Eur J Immunol. 2005 Apr;35(4):1220-9.||Ref.11835991|||11835991|||Peptides 2002; 23:427-435. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||2002 Mar;23(3):427-35. doi: 10.1016/s0196-9781(01)00641-6.|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435.|||https://pubmed.ncbi.nlm.nih.gov/11835991|||Peptides 2002; 23:427-435. PubMed." 27 L FPDB00008 AP00121|||DRAMP30312|||AP00121|||DRAMP30312 GLMDTVKNVAKNLAGHMLDKLKCKITGC "Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-S. aureus, activity value is MIC = 50 uM||Anti-E. coli, activity value is MIC = 13 uM||Anti-and C. albicans, activity value is MIC = 67 uM||Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 uM); Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(99% inhibition at 50 uM)." North American frog, Rana pipiens , or Lithobates pipiens, ALSO: the Oregon spotted frog Rana pretiosa|||Rana pipiens (Northern leopard frog)|||North American frog, Rana pipiens , or Lithobates pipiens, ALSO: the Oregon spotted frog Rana pretiosa|||Rana pipiens (Northern leopard frog) N/A N/A "Eur J Biochem. 2000 Feb;267(3):894-900. PubMed|||Eur J Biochem. 2000 Feb;267(3):894-900. doi: 10.1046/j.1432-1327.2000.01074.x.|||Comparative Study Eur J Biochem . 2000 Feb;267(3):894-900. doi: 10.1046/j.1432-1327.2000.01074.x.|||Ref.11601906|||2000 Feb;267(3):894-900. doi: 10.1046/j.1432-1327.2000.01074.x.|||Virology. 2001 Sep 30;288(2):351-7.||Ref.11601906|||Eur J Biochem. 2000 Feb;267(3):894-900. PubMed." 28 FPDB00009 AP00139|||1317|||1318|||1319|||1320|||1329|||1330|||1331|||1332|||1341|||1342|||1343|||1344|||AP00139|||Cecropin-A|||DRAMP03510 KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Anti-Gram+ & Gram-||Antiviral||Antiparasitic||Anti-HIV||Anticancer||Active against insect pathogens S. marcescens||P. aeruginosa||X. nematophilus||E. coli K12||and B. megaterium||no inhibition: B.subtilis (inhibition zone assays). ActivityG: D=L.||activity value is IC50 = 251.47 ug/ml||activity value is IC50 = 231.26 ug/ml||activity value is IC50 = 185.39 ug/ml||activity value is IC50 = 212.07 ug/ml||activity value is IC50 = 69.2 ug/ml||activity value is IC50 = 96.22 ug/ml||activity value is IC50 = 28.74 ug/ml||activity value is IC50 = 99.01 ug/ml||activity value is IC50 = 373.3||activity value is IC50 = 289.3 ug/ml||activity value is IC50 = 200.7 ug/ml||activity value is IC50 = 319.2 ug/ml||Antibacterial||Anti-Xenorhabdus nematophilus Xn21 . Gram-negative bacterium:Escherichia coli CVCC 245, activity value is MIC = 4.2||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 198||Anti-L. mono. CVCC 1599, activity value is MIC = 64.5 jiant silk moth, Hyalophora cecropia|||jiant silk moth, Hyalophora cecropia|||Hyalophora cecropia [Cecropia moth]|||Hyalophora cecropia Helix||Alpha-helix "Strong hemolytic activity (100% hemolysis at 10 μM)|||Hemolytic activity of Cecropin A: No significant hemolytic effect on Chang liver cells was observed at concentrations up to 20 µM. Hemolytic activity of Melittin: It exhibits high hemolytic activity against both E. coli and Chang liver cells, and at a concentration of 20 µM, the hemolytic effect on Chang liver cells is significant.|||Sheep RBC (HC50 = 169 ± 15.1 ug/ml)|||[Ref.29925795] 50% hemolysis at 169 ± 8.2 ug/ml against sheep red blood cells.|||Astragaloside A has no hemolytic effect on Chang liver cells even at concentrations up to 20 μM, whereas melittin exhibits high hemolytic activity against bacteria and Chang liver cells at low concentrations." "Nature. 1981 Jul 16;292(5820):246-8. PubMed|||Steiner H, Hultmark D, Engström A, Bennich H, Boman HG1981 Nature. 1981 Jul 16;292(5820):246-8. PubMed.|||Nature. 1981 Jul 16;292(5820):246-8. doi: 10.1038/292246a0.|||Nature . 1981 Jul 16;292(5820):246-8. doi: 10.1038/292246a0.|||7140755, 27367675|||Ref.7140755||Ref.29925795|||1981 Jul 16;292(5820):246-8. doi: 10.1038/292246a0." 37 L FPDB00010 AP00146|||1841|||1993|||2145|||2297|||2450|||2593|||2736|||3337|||3338|||3339|||3340|||3791|||3797|||3803|||3809|||3815|||AP00146|||Melittin|||DRAMP03002|||AP00146|||Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Insecticidal||Anti-HIV||anti-sepsis||Hemolytic||Anticancer||Anti-E. coli W 160-37, activity value is MIC = 5||Anti-S. aureus 8530B, activity value is MIC = 10||Anti-B. subtilis, activity value is MIC = 2||Anti-and P. putida NCIM 2102, activity value is MIC = 25||Anti-and E. agglomerans Bo-1S . ActivityG: D=L. Also active against colistin-resistant A. baumannii. C. albicans, activity value is MIC = 3||Anti-HSV-2 . It is also insecticidal, activity value is EC50 = 5.9||Anti-S. aureus, activity value is MIC = 4.4 uM||Anti-and E. faecium, activity value is MIC = 2.2 uM||Anti-P. aeruginosa, activity value is MIC = 2.2 uM||Anti-and V. vulnificus, activity value is MIC = 4.4 uM||Anti-T. beigelii, activity value is MIC = 4.4 uM||Anti-M. furfur, activity value is MIC = 8.8 uM||activity value is LD50 = 9 ug/ml||activity value is LD50 = 23 ug/ml||activity value is LD50 = 18 ug/ml||activity value is LD50 = 25 ug/ml||activity value is LD50 = 13 ug/ml||activity value is LD50 = 35 ug/ml||activity value is IC50 = 3.2||activity value is IC50 = 2.1||activity value is IC50 = 1.8||activity value is IC50 = 1.4||Anti-and E. agglomerans Bo-1S . ActivityG: D=L. Also active against colistin-resistant A. baumannii. Active against Gram+ bacteria S. mutants, activity value is MIC = 1.1 uM||Anti-S. aureus 29213 or 25923, activity value is MIC = 2 uM||Anti-L.rhamnosus 1.0385 or 1.0911, activity value is MIC > 128 uM||Anti-L.plantarum 7469, activity value is MIC > 128 uM||Anti-S.thermophilus YM-C, activity value is MIC > 128 uM||Anti-C. tropicalis cgmcc 2.1975, activity value is MIC = 2 uM||Anti-and C. parapsilosis cgmcc 2.3989, activity value is MIC = 2 uM||Anti-SARS CoV2, activity value is EC50 = 0.656 ug||Anti-E. coli 25922, activity value is MIC = 1 uM||Anti-E. coli UB1005, activity value is MIC = 1 uM||Anti-E. coli K88, activity value is MIC = 1 uM||Anti-E. coli K99, activity value is MIC = 1 uM||Anti-E. coli 078, activity value is MIC = 2 uM||Anti-E. coli 987P, activity value is MIC = 1 uM||Anti-P. aeruginosa 27853, activity value is MIC = 2 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 2 uM||Anti-S. typhimurium 14028, activity value is MIC = 2 uM||Anti-S. typhimurium 7731, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 2 uM||Anti-Listeria monocytogenes CMCC 54004, activity value is MIC = 1 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli UB 1005, activity value is MIC = 2 uM||Anti-Salmonella pullorum C7913, activity value is MIC = 8 uM||Anti-Salmonella enterica subsp enterica CMCC 50071, activity value is MIC = 2 uM||Enzyme inhibitor Honeybee venom, Apis mellifera (also A. florea, A. cerana)|||Honeybee venom, Apis mellifera (also A. florea, A. cerana ), Europe|||Honeybee venom, Apis mellifera (also A. florea, A. cerana ), Europe|||Honeybee venom, Apis mellifera (also A. florea, A. cerana)|||Apis mellifera [Honeybee]|||Apis mellifera (Honeybee)|||Honeybee venom, Apis mellifera (also A. florea, A. cerana ), Europe|||Apis mellifera [Honeybee] Helix||Alpha helix "Since these amphiphilic peptides may be membrane dis ruptive (12), magainin 2 was assayed for hemolytic activityagainst human erythrocytes (Fig. 4B). Unlike mellitin, ahemolytic, amphiphilic 26-amino acid peptide from beevenom (12), magainin 2 was not hemolytic up to at least 0.00015 ug/ml in phosphate-buffered normal saline (Fig. 4B). Theabsence of hemolytic activity of magainin 2 is striking in thatit possesses a potential hydrophobic moment very similar tomellitin (12)|||Moderate hemolytic activity (50% hemolysis at 50 µM)|||Under physiological salt concentration, when melittin at concentrations up to 500 µg was incubated with 1×10⁹/ml human red blood cells at 37°C for 3 hours, no significant hemolytic activity was observed (<0.5%); however, in 10,000 µM sodium phosphate buffer containing 340,000 µM sucrose, high concentrations of melittin exhibited significant hemolytic activity, although the exact values were not specified.|||​|||sheep red blood cells (11000 uM)|||In Document 11 (Gene 2018), the recombinant hybrid antimicrobial peptide AL32-P113 and the synthetic hybrid peptide L31-P113 both exhibited hemolytic activity against human erythrocytes. At a concentration of 500 μg/ml, the hemolysis rate of AL32-P113 was 10.4% ± 2.2%, and that of L31-P113 was 12.0% ± 0.7%; as controls, the hemolysis rate of LL-37 was 2.9% ± 0.7%, and that of Hst-5 was 1.6% ± 0.6%.|||Moderate hemolytic activity (50% hemolysis at 50 µM)|||sheep red blood cells (11000 uM)|||It is highly hemolytic (100% at 6.25 uM) and can cause histamine release (85% at 10 uM) (Kawakami et al., 2017)." "Res Dev Tech Rep. 1967 Dec 5:1-13.Pub-Med.|||Fennell JF, Shipman WH, Cole LJ.1967 Res Dev Tech Rep. 1967 Dec 5:1-13.Pub-Med.||ref AP252||Ref. AP83||ref, see AP2411||see ref. AP1480||Yasin et al., 2000||Perez-Cordero JJ et al. 2011 Peptides 32, 683-90|||Res Dev Tech Rep. 1967 Dec 5:1-13. doi: 10.21236/ad0658324.||ref AP252||Ref. AP83||see ref. AP1480||for ref, see AP5638|||. 1967 Dec 5:1-13. doi: 10.21236/ad0658324.||ref AP252||Ref. AP83||see ref. AP1480||for ref, see AP5638||Yasin et al., 2000|||Res Dev Tech Rep . 1967 Dec 5:1-13. doi: 10.21236/ad0658324.||ref AP252||Ref. AP83||ref, see AP2411||see ref. AP1480||Yasin et al., 2000||Perez-Cordero JJ et al. 2011 Peptides 32, 683-90|||9568968, 35236909|||31199117|||Eur J Biochem. 1983 Sep 1;135(1):123-126.||Ref.29783753|||Res Dev Tech Rep. 1967 Dec 5:1-13.doi: 10.21236/ad0658324.||ref AP252||Ref. AP83||see ref. AP1480||for ref, see AP5638|||9568968, 35236909|||Res Dev Tech Rep. 1967 Dec 5:1-13.Pub-Med." 26 L FPDB00011 AP00150|||1812|||1827|||1964|||1979|||2116|||2131|||2268|||2283|||2420|||2435|||2563|||2578|||2706|||2721|||AP00150|||Indolicidin|||DRAMP02857 ILPWKWPWWPWRR Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Hemolytic||Antibiofilm||Wound healing||Anticancer||Anti-S. aureus ATCC29213 or NCDC-0111 or MRSA, activity value is MIC = 1.5||Anti-L. monocytogenes ATCC-19111, activity value is MIC = 6 uM||Anti-B. cereus NCDC-0240, activity value is MIC = 0.8 uM||Anti-P. aeruginosa ATCC-27853 or NCDC-0105, activity value is MIC = 12.5||Anti-S. enterica serovar typhimurium ATCC-14028, activity value is MIC = 12.5 uM||Anti-E. coli MTCC-0723, activity value is MIC = 0.8 uM||Anti-and A. johnsonii NCDC-0072, activity value is MIC = 6 uM||activity value is LD50 = 64 ug/ml||activity value is LD50 = 12 ug/ml||activity value is LD50 = 345 ug/ml||activity value is LD50 = 30 ug/ml||activity value is LD50 = 200 ug||activity value is LD50 = 180 ug/ml||activity value is LD50 = 200 ug/ml||activity value is LD50 = 270 ug/ml||activity value is LD50 = 290 ug/ml||activity value is LD50 = 31 ug/ml||activity value is LD50 = 20 ug/ml||Anti-E. coli, activity value is MIC = 20 ug/ml||Anti-P. aeruginosa, activity value is MIC = 40 ug/ml||Anti-S. typhimurium, activity value is MIC = 20 ug/ml||Anti-B. subtilis, activity value is MIC = 10 ug/ml||Anti-S. epidermidis, activity value is MIC = 20 ug/ml||Anti-S. aureus, activity value is MIC = 5 ug/ml||Anti-K. pneumoniae strains NTUH-K2044, activity value is MIC = 32 ug/ml||Anti-ATCC 43816, activity value is MIC = 16 ug/ml||Anti-ATCC 13883, activity value is MIC = 32 ug/ml||Anti-ATCC 700603, activity value is MIC = 16 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- bovine neutrophils, cattle, Bos taurus|||bovine neutrophils, cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||bovine neutrophils, cattle, Bos taurus Nonhelixbeta "The document does not provide the half-hemolytic concentration (HC₅₀) of each peptide directly, but hemolytic activity is reflected through the percentage of hemolysis. The core data are as follows: 1. Hybrid Peptides (RN7-IN series) RN7-IN10: At a concentration of 15.62 µg/ml, the hemolysis rate is 5.9%; no hemolytic activity is observed at its minimum inhibitory concentration (MIC = 7.81–15.62 µg/ml). RN7-IN9, RN7-IN8, RN7-IN6: At a concentration of 15.62 µg/ml, the hemolysis rate is 0.0%; no hemolytic activity is observed at each respective MIC. RN7-IN7: No hemolytic toxicity observed even at the highest tested concentration of 250 µg/ml (hemolysis rate 0.0%). 2. Indolicidin Analogs (IN series) IN1: At a concentration of 250 µg/ml, the hemolysis rate is 3.6%; no hemolytic activity at its MIC (31.25–62.5 µg/ml). IN2: At 250 µg/ml, hemolysis rate is 15.39%; no hemolytic activity at its MIC. IN3: At 250 µg/ml, hemolysis rate is 2.39%; no hemolytic activity at its MIC (62.5 µg/ml). IN4: Specific hemolysis data are not mentioned, but the document notes weak activity against Streptococcus pneumoniae (MIC = 250 µg/ml), suggesting low hemolysis risk at effective concentrations. 3. Parent Peptides Indolicidin: At 20 µg/ml, hemolysis rate reaches 56.98%, showing the strongest hemolytic toxicity among all peptides. Ranalexin: At 250 µg/ml, hemolysis rate is <15%, with hemolytic toxicity lower than Indolicidin. The above data were measured by human red blood cell hemolysis experiments: a 4% human red blood cell suspension was incubated with peptides at 1.95–250 µg/ml at 37 °C for 1 hour, with PBS as a negative control (0% hemolysis) and 0.1% Triton X-100 as a positive control (100% hemolysis). Hemolysis rates were calculated based on absorbance at 560 nm. All peptides showed no cytotoxicity or hemolytic effects at their MIC values, and only some peptides exhibited slight hemolysis at concentrations far above their MICs.|||hRBC(50% hemolysis at 200 ug/ml)|||V- The 13 designed peptides exhibited no hemolysis or cytotoxicity at their minimum inhibitory concentrations (MIC). Among them, the hybrid peptides RN7-IN10, RN7-IN9, RN7-IN8, and RN7-IN6 showed hemolysis rates of 5.9%, 0.0%, 0.0%, and 0.0% at a concentration of 15.62 µg/ml, respectively; RN7-IN7 showed no hemolysis at a concentration of 250 µg/ml. - Indolicidin exhibited a hemolysis rate of 56.98% at 20 µg/ml; Ranalexin exhibited a hemolysis rate of less than 15% at 250 µg/ml. Indolicidin analogues IN1 and IN3 showed hemolysis rates of 3.6% and 2.39% at 250 µg/ml, respectively; IN2 showed a hemolysis rate of 15.39% at 250 µg/ml." "J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med|||Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS.1992 J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med||Brahma B et al., 2015||Yasin et al., 2000|||J Biol Chem. 1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000|||J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med|||J Biol Chem . 1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000|||1537821, 19191872, 35254120||Refer PubMed ID: 19191872||Refer PubMed ID: 35254120|||J Biol Chem. 1992 Mar 5;267(7):4292-4295.Biochemistry. 2000 Dec 26;39(51):15765-74.Life Sci. 2002 Jul 5;71(7):747-50.|||1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000" 13 L FPDB00012 AP00157|||1708|||AP00157|||Dermaseptin-1|||DRAMP01668|||Dermaseptin-1|||AP00157|||DRAMP01668 ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Spermicidal||Anti-HIV||Anti-A. caviae IP67-16T, activity value is MIC = 0.5 uM||Anti-E. coli IP76-24, activity value is MIC = 1 uM||Anti-S. aureus IP76-25, activity value is MIC = 5 uM||Anti-N. brasiliensis IP118079, activity value is MIC = 35 uM||Anti-S. cerevisiae IP118079, activity value is MIC = 5 uM||Anti-IP886-65, activity value is MIC = 10 uM||Anti-C. neoformans IP960-67 and IP962-67, activity value is MIC = 0.5||Anti-M. canis IP1194, activity value is MIC = 15 uM||Anti-T. rubrum IP2043-92, activity value is MIC = 35 uM||Anti-T. metagrophytes IP877-71, activity value is MIC = 20 uM||Anti-mutant, activity value is MIC = 30 uM||Anti-A. simii J43, activity value is MIC = 15 uM||Anti-A. niger IP218-53 and A. fumigatus IP1025-70, activity value is MIC = 30 uM||Antibacterial||Anti-Microsporum canis, activity value is MIC = 50 ug/ml||Anti-Tricophyton rubrum, activity value is MIC = 100 ug/ml||Anti-Arthroderma simii, activity value is MIC = 100 ug/ml||Anti-Aspergillus fumigatus, activity value is MIC = 100 ug/ml||Anti-Aerornonas caviae IP T, activity value is MIC = 50 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC = 15 ug/ml||Anti-Candida albicans, activity value is MIC = 60 ug/ml||Anti-Escherichia coli, activity value is MIC = 5 ug/ml||Anti-Nocardia brasiliensis, activity value is MIC = 200 ug/ml||Anti-usporum canis IP 11 94, activity value is MIC = 50 ug/ml||Anti-Tricophyton rubrum IP 1400-82, activity value is MIC = 100 ug/ml||Anti-Arthroderma simii IP 1063-74, activity value is MIC = 100 ug/ml||Anti-Aspergillus fumigatus IP 1025-70, activity value is MIC = 100 ug/ml||Anti-Aerornonas caviae IP 67-16 T, activity value is MIC = 50 ug/ml||Anti-Escherichia coli IP 76-24, activity value is MIC = 5 ug/ml||Anti-Nocardia brasiliensis IP 16-80, activity value is MIC = 200 ug/ml||Anti-Cryptococcus neoformans IP 960-67, activity value is MIC = 15 ug/ml||Anti-Cryptococcus neofonnans IP 962-67, activity value is MIC = 15 ug/ml||Anti-Candida albicans IP 884-65, activity value is MIC = 60 ug/ml Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagii [Sauvage leaf frog]|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagii [Sauvage leaf frog]|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog) Helix||Alpha helix (CD) No hemolytic activity (0% hemolysis at 200 μM)|||When incubated with rabbit red blood cells at 1000 µg/ml of dermaseptin for 20 minutes, 100% hemolysis was observed; however, no hemolysis was detected after 2 hours of incubation at a concentration of 200 µg/ml, and within the concentration range of 0.8–1000 µg/ml, there was no significant effect on normal clotting time (120 seconds).|||Dermaseptin in (Biochemistry 1991), at a concentration of 1000 µg/ml for 20 minutes, can cause 100% hemolysis, but at a concentration of 200 µg/ml for 2 hours, it has no hemolytic effect on rabbit red blood cells.|||No hemolytic activity (0% hemolysis at 200 μM) "Biochemistry. 1991;30(36):8824-8830. doi:10.1021/bi00100a014.PubMed.|||Biochemistry. 1991;30(36):8824-8830. doi:10.1021/bi00100a014.||Perez-Cordero JJ et al. 2011 Peptides 32 (4), 683-90|||J Biol Chem . 1994 Dec 16;269(50):31635-41.||Perez-Cordero JJ et al. 2011 Peptides 32 (4), 683-90|||9614066 , 1909573|||Biochemistry. 1991 Sep 10;30(36):8824-8830.|||1909573|||9614066 , 1909573|||Biochemistry. 1991;30(36):8824-8830. doi:10.1021/bi00100a014.||Perez-Cordero JJ et al. 2011 Peptides 32 (4), 683-90|||1994 Dec 16;269(50):31635-41.||Perez-Cordero JJ et al. 2011 Peptides 32 (4), 683-90" 34 L FPDB00013 AP00160|||AP00160|||DS4|||DRAMP18708|||AP00160|||DRAMP18708 ALWMTLLKKVLKAAAKAALNAVLVGANA Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Spermicidal||Anti-HIV||anti-sepsis||Antimalarial||Hemolytic||Anti-A. caviae IP67-16T, activity value is MIC = 0.5 uM||Anti-E. coli IP76-24, activity value is MIC = 4 uM||Anti-S. aureus IP76-25, activity value is MIC = 10||Anti-N. brasiliensis IP118079, activity value is MIC = 10 uM||Anti-S. cerevisiae IP118079, activity value is MIC = 20 uM||Anti-IP886-65, activity value is MIC = 20 uM||Anti-C. neoformans IP960-67 and IP962-67, activity value is MIC = 1||Anti-M. canis IP1194, activity value is MIC = 15 uM||Anti-T. rubrum IP2043-92, activity value is MIC = 40 uM||Anti-T. metagrophytes IP877-71, activity value is MIC = 20 uM||Anti-mutant, activity value is MIC = 30 uM||Anti-A. simii J43, activity value is MIC = 20 uM||Anti-A. niger IP218-53 and A. fumigatus IP1025-70, activity value is MIC = 20||Anti-C. albicans, activity value is MIC = 11.5||Anti-S1, activity value is MIC = 295.97 ug/ml||Anti-S2, activity value is MIC = 380.82 ug/ml||Anti-S3, activity value is MIC = 343.68 ug/ml||Anti-S4, activity value is MIC = 358.13 ug/ml||Anti-S5, activity value is MIC = 274.17 ug/ml||Anti-S6, activity value is MIC = 330.65 ug/ml||Anti-S7, activity value is MIC = 411.06 ug/ml||Anti-S1, activity value is MIC = 250.22 ug/ml||Anti-S2, activity value is MIC = 269.06 ug/ml||Anti-S3, activity value is MIC = 490.77 ug/ml||Anti-S4, activity value is MIC = 257.4 ug/ml||Anti-S5, activity value is MIC = 308.89 ug/ml||Anti-S6, activity value is MIC = 344.32 ug/ml||Anti-S7, activity value is MIC = 275.73 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||[Swiss_Prot Entry P80280]Possesses a potent antimicrobial activity against Gram-negative and Gram-positive bacteria||fungi||protozoa||and the enveloped herpes simplex virus type 1 Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa hypochondrialis [orange-legged leaf frog]|||Synthetic construct|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog) Helix||Alpha helix No hemolytic activity (0% hemolysis at 200 μM)|||Dermaseptin S1: At a concentration of 70 µM, treatment for 1 hour did not cause hemolysis of human red blood cells. Dermaseptin S2: At 70 µM, hemolysis of red blood cells occurred within 1 hour. Dermaseptin S3: At 80 µM, hemolysis of red blood cells occurred within 1 hour. Dermaseptin S4: At 1 µM, 100% hemolysis occurred within 1 hour; at 0.5 µM, 50% hemolysis was observed. Dermaseptin S5: At a concentration of 90 µM, treatment for 1 hour did not cause hemolysis of human red blood cells.|||hRBCs, >50% hemolysis at 8 ug/ml|||hRBCs, >50% hemolysis at 128 ug/ml|||[Swiss_Prot Entry P80280]Strong hemolytic activity "J Biol Chem. 1994;269(50):31635-31641.PubMed.|||J Biol Chem. 1994;269(50):31635-31641.|||1994 Dec 16;269(50):31635-41.|||J Biol Chem . 1994 Dec 16;269(50):31635-41.|||33774792|||Eur. J. Biochem. 1994; 219:145-154.|||J Biol Chem. 1994;269(50):31635-31641.|||Eur. J. Biochem. 1994; 219:145-154." 28 FPDB00014 AP00176|||AP00176|||Human defensin 1|||DRAMP03591|||AP00176|||DRAMP03591|||AP00176|||DRAMP03591 ACYCRIPACIAGERRYGTCIYQGRLWAFCC Chemotactic||Anti-MRSA||Anti-toxin||Enzyme inhibitor||anti-sepsis||Wound healing||Anticancer||Anti-Killed C. difficile. Active against L. monocytogenes, activity value is MIC = 39.7 ug/ml||Anti-S.epidermis, activity value is MIC = 2.2 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 5.2||Anti-and S. maltophilia, activity value is MIC = 1.8||Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-HIV||T. cruzi||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2) neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human) Beta||Beta strand Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry "J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI1985 J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Comparative Study J Clin Invest . 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||17635867|||Viruses. 2021 Jun 26;13(7):1246.|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Viruses. 2021 Jun 26;13(7):1246.Proteomics. 2009 Mar;9(5):1364-1373.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-8.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Viruses. 2021 Jun 26;13(7):1246." 30 FPDB00015 AP00177|||AP00177|||Human neutrophil peptide-2|||DRAMP03592|||AP00177|||DRAMP03592|||AP00177|||DRAMP03592 CYCRIPACIAGERRYGTCIYQGRLWAFCC Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Chemotactic||Anti-toxin||Enzyme inhibitor||Anticancer||Anti-P. aeruginosa CIP 76.110, activity value is MIC = 1 ug/ml||Anti-S. aureus ATCC 29213 and S. epidermidis CIP 68.21, activity value is MIC = 0.5 ug/ml||Anti-E. coli ATCC 8739 ( v, activity value is LD50 = 3.5||Anti-E. coli ATCC 25922 ( v, activity value is LD50 = 3.5||Anti-E. aerogenes ATCC 13048 ( v, activity value is LD50 = 16||Anti-S. aureus ATCC 25923 ( v, activity value is LD50 = 4.2||Anti-S. aureus ATCC 29213 ( v, activity value is LD50 = 2.4||Anti-B. cereus ATCC 10876 ( v, activity value is LD50 = 0.22||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2) neutrophils; natural killer cells, monocytes; sairway, aliva; Homo sapiens|||neutrophils; natural killer cells, monocytes; sairway, aliva; Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; sairway, aliva; Homo sapiens|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; sairway, aliva; Homo sapiens|||Homo sapiens (Human) Beta||Beta strand Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry "J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI1985 J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.|||Comparative Study J Clin Invest . 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.|||15616305|||Viruses. 2021 Jun 26;13(7):1246.|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.|||Viruses. 2021 Jun 26;13(7):1246.Proteomics. 2009 Mar;9(5):1364-1373.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-8.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.|||Viruses. 2021 Jun 26;13(7):1246." 29 FPDB00016 AP00178|||AP00178|||HNP3|||DRAMP03593|||AP00178|||DRAMP03593|||AP00178|||DRAMP03593 DCYCRIPACIAGERRYGTCIYQGRLWAFCC Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Chemotactic||Anti-toxin||Enzyme inhibitor||Anticancer||Anti-P. aeruginosa CIP 76.110, activity value is MIC = 1 ug/ml||Anti-S. aureus ATCC 29213 and S. epidermidis CIP 68.21, activity value is MIC = 0.5 ug/ml||Anti-E. coli MG1655, activity value is MBC = 20 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2)||Antiviral(SARS-CoV-3) neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human) Beta||Beta strand Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry "J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI1985 J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||Comparative Study J Clin Invest . 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||28423004|||Viruses. 2021 Jun 26;13(7):1246.|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||Viruses. 2021 Jun 26;13(7):1246.J Clin Invest. 1985 Oct;76(4):1436-1439.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Buck et al., 2006||Xu et al., 2021||Cardot-Martin E et al. 2015|||Viruses. 2021 Jun 26;13(7):1246." 30 FPDB00017 AP00179|||DRAMP03594|||Neutrophil defensin 4|||AP00179|||DRAMP03594|||AP00179|||DRAMP03594 VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-toxin||Active against E. coli||S. faecalis||and C. albicans.||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2)||Antiviral(SARS-CoV-4) Homo sapiens|||Homo sapiens (Human)|||Homo sapiens [Human]|||Homo sapiens|||Homo sapiens (Human)|||Homo sapiens|||Homo sapiens (Human) Beta||Beta strand No hemolysis information or data found in the reference(s) presented in this entry "J. Biol. Chem. 1989; 264:11200-11203. PubMed.|||1989 Jul 5;264(19):11200-3.|||J. Biol. Chem. 1989; 264:11200-11203.|||Comparative Study J Biol Chem . 1989 Jul 5;264(19):11200-3.|||Viruses. 2021 Jun 26;13(7):1246.|||2500436, 17088326, 30658057|||J. Biol. Chem. 1989; 264:11200-11203.|||Viruses. 2021 Jun 26;13(7):1246.Protein Sci. 2006 Dec;15(12):2749-2760.FEBS Lett. 2005 Jan 3;579(1):162-166.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.|||1989 Jul 5;264(19):11200-3.|||Viruses. 2021 Jun 26;13(7):1246." 33 FPDB00018 AP00195|||1426|||AP00195|||IB-200|||IB-445|||OLAP-311|||Protegrin-1|||Recombinant Protegrin-1|||PG-1|||Protegrin|||IB-247 RGGRLCYCRRRFCVCVGR "Anti-Gram+||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||anti-sepsis||Synergistic AMPs||Hemolytic||Antibiofilm||61% Cytotoxicity at 0.5 ug/ml||Anti-E. coli 004, activity value is MIC = 0.12 ug/ml||Anti-V, activity value is MIC = 0.25 ug/ml||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 0.5 ug/ml||Anti-S. aureus ATCC 33591 or MRSA, activity value is MIC = 2 ug/ml||Anti-MRSA, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 2 ug/ml||MIC E.Coli (ATCC 25922: 2 ug/ml||ATCC 700926: 0.25 ug/ml||MB 4902: 0.015 ug/ml)||K. pneumoniae (ATCC 13883: 0.5 ug/ml||ATCC 700603: 4 ug/ml||BAA 2146: 4 ug/ml)||A. baumannii (ATCC 19606): 0.25 ug/ml||P. aeruginosa (ATCC 27853): 4 ug/ml||B. subtilis (ATCC 6051): 0.03 ug/ml||S. aureus ATCC 43300 (MRSA): 4 ug/ml||C. albicans (ATCC 90028): 2 ug/ml||C. neoformans (ATCC 208821): 0.06 ug/ml||Anti-E. coli, activity value is MIC = 64 ug/ml||Anti-S. aureus, activity value is MIC = 64 ug/ml||Anti-S. epiderrnidis, activity value is MIC = 2 ug/ml||Anti-Escherichia coli ATCC 25377, activity value is MIC = 3 ug/ml||Anti-A. baumannii ATCC 238719, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 361823, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 371484, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC 371981, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 378177, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 378648, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 379385, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 379622, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 380023, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 380667, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 381577, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 382933, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 383074, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 383290, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 386052, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 388538, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 5615, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 12316, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 12834, activity value is MIC = 4 ug/ml||Anti-S. aureus 29213, activity value is MIC = 1.7 ug/ml||Anti-E. coli 25922, activity value is MIC = 0.75 ug/ml||Anti-P. aeruginosa 27853, activity value is MIC = 0.5 ug/ml||Anti-E. faecalis 29212, activity value is MIC = 2.7 ug/ml||Anti-""A. baumannii ATCC 238719, activity value is MIC = 4 ug/ml||Antibacterial||Anti-K. pneumoniae strains NTUH-K2044, activity value is MIC = 0.5 ug/ml||Anti-ATCC 43816, activity value is MIC = 0.5 ug/ml||Anti-ATCC 13883, activity value is MIC = 0.5 ug/ml||Anti-ATCC 700603, activity value is MIC = 0.5 ug/ml||Anti-MKP103, activity value is MIC = 2 ug/ml||Anti-MKP103 wza mutant, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 0.5 ug/ml" leukocytes; porcine neutrophil, pig, Sus scrofa|||eukocytes; porcine neutrophil, pig, Sus scrofa|||leukocytes; porcine neutrophil, pig, Sus scrofa|||Synthetic construct|||Porcine neutrophils|||Sus scrofa [pig] Beta 96.1% hemolysis at 64 uM (see ref. AP05000). Chem Pharm Bull (Tokyo). 1995 May;43(5):853-8|||Chem Pharm Bull (Tokyo). 1995 May;43(5):853-8||Blower et al., 2018||Yasin et al., 2000||Guo C et al., 2014||Sousa et al., 2017|||Blower et al., 2018||Yasin et al., 2000||Guo C et al., 2014||Sousa et al., 2017|||8647100|||31399625|||31214759|||28382709, 9257752, 31214759||Refer 31214759|||34502403|||35254120|||10931444 18 L FPDB00019 AP00211|||AP00211|||OLAP-313|||Polyphemusin-1|||L-Polyphemusin|||DRAMP02933|||Polyphemusin-1|||AP00211 RRWCFRVCYRGFCYRKCR Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||anti-sepsis||Anti-Gram- S. typhimurium LT2 and 1102, activity value is MIC = 3.1 ug/ml||Anti-E. coli K12, activity value is MIC = 6.3 ug/ml||Anti-S. Minnesota 1114W or R595, activity value is MIC = 3.1||Anti-S. aureus 209P or ATCC 25923, activity value is MIC = 6.3 ug/ml||Anti-and C. albicans M9, activity value is MIC = 6.3 ug/ml||MIC E.Coli (ATCC 25922: 0.5 ug/ml||ATCC 700926: 0.06 ug/ml||MB 4902: 0.03 ug/ml)||K. pneumoniae (ATCC 13883: 0.5 ug/ml||ATCC 700603: 1 ug/ml||BAA 2146: 2 ug/ml)||A. baumannii (ATCC 19606): 0.06 ug/ml||P. aeruginosa (ATCC 27853): 2 ug/ml||B. subtilis (ATCC 6051): 0.25 ug/ml||S. aureus ATCC 43300 (MRSA): 2 ug/ml||C. albicans (ATCC 90028): 1 ug/ml||C. neoformans (ATCC 208821): 0.06 ug/ml||Antibacterial||Anti-S.aureus, activity value is MIC = 16 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 0.5 ug/ml||Anti-E. coli DC2, activity value is MIC = 1 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 0.25 ug/ml||Anti-S. typhimurium, activity value is MIC = 1 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-Staphylococcus aureus SAP0017, activity value is MIC = 2 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 1 ug/ml||Anti-Enterococcus faecalis, activity value is MIC = 1 ug/ml||Antifungal ; Candida albicans M9||Anti-Active against Gram- S. typhimurium LT2 and 1102, activity value is MIC = 3.1 ug/ml Limulus polyphemus|||Limulus polyphemus|||Limulus polyphemus [Atlantic horseshoe crab]|||Synthetic construct|||Limulus polyphemus (Atlantic horseshoe crab)|||Limulus polyphemus Beta||No secondary structure (CD) Moderate hemolytic activity (40% hemolysis at 20 μM)|||IC50 for hRBC = 1885 ug/ml "J. Biochem. 1989; 106: 663-668. PubMed|||J. Biochem. 1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913.|||1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913.|||J Biochem . 1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913.|||2514185|||28453851|||Biochim Biophys Acta. 2004 May 6;1698(2):239-250.|||2514185|||J. Biochem. 1989; 106: 663-668. doi: 10.1093/oxfordjournals.jbchem.a122913." 18 FPDB00020 AP00212|||AP00212|||Polyphemusin-2|||DRAMP02935|||Polyphemusin-2|||AP00212|||DRAMP02935 RRWCFRVCYKGFCYRKCR Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-Gram- S. typhimurium LT2 and 1102, activity value is MIC = 3.1||Anti-E. coli K12, activity value is MIC = 12.5 ug/ml||Anti-S. Minnesota 1114W or R595, activity value is MIC = 3.1||Anti-S. aureus 209P or ATCC 25923, activity value is MIC = 6.3||Anti-and C. albicans M9, activity value is MIC = 6.3 ug/ml||Antibacterial||Antimicrobial||Antifungal ; Candida albicans M9||Anti-Active against Gram- S. typhimurium LT2 and 1102, activity value is MIC = 3.1 Atlantic Limulus polyphemus|||Atlantic Limulus polyphemus|||Limulus polyphemus [Atlantic horseshoe crab]|||Limulus polyphemus (Atlantic horseshoe crab)|||Atlantic Limulus polyphemus|||Limulus polyphemus (Atlantic horseshoe crab) Bridge Moderate hemolytic activity (45% hemolysis at 20 μM) "J. Biochem. 1989; 106: 663-668. PubMed|||J. Biochem. 1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913.|||J Biochem . 1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913.|||2514185|||J Biochem. 1989 Oct;106(4):663-668.|||2514185|||J. Biochem. 1989; 106: 663-668. doi: 10.1093/oxfordjournals.jbchem.a122913.|||J Biochem. 1989 Oct;106(4):663-668.Biochim Biophys Acta. 2004 May 6;1698(2):239-250.|||1989 Oct;106(4):663-8. doi: 10.1093/oxfordjournals.jbchem.a122913." 18 FPDB00021 AP00214|||AP00214|||OLAP-314|||Tachyplesin-1|||TAC1_CARRO Tachyplesin-1|||TP I|||AP00214|||DRAMP02926 KWCFRVCYRGICYRRCR Anti-Gram+ & Gram-||Antiviral||Anti-HIV||anti-sepsis||Hemolytic||Anticancer||Anti-Gram- S. typhimurium LT2 or 1102, activity value is MIC = 0.8||Anti-E. coli K12, activity value is MIC = 1.6||Anti-S. Minnesota 1114W or R595, activity value is MIC = 1.6||Anti-P. aeruginosa, activity value is MIC = 12.5 ug/ml||Anti-S. aureus 209P or ATCC 25923, activity value is MIC = 3.1||Anti-B. subtilis, activity value is MIC = 3.1 ug/ml||Anti-C. albicans M9, activity value is MIC = 3.1 ug/ml||Anti-and C. neoformans IMF 40040, activity value is MIC = 1.56 ug/ml||MIC E.Coli (ATCC 25922: 0.06 ug/ml||ATCC 700926: 0.03 ug/ml||MB 4902: 0.016 ug/ml)||K. pneumoniae (ATCC 13883: 0.125 ug/ml||ATCC 700603: 0.25 ug/ml||BAA 2146: 0.25 ug/ml)||A. baumannii (ATCC 19606): 0.125 ug/ml||P. aeruginosa (ATCC 27853): 0.25 ug/ml||B. subtilis (ATCC 6051): 0.125 ug/ml||S. aureus ATCC 43300 (MRSA): 1 ug/ml||C. albicans (ATCC 90028): 4 ug/ml||C. neoformans (ATCC 208821): 0.125 ug/ml||Anti-28960954: E.coli ATCC25922, activity value is MIC = 0.06 ug/ml||Anti-K. pneumoniae ATCC13883, activity value is MIC = 0.06 ug/ml||Anti-A. baumannii ATCC 700603, activity value is MIC = 0.25 ug/ml||Anti-A. baumannii BAA, activity value is MIC = 0.25 ug/ml||Anti-PmxR, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC19606, activity value is MIC = 0.06 ug/ml||Anti-PmxR, activity value is MIC = 0.125 ug/ml||Anti-P.aeuroginsa ATCC 27853, activity value is MIC = 0.125 ug/ml||Anti-P.aeuroginsa FADDI-FAO70, activity value is MIC = 0.25 ug/ml||Anti-B.subtilis ATCC6051, activity value is MIC = 0.06 ug/ml||Anti-S.aureus ATCC43300, activity value is MIC = 0.25 ug/ml||Anti-C.albicans ATCC90028, activity value is MIC = 2 ug/ml||Anti-C.neoformanas ATCC208821, activity value is MIC = 0.125 ug/ml||Anti-31455019 : Escherichia coli ATCC 25922, activity value is MIC = 0.5||Anti-Escherichia coli DC2 CGSC 7139, activity value is MIC = 0.0625||Anti-S. aureus ATCC 25923, activity value is MIC = 1||Anti-S. aureus ATCC 6538, activity value is MIC = 4||Anti-Escherichia coli ML-35p, activity value is MIC = 0.062 uM||Anti-Klebsiella pneumoniae, activity value is MIC = 0.5 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 0.5 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 8 uM||Anti-Staphylococcus aureus 209P, activity value is MIC = 0.5 uM||Anti-B. subtilis B-886, activity value is MIC = 0.5 uM||Anti-M. luteus B-1314, activity value is MIC = 1 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-cancer hemocytes, Southeast Asia, Tachypleus tridentatus; Tachypleus gigas; Carcinoscorpius rotundicauda|||hemocytes, Southeast Asia, Tachypleus tridentatus; Tachypleus gigas; Carcinoscorpius rotundicauda|||Tachypleus tridentatus|||Tachypleus gigas|||Carcinoscorpius rotundicauda|||Limulus polyphemus [Atlantic horseshoe crab]|||hemocytes, Southeast Asia, Tachypleus tridentatus; Tachypleus gigas; Carcinoscorpius rotundicauda|||Tachypleus tridentatus (Japanese horseshoe crab) Beta||Beta strand Weak hemolytic activity (15% hemolysis at 20 μM)|||hRBC (38% hemolysis at 100 uM)|||[Ref.29870123] 9.6% hemolytic activity at 8 ug/ml and 72.8% hemolytic activity at 512 ug/ml against human red blood cells. "J Biol Chem. 1988 Nov 15;263(32):16709-13.PubMed.|||Nakamura T, Furunaka H, Miyata T, Tokunaga F, Muta T, Iwanaga S, Niwa M, Takao T, Shimonishi Y.1988 J Biol Chem. 1988 Nov 15;263(32):16709-13.PubMed.||Peschel et al., 2001|||J Biol Chem. 1988 Nov 15;263(32):16709-13.||Peschel et al., 2001|||1988 Nov 15;263(32):16709-13.||Peschel et al., 2001|||J Biol Chem . 1988 Nov 15;263(32):16709-13.||Peschel et al., 2001|||3141410, 28960954, 31455019|||2229025|||30486233|||1988 Nov 15;263(32):16709-13.||Peschel et al., 2001|||Biochemistry 2002; 41: 12359.J Biochem. 1990 Aug;108(2):261-266. Int J Mol Sci. 2019 Aug 26;20(17):4184." 17 FPDB00022 AP00240|||AP00240|||Caerin-1.1|||Caerin 1.1|||Caerin|||DRAMP01549|||AP00240|||DRAMP01549|||Caerin-1.1 GLLSVLGSVAKHVLPHVVPVIAEHL Anti-Gram+ & Gram-||Antiviral||Antiparasitic||Anti-HIV||Anti-MRSA||Antibiofilm||Anticancer||Anti-B. cereus, activity value is MIC = 50 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 1.5 uM||Anti-L. innocua, activity value is MIC = 25 ug/ml||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-S. aureus ATCC 25923 or 29213, activity value is MIC = 3||Anti-S. epidermidis, activity value is MIC = 12 ug/ml||Anti-S. uberis, activity value is MIC = 12 ug/ml||Anti-E.clocae, activity value is MIC > 100 ug/ml||Anti-P. multocida, activity value is MIC = 12||Anti-and P. haemolytica, activity value is MIC = 25 ug/ml||Antibacterial||Anti-Bacillus cereus, activity value is MIC = 50 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 1.5 ug/ml||Anti-Listeria innocua, activity value is MIC = 25 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Pasteurella haemolytica, activity value is MIC = 25 ug/ml||Anti-Pasteurella multocida, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 12 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 12 ug/ml||Anti-S.aureus, activity value is MIC = 18.75 uM||activity value is MBC = 125 uM||Anti-E.Coli, activity value is MIC = 115 uM||activity value is MBC = 250 uM||Antimicrobial||Anti-Gram+||Anti-Gram-||Anti-Micrococcus luteus, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3||Anti-Staphylococcus epidermis, activity value is MIC = 12.5 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 12.5 ug/ml||Anti-GDM1.441, activity value is MIC = 15 ug/ml||Anti-GDM1.1263, activity value is MIC = 30 ug/ml||Anti-P. aeruginosa GDM1.443, activity value is MIC = 60 ug/ml||Anti-S. hemolyiicus GDM1.245, activity value is MIC = 15 ug/ml||Anti-MRSA1, activity value is MIC = 60 ug/ml||Anti-MRSA2, activity value is MIC = 15 ug/ml||Anti-MRSA3, activity value is MIC = 30 ug/ml Australian green tree frog, Litoria splendida; Litoria rothii|||Australian green tree frog, Litoria splendida; Litoria rothii|||Litoria splendida [magnificent tree frog]|||Litoria gilleni [Centralian tree frog]|||Litoria rothii [Roth's tree frog]|||Uperoleia mjobergii [Australian toadlet]|||Litoria raniformis [Australian tree frog]|||Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea)|||Australian green tree frog, Litoria splendida; Litoria rothii|||Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea)|||Litoria splendida [magnificent tree frog]|||Litoria gilleni [Centralian tree frog] Helix||Alpha helix "No hemolytic activity (0% hemolysis at 100 µM)|||The hemolytic values of peptides related to the skin granular gland secretions of African clawed frog (Xenopus) in the document are as follows. The experiment measured the hemolysis rate by adding peptides at different concentrations to a 5% human red blood cell suspension and incubating at 37°C for 30 minutes (100% hemolysis was induced by 0.2% Triton X-100): - At a peptide concentration of 0 μg/ml: Hemolysis rates for Magainin 2, PGLa, XPF, and bee venom peptide Mellitin were all 0%. - At a peptide concentration of 50 μg/ml: Hemolysis rates were 4% for Magainin 2, 4% for PGLa, 1% for XPF, and 100% for bee venom peptide Mellitin. - At a peptide concentration of 100 μg/ml: Hemolysis rates were 3% for Magainin 2, 3% for PGLa, 1% for XPF (bee venom peptide Mellitin was not tested). - At a peptide concentration of 200 μg/ml: Hemolysis rates were 3% for Magainin 2, 4% for PGLa, 2% for XPF (bee venom peptide Mellitin was not tested). - At a peptide concentration of 500 μg/ml: Hemolysis rates were 4% for Magainin 2, 5% for PGLa, 5% for XPF (bee venom peptide Mellitin was not tested). - At a peptide concentration of 1000 μg/ml: Hemolysis rates were 6% for Magainin 2, 7% for PGLa, 6% for XPF (bee venom peptide Mellitin was not tested). Among them, bee venom peptide Mellitin served as the positive control. Magainin 2, PGLa, and XPF, three antimicrobial peptides derived from Xenopus, showed extremely low hemolytic activity, with hemolysis rates still below 8% even at the high concentration of 1000 μg/ml.|||Bacillus cereus ( MIC = 50 ug/ml), Leuconostoc lactis ( MIC = 1.5 ug/ml), Listeria innocua ( MIC = 25 ug/ml) , Micrococcus luteus ( MIC = 12.5 ug/ml), Pasteurella multocida ( MIC = 25 ug/ml), Staphylococcus aureus ( MIC = 3-12 ug/ml), Staphylococcus epidermis ( MIC = 12.5 ug/ml), Streptococcus uberis ( MIC = 12.5 ug/ml); [Refer PubMed ID - 34259550: S. aureus, GDM1.441 (MIC= 15 ug/ml), MRSA, GDM1.1263 (MIC= 30 ug/ml), P. aeruginosa GDM1.443 (MIC= 60 ug/ml), S. hemolyiicus GDM1.245 (MIC= 15 ug/ml), MRSA1 (Clincial isolate) (MIC= 60 ug/ml), MRSA2 (Clincial isolate) (MIC= 15 ug/ml), MRSA3 (Clincial isolate) (MIC= 30 ug/ml)]|||No hemolysis information or data found in the reference(s) presented in this entry" "Eur J Biochem 1997; 247 (2): 545-57|||Wong H, Bowie JH, Carver JA.1997, Australia Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||Eur J Biochem 1997; 247 (2): 545-57|||same ref as AP2008|||10601876, 34259550|||10461748|||28478484|||[Ref.15203252]Gram-positive bacteria: Bacillus cereus (MIC=50 ug/ml), Leuconostoc lactis (MIC=1.5 ug/ml), Listeria innocua (MIC=25 ug/ml), Micrococcus luteus (MIC=12.5 ug/ml), Staphylococcus aureus (MIC=3-12 ug/ml), Staphylococcus epidermis (MIC=12.5 ug/ml), Streptococcus uberis (MIC=12.5 ug/ml); Gram-negative bacterium: Pasteurella multocida (MIC=25 ug/ml). [Ref.16140737]Virus:HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=7.8 uM);inhibition of HIV transfer by dendritic cells to T cells(IC50=12.6 uM)|||Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||J Virol. 2005 Sep;79(18):11598-606.Eur J Biochem. 1997 Jul 15;247(2):545-557.Eur J Biochem. 2003 May;270(9):2068-2081.Peptides. 2004 Jun;25(6):1035-1054.|||10601876, 34259550" 25 FPDB00023 AP00241|||AP00241|||Caerin-1.2|||DRAMP01551|||AP00241|||DRAMP01551 GLLGVLGSVAKHVLPHVVPVIAEHL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||anti-sepsis||Hemolytic||Anticancer||Antibacterial||Antimicrobial Australian frog Litoria caerula|||Australian frog Litoria caerula|||Litoria caerulea [Green tree frog]|||Litoria caerulea (Australian frog)|||Australian frog Litoria caerula|||Litoria caerulea (Australian frog) N/A No hemolytic activity (0% hemolysis at 100 µM)|||No hemolysis information or data found in the reference(s) presented in this entry "J. Chem. Res. 1993; 138: 910-936. PubMed.|||J. Chem. Res. 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Comparative Study J Pept Res . 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Peptides. 2015 Sep;71:296-303.J. Chem. Res. 1993; 138: 910-936.|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Peptides. 2015 Sep;71:296-303.J. Chem. Res. 1993; 138: 910-936." 25 FPDB00024 AP00242|||AP00242|||Caerin-1.3|||DRAMP01552 GLLSVLGSVAQHVLPHVVPVIAEHL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-B. cereus, activity value is MIC = 50 ug/ml||Anti-E. coli, activity value is MIC = 100 ug/ml||Anti-L. lactis, activity value is MIC = 25 ug/ml||Anti-L. innocua, activity value is MIC = 100 ug/ml||Anti-M. luteus, activity value is MIC = 1.5 ug/ml||Anti-P. multocida, activity value is MIC = 25 ug/ml||Anti-S. aureus, activity value is MIC = 100 ug/ml||Anti-S. epidermidis, activity value is MIC = 100 ug/ml||Anti-and S. uberis, activity value is MIC = 100 ug/ml||Antibacterial Australian frog Litoria caerula|||Australian frog Litoria caerula|||Litoria caerulea [Green tree frog]|||Litoria caerulea (Australian frog) N/A No hemolytic activity (0% hemolysis at 100 µM) "J. Chem. Res. 1993; 138: 910-936. PubMed.|||Stone DJ, Waugh RJ, Bowie JH, Wallace JC, Tyler MJ.1993, Australia J. Chem. Res. 1993; 138: 910-936. PubMed.||VanCompernolle et al., 2015|||J. Chem. Res. 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.||VanCompernolle et al., 2015|||Comparative Study J Pept Res . 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.||VanCompernolle et al., 2015|||Gram-positive bacteria: Bacillus cereus (MIC=50 ug/ml), Leuconostoc lactis (MIC=3 ug/ml), Listeria innocua (MIC=50 ug/ml), Micrococcus luteus (MIC=25 ug/ml), Staphylococcus aureus (MIC=6-12 ug/ml), Staphylococcus epidermis (MIC=12 ug/ml), Streptococcus uberis (MIC=25 ug/ml); Gram-negative bacterium: Pasteurella multocida (MIC=50 ug/ml). (Ref.2)|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.||VanCompernolle et al., 2015" 25 FPDB00025 AP00243|||AP00243|||Caerin-1.4|||DRAMP01553 GLLSSLSSVAKHVLPHVVPVIAEHL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||anti-sepsis||Hemolytic||Anticancer||Antibacterial Australian frog Litoria caerula|||Australian frog Litoria caerula|||Litoria gilleni [Centralian tree frog]|||Litoria caerulea [Green tree frog]|||Litoria caerulea (Green tree frog) (also Litoria gilleni) (Centralian tree frog) N/A No hemolytic activity (0% hemolysis at 100 µM) "J. Chem. Res. 1993; 138: 910-936. PubMed.|||J. Chem. Res. 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Comparative Study J Pept Res . 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Gram-positive bacteria: Bacillus cereus (MIC=50 ug/ml), Leuconostoc lactis (MIC=12 ug/ml), Listeria innocua (MIC=100 ug/ml), Micrococcus luteus (MIC=0.4 ug/ml), Staphylococcus aureus (MIC=100 ug/ml), Staphylococcus epidermis (MIC=25 ug/ml), Streptococcus uberis (MIC=100 ug/ml); Gram-negative bacteria: Escherichia coli (MIC=50 ug/ml), Pasteurella multocida (MIC=25 ug/ml). (Ref.2)|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x." 25 FPDB00026 AP00244|||AP00244|||Caerin-1.5|||DRAMP01555|||AP00244|||DRAMP01555 GLLSVLGSVVKHVIPHVVPVIAEHL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-L. lactis, activity value is MIC = 3 ug/ml||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-S. epidermidis, activity value is MIC = 25 ug/ml||Anti-L. innocua and S. uberis, activity value is MIC = 50 ug/ml||Antibacterial||Anti-Bacillus cereus, activity value is MIC = 50 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 3 ug/ml||Anti-Listeria innocua, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Pasteuretla multocida, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 25 ug/ml||Anti-S.aureus ATCC 29213, activity value is MIC = 25 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 25 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 50 ug/ml||Antimicrobial||Anti-Gram+||Anti-Gram- Australian frog Litoria caerula|||Australian frog Litoria caerula|||Litoria caerulea [Green tree frog]|||Litoria caerulea|||Litoria caerulea (Green tree frog)|||Australian frog Litoria caerula|||Litoria caerulea (Green tree frog) N/A No hemolytic activity (0% hemolysis at 100 µM)|||No hemolysis information or data found in the reference(s) presented in this entry "J. Chem. Res. 1993; 138: 910-936. PubMed.|||Stone DJ, Waugh RJ, Bowie JH, Wallace JC, Tyler MJ.1993, Australia J. Chem. Res. 1993; 138: 910-936. PubMed.||VanCompernolle et al., 2015|||J. Chem. Res. 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Comparative Study J Pept Res . 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||15203252|||[Ref.15203252]Gram-positive bacteria: Bacillus cereus (MIC=50 ug/ml), Leuconostoc lactis (MIC=3 ug/ml), Listeria innocua (MIC=50 ug/ml), Micrococcus luteus (MIC=12 ug/ml), Staphylococcus aureus (MIC=25 ug/ml), Staphylococcus epidermis (MIC=25 ug/ml), Streptococcus uberis (MIC=50 ug/ml); Gram-negative bacterium: Pasteurella multocida (MIC=25 ug/ml). [Ref.26026377]Virus:HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=3 uM).|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||Peptides. 2015 Sep;71:296-303.Peptides. 2004 Jun;25(6):1035-1054.J. Chem. Res. 1993; 138: 910-936." 25 FPDB00027 AP00245|||AP00245|||Caerin-1.6|||Caerin 1.6|||Caerin-1.16|||DRAMP01556|||AP00245|||DRAMP01556 GLFSVLGAVAKHVLPHVVPVIAEKL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-B. cereus, activity value is MIC = 100 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 3 uM||Anti-L. innocua, activity value is MIC = 50 ug/ml||Anti-M. luteus, activity value is MIC = 25 ug/ml||Anti-S. aureus ATCC 25923 or 29213, activity value is MIC = 6||Anti-S. epidermidis, activity value is MIC = 12.5 ug/ml||Anti-S. uberis, activity value is MIC = 25 ug/ml||Anti-E.clocae, activity value is MIC > 100 ug/ml||Anti-P. multocida, activity value is MIC = 25 ug/ml||Anti-and P. haemolytica, activity value is MIC = 50 ug/ml||Antibacterial||Antimicrobial skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||Litoria xanthomera [Orange-thighed frog]|||Litoria splendida [magnificent tree frog]|||Litoria rothii [Roth's tree frog]|||Litoria xanthomera (Orange-thighed frog) (Litoria chloris)|||skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||Litoria xanthomera (Orange-thighed frog) (Litoria chloris) N/A No hemolytic activity (0% hemolysis at 100 µM)|||Escherichia coli ( MIC = 50 ug/ml), Leuconostoc lactis ( MIC = 3 ug/ml), Listeria innocua ( MIC = 50 ug/ml) , Micrococcus luteus ( MIC = 25 ug/ml), Pasteurella multocida ( MIC = 25 ug/ml), Staphylococcus aureus ( MIC = 6 ug/ml), Staphylococcus epidermis ( MIC = 12 ug/ml), Streptococcus uberis ( MIC = 25 ug/ml)|||No hemolysis information or data found in the reference(s) presented in this entry "J Pept Sci. 1997 May-Jun;3(3):181-5. PubMed.|||Steinborner ST, Waugh RJ, Bowie JH, Wallace JC, Tyler MJ, Ramsay SL.1997, Australia J Pept Sci. 1997 May-Jun;3(3):181-5. PubMed.||same ref as AP2008||VanCompernolle et al., 2015|||J Pept Sci. 1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.||same ref as AP2008||VanCompernolle et al., 2015|||J Pept Sci . 1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.||same ref as AP2008||VanCompernolle et al., 2015|||9230483|||10601876|||16124032, 19539637|||Peptides. 2015 Sep;71:296-303.J Pept Sci. 1997 May-Jun;3(3):181-185.Rapid Commun Mass Spectrom. 1997;11(9):997-1000.J Pept Res. 1998 Feb;51(2):121-126.|||1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.||same ref as AP2008||VanCompernolle et al., 2015|||J Pept Sci. 1997 May-Jun;3(3):181-185.Rapid Commun Mass Spectrom. 1997;11(9):997-1000.J Pept Res. 1998 Feb;51(2):121-126." 25 FPDB00028 AP00246|||AP00246|||Caerin-1.7|||DRAMP01557|||AP00246|||DRAMP01557 " GLFKVLGSVAKHLLPHVAPVIAEKL" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-B. cereus, activity value is MIC = 100 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 3 uM||Anti-L. innocua, activity value is MIC = 50 ug/ml||Anti-M. luteus, activity value is MIC = 12.5 ug/ml||Anti-S. aureus ATCC 25923 or 29213, activity value is MIC = 12.5||Anti-S. epidermidis, activity value is MIC = 50 ug/ml||Anti-and S. uberis, activity value is MIC = 50 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 3 ug/ml||Anti-Listeria innocua, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Pasteuretla multocida, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12||Anti-S.aureus ATCC 29123, activity value is MIC = 12||Anti-Staphylococcus epidermidis, activity value is MIC = 50 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 50 ug/ml||Antimicrobial||Antibacterial skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||Litoria xanthomera|||Litoria xanthomera (Orange-thighed frog) (Litoria chloris)|||skin secretions, Orange-thighed frog, Litoria xanthomera, Australia|||Litoria xanthomera (Orange-thighed frog) (Litoria chloris) N/A No hemolytic activity (0% hemolysis at 100 µM)|||No hemolysis information or data found in the reference(s) presented in this entry "J Pept Sci. 1997 May-Jun;3(3):181-5. PubMed.|||Steinborner ST, Waugh RJ, Bowie JH, Wallace JC, Tyler MJ, Ramsay SL.1997, Australia J Pept Sci. 1997 May-Jun;3(3):181-5. PubMed.|||J Pept Sci. 1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.|||J Pept Sci . 1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.||VanCompernolle et al., 2015|||15203252|||Peptides. 2015 Sep;71:296-303.J Pept Sci. 1997 May-Jun;3(3):181-185.Rapid Commun Mass Spectrom. 1997;11(9):997-1000.J Pept Res. 1998 Feb;51(2):121-126.|||1997 May-Jun;3(3):181-5. doi: 10.1002/(sici)1099-1387(199705)3:3<181::aid-psc97>3.0.co;2-k.|||Peptides. 2015 Sep;71:296-303.J Pept Sci. 1997 May-Jun;3(3):181-185.Rapid Commun Mass Spectrom. 1997;11(9):997-1000.J Pept Res. 1998 Feb;51(2):121-126." 25 FPDB00029 AP00248 " GLFGVLGSIAKHVLPHVVPVIAEK" Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Antibiofilm||Anticancer||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 12 ug/ml||Anti-L. innocua, activity value is MIC = 25 ug/ml||Anti-S. epidermidis, activity value is MIC = 25 ug/ml||Anti-S. uberis, activity value is MIC = 25 ug/ml||Enzyme inhibitor Blue-thighed frog, Litoria chloris, Australia|||Litoria chloris, Australia N/A No hemolytic activity (0% hemolysis at 100 µM) "J. Pept. Res.1998; 51: 121-126. PubMed.|||Steinborner ST, Currie GJ, Bowie JH, Wallace JC, Tyler MJ.1998, Australia J. Pept. Res.1998; 51: 121-126. PubMed.|||J. Pept. Res.1998; 51: 121-126. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||J. Pept. Res.1998; 51: 121-126. PubMed.|||Comparative Study J Pept Res . 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x." 24 FPDB00030 AP00257|||AP00257|||Caerin-4.1|||AP00257|||DRAMP01574 " GLWQKIKSAAGDLASGIVEGIKS" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-M. luteus, activity value is MIC = 12 ug/ml||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- Green tree frog Litoria caerula, Australia|||Green tree frog Litoria caerula, Australia|||Litoria caerulea [Green tree frog]|||Green tree frog Litoria caerula, Australia|||Litoria caerulea (Green tree frog) Helix No hemolysis information or data found in the reference(s) presented in this entry J. Chem. Res. 1993; 138: 910-936. PubMed.|||J. Chem. Res. 1993; 138: 910-936|||J. Chem. Res. 1993; 138: 910-936|||Peptides. 2004 Jun;25(6):1035-1054.J. Chem. Res. 1993; 138: 910-936. 23 FPDB00031 AP00260|||AP00260|||Maculatin-1.1|||Maculatin 1.1|||Mac1-NH2|||Mac1-OH|||DRAMP01364|||AP00260|||DRAMP01364|||AP00260|||DRAMP01364 " GLFGVLAKVAAHVVPAIAEHF" Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anticancer||Anti-B. cereus, activity value is MIC = 50 ug/ml||Anti-L. lactis, activity value is MIC = 3 ug/ml||Anti-L. innocua, activity value is MIC = 100 ug/ml||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-P. multocida, activity value is MIC = 50 ug/ml||Anti-S. aureus, activity value is MIC = 6||Anti-S. uberis, activity value is MIC = 3 ug/ml||Anti-S. epidermidis, activity value is MIC = 12 ug/ml||Anti-S. faecalis, activity value is MIC = 25 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Antibacterial||Anti-S.aureus, activity value is MIC = 8 uM||activity value is MBC = 37.5 uM||Anti-E.Coli, activity value is MIC = 110 uM||activity value is MBC = 125 uM||Anti-S. aureus ATCC29213, activity value is MIC = 5.4||Anti-E. coli ATCC25922, activity value is MIC = 7.7||Anti-S. aureus ATCC29213, activity value is MIC = 94.2||Anti-E. coli ATCC25922, activity value is MIC = 26.6||Anti-Bacillus cereus, activity value is MIC = 25 ug/ml||Anti-Bacillus cereus, activity value is MIC = 3 ug/ml||Anti-Listeria innocua, activity value is MIC = 100 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 6 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 12 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 3 ug/ml||Anti-Pasteurella multocida, activity value is MIC = 50 ug/ml||Antimicrobial||Anti-Gram+||Anti-Gram- skin secretions, Litoria genimaculate, Litoria eucnemis, Australia|||skin secretions, Litoria genimaculate, Litoria eucnemis, Australia|||Litoria genimaculata [Green-eyed tree frog]|||Litoria raniformis [Australian tree frog]|||Litoria genimaculata (Green-eyed tree frog)|||skin secretions, Litoria genimaculate, Litoria eucnemis, Australia|||Litoria genimaculata (Green-eyed tree frog)|||skin secretions, Litoria genimaculate, Litoria eucnemis, Australia|||Litoria genimaculata (Green-eyed tree frog) Helix||Alpha helix No hemolysis information or data found in the reference(s) presented in this entry "J. Pept. Sci. 1998; 4: 111-115. PubMed.|||Rozek T, Waugh RJ, Steinborner ST, Bowie JH, Tyler MJ, Wallace JC.1998, Australia J. Pept. Sci. 1998; 4: 111-115. PubMed.|||J. Pept. Sci. 1998; 4: 111-115. doi: 10.1002/(sici)1099-1387(199804)4:2<111::aid-psc134>3.0.co;2-8.|||Comparative Study J Pept Sci . 1998 Apr;4(2):111-5. doi: 10.1002/(sici)1099-1387(199804)4:2<111::aid-psc134>3.0.co;2-8.|||9620615|||28478484|||33891157|||J Virol. 2005 Sep;79(18):11598-606.||Ref.15203252||Ref.161407|||16140737||Ref.15203252||Ref.16140737|||J. Pept. Sci. 1998; 4: 111-115. doi: 10.1002/(sici)1099-1387(199804)4:2<111::aid-psc134>3.0.co;2-8.|||Ref.15203252||Ref.16140737|||1998 Apr;4(2):111-5. doi: 10.1002/(sici)1099-1387(199804)4:2<111::aid-psc134>3.0.co;2-8.|||J Virol. 2005 Sep;79(18):11598-606.J Pept Sci. 1998 Apr;4(2):111-115.Peptides. 2004; 25: 1035-1054." 21 FPDB00032 AP00274|||AP00274|||Circulin-A|||DRAMP00877|||DRAMP00878|||Circulin-A|||AP00274|||DRAMP00877|||AP00274|||DRAMP00877 GIPCGESCVWIPCISAALGCSCKNKVCYRN Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-Gram- E.coli, activity value is MIC > 500 uM||Anti-P.aeruginosa, activity value is MIC > 500 uM||Anti-P. vulgaris, activity value is MIC = 54.6 uM||Anti-K.oxytoca, activity value is MIC > 500 uM||Anti-S. aureus, activity value is MIC = 0.19 uM||Anti-M.luteus, activity value is MIC > 500 uM||Anti-C.albicans, activity value is MIC > 500 uM||Anti-C. kefyr, activity value is MIC = 18.6 uM||Anti-and C. tropicalis, activity value is MIC = 19.4 uM||Anti-Proteus.vulgaris, activity value is MIC = 54.6 uM||Anti-C. tropicalis, activity value is MIC = 19.4 uM||Anti-Staphylococcus aureus, activity value is MIC = 0.19 uM||Anti-Staphylococcus aureus, activity value is MIC = 13.5 uM||Anti-15.6). Fungi : Candida kefyr, activity value is MIC = 29 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- Chassalia parviflora Combine Helix and Beta structure||Alpha helix (1 helices; 4 residues)||Beta strand (5 strands; 10 residues) The half-hemolysis concentrations (the concentrations causing 50% hemolysis) of four cyclotides (kalata, circulin A, circulin B, cyclopsychotride) on human erythrocytes are all greater than 400 μM, among which circulin B and cyclopsychotride have relatively higher hemolytic activities, with half-hemolysis concentrations of 550 μM and 405 μM, respectively, while the half-hemolysis concentrations of kalata and circulin A are 1510 μM and 1020 μM, respectively.|||[Ref.10430870] EC50 = 1020 uM against blood type A human erythrocytes.|||[Ref.10430870] EC50 = 1020 uM against blood type A human erythrocytes. "Experientia. 1965 Jun 15;21(6):307-8.PubMed.|||Experientia. 1965 Jun 15;21(6):307-8.doi: 10.1007/BF02144681.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||Experientia . 1965 Jun 15;21(6):307-8. doi: 10.1007/BF02144681.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||10430870|||Biopolymers. 2008;90(1):51-60. doi: 10.1002/bip.20886.||Ref.10430870|||Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8918.||Ref.10430870|||18008336||Ref.10430870||Ref.18008336|||10430870|||Experientia. 1965 Jun 15;21(6):307-8.doi: 10.1007/BF02144681.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||Ref.10430870||Ref.18008336|||. 1965 Jun 15;21(6):307-8. doi: 10.1007/BF02144681.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||Biopolymers. 2008;90(1):51-60. doi: 10.1002/bip.20886.Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8918.J. Mol. Biol. 1999; 285:333-345.Biochem Biophys Res Commun. 1996 Nov 12;228(2):632-8." 30 FPDB00033 AP00275|||AP00275|||Circulin-B|||DRAMP00878|||AP00275|||DRAMP00878|||AP00275|||DRAMP00878 " GVIPCGESCVFIPCISTLLGCSCKNKVCYRN" Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-Gram- E. coli, activity value is MIC = 0.41 uM||Anti-P. aeruginosa, activity value is MIC = 25.5 uM||Anti-P. vulgaris, activity value is MIC = 6.8 uM||Anti-K. oxytoca, activity value is MIC = 8.2 uM||Anti-S. aureus, activity value is MIC = 13.5 uM||Anti-M.luteus, activity value is MIC > 500 uM||Anti-C.albicans, activity value is MIC > 500 uM||Anti-C. kefyr, activity value is MIC = 29 uM||Anti-and C.tropicalis, activity value is MIC > 500 uM||Antibacterial||Anti-Staphylococcus aureus, activity value is MIC = 13.5 uM||Anti-15.6). Fungi : Candida kefyr, activity value is MIC = 29 uM||Anti-H-salt = L-salt supplemented with 100000 uM NaCl. Virus:HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.04||Antimicrobial||Anti-Gram+||Anti-Gram- Chassalia parviflora Beta||Beta strand (5 strands; 10 residues) [Ref.10430870] EC50 = 550 uM against blood type A human erythrocytes. "Experientia. 1968 Jul 15;24(7):656-7. PubMed.|||Experientia. 1968 Jul 15;24(7):656-7. doi: 10.1007/BF02144681.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||Experientia . 1968 Jul 15;24(7):656-7. doi: 10.1007/BF02138292.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||10430870|||10430870||Ref.10430870||Ref.18008336|||Experientia. 1968 Jul 15;24(7):656-7. doi: 10.1007/BF02138292.||See ref AP00729, Tam JP et al. PNAS 96:8913-8||Ireland et al., 2008|||Ref.10430870||Ref.18008336|||1968 Jul 15;24(7):656-7. doi: 10.1007/BF02138292.||See ref AP00729, Tam JP et al. PNAS 96:8913-8|||Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8918.Biopolymers. 2008;90(1):51-60.Biochem Biophys Res Commun. 1996 Nov 12;228(2):632-8. doi: 10.1006/bbrc.1996.1708." 31 FPDB00034 AP00277|||AP00277|||Clavanin-B|||DRAMP02598|||Clavanin-B|||AP00277|||DRAMP02598 " VFQFLGRIIHHVGNFVHGFSHVF" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-L. monocytogenes EGD and C. albicans in radial diffusion assays . Recent microdilution assays revealed that the MIC value was reduced 32 fold against E. faecalis ATCC 29212, activity value is MIC = 8 ug/ml||Anti-while the activity against C. albicans ATCC 10231, activity value is MIC = 64 ug/ml||Antibacterial||Antimicrobial||Antifungal ; E.coli||L.monocytes||C.albicans invertebrate Styela clava|||invertebrate Styela clava|||Styela clava [Sea squirt]|||Styela clava (Sea squirt)|||invertebrate Styela clava|||Styela clava (Sea squirt) Alpha helix N/A "FEBS Lett. 1997; 400:158-162. PubMed.|||FEBS Lett. 1997; 400:158-162. doi: 10.1016/s0014-5793(96)01374-9.||dose dependent, see Fig. 6 in the ref||Miller et al., 2023|||FEBS Lett . 1997 Jan 3;400(2):158-62. doi: 10.1016/s0014-5793(96)01374-9.||dose dependent, see Fig. 6 in the ref||Miller et al., 2023|||9001389|||FEBS Lett. 1997 Jan 3;400(2):158-162.|||9001389|||FEBS Lett. 1997; 400:158-162. doi: 10.1016/s0014-5793(96)01374-9.||dose dependent, see Fig. 6 in the ref||Miller et al., 2023|||FEBS Lett. 1997 Jan 3;400(2):158-162.|||1997 Jan 3;400(2):158-62. doi: 10.1016/s0014-5793(96)01374-9.||dose dependent, see Fig. 6 in the ref||Miller et al., 2023" 23 FPDB00035 AP00283|||AP00283|||HBD3|||DRAMP03599|||AP00283 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Chemotactic||Anti-MRSA||Anti-toxin||Anti-inflammatory||Channel inhibitors||Synergistic AMPs||Antibiofilm||Wound healing||Anticancer||Anti-An inducible human AMP. Active against E. coli DSM1103, activity value is MIC = 9.4 ug/ml||Anti-K. pneumoniae DSM681, activity value is MIC = 25 ug/ml||Anti-P. aeruginosa DSM1128, activity value is MIC = 18.75 ug/ml||Anti-S. aureus ATCC25923 or MRSA, activity value is MIC = 4.7 ug/ml||Anti-and S. pneumoniae DSM11865, activity value is MIC = 4.7 ug/ml||Anti-Escherichia coli DSM1103, activity value is MIC = 9.4 ug/ml||Anti-Klebsiella pneumoniae DSM681, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa DSM1128, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 4.7 ug/ml||Anti-Streptococcus pneumoniae DSM11865, activity value is MIC = 4.7 ug/ml skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens|||skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens|||Synthetic construct|||Homo sapiens (Human)|||skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens Combine Helix and Beta structure||Combine helix and strand structure "Because several cationic antimicrobial peptides have been reported to exhibit cytotoxic activity against eukaryotic cells, hBD-3 was also assayed for hemolytic activity against human erythrocytes. No significant hemolytic activity (,0.5%) was observed using concentrations of hBD-3 up to 500000 ug/ml at physiologic salt concentrations. However, significant hemolytic activity was seen at high hBD-3 concentrations in 10000 uM so-dium phosphate buffer containing 340000 uM sucrose|||Strong hemolytic activity (100% hemolysis at 10 μM)|||The document explicitly mentions the hemolytic values of human β-defensin 3 (hBD-3), with specific information as follows: 1. Under physiological saline conditions (phosphate-buffered saline, PBS): When the concentration of hBD-3 reaches as high as 500 µg/ml, the hemolysis rate of human red blood cells is still **<0.5%**, showing no significant hemolytic activity. 2. In a specific buffer (10000 µM sodium phosphate buffer containing 340,000 µM sucrose, pH 7.4): Significant hemolytic activity is only observed under high concentrations of hBD-3 (the specific concentration is not clearly marked as a fixed threshold and should be interpreted as far above physiologically relevant concentrations in the experimental context). These results indicate that hBD-3 exhibits almost no hemolytic toxicity to human red blood cells under physiological saline conditions and only shows hemolytic activity at non-physiological high concentrations and in specific buffer systems, reflecting good biocompatibility.|||The document explicitly mentions the hemolytic values of human β-defensin 3 (hBD-3), as follows: 1. Under physiological saline conditions (phosphate-buffered saline, PBS) Even when the concentration of hBD-3 reaches 500 µg/ml, the hemolysis rate of human red blood cells remains **<0.5%**, showing no significant hemolytic activity. 2. Hypotonic buffer containing 340,000 µM sucrose (10,000 µM sodium phosphate buffer, pH 7.4) Significant hemolytic activity is observed only at relatively high concentrations of hBD-3, but this condition is a non-physiological hypotonic environment that does not correspond to in vivo physiological conditions. These results indicate that hBD-3 exhibits no obvious cytotoxicity to eukaryotic cells (red blood cells) at physiologically relevant concentrations, and the risk of hemolysis is extremely low.|||At physiological salt concentrations, hBD-3 at concentrations up to 500 ug/ml did not exhibit significant hemolytic activity (<0.5%); however, in 10000 uM sodium phosphate buffer containing 340000 uM sucrose, hBD-3 at high concentrations had significant hemolytic activity (specific values not clear)." "J. Biol. Chem. 2001; 276:5707-5713|||Harder J, Bartels J, Christophers E, Schroeder JM.2001 J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315|||J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315|||J. Biol. Chem. 2001; 276:5707-5713|||ref see AP1315|||J Biol Chem. 2001 Feb 23;276(8):5707-5713.||Ref.11085990|||J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315" 45 FPDB00036 AP00310|||AP00310|||LL-37|||LL-37|||AP00310 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Spermicidal||Anti-HIV||Chemotactic||Anti-MRSA||Enzyme inhibitor||anti-TB||anti-sepsis||Synergistic AMPs||Hemolytic||Antibiofilm||Wound healing||Anticancer||Anti-L. monocytogenes EGD, activity value is MIC = 1.5 ug/ml||Antibacterial||Anti-S. aureusNCTC 6571, activity value is MIC = 19.3||Anti-E. coli ATCC 25922, activity value is MIC = 9.8||Anti-27367675: E.coli K88, activity value is MIC = 61||Anti-E.coli CVCC245, activity value is MIC = 61||Anti-S.aureus CVCC 26003, activity value is MIC = 36||Anti-S.aureus ATCC 25923, activity value is MIC = 58||Anti-Listeria monocytogene CVCC 1599, activity value is MIC = 13||Anti-Micrococcus luteus CVCC 28001, activity value is MIC = 90||Anti-A. baumannii ATCC 19606, activity value is MIC = 4 ug/ml||Anti-29022391 : S. mutans, activity value is MIC = 250 ug/ml||Anti-A. israelii, activity value is MIC = 7.81 ug/ml||Anti-E. faecalis, activity value is MIC = 2000 ug/ml||Anti-31417238: Streptococcus agalactiae NEM 316, activity value is MIC = 90||Anti-C-terminal:COOH): A. baumannii 6043, activity value is MIC = 14.2 uM||Anti-P. aeruginosa ATCC 19660, activity value is MIC = 28.5 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 28.5 uM||Anti-28649410: P. aeruginosa ATCC 9027, activity value is EC50 = 0.525 uM||Anti-P. aeruginosa PAO1 (pTDKGFP, activity value is EC50 = 0.599 uM||Anti-F. novicida U112, activity value is EC50 = 0.0534 uM||Anti-B. thailandensis E264, activity value is EC50 = 1.88 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 0.552 uM||Anti-31016971: Staphylococcus aureus SA113 WT, activity value is MIC = 256 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 256 uM gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||Homo sapiens|||Homo sapiens [Human]|||Homo sapiens [Human]|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes Helix Moderate hemolytic activity (60% hemolysis at 50 μM)|||hRBC (4.47 (±0.35)% hemolysis at 175 ug/ml), Sheep RBC (HC₅₀=32 ± 0.68 ug/ml)|||hRBC (4.47 (±0.35)% hemolysis at 175 ug/ml), Sheep RBC = (HC50=32 ± 0.68 ug/ml) "Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. T.1996 Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||Eur J Biochem . 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||28476579|||28408902, 30076860, 28400226, 27367675, 30076864, 30043322, 29022391, 31417238, 31396193, 31016971|||35254120|||28408902, 30076860, 28400226, 27367675, 30076864, 30043322, 29022391, 31417238, 31396193, 31016971||Refer 30076860||Refer PubMed ID: 30076864||Refer PubMed ID: 30043322|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed" 37 FPDB00037 AP00325|||AP00325|||Uperin 3.6|||DRAMP20797 GVIDAAKKVVNVLKNLF Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-L. lactis, activity value is MIC = 3 ug/ml||Anti-S. uberis, activity value is MIC = 12.5 ug/ml||Anti-S. epidermidis, activity value is MIC = 12.5 ug/ml||Anti-B. cereus, activity value is MIC = 25 ug/ml||Anti-S. aureus, activity value is MIC = 25 ug/ml||Anti-P.multocida, activity value is MIC > 100 ug/ml||Anti-M. luteus, activity value is MIC = 25 ug/ml||Anti-and L. innocua, activity value is MIC = 50 ug/ml||Anti-Bacillus cereus, activity value is MIC = 25 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 3 ug/ml||Anti-Listeria innocua, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 50 ug/ml||Anti-Pasteurella haemolytica, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 25 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 12 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 12 ug/ml||Anti-##Gram-negative bacterium: Pasteurella haemolytica, activity value is MIC = 25 ug/ml Floodplain toadlet Uperoleia inundata, Australia|||Floodplain toadlet Uperoleia inundata, Australia|||Uperoleia mjobergii [Australian toadlet]|||Uperoleia mjobergii (Australian toadlet)|||Floodplain toadlet Uperoleia inundata, Australia Helix||Alpha helix No hemolysis information or data found in the reference(s) presented in this entry Aust. J. Chem. 1996; 49:475-484. Publiser|||Aust. J. Chem. 1996; 49:475-484.|||Aust. J. Chem. 1996; 49:475-484. Publiser|||10461748|||J Pept Res. 1999 Aug;54(2):137-45.||Ref.10461748 17 FPDB00038 AP00327|||AP00327|||Uperin-7.1|||DRAMP01161|||AP00327|||DRAMP01161 GWFDVVKHIASAV Anti-Gram+||Antiviral||Anti-HIV||Antibacterial||Antimicrobial Brown tree frog Litoria ewingi, Australia|||Brown tree frog Litoria ewingi, Australia|||Litoria ewingii [Brown tree frog]|||Litoria ewingi (Brown tree frog) (Ewing's tree frog)|||Brown tree frog Litoria ewingi, Australia|||Litoria ewingi (Brown tree frog) (Ewing's tree frog) N/A No hemolysis information or data found in the reference(s) presented in this entry Aust. J. Chem. 1997; 50:889-894|||Aust. J. Chem. 1997; 50:889-894.|||Aust. J. Chem. 1997; 50:889-894|||Aust. J. Chem. 1997; 50:889-894. 13 FPDB00039 AP00345|||AP00345|||Caerin-1.10|||AP00345|||DRAMP01577 GLLSVLGSVAKHVLPHVVPVIAEKL Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anticancer||Anti-a minor component that is not present in the glandular secretion of the female. Activity against B.cereus, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 6 uM||Anti-L. innocua, activity value is MIC = 50 ug/ml||Anti-M. luteus, activity value is MIC = 25 ug/ml||Anti-or 29213, activity value is MIC > 100 ug/ml||Anti-S. epidermidis, activity value is MIC = 100 ug/ml||Anti-S. uberis, activity value is MIC = 50 ug/ml||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- Magnificent tree frog, Litoria splendida, Australia|||Magnificent tree frog, Litoria splendida, Australia|||Litoria splendida [magnificent tree frog]|||Litoria rothii [Roth's tree frog]|||Magnificent tree frog, Litoria splendida, Australia|||Litoria rothii (Roth's tree frog); also Litoria splendida (Magnificent tree frog) N/A No hemolytic activity (0% hemolysis at 100 µM)|||L. lactis ( MIC = 6 ug/ml ), L. innocua ( MIC = 50 ug/ml ), M. luteus ( MIC = 25 ug/ml ), S. uberis ( MIC = 50 ug/ml ) , P. multocida ( MIC = 100 ug/ml ), S. epidermidis ( MIC = 100 ug/ml )|||No hemolysis information or data found in the reference(s) presented in this entry "Eur. J. Biochem. 2000; 267:269-275|||Wabnitz PA., Bowie JH, Tyler MJ, Wallace JC.2000, Australia Eur. J. Biochem. 2000; 267:269-275||same ref as AP2008||VanCompernolle et al., 2015|||Eur. J. Biochem. 2000; 267:269-275|||10601876|||16124032, 19539637|||Eur. J. Biochem. 2000; 267:269-275|||Peptides. 2015 Sep;71:296-303.Rapid Commun Mass Spectrom. 2005;19(18):2716-2724.Eur J Biochem. 2000 Jan;267(1):269-275." 25 FPDB00040 AP00355|||DRAMP00341|||Ginkbilobin|||AP00355|||DRAMP00341|||AP00355|||DRAMP00341 ANTAFVSSAHNTQKIPAGAPFNRNLRAMLADLRQNAAFAG Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- seeds, Ginkgo biloba, Asia|||Ginkgo biloba (Ginkgo) (Maidenhair tree)|||Ginkgo biloba [Ginkgo]|||seeds, Ginkgo biloba, Asia|||Ginkgo biloba (Ginkgo) (Maidenhair tree)|||seeds, Ginkgo biloba, Asia|||Ginkgo biloba (Ginkgo) (Maidenhair tree) N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem. Biophys. Res. Commun. 2000; 279:407-411|||Biochem Biophys Res Commun. 2000 Dec 20;279(2):407-411.|||11118300|||Biochem. Biophys. Res. Commun. 2000; 279:407-411|||Biochem Biophys Res Commun. 2000 Dec 20;279(2):407-411.|||Biochem. Biophys. Res. Commun. 2000; 279:407-411|||Biochem Biophys Res Commun. 2000 Dec 20;279(2):407-411. 40 FPDB00041 AP00384|||AP00384|||Ponericin-L2|||DRAMP02761|||AP00384|||DRAMP02761 LLKELWTKIKGAGKAVLGKIKGLL "Anti-Gram+ & Gram-||Antiviral||Insecticidal||Anti-HIV||Anti-MRSA||Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 1.4 uM||Antibacterial||Gram-positive bacteria: Bacillus cereus CIP 6624a(Inhibition zone = 6.5mm)||B. megaterium ATCC 9885b(Inhibition zone = 14mm)||B. stearothermophilus CIP 675(Inhibition zone = 21mm)||B. subtilis ATCC 6623(Inhibition zone = 13.5mm)||Enterococcus faecalis CIP 636(Inhibition zone = 4mm)||Lactococcus lactis ssp. cremoris I116(Inhibition zone = 15.5mm)||Streptococcus pyogenes CIP 561(Inhibition zone = 12.5mm)||S. sanguinis CIP 55128(Inhibition zone = 6mm)||Listeria ivanovii LMA 94d(Inhibition zone = 9.5mm)||Listeria monocytogenes ATCC 15313(Inhibition zone = 9.5mm)||Micrococcus luteus CIP 5345(Inhibition zone = 10.5mm)||Staphylococcus aureus CIP 677(Inhibition zone = 4.5mm)||Staphylococcus aureus LMA(Inhibition zone = 11mm)||S. epidermidis CIP 53134(Inhibition zone = 11.5mm); Gram-negative bacteria: Escherichia coli(Inhibition zone = 4mm)||Enterobacter cloacae CIP 6085(Inhibition zone = 5mm)||Klebsiella pneumoniae CIP 8291(Inhibition zone = 3.5mm)||Proteus mirabilis LMA TP(Inhibition zone = 9mm)||Salmonella enterica CIP 813(Inhibition zone = 1.5mm)||Serratia marcescens LMA TP(Inhibition zone = 9mm)||Flavobacterium meningosepticum CIP 6057(Inhibition zone = 7mm)||Pseudomonas aeruginosa CIP A22(Inhibition zone = 14mm).||Antimicrobial||Anti-Gram+||Anti-Gram-" ants, Pachycondyla goeldii|||ants, Pachycondyla goeldii|||Pachycondyla goeldii [Ponerine ant]|||Pachycondyla goeldii (Ponerine ant)|||ants, Pachycondyla goeldii|||Pachycondyla goeldii (Ponerine ant) Helix||Alpha helix "Weak hemolytic activity (20% hemolysis at 100 μM)|||The document explicitly mentions hemolytic data of 10 synthetic ponericin peptides (and crude venom) from Pachycondyla goeldii on sheep and horse erythrocytes. The core information is as follows (all tested concentrations were 400–500 µM, activity measured by hemolytic zone diameter, ""none"" means no hemolytic effect detected): 1. Hemolytic activity of crude venom Caused complete hemolysis for both sheep and horse erythrocytes (specific hemolytic zone diameters not mentioned, only ""total lysis"" explicitly stated). 2. Hemolytic activity of each ponericin peptide family (classified by family) (1) Ponericin G family (G1, G3, G4, G6) No hemolytic activity: none of the 4 peptides (G1, G3, G4, G6) exhibited hemolysis against sheep or horse erythrocytes (marked as ""none"" or no hemolytic zone diameter in Table I). (2) Ponericin W family (W1, W3-desK, W4, W5, W6) This family is the only one showing hemolytic activity, with horse erythrocytes being more sensitive than sheep erythrocytes: W1, W5, W6: Caused complete hemolysis for both sheep and horse erythrocytes (no specific diameters, text explicitly states ""total lysis of both horse and sheep erythrocytes""). W3-desK: Hemolytic activity only against horse erythrocytes, none against sheep erythrocytes (no data for sheep in Table I; hemolytic activity shown for horse erythrocytes). W4: Hemolytic activity only against horse erythrocytes, none against sheep erythrocytes (same trend as W3-desK). (3) Ponericin L family (L2) No hemolytic activity: no hemolysis detected against sheep or horse erythrocytes (no hemolytic zone diameter in Table I, text explicitly states ""no hemolytic action was found for L2""). Additional notes Detection method: Blood agar plate assay. Wells were punched into agar containing sheep or horse erythrocytes, 0.02 ml peptide solution added, incubated overnight at 4 °C, then left at room temperature for 24 h, and the diameter of complete hemolysis zones measured; absence of a hemolytic zone was considered as no hemolytic activity. Species differences: All hemolytically active peptides (all from the W family) exhibited stronger hemolysis against horse erythrocytes, while sheep erythrocytes were more resistant to these peptides. This is related to species-specific differences in red blood cell membrane composition.|||Hemolysis experiment of horse and sheep red blood cells: At concentrations of 400-500 μM, the crude toxin and three synthetic peptides (W1, W5, W6) can cause complete hemolysis of horse and sheep red blood cells; W3-desK and W4 only exhibit hemolytic activity against horse red blood cells, with no obvious effect on sheep red blood cells; the remaining five synthetic peptides (G1, G3, G4, G6, L11) did not show hemolytic activity. However, the document did not specify the exact hemolysis rate values, only describing whether hemolysis occurred and the range of hemolysis.|||[Ref.11279030]Not found|||The document mentions hemolytic data of ponericins on horse and sheep red blood cells, as follows: - Whole venom: hemolysis ring diameter of 6 mm for horse red blood cells, 3 mm for sheep red blood cells. - Ponericin W1: causes complete hemolysis on both horse and sheep red blood cells (specific diameter not specified). - Ponericin W5: causes complete hemolysis on both horse and sheep red blood cells (specific diameter not specified). - Ponericin W6: hemolysis ring diameter of 4 mm for horse red blood cells, 1.5 mm for sheep red blood cells. - Ponericin W3-desK: hemolytic effect only on horse red blood cells, hemolysis ring diameter of 2 mm; no hemolytic effect on sheep red blood cells. - Ponericin W4: hemolytic effect only on horse red blood cells, hemolysis ring diameter of 2 mm; no hemolytic effect on sheep red blood cells. - Ponericin G1, G3, G4, G6, L2: no hemolytic effect. All the above data were measured at peptide concentrations of 400–500 μM, with hemolysis ring diameters in millimeters (mm).|||[Ref.11279030]Not found" "J. Biol. Chem. 2001; 276: 17823-17829. PubMed.|||J. Biol. Chem. 2001; 276: 17823-17829. doi: 10.1074/jbc.M100216200. Epub 2001 Feb 22.|||J Biol Chem . 2001 May 25;276(21):17823-9. doi: 10.1074/jbc.M100216200. Epub 2001 Feb 22|||11279030|||Ref.11279030|||J. Biol. Chem. 2001; 276: 17823-17829.|||J. Biol. Chem. 2001; 276: 17823-17829. PubMed.|||J. Biol. Chem. 2001; 276: 17823-17829." 24 FPDB00042 AP00399|||AP00399|||Spinigerin|||DRAMP03181|||AP00399 HVDKKVADKVLLLKQLRIMRLLTRL Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-Bacillus megaterium, activity value is MIC = 0.8||Anti-Micrococcus luteus, activity value is MIC = 0.8||Anti-Escherichia coli SBS 363, activity value is MIC = 3||Anti-Escherichia coli D22, activity value is MIC = 3||Anti-Klebsiella pneumoniae, activity value is MIC = 50||Anti-Salmonella typhimurium, activity value is MIC = 3||Anti-Pseudomonas aeruginosa, activity value is MIC = 50||Anti-Trichoderma viride, activity value is MIC = 1.5||Anti-Neurospora crassa, activity value is MIC = 3||Anti-Neurospora crassa, activity value is MIC = 6||Anti-Fusarium culmorum, activity value is MIC = 1.5||Anti-Fusarium haematococcum, activity value is MIC = 0.4||Anti-Candida albicans, activity value is MIC = 3||Anti-Staphylococcus aureus USA 300, activity value is MIC > 81 uM||Anti-Escherichia coli K-12, activity value is MIC > 81 uM||Anti-Escherichia coli KCTC 1682, activity value is MIC = 16 uM||Anti-Salmonella typhimurium KCTC 1926, activity value is MIC = 32 uM||Anti-Pseudomonas aeruginosa KCTC 1637, activity value is MIC = 16 uM||Anti-Bacillus subtilis KCTC 3068, activity value is MIC = 2 uM||Anti-Staphylococcus epidermidis KCTC 1917, activity value is MIC = 8 uM||Anti-Staphylococcus aureus KCTC 1916, activity value is MIC = 8 uM||Anti-Bacillus subtilis ATCC 9372, activity value is MIC = 16||Anti-Bacillus anthracis Sterne 34F2, activity value is MIC = 35||Anti-Burkholderia thailandensis, activity value is MIC > 50 uM||Anti-Escherichia coli SBS363, activity value is MIC = 3||Anti-E. coli D22, activity value is MIC = 3||Anti-Nectria haematococca, activity value is MIC = 0.4 termite, Pseudacanthotermes spiniger|||termite, Pseudacanthotermes spiniger|||Pseudacanthotermes spiniger|||Pseudacanthotermes spiniger (Termite)|||termite, Pseudacanthotermes spiniger Helix||Alpha helix No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% Cell death at >33.3 uM, Human erythrocytes (1% Hemolysis at 6.3 uM J. Biol. Chem. 2001; 276:4085-4092|||J. Biol. Chem. 2001; 276:4085-4092|||20692130, 12963031|||Biopolymers. 2006 Feb 5;81(2):92-103.|||J. Biol. Chem. 2001; 276:4085-4092 25 FPDB00043 AP00405|||AP00405|||Ranatuerin-6|||AP00405|||DRAMP02233 FISAIASMLGKFL Anti-Gram+||Antiviral||Anti-HIV||Anti-S.aureus, activity value is MIC = 100 uM||Antimicrobial||Antibacterial Rana catesbeiana, North America|||Rana catesbeiana, North America|||Rana catesbeiana [American bullfrog]|||Rana catesbeiana, North America|||Lithobates catesbeiana (American bullfrog) (Rana catesbeiana) N/A "The document clearly states that at a concentration of 20 µg/ml, the tested ranatuerins 1-9 showed no detectable hemolytic activity on human red blood cells.|||ranatuerins information about the hemolysis of human red blood cells is mentioned in the document: None of ranatuerins 1-9 exhibited detectable hemolytic activity against human erythrocytes at a concentration of 20 ug/ml. The results showed that these antimicrobial peptides had no significant destructive effect on human red blood cells at the tested concentrations, reflecting a certain degree of biological safety.|||No hemolysis information or data found in the reference(s) presented in this entry" "Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. doi: 10.1006/bbrc.1998.9362.|||Biochem Biophys Res Commun . 1998 Sep 29;250(3):589-92. doi: 10.1006/bbrc.1998.9362.|||9784389|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem Biophys Res Commun. 1998 Sep 29;250(3):589-592." 13 FPDB00044 AP00408|||AP00408|||CAMPSQ432|||AP00408|||DRAMP02236 FLFPLITSFLSKVL Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus or MRSA, activity value is MIC = 50 uM||Anti-S.aureus, activity value is MIC = 130 uM||Antimicrobial||Antibacterial Rana catesbeiana, North America|||Rana catesbeiana, North America|||Rana catesbeiana [American bullfrog]|||Rana catesbeiana, North America|||Lithobates catesbeiana (American bullfrog) (Rana catesbeiana) N/A "The document only mentions one hemolysis-related test result, with the key information as follows: Hemolysis of Ranatuerins 1-9 All nine ranatuerin peptides (ranatuerin 1-9) isolated from the skin of American bullfrogs (Rana catesbeiana) showed no detectable hemolytic activity towards human erythrocytes at a concentration of 20 μg/ml (the text explicitly states: “showed no detectable hemolytic activity towards human erythrocytes”). The document does not provide hemolysis data at other concentrations, nor does it mention hemolysis test results for erythrocytes of other species (such as sheep or horses).|||1|||The document mentions information related to the hemolytic activity of ranatuerins on human red blood cells: Ranatuerins 1-9 showed no detectable hemolytic activity on human red blood cells at a concentration of 20 µg/ml. These results indicate that these antimicrobial peptides do not cause significant damage to human red blood cells at the tested concentration, demonstrating a certain level of biosafety.|||No hemolysis information or data found in the reference(s) presented in this entry" "Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. doi: 10.1006/bbrc.1998.9362.|||Biochem Biophys Res Commun . 1998 Sep 29;250(3):589-92. doi: 10.1006/bbrc.1998.9362.|||9784389|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem Biophys Res Commun. 1998 Sep 29;250(3):589-592." 14 FPDB00045 AP00445|||AP00445|||RTD-1|||DRAMP02642|||AP00445|||DRAMP02642|||AP00445|||DRAMP02642 GFCRCLCRRGVCRCICTR Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Anti-toxin||Enzyme inhibitor||Active against S. aureus 502a or MRSA||L. monocytogenes||E. coli ML 35||S. typhimurium||C. albicans 16820||and C. neoformans. Theta-defensins are particularly important for antifungal activity of the granule extracts as alpha-defensins are poorly active (Tongaonkar P et al 2011 J Leuko Biol 89||283-90). It is also active against HIV-1. RTD-1 inhibits human Papillomavirus (hrHPV||nonenvelope DNA virus) infection through a mechanism involving capsid clustering that inhibits virions from binding to cell surface receptor complexes .||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- leukocytes, Rhesus Macaque (Macaca mulatta)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta [Rhesus macaque]|||Macaca mulatta (Rhesus macaque)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus macaque)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus macaque) Beta||Beta strand (4 strands; 10 residues) Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry Science. 1999 Oct 15;286(5439):498-502|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||11675394|||Science. 1999 Oct 15;286(5439):498-502.|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||Science. 1999 Oct 15;286(5439):498-502.J Leukoc Biol. 2001 Sep;70(3):461-464.J Biol Chem. 2002 Feb 1;277(5):3079-3084.|||Science. 1999 Oct 15;286(5439):498-502|||Science. 1999 Oct 15;286(5439):498-502. 18 FPDB00046 AP00449|||AP00449|||Alpha-MSH|||Alpha-MSH|||AP00449|||DRAMP02876 SYSMEHFRWGKPV "Anti-Gram+||Antiviral||Antifungal||candidacidal||Anti-HIV||Antibacterial||Gram-positive bacterium: Staphylococcus aureus. Yeast: Candida albicans.||Antimicrobial" Brain, Homo sapiens|||Brain, Homo sapiens|||Homo sapiens [Human]|||Homo sapiens [Human]|||Brain, Homo sapiens|||Bos taurus (Bovine) N/A "The document provides hemolytic values for some peptide compounds, as follows: - DNal: Hemolysis rate is 7% ± 2.1% at a concentration of 100 μM. - Peptide 3: Hemolysis rate is 23% ± 0.1% at a concentration of 100 μM. - Peptide 4: Hemolysis rate is 30% ± 0.2% at a concentration of 100 μM. - Peptide 8: Hemolysis rate is 24% ± 0.4% at a concentration of 100 μM. - Peptide 9: Hemolysis rate is 49% ± 4.1% at a concentration of 100 μM. - Peptide 10: Hemolysis rate is 34% ± 1% at a concentration of 100 μM. These data indicate that different peptide compounds have varying hemolytic effects on red blood cells at different concentrations. Some peptides show certain hemolytic activity at higher concentrations, but the overall hemolysis rate is relatively low, suggesting a certain safety potential." J Leukoc Biol 2000; 67(2): 233-9|||J Leukoc Biol 2000; 67(2): 233-9|||10670585|||10670585|||J Leukoc Biol 2000; 67(2): 233-9|||J Leukoc Biol 2000; 67(2): 233-239. 13 FPDB00047 AP00451|||AP00451|||HBD1|||DRAMP02722 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-toxin||Channel inhibitors||Synergistic AMPs||Anticancer||While the reduced form is active against both Gram+ and Gram- bacteria||the oxidized form is only active against Gram- bacteria with little effect on cell envelope . Interestingly||it inhibits the growth of clinical S. aureus strains but NOT lab strains. It was observed that hBD-1 from human platelets can cluster bacteria and signals NETs formation .||Antimicrobial||Antibacterial airway, hemofiltrates, urine, kidney; keratinocytes; skin; platelets; oral saliva; milk, mammary gland epithelium, colonic mucosa, Homo sapiens|||airway, hemofiltrates, urine, kidney; keratinocytes; skin; platelets; oral saliva; milk, mammary gland epithelium, colonic mucosa, Homo sapiens|||Synthetic construct Combine Helix and Beta structure Moderate hemolytic activity (50% hemolysis at 50 µM) "FEBS Lett. 1995 Jul 17;368(2):331-5. PubMed|||Bensch KW, Raida M, Mägert HJ, Schulz-Knappe P, Forssmann WG.1995 FEBS Lett. 1995 Jul 17;368(2):331-5. PubMed||Raschig J et al., 2017||Kraemer BF et al. 2011 PLoS Pathog Nov 7|||1995 Jul 17;368(2):331-5. doi: 10.1016/0014-5793(95)00687-5.||Raschig J et al., 2017||Kraemer BF et al. 2011 PLoS Pathog Nov 7|||FEBS Lett. 1995 Jul 17;368(2):331-5. doi: 10.1016/0014-5793(95)00687-5.||Raschig J et al., 2017||Kraemer BF et al. 2011 PLoS Pathog Nov 7|||FEBS Lett . 1995 Jul 17;368(2):331-5. doi: 10.1016/0014-5793(95)00687-5.||Raschig J et al., 2017||Kraemer BF et al. 2011 PLoS Pathog Nov 7|||FEBS Lett. 1995 Jul 17;368(2):331-5. PubMed||Raschig J et al., 2017||Kraemer BF et al. 2011 PLoS Pathog Nov 7|||Pongo pygmaeus (Bornean orangutan)||Immunogenetics. 2002 Feb;53(10-11):907-913.Submitted (NOV-2006) to the EMBL/GenBank/DDBJ databases.|||FEBS Lett. 1995 Jul 17;368(2):331-5. PubMed" 36 FPDB00048 AP00473|||AP00473|||Piscidins p1|||Piscidin-1|||Moronecidin|||DRAMP02330|||AP00473|||AP00473|||Piscidin-1 FFHHIFRGIVHVGKTIHRLVTG Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Hemolytic||Anticancer||Anti-E. coli, activity value is MIC = 12.5 uM||Anti-P. aeruginosa, activity value is MIC = 50 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and S. aureus USA300 or MRSA, activity value is MIC = 1||Antibacterial||Anti-Enterococcus faecalis VRE, activity value is MIC = 5||Anti-E. faecalis, activity value is MIC = 2.5||Anti-Listeria monocytogenes, activity value is MIC = 2.5||Anti-Micrococcus luteus, activity value is MIC = 10||Anti-Staphylococcus aureus MRSA, activity value is MIC = 1.25||Anti-S. epidermitis, activity value is MIC = 5||Anti-S. saprophiticus, activity value is MIC = 5||Anti-Staphylococcus xylosus, activity value is MIC > 20 uM||Anti-S. agalactiae, activity value is MIC = 1.25||Anti-S. bovis, activity value is MIC = 1.25||Anti-S. equisimilis, activity value is MIC = 2.5||Anti-S. mitis, activity value is MIC = 1.25||Anti-S. Pneumonae, activity value is MIC = 1.25||Anti-S. pyrogenes, activity value is MIC = 1.25||Anti-Streptococcus iniae KST740 ak, activity value is MIC = 1.25||Anti-S. iniae KSTSi 6P, activity value is MIC = 1.25||Anti-Aeromonas hydrophila, activity value is MIC > 20 uM||Anti-Burkholderia cepacia, activity value is MIC > 20 uM||Anti-Vibrio Cholera, activity value is MIC = 2.5||Anti-Escherichia coli, activity value is MIC = 5||Anti-Enterobacter cloacae, activity value is MIC = 10||Anti-E. Aerogenes, activity value is MIC = 10||Anti-Klebsiella pneumoniae, activity value is MIC = 2.5||Anti-K. oxytoca, activity value is MIC = 5||Anti-Salmonella choleraesuis, activity value is MIC = 10||Anti-S. typhimurium, activity value is MIC = 10||Anti-S. arizonae, activity value is MIC = 10||Anti-Serratia marcescens, activity value is MIC > 20 uM||Anti-Shigella flexneri, activity value is MIC = 2.5||Anti-S. sonnei, activity value is MIC = 5||Anti-Yersinia enterocolitica, activity value is MIC = 2.5||Anti-Neurospora crassa, activity value is MIC = 1.56||Anti-A. fumigatus, activity value is MIC = 50||Anti-F. axysporum, activity value is MIC = 0.78||Anti-F. culmorum, activity value is MIC = 0.39||Anti-C. ablicans, activity value is MIC = 10||Anti-C. glabrata, activity value is MIC = 10||Anti-C. lusitania, activity value is MIC = 10||Anti-C. tropacalis, activity value is MIC = 10||Anti-Escherichia coli, activity value is MIC = 3.1 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 25 ug/ml||Anti-Clinical strain of colistin-resistant A. baumannii, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 1.5 ug/ml||Anti-Clinical strain of methicillin resistant Staphylococcus aureus, activity value is MIC = 3.1 ug/ml mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||Hybrid striped bass|||Morone chrysops x Morone saxatilis|||Lates calcarifer [Asian sea bass]|||Morone saxatilis (Striped bass)|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||Morone chrysops x Morone saxatilis Helix "The document provides information on the hemolytic properties of piscidins (fish-derived antimicrobial peptide) only through the hemolytic activity comparison curve (Figure 1c), without clearly indicating a specific 50% hemolytic concentration (HC₅₀) value. The core comparison results are as follows: 1. Trends in Hemolytic Activity of Major Peptides (Testing Human Red Blood Cells) piscidins (P1, P2, P3): Hemolytic activity increases with concentration, all higher than the antibacterial peptide magainin 2 but lower than the metin peptide mellitin (mellitin has weaker antibacterial activity but stronger hemolytic activity). Among them, piscidin 3 is the member with the lowest hemolytic activity in the piscidin family, and its structure is speculated to be related — histidine (His) at position 17 is replaced by glycine (Gly), disrupting amphiphilic α-helix structure, reducing amphiphilic activity, and thereby weakening hemolytic ability. Magainin 2 (control, sourced from the clawed toad): At the same concentration, hemolytic rates were significantly lower than all piscidins. mellitin (control, source of bee venom): At the same concentration, its hemolytic rate is significantly higher than all piscidins, making it the peptide with the strongest hemolytic activity among the three. 2. Key Points The document only shows relative hemolysis capacity using the ""concentration-hemolysis rate"" curve (horizontal axis 1-1000 μg/ml, vertical axis 0%-100%), without providing precise hemolysis rate values corresponding to specific concentrations (such as hemolysis percentage at a certain concentration), nor calculating and recording HC₅₀ (the peptide concentration causing 50% hemolysis of red blood cells) as a core quantitative indicator.|||The document provides some hemolytic values, as follows: - Piscidins 1-3: At concentrations of 1-1000 μg/ml, there are differences in hemolysis rates on human red blood cells. Among them, piscidin 3 has a relatively lower hemolysis rate, which may be related to the substitution of histidine at position 17 in its structure with glycine, disrupting the amphipathic α-helix structure. - Magainin 2: The hemolytic activity is lower than that of piscidins, and the hemolysis rate is relatively low within the same concentration range. - Melittin: The hemolytic activity is relatively strong, with a higher hemolysis rate at higher concentrations, but its antibacterial activity is comparatively weaker. These data indicate that the hemolytic activity of different peptide antibiotics is closely related to structural features, and the integrity of the amphipathic α-helix may be an important factor affecting hemolytic activity.|||Human RBCs (100% hemolysis at 100 ug/ml)|||human RBC ( 57 ug/ml)|||In Document 10 (NATURE 2001), piscidin family antimicrobial peptides (piscidin 1, piscidin 2, piscidin 3) isolated from the tissues of hybrid striped bass (Morone saxatilis × M. chrysops) exhibit hemolytic activity, with hemolytic capacity stronger than magainin 2 derived from Xenopus but weaker than melittin; among them, piscidin 3 has the lowest hemolytic activity, and its hemolytic ability is related to the integrity of the amphipathic α-helical structure.|||The document mentions the hemolytic data of piscidins, magainin 2, and mellitin, as follows: - Piscidins 1-3 (P1, P2, P3): At a concentration of 1 µg/ml, the hemolysis rate is close to 0; at 10 µg/ml, the hemolysis rate is about 10%-30% (with P3 having the lowest hemolysis rate); at 100 µg/ml, the hemolysis rate is about 40%-70%; at 1000 µg/ml, the hemolysis rate is about 70%-90%. - Magainin 2 (Mag 2): Hemolysis is lower than that of piscidins, with a hemolysis rate of about 40% at 1000 µg/ml. - Mellitin: The most hemolytic, showing some hemolysis even at 1 µg/ml, and almost 100% hemolysis at 100 µg/ml. The above data are presented in Figure 1c (human red blood cell hemolytic activity curve), showing the hemolysis percentages of each peptide at different concentrations.|||Human RBCs (100% hemolysis at 100 ug/ml)" "Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||Silphaduang U, Noga E.J.2001 Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690.||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||Nature . 2001 Nov 15;414(6861):268-9. doi: 10.1038/35104690.||Kim JP et al 2010|||31653020|||31354312, 30021422|||30365554|||Nature. 2001 Nov 15;414(6861):268-269.||Ref.11713517|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||31354312, 30021422||Refer PubMed ID: 30021422" 22 FPDB00049 AP00497|||AP00497|||Maximin-H5|||DRAMP01127 ILGPVLGLVSDTLDDVLGIL Anti-Gram+||Antiviral||Anti-HIV||Anticancer||Anti-S. aureus, activity value is MIC = 90 uM||Anti-T98G, activity value is EC50 = 125 uM||Antibacterial ; Bombina maxima [Giant fire-bellied toad]||Antibacterial||Antimicrobial Bombina maxima, China, Asia|||Bombina maxima, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad) N/A "Hemolytic assay was tested with rabbit red cells in liquid medium as reported [12]. Serial dilutions of the peptides were used, and after incubation at 37 _x0002_C for 0.5 h, the cells were centri-fuged and the absorbance in the supernatant was measured at 595 nm. Maximum hemolysis was determined by adding 1% Triton X-100 to a sample of cells.|||In the hemolysis experiment targeting the anionic antimicrobial peptide Maximin H5 from the toad (Bombina maxima), no hemolysis of rabbit red blood cells was observed at a concentration as high as 80 μM, that is, the hemolytic value was: no hemolysis at a concentration of 80 μM." "Biochem Biophys Res Commun 2002 Jul 26;295(4):796-9|||Lai R, Liu H, Hui Lee W, Zhang Y.2002 Biochem Biophys Res Commun 2002 Jul 26;295(4):796-9||Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346|||Biochem Biophys Res Commun 2002 Jul 26;295(4):796-9|||Biochem Biophys Res Commun 2002 Jul 26;295(4):796-9|||https://pubmed.ncbi.nlm.nih.gov/12127963|||Biochem Biophys Res Commun 2002 Jul 26;295(4):796-799." 20 FPDB00050 AP00499|||AP00499|||Gramicidin A|||DRAMP00245|||AP00499|||DRAMP00245 VGALAVVVWLWLWLW Anti-Gram+ & Gram-||Antiviral||Spermicidal||Anti-HIV||Anticancer||This peptide shows effects on HIV and HSV infections (Arch Virol 1997; 142: 2225-35). gA also has anticancer effect.||Antimicrobial||Antbacterial soil bacterium, Bacillus brevis|||soil bacterium, Bacillus brevis|||Bacillus brevis|||Bacillus brevis (soil bacterium) (Gram-positive bacteria)|||soil bacterium, Bacillus brevis|||Bacillus brevis (soil bacterium) (Gram-positive bacteria) Helix||Beta strand (1 strands; 13 residues) No hemolysis information or data found in the reference(s) presented in this entry "J Exp Med. 1939 Jun 30;70(1):1-10|||Dubos RJ1939 J Exp Med. 1939 Jun 30;70(1):1-10|||J Exp Med. 1939 Jun 30;70(1):1-10|||19870884|||J Exp Med. 1939 Jun 30;70(1):1-10.J Biomol NMR. 1996 Jul;8(1):1-14.|||J Exp Med. 1939 Jun 30;70(1):1-10|||J Exp Med. 1939 Jun 30;70(1):1-10.J Biomol NMR. 1996 Jul;8(1):1-14." 15 FPDB00051 AP00505|||AP00505|||Histatin5|||DRAMP03580|||Histatin5|||AP00505|||DRAMP03580 DSHAKRHHGYKRKFHEKHHSHRGY Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Enzyme inhibitor||Anti-C. albicans, activity value is LD50 = 2.3 ug/ml||Anti-and E. faecium . Also active against bacteria A.actinomycetemcomitans, activity value is ED50 > 100 uM||Anti-S. mutans cariogenic bacteria, activity value is ED50 = 92 uM||Anti-C. albicans DIS or azole resistant, activity value is ED50 = 6.4||Anti-C. glabrata or fluconazole resistant, activity value is ED50 = 38.7||Anti-C. krusei, activity value is ED50 = 6.47 uM||Anti-and C. neoformans CN2 or amphotericin B resistant, activity value is ED50 = 3.71||Anti-and S. cerevisiae, activity value is MIC = 74 uM||Antibacterial||Antimicrobial||Anti-Streptococcus mutans U159, activity value is MIC = 234 ug/ml||Anti-Candida albicans ATCC10231, activity value is IC50 = 8.5 ug/ml||Anti-31417503: C. albicans ATCC 90028, activity value is MIC = 64.45 ug/ml||Anti-11302797: Candida albicans, activity value is LD50 = 7.3 salivary glands, Homo sapiens|||salivary glands, Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||Homo sapiens [Human]|||salivary glands, Homo sapiens|||Homo sapiens (Human) Helix||Alpha helix Streptococcus mutans U159 (MIC= 234 ug/ml), Candida albicans ATCC10231 (IC50= 8.5 ug/ml); Refer PubMed ID- 31417503: C. albicans ATCC 90028 (MIC = 64.45 ug/ml); Refer PubMed ID- 11302797: Candida albicans (LD50 = 7.3 ± 0.52 ug/ml); Refer PubMed ID- 3286634: C. albicans ( 100 % inhibition at 54 nmol) J Biol Chem. 1988 Jun 5;263(16):7472-7.|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||34417532, 33740624, 31417503, 11302797, 3286634|||J Biol Chem. 1988 Jun 5;263(16):7472-7477.|||34417532, 33740624, 31417503, 11302797, 3286634|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||J Biol Chem. 1988 Jun 5;263(16):7472-7477. 24 FPDB00052 AP00512|||DRAMP01047|||Shepherin II|||AP00512|||DRAMP01047 GYHGGHGGHGGGYNGGGGHGGHGGGYNGGGHHGGGGHG "Anti-Gram-||Antiviral||Antifungal||Anti-HIV Crucial residues:||Anti-Gram- E. herbicola, activity value is IC50 = 25 ug/ml||Anti-E. coli, activity value is IC50 < 2.5 ug/ml||Anti-P. putida, activity value is IC50 < 2.5 ug/ml||Anti-P. syringae, activity value is IC50 < 2.5 ug/ml||Anti-S. typhimurium, activity value is IC50 = 65 ug/ml||Anti-Serratia sp, activity value is IC50 < 2.5 ug/ml||Anti-B.subtilis, activity value is IC50 > 100 ug/ml||Anti-S.aureus, activity value is IC50 > 100 ug/ml||Anti-S.mutans, activity value is IC50 > 100 ug/ml||Anti-C. albicans, activity value is IC50 = 5 ug/ml||Anti-C. neoformans, activity value is IC50 < 2.5 ug/ml||Anti-S. cerevisiae, activity value is IC50 = 3 ug/ml||Anti-A.alternata, activity value is IC50 > 100 ug/ml||Anti-A. flavus, activity value is IC50 = 60 ug/ml||Anti-A.fumigatus, activity value is IC50 > 100 ug/ml||Anti-and F. culmorum, activity value is IC50 = 68 ug/ml||Antimicrobial||Antibacterial||Antifungal ; Erwinia herbicola (IC(50) = 25 ug/ml)||Escherichia coli (IC(50) < 2.5 ug/ml)||Pseudomonas putida (IC(50) < 2.5 ug/ml)||Pseudomonas syringae (IC(50) < 2.5 ug/ml)||Salmonella typhimurium (IC(50) = 65 ug/ml)||Serratia sp. (IC(50) < 2.5 ug/ml)||Candida albicans (IC(50) = 5 ug/ml)||Cryptococcus neoformans (IC(50) < 2.5 ug/ml)||Saccharomyces cerevisiae (IC(50) = 3 ug/ml)||Aspergillus flavus (IC(50) = 60 ug/ml)||Fusarium culmorum (IC(50) = 68 ug/ml)||Anti-HIV" roots, shepherd's purse, Capsella bursa-pastoris|||roots, shepherd's purse, Capsella bursa-pastoris|||Capsella bursa-pastoris (shepherd's purse)|||Capsella bursa-pastoris [Shepherd purse]|||roots, shepherd's purse, Capsella bursa-pastoris|||Capsella bursa-pastoris (shepherd's purse) Rich N/A "Plant Mol Biol. 2000 Sep;44(2):187-97. Pub-Med.|||Plant Mol Biol. 2000 Sep;44(2):187-97. doi: 10.1023/a:1006431320677.|||Plant Mol Biol . 2000 Sep;44(2):187-97. doi: 10.1023/a:1006431320677.|||Plant Mol Biol. 2000 Sep;44(2):187-197.|||11117262|||Plant Mol Biol. 2000 Sep;44(2):187-97. Pub-Med.|||Plant Mol Biol. 2000 Sep;44(2):187-197." 38 FPDB00053 AP00524|||AP00524|||HBD2|||Human beta-defensin-2 WT hBD - 2|||AP00524|||DRAMP03598 " GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Chemotactic||Anti-toxin||Channel inhibitors||Synergistic AMPs||Antibiofilm||Wound healing||Anti-synthetic: Active against E. coli DSM1103, activity value is MIC = 18.8 ug/ml||Anti-K. pneumoniae DSM681, activity value is MIC = 37.5 ug/ml||Anti-P. aeruginosa DSM1128, activity value is MIC = 25 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 100 ug/ml||Anti-and S.pneumoniae DSM11865, activity value is MIC = 300 ug/ml||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- airway, skin, lung, trachea epithelia, and uterus, oral (saliva); Homo sapiens|||airway, skin, lung, trachea epithelia, and uterus, oral (saliva); Homo sapiens|||Synthetic construct|||Homo sapiens [Human]|||airway, skin, lung, trachea epithelia, and uterus, oral (saliva); Homo sapiens|||Homo sapiens (Human) Combine Helix and Beta structure [Ref.15625724] It is slightly hemolytic (<12%) against human erythrocytes at the highest concentration of 500 ug/ml. "Nature. 1997 Jun 26;387(6636):861. PubMed.|||1997 Jun 26;387(6636):861. doi: 10.1038/43088.||see ref AP1315|||Nature. 1997 Jun 26;387(6636):861. doi: 10.1038/43088.|||Nature . 1997 Jun 26;387(6636):861. doi: 10.1038/43088.||see ref AP1315|||9727055|||Nature. 1997 Jun 26;387(6636):861. PubMed.|||Nature. 1997 Jun 26;387(6636):861.J Biol Chem. 2000 Oct 20;275(42):32911-32918.Plant Cell Rep. 2007 Aug;26(8):1391-1398." 41 FPDB00054 AP00532|||AP00532|||Lunatusin|||DRAMP01010|||Lunatusin|||AP00532|||DRAMP01010|||AP00532|||DRAMP01010 KTCENLADTFRGPCFATSNC Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anticancer||Anti-a minor component that is not present in the glandular secretion of the female. Activity against B.cereus, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 6 uM||Anti-L. innocua, activity value is MIC = 50 ug/ml||Anti-M. luteus, activity value is MIC = 25 ug/ml||Anti-or 29213, activity value is MIC > 100 ug/ml||Anti-S. epidermidis, activity value is MIC = 100 ug/ml||Anti-S. uberis, activity value is MIC = 50 ug/ml||Antibacterial||Antifungal ; Phaseolus lunatus L [Lima bean]||Antimicrobial||Anti-Gram+||Anti-Gram-||Antifungal ; Fusarium oxysporum||Mycosphaerella arachidicola||Botrytis cinerea||Bacillus megaterium||Bacillus subtilis||Proteus vulgaris||Mycobacterium phlei Phaseolus lunatus L. (lima bean)|||Phaseolus lunatus L. (lima bean)|||Phaseolus lunatus L [Lima bean]|||Phaseolus lunatus L.(Chinese lima bean)|||Phaseolus lunatus L. (lima bean)|||Phaseolus vulgaris cv. white cloud beans|||Phaseolus lunatus L. (lima bean)|||Phaseolus lunatus L.(Chinese lima bean) N/A No hemolysis information or data found in the reference(s) presented in this entry "Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.|||Jack Ho Wong and Tzi Bun Ng2005 Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.||same ref as AP2008||VanCompernolle et al., 2015|||Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.|||Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.|||https://pubmed.ncbi.nlm.nih.gov/16269344|||Peptides. 2005 Nov;26(11):2086-2092.|||16269344|||Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.|||Peptides. 2005 Nov;26(11):2086-2092.|||Peptides. 2005 Nov;26(11):2086-92. Epub 2005 Apr 25.|||Peptides. 2005 Nov;26(11):2086-2092." 20 FPDB00055 AP00553|||AP00553|||Sesquin|||DRAMP00409|||Sesquin|||AP00553|||DRAMP00409|||AP00553|||CAMPSQ7|||DRAMP00409 " KTCENLADTY" Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anticancer||Active against fungi B. cinerea||F.oxysporum||and M. arachidicola. Inhibit leukemia cells M1 and breast cancer cells MCF-7. HIV (50 uM inhibit 35%).||Anti-Botrytis cinerea, activity value is IC50 = 2.5 uM||Anti-Fusarium oxysporum, activity value is IC50 = 1.4 uM||Anti-Mycosphaerella arachidicola, activity value is IC50 = 0.15 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral ; N.A Seeds, Vigna sesquipedalis, ground bean|||Seeds, Vigna sesquipedalis, ground bean|||Synthetic construct|||Vigna unguiculata subsp. sesquipedalis (Yard-Long bean)|||Vigna unguiculata subsp. sesquipedalis|||Seeds, Vigna sesquipedalis, ground bean|||Vigna unguiculata subsp. sesquipedalis (Yard-Long bean)|||Seeds, Vigna sesquipedalis, ground bean|||Vigna unguiculata subsp. sesquipedalis [Cowpea]|||Vigna unguiculata subsp. sesquipedalis (Yard-Long bean) N/A No hemolysis information or data found in the reference(s) presented in this entry "Peptides. 2005 Jul;26(7):1120-6|||Wong JH, Ng TB2005 Peptides. 2005 Jul;26(7):1120-6|||Peptides. 2005 Jul;26(7):1120-6|||Peptides. 2005 Jul;26(7):1120-6|||15949629|||Peptides. 2005 Jul;26(7):1120-1126.|||http://www.ncbi.nlm.nih.gov/protein/109894868|||Peptides. 2005 Jul;26(7):1120-6|||Peptides. 2005 Jul;26(7):1120-1126.|||Peptides. 2005 Jul;26(7):1120-6|||15949629|||Peptides. 2005 Jul;26(7):1120-1126." 10 FPDB00056 AP00590|||Siamycin II|||AP00590|||DRAMP18350|||Siamycin II " CLGIGSCNDFAGCGYAIVCFW" Antiviral||Anti-HIV||Anti-Staphylococcus aureus FDA209P JC-1, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus smith, activity value is MIC = 6.3 ug/ml||Anti-Staphylococcus aureus A15036, activity value is MIC = 3.1 ug/ml||Anti-Micrococcus luteus ATCC 9341, activity value is MIC = 1.6 ug/ml||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 1.6 ug/ml||Anti-Escherichia coli Juhl, activity value is MIC > 100 ug/ml||Anti-E. coli K12, activity value is MIC > 100 ug/ml||Anti-E. coli NIHJ JC-2, activity value is MIC > 100 ug/ml||Anti-K. pneumoniae ATCC 10031, activity value is MIC > 100 ug/ml||Anti-Citrobacter freundii GN 7391, activity value is MIC > 100 ug/ml||Anti-Salmonella typhi 901, activity value is MIC > 100 ug/ml||Anti-P. aeruginosa A9843A, activity value is MIC > 100 ug/ml||Antimicrobial||Antiviral ; HIV-1 Streptomyces strains AA3891|||Streptomyces strain AA6532 Beta||Beta strand No hemolysis information or data found in the reference(s) presented in this entry J Biomol NMR. 1995 Apr;5(3):271-86. PubMed.|||J Biomol NMR. 1995 Apr;5(3):271-86. doi: 10.1007/BF00211754.|||8557614|||J Biomol NMR. 1995 Apr;5(3):271-86. PubMed.|||J Biomol NMR. 1995 Apr;5(3):271-86.|||7787424 21 FPDB00057 AP00599|||AP00599|||Brevinin-2-related peptide|||DRAMP01873|||Brevinin-2-related peptide|||AP00599|||DRAMP01873 GIWDTIKSMGKVFAGKILQNL Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Anti-E. coli, activity value is MIC = 13||Anti-S. aureus or MRSA, activity value is MIC = 25 uM||Anti-and C. albicans, activity value is MIC = 25 uM||Anti-Escherichia coli, activity value is MIC = 13 uM||Anti-Staphylococcus aureus, activity value is MIC = 25 uM||Anti-Candida albicans, activity value is MIC = 25 uM||Anti-19793185 : E. coli, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-A. baumannii, activity value is MIC = 6.25 uM||Anti-31549575 : Staphylococcus aureus, activity value is MIC = 16||Anti-Escherichia coli, activity value is MIC = 32 uM||Anti-Candida albicans, activity value is MIC = 16 uM||Anti-Candida albicans, activity value is MIC = 70 uM mink frog, Rana septentrionalis, North America|||Rana septentrionalis (mink frog)|||mink frog, Rana septentrionalis, North America|||Rana septentrionalis (mink frog) N/A "The document explicitly provides the hemolytic values of five major antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), expressed as the concentration required to induce 50% hemolysis of human red blood cells (HC₅₀). The specific data are as follows: Brevinin-1SPa: The hemolytic concentration HC₅₀ is 7 μM, and its minimum inhibitory concentrations (MICs) against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Candida albicans (C. albicans) are 13 μM, 3 μM, and 6 μM, respectively. Brevinin-1SPb: hemolytic activity, HC₅₀ = 25 μM; MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are 50 μM, 6 μM, and 13 μM, respectively. Brevinin-1SPd: hemolytic activity HC₅₀ = 8 μM; the MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are all 3 μM. Temporin-1SPb: hemolytic activity, HC₅₀ = 60 μM; only a MIC of 6 μM against Staphylococcus aureus was detected, while the MICs against Escherichia coli and Candida albicans were not determined (ND). Brevinin-2-related peptide: hemolytic activity, HC₅₀ = 70 µM; MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are 13 µM, 25 µM, and 25 µM, respectively.|||The document mentioned hemolysis-related content, and the specific hemolytic values are as follows: - Brevinin-1SPa: The concentration causing 50% hemolysis of human red blood cells (HC₅₀) is 7 μM. - Brevinin-1SPb: HC₅₀ is 25 μM. - Brevinin-1SPd: HC₅₀ is 8 μM. - Temporin-1SPb: HC₅₀ is 60 μM. - Brevinin-2 related peptides: HC₅₀ is 71 μM.|||Human erythrocytes ( HC50 = 70 uM ); Refer PubMed ID - 19793185: hRBC(LC50= 90 uM)|||In Document 2 (Comparative Biochemistry and Physiology, Part C 2004), among the antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), brevinin-1SPa has an HC₅₀ of 7 μM for human red blood cells, brevinin-1SPb has an HC₅₀ of 25 μM, brevinin-1SPd has an HC₅₀ of 8 μM, temporin-1SPb has an HC₅₀ of 60 μM, and brevinin-2 related peptide has an HC₅₀ of 70 μM.|||[Ref.15556063]HC50=70 uM against human erythrocytes|||Human erythrocytes ( HC50 = 70 uM ); Refer PubMed ID - 19793185: hRBC(LC50= 90 uM)|||[Ref.15556063]HC50=70 uM against human erythrocytes|||The document mentions the hemolytic activity values of several antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), expressed as HC_{50}, which is the peptide concentration causing 50% hemolysis. The details are as follows: - Brevinin-1SPa: HC_{50} = 7 μM - Brevinin-1SPb: HC_{50} = 25 μM - Brevinin-1SPd: HC_{50} = 8 μM - Temporin-1SPb: HC_{50} = 60 μM - Brevinin-2-related peptide: HC_{50} = 70 μM These values reflect the hemolytic capability of different peptides on human red blood cells; the lower the value, the stronger the hemolytic activity." Comp. Biochem. Physiol. C 2004; 139: 31-38|||omp. Biochem. Physiol. C 2004; 139: 31-38|||15556063, 19793185, 31549575|||Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):31-38.||Ref.15556063|||15556063||Ref.15556063|||15556063, 19793185, 31549575|||Comp. Biochem. Physiol. C 2004; 139: 31-38|||Ref.15556063 21 FPDB00058 AP00640|||AP00640|||Maculatin-1.3|||DRAMP01366|||AP00640|||DRAMP01366 " GLLGLLGSVVSHVVPAIVGHF" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-S. aureus USA300 MRSA, activity value is MIC = 6.2 uM||Anti-E.coli, activity value is MIC > 100 uM||Anti-B. subtilis, activity value is MIC = 25 uM||Anti-and P.aeruginosa, activity value is MIC > 100 uM||Anti-MRSA||Antibacterial||Antimicrobial Anti-Gram+ & Gram-, Antiviral, Anti-HIV, Anticancer|||Litoria eucnemis, Australia|||Litoria eucnemis, Australia|||Litoria eucnemis, Australia|||Litoria eucnemis [Australian anurans]|||Litoria eucnemis (Australian anurans)|||Litoria eucnemis, Australia|||Litoria eucnemis (Australian anurans) N/A "The document clearly provides the hemolytic values of two types of peptides in the skin secretions of the European common frog (Rana temporaria) (expressed as the concentration causing hemolytic effect on human red blood cells). The specific data are as follows: 1. Brevinin-1 family peptides Brevinin-1T, Brevinin-1Ta: They have hemolytic activity, but the document does not provide specific concentration values, only mentioning that both have dual antibacterial and hemolytic activity and were initially isolated from the skin secretions of the European common frog. Brevinin-1Tb: No clear hemolytic value is provided; it is only mentioned that it has antibacterial activity against Staphylococcus aureus (concentration 7.6 uM) and no activity against Salmonella enterica serovar typhimurium, with no hemolytic data mentioned. New Brevinin-1Tc (specific to the Slovenian population): Hemolytic values have not been directly measured, but its bioactivity is inferred to be similar to that of Brevinin-1T, 1Ta, and 1Tb through 2D mass spectrometry mapping (NMD-NIS coordinates), potentially having hemolytic activity, but the specific concentration is unknown. 2. Melittin-related peptides (MRP-1) Hemolytic value: Lethal concentration (LC) for human red blood cells is 0.5 uM, which is a potent hemolytic agent, present in both Moscow and Slovenian populations, and can serve as a species biomarker for the European common frog. 3. Temporin family peptides Known temporins (A, B, L, etc.): Only described as having ""low"" hemolytic activity (for example, temporins A and B are active against Gram-positive bacteria and fungi but have weak hemolytic activity) or mentioning that temporin L has hemolytic activity against human red blood cells, with no specific HC_{50} or LC values provided. Six new temporins (O, P, Q, R, S, T, specific to the Slovenian population): Bioactivity inferred through 2D mass spectrometry mapping: Short-chain new temporins (O, T): Similar activity to temporins A and B, low hemolytic activity, no specific values; Long-chain new temporins (Q, R, S): Activity similar to temporin L (which has hemolytic activity), but no specific hemolytic concentration measured; temporin P: Due to the absence of basic amino acid residues in the sequence, it is inferred to have no hemolytic activity or extremely weak activity, with no specific values.|||The document only mentions the hemolytic information of caerin 1.1, specifically: caerin 1.1 lyses red blood cells at >250 μg/ml, meaning that the peptide lyses red blood cells at concentrations above 250 μg/ml, but does not specify the exact hemolytic values such as the half-maximal hemolytic concentration (HC₅₀). For other antimicrobial peptides (such as aureins, citropins, maculatins, etc.), the descriptions mainly involve antibacterial, anticancer, antifungal activities, and do not mention hemolytic values.|||No hemolysis information or data found in the reference(s) presented in this entry" Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004 Jun;25(6):1035-54|||Peptides. 2004 Jun;25(6):1035-54.||Menousek et al., 2012|||Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004 Jun;25(6):1035-54||Menousek et al., 2012|||15203252|||Peptides. 2004; 25: 1035-1054.|||Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004; 25: 1035-1054. 21 FPDB00059 AP00663|||DRAMP01517|||AP00663|||DRAMP01517 GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC Anti-Gram-||Antiviral||Anti-HIV||Anti-Escherichia coli, activity value is MIC = 10 uM||Antimicrobial||Antibacterial North American frog, Rana pipiens|||Rana pipiens (northern leopard frog)|||North American frog, Rana pipiens|||Rana pipiens (northern leopard frog) N/A No hemolytic activity (0% hemolysis at 100 µM)|||No hemolysis information or data found in the reference(s) presented in this entry "Eur J Biochem. 2000 Feb;267(3):894-900. PubMed.|||Eur J Biochem. 2000 Feb;267(3):894-900. doi: 10.1046/j.1432-1327.2000.01074.x.|||Eur J Biochem . 2000 Feb;267(3):894-900. doi: 10.1046/j.1432-1327.2000.01074.x.|||Ref.10651828||Ref.11601906|||Eur J Biochem. 2000 Feb;267(3):894-900. PubMed.|||Virology. 2001 Sep 30;288(2):351-7.Eur J Biochem. 2000 Feb;267(3):894-900." 37 FPDB00060 AP00706 GLLASLGKVFGGYLAEKLKPK Anti-Gram+ & Gram-||Antiviral||Anti-HIV Litoria dahlii, Australia N/A N/A "Rapid Commun Mass Spectrom. 2001;15(18):1726-34. PubMed.|||Rapid Commun Mass Spectrom. 2001;15(18):1726-34. doi: 10.1002/rcm.429.|||Rapid Commun Mass Spectrom . 2001;15(18):1726-34. doi: 10.1002/rcm.429." 21 FPDB00061 AP00708|||AP00708|||GF-17|||GI-17 GFKRIVQRIKDFLRNLV Anti-Gram+ & Gram-||Antiviral||Spermicidal||Anti-HIV||Anti-MRSA||Synergistic AMPs||Anticancer||Anti-and S. aureus USA300 MRSA, activity value is MIC = 3.1||Anti-E. faecium ATCC 51559, activity value is MIC = 3.1 uM||Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 3.1 uM||Anti-A. baumannii B28-16, activity value is MIC = 3.1 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-E. cloacae B2366-1, activity value is MIC = 3.1 uM||Anti-S. aureus Newman, activity value is MIC = 1.6 uM||Anti-S. aureus Mu50, activity value is MIC = 1.6 uM||Anti-S. aureus UAMS1, activity value is MIC = 3.1 uM||Anti-E. faecium V284-17, activity value is MIC = 2 uM||Anti-S. aureus USA300, activity value is MIC = 2||Anti-A. baumannii B28-16, activity value is MIC = 4 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 16 uM||Anti-E. coli E423-17, activity value is MIC = 16 uM Derivative of LL-37; NMR-based discovery; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Derivative of LL-37; NMR-based discovery; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct Helix Moderate hemolytic activity (55% hemolysis at 50 μM)|||Human RBCs [Hemolytic concentration (HL50) = 180 uM]|||Human RBC (65% hemolysis at 200 uM) "J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed.|||J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed|||J Am Chem Soc. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875.||Golla R. et al., 2020|||J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed.|||J Am Chem Soc . 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875.||Golla R. et al., 2020|||31319057|||34959645" 17 FPDB00062 AP00724|||AP00724|||RTD-2|||DRAMP31352|||AP00724|||DRAMP31352 " GVCRCLCRRGVCRCLCRR" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-toxin||Antibacterial||Antimicrobial Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Macaca mulatta [Rhesus macaque]|||Macaca mulatta (Rhesus macaque)|||Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Macaca mulatta (Rhesus macaque) Bridge Strong hemolytic activity (100% hemolysis at 5 μM) J Leukoc Biol 2001; 70:461-464|||J Leukoc Biol 2001; 70:461-464|||11675394|||J Immunol. 2004 Jul 1;173(1):515-20.|||J Leukoc Biol 2001; 70:461-464|||J Immunol. 2004 Jul 1;173(1):515-20. 18 FPDB00063 AP00725|||AP00725|||Rhesus theta defensin-1/3, subunit A precursor|||DRAMP31353|||AP00725|||Rhesus theta defensin-1/3, subunit A precursor|||DRAMP31353 " GFCRCICTRGFCRCICTR" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-toxin||Antibacterial||Antimicrobial||Antiviral ; Staphylococcus aureus 502a||Escherichia coli ML35||and yeast forms of Candida albicans 16820 and Cryptococcus neoformans 271A||HIV Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Macaca mulatta [Rhesus macaque]|||Macaca mulatta (Rhesus macaque)|||Bone marrow, or blood leukocytes, rhesus monkey, Macaca mulatta|||Macaca mulatta [Rhesus macaque]|||Macaca mulatta (Rhesus macaque) Bridge Strong hemolytic activity (100% hemolysis at 5 μM) J Leukoc Biol 2001; 70:461-464|||J Leukoc Biol 2001; 70:461-464|||11675394|||J Immunol. 2004 Jul 1;173(1):515-20.|||J Leukoc Biol 2001; 70:461-464|||https://pubmed.ncbi.nlm.nih.gov/11675394|||J Immunol. 2004 Jul 1;173(1):515-20. 18 FPDB00064 AP00764|||AP00764|||Dermaseptin-S9|||DRAMP01682 GLRSKIWLWVLLMIWQESNKFKKM Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Chemotactic||Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 31.6 uM||Antibacterial||Antimicrobial South America, hylid frog, Phyllomedusa sauvagei|||South America, hylid frog, Phyllomedusa sauvagei|||Phyllomedusa sauvagei [Sauvage's leaf frog]|||Phyllomedusa sauvagei (South American hylid frog) Helix N/A Biochemistry 2006; 45: 468-480|||Biochemistry 2006; 45: 468-480|||16401077|||Biochemistry. 2006 Jan 17;45(2):468-480. 24 FPDB00065 AP00729|||Kalata B1|||DRAMP00856|||Kalata B1|||AP00729|||DRAMP00856|||AP00729|||DRAMP00856|||Kalata B1 GLPVCGETCVGGTCNTPGCTCSWPVCTRN Anti-Gram+ & Gram-||Antiviral||Antifungal||Insecticidal||Anti-HIV||Enzyme inhibitor||Hemolytic||Anti-Gram- E.coli, activity value is MIC > 500 uM||Anti-P.aeruginosa, activity value is MIC > 500 uM||Anti-P.vulgaris, activity value is MIC > 500 uM||Anti-K. oxytoca, activity value is MIC = 54.8 uM||Anti-S. aureus, activity value is MIC = 0.26 uM||Anti-M. luteus, activity value is MIC = 40.4 uM||Anti-C.albicans, activity value is MIC > 500 uM||Anti-C. kefyr, activity value is MIC = 21.4 uM||Anti-and C.tropicalis, activity value is MIC > 500 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC > 500 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 500 uM||Anti-Proteus vulgaris ATCC 49132, activity value is MIC > 500 uM||Anti-Klebsiella oxytoca ATCC 49131, activity value is MIC = 54.8 uM||Anti-Staphylococcus aureus 29213, activity value is MIC = 0.26 uM||Anti-Micrococcus luteus ATCC 49732, activity value is MIC = 40.4 uM||Anti-Candida albicans ATCC 37092, activity value is MIC > 500 uM||Anti-Candida kefyr ATCC 37095, activity value is MIC = 21.4 uM||Anti-Candida tropicalis ATCC 37097, activity value is MIC > 500 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 40 uM||Anti-Staphylococcus aureus, activity value is MIC = 0.26 uM||Anti-Micrococcus luteus, activity value is MIC = 40.4 uM||Anti-Klebsiella oxytoca, activity value is MIC = 54.8 uM||Anti-Candida kefyr, activity value is MIC = 21.4 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Anti-HIV, activity value is EC50 = 0.66 uM African herb, Oldenlandia affinis|||Oldenlandia affinis|||Oldenlandia affinis|||African herb, Oldenlandia affinis|||African herb, Oldenlandia affinis|||Oldenlandia affinis|||Viola yedoensis Beta||Beta strand (3 strands; 7 residues) "Human blood type A erythrocytes|||The half-hemolysis concentrations (the concentrations causing 50% hemolysis) of four cyclotides (kalata, circulin A, circulin B, cyclopsychotride) on human erythrocytes are all greater than 400 μM, among which circulin B and cyclopsychotride have relatively higher hemolytic activities, with half-hemolysis concentrations of 550 μM and 405 μM, respectively, while the half-hemolysis concentrations of kalata and circulin A are 1510 μM and 1020 μM, respectively.|||[Ref.12779323] HD50 = 300 uM against Human type A red blood cells.|||Human blood type A erythrocytes|||EC₅₀=1510 uM|||[Ref.12779323] HD50 = 300 uM against Human type A red blood cells.|||The document mentions the hemolytic values of four cyclotides (kalata, circulin A, circulin B, cyclopsychotride), as follows: - The concentration at which all four cyclotides cause 50% hemolysis of human red blood cells is greater than 400 μM. - Among them, circulin B and cyclopsychotride have relatively higher hemolytic activity, with 50% hemolysis concentrations of 550 μM and 405 μM, respectively; kalata and circulin A have lower hemolytic activity, with 50% hemolysis concentrations of 1510 μM and 1020 μM, respectively. These data come from hemolysis experiments, in which the hemolytic effects of different concentrations of peptides on human type A red blood cells were measured, and the 50% hemolysis concentration (EC₅₀) was determined from the dose-response curve.|||[Ref.12779323] HD50 = 300 uM against Human type A red blood cells." Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8.PubMed.|||Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8.doi: 10.1073/pnas.96.16.8913.||see ref|||10430870|||28669767|||Biopolymers. 2008;90(1):51-60.||Ref.10430870|||18008336||Ref.10430870||Ref.18008336|||10430870|||Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8.PubMed.||see ref|||Ref.10430870||Ref.18008336|||Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8.PubMed.|||Biopolymers. 2008;90(1):51-60.Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8918.Biochemistry. 1995 Apr 4;34(13):4147-4158.J Biol Chem. 2012 Dec 21;287(52):43884-98.|||https://pubmed.ncbi.nlm.nih.gov/18081258 29 FPDB00066 AP00730|||DRAMP00863|||AP00730|||DRAMP00863|||Kalata-B8 GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD Antiviral||Anti-HIV||Hemolytic||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 2.5 uM||Antimicrobial||Antiviral ; HIV African herb, Oldenlandia affinis|||Staphylococcus warneri ISK-1|||African herb, Oldenlandia affinis|||Oldenlandia affinis Beta||Beta strand (3 strands; 7 residues) [Ref.20564013] It produced 7% hemolysis at the 62 uM. Biochem J 2006; 393: 619-626|||Biosci Biotechnol Biochem. 2000 Nov;64(11):2420-8.Vet Microbiol. 2010 Nov 20;146(1-2):124-31.|||Biochem J 2006; 393: 619-626|||Biopolymers. 2008;90(1):51-60.Biochem J. 2006 Feb 1;393(Pt 3):619-626.Chembiochem. 2007 Jun 18;8(9):1001-1011.|||https://pubmed.ncbi.nlm.nih.gov/16207177 31 FPDB00067 AP01022|||DRAMP00799|||AP01022|||DRAMP00799|||Cycloviolin-A " GVIPCGESCVFIPCISAAIGCSCKNKVCYRN" Antiviral||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.13 uM||Antimicrobial Leonia cymosa|||Clitoria ternatea (Butterfly pea)|||Leonia cymosa|||Leonia cymosa (Sacha uba) Bridge No hemolysis information or data found in the reference(s) presented in this entry J Org Chem. 2000 Jan 14;65(1):124-8|||J Biol Chem. 2011 Jul 8;286(27):24275-24287.|||J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10813905 31 FPDB00068 AP01023|||DRAMP00800|||AP01023|||DRAMP00800|||Cycloviolin-B GTACGESCYVLPCFTVGCTCTSSQCFKN Antiviral||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.13 uM||Antimicrobial||Antiviral ; HIV Leonia cymosa|||Clitoria ternatea (Butterfly pea)|||Leonia cymosa|||Leonia cymosa (Sacha uba)|||Synthetic construct Bridge No hemolysis information or data found in the reference(s) presented in this entry J Org Chem. 2000 Jan 14;65(1):124-8|||J Biol Chem. 2011 Jul 8;286(27):24275-24287.|||J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10813905 28 FPDB00069 AP01024|||DRAMP00801|||AP01024|||DRAMP00801|||Cycloviolin-C GIPCGESCVFIPCLTTVAGCSCKNKVCYRN Antiviral||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.13 uM||Antimicrobial Leonia cymosa|||Leonia cymosa (Sacha uba)|||Leonia cymosa|||Leonia cymosa (Sacha uba) Bridge No hemolysis information or data found in the reference(s) presented in this entry J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10813905 30 FPDB00070 AP01025|||DRAMP00802|||AP01025|||DRAMP00802|||Cycloviolin-D " GFPCGESCVFIPCISAAIGCSCKNKVCYRN" Antiviral||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.13 uM||Antimicrobial Leonia cymosa|||Leonia cymosa (Sacha uba)|||Leonia cymosa|||Leonia cymosa (Sacha uba) Bridge No hemolysis information or data found in the reference(s) presented in this entry J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||J Org Chem. 2000 Jan 14;65(1):124-8|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10813905 30 FPDB00071 AP01030|||AP01030|||DRAMP00788|||Varv E " GLPICGETCVGGTCNTPGCSCSWPVCTRN" Antiviral||Anti-HIV||Hemolytic||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.35 uM||Anti-cancer||Anti-HIV, activity value is EC50 = 0.35 uM Viola arvensis|||Viola arvensis|||Viola arvensis (European field pansy) (Field violet)|||Viola yedoensis Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 1999 Feb;62(2):283-6. Pub-Med.|||J Nat Prod. 1999 Feb;62(2):283-6. doi: 10.1021/np9803878.||Ireland et al., 2008|||J Nat Prod. 1999 Feb;62(2):283-6. Pub-Med.|||Biopolymers. 2008;90(1):51-60.J Nat Prod. 1999 Feb;62(2):283-286.J Nat Prod. 2004 Feb;67(2):144-147.Peptides. 2010 Aug;31(8):1434-40|||https://pubmed.ncbi.nlm.nih.gov/18081258 29 FPDB00072 AP01034|||DRAMP00803|||AP01034|||DRAMP00803 " GDPTFCGETCRVIPVCTYSAALGCTCDDRSDGLCKRN" Antiviral||Anti-HIV||Antimicrobial Palicourea condensata|||Leonia cymosa (Sacha uba)|||Palicourea condensata|||Palicourea condensata (Cappel) Combine Helix and Beta structure||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2001 Feb;64(2):249-50.|||J Org Chem. 2000 Jan 14;65(1):124-128.Biopolymers. 2008;90(1):51-60.|||J Nat Prod. 2001 Feb;64(2):249-50.|||J Nat Prod. 2001 Feb;64(2):249-250.Structure. 2004 Jan;12(1):85-94.Biopolymers. 2008;90(1):51-60. 37 FPDB00073 AP01058|||DRAMP00875|||AP01058|||DRAMP00875|||Vhl-1 " SISCGESCAMISFCFTEVIGCSCKNKVCYLN" Antiviral||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.87 uM||Antimicrobial Viola hederaceae|||Macadamia integrifolia (Macadamia nut)|||Viola hederaceae|||Viola hederacea (Australian violet)|||Viola hederacea Combine Helix and Beta structure||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry J Biol Chem. 2005 Jun 10;280(23):22395-405. Pub-Med.|||J Biol Chem. 2005 Jun 10;280(23):22395-405. doi: 10.1074/jbc.M501737200. Epub 2005 Apr 11.||Ireland et al., 2008|||Plant J. 1999 Sep;19(6):699-710.|||J Biol Chem. 2005 Jun 10;280(23):22395-405. Pub-Med.|||Biopolymers. 2008;90(1):51-60.J Biol Chem. 2005 Jun 10;280(23):22395-22405.|||https://pubmed.ncbi.nlm.nih.gov/15824119 31 FPDB00074 AP01060|||DRAMP00879|||AP01060|||DRAMP00879|||Circulin C GIPCGESCVFIPCITSVAGCSCKSKVCYRN Antiviral||Anti-HIV||Anti-HIV-1 strain IIIB/CEM-SS cell, activity value is EC50 = 0.073 uM||Anti-H1122 strain/MT-2 cell, activity value is EC50 = 0.048 uM||Anti-and A17 strain/MT-2, activity value is EC50 = 0.247 uM||Antimicrobial||Anti-HIV-1, activity value is EC50 = 50 tropical tree Chassalia parvifolia|||Viola hederacea (Australian violet)|||tropical tree Chassalia parvifolia|||Chassalia parviflora|||Chassalia parvifolia Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-8. doi: 10.1021/np990432r.|||J Biol Chem. 2005 Jun 10;280(23):22395-22405.Aust. J. Chem. 2010;63:771-778.|||J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10691702 30 FPDB00075 AP01061|||DRAMP00880|||AP01061|||DRAMP00880|||Circulin D " KIPCGESCVWIPCVTSIFNCKCKENKVCYHD" Antiviral||Anti-HIV||Circulins C-F showed anti HIV-1 effect with EC50 values (concentration for 50% inhibition) in the range from 50 to 0.275 uM||depending upon the particular virus strain and host cell line used in the assay.||Antimicrobial||Anti-HIV-1, activity value is EC50 = 50 tropical tree Chassalia parvifolia|||Chassalia parviflora|||tropical tree Chassalia parvifolia|||Chassalia parviflora|||Chassalia parvifolia Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-8. doi: 10.1021/np990432r.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10691702 31 FPDB00076 AP01062|||DRAMP00881|||AP01062|||DRAMP00881|||Circulin-E " KIPCGESCVWIPCLTSVFNCKCENKVCYHD" Antiviral||Anti-HIV||Circulins C-F showed anti HIV-1 effect with EC50 values (concentration for 50% inhibition) in the range from 50 to 0.275 uM||depending upon the particular virus strain and host cell line used in the assay.||Antimicrobial tropical tree Chassalia parvifolia|||Chassalia parviflora|||tropical tree Chassalia parvifolia|||Chassalia parviflora Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-8. doi: 10.1021/np990432r.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10691702 30 FPDB00077 AP01063|||DRAMP00882|||AP01063|||DRAMP00882|||Circulin F KVCYRAIPCGESCVWIPCISAAIGCSCKN Antiviral||Anti-HIV||Circulins C-F showed anti HIV-1 effect with EC50 values (concentration for 50% inhibition) in the range from 50 to 0.275 uM||depending upon the particular virus strain and host cell line used in the assay.||Antimicrobial||Anti-HIV-1, activity value is EC50 = 50 tropical tree Chassalia parvifolia|||Chassalia parviflora|||tropical tree Chassalia parvifolia|||Chassalia parviflora|||Chassalia parvifolia Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-8. doi: 10.1021/np990432r.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||J Nat Prod. 2000 Feb;63(2):176-8. Pub-Med.|||J Nat Prod. 2000 Feb;63(2):176-178.Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/10691702 29 FPDB00078 AP01064|||AP01064|||DRAMP00816|||DRAMP00816 " GIPCGESCVWIPCISAAIGCSCKSKVCYRN" Antiviral||Antifungal||Antiparasitic||Anti-HIV||Active against nematode parasites of sheep (e.g. Haemonchus contortus or Trichostrongylus colubriformis).||Insecticidal Viola odorata|||Viola odorata|||Viola odorata (Sweet violet)|||Viola odorata (Sweet violet) Bridge "Peptides were dissolved in water and serially diluted in PBS to give 0.02 ml test solutions in a 96-well U-bottomed microtitre plate (Nunc). Human type A RBCs (red blood cells) were washed with PBS and centrifuged at 1500000000 ug for 60 s in a microcentrifuge several times until a clear supernatant was obtained. A 0.25% suspension of washed RBCs in PBS (0.1 ml) was added to the peptide solutions. The plate was incubated at 37◦Cfor 1 h and centrifuged at 150000000 ug for 0.083333 h. Aliquots of 0.1 mlweretransferred to a 96-well flat-bottomed microtitre plate (Falcon) and the absorbance was measured at 405 nm with an automatic Multiskan Ascent plate reader (Labsystems). The amount of haemolysis was calculated as the percentage ofmaximum lysis (1%Triton X-100 control) after adjusting for minimum lysis (PBS control). Synthetic melittin (Sigma) was used for comparison. The haemolytic dose necessary to lyse 50% of the RBCs (HD50) was calculated using the regression constant from the linear portion of the haemolytic titration curve (Graphpad Prism software).|||The document mentions hemolysis-related data for various cyclic peptides isolated from Viola odorata, as follows: - cycloviolacin O2: At a concentration of 25 µM, the hemolysis rate is about 40%, and the half-hemolysis concentration (HD_{50}) is about 36 µM. - cycloviolacin O13: At a concentration of 25 µM, the hemolysis rate is about 60%, and the HD_{50} is about 11 µM. - cycloviolacin O14: At a concentration of 25 µM, the hemolysis rate is about 11%, making it the cyclic peptide with the lowest hemolysis among the new peptides. - cycloviolacin O15: At a concentration of 25 µM, the hemolysis rate is about 25%. - cycloviolacin O24: At a concentration of 25 µM, the hemolysis rate is about 75%, making it the cyclic peptide with the highest hemolysis among the new peptides. - varv A: At a concentration of 25 µM, the hemolysis rate is about 50%. - kalata B1: At a concentration of 25 µM, the hemolysis rate is about 30%. These data were obtained through hemolysis experiments using human type A red blood cells as the experimental subject, with 1% Triton X-100 treated group as the maximum hemolysis control and PBS treated group as the minimum hemolysis control, and the hemolysis percentage was calculated accordingly.|||[Ref:16872274] It has 50% hemolytic activity at 1 uM and 75% hemolytic activity at 1.5 uM against human type A red blood cells|||[Ref:16872274] It has 50% hemolytic activity at 1 uM and 75% hemolytic activity at 1.5 uM against human type A red blood cells" Biochem J. 2006 Nov 15;400(1):1-12. Pub-Med.|||Biochem J. 2006 Nov 15;400(1):1-12. doi: 10.1042/BJ20060627.|||Biochem J. 2006 Nov 15;400(1):1-12.Biopolymers. 2008;90(1):51-60. 30 FPDB00079 AP01065|||AP01065|||DRAMP00817|||DRAMP00817 GSIPACGESCFKGKCYTPGCSCSKYPLCAKN Antiviral||Antiparasitic||Anti-HIV||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.44 uM||Insecticidal Viola odorata|||Viola odorata|||Viola odorata (Sweet violet)|||Viola odorata (Sweet violet) Combine||Combine helix and strand structure "The document mentions hemolysis-related data for various cyclic peptides isolated from Viola odorata, as follows: - cycloviolacin O2: At a concentration of 25 µM, the hemolysis rate is about 40%, and the half-hemolysis concentration (HD_{50}) is about 36 µM. - cycloviolacin O13: At a concentration of 25 µM, the hemolysis rate is about 60%, and the HD_{50} is about 11 µM. - cycloviolacin O14: At a concentration of 25 µM, the hemolysis rate is about 11%, making it the cyclic peptide with the lowest hemolysis among the new peptides. - cycloviolacin O15: At a concentration of 25 µM, the hemolysis rate is about 25%. - cycloviolacin O24: At a concentration of 25 µM, the hemolysis rate is about 75%, making it the cyclic peptide with the highest hemolysis among the new peptides. - varv A: At a concentration of 25 µM, the hemolysis rate is about 50%. - kalata B1: At a concentration of 25 µM, the hemolysis rate is about 30%. These data were obtained through hemolysis experiments using human type A red blood cells as the experimental subject, with 1% Triton X-100 treated group as the maximum hemolysis control and PBS treated group as the minimum hemolysis control, and the hemolysis percentage was calculated accordingly.|||[Ref:16872274] It has 3% hemolytic activity at 1 uM and 13% hemolytic activity at 1.5 uM against human type A red blood cells|||[Ref:16872274] It has 3% hemolytic activity at 1 uM and 13% hemolytic activity at 1.5 uM against human type A red blood cells" Biochem J. 2006 Nov 15;400(1):1-12. Pub-Med.|||Biochem J. 2006 Nov 15;400(1):1-12. doi: 10.1042/BJ20060627.||Ireland et al., 2008|||Biochem J. 2006 Nov 15;400(1):1-12. Pub-Med.|||Biochem J. 2006 Nov 15;400(1):1-12.Biopolymers. 2008;90(1):51-60.|||Biochem J. 2006 Nov 15;400(1):1-12.Biopolymers. 2008;90(1):51-60. 31 FPDB00080 AP01066|||AP01066|||DRAMP00828 GLPTCGETCFGGTCNTPGCTCDPWPVCTHN Antiviral||Anti-HIV||Hemolytic||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.308 uM||Insecticidal Viola odorata|||Viola odorata|||Viola odorata (Sweet violet) Bridge "The document mentions hemolysis-related data of cyclic peptides isolated from Viola yedoensis, as follows: - Kalata B1: half-hemolysis concentration (HD_{50}) is 11.7 µM, 95% confidence interval 10.2–13.4 µM. - Cycloviolacin Y4: HD_{50} is 9.3 µM, 95% confidence interval 7.7–11.1 µM. - Cycloviolacin Y5: HD_{50} is 8.7 µM, 95% confidence interval 7.4–10.2 µM. - Cycloviolacin Y1: within the tested concentration range, hemolysis is significantly lower than the above cyclic peptides and is the lowest among them. - Melittin (positive control): HD_{50} is 0.94 µM, 95% confidence interval 0.9–0.97 µM, with hemolysis much higher than the tested cyclic peptides. These data were obtained via hemolysis experiments using human type A red blood cells, with 1% Triton X-100 treatment as the maximum hemolysis control and PBS treatment as the minimum hemolysis control, and the hemolysis percentage was calculated.|||[Ref:16872274] It has 75% hemolytic activity at 25 uM against human type A red blood cells." Biochem J. 2006 Nov 15;400(1):1-12. Pub-Med.|||Biochem J. 2006 Nov 15;400(1):1-12. doi: 10.1042/BJ20060627.||Ireland et al., 2008|||Biochem J. 2006 Nov 15;400(1):1-12. Pub-Med.|||Biochem J. 2006 Nov 15;400(1):1-12.Biopolymers. 2008;90(1):51-60.|||Biochem J. 2006 Nov 15;400(1):1-12.##Biopolymers. 2008;90(1):51-60. 30 FPDB00081 AP01077|||DRAMP00833|||AP01077|||DRAMP00833|||Cycloviolacin Y1 " GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN" Antiviral||Anti-HIV||Hemolytic||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 1.21 uM||Antimicrobial||Anti-HIV, activity value is EC50 = 1.2 uM Chinese herb Viola yedoensis and Viola odorata|||Pelophylax esculentus (Edible frog) (Rana esculenta)|||Chinese herb Viola yedoensis and Viola odorata|||Viola yedoensis (Chinese herb)|||Viola yedoensis Bridge "The document mentions hemolysis-related data of cyclic peptides isolated from Viola yedoensis, as follows: - Kalata B1: half-hemolysis concentration (HD_{50}) is 11.7 µM, 95% confidence interval 10.2–13.4 µM. - Cycloviolacin Y4: HD_{50} is 9.3 µM, 95% confidence interval 7.7–11.1 µM. - Cycloviolacin Y5: HD_{50} is 8.7 µM, 95% confidence interval 7.4–10.2 µM. - Cycloviolacin Y1: within the tested concentration range, hemolysis is significantly lower than the above cyclic peptides and is the lowest among them. - Melittin (positive control): HD_{50} is 0.94 µM, 95% confidence interval 0.9–0.97 µM, with hemolysis much higher than the tested cyclic peptides. These data were obtained via hemolysis experiments using human type A red blood cells, with 1% Triton X-100 treatment as the maximum hemolysis control and PBS treatment as the minimum hemolysis control, and the hemolysis percentage was calculated.|||[Ref.18081258] It has hemolytic activity.|||Human type A erythrocytes ( IC50 > 4.5 uM )" J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52. doi: 10.1021/np70393000000 ug. Epub 2007 Dec 15.||Ireland et al., 2008|||J. Biol. Chem. 269:11956-11961(1994)|||J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52. Biopolymers. 2008;90(1):51-60.|||https://pubmed.ncbi.nlm.nih.gov/18081258 33 FPDB00082 AP01080|||DRAMP00836|||AP01080|||DRAMP00836|||Cycloviolacin Y4 " GVPCGESCVFIPCITGVIGCSCSSNVCYLN" Antiviral||Anti-HIV||Hemolytic||Antimicrobial||Anti-HIV, activity value is EC50 = 0.12 uM Chinese herb Viola yedoensis and Viola odorata|||Chinese herb Viola yedoensis|||Viola hederacea (Australian violet)|||Chinese herb Viola yedoensis|||Viola yedoensis (Chinese herb)|||Viola yedoensis Bridge "The document mentions hemolysis-related data of cyclic peptides isolated from Viola yedoensis, as follows: - Kalata B1: half-hemolysis concentration (HD_{50}) is 11.7 µM, 95% confidence interval 10.2–13.4 µM. - Cycloviolacin Y4: HD_{50} is 9.3 µM, 95% confidence interval 7.7–11.1 µM. - Cycloviolacin Y5: HD_{50} is 8.7 µM, 95% confidence interval 7.4–10.2 µM. - Cycloviolacin Y1: within the tested concentration range, hemolysis is significantly lower than the above cyclic peptides and is the lowest among them. - Melittin (positive control): HD_{50} is 0.94 µM, 95% confidence interval 0.9–0.97 µM, with hemolysis much higher than the tested cyclic peptides. These data were obtained via hemolysis experiments using human type A red blood cells, with 1% Triton X-100 treatment as the maximum hemolysis control and PBS treatment as the minimum hemolysis control, and the hemolysis percentage was calculated.|||[Ref:18081258] HD50=9.3 uM against human type A red blood cells." J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52. doi: 10.1021/np70393000000 ug. Epub 2007 Dec 15.|||J Mol Biol. 1999 Dec 17;294(5):1327-1336.|||J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52.Biopolymers. 2008;90(1):51-60.Chembiochem. 2008 Aug 11;9(12):1939-45. doi: 10.1002/cbic.200800174.|||https://pubmed.ncbi.nlm.nih.gov/18081258 30 FPDB00083 AP01081|||DRAMP00837|||AP01081|||DRAMP00837|||Cycloviolacin Y5 GIPCAESCVWIPCTVTALVGCSCSDKVCYN Antiviral||Anti-HIV||Hemolytic||Anti-It inhibited HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.04 uM||Antimicrobial||Anti-HIV, activity value is EC50 = 0.04 uM Chinese herb Viola yedoensis and Viola odorata|||Chinese herb Viola yedoensis|||Viola yedoensis (Chinese herb)|||Chinese herb Viola yedoensis|||Viola yedoensis (Chinese herb)|||Viola yedoensis Bridge "The document mentions hemolysis-related data of cyclic peptides isolated from Viola yedoensis, as follows: - Kalata B1: half-hemolysis concentration (HD_{50}) is 11.7 µM, 95% confidence interval 10.2–13.4 µM. - Cycloviolacin Y4: HD_{50} is 9.3 µM, 95% confidence interval 7.7–11.1 µM. - Cycloviolacin Y5: HD_{50} is 8.7 µM, 95% confidence interval 7.4–10.2 µM. - Cycloviolacin Y1: within the tested concentration range, hemolysis is significantly lower than the above cyclic peptides and is the lowest among them. - Melittin (positive control): HD_{50} is 0.94 µM, 95% confidence interval 0.9–0.97 µM, with hemolysis much higher than the tested cyclic peptides. These data were obtained via hemolysis experiments using human type A red blood cells, with 1% Triton X-100 treatment as the maximum hemolysis control and PBS treatment as the minimum hemolysis control, and the hemolysis percentage was calculated.|||[Ref:18081258] HD50=8.7 uM against human type A red blood cells." J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52. doi: 10.1021/np70393000000 ug. Epub 2007 Dec 15.||Ireland et al., 2008|||J Nat Prod. 2008 Jan;71(1):47-52.Biopolymers. 2008;90(1):51-60.Chembiochem. 2008 Aug 11;9(12):1939-45. doi: 10.1002/cbic.200800174.|||J Nat Prod. 2008 Jan;71(1):47-52. Pub-Med.|||J Nat Prod. 2008 Jan;71(1):47-52. Biopolymers. 2008;90(1):51-60.Chembiochem. 2008 Aug 11;9(12):1939-45. doi: 10.1002/cbic.200800174.|||https://pubmed.ncbi.nlm.nih.gov/18081258 30 FPDB00084 AP01136|||AP01136|||Tricyclon A GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN Anti-Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-E.coli, activity value is MIC = 160 uM||Anti-P. aeruginosa, activity value is MIC = 80 uM||Anti-S.aureus, activity value is MIC = 160 uM||Anti-C. albicans, activity value is MIC = 80 uM||Antibacterial Australian flowers, Viola tricolor|||Australian flowers, Viola tricolor|||Viola odorata L. and Viola tricolor L Beta "Under specific hemolysis experimental conditions, after incubating 500 uM of tricyclon A with red blood cells at 37°C for 1 hour, the hemolysis rate was only 2%; under the same conditions, about 100 uM of kalata B1 resulted in a hemolysis rate of 50%. The HD50 of kalata B1 at 37°C is 100 uM, while tricyclon A exhibits very low hemolytic activity.|||The document mentions hemolytic-related data for tricyclon A and kalata B1, as follows: - Tricyclon A: At a concentration of 500 µM, after incubation at 37°C for 1 hour, it only caused 2% hemolysis of red blood cells, indicating very low hemolytic activity. - Kalata B1 (for comparison): Under the same experimental conditions, the half-hemolysis concentration (HD_{50}) is about 100 µM, meaning the concentration that causes 50% hemolysis of red blood cells is 100 µM. These data were obtained through hemolysis experiments using human type A red blood cells as the experimental subject, with a 1% Triton X-100 treatment group as the maximum hemolysis control and a PBS treatment group as the minimum hemolysis control. The hemolysis percentage was calculated accordingly." Structure. 2005 May;13(5):691-701|||Structure. 2005 May;13(5):691-701||Strömstedt et al., 2017|||Structure. 2005 May;13(5):691-701|||28669767 33 FPDB00085 AP01137|||AP01137|||Siamycin I|||AP01137|||DRAMP18349|||Siamycin I CLGVGSCNDFAGCGYAVVCFW Anti-Gram+||Antiviral||Anti-HIV||Anti-Gram+ bacteria WT S. aureus ATCC29213, activity value is MIC = 3.7 uM||Anti-Staphylococcus aureus FDA209P JC-1, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus smith, activity value is MIC = 6.3 ug/ml||Anti-Staphylococcus aureus A15036, activity value is MIC = 3.1 ug/ml||Anti-Micrococcus luteus ATCC 9341, activity value is MIC = 1.6 ug/ml||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 1.6 ug/ml||Anti-Escherichia coli Juhl, activity value is MIC > 100 ug/ml||Anti-E. coli K12, activity value is MIC > 100 ug/ml||Anti-E. coli NIHJ JC-2, activity value is MIC > 100 ug/ml||Anti-K. pneumoniae ATCC 10031, activity value is MIC > 100 ug/ml||Anti-Citrobacter freundii GN 7391, activity value is MIC > 100 ug/ml||Anti-Salmonella typhi 901, activity value is MIC > 100 ug/ml||Anti-P. aeruginosa A9843A, activity value is MIC > 100 ug/ml||Antimicrobial Streptomyces strain AA6532 Beta||Beta strand No hemolysis information or data found in the reference(s) presented in this entry J Antibiot (Tokyo). 1995 Dec;48(12):1515-7|||J Antibiot (Tokyo). 1995 Dec;48(12):1515-7|||8557614|||J Antibiot (Tokyo). 1995 Dec;48(12):1515-7|||J Antibiot (Tokyo). 1995 Dec;48(12):1515-7.|||8557614 21 FPDB00086 AP01138|||AP01138|||DRAMP18347|||NP-06 CLGVGSCNDFAGCGYAIVCFW Antiviral||Anti-HIV||Antimicrobial||Anti-HIV-1LAI, activity value is IC50 = 2.8 uM||Anti-HIV 2ROD, activity value is IC50 = 6 uM||Anti-HIV-1ERS104pre, activity value is IC50 = 1.3 uM Streptomyces strain AA6532|||Streptomyces strain AA6532|||Streptomyces sp. No. 73264 Bridge No hemolysis information or data found in the reference(s) presented in this entry Antimicrob Agents Chemother. 1995 Oct;39(10):2345-7|||Antimicrob Agents Chemother. 1995 Oct;39(10):2345-7|||Antimicrob Agents Chemother. 1995 Oct;39(10):2345-7.|||8619594 21 FPDB00087 AP01184|||DRAMP31009|||AP01184|||Mucroporin-M1|||DRAMP31009 " LFRLIKSLIKRLVSAFK" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-Mucroporin-M1 is active against E. coli AB94012, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 100 ug/ml||Anti-B. thuringiensis AB92037, activity value is MIC = 25 ug/ml||Anti-B. subtilis AB91021, activity value is MIC = 25 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 5 ug/ml||Anti-clincal stain 1538 as well as HIV-1. Also active against measles McV, activity value is EC50 = 7.15 ug/ml||Anti-SARS-CoV, activity value is EC50 = 14.46 ug/ml||Anti-and influenza A virus H5N1, activity value is EC50 = 2.1 ug/ml||Anti-measles virus :inhibition of MeV infection in Vero cells, activity value is EC50 = 7.15 ug/ml||Anti-SARS-CoV :inhibition of SARS-CoV infection in MDCK cells, activity value is EC50 = 14.46 ug/ml||Anti-H5N1 :inhibition of H5N1 infection in MDCK cells, activity value is EC50 = 2.1 ug/ml||Anti-Measles virus, activity value is EC50 = 7.15 ug/ml||Anti-H5N1, activity value is EC50 = 2.1 ug/ml||Antimicrobial Enterococcus faecium T8|||animal-derived, natural derivative|||Enterococcus faecium T8|||Synthetic construct(derived from Mucroporin)|||Enterococcus faecium T8|||Synthetic construct|||Synthetic construct(derived from Mucroporin) N/A BACTER Appl Environ Microbiol. 2006 Jul;72(7):4761-6|||Appl Environ Microbiol. 2006 Jul;72(7):4761-6||Li et al., 2011|||Ref.21620914|||Appl Environ Microbiol. 2006 Jul;72(7):4761-6|||https://pubmed.ncbi.nlm.nih.gov/26492266,|||Peptides. 2011 Jul;32(7):1518-25. 17 FPDB00088 AP01207|||AP01207|||Retrocyclin-1 GICRCICGRGICRCICGR Antiviral||Anti-HIV||Anti-toxin||Antiviral ; HIV-1 mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||Synthetic construct Bridge N/A Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1813-8|||Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1813-8|||https://pubmed.ncbi.nlm.nih.gov/15210812 18 FPDB00089 AP01208|||AP01208|||Retrocyclin-2 " GICRCICGRRICRCICGR" Antiviral||Anti-HIV||Anti-toxin||RC2 is most active against primary isolates of HIV-1. The molecule can self associate in water in a concentration dependent manner.||Antiviral ; HIV-1 mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||Synthetic construct Beta N/A J Immunol. 2004 Jul 1;173(1):515-20|||J Immunol. 2004 Jul 1;173(1):515-20|||https://pubmed.ncbi.nlm.nih.gov/15210812 18 FPDB00090 AP01223|||AP01223|||Ascaphin-8|||Ascaphin-8|||AP01223|||DRAMP01847|||AP01223|||DRAMP01847 " GFKDLLKGAAKALVKTVLF" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Enzyme inhibitor||Anticancer||Anti-E. coli, activity value is MIC = 6 uM||Anti-P. aeruginosa, activity value is MIC = 13 uM||Anti-E. cloacae, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 6 uM||Anti-S. epidermidis, activity value is MIC = 6 uM||Anti-Streptococcus Group B, activity value is MIC = 6 uM||Anti-E. faecalis, activity value is MIC = 50 uM||Anti-and C. albicans, activity value is MIC = 25 uM||Anti-Escherichia coli, activity value is MIC = 6 uM||Anti-Staphylococcus aureus, activity value is MIC = 6 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 50 uM||Anti-Enterobacter cloacae, activity value is MIC = 13 uM||Anti-Klebsiella pneumoniae, activity value is MIC = 25 uM||Anti-Proteus mirabilis, activity value is MIC > 100 uM||Anti-S. epidermidis, activity value is MIC = 25 uM||Anti-E. faecalis, activity value is MIC > 100 uM||Anti-Streptococcus Group B, activity value is MIC = 13 uM||Anti-C. albicans, activity value is MIC = 100 uM||Anti-E. coli ATCC25922, activity value is MIC = 3 uM||Anti-S. aureus ATCC25923, activity value is MIC = 3 uM||Anti-E. coli ML35p, activity value is MIC = 1.6 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 3 uM||Anti-S. aureus multiresistant ATCCBAA-44, activity value is MIC = 3 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 12.5 uM||Anti-A549, activity value is IC50 = 33.79 uM||Anti-C4-2B, activity value is IC50 = 42.91 uM||Anti-HEK293T, activity value is IC50 = 53.67 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Ascaphus truei [Coastal tailed frog]|||Ascaphus truei (Coastal tailed frog)|||Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Ascaphus truei (Coastal tailed frog) Helix "Free acid HC50>200 Amidated HC50=55|||Endogenous peptides: ascaphin-1: Half-maximal hemolytic concentration (HC_{50}) for human red blood cells >200 μM. ascaphin-3: HC_{50} >200 μM. ascaphin-7: HC_{50} >200 μM. ascaphin-8: HC_{50} is 50 μM. Synthetic peptides: ascaphin-1 (free acid form): HC_{50} >200 μM; amidated form: HC_{50} >200 μM. ascaphin-5 (free acid form): HC_{50} >200 μM. ascaphin-8 (amidated form): HC_{50} is 55 μM. The above results were obtained through hemolysis experiments. In the experiments, peptides at different concentrations were incubated with washed human red blood cells for 1 hour, and the degree of hemolysis was measured by absorbance at 450 nm. The 1% Tween 20 treated group was used as the 100% hemolysis control, and HC_{50} was defined as the peptide concentration producing 50% hemolysis.|||Ascaphin-1: HC₅₀ > 200 uM. Ascaphin-3: HC₅₀ > 200 uM. Ascaphin-7: HC₅₀ > 200 uM. Ascaphin-8: Endogenous Ascaphin-8: HC₅₀ = 50 uM. Synthetic amidated Ascaphin-8: HC₅₀ = 55 uM. Ascaphin-5: HC₅₀ > 200 uM.|||Human erythrocytes ( HC50 = 50 uM ); Refer PubMed ID 23094651: Rat RBCs [HC50 = 115 uM], PubMed ID 33932712: Rabbit RBC [HC50 = >100 miroM]|||Human erythrocytes ( HC50 = 50 uM ); Refer PubMed ID 23094651: Rat RBCs [HC50 = 115 uM], PubMed ID 33932712: Rabbit RBC [HC50 = >100 miroM]|||The therapeutic potential of ascaphin-8 as an antiinfective agent is limited by its moderately high haemolytic activity (HC50 ¼ 55 lM) In contrast, ascaphin-1 and ascaphin-5, although displaying high potencies only against Gram-negative bacteria, have very low haemolytic activities (HC50 >200 lM) compared with many other frog skin peptides. By way of comparison, the HC50 values of brevinin-1E from Rana esculenta [22] and temporin L from Rana temporaria [23] are less than 2 lM.|||[Ref.15207717]HC50=50 uM against human erythrocytes|||The document mentions the hemolytic values of various ascaphin peptides (expressed as HC_{50}, which is the peptide concentration that causes 50% hemolysis), as follows: Hemolytic values of endogenous peptides (Table 1) - Ascaphin-1: HC_{50} > 200 μM - Ascaphin-3: HC_{50} > 200 μM - Ascaphin-7: HC_{50} > 200 μM - Ascaphin-8: HC_{50} = 50 μM Hemolytic values of synthetic peptides (Table 2) - Ascaphin-1 (free acid form): HC_{50} > 200 μM - Ascaphin-1 (amidated form): HC_{50} > 200 μM - Ascaphin-5 (free acid form): HC_{50} > 200 μM - Ascaphin-8 (amidated form): HC_{50} = 55 μM|||[Ref.15207717]HC50=50 uM against human erythrocytes|||hemolytic HC50 50 uM. TC50 2.9 uM in CEM-SS cells(Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346)." "Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||Comparative Study Biochem Biophys Res Commun . 2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.|||2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||15207717, 33932712, 23094651||Refer PubMed ID 23094651|||15207717, 33932712, 23094651||Refer PubMed ID 23094651||Refer PubMed ID 33932712|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||Ref.15207717|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-175." 19 FPDB00091 AP01269|||AP01269|||Melectin " GFLSILKKVLPKVMAHMK" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Anti-B. subtilis, activity value is MIC = 0.8 uM||Anti-S. aureus MRSA, activity value is MIC = 6.8||Anti-E. coli, activity value is MIC = 2||Anti-and P. aeruginosa, activity value is MIC = 18.5 uM||Anti-the peptide was found to inhibit Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 4.34 uM||Anti-B.subtilis, activity value is MIC = 0.8 uM||Anti-S.aureus, activity value is MIC = 6.8 uM||Anti-E.coli, activity value is MIC = 2 uM||Anti-P.aeruginosa, activity value is MIC = 18.5 uM the Cleptoparasitic bee, Melecta albifrons|||the Cleptoparasitic bee, Melecta albifrons|||Melecta albifrons [Cuckoo bee] Helix "MEP: The half-maximal hemolytic concentration (LC_{50}) on rat red blood cells is >100 µM, indicating low hemolytic activity. MEP-1: LC_{50} is 27.3 µM. MEP-2: LC_{50} is 22.9 µM. MEP-3: LC_{50} is 29.7 µM. MEP-4: LC_{50} is 41.4 µM. MEP-5, MEP-6, MEP-7, MEP-8, MEP-9, MEP-10: LC_{50} are all >100 µM, showing no significant hemolytic activity. The above results were obtained through hemolysis experiments, in which peptides at different concentrations were incubated with rat red blood cells at 37°C for 1 hour. Hemolysis was measured by absorbance at 540 nm, with a 0.2% Triton X-100 treated group as the 100% hemolysis control. LC_{50} refers to the peptide concentration that produces 50% hemolysis. The results indicate that the original MEP has the lowest hemolytic activity, whereas analogs in which Pro11 was replaced or deleted (MEP-1 to MEP-4) show significantly increased hemolytic activity.|||The document mentions that the hemolytic concentration (LC₅₀) of natural bee venom peptide Melectin (MEP) is greater than 100 μM, showing extremely low hemolytic activity. In contrast, the hemolytic values of its analogs (such as MEP-1, MEP-2, etc.) range from 22.9 μM to 41.4 μM.|||The hemolytic value LC_{50} of MEP is > 100 μM; the hemolytic value LC_{50} of MEP-1 is 27.3 μM; the hemolytic value LC_{50} of MEP-2 is 22.9 μM; the hemolytic value LC_{50} of MEP-3 is 29.7 μM; the hemolytic value LC_{50} of MEP-4 is 41.4 μM; the hemolytic value LC_{50} of MEP-5 is > 100 μM; the hemolytic value LC_{50} of MEP-6 is > 100 μM; the hemolytic value LC_{50} of MEP-7 is > 100 μM; the hemolytic value LC_{50} of MEP-8 is > 100 μM; the hemolytic value LC_{50} of MEP-9 is > 100 μM; the hemolytic value LC_{50} of MEP-10 is > 100 μM." "Chembiochem. 2008 Nov 24;9(17):2815-21. PubMed|||Chembiochem. 2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.||Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346|||Chembiochem . 2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.|||2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.||Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346|||18942691" 18 FPDB00092 AP01271|||DRAMP01225|||AP01271|||DRAMP01225 GIFPKIIGKGIVNGIKSLAKGVGMKVFKAGLNNIGNTGCNNRDEC Anti-Gram-||Antiviral||Anti-HIV||Anti-E. coli, activity value is MIC = 6 uM||Anti-but not Staph (S.aureus or C.albicans, activity value is MIC > 200 uM||Antimicrobial||Antibacterial the crawfish frog, Rana areolata, North America|||the crawfish frog, Rana areolata, North America|||Amolops jingdongensis (Chinese torrent frog)|||the crawfish frog, Rana areolata, North America|||Rana areolata (North American crawfish frog) N/A "The document mentions the hemolytic values of various peptides, with the following specific information: palustrin-3AR: hemolytic concentration (HC₅₀) is 200 µM. esculentin-1ARa: HC₅₀ is 180 µM. esculentin-1ARb: HC₅₀ is 120 µM. ranatuerin-2ARa: HC₅₀ is 100 µM. ranatuerin-2ARb: HC₅₀ is 150 µM. temporin-1AR: HC₅₀ is 210 µM. palustrin-2AR: no significant hemolysis observed at a concentration of 300 µM.|||The hemolytic values of various antimicrobial peptides mentioned in the document (expressed as HC_{50}, the peptide concentration that causes 50% hemolysis of human red blood cells) are as follows: - Palustrin-3AR: HC_{50} = 200 μM - Esculentin-1ARa: HC_{50} = 180 μM - Esculentin-1ARb: HC_{50} = 120 μM - Ranatuerin-2ARa: HC_{50} = 100 μM - Ranatuerin-2ARb: HC_{50} = 150 μM - Palustrin-2AR: HC_{50} > 300 μM - Temporin-1AR: HC_{50} = 210 μM|||[Ref:12429503] HC50=200 uM against human erythrocytes" Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. PubMed|||Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. doi: 10.1016/s1570-9639(02)00432-6.|||2002 Nov 19;1601(1):55-63. doi: 10.1016/s1570-9639(02)00432-6.|||Biochimie. 2012 Feb;94(2):328-334.|||Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. PubMed|||Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. 45 FPDB00093 AP01273|||DRAMP01475 GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-E. coli, activity value is MIC = 3 uM||Anti-but not C.albicans, activity value is MIC > 200 uM the crawfish frog, Rana areolata, North America|||the crawfish frog, Rana areolata, North America|||Rana areolata (crawfish frog) N/A "The document mentions the hemolytic values of various peptides, with the following specific information: palustrin-3AR: hemolytic concentration (HC₅₀) is 200 µM. esculentin-1ARa: HC₅₀ is 180 µM. esculentin-1ARb: HC₅₀ is 120 µM. ranatuerin-2ARa: HC₅₀ is 100 µM. ranatuerin-2ARb: HC₅₀ is 150 µM. temporin-1AR: HC₅₀ is 210 µM. palustrin-2AR: no significant hemolysis observed at a concentration of 300 µM.|||[Ref:12429503] HC50=120 uM against human erythrocytes|||The hemolytic values of various antimicrobial peptides mentioned in the document (expressed as HC_{50}, the peptide concentration that causes 50% hemolysis of human red blood cells) are as follows: - Palustrin-3AR: HC_{50} = 200 μM - Esculentin-1ARa: HC_{50} = 180 μM - Esculentin-1ARb: HC_{50} = 120 μM - Ranatuerin-2ARa: HC_{50} = 100 μM - Ranatuerin-2ARb: HC_{50} = 150 μM - Palustrin-2AR: HC_{50} > 300 μM - Temporin-1AR: HC_{50} = 210 μM" "Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. PubMed|||Biochim Biophys Acta. 2002 Nov 19;1601(1):55-63. doi: 10.1016/s1570-9639(02)00432-6.|||2002 Nov 19;1601(1):55-63. doi: 10.1016/s1570-9639(02)00432-6.|||[Ref.12429503]Gram-negative bacterium: Escherichia coli (MIC=3 uM); Gram-positive bacterium: Staphylococcus aureus (MIC=60 uM)." 46 FPDB00094 AP01348|||AP01348|||Temporin-LTc|||DRAMP01784|||AP01348|||DRAMP01784 " SLSRFLSFLKIVYPPAF" Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 50 ug/ml||Anti-Bacillus subtilis ATCC6633, activity value is MIC = 50 ug/ml||Anti-Pseudomonas fluorescens ATCC13525, activity value is MIC = 100 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 50 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 50 ug/ml||Anti-Pseudomonas fluorescens, activity value is MIC = 100 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- Chinese broad-folded frog, Hylarana latouchii (Anura:Ranidae), China, Asia|||Chinese broad-folded frog, Hylarana latouchii (Anura:Ranidae), China, Asia|||Hylarana latouchii|||Hylarana latouchii (broad-folded frog)|||Chinese broad-folded frog, Hylarana latouchii (Anura:Ranidae), China, Asia|||Hylarana latouchii (broad-folded frog) N/A "The document mentions the following values related to hemolysis: brevinin-1LTa: The median lethal concentration (LD₅₀) for rabbit red blood cells is 1.5 µg/ml, showing strong hemolytic activity. temporin-LTa: The median lethal concentration (LD₅₀) for rabbit red blood cells is 9 µg/ml, with relatively weak hemolytic activity. temporin-LTb and temporin-LTc: No significant hemolytic activity was detected at concentrations up to 200 µg/ml.|||Rabbit erythrocytes ( LD50 > 200 ug/ml )|||No hemolysis information or data found in the reference(s) presented in this entry" Peptides. 2009 Feb;30(2):273-82. Pub-Med.|||Peptides. 2009 Feb;30(2):273-82. doi: 10.1016/j.peptides.2008.10.016. Epub 2008 Nov 5.|||2009 Feb;30(2):273-82. doi: 10.1016/j.peptides.2008.10.016. Epub 2008 Nov 5.|||19022312|||Peptides. 2009 Feb;30(2):273-82. Pub-Med.|||Peptides. 2009 Feb;30(2):273-282. 17 FPDB00095 AP01434|||AP01434|||Temporin-PTa|||DRAMP01802 FFGSVLKLIPKIL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Antibiofilm||Anti-the natural form was not evaluated due to a low amount of the peptide. A synthetic peptide was found to be active. The L and D-forms of the peptide showed identical antibacterial activity against E. coli, activity value is MIC = 25 uM||Anti-B. subtilis, activity value is MIC = 6.25 uM||Anti-and S. aureus USA300 MRSA, activity value is MIC = 3.1 uM||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- Hylarana picturata, Asia|||Hylarana picturata, Asi|||Rana picturata [Malaysian fire frog]|||Rana picturata (Malaysian fire frog) (Hylarana picturata) Helix N/A "Toxicon. 2008 Sep 1;52(3):465-73. Pub-Med.|||Toxicon. 2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||Toxicon . 2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||18621071|||Toxicon. 2008 Sep 1;52(3):465-473." 13 FPDB00096 AP01580|||AP01580|||Elafin AQEPVKGPVSTKPGSCPIILIRCAMLNPPNRCLKDTDCPGIKKCCEGSCGMACFVPQ Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-HIV||Enzyme inhibitor||Antimalarial||active against P. aeruginosa PAO1 and S. aureus C1705. Active against HIV-1 and HSV-2 (Drannik AG||et al 2013). The anti-HIV activity of Elafin is 130 times more potent than its precursor serine antiprotease trappin-2 (Drannik AG||et al 2012).||Antibacterial ; S. aureus||P. aeruginosa gammadelta T cells, keratinocytes, epithelial cells, skin, Homo sapiens|||skin, Homo sapiens|||Homo sapiens [Human] Beta no hemolytic activity FEBS Lett. 1999 Jun 11;452(3):309-13. doi: 10.1016/s0014-5793(99)00670-5. PubMed|||FEBS Lett. 1999 Jun 11;452(3):309-13. doi: 10.1016/s0014-5793(99)00670-5.|||Scand J Immunol. 2009 Dec;70(6):547-52|||16336202 57 FPDB00097 AP01654|||AP01654|||Caerin-1.19|||AP01654|||DRAMP01586 GLFKVLGSVAKHLLPHVAPIIAEKL Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- skin dorsal glands, Australian dainty green tree frog, Litoria gracilenta|||skin dorsal glands, Australian dainty green tree frog, Litoria gracilenta|||Litoria gracilenta [Dainty green tree frog]|||skin dorsal glands, Australian dainty green tree frog, Litoria gracilenta|||Litoria gracilenta (Dainty green tree frog) N/A Bacillus cereus ( MIC = 50 ug/ml), Leuconostoc lactis ( MIC = 3 ug/ml), Listeria innocua ( MIC = 12 ug/ml), Micrococcus luteus ( MIC = 25 ug/ml), Staphylococcus aureus Strain ATCC 25923 ( MIC = 12 ug/ml), Staphylococcus aureus Strain ATCC 29213 ( MIC = 12 ug/ml), Staphylococcus epidermidis ( MIC = 12 ug/ml), Streptococcus uberis ( MIC = 25 ug/ml), Pasteurella multocida ( MIC = 50 ug/ml)|||No hemolysis information or data found in the reference(s) presented in this entry Toxicon. 2006 May;47(6):664-75|||Toxicon. 2006 May;47(6):664-75|||16554081|||Toxicon. 2006 May;47(6):664-75|||Peptides. 2015 Sep;71:296-303.Toxicon. 2006 May;47(6):664-675. 25 FPDB00098 AP01672|||AP01627|||AP01672|||RC-101 " GICRCICGKGICRCICGR" Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-toxin||Antibiofilm||inhibit S. aureus USA300||viruses HIV-1||SARS-Cov-2||influenza.||Antibacterial amino acid substitution, mammal theta-defensin analog, animal-derived, natural derivative|||amino acid substitution, mammal theta-defensin analog, animal-derived, natural derivative|||Synthetic construct Bridge N/A "RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. PubMed.|||2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.||Lamers et al., 2011|||AIDS Res Hum Retroviruses.2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.||Lamers et al., 2011|||AIDS Res Hum Retroviruses . 2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.|||AIDS Res Hum Retroviruses . 2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.|||16790431" 18 FPDB00099 AP01978|||AP01978|||BmKn2|||CAMPSQ14088|||CAMPSQ14139|||CAMPSQ14397 " FIGAIARLLSKIF" "Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Hemolytic||Antibiofilm||Wound healing||Anticancer Crucial residues:||Anticancer||Anti-Gram+ bacteria S. aureus AB94004 or ATCC 25923 or MRSA P1386, activity value is MIC = 0.6 ug/ml||Anti-M. luteus AB93113, activity value is MIC = 8 ug/ml||Anti-B. subtilis AB91021, activity value is MIC = 5 ug/ml||Anti-B. thuringiensis AB92037, activity value is MIC = 12.5 ug/ml||Anti-S. epidermidis, activity value is MIC = 2.5||Anti-E. faecalis, activity value is MIC = 10 ug/ml||Anti-E. faecium, activity value is MIC = 10 ug/ml||Anti-E. coli, activity value is MIC = 1.5 ug/ml||Anti-P. aeruginosa AB93066 and 5 more strains, activity value is MIC = 21.3||Anti-S.aureus, activity value is MIC = 0.6 ug/ml||Anti-M.luteus, activity value is MIC = 8 ug/ml||Anti-B.subtilis, activity value is MIC = 5 ug/ml||Anti-E.coli, activity value is MIC = 1.5 ug/ml||Anti-P.aeruginosa, activity value is MIC = 21.3 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 6.25 ug/ml||Anti-Bacillus subtilis AB91021, activity value is MIC = 12.5 ug/ml||Anti-Bacillus thuringiensis AB92037, activity value is MIC = 12.5 ug/ml||Anti-Micrococcus luteus AB93113, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-S. aureus ATCC29213, activity value is MIC = 10 ug/ml||M. abscessus ATCC19977 (MIC= >400 ug/ml)" venom, Buthus martensii Karsch|||venom, Buthus martensii Karsch|||venom, Buthus martensii Karsch, China, Asia|||Mesobuthus martensii [Manchurian scorpion]|||Mesobuthus martensii|||Synthetic construct Helix venom, Buthus martensii Karsch|||Human RBCs (< 40% percent hemolysis at 100 ug/ml) "Peptides. 2004 Feb;25(2):143-50.PubMed|||Peptides. 2004 Feb;25(2):143-50.doi: 10.1016/j.peptides.2003.12.003.||Arpornsuwan et al., 2014||Mangmee et al. 2021|||Peptides . 2004 Feb;25(2):143-50. doi: 10.1016/j.peptides.2003.12.003.|||Peptides. 2004 Feb;25(2):143-50. doi: 10.1016/j.peptides.2003.12.003.||Arpornsuwan et al., 2014||Mangmee et al. 2021|||15062994|||22792229|||34335511|||34361810|||34780520" 13 FPDB00100 AP02010|||AP02010|||Caerin 1.20|||DRAMP30311|||AP02010|||DRAMP30311 GLFGILGSVAKHVLPHVIPVVAEHL Anti-Gram+||Antiviral||Anti-HIV||Anti-B. cereus, activity value is MIC = 100 ug/ml||Anti-E.faecalis, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 25 uM||Anti-L. innocua, activity value is MIC = 25 ug/ml||Anti-M. luteus, activity value is MIC = 20 ug/ml||Anti-or 29213, activity value is MIC = 25||Anti-S. epidermidis, activity value is MIC = 25 ug/ml||Anti-S. uberis, activity value is MIC = 50 ug/ml||Anti-E.clocae, activity value is MIC > 100 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-and P.multocida, activity value is MIC > 100 ug/ml||Antibacterial||Anti-Human immunodeficiency virus : inhibition of HIV Pseudovirus infection in CD4+ T cells, activity value is IC50 = 7 uM the skin secretions, hybrid between female Litoria splendida and male Litoria caerulea , Australia|||Hybrid between female Litoria splendida and male Litoria caerulea|||Litoria caerulea/Litoria splendida|||the skin secretions, hybrid between female Litoria splendida and male Litoria caerulea , Australia|||Litoria caerulea/Litoria splendida N/A the skin secretions, hybrid between female Litoria splendida and male Litoria caerulea , Australia||At a concentration of 400 μM, the hemolysis rate is < 10%. FEBS J. 2006 Aug;273(15):3511-9.PubMed|||FEBS J. 2006 Aug;273(15):3511-9.doi: 10.1111/j.1742-4658.2006.05358.x. Epub 2006 Jul 5.|||FEBS J. 2006 Aug;273(15):3511-9. doi: 10.1111/j.1742-4658.2006.05358.x. Epub 2006 Jul 5.|||16824041|||Ref.26026377|||FEBS J. 2006 Aug;273(15):3511-9.PubMed|||Peptides. 2015 Sep;71:296-303.Antibiotics (Basel). 2020 Sep 30;9(10):661.||Ref.26026377 25 FPDB00101 AP02034|||DRAMP00264|||Antifungal protein from coconut|||DRAMP00264|||AP02034|||CAMPSQ771|||DRAMP00264 EQCREEEDDR Antiviral||Antifungal||Anti-HIV||Antimicrobial||Antibacterial||Antifungal ; N.A Cocos nucifera|||Cocos nucifera|||Cocos nucifera [Coconut] N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2005 Dec;26(12):2392-6. PubMed|||Peptides. 2005 Dec;26(12):2392-2396.|||https://pubmed.ncbi.nlm.nih.gov/16308082|||Peptides. 2005 Dec;26(12):2392-2396.|||Peptides. 2005 Dec;26(12):2392-6. PubMed|||16308082|||Peptides. 2005 Dec;26(12):2392-2396. 10 FPDB00110 AP02526|||DRAMP18204|||AP02526|||DRAMP18204 " SNASVWECCSTGSWVPFTCC" Antiviral||Anti-HIV||Anti-It inhibited HIV-1, activity value is IC50 = 1.7 uM||Anti-HIV-2, activity value is IC50 = 1.9 uM||Anti-HSV-1, activity value is IC50 = 0.6 uM||Anti-HSV-2, activity value is IC50 = 0.3 uM||Anti-including dengue virus DENV-2, activity value is IC50 = 0.55 uM||activity value is IC50 = 0.51||Anti-West Nile virus (WNV, activity value is IC50 = 0.2 uM||Anti-hepatitis C virus (HCV, activity value is IC50 = 1.1 uM||activity value is IC50 = 2.2 uM||Antimicrobial||Anti-HSV Actinomadura namibiensis DSM 6313 N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS One. 2013 May 28;8(5):e64010. PubMed|||PLoS One. 2013 May 28;8(5):e64010. doi: 10.1371/journal.pone.0064010. Print 2013.|||PLoS One. 2013 May 28;8(5):e64010.|||PLoS One. 2013 May 28;8(5):e64010. PubMed|||PLoS One. 2013 May 28;8(5):e64010. 20 FPDB00111 AP03795|||1528|||1534|||1540|||AP03795|||Ll-37|||DRAMP03075|||DRAMP03575 " FKRIVQRIKDFLR" Anti-Gram+ & Gram-||Antiviral||Antiparasitic||Anti-HIV||Synergistic AMPs||LC50=60 uM||LC50=57 uM||LC50=55 uM||Anti-E. coli KCTC 1682, activity value is MIC = 16 uM||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 32 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 16 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 4 uM||Anti-S. epidermidis KCTC 1917, activity value is MIC = 16 uM||Anti-and S. aureus KCTC1621, activity value is MIC = 16 uM||Anti-E. coli K12, activity value is MIC = 40 uM||Anti-Escherichia coli K12, activity value is MIC = 40 uM||Anti-Drug-sensitive KB cancer cells . Gram-positive bacteria: Staphylococcus aureus ATCC 29213, activity value is MIC = 16 uM||Anti-S. faecalis ATCC 29212, activity value is MIC = 32 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 16 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 16 uM||Anti-Escherichia coli UB 1005, activity value is MIC = 16 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 16 uM||Anti-Salmonella typhimurium ATCC 14028, activity value is MIC = 32 uM||Anti-Salmonella typhimurium ATCC 7731, activity value is MIC = 16 uM||Anti-Escherichia coli, activity value is MIC = 5 uM||Anti-Drug-sensitive KB cancer cells .## Gram-positive bacteria: Staphylococcus aureus ATCC 29213, activity value is MIC = 16 uM||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 16 uM||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 5 uM NMR-discovered, Sequence truncation; TOCSY-trim, human cathelicidin analog, animal-derived, natural derivative|||NMR-discovered, Sequence truncation; TOCSY-trim, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Homo sapiens|||Homo sapiens Helix||Alpha helix##Random coil No hemolytic activity (0% hemolysis at 100 µM)|||human RBC: HC50 > 256 uM, not hemo.lytic.|||[Ref.28161291] HC50>256 uM against human red blood cells. [Ref.23894079] MHC10=160 uM against human red blood cells J Am Chem Soc. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875, PubMed|||J Am Chem Soc. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875,||Rajasekaran et al., 2017|||J Am Chem Soc. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875, PubMed||Rajasekaran et al., 2017|||16637646|||Ref.16637646||Ref.28178190||Ref.23894079|||J Am Chem Soc. 2006 May 3;128(17):5776-5785.##Int J Mol Sci. 2017 Feb 6;18(2). pii: E339. ##Biochim Biophys Acta Biomembr. 2017 May;1859(5):722-733.##ChemMedChem. 2013 Oct;8(10):1638-42.||Ref.16637646||Ref.28178190||Ref.23894079 13 L FPDB00112 AP03807|||AP03807|||GI-20|||DRAMP31340|||AP03807|||DRAMP31340 " GIKEFKRIVQRIKDFLRNLV" Anti-Gram+ & Gram-||Antiviral||Spermicidal||Anti-HIV||Anti-It inhibits HIV-1. Active against E. faecium V284-17, activity value is MIC = 2 uM||Anti-S. aureus USA300, activity value is MIC = 2||Anti-K-pneumoniae E406-17, activity value is MIC > 32 uM||Anti-P-aeruginosa E411-17, activity value is MIC > 32 uM||Anti-and E. coli E423-17, activity value is MIC = 32 uM||Anti-MRSA||Antibiofilm||Anti-E. faecium V284-17, activity value is MIC = 2 uM||Anti-A. baumannii B28-16, activity value is MIC = 8 uM||Anti-E. coli E423-17, activity value is MIC = 32 uM||Antimicrobial Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37)|||Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37) Helix No hemolytic activity (0% hemolysis at 100 µM)|||human RBC: HC50 ~150 uM, some hemolytic.|||Human RBC (62% hemolysis at 200 uM) "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.||Zhang et al., 2021|||Antimicrob Agents Chemother . 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. Epub 2008 Jun 30.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed||Zhang et al., 2021|||34959645|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40." 20 FPDB00113 AP03814|||Tat " YGRKKRRQRRRD" Anti-Gram+||Antiviral||Anti-HIV||active against MRSA demonstrated in human HeLa cells in vitro. D-form is more effective due to resistance to proteases (D>L). A similar sequence TAT(48-57) (seq: GRKKRRQRRR) inhibits HIV-1 .||Antifungal designed, man-made sequences|||Synthetic construct N/A "Human erythrocytes (0% Hemolysis at 25 uM|||The document mentions Tat (47-58) and its enantiomer's hemolytic-related data, specifically as follows: - L-Tat (47-58): At concentrations ranging from 1.25-20 µM, it shows no hemolytic activity against human red blood cells (RBCs), with a hemolysis rate of 0%. - D-Tat (47-58): Within the same concentration range (1.25-20 µM), it also shows no hemolytic activity against human red blood cells, with a hemolysis rate of 0%. - Control (Melittin, bee venom peptide): Used as a positive control, with a hemolysis rate of 100% at 20 µM, 95.4% at 10 µM, 61.1% at 5 µM, 34.5% at 2.5 µM, and 0% at 1.25 µM. Note: In the hemolysis assay, the PBS-treated group was used as the 0% hemolysis control, and the 0.1% Triton X-100-treated group was used as the 100% hemolysis control. Hemolysis rates were calculated by measuring the absorbance at 414 nm." J Microbiol Biotechnol. 2008 May;18(5):990-6. PubMed|||J Microbiol Biotechnol. 2008 May;18(5):990-6.||Keogan et al., 2012|||J Microbiol Biotechnol. 2008 May;18(5):990-6. PubMed||Keogan et al., 2012|||16678135 12 FPDB00114 AP03839|||DRAMP31336|||AP03839|||LL-37|||DRAMP31336 " SKEKIGKEFKRIVQRIKDFLR" Antiviral||Anti-HIV||Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 10.8 uM||Antimicrobial||Antiviral ; HIV[IC50 REP = 10.8 uM] Sequence truncation, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37)|||Sequence truncation, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37) N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 22.5 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 21 FPDB00115 AP03840|||DRAMP31342|||AP03840|||LL-37|||DRAMP31342 GIKEWKRIVQRIKDFLRNLV Antiviral||Anti-HIV||Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 7.4 uM||Antimicrobial||Antiviral ; HIV[IC50 REP = 7.4 uM] Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37)|||Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37) N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 23.6 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 20 FPDB00116 AP05207|||DRAMP31354|||AP05207|||Apelin-12|||DRAMP31354 RPRLSHKGPMPF Anti-HIV-1 infection, activity value is IC50 = 63 ug/ml||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 E = 63 ug/ml] sequence truncation, mammals, animal-derived, natural derivatives|||Synthetic construct|||sequence truncation, mammals, animal-derived, natural derivatives|||Synthetic construct N/A N/A "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. 2000 FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3.|||FEBS Lett. 2000 May 4;473(1):15-8.|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||https://pubmed.ncbi.nlm.nih.gov/10802050|||FEBS Lett. 2000 May 4;473(1):15-8." 12 FPDB00117 AP05206|||DRAMP31355|||AP05206|||Apelin-13|||DRAMP31355 QRPRLSHKGPMPF Anti-HIV-1 infection, activity value is IC50 = 26 ug/ml||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 E = 26 ug/ml] sequence truncation, mammals, animal-derived, natural derivatives|||Bos taurus (Bovine)|||sequence truncation, mammals, animal-derived, natural derivatives|||Bos taurus|||Bos taurus (Bovine) N/A N/A "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. 2000 FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3.|||FEBS Lett. 2000 May 4;473(1):15-8.|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||https://pubmed.ncbi.nlm.nih.gov/10802050|||FEBS Lett. 2000 May 4;473(1):15-8." 13 FPDB00118 AP05205|||DRAMP31356|||AP05205|||Apelin-17|||DRAMP31356 KFRRQRPRLSHKGPMPF Anti-HIV-1 infection, activity value is IC50 = 4.8 ug/ml||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 E = 4.8 ug/ml] sequence truncation, mammals, animal-derived, natural derivatives|||Synthetic construct|||sequence truncation, mammals, animal-derived, natural derivatives|||Synthetic construct N/A N/A "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. 2000 : FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3.|||FEBS Lett. 2000 May 4;473(1):15-8.|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||https://pubmed.ncbi.nlm.nih.gov/10802050|||FEBS Lett. 2000 May 4;473(1):15-8." 17 FPDB00119 AP05204|||DRAMP31357|||AP05204|||DRAMP31357 LVQPRGPRSGPGPWQGGRRKFRRQRPRLSHKGPMPF Anti-HIV-1 infection, activity value is IC50 = 0.3 ug/ml||Antimicrobial||Antiviral||Anti-HIV sequence truncation, mammals, animal-derived, natural derivatives|||Bos taurus (Bovine)|||sequence truncation, mammals, animal-derived, natural derivatives|||Bos taurus (Bovine) N/A N/A "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. 2000 FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3.|||J Virol. 2000 Dec;74(24):11972-6.|||FEBS Lett. 2000 May 4;473(1):15-8. doi: 10.1016/s0014-5793(00)01487-3. PubMed|||J Virol. 2000 Dec;74(24):11972-6." 36 FPDB00120 AP05191 PKGPTYSWDEAKNPGGPNRCSNSKQCDGARTCSSSGFCQGTAGHAAA Anti-HIV-1, activity value is EC50 = 0.182 uM||Antiviral||Anti-HIV amino acid substitution, sequence truncation, bacteria-derived, natural derivatives N/A N/A "Xiong C, O'Keefe BR, Byrd RA, McMahon JB.2006 Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018.|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed" 47 FPDB00121 AP05190 GSGPTYSWNEANNPGGPNRCSNNKQCDGARTCSSSGFCQG Anti-HIV-1, activity value is EC50 = 0.0345 uM||Antiviral||Anti-HIV amino acid substitution, sequence truncation, bacteria-derived, natural derivatives N/A N/A "Xiong C, O'Keefe BR, Byrd RA, McMahon JB.2006 Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018.|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed" 40 FPDB00122 AP05189 GSGPTYSWNEANNPGGPNRCSNNKQCDGARTCSSSGFCQGTSRKPDPG Anti-HIV-1, activity value is EC50 = 0.0076 uM||Antiviral||Anti-HIV amino acid substitution, sequence truncation, bacteria-derived, natural derivatives N/A N/A "Xiong C, O'Keefe BR, Byrd RA, McMahon JB.2006 Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018.|||Peptides. 2006 Jul;27(7):1668-75. doi: 10.1016/j.peptides.2006.03.018. PubMed" 48 FPDB00124 AP03863 CRLGRLLRRLGRCLLR Anti-E. coli, activity value is MIC = 60 uM||Anti-B. subtilis, activity value is MIC = 60 uM||Antiviral||Anti-HIV De novo designed, man-made sequences N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 16 FPDB00125 AP03862 GCRRLCGRLGRRLCRLLCR Anti-HSV-2MS in Vero cells, activity value is EC50 = 69.3 ug/ml||Anti-HSV-2MS in Vero cells, activity value is EC50 = 64.7 ug/ml||Anti-B.subtilis, activity value is MIC > 120 uM||Antiviral||Anti-HIV De novo designed, man-made sequences N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 19 FPDB00126 AP03861 GLRRLCGRLGRRLCRLLLR Anti-HSV-2MS in Vero cells, activity value is EC50 = 6.37 ug/ml||Anti-HSV-2MS in Vero cells, activity value is EC50 = 15 ug/ml||Anti-B.subtilis, activity value is MIC > 120 uM||Antiviral||Anti-HIV De novo designed, man-made sequences N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 19 FPDB00127 AP03860 GLRCRLGRLLRRLGRCLLR Anti-HSV-2MS in Vero cells, activity value is EC50 = 1.81 ug/ml||Anti-HSV-2MS in Vero cells, activity value is EC50 = 5.43 ug/ml||Anti-B.subtilis, activity value is MIC > 120 uM||Antiviral||Anti-HIV De novo designed, man-made sequences N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 19 FPDB00128 AP03859 GCRRLLGRLLRRLGRLLCR Anti-HSV-2MS in Vero cells, activity value is EC50 = 30 ug/ml||Anti-B.subtilis, activity value is MIC > 120 uM||Antiviral||Anti-HIV De novo designed, man-made sequences N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 19 FPDB00129 AP03858 GSRRPVPIIYCNRRTGRCQRI Anti-Human Immunodeficiency Virus Type 1 HIV-1IIIB, activity value is EC50 = 3.33 ug/ml||Antiviral||Anti-HIV amino acid substitution, insects, animal-derived, natural derivative N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 21 FPDB00130 AP03857 GSKKPVPIIYCNRRTGKCQRI Anti-Human Immunodeficiency Virus Type 1 HIV-1IIIB, activity value is EC50 = 13.1 ug/ml||Anti-HSV-2MS in Vero cells, activity value is EC50 = 2320000 ug/ml||Antiviral||Anti-HIV Amino acid substitution, insects, animal-derived, natural derivatives N/A "No hemolytic activity (0% hemolysis at 100 µM)|||The document mentions hemolytic-related data of the V series antimicrobial peptides, as follows: - V1: Hemolytic activity EC_{50} against human red blood cells is 880.0 μM. - V2: Hemolytic activity EC_{50} against human red blood cells is 589.0 μM. - V3: Hemolytic activity EC_{50} against human red blood cells is 590.0 μM. - V4: Hemolytic activity EC_{50} against human red blood cells is 3,226.0 μM. - V5: Hemolytic activity EC_{50} against human red blood cells is 1,055.0 μM. - V6: Hemolytic activity EC_{50} against human red blood cells is 35.0 μM. - V7: Hemolytic activity EC_{50} against human red blood cells is 45.0 μM. Note: EC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells; a higher value indicates lower hemolytic activity. In the experiment, the peptide concentration ranged from 0.01 to 375 μg/ml, and hemolysis was assessed by measuring the hemoglobin released from human red blood cells." "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011 J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.|||J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003. Wang HIV screen project" 21 FPDB00131 AP03856|||DRAMP30306|||AP03856|||DRAMP30306 GLRRLLGRLLRRLGRLLLR Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 4.4 uM||Anti-HSV-2MS in Vero cells, activity value is EC50 = 2.32 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 4.4 uM||Antiviral||Anti-HIV Amino acid substitution, de novo designed, man-made sequences|||Synthetic construct|||Amino acid substitution, de novo designed, man-made sequences|||Synthetic construct N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 19 FPDB00132 AP03855|||DRAMP30305|||AP03855|||DRAMP30305 GLRSRIWLWVLLMIWQESNRFKRM Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 1.25 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 1.25 uM||Antiviral||Anti-HIV Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct(derived from Dermaseptin S9)|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct(derived from Dermaseptin S9) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 24 FPDB00133 AP03854|||DRAMP30303|||AP03854|||DRAMP30303 ILGPVLGLVSRTLRRVLGIL Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 2.2 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 2.2 uM||Antiviral||Anti-HIV Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct(derived from Maximin H5)|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct(derived from Maximin H5) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 20 FPDB00134 AP03853|||DRAMP30302|||AP03853|||DRAMP30302 GWLKKIESIIDAF Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 29.5 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 29.5 uM||Antiviral||Anti-HIV template-based designed, man-made sequences|||Synthetic construct(derived from Cecropin)|||template-based designed, man-made sequences|||Synthetic construct(derived from Cecropin) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 13 FPDB00135 AP03852|||DRAMP30301|||AP03852|||DRAMP30301 GFLDIIEKIAKSW Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 10.5 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 10.5 uM||Antiviral||Anti-HIV template-based designed, man-made sequences|||Synthetic construct(derived from Ranatuerin 3)|||template-based designed, man-made sequences|||Synthetic construct(derived from Ranatuerin 3) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 13 FPDB00136 AP03851|||DRAMP30300|||AP03851|||DRAMP30300 GIWSDLAEIIKKF Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 11.4 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 11.4 uM||Antiviral||Anti-HIV template-based designed, man-made sequences|||Synthetic construct(derived from Ponericin W3)|||template-based designed, man-made sequences|||Synthetic construct(derived from Ponericin W3) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 13 FPDB00137 AP03850|||DRAMP30298|||AP03850|||DRAMP30298 GWFDIIKKIASEL Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 10.7 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 10.7 uM||Antiviral||Anti-HIV template-based designed, man-made sequences|||Synthetic construct(derived from Uperin 7.1)|||template-based designed, man-made sequences|||Synthetic construct(derived from Uperin 7.1) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 13 FPDB00138 AP03849|||DRAMP30297|||AP03849|||DRAMP30297 GIIDIAKKLFESW Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 20.1 uM||Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 20.1 uM||Antiviral||Anti-HIV template-based designed, man-made sequences|||Synthetic construct(derived from Uperin 2.7)|||template-based designed, man-made sequences|||Synthetic construct(derived from Uperin 2.7) N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159" 13 FPDB00139 AP03848 GLFDIIKKIAESW Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 11.7 uM||Antiviral||Anti-HIV amino acid substitution, amphibians, animal-derived, natural derivative N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed" 13 FPDB00140 AP03847|||AP03847|||Temporin-LTc-3r SLSRFLRFLKIVYRRAF Anti-S. aureus USA300 MRSA, activity value is MIC = 12.5 uM||Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM Amino acid substitution, amphibians, animal-derived, natural derivative|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Antimicrob Agents Chemother . 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||22445495|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed" 17 FPDB00141 AP03846|||AP03846|||DASamP1|||DRAMP04317 FFGKVLKLIRKIF Anti-S. aureus USA300 MRSA, activity value is MIC = 3.1 uM||Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-Bacillus subtilis, activity value is MIC > 100 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 100 uM||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC > 100 uM||Antimicrobial||Antibacterial Amino acid substitution, amphibians, animal-derived, natural derivative|||FFGKVLKLIRKIF|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct N/A No hemolytic activity (0% hemolysis at 100 µM)|||hemolytic HC50 25 uM.|||Human RBC (HL50 = 25 uM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed||Menousek et al., 2012|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.||Menousek et al., 2012|||Antimicrob Agents Chemother . 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed||Menousek et al., 2012|||22445495|||Int J Antimicrob Agents. 2012 May;39(5):402-406.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed" 13 FPDB00142 AP03845|||Uperin 7.1KRF GWFDVVKHIAKRF Anti-S. aureus USA300 MRSA, activity value is MIC = 50 uM||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus, activity value is MIC = 50 uM||Anti-E. coli, activity value is MIC = 12.5 uM Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct N/A No hemolytic activity (0% hemolysis at 100 µM) "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Antimicrob Agents Chemother . 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||22445495|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed" 13 FPDB00143 AP03844|||DRAMP31346|||AP03844|||Cathelicidin-6|||DRAMP31346 GRFKRFRKPFKKLFKKIS Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 3.2 uM||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 REP = 3.2 uM] Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from BMAP-27)|||Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from BMAP-27) N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 18.9 uM "Wang G, Watson KM, Buckheit RW Jr. 2008 Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||https://pubmed.ncbi.nlm.nih.gov/18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40." 18 FPDB00144 AP03843|||DRAMP31345|||AP03843|||BMAP-18|||DRAMP31345 GRFKRFRKKFKKLFKKIS Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 0.35 uM||Anti-HSV-2MS in Vero cells, activity value is EC50 = 27.2 uM||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV-1[IC50 REP = 0.35 uM] Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from BMAP-27)|||Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from BMAP-27) N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 8.45 uM "Wang G, Watson KM, Buckheit RW Jr. 2008 Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||https://pubmed.ncbi.nlm.nih.gov/18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40." 18 FPDB00156 AP00024|||DRAMP03065|||CAMPSQ2708|||DRAMP03065 GVSGHGQHGVHG During screening||it was found to be cytotoxic against cancer cells but not further chracterized yet. Updated 9/2017; 12/2017; 6/2022||Antimicrobial||Antibacterial||Antifungal||Antiviral||Antitumour Blow fly Calliphora vicina|||Calliphora vicina (Blue blowfly) (Calliphora erythrocephala)|||Calliphora vicina [Blow fly]|||Calliphora vicina (Blue blowfly) (Calliphora erythrocephala) N/A No hemolysis information or data found in the reference(s) presented in this entry "Chernysh S, Kim SI, Bekker G, Pleskach VA, Filatova NA, Anikin VB, Platonov VG, Bulet P.2002 Proc Natl Acad Sci U S A 2002; 99 (20):12628-32. PubMed.|||Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32.|||12235362|||Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32." 12 FPDB00157 AP00025|||DRAMP03064|||Alloferon-1|||DRAMP03064 HGVSGHGQHGVHG Anti-It inhibited the Human Herpes Virus type 1 multiplication . Active against Gram+ S. aureus ATCC25923 or penicillin-resistant, activity value is MIC = 16||Anti-S. epidermidis penicillin-resistant, activity value is MIC = 32 ug/ml||Anti-E. coli ATCC25922 or penicillin-resistant, activity value is MIC = 8||Anti-P. aeruginosa ATCC27853 or penicillin-resistant, activity value is MIC = 8||Anti-and K. pneumoniae ATCC13883 or penicillin-resistant, activity value is MIC = 16 ug/ml||Anti-Gram+ & Gram-||Antiviral||Anticancer||Antimicrobial||Antiparasitic||Antitumor||Anti-Influenzae virus, activity value is MIC = 25 ug Blow fly Calliphora vicina|||Calliphora vicina (Blue blowfly) (Calliphora erythrocephala)|||Calliphora vicina [Blue blowfly]|||Calliphora vicina (Blue blowfly) (Calliphora erythrocephala) Rich No hemolysis information or data found in the reference(s) presented in this entry "Chernysh S, Kim SI, Bekker G, Pleskach VA, Filatova NA, Anikin VB, Platonov VG, Bulet P.2002 Proc Natl Acad Sci U S A 2002; 99 (20):12628-32. PubMed.||Kuczer et al. 2011||Tu J et al., 2015|||Proc Natl Acad Sci U S A . 2002 Oct 1;99(20):12628-32. doi: 10.1073/pnas.192301899. Epub 2002 Sep 16.|||Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32.|||https://pubmed.ncbi.nlm.nih.gov/12235362|||Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32." 13 FPDB00158 AP00029|||1186|||1190|||1194|||1198|||CE-MA|||DRAMP03914|||DRAMP03963 KWKLFKKIKFLHSAKKF Antiviral||Antiparasitic||anti-sepsis||Antimalarial||Anticancer||activity value is IC50 = 85.3 uM||activity value is IC50 = 100 uM||activity value is IC50 = 65 uM||Anti-Gram- E. coli, activity value is MIC = 6.25 uM||Anti-S. typhimurium, activity value is MIC = 0.78 uM||Anti-P. aeruginosa, activity value is MIC = 1.56 uM||Anti-B. subtilis, activity value is MIC = 1.56 uM||Anti-S. pyogenes, activity value is MIC = 0.78 uM||Anti-and S. aureus, activity value is MIC = 3.12 uM||Anti-Candida albicans, activity value is MIC = 250 ug/ml||Anti-C. glabrata, activity value is MIC = 512 ug/ml||Anti-A. fumigatus, activity value is MIC > 1000 ug/ml||Anti-M. canis, activity value is MIC > 1000 ug/ml||Antimicrobial||Antifungal||Antibacterial hybrid peptide, designed, man-made sequences|||Synthetic construct (De novo design)|||Synthetic construct Helix The hemolytic activity of CA-MA and its analogs on human red blood cells was tested at a concentration of 100 μM, and the results showed that the hemolysis rate of all peptides was 0% (see Table 2 for specific data). "Oh H, Hedberg M, Wade D, Edlund C. Antimicrob Agents Chemother. 2000 Jan;44(1):68-72.PubMed.|||2000 Feb 15;1463(2):209-18. doi: 10.1016/s0005-2736(99)00210-2.|||33676184|||Int J Mol Sci. 2012; 13(11): 15042-15053.|||Biochemistry. 2000 Oct 3;39(39):11855-11864." 17 L FPDB00162 AP00094|||1427|||AP00094|||Temporin-A FLPLIGRVLSGIL Anti-S. pyogenes beta hem. group A, activity value is MIC = 1||Anti-E. coli, activity value is MIC = 6.2||Anti-and A. baumannii, activity value is MIC = 24 uM||Anti-including parasites L. donovani and L. mexicana . Also active against C. jeikeium ATCC BAA-949, activity value is MIC = 8 uM||15% Cytotoxicity at 0.5 ug/ml||Anti-B. megateriurn Bml I, activity value is MIC = 1.2 uM||Anti-S. aureus Cowanl, activity value is MIC = 2.3 uM||Anti-Y. pseudotuberculosis, activity value is MIC = 2 uM||Anti-S. pyogenes/3 hem. group A, activity value is MIC = 2 uM||Anti-E. coli D21, activity value is MIC = 11.9 uM||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Chemotactic||Wound healing||Anticancer European common frog, Rana temporaria|||European common frog, Rana temporaria|||Rana temporaria [european common frog] Helix "Hemolytic activity test results: Temporin A and Temporin B both showed less than 1% hemolysis of human red blood cells at a concentration of 120 μM, whereas bee venom peptide (melittin) can cause more than 90% red blood cell hemolysis at 0.9 μM. Example data: Temporin A: Hemolytic concentration > 120 μM. Temporin B: Hemolytic concentration > 120 μM. Melittin: Hemolytic concentration 0.9 μM.|||The hemolytic concentration of temporin A on human red blood cells is >120 µM. The hemolytic concentration of temporin B on human red blood cells is >120 µM. The hemolytic concentration of melittin on human red blood cells is 0.9 µM. The hemolytic concentration of melittin-like peptide (MLP) on human red blood cells is 0.5 µM. The hemolytic concentration of defensin 1 (esculentin 1) on human red blood cells is >200 µM. The hemolytic concentration of cecropin A on human red blood cells is >400." "Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML, Barra D.1996 Eur J Biochem. 1996 Dec 15;242(3):788-92. PubMed.||Swithenbank et al., 2020||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||Eur J Biochem . 1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Swithenbank et al., 2020||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||9022710, 30043322|||Eur J Biochem. 1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Swithenbank et al., 2020||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||Eur J Biochem. 1996 Dec 15;242(3):788-92. PubMed." 13 L FPDB00168 AP00144|||1116|||1306|||1307|||1308|||1309|||1310|||1311|||1312|||1313|||1314|||1359|||1365|||1371|||1377|||1383|||1389|||1395|||1401|||1407|||1413|||AP00144|||Magainin-2|||Magainin-2 amide|||DRAMP02271|||Magainin 2|||AP00144 GIGKFLHSAKKFGKAFVGEIMNS Anti-E. coli D31, activity value is MIC = 5 ug/ml||Anti-S. epidermidis, activity value is MIC = 10 ug/ml||Anti-C. freundii, activity value is MIC = 30 ug/ml||Anti-S. aureus, activity value is MIC = 50 ug/ml||Anti-C. albicans, activity value is MIC = 80 ug/ml||Anti-and S. marcescens, activity value is MIC = 100 ug/ml||activity value is IC50 = 110 uM||activity value is IC50 = 32.3 uM||activity value is IC50 = 54.1 uM||activity value is IC50 = 28.6 uM||activity value is IC50 = 484 uM||activity value is IC50 = 52.4 uM||activity value is IC50 = 57.8 uM||activity value is IC50 = 135.3 uM||activity value is IC50 = 31 uM||activity value is IC50 = 59.4 uM||activity value is IC50 > 150 ug/ml||activity value is IC50 > 200 ug/ml||Antibacterial||Antifungal||Antiparasitic||Anti-Escherichia coli D31, activity value is MIC = 5 ug/ml||Anti-Klebsiella pneumoniae, activity value is MIC = 10 ug/ml||Anti-Escherichia coli, activity value is MIC = 50 ug/ml||Anti-Pseudomonas putida, activity value is MIC = 10 ug/ml||Anti-Citrobacter freundii, activity value is MIC = 30 ug/ml||Anti-Enterobacter cloacae, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 100 ug/ml||Anti-Serratia marcescens, activity value is MIC = 100 ug/ml||Anti-Proteus mirabilis, activity value is MIC > 100 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 10 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 50 ug/ml||Anti-Streptococcus fecalis, activity value is MIC > 100 ug/ml||Anti-Candida albicans, activity value is MIC = 80 ug/ml||Anti-Streptococcus fecalis Paramecium caudatum, activity value is MIC = 10 ug/ml||Anti-Euglena gracilis ] [ - E.coli ATCC 25922, activity value is MIC = 62||Anti-Klebsiella Pneumonae ATCC 13883, activity value is MIC = 125||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 125||Anti-Candida ablicansATCC 14053, activity value is MIC = 250||Anti-Gram+ & Gram-||Antiviral||candidacidal||Insecticidal||Spermicidal||anti-sepsis||Antimalarial||Synergistic AMPs||Wound healing||Anticancer skin; Stomach, African clawed frog, Xenopus laevis, Africa|||skin; Stomach, African clawed frog, Xenopus laevis, Africa|||Xenopus laevis [African clawed frog]|||Xenopus ruwenzoriensis (Uganda clawed frog)|||skin; Stomach, African clawed frog, Xenopus laevis, Africa Helix "Since these amphiphilic peptides may be membrane dis ruptive (12), magainin 2 was assayed for hemolytic activityagainst human erythrocytes (Fig. 4B). Unlike mellitin, ahemolytic, amphiphilic 26-amino acid peptide from beevenom (12), magainin 2 was not hemolytic up to at least 0.00015 ug/ml in phosphate-buffered normal saline (Fig. 4B). Theabsence of hemolytic activity of magainin 2 is striking in thatit possesses a potential hydrophobic moment very similar tomellitin (12)|||​|||[ Refer PubMed : 3299384 :- Escherichia coli D31 ( MIC = 5 ug/ml), Klebsiella pneumoniae ( MIC = 10 ug/ml), Pseudomonas putida ( MIC = 10 ug/ml), Staphylococcus epidermidis ( MIC = 10 ug/ml), Citrobacter freundii ( MIC = 30 ug/ml), Enterobacter cloacae ( MIC = 50 ug/ml), Escherichia coli ( MIC = 50 ug/ml), Staphylococcus aureus ( MIC = 50 ug/ml), Candida albicans ( MIC = 80 ug/ml), Pseudomonas aeruginosa ( MIC = 100 ug/ml), Serratia marcescens ( MIC = 100 ug/ml), Proteus mirabilis ( MIC = >100 ug/ml), Streptococcus fecalis ( MIC = >100 ug/ml)Paramecium caudatum ( MIC = 10 ug/ml), Amoeba proteus , Euglena gracilis ] [ Refer PubMed : 1717472 :- E.coli ATCC 25922 ( MIC = 62-125 ug/ml), Klebsiella Pneumonae ATCC 13883 ( MIC = 125-250 ug/ml), Pseudomonas aeruginosa ATCC 27853 ( MIC = 125-250 ug/ml), Staphylococcus aureus ATCC 29213 ( MIC = >500 ug/ml), Streptococcus faecalis ATCC 29212 ( MIC = >500 ug/ml), Candida ablicansATCC 14053 ( MIC = 250-500 ug/ml) ], [ Refer Pubmed ID 35073323: Mycoplasma pneumoniae ]|||Xanthomonas axonopodis pv. glycines (MIC = 13 uM), Escherichia coli (MIC = 13 uM), Pseudomonas aeruginosa (MIC = 26 uM)|||In Document 4 (Proc. Natl. Acad. Sci. USA 1987), magainin 1 and magainin 2, isolated from the skin of the African clawed frog (Xenopus laevis), showed no hemolytic activity against human erythrocytes, and no hemolysis was observed even at concentrations up to 150 µg/ml in phosphate-buffered saline.|||Magainin 2 shows no hemolytic activity on human red blood cells even at concentrations as high as 150 µg/ml; whereas melittin, the bee venom peptide, exhibits significant hemolytic effects at low concentrations." "Zasloff M.1987 Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-53. PubMed.||Peschel et al., 2001|||1987 Aug;84(15):5449-53. doi: 10.1073/pnas.84.15.5449.||see ref AP4787||Peschel et al., 2001|||Proc Natl Acad Sci U S A . 1987 Aug;84(15):5449-53. doi: 10.1073/pnas.84.15.5449.||Peschel et al., 2001|||1717472 , 3299384, 35073323|||23029273|||Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-5453.|||1717472 , 3299384, 35073323||PubMed : 3299384||PubMed : 1717472||Refer Pubmed ID 35073323|||Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-53. doi: 10.1073/pnas.84.15.5449.|||1987 Aug;84(15):5449-53. doi: 10.1073/pnas.84.15.5449.|||Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-53. PubMed." 23 L FPDB00176 AP00204|||AP00204|||Nisin-Z ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK Anti-L. lactis MG1363, activity value is MIC = 0.02 ug/ml||Anti-L. monocytogenes LMG10470 or TT82E or LK132, activity value is MIC = 1.5||Anti-B. cereus CH-85, activity value is MIC = 6.25 ug/ml||Anti-S. aureus LMG10147 or LMG15975 or MRSA, activity value is MIC = 6.25 ug/ml||Anti-and E. faecium LMG11423 or LMG16003 or LMG16216, activity value is MIC = 3.13 ug/ml||Anti-Gram+||Antiviral||Anti-MRSA||Anticancer||Antibacterial Lactococcus lactisNIZO 221 86|||Lactococcus lactisNIZO 221 86|||Lactococcus lactis  [Bacteria] N/A N/A "Mulders JWM, Boerrigter IJ, Rollema HS, Siezen RJ, de Vos WM.1991 Eur. J. Biochem. 1991; 201: 581-584|||Eur. J. Biochem. 1991; 201: 581-584|||28461263" 34 FPDB00177 AP00205 ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK Anti-l inhibitory activity was first reported in 1928. Active against Micrococcus spp, activity value is MIC = 1.1 ug/ml||Anti-Enterococcus spp, activity value is MIC = 16.7||Anti-Bacillus spp, activity value is MIC = 4.2||Anti-Clostridium spp, activity value is MIC = 1.1 ug/ml||Anti-A. viscosus, activity value is MIC = 83.6 ug/ml||Anti-P. acnes, activity value is MIC = 2.1||Anti-and Gram- bacteria: C. jejune, activity value is MIC = 1.1 ug/ml||Anti-H. influenzae, activity value is MIC = 66.9 ug/ml||Anti-H. pylori, activity value is MIC = 0.3 ug/ml||Anti-and Neisseria spp, activity value is MIC = 8.4 ug/ml||Anti-Gram+||Antiviral||Spermicidal||Anti-MRSA||Synergistic AMPs||Antibiofilm||Wound healing||Anticancer Streptococcus lactis, reclassified as Lactococcus lactis Nonhelixbeta N/A "Rogers, LA1928 J. Bacteriol. 1928; 16:321-325. PubMed.||Ref see AP1003|||J. Bacteriol. 1928; 16:321-325. PubMed.|||J Bacteriol . 1928 Nov;16(5):321-5. doi: 10.1128/jb.16.5.321-325.1928.||Ref see AP1003|||1928 Nov;16(5):321-5. doi: 10.1128/jb.16.5.321-325.1928.||Ref see AP1003" 34 FPDB00183 AP00281|||AP00281|||Cathelin-related antimicrobial peptide|||DRAMP03405|||AP00281 GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE Anti-E. coli ATCC 25922 or ML35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-P-vulgaris ATCC 13315, activity value is MIC > 64 uM||Anti-S. aureus ATCC 25923 or Cowan I MRSA, activity value is MIC = 32||Anti-S. epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-S. faecalis ATCC 29212, activity value is MIC = 32 uM||Anti-B. megaterium Bm11, activity value is MIC = 4 uM||Anti-fumgi C-albicans, activity value is MIC > 64 uM||Anti-C. neoformans, activity value is MIC = 16 uM||Anti-and the single-stranded RNA virus respiratory syncytial virus . It also inhibit B. anthracis, activity value is MIC = 8 ug/ml||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-MRSA||Anticancer||Antibacterial||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli ML35, activity value is MIC = 2 uM||Anti-Escherichia coli D21, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 32 uM||Anti-Staphylococcus aureus Cowan I, activity value is MIC = 32 uM||Anti-Staphylococcus aureus, activity value is MIC > 64 uM||Anti-Staphylococcus aureus, activity value is MIC = 64 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-Streptococcus faecalis ATCC 29212, activity value is MIC = 16 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 4 uM||Anti-Cryptococcus neoformans, activity value is MIC = 16 uM precursor sequence homology, sequence alignment, other predictions|||precursor sequence homology, sequence alignment, other methods predicted|||precursor sequence homology, sequence alignment, other predictions|||Mus musculus [Mouse]|||Mus musculus (Mouse)|||precursor sequence homology, sequence alignment, other methods predicted Helix||Alpha helix (CD) CRAMP peptide does not lyse human or sheep red blood cell membranes at a concentration of 50 μM, but specific hemolytic values are not mentioned.|||CRAMP is also anticancer (tumor cells A549, K562, Jurkat, IC50 16-28 uM) with 2.2% hemolysis at 100 uM (little hemo.lytic). Change residue 2, 9, or 13 to K made CRAMP-18 anticancer as well but not better than its parent molecule. CRAMP also inactivates Zika virus (ZIKV). Updated 11/2015; 4/2016; 10/2016; 3/2023; seq corrected 5/2023; 6/2024. "Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R.1997 J. Biol. Chem. 1997: 272:13088-13093. PubMed||Blower et al., 2018||Archer NK et al., 2016|||J. Biol. Chem. 1997: 272:13088-13093. PubMed|||J Biol Chem . 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088.||Blower et al., 2018||Archer NK et al., 2016|||9148921|||FEBS Lett. 1996 Aug 5;391(1-2):5-8.|||J. Biol. Chem. 1997: 272:13088-13093. PubMed||Blower et al., 2018||Archer NK et al., 2016|||1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088.||Blower et al., 2018" 33 FPDB00191 AP00367|||AP00367|||Cathelicidin-5 , Antibacterial peptide BMAP-28 , Myeloid antibacterial peptide 28|||DRAMO02854|||Cathelicidin-5 , Antibacterial peptide BMAP-28 , Myeloid antibacterial peptide 28|||AP00367 GGLRSLGRKILRAWKKYGPIIVPIIRIG Anti-E. coli ATCC 25922 ML-35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 1 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923 or Cowan 1 MRSA, activity value is MIC = 1||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 1 uM||Anti-C. albicans, activity value is MIC = 8 uM||Anti-and C. neoformans, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Anti-MRSA||Hemolytic||Antibiofilm||Anticancer||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-E. coli ML35, activity value is MIC = 2 uM||Anti-E. coli D21, activity value is MIC = 0.5 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-S. aureus Cowan 1, activity value is MIC = 1 uM||Anti-S. aureus, activity value is MIC = 4 uM||Anti-B. megaterium Bm11, activity value is MIC = 2 uM||Anti-C. neoformans, activity value is MIC = 4 uM||Anti-E.coli(LOG 2, activity value is MIC = 5.80||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Salmonella typhimurium ATCC 14028, activity value is MIC = 1 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 4 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 2 uM||Anti-Cryptococcus neoformans, activity value is MIC = 4 uM peripheral neutrophils; cattle, Bos taurus|||peripheral neutrophils; cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||Bos taurus [Bovine]|||peripheral neutrophils; cattle, Bos taurus Helix "The hemolytic activity of the two BMAPs was much lower, when measured on bovine erythrocytes (data not shown). These cells were 5–10-fold less susceptible than human red blood cells to BMAP-28 (3, 6, and 22% hemolysis at 10, 30, and 100000 uM peptide), and virtually unaffected by BMAP-27 even at 100000 uM. We speculate that the different susceptibility of human and bovine red blood cells to these molecules may be accounted for by species-specific differences in the erythrocyte membrane composition, and may reflect the need to protect the host cells from undesired cytotoxic effects. We have also noted that the effects of BMAP-28 on the cell membranes are consistently higher than BMAP-27, in spite of the structural similarity of the two molecules, thus suggesting that minor structural dif-ferences can modulate the activity of these peptides.|||The document explicitly mentions the hemolytic values of two novel antimicrobial peptides (BMAP-27, BMAP-28) and their derivatives (BMAP-27(1–18), BMAP-28(1–18), mBMAP-28) on human red blood cells. The core data are as follows: 1. Hemolytic properties of parent peptides (BMAP-27, BMAP-28). BMAP-28 (for human red blood cells): At a concentration of 3 μM, the hemolysis rate is 14.5%; At a concentration of 100 μM, the hemolysis rate exceeds 90% (specifically 94.1%). BMAP-27 (against human red blood cells): At a concentration of 3 μM, the hemolysis rate is only 3.5%; At a concentration of 100 μM, the hemolysis rate is 32.7%. Its hemolytic effect on bovine red blood cells is significantly lower than that of human red blood cells: BMAP-28 had hemolytic rates of 3%, 6%, and 22% at concentrations of 10 uM, 30 uM, and 100 uM, respectively; BMAP-27 has almost no hemolytic effect on bovine red blood cells even at a concentration of 100 uM. 2. Hemolytic properties of truncated derivatives (BMAP-27(1–18), BMAP-28(1–18)). The hemolytic effect of truncated peptides (retaining only 18 residues at the N-terminus and removing the hydrophobic tail at the C-terminus) is significantly reduced: BMAP-27 (1–18): Has almost no hemolytic activity against human red blood cells (Figure 6 shows no significant hemolytic rate; combined with text description of ""hemolytic effect disappears""). BMAP-28(1–18): hemolytic rate of human red blood cells is significantly lower than that of parent peptides (the curve in Figure 6 is close to baseline, no specific value, but the text clearly states ""hemolytic effect greatly reduced""). 3. Hemolytic properties of modified derivatives (mBMAP-28). Significant loss of hemolytic activity in mBMAP-28 (replacement of hydrophobic residues at the C-terminal for hydrophilic residues): At a concentration of 100 μM, the hemolytic rate for human red blood cells is only 3.3%, far lower than the 94.1% of the parent peptide BMAP-28. Additional notes Hemolysis detection method: Using standard hemolysis experiments, 10% (v/v) red blood cell suspension and peptides of different concentrations were incubated at 37°C for 15 minutes to measure absorbance at 415nm, using complete hemolysis induced by 0.2% Triton X-100 as a 100% control. Relationship between hemolysis and antibacterial activity: The hemolytic concentration of parental peptides (≥3 uM) is much higher than that of their antibacterial activity concentration (MIC: 0.25–4 uM); Truncated/modified derivatives retain antibacterial activity while significantly reducing hemolytic activity and improving targeted selectivity.|||The document clearly mentions the hemolytic values of BMAP-27, BMAP-28, and their analogues (truncated or modified forms) on human and bovine red blood cells. The core data are as follows: I. Hemolytic values for human red blood cells (key indicators) Measured by standard hemolysis experiments, presented as ""peptide concentration (uM) - hemolysis rate (%)"", the results are the average of multiple independent experiments (S.E. ≤1.8): 1. BMAP-28 3 uM: 14.5% 100 uM: >90% (specifically 94.1%) 2. BMAP-27 3 uM: 3.5% 100 uM: 32.7% 3. Truncated forms: BMAP-27(1–18), BMAP-28(1–18) BMAP-27(1–18): nearly no hemolytic activity (no specific value given, only mentioned as ""hemolytic effect disappeared""). BMAP-28(1–18): hemolytic activity significantly reduced (no specific concentration-hemolysis correspondence given, only mentioned as ""declined markedly""). 4. Modified form: mBMAP-28 (hydrophobic residues at C-terminus replaced with hydrophilic residues) 100 uM: only 3.3% hemolysis (much lower than parent BMAP-28's 94.1%). II. Hemolytic values for bovine red blood cells (species difference comparison) Bovine red blood cells are significantly less sensitive to BMAPs than human red blood cells: 1. BMAP-28 10 uM: 3% 30 uM: 6% 100 uM: 22% 2. BMAP-27 100 uM: virtually no hemolysis (""virtually unaffected""). III. Supplementary notes Hemolysis experiment conditions: 10% (v/v) red blood cell suspension in pH 7.4 PBS, incubated with peptides at 37 °C for 15 minutes, with complete hemolysis induced by 0.2% Triton X-100 as the 100% control. Trend: The hemolytic activity of peptides is mainly mediated by the hydrophobic domain at the C-terminus—removal (truncated forms) or modification (mBMAP-28) of this region significantly reduces hemolysis, but antibacterial activity (MIC) is largely retained.|||BMAP-28 can cause 14.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate exceeds 90% at 100 μM. BMAP-27 can cause 3.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate is 32.7% at 100 μM. Cow red blood cells are 5-10 times less sensitive to BMAP-28 than human red blood cells, with hemolysis rates of 3%, 6%, and 22% at concentrations of 10 μM, 30 μM, and 100 μM, respectively; BMAP-27 shows almost no hemolytic effect on cow red blood cells at 100 μM. The hemolytic effect of the truncated analog BMAP-27(1-18) disappears, and the hemolytic effect of BMAP-28(1-18) is greatly reduced. The modified analog mBMAP-28 has a hemolysis rate of only 3.3% for human red blood cells at 100 μM, far lower than the 94.1% of the parent peptide BMAP-28.|||At 3 uM, the hemolysis rate of BMAP-28 is 14.5%, and it exceeds 90% at 100 uM.|||The document mentions experimental results related to hemolysis, as follows: - Hemolytic effect of BMAP-28 on human red blood cells: at a concentration of 3 µM, 14.5% of cells were lysed; at 100 µM, more than 90% of cells were lysed. - Hemolytic effect of BMAP-27 on human red blood cells: at a concentration of 3 µM, 3.5% of cells were lysed; at 100 µM, 32.7% of cells were lysed. - Hemolytic effect of BMAP-28 on bovine red blood cells: at concentrations of 10 µM, 30 µM, and 100 µM, 3%, 6%, and 22% of cells were lysed, respectively. - Hemolytic effect of BMAP-27 on bovine red blood cells: even at a concentration of 100 µM, bovine red blood cells were almost unaffected. - Hemolytic effect of BMAP-28(1-18) on human red blood cells: hemolytic activity was significantly reduced (specific values were not clearly listed). - Hemolytic effect of BMAP-27(1-18) on human red blood cells: completely lost hemolytic activity. - Hemolytic effect of mBMAP-28 on human red blood cells: at a concentration of 100 µM, only 3.3% of cells were lysed.|||Human RBC: HC50 < 100 uM (at 100 uM, 90% hemolysis). However, lower hemolysis to bovine RBC BMAP-28 (3, 6, and 22% hemolysis at 10, 30, and 100000 uM peptide)." "Skerlavaj B., Gennaro R., Bagella L., Merluzzi L, Risso A, Zanetti M.1996 J. Biol. Chem. 1996; 271: 28375-28381. PubMed.|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed.|||J Biol Chem . 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375.|||8910461, 29103679||Refer PubMed ID: 29103679|||J Biol Chem. 1996 Nov 8;271(45):28375-28381.|||8910461, 29103679||Refer PubMed ID: 29103679|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed." 28 FPDB00262 AP03190|||AP03190|||Figainin 2, Figainin-02|||Figainin 2, Figainin-02|||AP03190|||DRAMP31416|||AP03190|||Figainin 2, Figainin-02|||DRAMP31416 FLGAILKIGHALAKTVLPMVTNAFKPKQ Anti-E. casseliflavus ATCC 700327, activity value is MIC = 4||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 16||Anti-DENV4, activity value is EC50 = 20.8 uM||Anti-and YFV, activity value is EC50 = 21.8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 32 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 8 uM||Anti-Klebsiella pneumoniae, activity value is MIC = 16 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 8 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 8 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 4 uM||Anti-Enterococcus casseliflavus ATCC 700327, activity value is MIC = 4 uM||Anti-Trypanosoma cruzi, activity value is IC50 = 6.32 uM||Anti-Mouse skin melanoma B16-F10, activity value is IC50 = 12.8 uM||Anti-Human breast adenocarcinoma MCF-7, activity value is IC50 = 15.3 uM||Antimicrobial||Antiviral||Anti-Gram+ & Gram-||Antiparasitic||Anticancer skin secretion, the Chaco tree frog, Boana raniceps, South America|||Boana raniceps (Hypsiboas raniceps)|||Boana raniceps (Hypsiboas raniceps)|||skin secretion, the Chaco tree frog, Boana raniceps, South America|||skin secretion, the Chaco tree frog, Boana raniceps, South America|||Boana raniceps (Hypsiboas raniceps) Helix "23% of hemolysis at 32000000 uM and 9% at 16000000 uM|||skin secretion, the Chaco tree frog, Boana raniceps, South America||Figure 2 shows that the HC50 is 48.9 µM, and it promotes hemolysis at a moderate rate, with a hemolysis rate of 23% at 32 µM and 9% at 16 µM.|||Human erythrocytes (9% Hemolysis at 16 uM|||Human erythrocytes (9% Hemolysis at 16 uM|||Figure 2 shows that the HC50 is 48.9 µM, and it promotes hemolysis at a moderate rate, with a hemolysis rate of 23% at 32 µM and 9% at 16 µM.|||The document mentions hemolytic-related data of Figainin 2, as follows: - Half-hemolytic concentration (HC₅₀): 48.9 µM, which can cause 50% hemolysis of human red blood cells at this concentration. - Hemolysis rates at different concentrations: - At 32 µM, the hemolysis rate is 23%; - At 16 µM, the hemolysis rate is 9%. Note: In the hemolysis experiment, hemolysis induced by 1% Triton X-100 was taken as the 100% hemolysis standard, while treatment with Tris-saline was used as the 0% hemolysis control.|||Human erythrocytes (9% Hemolysis at 16 uM" "Santana CJC, Magalhães ACM, Prías-Márquez CA, et al. 2020 Biomolecules. 2020;10(5):E790. PubMed|||Biomolecules . 2020 May 20;10(5):790. doi: 10.3390/biom10050790.|||32443921|||32443921|||Biomolecules . 2020 May 20;10(5):790. doi: 10.3390/biom10050790.|||Biomolecules. 2020 May 20;10(5):790.|||Biomolecules. 2020;10(5):E790. PubMed|||https://pubmed.ncbi.nlm.nih.gov/32443921|||Biomolecules. 2020 May 20;10(5):790." 28 FPDB00304 AP02378|||AP02378|||Surfactin|||Surfactin|||AP02378|||DRAMP33490|||DRAMP33491|||DRAMP33492|||DRAMP33493|||DRAMP33494|||DRAMP33495|||DRAMP33496|||DRAMP33497|||DRAMP33498|||CAMPSQ21265 ELLVDLL Anti-B. cinerea and C. acutatum, activity value is MIC = 4||Anti-Rhizoctonia solani, activity value is MIC = 4 ug/ml||Anti-Colletotrichum acutatum, activity value is MIC = 8 ug/ml||Anti-Botrytis cinerea, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 16 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 16 ug/ml||Anti-Salmonella typhi, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 16 ug/ml||Anti-Human breast adenocarcinoma MDA-MB-231, activity value is IC50 = 14.9 ug/ml||Anti-Human colon adenocarcinoma HCT-15, activity value is IC50 = 11.4 ug/ml||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 10.8 ug/ml||Anti-Human lung adenocarcinoma NCI-H23, activity value is IC50 = 11.2 ug/ml||Anti-Human gastric cancer NUGC-3, activity value is IC50 = 11.8 ug/ml||Anti-Human renal adenocarcinoma ACHN, activity value is IC50 = 11.5 ug/ml||Anti-Rhizoctonia solani, activity value is MIC = 8 ug/ml||Anti-Botrytis cinerea, activity value is MIC = 8 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 32 ug/ml||Anti-Salmonella typhi, activity value is MIC = 32 ug/ml||Anti-Human breast adenocarcinoma MDA-MB-231, activity value is IC50 = 16.1 ug/ml||Anti-Human colon adenocarcinoma HCT-15, activity value is IC50 = 18.3 ug/ml||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 19.4 ug/ml||Anti-Human lung adenocarcinoma NCI-H23, activity value is IC50 = 11.7 ug/ml||Anti-Human gastric cancer NUGC-3, activity value is IC50 = 13.9 ug/ml||Anti-Human renal adenocarcinoma ACHN, activity value is IC50 = 18.4 ug/ml||Anti-Rhizoctonia solani, activity value is MIC = 32 ug/ml||Anti-Colletotrichum acutatum, activity value is MIC = 16 ug/ml||Anti-Botrytis cinerea, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 64 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 64 ug/ml||Anti-Human breast adenocarcinoma MDA-MB-231, activity value is IC50 = 11.2 ug/ml||Anti-Human colon adenocarcinoma HCT-15, activity value is IC50 = 23.2 ug/ml||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 11.7 ug/ml||Anti-Human lung adenocarcinoma NCI-H23, activity value is IC50 = 10.9 ug/ml||Anti-Human gastric cancer NUGC-3, activity value is IC50 = 10.5 ug/ml||Anti-Human renal adenocarcinoma ACHN, activity value is IC50 = 12.3 ug/ml||Anti-Mycoplasmopsis pulmonis MpUR1.1, activity value is MIC = 25 uM||Anti-Mycoplasmopsis pulmonis MpUR1.1, activity value is MBC = 100 uM||Anti-Microsporum canis, activity value is EC50 = 80 ug/ml||Anti-Venturia inaequalis S755, activity value is IC50 = 5.984 ug/ml||Anti-Venturia inaequalis Rs552, activity value is IC50 > 100 ug/ml||Anti-Carnobacterium divergens NCFB 2763, activity value is MIC > 1000 ug/ml||Anti-Brochothrix thermosphacta NCDO 1676, activity value is MIC > 1000 ug/ml||Anti-Candida krusei ATCC 6258, activity value is MIC > 256 ug/ml||Anti-Zygosaccharomyces bailii NCYC 464, activity value is MIC > 256 ug/ml||Anti-Debaryomyces hansenii NCYC 102, activity value is MIC > 256 ug/ml||Anti-Rhizopus stolonifer IMI 017314, activity value is MIC > 64 ug/ml||Anti-Paecilomyces variotii, activity value is MIC > 64 ug/ml||Anti-Byssochlamys fulva IMI 040021, activity value is MIC > 64 ug/ml||Anti-Human colon adenocarcinoma Caco-2, activity value is IC50 = 200 ug/ml||Antimicrobial||Anticancer||Antibacterial||Antiviral||Antifungal Bacillus subtilis N/A Bacillus subtilis|||, Pig erythrocytes (50% Hemolysis at 45.9+-0.9 ug/ml, Intestinal Porcine Epithelial Cells IPEC-J2 (50% Cell death at 100 ug/ml, Pig kidney epithelial cells PK15 (50% Cytotoxicity at 32.87 ug/ml, Chicken Embryonic Fibroblasts (CEF) (50% Cytotoxicity at 89.16 uM, Vero cells (IC50 at 200 ug/ml|||, Pig erythrocytes (50% Hemolysis at 45.9+-0.9 ug/ml, Intestinal Porcine Epithelial Cells IPEC-J2 (50% Cell death at 100 ug/ml, Pig kidney epithelial cells PK15 (50% Cytotoxicity at 32.87 ug/ml, Chicken Embryonic Fibroblasts (CEF) (50% Cytotoxicity at 89.16 uM, Vero cells (IC50 at 200 ug/ml "Tareq FS, Lee MA, Lee HS, Lee JS, Lee YJ, Shin HJ.2014 Mar Drugs. 2014 Jan 31;12(2):871-85. doi: 10.3390/md12020871.PubMed|||Mar Drugs. 2014 Jan 31;12(2):871-85. doi: 10.3390/md12020871.PubMed|||24492520, 30973929, 30068648, 17101680|||https://pubmed.ncbi.nlm.nih.gov/24492520,|||Mar Drugs . 2014 Jan 31;12(2):871-85. doi: 10.3390/md12020871.|||Mar Drugs. 2014 Jan 31;12(2):871-85|||24492520" 7 FPDB00327 AP00780|||DRAMP31474 GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA Anti-Gram+ & Gram-||Anticancer||Antimicrobial||Antiviral milk, Homo sapiens|||milk, Homo sapiens|||Synthetic construct Helix N/A Scand J Infect Dis. 1998;30(5):513-7. PubMed|||1998;30(5):513-7. doi: 10.1080/00365549850161557.|||Antiviral Res. 2007 Sep;75(3):258-65. 49 FPDB00329 AP00809|||DRAMP32374 GIKCRFCCGCCTPGICGVCCRF Anti-Gram+ & Gram-||Antiviral||Anticancer||Antimicrobial tilapia, Oreochromis mossambicus|||tilapia, Oreochromis mossambicus|||Skin Secretion of the African Frog, Kassina senegalensis Bridge N/A Mol Immunol 2007; 44: 1922-1934. PubMed|||2007 Mar;44(8):1922-34. doi: 10.1016/j.molimm.2006.09.031. Epub 2006 Oct 25.|||Mol Immunol 2007; 44: 1922-1934. PubMed 22 FPDB00330 AP00810|||DRAMP31546 " QSHLSLCRWCCNCCRSNKGC" Anti-Gram-||Anticancer||Antimicrobial||Antiviral tilapia, Oreochromis mossambicus|||tilapia, Oreochromis mossambicus|||Oreochromis mossambicus N/A N/A Mol Immunol 2007; 44: 1922-1934|||Peptides. 2018 Aug;106:91-95. 20 FPDB00332 AP00832|||AP00832|||Maximin H1|||DRAMP01123|||Maximin H1|||AP00832|||DRAMP01123 " ILGPVISTIGGVLGGLLKNL" Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anticancer||Antibacterial ; Bombina maxima [Giant fire-bellied toad]||Anti-Escherichia coli ATCC25922, activity value is MIC = 9 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 4.5 ug/ml||Anti-Bacillus pyocyaneus CMCCB1010, activity value is MIC = 9 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 4.5 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 9 ug/ml||Anti-Staphylococcus aureus ATCC 2592, activity value is MIC = 4.5 ug/ml||Anti-Bacillus pyocyaneus CMCCB 1010, activity value is MIC = 9 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 9 ug/ml||Anti-and fungi C. albicans ATCC2002, activity value is MIC = 4.5 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram- skin secretions, Bombina maxima, China, Asia|||skin secretions, Bombina maxima, China, Asia|||Bombina maxima [Giant fire-bellied toad]|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||skin secretions, Bombina maxima, China, Asia|||Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)|||skin secretions, Bombina maxima, China, Asia N/A "strongly hemolytic|||Maximins: At peptide concentrations up to 50 µg/ml, maximins peptides showed almost no hemolytic activity. Maximin H peptide: At a concentration of 50 µg/ml, all maximin H peptides were able to lyse 90-100% of rabbit red blood cells.|||Escherichia coli ATCC25922 ( MIC = 9 ug/ml ), Staphylococcus aureus ATCC2592 ( MIC = 4.5 ug/ml ), Bacillus pyocyaneus CMCCB1010 ( MIC = 9 ug/ml ), Candida albicans ATCC2002 ( MIC = 4.5 ug/ml )|||The document mentions information related to the hemolytic activity of antimicrobial peptides in the skin secretions of the large-webbed bell toad (Bombina maxima): - Maxims (first group of peptides): Even at concentrations as high as 50 µg/ml, they show almost no hemolytic activity against red blood cells. - Maxims H (second group of peptides): They have strong hemolytic activity, causing 90%-100% hemolysis of rabbit red blood cells at a concentration of 50 µg/ml. In the experiments, the group treated with 1% Triton X-100 was used as the maximum hemolysis control, and the degree of hemolysis was assessed by measuring the absorbance at 595 nm. The results showed that maximins H peptides have a significantly stronger hemolytic effect on red blood cells than maximins." Peptides 2002; 23: 427-435|||Peptides 2002; 23: 427-435|||https://pubmed.ncbi.nlm.nih.gov/11835991|||Eur J Immunol. 2005 Apr;35(4):1220-9.||Ref.11835991|||11835991|||Peptides 2002; 23: 427-435||Lai R et al., 2012|||Eur J Immunol. 2005 Apr;35(4):1220-9.Peptides. 2002 Mar;23(3):427-435. 20 FPDB00351 AP01239|||Cathelicidin-BF antimicrobial peptide|||CWA|||DRAMP02473|||Cathelicidin-BF antimicrobial peptide|||AP01239|||BF-30 " KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF" Anti-Gram+ & Gram-||Antifungal||candidacidal||Enzyme inhibitor||Anticancer||Anti-Bacillus subtilis, activity value is MIC = 9.4 ug/ml||Anti-Bacillus pumilus, activity value is MIC = 9.4 ug/ml||Anti-Bacillus cereus, activity value is MIC = 1.2 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 1.2 ug/ml||Anti-DR, activity value is MIC = 2.3 ug/ml||Anti-DR, activity value is MIC = 9.4 ug/ml||Anti-DR, activity value is MIC = 18.7 ug/ml||Anti-Escherichia coliATCC25922, activity value is MIC = 2.3 ug/ml||Anti-DR, activity value is MIC = 1.2 ug/ml||Anti-DR, activity value is MIC = 0.6 ug/ml||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 4.7 ug/ml||Anti-DR, activity value is MIC = 75 ug/ml||Anti-Acinetobacter calcoaceticus, activity value is MIC = 2.3 ug/ml||Anti-Sphingobacterium siyangense, activity value is MIC = 9.4 ug/ml||Anti-Sacharibacillus kuerlensis, activity value is MIC = 4.7 ug/ml||Anti-Pseudomonas luteola, activity value is MIC = 1.2 ug/ml||Anti-DR, activity value is MIC = 4.7 ug/ml||Anti-DR, activity value is MIC = 0.3 ug/ml||Anti-DR, activity value is MIC = 150 ug/ml||Anti-Aspergillus terreus GIM3.34, activity value is MIC = 18.7 ug/ml||Anti-Aspergillus niculans, activity value is MIC = 18.7 ug/ml||Anti-Chaetomium globosum, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 4.7 ug/ml||Anti-Pichia pastoris, activity value is MIC = 0.3 ug/ml||E. coli K88||Anti-P. aeruginosa IS/DR, activity value is MIC = 2.3 ug/ml||Anti-P. aeruginosa 08031205 IS/DR, activity value is MIC = 9.4 ug/ml||Anti-P. aeruginosa 08031014 IS/DR, activity value is MIC = 18.7 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 2.3 ug/ml||Anti-E. coli 08A852 IS/DR, activity value is MIC = 1.2 ug/ml||Anti-E. coli 08A866 IS/DR, activity value is MIC = 0.6 ug/ml||Anti-E. coli 08031017 IS/DR, activity value is MIC = 2.3 ug/ml||Anti-E. coli 08032813 IS/DR, activity value is MIC = 2.3 ug/ml||Anti-E. coli 08040726 IS/DR, activity value is MIC = 0.6 ug/ml||Anti-E. coli 08040722 IS/DR, activity value is MIC = 0.6 ug/ml||Anti-Klebsiella pneumoniae IS/DR, activity value is MIC = 4.7 ug/ml||Anti-K. pneumoniae 08031012 IS/DR, activity value is MIC = 9.4 ug/ml||Anti-K. pneumoniae 08040202 IS/DR, activity value is MIC = 0.6 ug/ml||Anti-K. pneumoniae 08040724 IS/DR, activity value is MIC = 0.3 ug/ml||Anti-Salmonella Typhi IS/DR, activity value is MIC = 1.2 ug/ml||Anti-Saccharibacillus kuerlensis, activity value is MIC = 4.7 ug/ml||Anti-B. pumilus, activity value is MIC = 9.4 ug/ml||Anti-B. cereus, activity value is MIC = 1.2 ug/ml||Anti-S. aureus 08A875 IS/DR, activity value is MIC = 75 ug/ml||Anti-S. aureus 08031002 IS/DR, activity value is MIC > 100 ug/ml||Anti-S. aureus 08031013 IS/DR, activity value is MIC > 100 ug/ml||Anti-S. aureus 08032706 IS/DR, activity value is MIC > 100 ug/ml||Anti-S. aureus 08032712 IS/DR, activity value is MIC > 100 ug/ml||Anti-S. aureus 08032810 IS/DR, activity value is MIC > 100 ug/ml||Anti-Enterococcus faecium IS/DR, activity value is MIC = 150 ug/ml||Anti-Aspergillus nidulans, activity value is MIC = 18.7 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 2.3 uM||Anti-P. aeruginosa ATCC278953, activity value is MIC = 1.2 uM||Anti-and C. albicans, activity value is MIC = 4.7 uM||Antiviral ; Influenza A virus venom, banded krait, Bungarus fasciatus|||Bungarus fasciatus [banded krait]|||Synthetic construct|||Bungarus fasciatus (Banded krait)|||Bungarus fasciatus [banded krait]|||venom, banded krait, Bungarus fasciatus, Asia|||Synthetic construct|||venom, banded krait, Bungarus fasciatus, Asia Helix had little hemolytic activity|||No hemolytic and cytotoxic activity was observed at the dose of up to 400 Âug/ml.|||(PLoS ONE 2008) reported that cathelicidin-BF, isolated from the venom of Bungarus fasciatus, showed no hemolytic activity and did not cause hemoglobin release from human red blood cells even at concentrations as high as 400 µg/ml.|||No hemolytic and cytotoxic activity was observed at the dose of up to 400 Âug/ml.|||Cathelicidin-BF had little hemolytic activity on human red blood cells even with peptide concentrations up to 400000 ug/ml. At the same concentration, cathelicidin-BF was neither cytotoxic for mouse macrophage (RAW264.7) nor for human liver tumor cell (HepG2) (data not shown). Thus, it showed considerable selectivity for microorganisms over mammalian cells in vitro.|||Importantly, it showed low toxicity against human blood cells. PLoS ONE. 2008 Sep 16;3(9):e3217. Pub-Med|||18795096|||29101873|||PLoS One. 2008 Sep 16;3(9):e3217.||Ref.18795096|||18795096|||PLoS ONE. 2008 Sep 16;3(9):e3217. Pub-Med||Tian Y et al. 2013|||https://pubmed.ncbi.nlm.nih.gov/30447229 30 FPDB00356 AP01279|||DRAMP00952 KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK Anticancer||Antimicrobial||Antibacterial||Antifungal||Antiviral seeds, Viscum album L|||Viscum album (European mistletoe) Combine Helix and Beta structure||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Biol Chem. 1997 Sep;378(9):989-96. PubMed|||Acta Crystallogr D Biol Crystallogr. 2008 Sep;64(Pt 9):985-992.|||Plant Mol Biol. 1993 Dec;23(6):1233-1242. 46 FPDB00362 AP01328|||2925|||2926|||2927|||2928|||2929|||2930|||2931|||2932|||2933|||2934|||2935|||2936|||2937|||2938|||2939|||2940|||2941|||2942|||2943|||2944|||2945|||2946|||2947|||2948|||AP01328|||Epinecidin-1|||DRAMP21241 GFIFHIIKGLFHAGKMIHGLV Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-MRSA||Anti-inflammatory||anti-sepsis||Wound healing||Anticancer||45% Cytotoxicity at 50 ug/ml||38% Cytotoxicity at 25 ug/ml||75% Cytotoxicity at 50 ug/ml||65% Cytotoxicity at 25 ug/ml||75 % Cytotoxicity at 50 ug/ml||83% Cytotoxicity at 50 ug/ml||77 % Cytotoxicity at 25 ug/ml||82 % Cytotoxicity at 50 ug/ml||85 % Cytotoxicity at 25 ug/ml||42 % Cytotoxicity at 12.5 ug/ml||41 % Cytotoxicity at 6.25 ug/ml||39 % Cytotoxicity at 3.125 ug/ml||90 % Cytotoxicity at 50 ug/ml||95 % Cytotoxicity at 25 ug/ml||45 % Cytotoxicity at 12.5 ug/ml||25 % Cytotoxicity at 6.25 ug/ml||25 % Cytotoxicity at 3.125 ug/ml||95 % Cytotoxicity at 50 ug/ml||96 % Cytotoxicity at 25 ug/ml||46 % Cytotoxicity at 12.5 ug/ml||Anti-ntiviral activity against foot-and-mouth disease virus in vitro, activity value is EC50 = 0.6 ug/ml||Anti-Antiviral activity against foot-and-mouth disease virus in vitro, activity value is EC50 = 0.6 ug/ml||Anti-17570764: Listeria monocytogenes, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 12.5 ug/ml||Anti-Streptococcus pyogenes, activity value is MIC = 25 ug/ml||Anti-Streptococcus agalactiae, activity value is MIC = 50 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC > 100 ug/ml||Anti-Staphylococcus sp, activity value is MIC = 50 ug/ml||Anti-Staphylococcus xylosus, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus subsp, activity value is MIC = 6.25 ug/ml||Anti-Enterobacter aerogenes, activity value is MIC = 50 ug/ml||Anti-Enterobacter cloacae subsp, activity value is MIC = 100 ug/ml||Anti-Vibrio alginolyticus, activity value is MIC = 12.5 ug/ml||Anti-Klebsiella oxytoca, activity value is MIC = 100 ug/ml||Anti-Salinivibrio costicola subsp, activity value is MIC = 12.5 ug/ml||Anti-Vibrio vulni cus, activity value is MIC = 50 ug/ml||Anti-Vibrio harveyi, activity value is MIC = 12.5 ug/ml||Anti-Vibrio vulnicus, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 60 ug/ml||Anti-Yersinia enterocolitica subsp, activity value is MIC = 100 ug/ml||Anti-Carbapenem-resistant K. pneumoniae Bacterial isolates CRKP-1, activity value is MIC = 8000 ug||Anti-CRKP-2, activity value is MIC = 16000 ug||Anti-CRKP-3, activity value is MIC = 8000 ug||Anti-CRKP-4, activity value is MIC = 8000 ug||Anti-CRKP-5, activity value is MIC = 8000 ug||Anti-CRKP-6, activity value is MIC = 16000 ug||Anti-CRKP-7, activity value is MIC = 8000 ug||Anti-CRKP-8, activity value is MIC = 8000 ug||Anti-CRKP-9, activity value is MIC = 8000 ug||Anti-CRKP-10, activity value is MIC = 4000 ug||Anti-CRKP-11, activity value is MIC = 4000 ug||Anti-CRKP-12, activity value is MIC = 16000 ug||Anti-CRKP-13, activity value is MIC = 16000 ug||Anti-CRKP-14, activity value is MIC = 8000 ug||Anti-CRKP-15, activity value is MIC = 4000 ug||Anti-CRKP-16, activity value is MIC = 8000 ug||Anti-CRKP-17, activity value is MIC = 8000 ug||Anti-CRKP-18, activity value is MIC = 8000 ug||Anti-CRKP-19, activity value is MIC = 8000 ug||Anti-CRKP-20, activity value is MIC = 8000 ug||Anti-CRKP-21, activity value is MIC = 8000 ug||Anti-CRKP-22, activity value is MIC = 16000 ug||Anti-CRKP-23, activity value is MIC = 16000 ug||Anti-Carbapenem-resistant K. aerogenes Bacterial isolates CRKA-1, activity value is MIC = 16000 ug||Anti-CRKA-2, activity value is MIC = 8000 ug||Anti-CRKA-3, activity value is MIC = 4000 ug||Anti-CRKA-4, activity value is MIC = 16000 ug||Anti-CRKA-5, activity value is MIC = 4000 ug||Anti-CRKA-6, activity value is MIC = 16000 ug||Anti-CRKA-7, activity value is MIC = 4000 ug||Anti-CRKA-8, activity value is MIC = 8000 ug||Anti-CRKA-9, activity value is MIC = 16000 ug||Anti-CRKA-10, activity value is MIC = 8000 ug||Anti-CRKA-11, activity value is MIC = 4000 ug||Anti-CRKA-12, activity value is MIC = 8000 ug||Anti-CRKA-13, activity value is MIC = 16000 ug||Anti-CRKA-14, activity value is MIC = 8000 ug||Anti-CRKA-15, activity value is MIC = 8000 ug||Anti-CRKA-16, activity value is MIC = 8000 ug||Anti-CRKA-17, activity value is MIC = 4000 ug||Anti-Carbapenem-resistant P. aeruginosa Bacterial isolates CRPA-1, activity value is MIC = 8000 ug||Anti-CRPA-2, activity value is MIC = 16000 ug||Anti-CRPA-3, activity value is MIC = 8000 ug||Anti-CRPA-4, activity value is MIC = 16000 ug||Anti-CRPA-5, activity value is MIC = 16000 ug||Anti-CRPA-6, activity value is MIC = 8000 ug||Anti-CRPA-7, activity value is MIC = 4000 ug||Anti-CRPA-8, activity value is MIC = 16000 ug||Anti-CRPA-9, activity value is MIC = 8000 ug||Anti-CRPA-10, activity value is MIC = 16000 ug||Anti-CRPA-11, activity value is MIC = 16000 ug||Anti-CRPA-12, activity value is MIC = 16000 ug||Anti-CRPA-13, activity value is MIC = 32000 ug||Anti-Carbapenem-resistant A. baumannii Bacterial isolates CRAB-1, activity value is MIC = 32000 ug||Anti-CRAB-2, activity value is MIC = 32000 ug||Anti-CRAB-3, activity value is MIC = 4000 ug||Anti-CRAB-4, activity value is MIC = 16000 ug||Anti-CRAB-5, activity value is MIC = 32000 ug||Anti-CRAB-6, activity value is MIC = 16000 ug||Anti-CRAB-7, activity value is MIC = 32000 ug||Anti-CRAB-8, activity value is MIC = 8000 ug||Anti-CRAB-9, activity value is MIC = 16000 ug||Anti-Methicillin-resistant S. aureus Bacterial isolates MRSA-1, activity value is MIC = 16000 ug||Anti-MRSA-2, activity value is MIC = 16000 ug||Anti-MRSA-3, activity value is MIC = 32000 ug||Anti-MRSA-4, activity value is MIC = 8000 ug||Anti-MRSA-5, activity value is MIC = 16000 ug||Anti-MRSA-6, activity value is MIC = 8000 ug||Anti-MRSA-7, activity value is MIC = 8000 ug||Anti-MRSA-8, activity value is MIC = 16000 ug||Anti-MRSA-9, activity value is MIC = 32000 ug||Anti-MRSA-10, activity value is MIC = 16000 ug||Anti-MRSA-11, activity value is MIC = 16000 ug||Anti-MRSA-12, activity value is MIC = 16000 ug||Anti-MRSA-13, activity value is MIC = 16000 ug||Anti-MRSA-14, activity value is MIC = 16000 ug||Anti-MRSA-15, activity value is MIC = 16000 ug||Anti-MRSA-16, activity value is MIC = 16000 ug||Anti-MRSA-17, activity value is MIC = 8000 ug||Anti-MRSA-18, activity value is MIC = 16000 ug||Anti-MRSA-19, activity value is MIC = 16000 ug||Anti-MRSA-20, activity value is MIC = 16000 ug||Anti-MRSA-21, activity value is MIC = 16000 ug||Anti-MRSA-22, activity value is MIC = 8000 ug||Anti-Micrococcus luteus, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 50 ug/ml||Anti-Streptococcus agalactiae, activity value is MIC >= 100 ug/ml||Anti-Staphylococcus sp, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria : Grouper Vibrio alginolyticus, activity value is MIC = 6.25 ug/ml||Anti-Vibrio harveyi, activity value is MIC = 6.25 ug/ml||Anti-Vibrio vulnificus, activity value is MIC = 50 ug/ml orange-spotted grouper, Epinephelus coioides|||orange-spotted grouper, Epinephelus coioides|||orange-spotted grouper, Epinephelus coioides|||Epinephelus coioides [orange-spotted grouper]|||Synthetic construct N/A gene|||hRBC(100% hemolysis at 156.25 ug/ml)|||[Ref.23598079] 0% hemolysis at 25 ug/ml , 10% hemolysis at 50 ug/ml , 15% hemolysis at 100 ug/ml , 30% hemolysis at 200 ug/ml , 50% hemolysis at 400 ug/ml against sheep red blood cells DNA Cell Biol. 2007 Jun;26(6):403-13|||DNA Cell Biol. 2007 Jun;26(6):403-13|||30552913, 28882626, 17570764, 35052952||Refer 28882626||Refer Pubmed ID 35052952|||Peptides. 2013 Jun;44:139-48. doi: 10.1016/j.peptides.2013.04.004.||Ref.23598079 21 L FPDB00388 AP01784|||DRAMP00763 " GLPVCGETCAGGTCNTPGCSCSWPICTRN" Anticancer||Antimicrobial||Antibacterial||Antifungal||Antiviral Africa, the Ethiopian highlands, Viola abyssinica|||Viola abyssinica (Ethiopian highlands)|||Arabidopsis thaliana (Mouse-ear cress) Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2011 Apr 25;74(4):727-31|||J Nat Prod. 2011 Apr 25;74(4):727-731. 29 FPDB00389 AP01785|||DRAMP00762 " GLPVCGETCFGGTCNTPGCTCDPWPVCTRN" Anticancer||Antimicrobial||Antibacterial||Antifungal||Antiviral Africa, the Ethiopian highlands, Viola abyssinica|||Viola abyssinica (Ethiopian highlands)|||Arabidopsis thaliana (Mouse-ear cress) Bridge No hemolysis information or data found in the reference(s) presented in this entry J Nat Prod. 2011 Apr 25;74(4):727-31|||J Nat Prod. 2011 Apr 25;74(4):727-731. 30 FPDB00417 AP02134|||AP02134|||TP3|||TP3|||DRAMP31547 " FIHHIIGGLFSVGKHIHSLIHGH" Anti-Gram+ & Gram-||Anti-MRSA||Wound healing||Anticancer||Anti-Gram-negative V. vulnificus 204, activity value is MIC = 2.44 ug/ml||Anti-A-hydrophila BCRC 13018, activity value is MIC > 19.55 ug/ml||Anti-V. alginolyticus, activity value is MIC = 2.44 ug/ml||Anti-P-aeruginosa ATCC 19660, activity value is MIC > 19.55 ug/ml||Anti-S. agalactiae 819, activity value is MIC = 9.78 ug/ml||Anti-E. faecalis BCRC 10066, activity value is MIC = 19.55 ug/ml||Antibacterial||Antifungal||Anti-S. aureus, activity value is MIC = 256 ug/ml||Anti-MRSA, activity value is MIC = 256 ug/ml||Anti-C. albicans, activity value is MIC = 128 ug/ml||Antimicrobial||Antiviral Nile Tilapia, Oreochromis niloticus|||Nile Tilapia, Oreochromis niloticus|||Oreochromis niloticus [Nile tilapia]|||Synthetic construct|||Oreochromis niloticus N/A "were hemolytic in fish red blood cells at 100000 ug/ml for 42% hemolysis|||The hemolytic values of five piscidin peptides (TP1-5) from Nile tilapia (Oreochromis niloticus) on fish red blood cells are as follows: Table Peptide Name Concentration (ug/ml) Hemolysis Rate (%) TP1 100 0 TP2 40 60 TP3 100 42 TP4 100 100 TP5 100 0 Note: TP1 and TP5 showed no hemolytic activity at the highest tested concentration (100 ug/ml); TP2 had a hemolysis rate of 60% at 40 ug/ml; TP3 had a hemolysis rate of 42% at 100 ug/ml; TP4 caused complete hemolysis (100%) at 100 ug/ml. The data are the average of three repeated experiments, and different letters indicate significant differences between groups (p<0.05).|||Nile Tilapia, Oreochromis niloticus||HC₅₀ = 8 uM。|||Vibrio vulnificus 204 ( MIC = 2.44 ug/ml ), Aeromonas hydrophila BCRC 13018 ( MIC >19.55 ug/ml ), Vibrio alginolyticus ( MIC = 2.44 ug/ml ), Pseudomonas aeruginosa ATCC 19660 ( MIC >19.55 ug/ml ), Streptococcus agalactiae 819 ( MIC = 9.78 ug/ml ), E. faecalis BCRC 10066 ( MIC = 19.55 ug/ml ), S. agalactiae BCRC 10787 ( MIC = 0.61 ug/ml )|||Mouse erythrocytes (100% hemolysis, 25 ug/ml)|||Mouse erythrocytes (100% hemolysis, 25 ug/ml)" "PLoS One. 2012;7(11):e50263. Pub-Med.|||PLoS One . 2012;7(11):e50263. doi: 10.1371/journal.pone.0050263. Epub 2012 Nov 30.|||PLoS One. 2012;7(11):e50263. doi: 10.1371/journal.pone.0050263. Epub 2012 Nov 30.|||23226256|||29040295|||29040295|||Peptides. 2018 Aug;106:91-95." 23 FPDB00526 1665|||1666|||1667|||1668|||1669|||DRAMP31157|||ApoE|||DRAMP31157 LRVRLASHLRKLRKRLLRDADDLQKRLAVY 55 % Cytotoxity at 40 ug/ml||60 % Cytotoxity at 40 ug/ml||35 % Cytotoxity at 40 ug/ml||65 % Cytotoxity at 40 ug/ml||Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 30 L FPDB00638 1888|||2040|||2192|||2344|||2497|||2640|||2783|||DRAMP31191|||D5F|||DRAMP31191 FAVGLRAIKRALKKLRRGVRKVAKDL activity value is LD50 = 240 ug/ml||activity value is LD50 = 530 ug/ml||activity value is LD50 = 600 ug/ml||activity value is LD50 = 315 ug/ml||activity value is LD50 = 375 ug/ml||LD50 = >1000 ug/ml||Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 5.47 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 5.47 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 26 L FPDB00658 1910|||2062|||2214|||2366|||2519|||2662|||2805|||D2A21 FAKKFAKKFKKFAKKFAKFAFAF activity value is LD50 = 64 ug/ml||activity value is LD50 = 76 ug/ml||activity value is LD50 = 140 ug/ml||activity value is LD50 = 77 ug/ml||activity value is LD50 = 45 ug/ml||activity value is LD50 = 170 ug/ml||Antibacterial||Anti-Feline immunodeficiency virus, activity value is IC50 = 3.05 uM Synthetic construct N/A Human erythrocytes (93.1% Hemolysis at 250 ug/ml, Feline kidney epithelial CRFK cells (50% Cytotoxicity at 3.43 uM 11751108, 32204024|||12208971 23 L FPDB00786 4191|||4192|||4193|||4194|||CAMPSQ21821 GRKKRRQRRR 7% apoptosis at 10 uM||15% apoptosis at 20 uM||35% apoptosis at 30 uM||65% apoptosis at 50 uM||Antiviral Synthetic construct N/A N/A 22319541 10 L FPDB00884 AP00180|||DRAMP03595|||Human Defensin-5|||AP00180|||DRAMP03595|||AP00180|||DRAMP03595|||Human Defensin-5 ATCYCRTGRCATRESLSGVCEISGRLYRLCCR "Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-toxin||anti-sepsis||Wound healing||Killed C. difficile. Human HD5 blocks papillomavirus infection (both cutaneous and mucosal papillomavirus types). HD-5 was particularly active against sexually transmitted HPV types . HD-5 is active against pseudotyped viruses expressing SARS-CoV-2 spike proteins . It also results in decreased bacterial presence||enhanced wound healing||and hair growth from tissues devoid of adnexal structures (Lough D||et al.||2013). It also neutralizes Clostridioides difficile Toxins TcdA||TcdB||and CDT .||Killed C. difficile. Human HD5 blocks papillomavirus infection (both cutaneous and mucosal papillomavirus types). HD-5 was particularly active against sexually transmitted HPV types . HD-5 is active against pseudotyped viruses expressing SARS-CoV-2 spike proteins .||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2)||Antiviral(SARS-CoV-5)||Antiviral ; E. coli ATCC 25922 ( IC99 = 49.5 +/- 0.2 ug/ml)||S. aureus ATCC 29123 ( IC99 = 6.3 +/- 1.8 ug/ml)||C. albicans ATCC 99788 amphotericin B resistant ( IC90 > 100 ug/ml )||Adenovirus||Refer PubMed ID: A. baumannii 4-MRGN||K. pneumoniae 4-MRGN||P. aeruginosa ATCC27853||E. faecium 475747||B. longum||L. fermentum||L. salivarius||S. salivarius salivarius||Akkermansia muciniphila||B. subtilis 168trpC||S. aureus USA300||B. adolescentis Ni3.29c||B. breve||B. vulgatus DSM1447||L. rhamnosus||E. coli MC1000" Paneth cells, intestine, urinary tract, Homo sapiens|||Homo sapiens (Human)|||Homo sapiens [Human]|||Paneth cells, intestine, urinary tract, Homo sapiens|||Homo sapiens (Human)|||Paneth cells, intestine, urinary tract, Homo sapiens|||Homo sapiens (Human)|||Homo sapiens Beta||Beta strand [Ref.26206286] It has 0% hemolysis at 100 uM against human red blood cells. J. Biol. Chem. 1992; 267:23216-23225|||J. Biol. Chem. 1992; 267:23216-23225||Buck et al., 2006||Xu et al., 2021||Korbmacher et al. 2020|||Buck et al., 2006||Xu et al., 2021|||Viruses. 2021 Jun 26;13(7):1246.|||18191790 , 17088326, 30808760|||J. Biol. Chem. 1992; 267:23216-23225||Buck et al., 2006||Xu et al., 2021|||Viruses. 2021 Jun 26;13(7):1246.Nat Immunol. 2002 Jun;3(6):583-590.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.Peptides. 2015 Sep;71:128-40. doi: 10.1016/j.peptides.2015.07.009. Epub 2015 Jul 20.|||J. Biol. Chem. 1992; 267:23216-23225||Buck et al., 2006||Xu et al., 2021|||Viruses. 2021 Jun 26;13(7):1246.|||https://pubmed.ncbi.nlm.nih.gov/18191790 32 FPDB00887 AP01209|||AP01209|||Retrocyclin-3 RICRCICGRRICRCICGR "Antiviral||Anti-toxin Crucial residues:||Anti-toxin||Antiviral ; HIV-2" mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||mammal theta-defensin; Derived from a silent human gene (pre-stop), animal-derived, natural derivative|||Synthetic construct Bridge N/A J Immunol. 2004 Jul 1;173(1):515-20|||J Immunol. 2004 Jul 1;173(1):515-20|||https://pubmed.ncbi.nlm.nih.gov/15210812 18 FPDB00891 AP02130|||DRAMP00261 GSGPTYCWNEANNPGGPNRCSNNKQCDGARTCSSSGFCQGTSRKPDPGPKGPTYCWDEAKNPGGPNRCSNSKQCDGARTCSSSGFCQGTAGHAAA inhibited HIV-1||Ebola virus.||Antimicrobial||Antiviral cyanobacterium, Scytonema varium|||Scytonema varium (cyanobacterium) Combine Helix and Beta structure||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Biochemistry. 2003 Mar 11;42(9):2578-84.doi: 10.1021/bi0205698.|||Biochemistry. 2003 Mar 11;42(9):2578-2584.Peptides. 2006 Jul;27(7):1668-1675.Protein Sci. 2007 Dec;16(12):2756-2760. 95 FPDB00892 AP02131|||DRAMP00262 LGKFSQTCYNSAIQGSVLTSTCERTNGGYNTSSIDLNSVIENVDGSLKWQPSNFIETCRNTQLAGSSELAAECKTRAQQFVSTKINLDDHIANIDGTLKYE It binds multiple mannose-rich glycans on HIV-1 gp120 .||Antimicrobial||Antiviral cyanobacterium (blue-green alga), Nostoc ellipsosporum|||Nostoc ellipsosporum (cyanobacterium) Beta||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.doi: 10.1128/AAC.41.7.1521.||Alexandre KB et al., 2013|||Antimicrob Agents Chemother. 1997 Jul;41(7):1521-1530.Nat Struct Biol. 1998 Jul;5(7):571-578. 101 FPDB00895 AP03841|||DRAMP31343|||AP03841|||LL-37|||DRAMP31343 GIKQFKRIVQRIKDFLRNLV Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 0.91 uM||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 REP = 0.91 uM] Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37)|||Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37) N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 13.7 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 20 FPDB00896 AP03842|||DRAMP31344|||AP03842|||LL-37|||DRAMP31344 GIKEFKREFQRIKDFLRNLV Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 0.91 uM||Antimicrobial||Antiviral||Anti-HIV||Antiviral ; HIV[IC50 REP = 1.6 uM] Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37)|||Amino acid substitution, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct N/A No hemolytic activity (0% hemolysis at 100 µM)|||CEM-SS cells (50% cell death at 9.9 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 20 FPDB00912 AP00549|||DRAMP00999|||AP00549|||DRAMP00999 GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY Anti-Gram+||Antiviral||Antifungal||Anti-MRSA||Anti-Gram+ bacteria S. pneumoniae PSSP 109 strains, activity value is MIC = 0.25||Anti-S. pneumoniae PRSP 24 strains, activity value is MIC = 0.125||Anti-S. pyogenes ESSP 12 strains, activity value is MIC = 0.063||Anti-S. aureus MSSA 5 strains, activity value is MIC = 4||Anti-S. aureus MRSA 4 strains, activity value is MIC = 16||Anti-S. epidermidis MSSE, activity value is MIC = 8||Anti-S. epidermidis MRSE, activity value is MIC = 4||Anti-E. faecalis 6 strains, activity value is MIC = 64||Anti-E. faecium 5 strains VSEF or 3 strains V, activity value is MIC = 16||Anti-C. diphtheriae 4 strains, activity value is MIC = 2||Anti-C. jeikeium 3 strains, activity value is MIC = 1||Anti-B. thuringiensis 3 strains, activity value is MIC = 32||Antimicrobial||Antibacterial Pseudoplectania nigrella|||Pseudoplectania nigrella (Ebony cup)|||Pseudoplectania nigrella|||Pseudoplectania nigrella (Ebony cup) Combine Helix and Beta structure||Combine helix and strand structure "The document clearly provides the hemolytic values for plectasin, with the core data as follows: Plectasin shows no significant hemolytic activity against human red blood cells, with a half-maximal effective concentration (EC_{50}) for hemolytic activity greater than 400 µg/ml. This data was determined through in vitro experiments. The document also mentions that plectasin has extremely low cytotoxicity to mammalian cells; for example, the EC_{50} values for mouse L929 fibroblasts and normal human epidermal keratinocytes (NHEK) are both greater than 512 µg/ml, indicating that its selectivity for bacteria is much higher than its toxicity to mammalian cells (including red blood cells), supporting its safety potential as a therapeutic antibiotic.|||The document mentions that plectasin has very low hemolytic activity on human red blood cells, with a half-maximal effective concentration (EC₅₀) greater than 400 μg/ml.|||In the provided PDF file content, **hemolytic activity** is mentioned on **page 4**: > Plectasin was neither cytotoxic for murine L929 fibroblasts (effector concentration for half-maximum response, \(\mathrm{EC}_{50} > 512\mathrm{mg}\mathrm{l}^{-1}\) ) and normal human epidermal keratinocytes (NHEK) cells \(\mathrm{EC}_{50} > 512\mathrm{mg}\mathrm{l}^{-1}\) ) **nor haemolytic for human erythrocytes \(\mathrm{EC}_{50} > 400\mathrm{mg}\mathrm{l}^{-1}\)** (data not shown). This statement clearly states: **Plectasin does not have hemolytic effect on human red blood cells**, and its half-hemolytic concentration is \(\mathrm{EC}_{50} > 400 \\mathrm{mg} \cdot \mathrm{L}^{-1}\). This means that even at higher concentrations, Plectasin does not cause significant red blood cell rupture, indicating good biocompatibility and suitability as a potential therapeutic agent.|||In this document, data related to the hemolytic activity of plectasin on human red blood cells is mentioned: hemolytic activity on human red blood cells (EC₅₀ > 400,000 µg·L⁻¹). This value indicates that plectasin has very weak hemolytic effects on human red blood cells in vitro, reflecting its low toxicity to mammalian cells and selective activity against bacteria." "Nature. 2005 Oct 13;437(7061):975-80. PubMed.|||Nature . 2005 Oct 13;437(7061):975-80. doi: 10.1038/nature04051.|||Nature. 2005 Oct 13;437(7061):975-780.|||Nature. 2005 Oct 13;437(7061):975-80. PubMed.|||Nature. 2005 Oct 13;437(7061):975-780." 40 FPDB01030 AP02527|||AP02527|||Dermal antimicrobial peptide Hs-1|||Dermal antimicrobial peptide Hs-1 " FLPLILPSIVTALSSFLKQG" Anti-Gram+||Anti-MRSA||Anti-Gram+ bacteria S. aureus ATCC 33591, activity value is MIC = 11.7 uM||Anti-B. cereus ATCC 14579, activity value is MIC = 23.3 uM||Anti-B. subtilis ATCC 23858, activity value is MIC = 23.3 uM||Anti-L. monocytogenes ATCC 7644, activity value is MIC = 46.6 uM||Anti-S.flexneri ATCC 12022, activity value is MIC > 187 uM||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 11.7 uM||Anti-Bacillus cereus ATCC 14579, activity value is MIC = 23.3 uM||Anti-Bacillus subtilis ATCC 23858, activity value is MIC = 23.3 uM||Anti-Listeria monocytogenes ATCC 7644, activity value is MIC = 46.6 uM skin, Hypsiboas semilineatus, Brazil, South America|||Hypsiboas semilineatus N/A "Median Lethal Concentration (LC₅₀) - Value: 82 µM - Description: This is the hemolytic concentration at which Hs-1 antimicrobial peptide causes 50% lysis of human red blood cells, representing the peptide concentration that can lead to 50% red blood cell rupture. This value was determined through a hemolysis assay, with 1% Triton X-100 (100% hemolysis) and physiological saline (0% hemolysis) used as controls. 2. Hemolysis within antimicrobial concentration range - Conclusion: Within the antimicrobial activity concentration range of Hs-1 (MIC = 11.7–46.6 µM), no significant hemolysis was observed. - Basis: When the peptide concentration is within the effective range for inhibiting the growth of Gram-positive bacteria, its destructive effect on red blood cells is weak, indicating low toxicity to host red blood cells during its antibacterial action. 3. Hemolysis of the control group (50% DMSO) - Conclusion: In the experiment, 50% dimethyl sulfoxide (DMSO), used as a solvent, showed no cytotoxicity to human red blood cells (no hemolytic effect), eliminating the interference of the solvent itself on the results of the hemolysis assay.|||skin, Hypsiboas semilineatus, Brazil, South America|||Human erythrocytes (50% Hemolysis at 82 uM, Vero cells (50% Cell death at 31.25 ug/ml|||Human erythrocytes (50% Hemolysis at 82 uM, Vero cells (50% Cell death at 31.25 ug/ml" "Toxicon . 2015 Jun 1:99:16-22. doi: 10.1016/j.toxicon.2015.03.006. Epub 2015 Mar 12.|||Toxicon. 2015 Jun 1;99:16-22. PubMed|||25772860, 29153860|||25772860, 29153860" 20 FPDB01078 AP03022|||DRAMP31413|||AP03022|||DRAMP31413 " GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR" Anti-Gram+||Antiviral||Anti-MRSA||Channel inhibitors||Anti-Hepatitis B Virus : HBeAg, activity value is IC50 = 3.95 uM||Anti-HBsAg, activity value is IC50 = 2.28 uM||Anti-this peptide can inhibit the growth of Gram+ S. aureus AB94004 or ATCC25923 or MRSA, activity value is MIC = 0.08||Anti-B. subtilis AB91021, activity value is MIC = 10 uM||Anti-B. thuringiensis AB92037, activity value is MIC = 20 uM||Anti-M. luteus AB93113, activity value is MIC = 0.16 uM||Anti-and S. epidermidis PRSE P1389, activity value is MIC = 0.31 uM||Antimicrobial Mesobuthus martensii Karsch|||Mesobuthus martensii|||Mesobuthus martensii Karsch|||Mesobuthus martensii Bridge "In ""A Scorpion Defensin BmKDfsin4 Inhibits Hepatitis B Virus Replication in Vitro,"" the key values related to the hemolytic activity of scorpion defensin BmKDfsin4 are as follows, determined by human red blood cell hemolysis assay (with 0.1% Triton-X100 as 100% hemolysis positive control and physiological saline as 0% hemolysis negative control): - Half-maximal hemolytic concentration (HC_{50}): The HC_{50} of BmKDfsin4 for human red blood cells is 66.85 uM, indicating that at this concentration, 50% of human red blood cells undergo hemolysis. When evaluating its feasibility as an anti-hepatitis B virus drug, this value is used to measure its toxicity to red blood cells. Compared with other substances with hemolytic activity, the higher this value, the more concentrated the substance needs to be to cause significant hemolysis, indicating relatively lower toxicity to red blood cells. - Hemolysis at low concentrations: When the concentration of BmKDfsin4 is below 10 uM, the survival rate of red blood cells is higher than 90%, meaning the hemolysis rate at this time is less than 10%. This data indicates that at lower concentrations, BmKDfsin4 causes minimal damage to red blood cells, exhibiting almost no hemolytic activity, providing strong support for its safety when used as a potential drug at low concentrations.|||Mesobuthus martensii Karsch||The feasibility of the further development of BmKDfsin4 as a candidate anti-HBV agent was determined by measuring its cytotoxicity. After being incubated with a serial dilution of BmKDfsin4 for 48 h, the cell viability of HepG2.2.15 (Figure 2a), HepG2 (Figure 2b) and L-02 (Figure 2c) cells was measured using MTT assays. The 50% cytotoxicity concentrations (CC50) of BmKDfsin4 to HepG2.2.15, HepG2 and L-02 were 167.82, 154.24 and 103.77 uM, respectively. At the concentration of 10 uM, the viability of the BmKDfsin4-treated cells was greater than 90% in all three kinds of cell lines. The hemolysis assay also showed that the viability of erythrocytes was more than 90% when the concentration of BmKDfsin4 was lower than 10 uM (Figure 2d). These data indicated that 10 uM or less BmKDfsin4 was minimally cytotoxic and suitable for further anti-HBV studies.|||[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 uM.|||In the provided document, the hemolysis-related data for the scorpion-derived defensin BmKDfsin4 are as follows: - Half-maximal hemolytic concentration (HC₅₀): 66.85 μM. This value indicates the peptide concentration that can cause 50% hemolysis of red blood cells. - Hemolysis at low concentrations: When the concentration of BmKDfsin4 is below 10 μM, the red blood cell survival rate is over 90%, indicating minimal hemolytic activity at this concentration. The above data were measured using human red blood cell hemolysis experiments, with 0.1% Triton X-100-induced hemolysis as the 100% control and physiological saline as the 0% control. The amount of hemoglobin released (degree of hemolysis) was assessed by measuring absorbance at 570 nm.|||[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 uM." "Toxins (Basel) . 2016 Apr 27;8(5):124. doi: 10.3390/toxins8050124.|||Toxins (Basel) . 2016 Apr 27;8(5):124. doi: 10.3390/toxins8050124.||Meng L et al., 2016|||Toxins (Basel). 2016 Apr 27;8(5):124.|||Toxins (Basel). 2016 Apr 27;8(5). pii: E124. doi: 10.3390/toxins8050124. PubMed|||Toxins (Basel). 2016 Apr 27;8(5):124." 37 FPDB01082 AP03063|||AP03063|||HD5 ATCYCRTGR Anti-Gram+ & Gram-||Antiviral||Anti-MRSA||Anti-it is active against A. baumannii 4-MRGN, activity value is MIC = 25 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-E. faecium 475747, activity value is MIC = 12.5 uM||Anti-and S. aureus USA300, activity value is MIC = 50 uM||Anti-A. baumannii 4-MRGN, activity value is MIC = 25 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 50 uM||Anti-S. aureus USA300, activity value is MIC = 50 uM Homo sapiens N/A Homo sapiens "Proc Natl Acad Sci U S A . 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.|||Proc Natl Acad Sci U S A . 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.|||30808760|||Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. PubMed" 9 FPDB01151 AP03638 " FTSISMCTPGCKTGALMTCNYKTATCHCSIKVSK" Anti-Gram+||Antiviral||Anti-MRSA||Anti-and S. uberis strain 42 . MIC values against S. aureus ATCC 29213 MSSA or MRSA, activity value is MIC = 0.19||Anti-E. faecalis ATCC 29212 or 51299 VRE, activity value is MIC = 1.56 uM||Anti-E. faecium ATCC 35667 or 700221 VRE, activity value is MIC = 0.39 uM||Anti-and B. subtilis 168, activity value is MIC = 0.1 uM Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut|||Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut N/A Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut "Appl Environ Microbiol . 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Epub 2015 Apr 3.|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med." 34 FPDB01433 AP05362 " KNRLNFLKKISQRYQKFALPQYLKTVYQHQKAMKPWIQPKTKVIPYVRYL" Anti-Gram- E. coli ATCC 25922, activity value is MIC = 1.25 uM||Anti-5 strains P. aeruginosa PA14 or KK27 or O1 or AA2 or RP73, activity value is MIC = 1.25||Anti-S. enteritidis 706 RIVM, activity value is MIC = 1.25 uM||Anti-A. baumannii ATCC 17878, activity value is MIC = 1.25 uM||Anti-B. multivorans LMG 17582, activity value is MIC = 1.25 uM||Anti-B. cenocepacia LMG 18863, activity value is MIC = 1.25 uM||Anti-S. enterica ATCC 14028, activity value is MIC = 1.25 uM||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 1.25 uM||Anti-S. aureus ATCC 12600 or 6538p or MRSA WKZ-2, activity value is MIC = 0.63||Anti-L. monocytogenes ATCC 7644, activity value is MIC = 1.25 uM||Anti-and E. faecalis ATCC 29212, activity value is MIC = 1.25 uM||Anti-Gram+ & Gram-||Antiviral||Anti-MRSA||Antibiofilm other methods predicted from bovine milk protein casein alphaS2 N/A "Significant hemolysis occurred only at 50 μM (≈70%). The IC₅₀ was calculated to be ≈31 μM.|||The document mentions the hemolytic-related results of the antimicrobial peptide KNR50, specifically as follows: - In hemolysis experiments with sheep red blood cells, KNR50 showed significant hemolysis at a concentration of 50 μM, with a hemolysis rate of approximately 70%; - Its half-maximal hemolytic concentration (IC_{50}) is 31 μM. It should be noted that the concentration at which KNR50 exerts its antibacterial effect is significantly lower than the concentration that causes hemolysis, indicating that it has good safety at effective antibacterial concentrations." 2025 Jun;311(Pt 3):143718. doi: 10.1016/j.ijbiomac.2025.143718. Epub 2025 May 7.|||Int J Biol Macromol. 2025 May 6:143718. doi: 10.1016/j.ijbiomac.2025.143718. PubMed 50 FPDB01454 AP02439|||AP02439|||CAMPSQ1879|||CAMPSQ1880|||CAMPSQ1881|||DRAMP00202 SCTTCVCTCSCCTT : Active against human malaria parasite P. falciparum (LC50 0.035 uM). Also active against M. tuberculosis (anti-TB) and hepatitis C virus ;||Active against human malaria parasite P. falciparum (LC50 0.035 uM). Also active against M. tuberculosis (anti-TB) and hepatitis C virus ;||Antimicrobial||Antibacterial||Anti-Gram+||Antiviral||Antiparasitic||anti-TB||Antimalarial 2733, from a French red smear cheese|||Bacillus cereus|||Bacillus badius|||Bacillus cereus (strain ATCC 14579 / DSM 31)|||Bacillus cereus); also Bacillus badius|||Staphylococcus epidermidis strain 115; Staphylococcus equorum WS 2733, from a French red smear cheese N/A Staphylococcus epidermidis strain 115; Staphylococcus equorum WS 2733, from a French red smear cheese 2014 Dec;196(24):4344-50. doi: 10.1128/JB.02243-14. Epub 2014 Oct 13.||Degiacomi G et al., 2016||Lee M et al., 2016|||J Bacteriol. 2014 Dec;196(24):4344-50. PubMed||Degiacomi G et al., 2016||Lee M et al., 2016|||J Antibiot (Tokyo). 1976 Apr;29(4):366-374.J Antibiot (Tokyo). 1981 Sep;34(9):1126-1136.|||J Bacteriol. 2014 Dec;196(24):4344-50. PubMed 14 FPDB01462 AP03627 AAHLPAEFTPAVHASLDKFLASVSTVLTSKYR radial diffusion assays: freshly solubilized peptide was active against E. faecium||L. monocytogenes||A. baumannii||P. aeruginosa in a concentration-dependent manner. Did not inhibit S.aureus||K.pneumoniae||and E.coli (bacteriostatic to this strain) till 1000 ug/ml. Both freshly solubilized and fibril forms kill L. monocytogenes and M. tuberculosis||where freshly solubilized and acidic pH 4.5 are preferred for L. monocytogenes. Also||AG-HBA(111–142) inhibited wildtype||acyclovir-resistant HSV-1 and HSV-2 isolates as well as HCMV and MeV in a dose-dependent manner||with IC50 values around 100 ug/ml.||Anti-Gram+ & Gram-||Antiviral||anti-TB Homo sapiens N/A Homo sapiens||No significant hemolytic activity was observed at a concentration as high as 1000 ug/ml.|||No significant hemolytic activity was observed at a concentration as high as 1000 ug/ml. 2023 May 17;80(6):151. doi: 10.1007/s00018-023-04795-8.|||Cell Mol Life Sci. 2023 May 17;80(6):151. doi: 10.1007/s00018-023-04795-8. Pub-Med.|||Cell Mol Life Sci. 2023 May 17;80(6):151. doi: 10.1007/s00018-023-04795-8. Pub-Med.|||Cell Mol Life Sci. 2023 May 17;80(6):151. doi: 10.1007/s00018-023-04795-8. Pub-Med. 32 FPDB01469 AP00102|||AP00102|||OLAP-310|||Thanatin|||DRAMP03057|||Thanatin|||AP00102 GSKKPVPIIYCNRRTGKCQRM Anti-Gram+ A. viridans, activity value is MIC = 0.6||Anti-M. luteus, activity value is MIC = 1.2||Anti-B. megaterium, activity value is MIC = 2.5||Anti-B. subtilis, activity value is MIC = 2.5||Anti-S-aureus, activity value is MIC > 40 uM||Anti-P. acidolactici, activity value is MIC = 20||Anti-E. coli, activity value is MIC = 0.3||Anti-S. typhimurium, activity value is MIC = 0.6||Anti-K pneumoniae, activity value is MIC = 0.6||Anti-E. cloacae, activity value is MIC = 1.2||Anti-E. carotovora, activity value is MIC = 10||Anti-P. aeruginosa, activity value is MIC = 20||Anti-N. crassa, activity value is MIC = 0.6||Anti-N. crassa, activity value is MIC = 1.2||Anti-N. haematococca, activity value is MIC = 1.2||Anti-T. viride, activity value is MIC = 1.2||Anti-A. brassicola, activity value is MIC = 2.5||Anti-F. culmorum, activity value is MIC = 2.5||Anti-A. pisi, activity value is MIC = 5||Anti-and F. oxysporum, activity value is MIC = 10||MIC E.Coli (ATCC 25922: 8 ug/ml||ATCC 700926: 8 ug/ml||MB 4902: 2 ug/ml)||K. pneumoniae (ATCC 13883: 8 ug/ml||ATCC 700603: 64 ug/ml||BAA 2146: 256 ug/ml)||A. baumannii (ATCC 19606): >256 ug/ml||P. aeruginosa (ATCC 27853): 256 ug/ml||B. subtilis (ATCC 6051): 128 ug/ml||S. aureus ATCC 43300 (MRSA): 256 ug/ml||C. albicans (ATCC 90028): 64 ug/ml||C. neoformans (ATCC 208821): 64 ug/ml||Anti-A. viridans, activity value is MIC = 0.6||Anti-P.acidolactici, activity value is MIC = 20||Anti-E. coli D22, activity value is MIC = 0.3||Anti-E. coli D31, activity value is MIC = 0.3||Anti-E. coli 1106, activity value is MIC = 0.6||Anti-K.pneumoniae, activity value is MIC = 0.6||Anti-E.cloacae, activity value is MIC = 1.2||Anti-E.carotovora, activity value is MIC = 10||Anti-P.aeuroginosa, activity value is MIC = 20||Anti-N.crassa, activity value is MIC = 0.6||Anti-B.cinerea, activity value is MIC = 1.2||Anti-N.haematococca, activity value is MIC = 1.2||Anti-T.viride, activity value is MIC = 1.2||Anti-A.brassicola, activity value is MIC = 2.5||Anti-F.culmorum, activity value is MIC = 2.5||Anti-A.pisi, activity value is MIC = 5||Anti-F.oxysporum, activity value is MIC = 10||Anti-Aerococcus viridans, activity value is MIC = 0.6||Anti-Micrococcus luteus, activity value is MIC = 1.2||Anti-Bacillus megaterium, activity value is MIC = 2.5||Anti-Bacillus subtilis, activity value is MIC = 2.5||Anti-Pediococcus acidilactici, activity value is MIC = 20||Anti-Escherichia coli D22, activity value is MIC = 0.3||Anti-Escherichia coli D31, activity value is MIC = 0.3||Anti-Escherichia coli 1106, activity value is MIC = 0.6||Anti-Salmonella typhimurium, activity value is MIC = 0.6||Anti-Klebsiella pneumoniae, activity value is MIC = 0.6||Anti-Enterobacter cloacae, activity value is MIC = 1.2||Anti-Erwinia carotovora, activity value is MIC = 10||Anti-Pseudomonas aeruginosa, activity value is MIC = 20||Anti-Neurospora crassa, activity value is MIC = 0.6||Anti-Botrytis cinerea, activity value is MIC = 1.2||Anti-Nectria haematococca, activity value is MIC = 1.2||Anti-Trichoderma viride, activity value is MIC = 1.2||Anti-Alternaria brassicicola, activity value is MIC = 2.5||Anti-Fusarium culmorum, activity value is MIC = 2.5||Anti-Ascochyta pisi, activity value is MIC = 5||Anti-Fusarium oxysporum, activity value is MIC = 10 Spined soldier bug, Podisus maculiventris (ALso: peptide conjugates available)|||Spined soldier bug, Podisus maculiventris|||Podisus maculiventris|||Podisus maculiventris [Spined soldier bug]|||Podisus maculiventris|||hemolymph, Spined soldier bug, Podisus maculiventris (ALso: peptide conjugates available)|||Spined soldier bug, Podisus maculiventris (ALso: peptide conjugates available) Beta||Beta strand Thanatin at a concentration of 40 μM did not exhibit hemolytic activity against pig red blood cells. 1996 Feb 6;93(3):1221-5. doi: 10.1073/pnas.93.3.1221.|||Active against Gram+ A. viridans (MIC 0.6-1.2 uM), M. luteus (MIC 1.2-2.5 uM), B. megaterium (MIC 2.5-5 uM), B. subtilis (MIC 2.5-5 uM), S-aureus (MIC >40 uM), P. acidolactici (MIC 20-40 uM), Gram- E. coli (MIC 0.3-1.2 uM), S. typhimurium (MIC 0.6-1.2 uM), K pneumoniae (MIC 0.6-1.2 uM), E. cloacae (MIC 1.2-2.5 uM), E. carotovora (MIC 10-20 uM), P. aeruginosa (MIC 20-40 uM), fungi N. crassa (MIC 0.6-1.2 uM), N. crassa (MIC 1.2-2.5 uM), N. haematococca (MIC 1.2-2.5 uM), T. viride (MIC 1.2-2.5 uM), A. brassicola (MIC 2.5-5 uM), F. culmorum (MIC 2.5-5 uM), A. pisi (MIC 5-10 uM), and F. oxysporum (MIC 10-20 uM).|||8577744|||Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1221-1225.||Ref.8577744|||8577744|||Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1221-5. doi: 10.1073/pnas.93.3.1221. 21 FPDB01476 AP00677|||AP00677|||Neutrophil cationic antibacterial polypeptide of 11000 Da|||DRAMP02984 GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI Anti-Gram+ & Gram-||Antiviral||anti-sepsis||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram- Guinea pig, Cavia porcellus|||Guinea pig, Cavia porcellus|||Cavia porcellus [Guinea pig]|||Cavia porcellus (Domestic guinea pig) N/A N/A Comp Biochem Physiol B Biochem Mol Biol. 1997 Jan;116(1):99-107|||Comp Biochem Physiol B Biochem Mol Biol. 1997 Jan;116(1):99-107|||8644997|||Arch Biochem Biophys. 1996 Apr 15;328(2):219-226. 43 FPDB01503 AP02569|||AP02569|||Hc-CATH|||DRAMP29102|||Hc-CATH|||AP02569|||DRAMP29102 KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL Anti-E. coli ATCC25922, activity value is MIC = 0.64 uM||Anti-K. oxytoca, activity value is MIC = 1.3 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 5.2||Anti-E. tarda, activity value is MIC = 0.64 uM||activity value is MIC = 1.3||Anti-and V. anguillarum . This peptide also showed good activity against aquatic bacteria Gram- V. alginolyticus, activity value is MIC = 2.59 uM||Anti-V. brasiliensis, activity value is MIC = 1.29 uM||Anti-V. cholerae, activity value is MIC = 0.64 uM||Anti-V. harveyi, activity value is MIC = 1.29 uM||Anti-V. parahaemolyticus, activity value is MIC = 0.64 uM||Anti-V. splendidus, activity value is MIC = 1.29 uM||Anti-V. vulnificus, activity value is MIC = 2.59 uM||Anti-A. hydrophila, activity value is MIC = 1.29 uM||Anti-A. sobria, activity value is MIC = 2.59 uM||Anti-A.veronii, activity value is MIC = 2.59 uM||Anti-and N. asteroides, activity value is MIC = 1.29||Anti-E. coli ATCC25922, activity value is MIC = 2.34 ug/ml||Anti-E. coli 1 Clinically isolated strain, activity value is MIC = 2.34 ug/ml||Anti-E. coli 2, activity value is MIC = 2.34 ug/ml||Anti-E. coli 3, activity value is MIC = 2.34 ug/ml||Anti-E. coli 4, activity value is MIC = 2.34 ug/ml||Anti-S. dysenteriae, activity value is MIC = 0.59 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 4.69 ug/ml||Anti-C. albicans 1 Clinically isolated strain, activity value is MIC = 4.69 ug/ml||Anti-A. hydrophila, activity value is MIC = 2.34 ug/ml||Anti-V. parahaemdyticus, activity value is MIC = 9.38 ug/ml||Anti-K. pneumoniae 2, activity value is MIC = 4.69 ug/ml||Anti-K. pneumoniae 3, activity value is MIC = 9.38 ug/ml||Anti-K. pneumoniae 4, activity value is MIC = 9.38 ug/ml||Anti-K. pneumoniae 5, activity value is MIC = 18.75 ug/ml||Anti-K. pneumoniae 6, activity value is MIC = 37.5 ug/ml||Anti-K. pneumoniae 7, activity value is MIC = 37.5 ug/ml||Anti-K. pneumoniae 8, activity value is MIC = 75 ug/ml||Anti-Klebsiella oxytoca, activity value is MIC = 4.69 ug/ml||Anti-Proteus mirabilis, activity value is MIC = 4.69 ug/ml||Anti-S. maltophilia 2, activity value is MIC = 9.38 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 18.75 ug/ml||Anti-P. aeruginosa 1, activity value is MIC = 37.5 ug/ml||Anti-Salmonella paratyphi A, activity value is MIC = 4.69 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 4.69 ug/ml||Anti-S. aureus 4, activity value is MIC = 4.69 ug/ml||Anti-S. aureus 5, activity value is MIC = 4.69 ug/ml||Anti-Bacillus cereus, activity value is MIC = 9.38 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 75 ug/ml||Anti-Enterococcus faecium, activity value is MIC = 37.5 ug/ml||Anti-Nocardia asteroides, activity value is MIC = 9.38 ug/ml||Anti-Candida albicans 1, activity value is MIC = 4.69 ug/ml||Anti-C. albicans 2, activity value is MIC = 4.69 ug/ml||Anti-C. albicans 3, activity value is MIC = 4.69 ug/ml||Anti-C. albicans 4, activity value is MIC = 4.69 ug/ml||Anti-C. albicans 5, activity value is MIC = 2.34 ug/ml||Anti-C. albicans 6, activity value is MIC = 2.34 ug/ml||Anti-Candida glabrata 1, activity value is MIC = 2.34 ug/ml||Anti-Arcyria cinerea, activity value is MIC = 9.38 ug/ml||Anti-Aeromonas sobria, activity value is MIC = 2.34 ug/ml||Anti-Aeromonas hydrophila, activity value is MIC = 2.34 ug/ml||Anti-Aeromonas veronii, activity value is MIC = 2.34 ug/ml||Anti-Vibrio vulnificus, activity value is MIC = 4.69 ug/ml||Anti-Vibrio harveyi, activity value is MIC = 9.38 ug/ml||Anti-Vibrio fluvialis, activity value is MIC = 4.69 ug/ml||Anti-Vibrio alginolyticus, activity value is MIC = 4.69 ug/ml||Anti-Vibrio parahaemdyticus, activity value is MIC = 9.38 ug/ml||Anti-Vibrio splendidus, activity value is MIC = 2.34 ug/ml||Anti-Vibrio anguillarum, activity value is MIC = 18.75 ug/ml||Anti-Edwardsiella tarda, activity value is MIC = 2.34 ug/ml||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-inflammatory||anti-sepsis||Antibiofilm||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2.34 ug/ml||activity value is MIC = 4.69 ug/ml||Anti-Escherichia coli 1, activity value is MIC = 2.34 ug/ml||Anti-Escherichia coli 2, activity value is MIC = 2.34 ug/ml||Anti-Escherichia coli 3, activity value is MIC = 2.34 ug/ml||Anti-Escherichia coli 4, activity value is MIC = 9.38 ug/ml||Anti-Shigella dysenteriae, activity value is MIC = 0.59 ug/ml||Anti-Klebsiella pneumoniae 1, activity value is MIC = 37.5 ug/ml||Anti-Klebsiella pneumoniae 2, activity value is MIC = 4.69 ug/ml||Anti-Klebsiella pneumoniae 3, activity value is MIC = 9.38 ug/ml||Anti-Klebsiella pneumoniae 4, activity value is MIC = 9.38 ug/ml||Anti-Klebsiella pneumoniae 5, activity value is MIC = 18.75 ug/ml||Anti-Klebsiella pneumoniae 6, activity value is MIC = 37.5 ug/ml||Anti-Klebsiella pneumoniae 7, activity value is MIC = 37.5 ug/ml||Anti-Klebsiella pneumoniae 8, activity value is MIC = 75 ug/ml||Anti-Serratia marcescens, activity value is MIC > 200 ug/ml||Anti-Proteus vulgaris, activity value is MIC > 200 ug/ml||Anti-Acinetobacter baumannii 1, activity value is MIC > 200 ug/ml||Anti-Acinetobacter baumannii 2, activity value is MIC > 200 ug/ml||Anti-Stenotrophomonas maltophilia, activity value is MIC > 200 ug/ml||Anti-Stenotrophomonas maltophilia 2, activity value is MIC = 9.38 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 18.75 ug/ml||Anti-Pseudomonas aeruginosa 1, activity value is MIC = 37.5 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC > 200 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 4.69 ug/ml||Anti-Staphylococcus aureus 1, activity value is MIC > 200 ug/ml||Anti-Staphylococcus aureus 2, activity value is MIC > 200 ug/ml||Anti-Staphylococcus aureus 3, activity value is MIC > 200 ug/ml||Anti-Staphylococcus aureus 4, activity value is MIC = 4.69 ug/ml||Anti-Staphylococcus aureus 5, activity value is MIC = 4.69 ug/ml||Anti-Enterococcus faecalis, activity value is MIC > 200 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC > 200 ug/ml||Anti-Candida albicans 2, activity value is MIC = 4.69 ug/ml||Anti-Candida albicans 3, activity value is MIC = 4.69 ug/ml||Anti-Candida albicans 4, activity value is MIC = 4.69 ug/ml||Anti-Candida albicans 5, activity value is MIC = 2.34 ug/ml||Anti-Candida albicans 6, activity value is MIC = 2.34 ug/ml||Anti-Candida glabrata, activity value is MIC > 200 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC > 200 ug/ml||Anti-Pathogenic bacteria:Aeromonas sobria, activity value is MIC = 2.34 ug/ml||Anti-Vibrio parahaemolyticus, activity value is MIC = 9.38 ug/ml||Anti-##Gram-positive bacteria:Staphylococcus aureus ATCC 25923, activity value is MIC = 4.69 ug/ml||Anti-##Fungi:Candida albicans 1, activity value is MIC = 4.69 ug/ml||Anti-##Pathogenic bacteria:Aeromonas sobria, activity value is MIC = 2.34 ug/ml venom gland, spleen, and lung, annulated sea snake, Hydrophis cyanocinctus, Asia|||Hydrophis cyanocinctus [Asian annulated sea snake ]|||venom gland, spleen, and lung, annulated sea snake, Hydrophis cyanocinctus, Asia|||Hydrophis cyanocinctus|||Hydrophis cyanocinctus [Asian annulated sea snake ]|||venom gland, spleen, and lung, annulated sea snake, Hydrophis cyanocinctus, Asia|||Hydrophis cyanocinctus Helix||Alpha helix,β-sheet,random coil "venom gland, spleen, and lung, annulated sea snake, Hydrophis cyanocinctus|||Human erythrocytes ( 5.25% at 200 ug/ml )|||The document explicitly provides the hemolytic values of sea snake cathelicidin (Hc-CATH), with specific information as follows: At a concentration of 200 μg/ml (approximately 55.12 μM, which is nearly 10 times the MIC value against most tested microorganisms), Hc-CATH has a hemolysis rate of 5.25% on human red blood cells. This data was determined through a hemolysis assay: 1% Triton X-100 (v/v) was used as the 100% hemolysis positive control, 0.9% physiological saline as the negative control, and the hemolysis rate of Hc-CATH at different concentrations was recorded. At a concentration of 200 μg/ml, the hemolysis rate was 5.25%, demonstrating its low hemolytic activity on mammalian red blood cells.|||The hemolytic value of Hc-CATH is: at a concentration of 200 µg/ml (55.12 µM), the hemolysis rate of human red blood cells is 5.25%.|||Human erythrocytes ( 5.25% at 200 ug/ml )|||HC-Cath has very low cytotoxicity to the tested mammalian cells. At a concentration of 200 μg/ml (55.12 μM, nearly 10 times higher than the MIC for most tested microorganisms), the cell death rates induced by HC-Cath were 4.70%, 3.63%, 1.30%, and 4.28%, respectively. In terms of hemolytic activity, the hemolysis rate of HC-Cath was 5.25% at the same concentration of 200 μg/ml. The adsorption and attachment of HC-CathBin to bacteria are the first steps of AMP-mediated cell killing.|||[Ref.26013823]5.25% Hemolysis against Human erythrocytes at 200 ug/ml(55.12 uM).|||Cytotoxicity and Hemolysis of Hc-CATH—As shown in Table6,Hc-CATH exhibited very low cytotoxicity toward the tested mammalian cells.At concentrations up to200 ug/ml(55.12u M,nearly 10-fold high than the MICs of most tested microorganisms), Hc-CATH induced cell death per-centages as low as 4.70, 3.63, 1.30, and 4.28% for HepG2, PC3,L929,and mouse peritoneal macrophage cells,respectively. As to hemolytic activity,Hc-CATH yielded a hemo lysis of 5.25%,at the same concentration of 200 ug/ml." "2015 Jul 3;290(27):16633-52. doi: 10.1074/jbc.M115.642645. Epub 2015 May 26||Ouyang et al., 2022||Wang et al., 2022|||J Biol Chem. 2015 Jul 3;290(27):16633-52. PubMed||Ouyang et al., 2022||Wang et al., 2022||He et al., 2022|||26013823|||J Biol Chem. 2015 Jul 3;290(27):16633-52. PubMed|||J Biol Chem. 2015 Jul 3;290(27):16633-52.||Ref.26013823|||26013823|||J Biol Chem . 2015 Jul 3;290(27):16633-52. doi: 10.1074/jbc.M115.642645. Epub 2015 May 26.||Ouyang et al., 2022||Wang et al., 2022||He et al., 2022|||J Biol Chem. 2015 Jul 3;290(27):16633-52.||Ref.26013823|||J Biol Chem. 2015 Jul 3;290(27):16633-52. PubMed" 30 FPDB01518 AP03031|||AP03031|||Esculentin-1GN GLFSKKGGKGGKSWIKGVFKGIKGIGKEVGGDVIRTGIEIAACKIKGEC Anti-E. coli ATCC 25922, activity value is MIC = 3.7 uM||Anti-P. aeruginosa, activity value is MIC = 50 uM||Anti-S. aureus ATCC 25923 or ampicillin and benzylpencillin-resistant, activity value is MIC = 1.9||Anti-P. acnes, activity value is MIC = 1.17 uM||Anti-S. subtilis ATCC 6633, activity value is MIC = 3.1 uM||Anti-and C. albicans, activity value is MIC = 4.7 uM||Antibacterial||Antifungal ; S.aureus||E. coli||P. aeruginosa||C. albicans||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antioxidant||Anti-inflammatory||anti-sepsis kin, Hylarana guentheri, Asia|||Hylarana guentheri [Günther's frog]|||skin, Hylarana guentheri, Asia|||skin, Hylarana guentheri, Asia Helix "Esculentin-1GN: At a concentration of 40 μM, the hemolysis rate on human red blood cells is only 6.2%.|||skin, Hylarana guentheri, Asia|||The hemolytic ability of hederagenin-1GN was determined using human red blood cells. As shown in Table S5, hederagenin-1GN has a low hemolytic activity on human red blood cells. At a concentration of 40 μM, the hemolysis rate of human red blood cells was only 6.2%.|||In the provided document, the hemolysis-related data for the novel antimicrobial peptide Esculentin-1GN are as follows: - Hemolysis rate: At a concentration of 40 μM, Esculentin-1GN exhibited a hemolysis rate of only 6.2% on human red blood cells, indicating low hemolytic activity. This data was measured through a human red blood cell hemolysis assay, in which hemolysis induced by 0.1% Triton X-100 was used as the 100% control to assess the degree of red blood cell damage (hemoglobin release) at different peptide concentrations.|||As shown in Table S5, Esculentin-1GN showed a low hemolytic activity on human red cells. At concentrations of 40 uM, the hemolysis ratio of human red cells was only 6.2%." "2018 Dec 13;61(23):10709-10723. doi: 10.1021/acs.jmedchem.8b01358. Epub 2018 Nov 27.|||J Med Chem . 2018 Dec 13;61(23):10709-10723. doi: 10.1021/acs.jmedchem.8b01358. Epub 2018 Nov 27.|||30427189|||J Med Chem . 2018 Dec 13;61(23):10709-10723. doi: 10.1021/acs.jmedchem.8b01358. Epub 2018 Nov 27.|||J Med Chem. 2018 Nov 14. 61 (23), 10709-10723. doi: 10.1021/acs.jmedchem.8b01358. PubMed|||J Med Chem. 2018 Nov 14. 61 (23), 10709-10723. doi: 10.1021/acs.jmedchem.8b01358. PubMed" 49 FPDB01573 AP00074|||Brevinin-1|||AP00074 FLPVLAGIAAKVVPALFCKITKKC Anti-B. Subtilis, activity value is MIC = 2 ug/ml||Anti-S. aureus, activity value is MIC = 8 ug/ml||Anti-and E. coli, activity value is MIC = 34 ug/ml||Antibacterial frog, Rana brevipoda porsa, Japan, Asia|||Rana porosa brevipoda [Japanese frog]|||frog, Rana brevipoda porsa, Japan, Asia N/A S. aureus ( MIC = 8 ug/ml), E. coli ( MIC = 34 ug/ml ) "Comparative Study Biochem Biophys Res Commun . 1992 Nov 30;189(1):184-90. doi: 10.1016/0006-291x(92)91542-x.||Li et al., 2007||Yasin et al., 2000|||1449472|||1992 Nov 30;189(1):184-90. doi: 10.1016/0006-291x(92)91542-x.||Li et al., 2007||Yasin et al., 2000" 24 FPDB01587 AP00095|||Temporin-B|||AP00095|||Temporin-B|||AP00095 LLPIVGNLLKSLL Anti-S. pyogenes beta hem. group A, activity value is MIC = 2.8||Anti-P.aeruginosa ATCC15692, activity value is MIC > 360 uM||Anti-and C. albicans, activity value is MIC = 4 uM||Anti-including parasites L. donovani promastigotes and L. mexicana, activity value is MIC = 24||Anti-and A. baumannii, activity value is MIC = 24 uM||Antibacterial||Antifungal||Anti-Gram+ & Gram-||Antiviral||candidacidal||Antiparasitic||Chemotactic||Antibiofilm||Anti-S. aureus, activity value is MIC = 12 European common frog, Rana temporaria|||Rana temporaria [european common frog]|||European common frog, Rana temporaria|||Rana temporaria [european common frog]|||European common frog, Rana temporaria Helix "Hemolytic activity test results: Temporin A and Temporin B both showed less than 1% hemolysis of human red blood cells at a concentration of 120 μM, whereas bee venom peptide (melittin) can cause more than 90% red blood cell hemolysis at 0.9 μM. Example data: Temporin A: Hemolytic concentration > 120 μM. Temporin B: Hemolytic concentration > 120 μM. Melittin: Hemolytic concentration 0.9 μM.|||The document clearly mentions the hemolytic values of four main peptides (temporin A, temporin B, esculentin 1, cecropin A) and two control peptides (MLP, melittin), specifically their hemolytic activity against human red blood cells (expressed as ""lethal concentration, LC"", which is the minimum concentration that induces hemolysis), as follows: temporin A: >120 µM (no hemolytic activity observed even at concentrations exceeding 120 µM) temporin B: >120 µM (no hemolytic activity observed even at concentrations exceeding 120 µM) esculentin 1: >200 µM (no hemolytic activity observed even at concentrations exceeding 200 µM) cecropin A: >400 µM (no hemolytic activity observed even at concentrations exceeding 400 µM) Control peptide MLP (melittin-like peptide): 0.5 µM (induces hemolysis at extremely low concentrations) Control peptide melittin (bee venom peptide): 0.9 µM (induces hemolysis at extremely low concentrations) The above values were determined by the following experiment: peptides at different concentrations were co-incubated with human red blood cells, and hemolysis was observed. The ""lethal concentration"" (minimum hemolytic concentration) was calculated using the inhibition zone assay, which is the lowest peptide concentration that can induce red blood cell hemolysis; the higher the value, the weaker the peptide's hemolytic activity. Furthermore, the study indicates that the temporin family (such as temporin A and B), although structurally similar to the hemolytic peptides in wasp venom, has no inherent hemolytic activity, whereas the control peptides (MLP and melittin) strongly induce hemolysis at very low concentrations, highlighting the low toxicity advantage of temporins toward eukaryotic cells.|||The hemolytic concentration of temporin A on human red blood cells is >120 µM. The hemolytic concentration of temporin B on human red blood cells is >120 µM. The hemolytic concentration of melittin on human red blood cells is 0.9 µM. The hemolytic concentration of melittin-like peptide (MLP) on human red blood cells is 0.5 µM. The hemolytic concentration of defensin 1 (esculentin 1) on human red blood cells is >200 µM. The hemolytic concentration of cecropin A on human red blood cells is >400." "Eur J Biochem . 1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Maisetta et al., 2016||Marcocci ME et al., 2018||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||9022710|||Eur J Biochem. 1996 Dec 15;242(3):788-92. PubMed.|||9022710|||Eur J Biochem. 1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Maisetta et al., 2016||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90|||1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||Maisetta et al., 2016||Molecules. 2015 Feb 6;20(2):2775-85; J Biol Chem. 2005 Jan 14;280(2):984-90" 13 FPDB01590 AP00099|||Temporin-G|||DRAMP29055|||AP00099 FFPVIGRILNGIL Anti-S. aureus, activity value is MIC = 12 uM||Anti-2012. Also active against C. jeikeium ATCC BAA-949, activity value is MIC = 8 uM||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-||Antifungal||Antibiofilm||S. aureus ATCC 25923 biofilm: TG was capable of killing at least 39%||78% and 87% at 3.12||6.25||12.5 and 25 uM. ## Summary: TG had specific bactericidal activities against E. coli ATCC2592||M. luteus or S. cerevisiae. European common frog, Rana temporaria|||Rana temporaria [european common frog]|||Rana temporaria (European common frog)|||European common frog, Rana temporaria Amphipathic alpha-helical (Uniprot:P79875) "Hemolytic activity test results: Temporin A and Temporin B both showed less than 1% hemolysis of human red blood cells at a concentration of 120 μM, whereas bee venom peptide (melittin) can cause more than 90% red blood cell hemolysis at 0.9 μM. Example data: Temporin A: Hemolytic concentration > 120 μM. Temporin B: Hemolytic concentration > 120 μM. Melittin: Hemolytic concentration 0.9 μM.|||No hemolysis information or data found in the reference(s) presented in this entry|||The hemolytic concentration of temporin A on human red blood cells is >120 µM. The hemolytic concentration of temporin B on human red blood cells is >120 µM. The hemolytic concentration of melittin on human red blood cells is 0.9 µM. The hemolytic concentration of melittin-like peptide (MLP) on human red blood cells is 0.5 µM. The hemolytic concentration of defensin 1 (esculentin 1) on human red blood cells is >200 µM. The hemolytic concentration of cecropin A on human red blood cells is >400." "Eur J Biochem . 1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||ref for AP00095|||9022710|||BMC Biotechnol. 2012 Mar 23;12:10. doi: 10.1186/1472-6750-12-10.|||Int J Mol Sci. 2020 Dec 10;21(24):9410. doi: 10.3390/ijms21249410.##BMC Biotechnol. 2012 Mar 23;12:10. doi: 10.1186/1472-6750-12-10.||Ref.33321906||Ref.22439858|||1996 Dec 15;242(3):788-92. doi: 10.1111/j.1432-1033.1996.0788r.x.||ref for AP00095" 13 FPDB01621 AP00140|||SK84|||DRAMP03113 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK It showed no activity against G- bacteria nor fungi tested.||Antibacterial||Antitumor ; Bacillus subtilis||Bacillus thuringiensis||Staphylococcus aureus||Anti-Bacillus thuringiensis ATCC 1041, activity value is MIC = 4 uM||Anti-B. subtilis ATCC 9372, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 8 uM||Antimicrobial||Anti-Gram+||Antifungal||Antiviral fly, Drosophila virilis|||Drosophila virilis [Fruit fly]|||Drosophila virilis (Fruit fly) Rich [Ref.19799950]0.01% hemolytic activity at 100 uM against human red blood cells "Peptides . 2010 Jan;31(1):44-50. doi: 10.1016/j.peptides.2009.09.028. Epub 2009 Sep 30.|||19799950|||Peptides. 2010 Jan;31(1):44-50.||Ref.19799950|||Peptides. 2010 Jan;31(1):44-50." 84 FPDB01632 AP00158|||DRAMP01669|||Dermaseptin-2|||AP00158|||DRAMP01669 ALWFTMLKKLGTMALHAGKAALGAAANTISQGTQ Anti-A. caviae IP67-16T, activity value is MIC = 1 uM||Anti-E. coli IP76-24, activity value is MIC = 2.5 uM||Anti-S. aureus IP76-25, activity value is MIC = 10||Anti-N. brasiliensis IP118079, activity value is MIC = 20 uM||Anti-S. cerevisiae IP118079, activity value is MIC = 5 uM||Anti-IP886-65, activity value is MIC = 5||Anti-C. neoformans IP960-67 and IP962-67, activity value is MIC = 1 uM||Anti-M. canis IP1194, activity value is MIC = 15 uM||Anti-T. rubrum IP2043-92, activity value is MIC = 35 uM||Anti-T. metagrophytes IP877-71, activity value is MIC = 20 uM||Anti-mutant, activity value is MIC = 20||Anti-A. simii J43, activity value is MIC = 20 uM||Anti-A. niger IP218-53 and A. fumigatus IP1025-70, activity value is MIC = 20 uM||Anti-C. albicans, activity value is MIC = 15 ug/ml||Anti-N. brasiliensis, activity value is MIC = 30 ug/ml||Antimicrobial||Antibacterial||Antifungal||Antiprotozoal||Anti-Active against A. caviae IP67-16T, activity value is MIC = 1 uM||Anti-Gram+ & Gram-||Antiviral||candidacidal||Antiparasitic Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagii [Sauvage frog]|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog) Alpha helix "Dermaseptin S3: At 80 μM, it can cause hemolysis of red blood cells within 1 hour. Dermaseptin S4: At 1 μM, it causes 100% hemolysis within 1 hour; at 0.5 μM, 50% hemolysis occurs. Dermaseptin S5: At a concentration of 90 μM, treatment for 1 hour does not cause hemolysis of human red blood cells.|||No hemolytic activity (0% hemolysis at 200 μM)" "J Biol Chem . 1994 Dec 16;269(50):31635-41.|||Eur J Biochem. 1994 Jan 15;219(1-2):145-154.|||8306981|||J Biol Chem. 1994;269(50):31635-31641.|||Eur J Biochem. 1994 Jan 15;219(1-2):145-154.|||1994 Dec 16;269(50):31635-41.|||J Biol Chem. 1994;269(50):31635-31641.PubMed." 34 FPDB01633 AP00159|||DRAMP01670|||Dermaseptin-3|||AP00159|||DRAMP01670|||AP00159|||Dermaseptin-3 ALWKNMLKGIGKLAGKAALGAVKKLVGAES Anti-A. caviae IP67-16T, activity value is MIC = 1 uM||Anti-E. coli IP76-24, activity value is MIC = 2.5 uM||Anti-S. aureus IP76-25, activity value is MIC = 10 uM||Anti-N. brasiliensis IP118079, activity value is MIC = 5 uM||Anti-S. cerevisiae IP118079, activity value is MIC = 5 uM||Anti-IP886-65, activity value is MIC = 10 uM||Anti-C. neoformans IP960-67 and IP962-67, activity value is MIC = 1 uM||Anti-M. canis IP1194, activity value is MIC = 15 uM||Anti-T. rubrum IP2043-92, activity value is MIC = 40 uM||Anti-T. metagrophytes IP877-71, activity value is MIC = 20 uM||Anti-mutant, activity value is MIC = 20||Anti-A. simii J43, activity value is MIC = 10 uM||Anti-A. niger IP218-53 and A. fumigatus IP1025-70, activity value is MIC = 10||Antimicrobial||Antibacterial||Antifungal||Antiprotozoal||Antiviral||Anti-Malarial parasite strain H, activity value is IC50 = 0.8 uM||Anti-Malarial parasite strain NF54, activity value is IC50 = 0.26 uM||Anti-Gram+ & Gram-||candidacidal||Antiparasitic||Antimalarial Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagii [Sauvage frog]|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Sauvage's leaf frog, Phyllomedusa sauvagii, South America|||Phyllomedusa sauvagii Alpha helix No hemolytic activity (0% hemolysis at 200 μM) "J Biol Chem . 1994 Dec 16;269(50):31635-41.||Ghosh et al., 1998|||Eur J Biochem. 1994 Jan 15;219(1-2):145-155.|||9395500|||J Biol Chem. 1994;269(50):31635-31641.||Ghosh et al., 1998|||Eur J Biochem. 1994 Jan 15;219(1-2):145-155.J Biol Chem. 1997 Dec 12;272(50):31609-31616.|||1994 Dec 16;269(50):31635-41.||Ghosh et al., 1998|||https://pubmed.ncbi.nlm.nih.gov/9395500|||J Biol Chem. 1994;269(50):31635-31641.PubMed." 30 FPDB01641 AP00173|||DRAMP02985|||Neutrophil cationic peptide 2 precursor|||AP00173|||DRAMP02985|||AP00173|||DRAMP02985|||Neutrophil cationic peptide 2 precursor RRCICTTRTCRFPYRRLGTCLFQNRVYTFCC "killed both S. aureus and E. coli at <22 ug/ml. seq updated 2/2023||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral||killed both S. aureus and E. coli at <22 ug/ml.||Antiviral ; S. aureus||E. coli" Cavia porcellus|||Cavia porcellus (Guinea pig)|||Cavia porcellus [Guinea pig]|||Cavia porcellus|||Cavia porcellus (Guinea pig)|||Cavia porcellus|||Cavia porcellus (Guinea pig) Bridge No hemolysis information or data found in the reference(s) presented in this entry "Infect Immun . 1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||DNA Seq. 1993;4(2):123-128.|||8173076|||Infect Immun. 1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||DNA Seq. 1993;4(2):123-128.Inflamm Res. 2000 Feb;49(2):73-79.|||1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||DNA Seq. 1993;4(2):123-128.|||https://pubmed.ncbi.nlm.nih.gov/8173076" 31 FPDB01642 AP00174|||DRAMP02986|||Neutrophil cationic peptide 1|||AP00174|||DRAMP02986|||AP00174|||DRAMP02986|||Neutrophil cationic peptide 1 RRCICTTRTCRFPYRRLGTCIFQNRVYTFCC "killed both S. aureus and E. coli at <22 ug/ml. Updated 2/2023||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral||killed both S. aureus and E. coli at <22 ug/ml.||Antiviral ; :S. aureus||E. coli ]||: P. aeruginosa||Streptococcus||C.albicans||HSV-1 ]" Cavia porcellus|||Cavia porcellus (Guinea pig)|||Cavia porcellus [Guinea pig]|||Cavia porcellus|||Cavia porcellus (Guinea pig)|||Cavia porcellus|||Cavia porcellus (Guinea pig) Bridge No hemolysis information or data found in the reference(s) presented in this entry "Infect Immun . 1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||Infect Immun. 1989 Aug;57(8):2405-2409.|||2473036 , 3623703|||Infect Immun. 1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||Infect Immun. 1989 Aug;57(8):2405-2409.Infect Immun. 1987 Sep;55(9):2281-2286.|||1989 Aug;57(8):2405-9. doi: 10.1128/iai.57.8.2405-2409.1989.|||nfect Immun. 1989 Aug;57(8):2405-2409.|||https://pubmed.ncbi.nlm.nih.gov/2473036||Refer 2473036||Refer 3623703" 31 FPDB01648 AP00187|||DRAMP03804|||Corticostatin-3 precursor|||AP00187|||DRAMP03804|||AP00187|||Corticostatin-3 precursor VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR Anti-C. neofonnans ATCC52817, activity value is MIC = 0.93 ug/ml||Anti-C. neofonnans ATCC 36556 and ATCC 52816, activity value is MIC = 3.75 ug/ml||Antimicrobial||Antibacterial||Antifungal||Antiviral||Antiviral ; Herpes simplex virus type I neutrophils and Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus (Rabbit)|||Oryctolagus cuniculus [Rabbit]|||neutrophils and Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus (Rabbit)|||neutrophils and Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus Bridge N/A "Infect Immun . 1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||Endocrinology. 1992 Mar;130(3):1413-1423.|||2745983|||Infect Immun. 1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||J Biol Chem. 1983 Dec 10;258(23):14485-14489.J Biol Chem. 1985 Apr 25;260(8):4579-4584.Endocrinology. 1992 Mar;130(3):1413-1423.|||1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||https://pubmed.ncbi.nlm.nih.gov/2745983" 33 FPDB01649 AP00188|||DRAMP03805|||Corticostatin-4 precursor|||AP00188|||DRAMP03805|||AP00188|||Corticostatin-4 precursor VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR log deduction after 0.333333 h incubation with 50 ug/ml peptide. Active against S. aureus strains 566||502A||J.F. (reduction 2.4->4.1 logs)||S. epidermidis UCLA-622 (reduction >4.1 logs)||S. pneumoniae Type III (reduction >3.5 log)||S. agalactiae Type I-A or III (reduction 2.0-2.9 logs)||L. monocytogenes 450 (reduction 2.1 logs)||P. aeruginosa PAO579 (reduction 3.2 logs)||E. coli ATCC 29648 (reduction 0.8 logs)||K. pneumoniae ATCC 13883 (reduction 1.1 logs)||S. marcescens (reduction 1.0 log)||H. influenzae Type 3A (reduction 2.1 log)||B. bronchiseptica UCLA-342 (reduction 0.1 log).||Antimicrobial||Antibacterial||Antifungal||Antiviral Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus (Rabbit)|||Oryctolagus cuniculus [Rabbit]|||Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Pardachirus marmoratus (Finless sole) (Achirus marmoratus)|||Macrophage, lung, Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus Beta||Bridge N/A "Infect Immun . 1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||Endocrinology. 1992 Mar;130(3):1413-1423.|||2745983|||Infect Immun. 1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||Eur J Biochem. 1993 Sep 1;216(2):653-659.|||1983 Oct;42(1):10-4. doi: 10.1128/iai.42.1.10-14.1983.|||https://pubmed.ncbi.nlm.nih.gov/2745983" 33 FPDB01666 AP00217|||DRAMP03802 GICACRRRFCPNSERFSGYCRVNGARYVRCCSRR log deduction after 0.333333 h incubation with 50 ug/ml peptide. Active against S. aureus strains 566||502A||J.F. (reduction 0-1.3 logs)||S. epidermidis UCLA-622 (reduction 1.3 logs)||S. pneumoniae Type III (reduction >3.5 log)||S. agalactiae Type I-A or III (reduction 0.3-0.6 logs)||L. monocytogenes 450 (reduction 0.2 logs)||P. aeruginosa PAO579 (reduction 3.3 logs)||E. coli ATCC 29648 (reduction 0.6 logs)||K. pneumoniae ATCC 13883 (reduction 2.4 logs)||S. marcescens (reduction 0.5 log)||H. influenzae Type 3A (reduction >1.1 log)||B. bronchiseptica UCLA-342 (reduction 0.1 log).||Antimicrobial||Antibacterial Rabbit, Oryctolagus cuniculus|||Oryctolagus cuniculus (Rabbit) Bridge N/A J Biol Chem. 1985 Apr 25;260(8):4579-84|||J Biol Chem. 1983 Dec 10;258(23):14485-14489.J Biol Chem. 1985 Apr 25;260(8):4579-4584.Endocrinology. 1992 Mar;130(3):1413-1423. 34 FPDB01667 AP00218|||Protegrin-2|||DRAMP02971|||Protegrin-2|||AP00218|||DRAMP02971|||AP00218 RGGRLCYCRRRFCICV Active against C. albicans .||Anti-L. monocytogenes, activity value is MIC > 25 ug/ml||Anti-E. coli, activity value is MIC > 25 ug/ml||Anti-C. albicans, activity value is MIC > 25 ug/ml||Anti-Listeria moncyrogenes strain EGD, activity value is MIC > 25 ug/ml||Anti-Escherichia coli ML-35, activity value is MIC > 25 ug/ml||Antibacterial||Antifungal||Antimicrobial||Anti-Gram+||Anti-Gram-||Anti-Gram+ & Gram-||Antiviral||candidacidal leukocyte, porcine neutrophil, pig, Sus scrofa|||Sus scrofa|||Sus scrofa (Pig)|||Sus scrofa [pig]|||leukocyte, porcine neutrophil, pig, Sus scrofa|||Sus scrofa (Pig)|||leukocyte, porcine neutrophil, pig, Sus scrofa Beta||Bridge N/A Cho Y et al., 1998|||8335113|||FEBS Lett. 1993 Jul 26;327(2):231-236.|||8335113|||Biochem Biophys Res Commun. 1993 Nov 15;196(3):1363-8||Cho Y et al., 1998|||FEBS Lett. 1993 Jul 26;327(2):231-236.Biochem Biophys Res Commun. 1993 Nov 15;196(3):1363-1368.|||Biochem Biophys Res Commun. 1993 Nov 15;196(3):1363-8||Cho Y et al., 1998|||Biochem Biophys Res Commun. 1993 Nov 15;196(3):1363-8 16 FPDB01668 AP00219|||Protegrin-3|||DRAMP02972|||Protegrin-3|||AP00219|||DRAMP02972|||AP00219 RGGGLCYCRRRFCVCVGR More active against a mprF mutant strain . Active against C. albicans .||Antibacterial||Antifungal||Antimicrobial||Anti-Gram+||Anti-Gram-||Antifungal ; L. monocytogenes||E. coli||C. albicans||: More active against a mprF mutant strain . Active against C. albicans .||Anti-Gram+ & Gram-||Antiviral||candidacidal porcine neutrophil, pig, Sus scrofa|||Sus scrofa [pig]|||Sus scrofa (Pig)|||porcine neutrophil, pig, Sus scrofa|||Sus scrofa (Pig)|||porcine neutrophil, pig, Sus scrofa Beta||Bridge N/A Peschel et al., 2001||Cho Y et al., 1998|||8335113|||FEBS Lett. 1993 Jul 26;327(2):231-236.|||8335113|||FEBS Lett. 1993; 327:231-236||Peschel et al., 2001||Cho Y et al., 1998|||FEBS Lett. 1993 Jul 26;327(2):231-236.|||FEBS Lett. 1993; 327:231-236||Peschel et al., 2001||Cho Y et al., 1998|||FEBS Lett. 1993; 327:231-236 18 FPDB01669 AP00220|||DRAMP02973 RGGRLCYCRGWICFCVGR PG-4 inhibited porcine reproductive and respiratory syndrome virus (PRRSV) in MARC-145 cells . PG-4 itself can form amyloid fibrils (amyloid AMPs) (Gour et al.||2019.||Antimicrobial||Antibacterial||Antifungal Pig, Sus scrofa|||Sus scrofa (Pig) Beta||Bridge N/A Sang et al., 2009|||FEBS Lett. 1994; 346: 285-288.|||FEBS Lett. 1994; 346: 285-288.ochemistry. 2003 Apr 29;42(16):4669-4680.|||FEBS Lett. 1994; 346: 285-288||Sang et al., 2009 18 FPDB01670 AP00221|||DRAMP02974|||AP00221|||DRAMP02974 " RGGRLCYCRPRFCVCVGR" More active against a mprF mutant strain . Active against C. albicans .||Antimicrobial||Antibacterial||Antifungal||Anti-Gram+ & Gram-||Antiviral||candidacidal Pig, Sus scrofa|||Sus scrofa (Pig)|||Pig, Sus scrofa|||Sus scrofa (Pig)|||Pig, Sus scrofa Beta||Bridge N/A Peschel et al., 2001||Cho Y et al., 1998|||FEBS Lett. 1995 Jul 17;368(2):197-202.|||FEBS Lett. 1995; 368:197-202||Peschel et al., 2001||Cho Y et al., 1998|||FEBS Lett. 1995 Jul 17;368(2):197-202.|||FEBS Lett. 1995; 368:197-202||Peschel et al., 2001||Cho Y et al., 1998|||FEBS Lett. 1995; 368:197-202 18 FPDB01671 AP00222|||Defensin NP-1 - rat|||NP-1|||DRAMP03419|||Defensin NP-1 - rat|||AP00222|||AP00222 " VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR" Active against E. coli ML-35||S. typhimurium LT2||P. aeruginosa mucoid and nonmucoid strains||K. pneumoniae 8N3||277||Chedid||S. aureus 502A||and C. albicans 820.||Antibacterial||Antifungal||Anti-Staphylococcus aureus 502A, activity value is MIC < 100||Anti-Escherichia coli ML-35, activity value is MIC < 100||Anti-Cryptococcus neoformans A-383, activity value is MIC = 1.7||Anti-S. aureus 502A, activity value is MIC < 100||Anti-E. coli ML-35, activity value is MIC < 100||Anti-C. albicans 820, activity value is MIC < 100||Anti-C. neoformans A-383, activity value is MIC = 1.7 Rattus norvegicus|||Rattus norvegicus [Rat]|||Synthetic construct|||Rattus norvegicus (Rat)|||Rattus norvegicus [Rat]|||Rattus norvegicus|||Rattus norvegicus Bridge Human RBC ( ? 5% hemolysis at >128 uM) "Infect Immun . 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||2543629|||29282543|||J. Immunol. 1995;155:4476-4484.|||2543629|||Infect Immun. 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989." 32 FPDB01673 AP00224|||Neutrophil antibiotic peptide NP-3 precursor|||DRAMP03421|||Neutrophil antibiotic peptide NP-3 precursor|||AP00224|||DRAMP03421|||AP00224|||DRAMP03421|||Neutrophil antibiotic peptide NP-3 precursor " CSCRTSSCRFGERLSGACRLNGRIYRLCC" "Active against E. coli ML-35||S. aureus 502A||C. neoformans A-383||and C. albicans 820. Updated 7/2021||S. aureus 502A [18 h ]||E. coli ML-35 [18 h]||C. albicans 820 [18 h]||C. neoformans A-383 [18 h ]||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral||and C. albicans 820.||Antiviral ; S. aureus 502A [18 h ]" Rattus norvegicus|||Rattus norvegicus [Rat]|||Rattus norvegicus (Rat)|||Rattus norvegicus [Rat]|||Rattus norvegicus|||Rattus norvegicus (Rat)|||Rattus norvegicus|||Rattus norvegicus (Rat) Bridge No hemolysis information or data found in the reference(s) presented in this entry "Infect Immun . 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||2543629|||Infect. Immun. 1990;58:3899-3902.|||2543629|||Infect Immun. 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||Infect. Immun. 1990;58:3899-3902.J. Immunol. 1995;155:4476-4484.|||1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||Infect. Immun. 1990;58:3899-3902.|||https://pubmed.ncbi.nlm.nih.gov/2543629" 29 FPDB01674 AP00225|||Neutrophil antibiotic peptide NP-4 precursor|||DRAMP03422|||Neutrophil antibiotic peptide NP-4 precursor|||AP00225|||AP00225|||DRAMP03422|||Neutrophil antibiotic peptide NP-4 precursor ACYCRIGACVSGERLTGACGLNGRIYRLCCR Active against E. coli ML-35||S. aureus 502A||C. neoformans A-383||and C. albicans 820. Updated 7/2021||Antibacterial||Antifungal||Antiviral||Anti-Staphylococcus aureus 502A, activity value is MIC = 50 ug/ml||Anti-Acinetobacter calcoaceticus, activity value is MIC = 50 ug/ml||Anti-S. aureus 502A, activity value is MIC = 50 ug/ml||Anti-C. neoformans, activity value is MIC = 10 ug/ml||Anti-A.calcoaceticus, activity value is MIC = 50 ug/ml||Antimicrobial||Anti-Gram+||Anti-Gram- Rattus norvegicus|||Rattus norvegicus [Rat]|||Rattus norvegicus (Rat)|||Rattus norvegicus [Rat]|||Rattus norvegicus|||Rattus norvegicus|||Rattus norvegicus (Rat) Bridge No hemolysis information or data found in the reference(s) presented in this entry "Infect Immun . 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||2543629|||J. Immunol. 1995;155:4476-4484.|||2543629|||Infect Immun. 1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||1989 Jul;57(7):2021-7. doi: 10.1128/iai.57.7.2021-2027.1989.|||Infect. Immun. 1989;57:2021-2027.J. Immunol. 1995;155:4476-4484.|||https://pubmed.ncbi.nlm.nih.gov/2543629" 31 FPDB01702 AP00272|||DRAMP03366|||AP00272|||DRAMP03366 DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS Anti-both Gram-positive and negative bacteria P. aeruginosa, activity value is MIC = 50 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Anti-Gram+ & Gram-||Antiviral||candidacidal kidney, tongue, esophagus, and trachea, Mouse, Mus musculus|||Mus musculus (Mouse)|||kidney, tongue, esophagus, and trachea, Mouse, Mus musculus|||Mus musculus (Mouse) Bridge N/A "FEBS Lett . 1997 Aug 11;413(1):45-9. doi: 10.1016/s0014-5793(97)00875-2.|||FEBS Lett. 1997 Aug 11;413(1):45-49.|||FEBS Lett. 1997 Aug 11;413(1):45-9. doi: 10.1016/s0014-5793(97)00875-2.|||FEBS Lett. 1997 Aug 11;413(1):45-49.|||. 1965 Jun 15;21(6):307-8. doi: 10.1007/BF02144681.|||FEBS Lett. 1997 Aug 11;413(1):45-9. Pub-Med." 37 FPDB01744 AP00333|||DRAMP02805|||AP00333|||DRAMP02805|||Mytilin-B SCASRCKGHCRARRCGYYVSVLYRGRCYCKCLRC Anti-Gram+ M. luteus, activity value is MIC = 0.17||Anti-S-aureus, activity value is MIC > 5.6 uM||Anti-L. monocytogenes, activity value is MIC = 0.35||Anti-E. faecalis, activity value is MIC = 0.17||Anti-E. coli D31, activity value is MIC = 0.7||Anti-B-suis, activity value is MIC > 11.2 uM||Anti-P-aeruginosa, activity value is MIC > 11.2 uM||Anti-E. aerogenes, activity value is MIC = 1.4||Anti-V. alginolyticus, activity value is MIC = 1.4||Anti-V. vulnificus, activity value is MIC = 1.4||Anti-V. splendidus, activity value is MIC = 0.17||Anti-and fungi F. oxysporum, activity value is MIC = 0.7||No MICs found in DRAMP database||Antimicrobial||Antibacterial||Antiviral||Anti-Gram+ & Gram-||Antifungal Blue mussel , Mytilus edulis and Mytilus galloprovincialis|||Mytilus edulis (Blue mussel)|||Blue mussel , Mytilus edulis and Mytilus galloprovincialis|||Mytilus edulis (Blue mussel)|||Mytilus edulis Combine Helix and Beta structure||Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry J. Biol. Chem. 1996; 271:21808-21813|||J Biol Chem. 1996 Sep 6;271(36):21808-21813.|||J. Biol. Chem. 1996; 271:21808-21813|||J Biol Chem. 1996 Sep 6;271(36):21808-21813.|||https://pubmed.ncbi.nlm.nih.gov/8702979, 34 FPDB01768 AP00371|||Antibacterial peptide PMAP-37|||AP00371 GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSEFFQS Anti-Gram+ & Gram-||Antibacterial||Anti-Gram+ S. aureus ATCC25923 or Cowan 1, activity value is MIC = 32||Anti-B. megaterium Bm11, activity value is MIC = 4 uM||Anti-S. epidermidis LY8, activity value is MIC = 25 ug/ml||Anti-L. monocytogenes CICC21634 or CICC21533, activity value is MIC = 4||Anti-B. subtilis CICC24434, activity value is MIC = 1.56 ug/ml||Anti-B. Globigii, activity value is MIC = 0.6 uM||Anti-S. choleraesuis C78-1, activity value is MIC = 1.56 ug/ml||Anti-S. typhimurium SL1344, activity value is MIC = 3.12||Anti-P. avium C48-3, activity value is MIC = 3.12 ug/ml||Anti-E. coli ATCC 25922, activity value is MIC = 1||Anti-and P. aeruginosa ATCC 27853 or PAO1, activity value is MIC = 1.25 myeloid cells, Pig, Sus scrofa|||Sus scrofa [Pig]|||myeloid cells, Pig, Sus scrofa Helix "PMAP-37 has certain hemolytic activity against human red blood cells, with specific hemolysis values as follows: - At 10 µM: hemolysis rate is 10%. - At 50 µM: hemolysis rate exceeds 30%.|||PMAP-37 data on hemolysis of human erythrocytes are mentioned in the document: -At a concentration of 10 uM, PMAP-37 results in 10% hemolysis of human erythrocytes. -At a concentration of 50 uM, the hemolysis rate exceeds 30%. Although the hemolysis of the peptide is lower than that of melittin (melittin), compared with other characterized antimicrobial peptides (such as some Cecropins, magainins, etc.), it shows certain hemolytic activity at antibacterial concentrations, which is more special." "Eur J Biochem . 1995 Mar 15;228(3):941-6. doi: 10.1111/j.1432-1033.1995.tb20344.x.|||7737198|||Eur J Biochem. 1995 Mar 15;228(3):941-6. PubMed." 37 FPDB01829 AP00444|||Corticostatin-6|||DRAMP03806 GICACRRRFCLNFEQFSGYCRVNGARYVRCCSRR Anti-Gram+ & Gram-||Antibacterial||Antifungal||Antiviral||Antimicrobial Rabbit|||Oryctolagus cuniculus [Rabbit]|||synthetic construct|||Oryctolagus cuniculus Bridge N/A Eur. J. Biochem. 1993; 216:653-659|||8397087|||Biophys J. 2002 Aug;83(2):1004-1013.J Biol Chem. 2010 Feb 5;285(6):3883-3895.J Biol Chem. 2004 Oct 29;279(44):45815-23.Peptides. 2013 Jun;44:139-48.|||https://pubmed.ncbi.nlm.nih.gov/8397087 34 FPDB01852 AP00474|||Piscidin-3|||Piscidins p3|||AP00474|||DRAMP02332|||AP00474|||DRAMP02332 FIHHIFRGIVHAGRSIGRFLTG Anti-fish pathogens S. iniae, activity value is MIC = 2.51 uM||Anti-L. garvieae, activity value is MIC = 20.07 uM||Anti-V. anguillarum, activity value is MIC = 2.51||Anti-A-salmonicida, activity value is MIC > 80.26 uM||Anti-human pathogens E. faecalis, activity value is MIC = 1.26 uM||Anti-S. flexneri, activity value is MIC = 20.07 uM||Anti-and E. coli, activity value is MIC = 80.26 uM||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-||Antiviral||Anti-Gram+ & Gram-||Antifungal||Hemolytic mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops)|||Morone chrysops x Morone saxatilis [White bass x Striped bass]|||Hybrid striped bass|||mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops)|||Morone chrysops x Morone saxatilis (white bass x striped sea-bass)|||mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops)|||Morone chrysops x Morone saxatilis (white bass x striped sea-bass) Helix "The document provides some hemolytic values, as follows: - Piscidins 1-3: At concentrations of 1-1000 μg/ml, there are differences in hemolysis rates on human red blood cells. Among them, piscidin 3 has a relatively lower hemolysis rate, which may be related to the substitution of histidine at position 17 in its structure with glycine, disrupting the amphipathic α-helix structure. - Magainin 3: The hemolytic activity is lower than that of piscidins, and the hemolysis rate is relatively low within the same concentration range. - Melittin: The hemolytic activity is relatively strong, with a higher hemolysis rate at higher concentrations, but its antibacterial activity is comparatively weaker. These data indicate that the hemolytic activity of different peptide antibiotics is closely related to structural features, and the integrity of the amphipathic α-helix may be an important factor affecting hemolytic activity.|||Has hemolytic activity|||The document mentions the hemolytic data of piscidins, magainin 2, and mellitin, as follows: - Piscidins 1-3 (P1, P2, P3): At a concentration of 1 µg/ml, the hemolysis rate is close to 0; at 10 µg/ml, the hemolysis rate is about 10%-30% (with P3 having the lowest hemolysis rate); at 100 µg/ml, the hemolysis rate is about 40%-70%; at 1000 µg/ml, the hemolysis rate is about 70%-90%. - Magainin 2 (Mag 2): Hemolysis is lower than that of piscidins, with a hemolysis rate of about 40% at 1000 µg/ml. - Mellitin: The most hemolytic, showing some hemolysis even at 1 µg/ml, and almost 100% hemolysis at 100 µg/ml. The above data are presented in Figure 1c (human red blood cell hemolytic activity curve), showing the hemolysis percentages of each peptide at different concentrations.|||[Ref.11713517]5% hemolytic activity at 100 ug/ml against human erythrocytes" "Nature . 2001 Nov 15;414(6861):268-9. doi: 10.1038/35104690.|||11713517|||31653020|||Nature 2001; 414, 268 - 269. (PubMed)|||Nature. 2001 Nov 15;414(6861):268-269.|||Nature 2001; 414, 268 - 269. (PubMed)|||Nature. 2001 Nov 15;414(6861):268-269." 22 FPDB02000 AP00694|||Prepromelittin-related peptide|||DRAMP01347|||Prepromelittin-related peptide|||AP00694|||DRAMP01347|||AP00694 AIGSILGALAKGLPTLISWIKNR Anti-S. aureus, activity value is MIC = 3.5 uM||Anti-E. coli, activity value is MIC = 20 uM||Anti-and C. albicans, activity value is MIC = 19 uM||Antibacterial||Antifungal||Anticancer||Antiviral||Anti-Staphylococcus aureus, activity value is MIC = 3.5 uM||Anti-Escherichia coli, activity value is MIC = 20 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 3.13 uM||Anti-Bacillus subtilis, activity value is MIC = 3.13 uM||Anti-Escherichia coli, activity value is MIC = 25 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 12.5 uM||Anti-Klebsiella pneumoniae, activity value is MIC = 12.5 uM||Anti-S. aureus, activity value is MIC = 3||Anti-C. albicans, activity value is MIC = 19 uM||Anti-EL4 T-lymphoma cells, activity value is MIC = 14 uM||Anti-E. coli, activity value is MIC = 20||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 6.25 uM||Anti-Gram+ & Gram-||candidacidal||Enzyme inhibitor||Hemolytic Rana tagoi, Asia|||Rana tagoi [Tago frog]|||Rana tagoi (Tago frog)|||Rana tagoi, Asia|||Rana tagoi (Tago frog)|||Rana tagoi, Asia Alpha helix||Helix "The document mentions that the half-hemolytic concentration (HC₅₀) of melittin on human red blood cells is 0.6 μM, while the HC₅₀ of melittin-related peptide (MRP) extracted from the skin of Japanese frogs is 8 μM. This indicates that the hemolytic activity of MRP is 13 times lower than that of melittin.|||Human erythrocytes (8 uM), L929 fibroblasts (20 uM)|||[Ref.27271216] 100% hemolysis at 20 uM against human red blood cells|||Human erythrocytes (8 uM), L929 fibroblasts (20 uM)|||[Ref.27271216] 100% hemolysis at 20 uM against human red blood cells|||The hemolytic values mentioned in the document are as follows: - Melittin-Related Peptide (MRP): the half-maximal hemolytic concentration (HC_{50}) on human red blood cells is 8 µM. - Melittin: the half-maximal hemolytic concentration (HC_{50}) on human red blood cells is 0.6 µM. These two values indicate that the hemolytic activity of MRP is significantly lower than that of melittin (approximately 13 times lower).|||Human erythrocytes (8 uM), L929 fibroblasts (20 uM)" "Biochem Biophys Res Commun . 2003 Jun 27;306(2):496-500. doi: 10.1016/s0006-291x(03)00999-9.|||12804591, 35055066|||12804591||Ref.12804591||Ref.27271216|||12804591, 35055066||Refer Pubmed ID 12804591||Refer Pubmed ID 35055066|||Biochem Biophys Res Commun. 2003 Jun 27;306(2):496-500. PubMed|||Ref.12804591||Ref.27271216|||Biochem Biophys Res Commun. 2003 Jun 27;306(2):496-500. PubMed|||12804591, 35055066||Refer Pubmed ID 12804591||Refer Pubmed ID 35055066|||Biochem Biophys Res Commun. 2003 Jun 27;306(2):496-500. PubMed" 23 FPDB02020 AP00742|||Gallinacin-6|||DRAMP03654|||AP00742 SPIHACRYQRGVCIPGPCRWPYYRVGSCGSGLKSCCVRNRWA Anti-Gram+ & Gram-||Antiviral||Antibacterial||Antimicrobial||Anti-Gram- Gallus gallus domestic; duck, Anas platyrhynchos|||Gallus gallus [Chicken]|||Gallus gallus (Chicken)|||Gallus gallus domestic; duck, Anas platyrhynchos Bridge "Gallinacin 4: at 0-30 ug/ml Gallinacin 7: at 0-30 ug/ml Gallinacin 9: at 0-30 ug/ml|||The document mentions hemolysis-related information for chicken defensins (gallinacins) 4, 7, and 9: In hemolysis experiments with chicken red blood cells, when the concentrations of these recombinant peptides were at bactericidal levels, the hemolysis rate was below 10%. In the experiment, the 0.2% Triton X-100 treated group was used as the 100% hemolysis control, and the PBS treated group was used as the 0% hemolysis control. The percentage of hemolysis was calculated by measuring the absorbance at 560 nm. The results showed that these avian cationic antimicrobial peptides had higher selectivity for bacterial cells than for mammalian cells, and at concentrations effective for antibacterial action, they exhibited weak hemolytic activity on red blood cells." Biochem Biophys Res Commun 2007; 356: 169-174|||17346671|||Biochem Biophys Res Commun. 2007 Apr 27;356(1):169-174.BMC Genomics. 2004 Aug 13;5(1):56.Immunogenetics. 2004 Jun;56(3):170-177.Reproduction. 2007 Jan;133(1):127-133.|||Biochem Biophys Res Commun 2007; 356: 169-174 42 FPDB02022 AP00744|||Gallinacin-5|||DRAMP03653|||AP00744 GLPQDCERRGGFCSHKSCPPGIGRIGLCSKEDFCCRSRWYS Anti-Gram-||Antiviral||Antibacterial||Antimicrobial Gallus gallus domestic|||Gallus gallus [ Chicken]|||Gallus gallus (Chicken)|||Gallus gallus domestic Bridge "Gallinacin 4: at 0-30 ug/ml Gallinacin 7: at 0-30 ug/ml Gallinacin 9: at 0-30 ug/ml|||The document mentions hemolysis-related information for chicken defensins (gallinacins) 4, 7, and 9: In hemolysis experiments with chicken red blood cells, when the concentrations of these recombinant peptides were at bactericidal levels, the hemolysis rate was below 10%. In the experiment, the 0.2% Triton X-100 treated group was used as the 100% hemolysis control, and the PBS treated group was used as the 0% hemolysis control. The percentage of hemolysis was calculated by measuring the absorbance at 560 nm. The results showed that these avian cationic antimicrobial peptides had higher selectivity for bacterial cells than for mammalian cells, and at concentrations effective for antibacterial action, they exhibited weak hemolytic activity on red blood cells." Biochem Biophys Res Commun 2007; 356: 169-174|||82173550|||Biochem Biophys Res Commun. 2007 Apr 27;356(1):169-174.BMC Genomics. 2004 Aug 13;5(1):56.Immunogenetics. 2004 Jun;56(3):170-177.Reproduction. 2007 Jan;133(1):127-133.|||Biochem Biophys Res Commun 2007; 356: 169-174 41 FPDB02043 AP00771|||Magainin-1|||DRAMP02270|||AP00771 GIGKFLHSAGKFGKAFVGEIMKS Anti-Gram+ & Gram-||Antiviral||Antibacterial||Antimicrobial Skin; Stomach, African clawed frog Xenopus laevis|||Xenopus laevis [African clawed frog]|||Xenopus laevis (African clawed frog)|||Skin; Stomach, African clawed frog Xenopus laevis N/A N/A Proc Natl Acad Sci USA 1987; 84: 5449-5453|||3299384|||Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-5453.|||Proc Natl Acad Sci USA 1987; 84: 5449-5453 23 FPDB02092 AP00846|||Mundticin KS|||DRAMP18273|||AP00846|||DRAMP18273 KYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS Anti-Gram+||Antiviral||Antibacterial||Antimicrobial Enterococcus mundtii NFRI 7397|||Enterococcus mundtii CRL35|||Enterococcus mundtii NFRI 7397|||Enterococcus mundtii CRL35 N/A No hemolysis information or data found in the reference(s) presented in this entry 2002 Aug;68(8):3830-40. doi: 10.1128/AEM.68.8.3830-3840.2002.|||12147478|||Int J Antimicrob Agents. 1999 Aug;12(4):293-9.FEMS Microbiol Lett. 2000 Nov 1;192(1):79-83.|||Appl Environ Microbiol 2002; 68: 3830-3840. PubMed.|||Int J Antimicrob Agents. 1999 Aug;12(4):293-9.FEMS Microbiol Lett. 2000 Nov 1;192(1):79-83. 43 FPDB02130 AP00898|||Temporin-1Sa|||Sha|||AP00898|||DRAMP01780|||Temporin-1Sa|||AP00898|||DRAMP01780 FLSGIVGMLGKLF Anti-S. aureus ATCC 25923, activity value is MIC = 3 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 10 uM||Anti-negative E. coli ATCC 25922 or ATCC 35218, activity value is MIC = 10 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 31 uM||Anti-C. albicans ATCC 90028, activity value is MIC = 16 uM||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 31 uM||Anti-and S. cerevisiae, activity value is MIC = 8 uM||Anti-B. megaterium, activity value is MIC = 2 uM||Anti-E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-E. coli ATCC 35218, activity value is MIC = 10 uM||Anti-S. cerevisiae, activity value is MIC = 8 uM||Anti-Listeria ivanovii, activity value is MIC = 6 uM||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Hemolytic||Antibiofilm||Anti-Staphylococcus aureus, activity value is MIC = 3 uM||Anti-Bacillus megaterium, activity value is MIC = 2 uM||Anti-Escherichia coli, activity value is MIC = 10 uM||Antibacterial Pelophylax saharica, North Africa|||Pelophylax saharica [Sahara frog]|||Synthetic construct|||Pelophylax saharica, North Africa|||Pelophylax saharica (North Africa)|||Pelophylax saharica [Sahara frog]|||Pelophylax saharica, North Africa|||Pelophylax saharica (North Africa) Helix||Alpha helix "Temporin-1Sa: LC₅₀ value is 25 uM. Temporin-1Sb: LC₅₀ value is greater than 116 uM. Temporin-1Sc: LC₅₀ value is greater than 80 uM.|||Erythrocytes ( LC50 = 25 uM)|||According to the document, the hemolytic values of three novel temporin peptides (temporin-1Sa, -1Sb, -1Sc) derived from the skin of the North African Sahara frog (Pelophylax saharica) are expressed as the half-maximal hemolytic concentration (LC_{50}), as detailed below: temporin-1Sa: The LC_{50} against human red blood cells is 25 μM, exhibiting moderate hemolytic activity, and its hemolytic concentration (25 μM) is higher than the minimum inhibitory concentration (MIC, 2–31 μM) for most tested strains. temporin-1Sb: The LC_{50} against human red blood cells is greater than 116 μM, showing no significant hemolytic activity; even at a concentration as high as 116 μM, the hemolysis rate does not reach 50%. temporin-1Sc: The LC_{50} against human red blood cells is greater than 80 μM, showing no significant hemolytic activity; even at a concentration as high as 80 μM, the hemolysis rate does not reach 50%. Note: LC_{50} refers to the peptide concentration that induces 50% hemolysis of human red blood cells. It is determined by incubating synthetic peptides at different concentrations (1–200 μM) with fresh human red blood cells for 1 hour and measuring the absorbance at 450 nm. The 0.1% Triton X-100 treated group is used as a 100% hemolysis control.|||Erythrocytes ( LC50 = 25 uM)|||The document mentions the hemolytic-related values of three temporin peptides secreted by the skin of the Sahara frog (Pelophylax saharica), as follows: - temporin-1Sa: the half-maximal hemolytic concentration (LC_{50}) against human red blood cells is 25 µM. - temporin-1Sb: showed no significant hemolytic activity at the tested concentration (>116 µM). - temporin-1Sc: showed no significant hemolytic activity at the tested concentration (>80 µM). In the experiment, the 0.1% Triton X-100 treatment group was used as a 100% hemolysis control, and the hemolysis rate was calculated by measuring the absorbance at 450 nm. The results showed that the hemolytic activity of temporin-1Sa was moderate and higher than its minimum inhibitory concentration (MIC) against most bacterial strains.|||highly hemolytic, 50% hemolysis at 25 uM." 2008 Sep;29(9):1526-33. doi: 10.1016/j.peptides.2008.05.008. Epub 2008 May 18.|||18584916|||30813478|||Peptides. 2008 Sep;29(9):1526-3. Pub-Med|||Biomolecules. 2019 Oct 11;9(10):598.|||31614561|||18584916|||Peptides. 2008 Sep;29(9):1526-3. Pub-Med 13 FPDB02142 AP00928|||Subtilosin A1|||Subtilosin A|||DRAMP00167|||AP00928 NKGCATCSIGAACLVDGPIPDFEIAGATGLFGLWG Anti-B. anthracis, activity value is MIC = 16 uM||Anti-B. thuringiensis, activity value is MIC = 40 uM||Anti-S. carnosus, activity value is MIC = 100 uM||Anti-L. monocytogenes, activity value is MIC = 40 uM||Anti-and S. pyogenes, activity value is MIC = 100 uM||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram+ & Gram-||Antiviral||Spermicidal Bacillus subtilis 168, Also Bacillus amyloliquefaciens, or Bacillus atrophaeus; Bacillus tequilensis FR9 from a dairy product|||Bacillus subtilis|||Bacillus subtilis (strain 168) (Gram-positive bacteria)|||Bacillus subtilis 168, Also Bacillus amyloliquefaciens, or Bacillus atrophaeus; Bacillus tequilensis FR9 from a dairy product Helix Rabbit erythrocytes ( Hemolytic activity at 16 uM )|||Rabbit RBC (MLC=250 uM) 1985 Sep;98(3):585-603. doi: 10.1093/oxfordjournals.jbchem.a135315.|||19633086|||Biochemistry. 2004 Mar 30;43(12):3385-3395.|||J Biochem. 1985 Sep;98(3):585-603. Pub-Med. 35 FPDB02175 AP01010|||Latarcin-1|||DRAMP03226|||Latarcin-1|||AP01010|||AP01010 SMWSGMWRRKLKKLRNALKKKLKGE Anti-Gram+ & Gram-||Antiviral||Antifungal||Antibacterial||Anti-Arthrobacter globiformis VKM Ac-1112, activity value is MIC = 0.5 uM||Anti-Bacillus subtilis VKM B-501, activity value is MIC = 1 uM||Anti-Escherichia coli DH5-alpha, activity value is MIC = 1 uM||Anti-Escherichia coli MH1, activity value is MIC = 0.7 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 4.1 uM||Anti-Pichia pastoris GS115, activity value is MIC = 17 uM||Anti-Saccharomyces cerevisiae Y190, activity value is MIC > 33 uM||Anti-A. globiformis VKM Ac-1112, activity value is MIC = 0.5 uM||Anti-B. subtilis VKM B-501, activity value is MIC = 1 uM||Anti-E. coli DH5-alpha, activity value is MIC = 1 uM||Anti-E. coli MH1, activity value is MIC = 0.7 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 4.1 uM||Anti-P. pastoris GS115, activity value is MIC = 17 uM Lachesana tarabaevi|||Lachesana tarabaevi [Spider]|||Lachesana tarabaevi (Spider)|||Lachesana tarabaevi [Spider]|||venom, Lachesana tarabaevi, Asia|||venom, Lachesana tarabaevi, Asia Helix||Alpha helix (1 helices; 16 residues) "Ltc1: 80Ltc2a: 6.0Ltc3a: >120Ltc3b: >120Ltc4a: >120Ltc4b: >120Ltc5: 40Ltc6a: >120Ltc7: >120|||A. globiformis VKM Ac-1112 ( MIC = 0.5 uM ), B. subtilis VKM B-501 ( MIC = 1 uM ), E. coli DH5-alpha ( MIC = 1 uM ), E. coli MH1 ( MIC = 0.7 uM ), P. aeruginosa PAO1 ( MIC = 4.1 uM ), P. pastoris GS115 ( MIC = 17 uM ), S. cerevisiae Y190 ( MIC = >33 uM)|||Ltc 1：80 uM； • Ltc 2a：6 uM； • Ltc 3a：120 uM； • Ltc 3b：120 uM； • Ltc 4a：120 uM； • Ltc 4b：120 uM； • Ltc 5：40 uM； • Ltc 6a：120 uM； • Ltc 7：120 uM。|||Tests to determine the hemolytic activity of latarcins were performed and showed that erythrocytes are highly resistant to Ltc 3a, Ltc 3b, Ltc 4a, Ltc 4b, Ltc 6a, and Ltc 7 (Table 3). Ltc 2a exhibited comparatively strong hemolytic activity, whereas Ltc 1 and Ltc 5 were moderately hemolytic. Ltc 6a and Ltc 7 (identified as putative AMPs) showed neither antimicrobial nor hemolytic activity.|||The relevant values for the hemolysis of the latarcins peptide on rabbit erythrocytes are mentioned in the document, as follows: -Ltc 1: 80 uM at a concentration that causes 20% hemolysis. -Ltc 2a: concentration of 6 uM causing 20% hemolysis. -Ltc 3a: does not cause 20% hemolysis at the tested concentration (>120 uM). -Ltc 3b: does not cause 20% hemolysis at the tested concentration (>120 uM). -Ltc 4a: does not cause 20% hemolysis at the tested concentration (>120 uM). -Ltc 4b: does not cause 20% hemolysis at the tested concentration (>120 uM). -Ltc 5: 40 uM at a concentration that causes 20% hemolysis. -Ltc 6a: does not cause 20% hemolysis at the tested concentration (>120 uM). -Ltc 7: does not cause 20% hemolysis at the tested concentration (>120 uM). In the experiment, the distilled water treatment group was used as a 100% hemolysis control, and the hemolysis rate was calculated by measuring the absorbance at 414nm. The results showed that there were significant differences in the hemolytic activity of different lattasin peptides, among which Ltc 2a had strong hemolytic activity, while Ltc 3a, Ltc 3b, etc. had almost no obvious hemolytic effect." 2006 Jul 28;281(30):20983-20992. doi: 10.1074/jbc.M602168200. Epub 2006 May 30.|||16735513|||Biochemistry. 2008 Mar 18;47(11):3525-3533.||Ref.16735513|||16735513|||J Biol Chem. 2006 Jul 28;281(30):20983-92. Pub-Med.|||J Biol Chem. 2006 Jul 28;281(30):20983-92. Pub-Med. 25 FPDB02183 AP01049|||Kalata B2|||AP01049|||DRAMP00857 GLPVCGETCFGGTCNTPGCSCTWPICTRD Anti-Gram+||Antiviral||Antifungal||Antiparasitic||Insecticidal||Hemolytic||Anti-Pseudomonas aeruginosa, activity value is MIC = 160 uM||Anti-Moderately active against S. aureus, activity value is MIC = 50 uM||Anti-inactive against E.coli, activity value is MIC > 160 uM||Anti-P.aeruginosa, activity value is MIC = 160 uM||Anti-S.aureus, activity value is MIC > 160 uM||Anti-C.albicans, activity value is MIC > 160 uM Viola betonicifolia|||Oldenlandia affinis|||Viola betonicifolia|||Oldenlandia affinis Combine Helix and Beta structure||Bridge It is mentioned in the document that cycloviolacin O1 and other cyclic peptides (cyclotides) are hemolytic, and the concentration that can cause 50% hemolysis of red blood cells is about 20 uM (the original expression is "cause 50% lysis of erythrocytes at a concentration of ~ 20 uM"). This is the only hemolytic value explicitly mentioned in the text.|||[Ref.20564013] HD50=3.3±1.9 uM against Human red blood cells . 1999 Dec 17;294(5):1327-36 doi: 10.1006/jmbi.1999.3383.|||28669767|||J Mol Biol. 1999 Dec 17;294(5):1327-36. Pub-Med.||Fensterseifer IC et al., 2014||Strömstedt et al., 2017|||J Mol Biol. 1999 Dec 17;294(5):1327-36. Pub-Med.|||J Mol Biol. 1999 Dec 17;294(5):1327-1336.Biochemistry. 2005 Jan 25;44(3):851-860.Biopolymers . 2010;94(5):647-58. 29 FPDB02204 AP01167|||DRAMP00135 LTTKLWSSWGYYLGKKARWNLKHPYVQF Anti-Gram+||Antiviral||Antimicrobial||Antibacterial Lactiplantibacillus plantarum; (old) Lactobacillus plantarum NC8|||Lactobacillus plantarum NC8 (Gram-positive bacteria)|||Lactiplantibacillus plantarum; (old) Lactobacillus plantarum NC8 N/A N/A Appl Environ Microbiol. 2003 Jan;69(1):383-9|||Appl Environ Microbiol. 2003 Jan;69(1):383-389. 28 FPDB02250 AP01224|||DRAMP00246 VGALAVVVWLFLWLW Anti-Gram+ & Gram-||Antimicrobial||Antbacterial||Antiviral Bacillus brevis|||Bacillus brevis (soil bacterium) (Gram-positive bacteria) Helix||Beta strand (1 strands; 13 residues) No hemolysis information or data found in the reference(s) presented in this entry Biochemistry 2001; 40: 11676-11686|||Biochemistry 2001; 40: 11676-11686. 15 FPDB02251 AP01225|||DRAMP00247 " VGALAVVVWLYLWLW" Anti-Gram+ & Gram-||Antimicrobial||Antbacterial||Antiviral Bacillus brevis|||Bacillus brevis (soil bacterium) (Gram-positive bacteria) Helix||Beta strand (1 strands; 13 residues) No hemolysis information or data found in the reference(s) presented in this entry Biochemistry 2001; 40: 11676-11686|||Biochemistry 2001; 40: 11676-11686. 15 FPDB02282 AP01264|||RV-23|||RV-23|||AP01264|||DRAMP01826|||AP01264 " RIGVLLARLPKLFSLFKLMGKKV" Anti-E. coli, activity value is MIC = 2.5 uM||Anti-S. aureus, activity value is MIC = 40 uM||Antibacterial||Antifungal||Anti-Escherichia coli, activity value is MIC = 2.5 uM||Anti-Staphylococcus aureus, activity value is MIC = 40 uM||Anti-Candida albicans, activity value is MIC = 80 uM||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 6.25 uM||Antimicrobial||Anti-Gram+||Anti-Gram-||Anti-Gram+ & Gram-||Antiviral||candidacidal||Hemolytic Rana draytonii, North America|||Rana draytonii [California red-legged frog]|||Synthetic construct|||Rana draytonii, North America|||Rana aurora draytonii (California red-legged frog) Helix "RV-23: Hemolytic concentration (LC₅₀) is 35 uM. temporin-1DRa: LC₅₀ is 70 uM. temporin-1DRb: LC₅₀ is 65 uM|||Escherichia coli ( MIC = 2.5 uM ), Staphylococcus aureus ( MIC = 40 uM ), Candida albicans ( MIC = 80 uM )|||Human RBC (2.56 ± 0.41% hemolysis at 6 uM)|||Human erythrocytes ( IC50 = 35 uM )|||The document mentions the hemolytic values of three peptides (expressed as LC_{50}, that is, the peptide concentration that induces 50% hemolysis), as follows: - RV-23: LC_{50} = 35 μM - Temporin-1DRa: LC_{50} = 70 μM - Temporin-1DRb: LC_{50} = 65 μM These values come from tests on peptides synthesized from the skin secretions of Rana aurora draytonii and reflect their hemolytic activity against human red blood cells." Peptides. 2006 Jun;27(6):1305-12|||16307827|||26975766|||16307827|||Peptides. 2006 Jun;27(6):1305-12|||Peptides. 2006 Jun;27(6):1305-1312.Sci Rep. 2016 Jun 8;6:27394. doi: 10.1038/srep27394.|||Peptides. 2006 Jun;27(6):1305-12 23 FPDB02326 AP01331|||Hylin-a1|||DRAMP02125|||Hylin-a1|||AP01331|||AP01331 IFGAILPLALGALKNLIK Anti-S. aureus, activity value is MIC = 8 uM||Anti-P. aeruginosa, activity value is MIC = 64 uM||Anti-E. coli, activity value is MIC = 32 uM||Anti-B. subtilis, activity value is MIC = 8 uM||Anti-and E. faecalis, activity value is MIC = 16 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 8 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 16 uM||Anti-Bacillus subtilis ATCC 19659, activity value is MIC = 8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 32 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 64 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 16.7 uM||Anti-Candida krusei ATCC 6258, activity value is MIC = 16.7 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC = 67 uM||Anti-Cryptococcus neoformans ATCC 90012, activity value is MIC = 33.5 uM||Anti-Citrobacter freundii KJ561092, activity value is MIC = 125 ug/ml||Anti-Citrobacter freundii MH155228, activity value is MIC = 125 ug/ml||Anti-Lactococcus garvieae KJ560984, activity value is MIC = 15.63 ug/ml||Anti-Lactococcus garvieae KJ560992, activity value is MIC = 15.63 ug/ml||Anti-Streptococcus agalactiae KJ561054, activity value is MIC = 62.5 ug/ml||Anti-Streptococcus agalactiae KJ561057, activity value is MIC = 15.63 ug/ml||Anti-Vibrio fluvialis MH155230, activity value is MIC = 125 ug/ml||Anti-20560142: E. coli, activity value is MIC = 32 uM||Anti-Candida albicans, activity value is MIC = 17 uM||Anti-Candida parapsilosis, activity value is MIC = 64 uM||Anti-Cryptococcus neoformans, activity value is MIC = 37 uM||Anti-Staphylococcus aureus ATCC 25926, activity value is MIC = 8 uM||Anti-C. krusei ATCC 6258, activity value is MIC = 16.7 uM||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 67 uM||Anti-E. coli ATCC 25992, activity value is MIC = 25||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 6.25 uM||Anti-Gram+ & Gram-||Antiviral||Antifungal||Hemolytic South America, (spotted tree frog, Hypsiboas albopunctatus|||Hypsiboas albopunctatus [Spotted tree frog]|||Hypsiboas albopunctatus (Spotted tree frog)|||South America, (spotted tree frog, Hypsiboas albopunctatus|||South America, (spotted tree frog, Hypsiboas albopunctatus Helix "In the document, the content regarding hemolytic values is as follows: Hemolytic value: The half-hemolytic concentration (HC₅₀) of synthetic hylin a1 against human red blood cells is 18 µM. This indicates that the peptide has certain hemolytic activity, but its hemolytic activity is stronger than that of melittin in bee venom (HC₅₀ = 1.8 µM).|||HC50 for hRBC = 18 uM|||In document 7(Peptides 2009), hylin a1, isolated from the skin secretion of the South American tree frog (Hypsiboas albopunctatus), is hemolytic to human erythrocytes with HCLY-18 uM.|||HC50 for hRBC = 18 uM" Peptides. 2009 Feb;30(2):291-6|||19056441, 33742508, 20560142|||Peptides. 2009 Feb;30(2):291-296.||Ref.19056441|||19056441, 33742508, 20560142|||Peptides. 2009 Feb;30(2):291-6|||Peptides. 2009 Feb;30(2):291-6 18 FPDB02358 AP01382|||DRAMP02742|||AP01382|||DRAMP02742 QKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK Anti-Gram-||Antiviral||Antimicrobial||Antibacterial||Anti-Gram+ Red sea turtle Caretta caretta|||Caretta caretta (Loggerhead sea turtle)|||Red sea turtle Caretta caretta|||Caretta caretta (Loggerhead sea turtle) Beta||Beta strand (2 strands; 2 residues) No hemolysis information or data found in the reference(s) presented in this entry Proteins. 2006 Aug 1;64(2):524-31|||Proteins. 2006 Aug 1;64(2):524-531.|||Proteins. 2006 Aug 1;64(2):524-31|||Proteins. 2006 Aug 1;64(2):524-531. 36 FPDB02464 AP01555|||DRAMP04528 TCRYWCKTPENQTYCCEDEREIPSKVGLKPGKCPPVRPVCPPTRGFFEPPKTCSNDGSCYGADKCCFDRCLGEHVCKPIQTRG Anti-M. tetragenus with, activity value is MIC < 0.5 uM||Anti-M. luteus, activity value is MIC = 0.23 uM||Anti-B. subtilis, activity value is MIC = 0.11 uM||Anti-B. thuringiensis, activity value is MIC = 0.11 uM||Antibacterial||Antifungal||Antiviral||In||Anti-Gram+||Antimicrobial Chinese mitten crab, Eriocheir sinensis, Asia|||Chinese mitten crab, Eriocheir sinensis N/A No hemolysis information or data found in the reference(s) presented in this entry Dev Comp Immunol. 2010 Jul;34(7):734-40|||Dev Comp Immunol. 2010 Jul;34(7):734-740. 83 FPDB02467 AP01559|||DRAMP03280|||AP01559|||DRAMP03280 ATYDGKCYKKDNICKYKAQSGKTAICKCYVKVCPRDGAKCEFDSYKGKCYC Inhibition zone: Inhibited A. niger (11 mm)||F. solani (15 mm)||and F. oxysporum (12 mm) using 0.05 ml of 200 ug/ml. This basic||Cys-rich antifungal peptide is also active against bacteria||including S. aureus (11-19 mm)||B. cereus (15-22 mm)||M. luteus (12-18 mm)||E. faecalis (10-13 mm)||E. coli (12-16 mm)||P. aeruginosa and K.pneumonia (0 mm) treated at 50 to 200 ug/ml.||Anti-Staphylococcus aureus, activity value is MIC = 20 ug/ml||Anti-Bacillus cereus, activity value is MIC = 10 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 10 ug/ml||Anti-Enterococcus faecalis, activity value is MIC = 50 ug/ml||Anti-Escherichia coli, activity value is MIC = 30 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 50 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral||Antifungal||Anti-Gram+ & Gram- Aspergillus clavatus ES1 Bridge No hemolysis information or data found in the reference(s) presented in this entry J Ind Microbiol Biotechnol. 2010 Aug;37(8):805-13|||J Ind Microbiol Biotechnol. 2010 Aug;37(8):805-813.|||J Ind Microbiol Biotechnol. 2010 Aug;37(8):805-13|||J Ind Microbiol Biotechnol. 2010 Aug;37(8):805-813. 51 FPDB02468 AP01565|||DRAMP03087 " DDMTMKPTPPPQYPLNLQGGGGGGSGDGFGFAVQGHQKVWTSDNGRHEIGLNGGYGQHLGGPYGNSEPSWKVGSTYTYRFPNF" Anti-Gram-||Antimicrobial||Antibacterial||Antifungal||Antiviral fruit fly, Drosophila melanogaster|||Drosophila melanogaster (Fruit fly) Nonhelixbeta No hemolysis information or data found in the reference(s) presented in this entry J Biol Chem. 1990 Dec 25;265(36):22493-8|||J Biol Chem. 1990 Dec 25;265(36):22493-8. 83 FPDB02472 AP01571|||Strongylocin 1|||DRAMP04582 IFGSIYHRKCVVKNRCETVSGHKTCKDLTCCRAVIFRHERPEVCRPQT Anti-Gram- L. anguillarum serotype O2, activity value is MIC = 2.5 uM||Anti-E. coli ATCC 25922, activity value is MIC = 5 uM||Anti-C. glutamicum ATCC 13032, activity value is MIC = 2.5 uM||Anti-and S. aureus ATCC 9144, activity value is MIC = 2.5 uM||Antibacterial||Antimicrobial||Antifungal||Antiviral||No MICs found in DRAMP database Live green sea urchins, Strongylocentrotus droebachiensis, Norway, Europe|||Strongylocentrotus droebachiensis [Green sea urchin]|||Strongylocentrotus droebachiensis Bridge "At a concentration of up to 17.5 uM, Strongylocins did not exhibit hemolytic activity.|||strongylocins 1 and 2: At concentrations of 17.5 μM, there is no hemolytic activity (this concentration is 3.5–13.5 times their minimum inhibitory concentration (MIC)). Positive control peptide: Mellitin B: Half hemolytic concentration (EC₅₀) is 2 uM; Cecropin B: Half hemolytic concentration (EC₅₀) is 40 uM.|||No hemolysis information or data found in the reference(s) presented in this entry" "Dev Comp Immunol . 2008;32(12):1430-40. doi: 10.1016/j.dci.2008.06.013. Epub 2008 Jul 24.|||18656496|||Dev Comp Immunol. 2008;32(12):1430-1440." 48 FPDB02495 AP01596|||DRAMP00060|||Lantibiotic cinnamycin CRQSCSFGPFTFVCDGNTK Anti-Gram+||Antifungal||Enzyme inhibitor||Hemolytic||Antimicrobial||Antbacterial||Antiviral||Antiviral ; Herpes Simplex Virus Streptomyces cinnamoneus cinnamoneus DSM 40005|||Streptomyces cinnamoneus cinnamoneus DSM 40005 (Gram-positive bacteria)|||Streptoverticillium griseoverticillatum Nonhelixbeta||Beta strand (2 strands; 2 residues) No hemolysis information or data found in the reference(s) presented in this entry "J Antibiot (Tokyo) . 1990 Nov;43(11):1403-12. doi: 10.7164/antibiotics.43.1403.|||J Antibiot (Tokyo). 1990 Nov;43(11):1403-12. PubMed|||J Antibiot (Tokyo). 1990 Nov;43(11):1403-1412.J Antibiot (Tokyo). 1989 Jun;42(6):837-845.J Biochem. 1996 Feb;119(2):226-230." 19 FPDB02497 AP01598|||SpStrongylocin 1|||DRAMP04584 IFNSIYHRKCVVKNRCETVSGHKTCKDLTCCRAVIFRHERPEVCRPST Anti-Gram- L. anguillarum serotype O2, activity value is MIC = 15 uM||Anti-E. coli ATCC 25922, activity value is MIC = 7.5 uM||Anti-C. glutamicum ATCC 13032, activity value is MIC = 7.5 uM||Anti-and S. aureus ATCC 9144, activity value is MIC = 15 uM||Antibacterial||Antimicrobial||Antifungal||Antiviral||No MICs found in DRAMP database Strongylocentrotus purpuratus|||Strongylocentrotus purpuratus [Purple sea urchin]|||Strongylocentrotus purpuratus Bridge No hemolysis information or data found in the reference(s) presented in this entry "Dev Comp Immunol . 2010 Mar;34(3):286-92. doi: 10.1016/j.dci.2009.10.006. Epub 2009 Oct 30.|||19852980|||Dev Comp Immunol. 2010 Mar;34(3):286-292." 48 FPDB02537 AP01649|||Moronecidin|||Moro-NH2|||DRAMP02331|||Moronecidin|||Moro-NH2|||AP01649|||AP01649 FFHHIFRGIVHVGKTIHKLVTG Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-HIV||Enzyme inhibitor||Antimalarial||Antibacterial||Anti-Enterococcus faecalis, activity value is MIC = 5||Anti-E. faecalis, activity value is MIC = 2.5||Anti-Listeria monocytogenes, activity value is MIC = 2.5||Anti-Micrococcus luteus, activity value is MIC = 10||Anti-Staphylococcus aureus, activity value is MIC = 1.25||Anti-S. epidermidis, activity value is MIC = 5||Anti-S. saprophiticus, activity value is MIC = 5||Anti-S. xylosus, activity value is MIC > 20 uM||Anti-Streptococcus agalactiae, activity value is MIC = 1.25||Anti-S. bovis, activity value is MIC = 1.25||Anti-S. equisimilis, activity value is MIC = 2.5||Anti-S. mitis, activity value is MIC = 1.25||Anti-Streptococcus pneumoniae, activity value is MIC = 1.25||Anti-Streptococcus pyogenes, activity value is MIC = 1.25||Anti-S. iniae KST740ak, activity value is MIC = 1.25||Anti-S. iniae KSTSi 6P, activity value is MIC = 1.25||Anti-Aeromonas hydrophila, activity value is MIC > 20 uM||Anti-Burkholderia cepacia, activity value is MIC > 20 uM||Anti-Vibrio cholera, activity value is MIC = 2.5||Anti-Escherichia coli, activity value is MIC = 5||Anti-Moraxella catarrhalis, activity value is MIC = 2.5||Anti-Neisseria gonorrhoeae, activity value is MIC > 20 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 5||Anti-Enterobacter cloacae, activity value is MIC = 10||Anti-E. aerogenes, activity value is MIC = 10||Anti-Klebsiella pneumoniae, activity value is MIC = 2.5||Anti-K. oxytoca, activity value is MIC = 5||Anti-Salmonella choleraesuis, activity value is MIC = 10||Anti-Salmonella typhimurium, activity value is MIC = 10||Anti-S. arizonae, activity value is MIC = 10||Anti-Serratia marcescens, activity value is MIC > 20 uM||Anti-Shigella flexneri, activity value is MIC = 2.5||Anti-S. sonnei, activity value is MIC = 5||Anti-Yersinia enterocolitica, activity value is MIC = 2.5||Anti-Aspergillus fumigatus, activity value is MIC = 50||Anti-Fusarium oxysporum, activity value is MIC = 0.78||Anti-F. culmorum, activity value is MIC = 0.39||Anti-Candida albicans, activity value is MIC = 10||Anti-C. glabrata, activity value is MIC = 10||Anti-C. lusitania, activity value is MIC = 10||Anti-C. tropicalis, activity value is MIC = 10||Anti-E. faecalis, activity value is MIC = 5||Anti-M. luteus, activity value is MIC = 10||Anti-S. aureus, activity value is MIC = 1.252||Anti-Staphylococcus epidermidis, activity value is MIC = 5||Anti-Staphylococcus saprophiticus, activity value is MIC = 5||Anti-Streptococcus bovis, activity value is MIC = 1.25||Anti-Streptococcus equisimilis, activity value is MIC = 2.5||Anti-Streptococcus mitis, activity value is MIC = 1.25||Anti-KST740ak, activity value is MIC = 1.25||Anti-KSTSi 6P, activity value is MIC = 1.25||Anti-E. coli, activity value is MIC = 5||Anti-Enterobacter aerogenes, activity value is MIC = 10||Anti-Klebsiella oxytoca, activity value is MIC = 5||Anti-P. aeruginosa, activity value is MIC = 5||Anti-Salmonella arizonae, activity value is MIC = 10||Anti-S. flexneri, activity value is MIC = 2.5||Anti-Shigella sonnei, activity value is MIC = 5||Anti-N. crassa, activity value is MIC = 1.56||Anti-A. fumigatus, activity value is MIC = 50||Anti-F. oxysporum, activity value is MIC = 0.78||Anti-Candida glabrata, activity value is MIC = 10||Anti-Candida lusitania, activity value is MIC = 10||Anti-Candida tropicalis, activity value is MIC = 10||Anti-Pseudomonas aeruginosa, activity value is MIC = 50 uM||Anti-E. cloacae ATCC 13047, activity value is MIC = 25 uM||Anti-S. sonnei, activity value is MIC = 5 uM||Anti-Psychrobacter sp, activity value is MIC = 2.5 uM||Anti-E. coli DH5alpha, activity value is MIC = 5 uM||Anti-E. faecalis, activity value is MIC = 5 uM||Anti-S. pyogenes, activity value is MIC = 2.5 uM||Anti-S. aureus, activity value is MIC = 2.5 uM||Anti-L. monocytogenes, activity value is MIC = 2.5 uM||Anti-C. tropicalis, activity value is MIC = 5 uM||Anti-fish pathogens S. iniae, activity value is MIC = 2.46 uM||Anti-L. garvieae, activity value is MIC = 0.61 uM||Anti-V. anguillarum, activity value is MIC = 4.91 uM||Anti-A-salmonicida, activity value is MIC > 78.61 uM||Anti-human pathogens E. faecalis, activity value is MIC = 1.23 uM||Anti-S. aureus, activity value is MIC = 2.46 uM||Anti-S. flexneri, activity value is MIC = 2.46 uM||Anti-and E. coli, activity value is MIC = 4.91 uM Mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops)|||Morone chrysops x Morone saxatilis [White bass x Striped bass]|||Hybrid striped bass|||Morone chrysops (White bass)|||Mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops)|||Mast cells, hybrid striped bass (Morone saxatilis x Morone chrysops) Helix E. faecalis ( MIC = 5-10 uM), E. faecalis ( MIC = 2.5-5 uM), Listeria monocytogenes ( MIC = 2.5-5 uM), M. luteus ( MIC = 10-20 uM), S. aureus ( MIC = 1.252-5 uM), Staphylococcus epidermidis ( MIC = 5-10 uM), Staphylococcus saprophiticus ( MIC = 5-10 uM), Staphylococcus xylosus ( MIC = >20 uM), Streptococcus agalactiae ( MIC = 1.25-2.5 uM), Streptococcus bovis ( MIC = 1.25-2.5 uM), Streptococcus equisimilis ( MIC = 2.5-5 uM), Streptococcus mitis ( MIC = 1.25-2.5 uM), Streptococcus pneumoniae ( MIC = 1.25-2.5 uM), Streptococcus pyogenes ( MIC = 1.25-2.5 uM), S. iniae, KST740ak ( MIC = 1.25-2.5 uM), S. iniae, KSTSi 6P ( MIC = 1.25-2.5 uM), A. hydrophila ( MIC = >20 uM), Burkholderia cepacia ( MIC = >20 uM), Vibrio cholera ( MIC = 2.5-5 uM), E. coli ( MIC = 5-10 uM), Enterobacter cloacae ( MIC = 10-20 uM), Enterobacter aerogenes ( MIC = 10-20 uM), Klebsiella pneumoniae ( MIC = 2.5-5 uM), Klebsiella oxytoca ( MIC = 5-10 uM), Moraxella catarrhalis ( MIC = 2.5-5 uM), N. gonorrhea ( MIC = >20 uM), P. aeruginosa ( MIC = 5-10 uM), Salmonella choleraesuis ( MIC = 10-20 uM), Salmonella typhimurium ( MIC = 10-20 uM), Salmonella arizonae ( MIC = 10-20 uM), S. marcescens ( MIC = >20 uM), S. flexneri ( MIC = 2.5-5 uM), Shigella sonnei ( MIC = 5-10 uM), Yersinia enterocolitica ( MIC = 2.5-5 uM), N. crassa ( MIC = 1.56-3.12 uM), A. fumigatus ( MIC = 50-100 uM), F. oxysporum ( MIC = 0.78-1.56 uM), F. culmorum ( MIC = 0.39-0.78 uM), Candida albicans ( MIC = 10-20 uM), Candida glabrata ( MIC = 10-20 uM), Candida lusitania ( MIC = 10-20 uM), Candida tropicalis ( MIC = 10-20 uM).|||Pseudomonas aeruginosa (ATCC 15442)(MIC = 50 uM), Burkholderia cepacia (ATCC 25416)(MIC = >50 uM), E. cloacae ATCC 13047 (MIC = 25 uM), S. sonnei (ATCC 29930) (MIC = 5 uM), Psychrobacter sp. (PAMC 25501) (MIC = 2.5 uM), E. coli DH5alpha (MIC = 5 uM), E. faecalis (ATCC 29212) (MIC = 5 uM), S. pyogenes (ATCC 19615) (MIC = 2.5 uM), S. aureus (ATCC 33591)(MIC= 2.5 uM), L. monocytogenes (ATCC 15313) (MIC =2.5 uM), C. tropicalis (ATCC 20115) (MIC = 5 uM), Candida glabrata (ATCC 2001)(MIC =>50 uM) Nature. 2001 Nov 15;414(6861):268-9|||11739390|||28122029|||11739390|||28122029|||Nature. 2001 Nov 15;414(6861):268-9||see ref AP2785|||Nature. 2001 Nov 15;414(6861):268-9 22 FPDB02558 AP01675|||AP01676|||Beta-amyloid peptide|||AP01676 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA Anti-Gram+ & Gram-||Antiviral||Antifungal||Synergistic AMPs||Antiparasitic||Anti-HIV||Enzyme inhibitor||Antimalarial||Antibacterial||It also inhibits Herpes simplex virus 1 (HSV-1) . H4 neuroglioma cells produced A-beta42 in response to HSV-1 infection thus inhibiting secondary replication . It also inhibits influenza A virus (White et al. 2014 ). Homo sapiens|||Homo sapiens [Humans]|||Homo sapiens Helix N/A PLoS One. 2010 Mar 3;5(3):e9505|||20209079|||PLoS One. 2010 Mar 3;5(3):e9505||Bourgade K et al., 2014||Bourgade K et al., 2016|||PLoS One. 2010 Mar 3;5(3):e9505 42 FPDB02568 AP01701 MKTFSVAVAVAIVLAFICTQESSALPVTGVEELVELVSSDDPVADHQELPVELGERLFNIRKKRASPKCTPYCYPTRDGVFCGVRCD Anti-Gram+ & Gram-||Antiviral liver (more)/stomach (less), Orange-spotted grouper, Epinephelus coioides Bridge N/A Fish Shellfish Immunol. 2011 Feb;30(2):559-68 87 FPDB02569 AP01702|||EC-hepcidin2|||DRAMP31351 MKTFSVAVAVAVVLAFICTQESSALPVTGIEELVEPVSSDNNDNHQGLPVELRERLVNIRKKRAPTDCIPYCYPTGDGFHCGVTCRF Anti-Gram-||Antiviral||Antibacterial ; Vibrio vulnificus||Staphylococcus aureus||Antimicrobial Orange-spotted liver, grouper, Epinephelus coioides|||Epinephelus coioides [Orange-spotted grouper]|||Epinephelus coioides Bridge N/A Fish Shellfish Immunol. 2011 Feb;30(2):559-68|||21145974|||Fish Shellfish Immunol. 2011 Feb;30(2):559-68. 87 FPDB02630 AP01788|||DRAMP02810|||AP01788|||DRAMP02810 QEAQSVACTSYYCSKFCGSAGCSLYGCYLLHPGKICYCLHCSR Anti-Gram+ & Gram-||Antiviral||candidacidal||Chemotactic||Wound healing||Antimicrobial||Antibacterial||Antifungal||No MICs found in DRAMP database the mediterranean mussel, Mytilus galloprovincialis|||Mytilus galloprovincialis (Mediterranean mussel)|||Mytilus galloprovincialis (Mediterranean mussel)|||Conus mustelinus (Weasel cone)|||the mediterranean mussel, Mytilus galloprovincialis|||Mytilus galloprovincialis (Mediterranean mussel) Bridge No hemolysis information or data found in the reference(s) presented in this entry "Dev Comp Immunol . 2008;32(3):213-26. doi: 10.1016/j.dci.2007.05.008. Epub 2007 Jun 26.|||Dev Comp Immunol. 2008;32(3):213-226.|||Biochemistry. 2007 Nov 6;46(44):12586-12593.|||Dev Comp Immunol. 2008;32(3):213-26. PubMed.|||Dev Comp Immunol. 2008;32(3):213-226." 43 FPDB02772 AP01958|||Lasiocepsin|||Lasiocepsin-NH2|||Las|||DRAMP02992|||Lasiocepsin|||Lasiocepsin-NH2|||Las|||AP01958|||DRAMP02992|||AP01958 GLPRKILCAIAKKKGKCKGPLKLVCKC Anti-B. subtilis, activity value is MIC = 0.4 uM||Anti-E. coli, activity value is MIC = 8.6 uM||Anti-P. aeruginosa, activity value is MIC = 15 uM||Anti-and C. albicans, activity value is MIC = 3.6 uM||Antibacterial||Antifungal||Anti-Bacillus subtilis, activity value is MIC = 0.3 uM||Anti-Staphylococcus aureus, activity value is MIC = 63 uM||Anti-Escherichia coli, activity value is MIC = 3 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 16 uM||Anti-Candida albicans, activity value is MIC = 8 uM||Anti-Bacillus subtilis, activity value is MIC = 0.6 uM||Anti-Staphylococcus aureus, activity value is MIC > 100 uM||Anti-Escherichia coli, activity value is MIC = 42 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 100 uM||Anti-Candida albicans, activity value is MIC = 25 uM||Anti-Bacillus subtilis, activity value is MIC = 4 uM||Anti-Escherichia coli, activity value is MIC > 100 uM||Anti-Candida albicans, activity value is MIC > 100 uM||Antimicrobial||Antiviral||Anti-Gram+ & Gram-||candidacidal Lasioglossum laticeps|||Lasioglossum laticeps (Eusocial Bee)|||Lasioglossum laticeps|||venom, eusocial bee Lasioglossum laticeps, Europe|||Lasioglossum laticeps (Eusocial Bee)|||venom, eusocial bee Lasioglossum laticeps, Europe Helix venom, eusocial bee Lasioglossum laticeps|||Hemolytic activity( LC50 >200 uM, Human RBC)|||Hemolytic activity( LC50 >200 uM, Human RBC)|||No hemolysis information or data found in the reference(s) presented in this entry "Amino Acids. 2012 Aug;43(2):751-61. doi: 10.1007/s00726-011-1125-6. Epub 2011 Oct 29.|||22038181|||Amino Acids. 2012 Aug;43(2):751-761.|||22038181|||Amino Acids . 2012 Aug;43(2):751-61. doi: 10.1007/s00726-011-1125-6. Epub 2011 Oct 29.|||Amino Acids. 2012 Aug;43(2):751-761.|||Amino Acids. 2012 Aug;43(2):751-61. PubMed." 27 FPDB02802 AP02007|||DRAMP01361 GLLGTLGNLLNGLGL Inhibition zone: active against M. luteus at 50 ug/ml and yellow fever virus (YFV; Muñoz-Camargo et al. 2016). 11/2018; 7/2021||Anti-Micrococcus luteus, activity value is MIC = 50 ug/ml||Anti-Gram+||Antiviral Litoria infrafrenata (Giant tree frog) (White-lipped tree frog)|||White-lipped Treefrog Litoria infrafrenata, Australia N/A White-lipped Treefrog Litoria infrafrenata, Australia||HC₅₀ = 3 uM J Pept Sci. 1996 Mar-Apr;2(2):117-24. doi: 10.1002/psc.60.||see ref|||J Pept Sci. 1996 Mar-Apr;2(2):117-24.PubMed 15 FPDB02852 AP02080|||CXCL10|||AP02080|||DRAMP03559 VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP Anti-it killed 100% E. coli and 77% S. aureus. Active against E. coli, activity value is MIC = 3.6 ug/ml||Anti-L. monocytogenes, activity value is MIC = 7 ug/ml||Antibacterial ; Escherichia coli ATCC25922||Staphylococcus aureus ATCC29213||Antimicrobial||Antibacterial||Antiparasitic||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Chemotactic Homo sapiens [Human]|||Homo sapiens|||Homo sapiens (Human) Combine Helix and Beta structure Homo sapiens "J Immunol. 2001 Jul 15;167(2):623-7. doi: 10.4049/jimmunol.167.2.623.||this ref; Yang et al., 2003||Liu et al., 2014|||12949249|||J Immunol . 2001 Jul 15;167(2):623-7. doi: 10.4049/jimmunol.167.2.623.||this ref; Yang et al., 2003|||J Leukoc Biol. 2003 Sep;74(3):448-455.Structure. 2003 May;11(5):521-32.|||J Immunol. 2001 Jul 15;167(2):623-7. Pub-Med. GenBank:AAH10954.1." 77 FPDB02894 AP02148|||Truncated beta-defensin 16|||DRAMP03289|||AP02148|||DRAMP03289 FFLLFLQGAAGNSVLCRIRGGRCHVGSCHFPERHIGRCSGFQACCIRTWG It also inhibits duck hepatitis virus (DHV).||Antibacterial||Antifungal ; Micrococcus tetragenus ATCC2835||Lactobacillus ATCC33222||Staphylococcus aureus ATCC 29213||Bacillus cereus ATCC 9193||Bordetella bronchiseptica S80103||Proteus mirabilis ATCC29245||Pseudomonas aeruginosa ATCC 9027||Pasteurella multocida ATCC 6529||Escherichia coli BL21||Salmonella pullorum C79-11-S11||Salmonella choleraesuis CVCC 2140||Salmonella enteritidis ATCC 3021||DHV-1||Antimicrobial||Antiviral||Anti-Gram+ & Gram- Anas platyrhynchos (Mallard) [Domestic duck]|||Anas platyrhynchos (Peking duck)|||Peking duck, Anas platyrhynchos|||Anas platyrhynchos (Peking duck) Bridge "Peking duck, Anas platyrhynchos|||Duck erythrocytes|||The document mentions that the recombinant protein (rApl_AvBDs) and synthetic peptide (sApl_AvBDs) of five new duck β-defensins (Apl_AvBD1, 3, 5, 6, 16) were tested for hemolytic activity, and the results showed that: In the concentration range of 0-500 ug/ml, all Apl_AvBDs had almost no hemolytic activity on duck red blood cells, and there was no significant difference compared with the negative control (PBS treatment group) (P>0.05). The 100% hemolysis control group is the 1% Triton X-100 treatment group. The hemolysis rate is calculated by the formula [(peptide-A, 1% Triton, PBS)/(A, X-100-A, PBS)]× 100%. The results show that the hemolysis rate at all concentrations is extremely low. These data indicate that these defensins are not toxic to animal cells at concentrations that have bactericidal activity.|||No hemolysis information or data found in the reference(s) presented in this entry" PLoS One. 2012;7(10):e47743. doi: 10.1371/journal.pone.0047743. Epub 2012 Oct 24.|||23112840|||PLoS One. 2012;7(10):e47743.|||PLoS One. 2012;7(10):e47743. Pub-Med.|||PLoS One. 2012;7(10):e47743. 50 FPDB02947 AP02218|||Um5|||DRAMP03712|||AP02218|||Hp1090|||DRAMP03712 IFKAIWSGIKSLF Anti-M. luteus, activity value is MIC = 2 uM||Anti-L. monocytogenes, activity value is MIC = 2 uM||Anti-and Hepatitis C virus, activity value is IC50 = 5 uM||Anti-E. coli, activity value is MIC = 15 uM||Anti-L. grayi, activity value is MIC = 2 uM||Anti-L. fleischmannii, activity value is MIC = 2 uM||Antimicrobial||Antibacterial||Antiviral||Anti-Gram+ & Gram-||Antiviral ; Hepatitis C virus (HCV) Urodacus manicatus|||Heterometrus petersii (Asian forest scorpion)|||Venom, Heterometrus petersii ; Also Urodacus manicatus, Asia|||Heterometrus petersii [Asian forest scorpion]|||Heterometrus petersii (Asian forest scorpion) Helix||Alpha helix (CD) Venom, Heterometrus petersii ; Also Urodacus manicatus|||Pig erythrocyte (50% hemolysis at 59.25 uM)|||No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2011 Jan;32(1):11-9.Pub-Med.|||28067810|||Peptides. 2011 Jan;32(1):11-19.|||Peptides. 2011 Jan;32(1):11-9.Pub-Med.|||https://pubmed.ncbi.nlm.nih.gov/20950663|||Peptides. 2011 Jan;32(1):11-19. 13 FPDB03050 AP02354 KINNPVSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKRK synthetic mBD-3 inhibited the growth of E. coli||P. aeruginosa||S. aureus||and C. albicans at concentrations from 25 to 50 ug/ml .||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal epithelia, respiratory system and other mucosal surfaces, mouse, Mus musculus|||epithelia, respiratory system and other mucosal surfaces, mouse, Mus musculus Bridge epithelia, respiratory system and other mucosal surfaces, mouse, Mus musculus "Infect Immun. 1999 Jul;67(7):3542-7.PubMed||Burd RS et al 2002|||Infect Immun . 1999 Jul;67(7):3542-7. doi: 10.1128/IAI.67.7.3542-3547.1999.||Burd RS et al 2002|||Infect Immun. 1999 Jul;67(7):3542-7.PubMed" 40 FPDB03125 AP02450|||DRAMP18237|||DRAMP18237|||DRAMP18224|||AP02450|||DRAMP18224 EKYTEAPEYI Active against Gram-positive bacteria (B. subtilis||L. acidophilus ATCC 4356||B. linens||C. Wmi NCTC 7547||L. monocytogenes||L. innocua||B. cereus||L. innocua ATCC 33090||L. innocua 1572||L. ivanovii 5 NCTC 11007||L. seeligeri AC 82/4||L. welshimeri AC 73/2||and Gram-negative bacteria (S. Gallinarum||E. carotovora 413||A. hydrophila||P. haemolytica||clinical isolate). Also inhibited the replication of viruses such as equine arteritis virus (EAV) and feline herpesvirus type 1 (FHV-1) by over 94%. Updated 9/2017.||Antimicrobial||Antibacterial||Antifungal||Anti-Gram+||Anti-Gram-||Antiviral||Anti-Gram+ & Gram- Bacillus subtilis K1|||Anopheles gambiae (African malaria mosquito)|||Bacillus sp. strain P34 N/A Bacillus sp. strain P34|||No hemolysis information or data found in the reference(s) presented in this entry Braz J Microbiol. 2014 Oct 9;45(3):1089-94. PubMed||Motta et al., 2007b|||J Am Soc Mass Spectrom. 2012 Oct;23(10):1716-28. Epub 2012 Jul 31.|||Bacillus subtilis K1||J Am Soc Mass Spectrom. 2012 Oct;23(10):1716-28. Epub 2012 Jul 31.|||Braz J Microbiol. 2014 Oct 9;45(3):1089-94. eCollection 2014.|||Braz J Microbiol. 2014 Oct 9;45(3):1089-94. PubMed|||Braz J Microbiol. 2014 Oct 9;45(3):1089-94. eCollection 2014. 10 FPDB03151 AP02478|||SmHep1P, Sm-Hepcidin-1|||AP02478 QSHISLCRWCCNCCKANKGCGFCCKF Anti-Gram- E. tarda, activity value is MIC = 2 uM||Anti-V. anguillarum, activity value is MIC = 4 uM||Anti-S. aureus, activity value is MIC = 2 uM||Anti-Edwardsiella tarda TX1, activity value is MIC = 2||Anti-Vibrio anguillarum C312, activity value is MIC = 4||Anti-Staphylococcus aureus, activity value is MIC = 2||Anti-Micrococcus luteus, activity value is MIC = 1||Anti-Gram+ & Gram-||Antiviral Scophthalmus maximus|||Turbot, Scophthalmus maximus N/A Turbot, Scophthalmus maximus Fish Shellfish Immunol. 2014 May;38(1):127-34.PubMed|||24647314|||Fish Shellfish Immunol. 2014 May;38(1):127-34.PubMed 26 FPDB03152 AP02479|||SmHep2P, Sm-Hepcidin-2|||AP02479 GMKCKFCCNCCNLNGCGVCCRF Anti-Gram- E. tarda, activity value is MIC = 1 uM||Anti-V. anguillarum, activity value is MIC = 2 uM||Anti-S. aureus, activity value is MIC = 4 uM||Antibacterial||Anti-Gram+ & Gram-||Antiviral Scophthalmus maximus|||Turbot, Scophthalmus maximus N/A Turbot, Scophthalmus maximus|||Edwardsiella tarda TX1[MIC = 1-2 uM], Vibrio anguillarum C312[MIC = 2-4 uM], Staphylococcus aureus[MIC = 4-8 uM], Micrococcus luteus[MIC = 2-4 uM] Fish Shellfish Immunol. 2014 May;38(1):127-34.PubMed|||24647314|||Fish Shellfish Immunol. 2014 May;38(1):127-34.PubMed 22 FPDB03212 AP02551|||Peptide Hp1165 ILGEIWKGIKDIL Anti-Gram+ & Gram-||Antiviral Heterometrus petersii [Asian forest scorpion] N/A venom, Heterometrus spinifer||It has relatively low hemolytic activity against humanred blood cells. Heterin-2 showed stronger antimicrobial activi-ties against Gram-positive bacteria than Gram-negative bacteria.It has high hemolytic activity against human red blood cells. Sec-ondary structure prediction indicated that Heterin-2 consists of an␣-helical domain and a random coiled hydrophilic tail (KKD). Wefound that deletion of KKD from the molecule markedly changed itsantimicrobial specificity and activity,and significantly reduced itshemolytic activity against human red blood cells. Spiniferin exhib-ited very weak antimicrobial activities against both Gram-positiveand Gram-negative bacteria. It has extremely weak hemolyticactivity against human red blood cells. We found that introductionof two residue mutations into the polar face of Spiniferin, whichresulted in the change of net charge from 0 into +5, markedlyenhanced its antimicrobial activities against the majority of thetested bacteria; however, for some of the tested bacterial species,net charge on the polar face is not important for the antimicrobialactivity of the peptide. Peptides. 2014 Mar;53:30-41. PubMed|||https://pubmed.ncbi.nlm.nih.gov/24315793 13 FPDB03276 AP02635 QGGIASCCRRHSKTQINREHLTHYYEQHRPPCPIKAVVFYVIGGARICADPNKVWTKTSKAFLDGVHYQRQHTSSKVSF Anti-Gram-||Antiviral||Chemotactic spleen (high), liver, heart, gill and HK (moderate), and low in muscle, brain and intestine, half-smooth tongue sole, Cynoglossus semilaevis Bridge spleen (high), liver, heart, gill and HK (moderate), and low in muscle, brain and intestine, half-smooth tongue sole, Cynoglossus semilaevis Fish Shellfish Immunol. 2015 Aug;45(2):771-9. PubMed 79 FPDB03277 AP02636 QEFYGNCCLGHVKPMKIKGKRIESYRMQETDGDCHISAVVFLIKKKPSHVKQKTICANPQEAWVQELMAAVDSRNPKN Anti-Gram-||Antiviral||Chemotactic induced in kidney, spleen, and liver, tongue sole, Cynoglossus semilaevis Bridge induced in kidney, spleen, and liver, tongue sole, Cynoglossus semilaevis Fish Shellfish Immunol. 2015 Nov;47(1):461-9. PubMed 78 FPDB03291 AP02653|||SA-hepcidin1|||SA-hepcidin1 QSHLSMCRYCCNCCRNNKGCGFCCKF Anti-Gram+ & Gram-||Anti-Staphylococcus aureus, activity value is MIC = 50 uM||Anti-Vibrio fluvialis, activity value is MIC = 25 uM||Anti-Vibrio anguillarum, activity value is MIC = 50 uM||Anti-Vibrio alginolyticus, activity value is MIC = 50 uM||Anti-Vibrio parahaemloyticus, activity value is MIC > 50 uM||Anti-Escherichia coli, activity value is MIC = 50 uM Scatophagus argus [spotted scat] Bridge spotted scat, Scatophagus argus Fish Shellfish Immunol. 2016 Mar;50:191-9. PubMed|||26845697|||26845697 26 FPDB03292 AP02654|||SA-hepcidin2 NPAGCRFCCGCCPNMIGCGVCCRF Anti-Gram+ & Gram-||Antiviral||Antibacterial||Anti-Staphylococcus aureus, activity value is MIC = 50 uM||Anti-Vibrio fluvialis, activity value is MIC > 50 uM||Anti-Vibrio anguillarum, activity value is MIC = 50 uM||Anti-Vibrio alginolyticus, activity value is MIC = 50 uM||Anti-Vibrio parahaemloyticus, activity value is MIC > 50 uM||Anti-Escherichia coli, activity value is MIC > 50 uM Scatophagus argus [spotted scat]|||liver, spotted scat, Scatophagus argus|||Scatophagus argus [spotted scat] Bridge liver, spotted scat, Scatophagus argus|||Staphylococcus aureus (MIC = 50 uM), Vibrio fluvialis (MIC > 50 uM), Vibrio anguillarum (MIC = 50 uM), Vibrio alginolyticus (MIC = 50 uM), Vibrio parahaemloyticus (MIC > 50 uM), Escherichia coli (MIC > 50 uM), Siniperca chuatsi rhabdovirus (SCRV), Micropterus salmoides reovirus (MsReV) Fish Shellfish Immunol. 2016 Mar;50:191-9. PubMed|||26845697 24 FPDB03469 AP02899|||As-CATH5|||AP02899|||Cathelicidin 5 TRRKFWKKVLNGALKIAPFLLG Active against Gram- bacteria E. coli||S. dysenteriae||K. pneumoniae||K. oxytoca||P. mirabilis||A. baumannii||S. maltophilia||and P. aeruginosa||Gram+ bacteria S. aureus||B. cereus||E. faecium||and S. epidermidis||and fungi C. albicans. Also active against aquatic pathogenic bacteria A. sobria||A. hydrophila||A. veronii||V. harveyi||V. parahaemdyticus||V. anguillarum||and V. cholerae. Antibacterial activity appears to be salt-resistant (salt-insensitive). At a high concentration of 200 ug/ml||it showed only 47% hemolysis (human red blood cells).||Antibacterial||Antiviral ; White spot syndrome virus||Anti-Gram+ & Gram-||Antifungal||candidacidal||anti-sepsis Alligator sinensis|||Chinese alligator, Alligator sinensis|||Alligator sinensis [Chinese alligator]|||Chinese alligator, Alligator sinensis Helix Chinese alligator, Alligator sinensis||As shown in Table 5, As-CATH4~6 exhibited selective cytotoxicity toward the tested mammalian cells. Among the three tested cells, CHO cell were the most sensitive to As-CATH4~6. At a concentration of 200 ug/ml, As-CATH4~6 induced CHO death rates of 55%, 89% and 89%, respectively. Among the three peptides, As-CATH4 was the least cytotoxic. At a concentration of 200 ug/ml, As-CATH4 induced death rates of 27%, 55% and 17% for BGC-823, CHO and mouse peritoneal macrophages, respectively. As to hemolytic activity, As-CATH4~6 yielded hemolytic rates of 4%, 47%, and 48% respectively toward human erythrocytes. However, it should be noted that the concentrations of As-CATH4~6 in cytotoxic and hemolytic assays were nearly 10-fold higher than their MICs toward most of the tested microorganisms. At a concentration of 20 ug/ml, the cytotoxic and hemolytic rates induced by As-CATH4~6 significantly decreased to below 10%, suggesting their potential in therapeutic application (data not shown). Unlike As-CATH4~6, As-CATH1~4 didn’t show apparent cytotoxic and hemolytic activities (data not shown).|||Aeromonas sobria (MIC=3.67 uM), Aeromonas hydrophila (MIC=3.67 uM), Aeromonas veronii (MIC=3.67 uM), Vibrio harveyi (MIC=3.67 uM), Vibrio parahaemotyticus (MIC=1.83 uM), Vibrio anguillarum (MIC=1.83 uM), Vibrio vulnificus (MIC=3.67 uM), Vibrio splendidus (MIC=1.83 uM), Vibrio splendidus (MIC=1.83 uM), Vibrio cholerae (MIC= 7.33 uM)|||As to hemolytic activity, As-CATH4~6 yielded hemolytic rates of 4%, 47%, and 48% respectively toward human erythrocytes. However, it should be noted that the concentrations of As-CATH4~6 in cytotoxic and hemolytic assays were nearly 10-fold higher than their MICs toward most of the tested microorganisms. At a concentration of 20 ug/ml, the cytotoxic and hemolytic rates induced by As-CATH4~6 significantly decreased to below 10%, suggesting their potential in therapeutic application (data not shown). Unlike As-CATH4~6, As-CATH1~3 didn’t show apparent cytotoxic and hemolytic activities (data not shown). "Biochem J . 2017 Aug 10;474(16):2861-2885. doi: 10.1042/BCJ20170334.|||29017942|||Biochem J . 2017 Aug 10;474(16):2861-2885. doi: 10.1042/BCJ20170334.|||31326585|||Biochem J. 2017 Aug 10;474(16):2861-2885. doi: 10.1042/BCJ20170334. PubMed" 22 FPDB03539 AP02996|||Epinecidin-1|||DRAMP04564|||Epinecidin-1|||DRAMP04564 FIFHIIKGLFHAGKMIHGLVTRRRH Anti-E. coli, activity value is MIC = 2.5 uM||Anti-S. aureus, activity value is MIC = 1.25 uM||Anti-and V. parahaemolyticus, activity value is MIC = 1.25 uM||Antibacterial||Antifungal||Antimicrobial||Antiviral||No MICs found in DRAMP database Epinephelus coioides [Orange-spotted grouper]|||Epinephelus coioides (Orange-spotted grouper) (Epinephelus nebulosus)|||Epinephelus coioides [Orange-spotted grouper]|||Epinephelus coioides (Orange-spotted grouper) (Epinephelus nebulosus) Helix Malabar grouper, Epinephelus malabaricus|||No hemolysis information or data found in the reference(s) presented in this entry "Probiotics Antimicrob Proteins . 2019 Jun;11(2):667-675. doi: 10.1007/s12602-018-9446-3.|||Aquaculture, Volume 253, Issues 1-4, 31 March 2006, Pages 204-211|||DNA Cell Biol. 2007 Jun;26(6):403-413.|||Aquaculture, Volume 253, Issues 1-4, 31 March 2006, Pages 204-211|||DNA Cell Biol. 2007 Jun;26(6):403-413." 25 FPDB03655 AP03166|||Brevinin-2GHk, BR2GK|||Brevinin-2GHk, BR2GK|||AP03166|||DRAMP30341|||AP03166|||DRAMP30341 GFSSLFKAGAKYLLKQVGKAGAQQLACKAANNC Anti-Weakly active against S. aureus, activity value is MIC = 64 uM||Anti-E.coli, activity value is MIC > 512 uM||Anti-P.aeruginosa, activity value is MIC > 512 uM||Anti-K.pneumoniae, activity value is MIC > 512 uM||Antibacterial||Antifungal||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC > 512 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC > 512 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 64 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 256 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 64 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 256 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC > 512 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC > 512 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 512 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC > 512 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MIC > 512 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MBC > 512 uM||Anti-Candida albicans NCYC 1467, activity value is MIC = 256 uM||Anti-Candida albicans NCYC 1467, activity value is MBC = 512 uM||Anti-Zika Virus: inhibition of infection of Zika virus in Vero cells, activity value is IC50 = 3.408||Anti-Gram+||Antiviral||Antimicrobial Sylvirana guentheri|||Sylvirana guentheri|||skin secretion, Sylvirana guentheri, Europe|||Fejervarya limnocharis|||skin secretion, Sylvirana guentheri, Europe|||Fejervarya limnocharis Helix "skin secretion, Sylvirana guentheri, Europe|||Human microvascular endothelial cells HMEC-1 (55% Killing at 100 uM|||Human microvascular endothelial cells HMEC-1 (55% Killing at 100 uM|||The document mentions hemolytic data related to some peptides, as follows: - BR2GK: At a concentration of 256 μM, the hemolysis rate exceeds 40%; significant hemolytic activity is observed starting from 32 μM. - BR2GK(1-25)a: At a concentration of 256 μM, the hemolysis rate is about 20%; significant hemolytic activity is observed starting from 32 μM. Among the truncated derivatives, it shows the strongest hemolysis, but still less than BR2GK. - The other four derivatives ([P¹⁴]BR2GK(1-25)a, [A¹⁴]BR2GK(1-25)a, [K¹⁴]BR2GK(1-25)a, [R¹⁴]BR2GK(1-25)a): At the tested concentrations, there is no significant hemolytic effect on red blood cells (less than 5%). Note: In the hemolysis experiment, the hemolysis effect produced by 0.1% Triton X-100 treatment was used as the 100% hemolysis standard." "Antibiotics (Basel) . 2020 Feb 14;9(2):85. doi: 10.3390/antibiotics9020085.|||32075067|||32075067|||Antibiotics (Basel) . 2020 Feb 14;9(2):85. doi: 10.3390/antibiotics9020085.|||Ref.34960651|||Antibiotics (Basel). 2020;9(2):E85. PubMed|||Viruses. 2021 Nov 28;13(12):2382." 33 FPDB03662 AP03174|||DRAMP35721 WYQLIRTFGNLIHQKYRKLLEAYRKLRD Anti-S. aureus ATCC 6538, activity value is MIC = 0.41 uM||Anti-Bacillus cereus ATCC 10876, activity value is MIC = 1.66 uM||Anti-and E. faecalis ATCC 29212, activity value is MIC = 0.55 uM||Anti-E. coli ATCC 25922, activity value is MIC = 1.38 uM||Antimicrobial||Anticancer||Anti-Gram+ & Gram-||Antiviral the gray short-tailed opossum, Monodelphis domestica, South America|||Synthetic Helix the gray short-tailed opossum, Monodelphis domestica, South America Front. Immunol., 03 March 2020 | https://doi.org/10.3389/fimmu.2020.00347.|||Front Immunol. 2020 Mar 3;11:348.|||Front. Immunol., 03 March 2020 | https://doi.org/10.3389/fimmu.2020.00347 Cho et al., 2020 28 FPDB03720 AP03278|||DRAMP18685|||Peptide Ctri9594|||DRAMP18685 GVVDTLKNLLMGLL Anti-S. aureus AB94004, activity value is MIC = 25 ug/ml||The HCV RNA level is screened that between 1.E-01% and 1.E+00% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral ; HCV||Antimicrobial||Antiviral venom, Chaerilus tricostatus, China, Asia|||Chaerilus tricostatus (Scorpion)|||Chaerilus tricostatus|||Chaerilus tricostatus (Scorpion) N/A venom, Chaerilus tricostatus, China, Asia||The cytotoxicity of catfish PACAP to human cells is less than that to fish cells. Hemolytic activity reached 50% hemolysis in any 328 cases (FIGS. 4A and B). PACAP was hemolytic to 329 fish red blood cell N/A at concentrations below 18.75 uM (0% hemolysis). At concentrations between 330 18.75 uM and 150 uM, the hemolytic activity was less than 20%. At the highest concentration analyzed (300 uM), PACAP reached 39% 331 the upper limit of hemolysis (FIG. 4A). On the other hand, PACAP was 332 to be hemolytic to human erythrocyte N/A (0% hemolysis) at concentrations below 75 uM. The hemolytic activity was less than 3% at 333 concentrations between 75 uM and 150 uM. At the highest concentration analyzed (300 uM), PACAP 334 reached the highest value of 6% hemolysis|||The cytotoxicity of catfish PACAP to human cells is less than that to fish cells. Hemolytic activity reached 50% hemolysis in any 328 cases (FIGS. 4A and B). PACAP was hemolytic to 329 fish red blood cell N/A at concentrations below 18.75 uM (0% hemolysis). At concentrations between 330 18.75 uM and 150 uM, the hemolytic activity was less than 20%. At the highest concentration analyzed (300 uM), PACAP reached 39% 331 the upper limit of hemolysis (FIG. 4A). On the other hand, PACAP was 332 to be hemolytic to human erythrocyte N/A (0% hemolysis) at concentrations below 75 uM. The hemolytic activity was less than 3% at 333 concentrations between 75 uM and 150 uM. At the highest concentration analyzed (300 uM), PACAP 334 reached the highest value of 6% hemolysis|||No hemolysis information or data found in the reference(s) presented in this entry "Antibiotics (Basel) . 2021 Jul 23;10(8):896. doi: 10.3390/antibiotics10080896.|||Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||https://pubmed.ncbi.nlm.nih.gov/23415044|||Biomaterials. 2013 Apr;34(13):3511-22." 14 FPDB03934 AP03614 SDSVVSDIICTTFCSVTWCQSNCC Anti-killed S. aureus MTCC 1430, activity value is MIC = 0.8 ug/ml||Anti-E. coli MTCC 1610, activity value is MIC = 1.2 ug/ml||Anti-and C. albicans MTCC 183, activity value is MIC = 30||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Hemolytic Brevibacillus sp. strain AF8 N/A "Brevibacillus sp. strain AF8||At 4 ug/ml, it causes approximately 20% hemolysis of red blood cells, and at 6 ug/ml, the hemolysis rate reaches 50%.|||highly hemolytic (HC50 6 ug/ml). HEK 293T (LC50 25-50 ug/ml) and vero cells (LC50 25 ug/ml).|||At 4 ug/ml, it causes approximately 20% hemolysis of red blood cells, and at 6 ug/ml, the hemolysis rate reaches 50%.|||highly hemolytic (HC50 6 ug/ml). HEK 293T (TC50 25-50 ug/ml) and vero cells (TC50 25 ug/ml).|||The document mentions hemolysis-related data of Brevicillin, as follows: - Hemolysis rates at different concentrations: - At 4 µg/ml, the hemolysis rate is approximately 20%; - At 6 µg/ml, the hemolysis rate is approximately 50%; - At 20 µg/ml and 40 µg/ml, the hemolysis rate approaches 100% (comparable to the positive control treated with 0.1% Triton X-100). Note: In hemolysis experiments, the hemolysis effect caused by treatment with 0.1% Triton X-100 is taken as the 100% hemolysis standard, while PBS treatment is used as the 0% hemolysis control.|||highly hemolytic (HC50 6 ug/ml)." J Appl Microbiol. 2023 Mar 13:lxad054. doi: 10.1093/jambio/lxad054. PubMed|||J Appl Microbiol. 2023 Mar 13:lxad054. doi: 10.1093/jambio/lxad054. PubMed|||J Appl Microbiol. 2023 Mar 13:lxad054. doi: 10.1093/jambio/lxad054. PubMed|||J Appl Microbiol. 2023 Mar 13:lxad054. doi: 10.1093/jambio/lxad054. PubMed 24 FPDB03951 AP03648|||RLLR5|||AP03648|||CAMPSQ17110 RLLRRLLRRLLRRLLRRLLR Anti-Gram- E. coli, activity value is MIC = 4 ug/ml||Anti-P. putida, activity value is MIC = 2 ug/ml||Anti-S. enteritidis, activity value is MIC = 1 ug/ml||Anti-B. subtilis, activity value is MIC = 2 ug/ml||Anti-S. aureus, activity value is MIC = 4 ug/ml||Anti-S. mutans, activity value is MIC = 2 ug/ml||Anti-C. neoformans, activity value is MIC = 1 ug/ml||Anti-S. cerevisiae, activity value is MIC = 1 ug/ml||Anti-and C. albicans, activity value is MIC = 1 ug/ml||MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antibacterial||Antiparasitic||Antiviral||Anti-Bacillus subtilis ATCC 62037, activity value is MIC = 2 ug/ml||Anti-Bacillus subtilis ATCC 62037, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 64 ug/ml||Anti-Streptococcus mutans ATCC 25175, activity value is MIC = 2 ug/ml||Anti-Streptococcus mutans ATCC 25175, activity value is MIC = 32 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 4 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 32 ug/ml||Anti-Pseudomonas putida ATCC 17426, activity value is MIC = 2 ug/ml||Anti-Pseudomonas putida ATCC 17426, activity value is MIC = 64 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Enteritidis ATCC 13076, activity value is MIC = 1 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Enteritidis ATCC 13076, activity value is MIC = 32 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 1 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 32 ug/ml||Anti-Saccharomyces cerevisiae ATCC 44774, activity value is MIC = 1 ug/ml||Anti-Saccharomyces cerevisiae ATCC 44774, activity value is MIC = 32 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 1 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 32 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 1 ug/ml||Anti-Streptococcus mutans, activity value is MIC = 2 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 2 ug/ml||Anti-Escherichia coli, activity value is MIC = 2 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 1 ug/ml||Anti-Serratia marcescens, activity value is MIC = 2 ug/ml||Anti-Pseudomonas putida, activity value is MIC = 2 ug/ml||Anti-Candida albicans, activity value is MIC = 8 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC = 8 ug/ml||Anti-Saccharomyces cerevisiae, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa ATCC 9027, activity value is IC50 = 28 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is IC50 = 16 uM de novo designed, man-made sequences|||Synthetic construct|||de novo designed, man-made sequences|||Synthetic construct Helix de novo designed, man-made sequences J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||17681018|||14718539, 10890923|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med. 20 FPDB03952 AP03649|||N-|||N-|||AP03649|||DRAMP31401|||CAMPSQ17109|||N-|||DRAMP31401|||AP03649 APKAMRLLRRLLRRLLR Anti-Gram- E. coli, activity value is MIC = 2 ug/ml||Anti-P. putida, activity value is MIC = 4 ug/ml||Anti-S. enteritidis, activity value is MIC = 2 ug/ml||Anti-B. subtilis, activity value is MIC = 2 ug/ml||Anti-S. aureus, activity value is MIC = 2 ug/ml||Anti-S. mutans, activity value is MIC = 4 ug/ml||Anti-C. neoformans, activity value is MIC = 2 ug/ml||Anti-S. cerevisiae, activity value is MIC = 2 ug/ml||Anti-and C. albicans, activity value is MIC = 1 ug/ml||MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Anti-Bacillus subtilis ATCC 62037, activity value is MIC = 2 ug/ml||Anti-Bacillus subtilis ATCC 62037, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 16 ug/ml||Anti-Streptococcus mutans ATCC 25175, activity value is MIC = 4 ug/ml||Anti-Streptococcus mutans ATCC 25175, activity value is MIC = 32 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 2 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 16 ug/ml||Anti-Pseudomonas putida ATCC 17426, activity value is MIC = 4 ug/ml||Anti-Pseudomonas putida ATCC 17426, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Enteritidis ATCC 13076, activity value is MIC = 2 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Enteritidis ATCC 13076, activity value is MIC = 16 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 2 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 16 ug/ml||Anti-Saccharomyces cerevisiae ATCC 44774, activity value is MIC = 2 ug/ml||Anti-Saccharomyces cerevisiae ATCC 44774, activity value is MIC = 8 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 1 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa ATCC 9027, activity value is IC50 > 53 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is IC50 = 2 uM||Antimicrobial||Antiviral||Antibacterial||Antiparasitic de novo designed, man-made sequences|||Synthetic construct|||de novo designed, man-made sequences|||Synthetic construct Helix de novo designed, man-made sequences J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||14718539|||14718539|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med.|||FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||https://pubmed.ncbi.nlm.nih.gov/14718539|||FEBS J. 2007 Sep;274(17):4511-25.|||J Biol Chem. 2004 Apr 2;279(14):13896-901. doi: 10.1074/jbc.M311418200. Pub-Med. 17 FPDB04150 AP04004 ITSKSLCTPGCKTGILMTCPLKTATCGCHF active against S. pyogenes 10 inhibited out of 11 tested; S. uberis 20/26 strains||S. agalactiae 2 inhibited/4 strains||S. dysgalactiae 3/4||S. simulans||S. cohnii||L. lactis 1/3||L. acidophilus 1/1||and S. mitis 2/2.||Anti-Gram+||Antiviral Streptococcus uberis N/A N/A Appl Environ Microbiol. 2006 Feb;72(2):1148-56. doi: 10.1128/AEM.72.2.1148-1156.2006. PubMed 30 FPDB04230 AP04144|||DRAMP20775|||AP04144|||CAMPSQ8167|||DRAMP20775 FLGFLKNLF Anti-Gram+ & Gram-||Antiviral||Anti-Hepatitis C virus, activity value is EC50 = 1.84 ug/ml||Antimicrobial venom, Chaerilus tryznai|||Chaerilus tryznai (Scorpion)|||venom, Chaerilus tryznai, Asia|||Chaerilus tryznai [Scorpion]|||Chaerilus tryznai (Scorpion) Helix "[Ref.23415044] HC50 = 137.9 ug/ml against human red blood cells.|||The document mentions hemolytic-related data for Ctry2459 and its histidine-rich mutants (Ctry2459-H2, Ctry2459-H3), as follows: - Ctry2459 (WT): 50% hemolytic concentration (HC_{50}) is 137.9 µg/ml. - Ctry2459-H2 (H2): 50% hemolytic concentration (HC_{50}) is 203.3 µg/ml, approximately 1.5 times that of the wild type. - Ctry2459-H3 (H3): 50% hemolytic concentration (HC_{50}) is 416.4 µg/ml, approximately 3 times that of the wild type. Note: HC_{50} refers to the peptide concentration that causes 50% lysis of human red blood cells; the higher the value, the lower the hemolytic activity. In the experiment, peptide concentrations ranged from 0 to 1000 µg/ml, and hemolysis was assessed by measuring the release of hemoglobin (absorbance at 570 nm), with 0.9% saline as a negative control and 0.1% Triton X-100 as a positive control.|||Human RBC ( HC50 = 137 ug/ml ) [HC50 (50% hemolysis concentration)]|||[Ref.23415044] HC50 = 137.9 ug/ml against human red blood cells." Biomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. PubMed|||Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. PubMed|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 9 FPDB04231 AP04150|||K4K20-S4|||DRAMP30336 ALWKTLLKKVLKAAAKAALKAVLVGANA Anti-Gram-||Anti-S. aureus, activity value is MIC = 90||Anti-P. aeruginosa, activity value is MIC = 90||Anti-E. coli, activity value is MIC = 90||Anti-HSV-2 acyclovir-sensitive strain :inhibition the cytopathic effect of HSV-2 in Vero cells, activity value is EC50 = 2.1 uM||Anti-HSV-2 acyclovir-resistant strain :inhibition of cytopathic effet of HSV-2 in Vero cells, activity value is EC50 = 5.4 uM||Antimicrobial||Antiviral amino acid substitution, AMPHIBIAN, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from Dermaseptin S4) N/A N/A Pharmaceuticals (Basel). 2024 Jan 29;17(2):171. doi: 10.3390/ph17020171. PubMed|||11850249|||Ref.23161023|||J Med Virol. 2013 Feb;85(2):272-81. 28 FPDB04232 AP04151|||K4-S4|||DRAMP31544 ALWKTLLKKVLKAAAK Anti-Gram-||Anti-S. aureus, activity value is MIC = 90||Anti-P. aeruginosa, activity value is MIC = 90||Anti-E. coli, activity value is MIC = 90||Antimicrobial||Antiviral sequence truncation, amino acid substitution, AMPHIBIAN, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct N/A hRBC(LC50= 57 ± 3 uM) Pharmaceuticals (Basel). 2024 Jan 29;17(2):171. doi: 10.3390/ph17020171. PubMed|||11850249|||10660589|||Virology. 2005 Apr 10;334(2):264-75. 16 FPDB04402 AP04648|||Antimicrobial peptide-57|||AP04648 KRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV active against Gram+ S. aureus ATCC 25923 (MEC 21.5 ug/ml)||L.monocytogenes (ATCC 19115 (MEC >200 ug/ml)||Actinomyce isolated from clinical specimens (MEC 12.33 ug/ml)||Gram- E. Coli ATCC 25922 (MEC 73.32 ug/ml)||P. aeruginosa PA01 (MEC 86.45 ug/ml)||S. typhi RE88 (MEC 91.69 ug/ml)||fungi C.albicans ATCC 10231 or CMCC(B) 98001 (MEC>200 ug/ml)||A. niger ATCC 16404 (MEC 28.55 ug/ml)||yeast ATCC 2601 (MEC>200 ug/ml)||M. hominis clinical (MEC 4.77 ug/ml)||and Lentivirus (MEC 16.5 ug/ml) and Adenovirus Ad5 (MEC >200 ug/ml). MEC: Minimum effective concentration||which is the lowest protein concentration at which visual effects were observed (e.g.||growth inhibition||microbe aggregation||infection efficiency decrease).||Antibacterial||Antifungal||Antiviral ; Staphylococcus aureus||Actinomyce||Aspergillus||mycoplasma||lentivirus.||Anti-Gram+ & Gram-||Antiviral antibody detection mainly in stomach, colon, and epityphlon tissues, Homo sapiens|||Homo sapiens [Human]|||antibody detection mainly in stomach, colon, and epityphlon tissues, Homo sapiens N/A N/A Biochem Biophys Res Commun. 2015 Feb 13;457(3):347-52. doi: 10.1016/j.bbrc.2014.12.115. PubMed|||25585381|||Biochem Biophys Res Commun. 2015 Feb 13;457(3):347-52. doi: 10.1016/j.bbrc.2014.12.115. PubMed 57 FPDB04430 AP04686 FLPIIINLKALAALAKKIL Anti-B. subtilis . Inhibited entry of Human alphaherpesvirus 1, activity value is EC50 = 6.68 uM||Anti-Gram+ & Gram-||Antiviral Designed, motif FLPII + natural AMP Helix "no observed toxic effect till 50000 ug/kg when IP injected.|||The document mentions hemolysis-related data for mast-L and mast-MO, as follows: - mast-L: The 100% lethal concentration (LC_{100}) for human red blood cells (hRBCs) is 7 μM, indicating strong hemolytic activity. - mast-MO: The 100% lethal concentration (LC_{100}) for human red blood cells (hRBCs) is greater than 400 μM, showing no significant hemolytic activity within the tested concentration range. In addition, the hemolytic activity of mast-MO on mouse red blood cells was tested, and no significant hemolysis was observed at concentrations up to 200 μM (Supplementary Table S5). The hemolysis experiment used a 1% Triton X-100 treatment group as the 100% hemolysis positive control, and hemoglobin release was assessed by measuring the absorbance at 540 nm." Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26936-26945. doi: 10.1073/pnas.2012379117. PubMed 19 FPDB04431 AP04687|||DRAMP18623 INLKILARLAKKIL Anti-Gram- E. coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 6.25 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 6.25 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 3 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 25 uM||Anti-S. pyogenes ATCC 19615, activity value is MIC = 6.25 uM||Anti-L. ivanovii Li 4pVS2, activity value is MIC = 50 uM||Anti-E.faecalis ATCC 29212, activity value is MIC > 100 uM||Anti-C. albicans ATCC 90028, activity value is MIC = 12.5 uM||Anti-and C. parapsilosis ATCC 22019, activity value is MIC = 25 uM||Antibacterial||Antifungal||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 25 uM||Anti-Streptococcus pyogenes ATCC 19615, activity value is MIC = 6.25 uM||Anti-Listeria ivanovii Li 4pVS2, activity value is MIC = 50 uM||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 6.25 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6.25 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 3 uM||Anti-##Fungi: Candida albicans ATCC 90028, activity value is MIC = 12.5 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC = 25 uM||Anti-Gram+ & Gram-||Antiviral||candidacidal designed, amino acid substitution, animal-derived, natural derivative|||Synthetic construct Alpha helix "rat RBC: HC50 > 200 uM, poor hemo.lytic. THP-1-derived macrophages (IC50 24..5 uM0, and HEK-293 (IC50 > 200 uM).|||Rat red blood cells (LC50 =>200 uM, )|||[Ref.27423268]LC50>200 uM against rat red blood cells|||The document mentions hemolytic data related to mastoparan L and [I^{5}, R^{8}] mastoparan, as follows: - Mastoparan L: In rat red blood cells, a concentration of 10 µM can cause 40% hemolysis (note e in Table 2). - [I^{5}, R^{8}] mastoparan: The 50% hemolytic concentration (LC_{50}) for human red blood cells is greater than 200 µM, indicating no significant hemolytic activity within the tested concentration range (Table 2). In the hemolysis assay, the group treated with 1% Triton X-100 was used as the 100% hemolysis positive control, and hemoglobin release was evaluated by measuring absorbance at 540 nm.|||rat RBC: HC50 > 200 uM, poor hemo.lytic." Biochim Biophys Acta. 2016 Nov;1858(11):2699-2708. doi: 10.1016/j.bbamem.2016.07.001. PubMed|||27423268|||Biochim Biophys Acta. 2016 Nov;1858(11):2699-2708.||Ref.27423268|||Biochim Biophys Acta. 2016 Nov;1858(11):2699-2708. doi: 10.1016/j.bbamem.2016.07.001. PubMed 14 FPDB04838 AP05208 RRHRLIIRRRMRNSFWSSRACLAW Anti-Gram+ & Gram-||Antiviral||Antifungal hemocytes, Pacific white shrimp, Litopenaeus vannamei N/A N/A Fish Shellfish Immunol. 2025 Mar 1:110243. doi: 10.1016/j.fsi.2025.110243. PubMed 24 FPDB05095 ApoEdp|||CAMPSQ17079 LRKLRKRLLLRKLRKRL MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Antiviral||Antibacterial Synthetic construct N/A N/A 17681018 17 FPDB05096 Octa 1|||CAMPSQ17103 RRWYRWWR MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antibacterial||Antiparasitic||Antiviral Synthetic construct N/A N/A 17681018 8 FPDB05097 MU89|||DRAMP31396|||CAMPSQ17104|||DRAMP31396 RRWYRWWRRRWYRWWR MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 16 FPDB05098 Hepta 1|||Peptide 111|||Peptide 111|||DRAMP31397|||CAMPSQ17105|||DRAMP31397 RWWRWWR MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Anti-S. aureus, activity value is MIC = 1.930876 uM||Anti-P. aeruginosa, activity value is MIC = 15.51 uM||Anti-C. albicans, activity value is MIC = 10.904159 uM||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A Hemolytic acitivity against Horse RBCs 34021253|||https://pubmed.ncbi.nlm.nih.gov/34021253|||FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 7 FPDB05099 MU92|||DRAMP31398|||CAMPSQ17106|||DRAMP31398 RWWRWWRRWWRWWR MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 14 FPDB05100 Deca 1|||DRAMP31399|||CAMPSQ17107|||DRAMP31399 YRWWRWARRW MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 10 FPDB05101 MU94|||DRAMP31400|||CAMPSQ17108|||DRAMP31400 YRWWRWARRWYRWWRWARRW MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 20 FPDB05102 MU103|||DRAMP31402|||CAMPSQ17111|||DRAMP31402 RRRRRRRWWWRRRRRRRR MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 18 FPDB05103 MU104|||DRAMP31403|||CAMPSQ17112|||DRAMP31403 RRRRRRRRRRRRRRRWWW MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||FEBS J. 2007 Sep;274(17):4511-25. 18 FPDB05104 ApoEdpL-W|||Human ApoE apolipoprotein derived peptide ApoEdpL-W|||Human ApoE apolipoprotein derived peptide ApoEdpL-W|||DRAMP31404|||CAMPSQ17089|||CAMPSQ17113|||Human ApoE apolipoprotein derived peptide ApoEdpL-W|||DRAMP31404 WRKWRKRWWWRKWRKRWW MIC against Pseudomonas aeruginosa||Staphylococcus aureus||Anti-HSV1 activity was assessed by plaque reduction assay||Sporozoite toxicity assay using Plasmodium berghei sporozoites||Anti-Candida albicans SC5314, activity value is MIC = 90||Anti-Candida albicans, activity value is MIC = 90||Anti-Candida glabrata, activity value is MIC = 90||Anti-Candida tropicalis, activity value is MIC = 90||Anti-Candida parapsilosis, activity value is MIC = 90||Anti-Pseudomonas aeruginosa ATCC 9027, activity value is IC50 = 7 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is IC50 = 7 uM||Antimicrobial||Antiviral||Antibacterial||Antiparasitic Synthetic construct N/A [Ref.17681018]15% hemolysis against human red blood cells at 35 uM. 21807970|||FEBS J. 2007 Sep;274(17):4511-25.|||17681018|||21807970|||FEBS J. 2007 Sep;274(17):4511-25. 18 FPDB05358 OLAP-416|||CAMPSQ23119 XaX Anti-Candida albicans CGMCC 2.2086, activity value is IC50 = 52 ug/ml||Anti-Candida albicans CGMCC 2.2086, activity value is MIC > 100 ug/ml||Anti-Staphylococcus aureus ATCC 6538, activity value is IC50 = 45 ug/ml||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC > 100 ug/ml||Anti-Bacillus subtilis ATCC 6663, activity value is IC50 = 52 ug/ml||Anti-Bacillus subtilis ATCC 6663, activity value is MIC > 100 ug/ml||Antibacterial||Antiviral Stagonospora trichophoricola,Aspergillus sp. N/A N/A 28676717 3 FPDB05709 Peptide 189|||CAMPSQ11784 WRWWWW Anti-S. aureus, activity value is MIC = 6.330149 uM||Anti-P. aeruginosa, activity value is MIC = 166.610105 uM||Anti-C. albicans, activity value is MIC = 91.530595 uM||Antibacterial||Antifungal ; S. aureus (MIC = >400 uM)||P. aeruginosa (MIC = >400 uM)||C. albicans (MIC = >400 uM)||Antiviral Synthetic construct N/A Hemolytic acitivity against Horse RBCs https://pubmed.ncbi.nlm.nih.gov/34021253|||28483551 6 FPDB06667 Defensin MGD1|||CAMPSQ20200 CGGWKRKRC Anti-Micrococcus luteus ATCC 4698, activity value is MIC = 0.8 uM||Anti-Trypanosoma brucei Antat1.1, activity value is LD50 = 4 uM||Anti-Leishmania major, activity value is LD50 = 12 uM||Antibacterial||Antiviral||Antiparasitic Synthetic construct N/A N/A 12823551, 15480442|||12823551 9 FPDB06670 Defensin MGD1|||CAMPSQ20197 CGGWHRLRC Anti-Micrococcus luteus ATCC 4698, activity value is MIC = 28 uM||Anti-Staphylococcus aureus ATCC 25293, activity value is MIC = 49 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 43 uM||Anti-Bacillus megaterium ATCC 17749, activity value is MIC = 51 uM||Anti-Vibrio alginolyticus ATCC 17749, activity value is MIC > 75 uM||Anti-Vibrio metschnikovii NCTC 8483, activity value is MIC > 75 uM||Anti-Escherichia coli 363 ATCC 11775, activity value is MIC > 75 uM||Anti-Salmonella enterica subsp. enterica serovar Newport, activity value is MIC > 75 uM||Anti-Fusarium oxysporum, activity value is MIC = 30 uM||Anti-Candida sp, activity value is MIC = 59 uM||Antibacterial||Antiviral||Antiparasitic||Antifungal ynthetic construct|||Synthetic construct N/A N/A 12823551, 15480442|||https://pubmed.ncbi.nlm.nih.gov/12823551,|||12823551 9 FPDB06811 PCN|||PC|||Peptide|||CAMPSQ14453|||CAMPSQ14454|||CAMPSQ14455 OFFHHHHHH Antibacterial||antiviral ; T4 bacteriophages (ATCC 113030-B4)||E. coli 25922||antiviral Synthetic construct N/A N/A 34746103 9 FPDB07599 TAT|||CAMPSQ12313 YGRKKRRQRRR Anti-33892275: S. aureus, activity value is MIC = 1.5||Anti-E. coli, activity value is MIC = 50||Antibacterial||Antiviral Synthetic construct N/A N/A 29907765, 33892275|||29907765 11 FPDB07970 CAMPSQ2450 FKAIWSGIKSLF Antibacterial||Antiviral Heterometrus petersii [Asian forest scorpion]|||Heterometrus petersii [Asian forest scorpion] N/A N/A 20950663 12 FPDB08222 CAMPSQ19243|||DRAMP30694|||Dermaseptin-S1|||DRAMP30694 ALWKTMLKKLGT Antibacterial||Antiviral||Antiparasitic||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 100 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC > 54 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 54 uM||Anti-Escherichia coli HB101, activity value is MIC > 54 uM||Anti-Escherichia coli HB101, activity value is LD50 = 54 uM||Anti-Leishmania major MHOM/IL/67/JERICHO-II, activity value is MIC = 54.2 uM||Antimicrobial Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at >100 uM|||[Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at >100 uM|||[Ref.20718719]human red cells:HC50>100 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 12 FPDB08680 Peptide 9|||DRAMP30314 FVPWFSKFlGRIL Anti-S. aureus ATCC 25923, activity value is MIC = 6.25 uM||Anti-S. epidermidis ATCC 12228, activity value is MIC = 6.25 uM||Anti-B. megaterium Bm11, activity value is MIC = 1.56 uM||Anti-E.coli ATCC 25922, activity value is MIC = 1.56 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 1.56 uM||Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 9.99 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 8.86 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 4.62 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 7.76 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 7.33 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A Human RBC ( 21(±4)% hemolysis at 50 uM)|||[Ref.35216177]showing residual hemolytic activity against human erythrocytes only at concentrations equal or above 50 uM. 34296619|||28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB08817 CAMPSQ19242|||DRAMP30693|||Dermaseptin-S1|||DRAMP30693 ALWKTMLKKLGTM Anti-Staphylococcus aureus Cowan 1, activity value is MIC > 50.6 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 50.6 uM||Anti-Escherichia coli HB101, activity value is MIC = 50.6 uM||Anti-Escherichia coli HB101, activity value is LD50 = 22.7 uM||Anti-Leishmania major MHOM/IL/67/JERICHO-II, activity value is MIC = 50.6 uM||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 10 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 100 uM|||[Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 100 uM|||[Ref.20718719]human red cells:HC50>100 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 13 FPDB09266 CAMPSQ19241|||DRAMP30692|||Dermaseptin-S1|||DRAMP30692 ALWKTMLKKLGTMA Anti-Staphylococcus aureus Cowan 1, activity value is MIC > 48.8 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 28.3 uM||Anti-Escherichia coli HB101, activity value is MIC = 48.8 uM||Anti-Escherichia coli HB101, activity value is LD50 = 20.5 uM||Anti-Leishmania major MHOM/IL/67/JERICHO-II, activity value is MIC = 48.8 uM||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 10.5 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 85 uM|||[Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 85 uM|||[Ref.20718719]human red cells:HC50>100 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 14 FPDB09587 CAMPSQ653|||DRAMP03778|||Agrocybin|||DRAMP03778|||Agrocybin|||DRAMP03778 ANDPQCLYGNVAAKF Antimicrobial||Antibacterial||Antifungal||Antiviral||Anti-M. arachidicola, activity value is IC50 = 125 uM||Anti-HIV-1 reverse transcriptase, activity value is IC50 = 60 uM Agrocybe cylindracea [Toadstool]|||Agrocybe cylindracea (Toadstool)|||Agrocybe cylindracea [Toadstool]|||Agrocybe cylindracea (Toadstool)|||Agrocybe cylindracea [Toadstool]|||Agrocybe cylindracea (Toadstool) N/A No hemolysis information or data found in the reference(s) presented in this entry 15629530|||Peptides. 2005 Feb;26(2):191-196.|||15629530|||Peptides. 2005 Feb;26(2):191-196.|||https://pubmed.ncbi.nlm.nih.gov/15629530|||Peptides. 2005 Feb;26(2):191-196. 15 FPDB09871 Dermaseptin-S1|||DRAMP30690|||Dermaseptin-S1|||DRAMP30690 ALHKTMLKKLGTMAL Anti-Staphylococcus aureus Cowan 1, activity value is MIC > 44.9 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 > 44.9 uM||Anti-Escherichia coli HB101, activity value is MIC > 44.9 uM||Anti-Escherichia coli HB101, activity value is LD50 > 44.9 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is MIC > 45 uM||Anti-Staphylococcus aureus, activity value is MIC > 45 uM||Anti-Bacillus subtilis ATCC 9466, activity value is MIC > 45 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC > 45 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 45 uM||Anti-Burkholderia cepacia 6/06, activity value is MIC > 45 uM||Anti-Stenotrophomonas maltophilia FC, activity value is MIC > 45 uM||Anti-Candida albicans, activity value is MIC > 45 uM||Antibacterial||Antiviral||Antiparasitic||Antifungal||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 5 uM||Antimicrobial Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at >100 uM|||[Ref.20718719]human red cells:HC50=100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at >100 uM|||[Ref.20718719]human red cells:HC50=100 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 15 FPDB09872 Dermaseptin-S1|||DRAMP30689 ALXKTMLKKLGTMAL Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 11.5 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 2.4 uM||Anti-Escherichia coli HB101, activity value is MIC = 2.8 uM||Anti-Escherichia coli HB101, activity value is LD50 = 0.9 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is MIC = 2.8 uM||Anti-Staphylococcus aureus, activity value is MIC = 22.5 uM||Anti-Bacillus subtilis ATCC 9466, activity value is MIC = 11.2 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 5.6 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 11.2 uM||Anti-Burkholderia cepacia 6/06, activity value is MIC = 25 uM||Anti-Stenotrophomonas maltophilia FC, activity value is MIC = 22.5 uM||Anti-Candida albicans, activity value is MIC = 11.2 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 2.5 uM||Anti-Staphylococcus aureus, activity value is MIC > 25 uM||Anti-Bacillus subtilis ATCC 9466, activity value is MIC = 5.6 uM||Anti-Stenotrophomonas maltophilia FC, activity value is MIC = 25 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 46.8 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 9.3 uM||Anti-Escherichia coli HB101, activity value is MIC = 11.7 uM||Anti-Escherichia coli HB101, activity value is LD50 = 3 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is MIC = 5.8 uM||Anti-Staphylococcus aureus, activity value is MIC > 46 uM||Anti-Bacillus subtilis ATCC 9466, activity value is MIC = 23 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC > 46 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 46 uM||Anti-Burkholderia cepacia 6/06, activity value is MIC = 23 uM||Anti-Stenotrophomonas maltophilia FC, activity value is MIC = 23 uM||Anti-Candida albicans, activity value is MIC = 5.8 uM||Antibacterial||Antifungal||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 2.7 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at 75 uM, Vero cells (50% Cytotoxicity at 50 uM, Human erythrocytes (50% Hemolysis at >100 uM|||[Ref.20718719]human red cells:HC50=75 uM. 18676150, 20718719|||Ref.20718719|||APMIS. 2010 Sep 1;118(9):674-80. 15 FPDB10343 K-Dermaseptin-S1|||DRAMP30691|||K-Dermaseptin-S1|||DRAMP30691 KALXKTMLKKLGTMAL Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 5.1 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 0.8 uM||Anti-Escherichia coli HB101, activity value is MIC = 1.2 uM||Anti-Staphylococcus aureus ATCC 6538P, activity value is MIC = 1.3 uM||Anti-Staphylococcus aureus, activity value is MIC = 21 uM||Anti-Bacillus subtilis ATCC 9466, activity value is MIC = 5.2 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 2.6 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 10.5 uM||Anti-Burkholderia cepacia 6/06, activity value is MIC = 42 uM||Anti-Stenotrophomonas maltophilia FC, activity value is MIC = 21 uM||Anti-Candida albicans, activity value is MIC = 10.5 uM||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 5 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at 80 uM, Vero cells (50% Cytotoxicity at 50 uM|||[Ref.20718719]human red cells:HC50=80 uM.|||Human erythrocytes (50% Hemolysis at 80 uM, Vero cells (50% Cytotoxicity at 50 uM|||[Ref.20718719]human red cells:HC50=80 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 16 FPDB10350 Dermaseptin S4 ALWMTLLKKVLKAAAK Anti-Escherichia coli TG1, activity value is IC50 = 20 Synthetic construct N/A Baby Hamster Kidney cells BHK-21 BSR (10% Cytotoxicity at 10 uM 29439871|||https://pubmed.ncbi.nlm.nih.gov/29439871 16 FPDB10501 Alyteserin-2b|||DRAMP01084 ILGAILPLVSGLLSNKL Antimicrobial||Antibacterial||Antifungal||Antiviral Alytes obstetricans|||Alytes obstetricans (European midwife toad) N/A "**Conclusion:** All tested **alyteserin peptides (including alyteserin-1 and alyteserin-2) in this study showed weak hemolytic activity against normal human red blood cells**, with **LC₅₀ values all above 100 µM**, indicating that these antimicrobial peptides have low toxicity to mammalian cells at effective antibacterial concentrations and possess relatively good **selective antibacterial activity**.|||No hemolysis information or data found in the reference(s) presented in this entry" 19463738|||Peptides. 2009 Jun;30(6):1069-1073. 17 FPDB10502 Alyteserin-2c|||DRAMP01086 ILGAILPLVSGLLSSKL Antimicrobial||Antibacterial||Antifungal||Antiviral Alytes obstetricans|||Alytes obstetricans (European midwife toad) N/A "**Conclusion:** All tested **alyteserin peptides (including alyteserin-1 and alyteserin-2) in this study showed weak hemolytic activity against normal human red blood cells**, with **LC₅₀ values all above 100 µM**, indicating that these antimicrobial peptides have low toxicity to mammalian cells at effective antibacterial concentrations and possess relatively good **selective antibacterial activity**.|||No hemolysis information or data found in the reference(s) presented in this entry" 19463738|||Peptides. 2009 Jun;30(6):1069-1073. 17 FPDB10533 AMC CPIFTKIQGTCGGRRKK Antibacterial||Antiviral ; P.aeruginosa||E.coli||E. faecalis||Herpes simplex virus type 1 Synthetic construct N/A N/A 26508857|||https://pubmed.ncbi.nlm.nih.gov/26508857 17 FPDB10653 F2.3S|||AP03034 GLVGTLLGHIGKAILGG Animalia||Amphibia||Antiviral Sphaenorhynchus lacteus [Orinoco lime treefrog]|||the Orinoco lime treefrog, Sphaenorhynchus lacteus, South America N/A Human RBCs (<50% hemolysis at 6.25-200 uM) 30044391|||J Antibiot (Tokyo). 2016 Nov;69(11):783-790. doi: 10.1038/ja.2016.16. PubMed 17 FPDB10679 17BIPHE2|||DRAMP29953 GXKRlVQRlKDXlRNLV Anti-E. faecium V284-17, activity value is MIC = 2 uM||Anti-S. aureus USA300, activity value is MIC = 4 uM||Anti-K. pneumoniae E406-17, activity value is MIC = 4||Anti-A. baumannii B28-16, activity value is MIC = 4||Anti-P. aeruginosa E411-17, activity value is MIC = 8 uM||Anti-E. coli E423-17, activity value is MIC = 4 uM||Anti-Ebola Virus :inhibition of viral infection in Hela cells, activity value is IC50 = 0.71 uM||Anti-ion of viral infection in primary macrophages, activity value is IC50 = 5.6 uM Synthetic construct|||Synthetic construct(derived from LL-37) N/A Human RBC (48% hemolysis at 200 uM) 34959645|||Ref.32252021 17 FPDB11112 RTD-2, Theta defensin 2 GVCRCLCRRGVCRCICRR Antibacterial||Antiviral||Antiviral ; Bacillus anthracis Sterne 7702(MEC = 0.72+-0.05 ug/ml) Synthetic construct N/A N/A 16790431|||https://pubmed.ncbi.nlm.nih.gov/16790431 18 FPDB11335 Cyclic Protegrin 1 RGGCLCYCRRRFCVCVCR Anti-Escherichia coli ATCC 25922, activity value is MIC = 0.64 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1.44 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1.21 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 3.62 uM||Anti-Proteus vulgaris ATCC 49132, activity value is MIC = 1.14 uM||Anti-Proteus vulgaris ATCC 49132, activity value is MIC = 0.89 uM||Anti-Klebsiella oxytoca ATCC 49131, activity value is MIC = 28.6 uM||Anti-Klebsiella oxytoca ATCC 49131, activity value is MIC = 53.2 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 0.73 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 0.72 uM||Anti-Micrococcus luteus ATCC 49732, activity value is MIC = 0.3 uM||Anti-Micrococcus luteus ATCC 49732, activity value is MIC = 0.62 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 5.2 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 5.82 uM||Anti-Candida albicans ATCC 37092, activity value is MIC = 8.02 uM||Anti-Candida albicans ATCC 37092, activity value is MIC = 26.4 uM||Anti-Candida kefyr ATCC 37095, activity value is MIC = 2.02 uM||Anti-Candida kefyr ATCC 37095, activity value is MIC = 1.68 uM||Anti-Candida tropicalis ATCC 37097, activity value is MIC = 10.2 uM||Anti-Candida tropicalis ATCC 37097, activity value is MIC = 19.8 uM Synthetic construct N/A Human erythrocytes (50% Hemolysis at 798.6 uM 10824115 18 FPDB11471 FP|||DRAMP31536|||AP05269|||DRAMP31536|||AP05269 MGRFKRFRKKFKKLFKKLS Anti-Cronobacter sakazakii, activity value is MIC = 125 ug/ml||Antimicrobial||Antiviral||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-4 strains S. aureus, activity value is MIC = 2||Anti-B. megaterium Bm 11, activity value is MIC = 2 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 4 uM||Anti-S. epidermidis KCTC 1917, activity value is MIC = 4 uM||Anti-10 strains E. faecalis, activity value is MIC = 8||Anti-5 strains E. faecium, activity value is MIC = 8||Anti-3 strains S. agalactiae, activity value is MIC = 1||Anti-10 strains A. baumannii, activity value is MIC = 0.5||Anti-3 strains E. coli, activity value is MIC = 2||Anti-S. typhimurium ATCC 14028, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-C. albicans, activity value is MIC = 16 uM||Anti-C. neoformans, activity value is MIC = 4 uM||Anti-E-coli ESBL, activity value is MIC > 50 uM||Anti-P-aeruginosa, activity value is MIC > 50 uM||Anti-A-baumannii, activity value is MIC > 50 uM Synthetic construct|||Amino acid extension, cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Amino acid extension, cathelicidin analog, animal-derived, natural derivative Helix "Human erythrocytes( 0.34% hemolysis at 500 ug/ml)|||The document mentions the hemolytic results of the antimicrobial peptide bomidin, specifically as follows: - In hemolysis experiments with mouse red blood cells, bomidin at concentrations of 0.5, 1, 2, and 4000 μg/ml did not cause hemolysis at 1, 2, 3, or 4 hours; - Slight hemolysis was observed at concentrations of 8000 μg/ml and 16000 μg/ml; - More obvious hemolysis occurred at concentrations of 32000 μg/ml and 64000 μg/ml. In conclusion, bomidin has no hemolytic activity at concentrations ≤4000 μg/ml, while hemolysis occurs to varying degrees at concentrations of 8000 μg/ml and above." 30716944|||Front Immunol. 2022 May 19;13:851642.|||Probiotics Antimicrob Proteins. 2022 Feb;14(1):169-179. doi: 10.1007/s12602-021-09857-6. PubMed|||Front Immunol. 2022 May 19;13:851642.|||Probiotics Antimicrob Proteins. 2022 Feb;14(1):169-179. doi: 10.1007/s12602-021-09857-6. PubMed 19 FPDB11785 Dermaseptin-S1|||DRAMP30688|||Dermaseptin-S1|||DRAMP30688 ALWKTMLKKLGTMALHAGK Antibacterial ; Synthetic construct||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 35.9 uM||Anti-Staphylococcus aureus Cowan 1, activity value is LD50 = 10.7 uM||Anti-Escherichia coli HB101, activity value is MIC = 3.6 uM||Anti-Leishmania major MHOM/IL/67/JERICHO-II, activity value is MIC = 17.9 uM||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 9 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Staphylococcus aureus Cowan 1[MIC = 35.9 uM], Staphylococcus aureus Cowan 1[LD50 = 10.7 uM], Escherichia coli HB101[MIC = 3.6 uM], Escherichia coli HB101[LD50 = <1.8 uM], Leishmania major MHOM/IL/67/JERICHO-II[MIC = 17.9 uM], Leishmania major MHOM/IL/67/JERICHO-II[LC50 = 7.9 uM], Trichomonas vaginalis SS22[LC50 = 30 uM], HSV-1[IC50 I = 9 uM], Human papillomavirus (HPV) PsV[20-30% Inhibition = 5 uM]|||[Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 80 uM|||[Ref.20718719]human red cells:HC50>100 uM. https://pubmed.ncbi.nlm.nih.gov/18676150,|||Ref.20718719|||18676150, 20718719|||APMIS. 2010 Sep 1;118(9):674-80. 19 FPDB12006 Pep19-2.5|||DRAMP31469 GCKKYRRFRWKFKGKFWFWG Antibacterial||Antimicrobial||Antiviral Synthetic construct N/A N/A 31112769|||J Infect Dis. 2012 Jun;205(11):1654-64. 20 FPDB12768 Alyteserin-1d|||DRAMP01087 GLKDIFKAGLGSLVKNIAAHVAN Antibacterial||Antimicrobial||Antifungal||Antiviral Alytes obstetricans [Common midwife toad]|||Alytes obstetricans (European midwife toad) N/A "**Conclusion:** All tested **alyteserin peptides (including alyteserin-1 and alyteserin-2) in this study showed weak hemolytic activity against normal human red blood cells**, with **LC₅₀ values all above 100 µM**, indicating that these antimicrobial peptides have low toxicity to mammalian cells at effective antibacterial concentrations and possess relatively good **selective antibacterial activity**.|||No hemolysis information or data found in the reference(s) presented in this entry" 19463738|||Peptides. 2009 Jun;30(6):1069-1073. 23 FPDB13108 DS4|||DRAMP30334 TLLKKVLKAAAKAALNAVLVGANA Antibacterial||Anti-HSV-2 acyclovir-sensitive strain :inhibition the cytopathic effect of HSV-2 in Vero cells, activity value is EC50 = 27.07 uM||Anti-HSV-2 acyclovir-resistant strain :inhibition of cytopathic effet of HSV-2 in Vero cells, activity value is EC50 = 25.27 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin S4) N/A hRBCs, >50% hemolysis at 128 ug/ml 33774792|||Ref.23161023|||J Med Virol. 2013 Feb;85(2):272-81. 24 FPDB13232 Caerin-1.9|||Caerin 1.9|||DRAMP01560 GLFGVLGSIAKHVLPHVVPVIAEKL Antibacterial||Anti-GDM1.441, activity value is MIC = 7.5 ug/ml||Anti-GDM1.1263, activity value is MIC = 7.5 ug/ml||Anti-P. aeruginosa GDM1.443, activity value is MIC = 60 ug/ml||Anti-A. Baumannii GDM1.609, activity value is MIC = 15 ug/ml||Anti-S. hemolyiicus GDM1.245, activity value is MIC = 7.5 ug/ml||Anti-MRSA1, activity value is MIC = 7.5 ug/ml||Anti-MRSA2, activity value is MIC = 7.5 ug/ml||Anti-MRSA3, activity value is MIC = 7.5 ug/ml||Anti-Bacillus cereus, activity value is MIC = 100 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 12 ug/ml||Anti-Listeria innocua, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 50 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 100 ug/ml||Anti-Staphylococcus epidermis, activity value is MIC = 25 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 50 ug/ml||Anti-Pasteurella multocida, activity value is MIC = 50 ug/ml||Anti-ion of HIV transfer by dendritic cells to T cells, activity value is IC50 = 1.6 uM||Antimicrobial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral Litoria chloris [Blue-thighed frog]|||Litoria chloris (Blue-thighed frog) (frog skin active peptide family) N/A Litoria splendida [Australian tree frog]|||No hemolysis information or data found in the reference(s) presented in this entry 9516047|||34259550|||Peptides. 2015 Sep;71:296-303.||Ref.15203252|||26026377||Ref.15203252||Ref.16140737||Ref.26026377|||Peptides. 2015 Sep;71:296-303.J Virol. 2005 Sep;79(18):11598-606.Peptides. 2004 Jun;25(6):1035-1054.J Pept Res. 1998 Feb;51(2):121-126. 25 FPDB13665 Pa-MAP, Antifreeze peptide analogue HTASDAAAAAALTAANAAAAAAASMA Anti-Escherichia coli ATCC 8739, activity value is MIC = 30 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC > 115 uM||Anti-Trichophyton mentagrophytes, activity value is MIC = 115 uM||Anti-Trichophyton rubrum, activity value is MIC = 115 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC > 115 uM||Anti-Human colon adenocarcinoma Caco-2, activity value is ED50 = 60 uM||Anti-Human colon adenocarcinoma HCT 116, activity value is ED50 > 115 uM||Anti-Human breast adenocarcinoma MCF-7, activity value is ED50 = 115 uM||Anti-HSV-1, activity value is ED50 = 90 uM||Anti-HSV-2, activity value is ED50 = 90 uM Synthetic construct N/A Human erythrocytes (- at NA , Vero cells (- at NA 27161201, 23056574|||https://pubmed.ncbi.nlm.nih.gov/27161201, 26 FPDB13731 Dermaseptin-4|||DRAMP01671|||Dermaseptin-4|||DRAMP01671 ALWMTLLKKVLKAAAKALNAVLVGANA Bacteria||Fungii||Protozoa||enveloped HSVtype1||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral||Antiviral ; Bacteria Phyllomedusa sauvagii [Sauvage frog]|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagii [Sauvage frog]|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagei (Sauvage's leaf frog)|||Phyllomedusa sauvagii Combine strand and Turn structure [Ref:11850249]IC50=20 uM against human erythrocytes 11850249|||Eur J Biochem. 1994 Jan 15;219(1-2):145-154.|||11850249|||Eur J Biochem. 1994 Jan 15;219(1-2):145-154.Antimicrob Agents Chemother. 2002 Mar;46(3):689-694.J Biol Chem. 1997 Dec 12;272(50):31609-31616.|||Eur J Biochem. 1994 Jan 15;219(1-2):145-154. Antimicrob Agents Chemother. 2002 Mar;46(3):689-694. J Biol Chem. 1997 Dec 12;272(50):31609-31616.|||https://pubmed.ncbi.nlm.nih.gov/11850249 27 FPDB13741 Ranatuerin-2YJ precursor LMDIFKVAVNKLLAAGMNKPRCKAAHC Anti-Rana grylio virus activity||Gram-positive bacteria and Gram-negative bacteria [ 22.5 ug/ml ]||Antibacterial||Antiviral ; Anti-Rana grylio virus activity Rana dybowskii [Dybowsky frog]|||Rana dybowskii N/A 7.64% hemolysis activity 22702542|||https://pubmed.ncbi.nlm.nih.gov/22702542 27 FPDB13742 RANATUERIN 2P|||DRAMP02257|||RANATUERIN 2P|||DRAMP02257 LMDTVKNVAKNLAGHMLDKLKCKITGC Anti-S. aureus, activity value is MIC = 50 uM||Anti-E. coli, activity value is MIC = 13 uM||Anti-C. albicans, activity value is MIC = 67 uM||Anti-Staphylococcus aureus, activity value is MIC = 50 uM||Anti-Escherichia coli, activity value is MIC = 13 uM||Anti-Candida albicans, activity value is MIC = 67 uM||Anti-##Gram-negative bacterium: Escherichia coli, activity value is MIC = 13 uM||Anti-##Yeast: Candida albicans, activity value is MIC = 67 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral Rana pipiens [Northern leopard frog]|||Rana pipiens (Northern leopard frog)|||Rana pipiens [Northern leopard frog]|||Rana pipiens (Northern leopard frog) N/A No hemolysis information or data found in the reference(s) presented in this entry 10651828|||Eur J Biochem. 2000 Feb;267(3):894-900.||Ref.10651828||Ref.11601906|||10651828|||Ref.10651828||Ref.11601906|||Virology. 2001 Sep 30;288(2):351-7.##Eur J Biochem. 2000 Feb;267(3):894-900.||Ref.10651828||Ref.11601906|||Virology. 2001 Sep 30;288(2):351-7.##Eur J Biochem. 2000 Feb;267(3):894-900. 27 FPDB13891 D4-S4|||DRAMP30337 ALWDTLLKKVLKAAAKAALDAVLVGANA E.coli(IC50= (69 ± 11 uM)||Anti-HSV-2 acyclovir-sensitive strain :inhibition the cytopathic effect of HSV-2 in Vero cells, activity value is EC50 = 5.41 uM||Anti-HSV-2 acyclovir-resistant strain :inhibition of cytopathic effet of HSV-2 in Vero cells, activity value is EC50 = 9.63 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin S4) N/A hRBC(LC50= 2.3 ± 0.3 uM) 10660589|||Ref.23161023|||J Med Virol. 2013 Feb;85(2):272-81. 28 FPDB13894 K4K20-S4|||DRAMP30335 ALWKTLLKKVLKAAAKAALNAVLVGANA E.coli(IC50= (0.3 ± 0.1 uM)||Anti-HSV-2 acyclovir-sensitive strain :inhibition the cytopathic effect of HSV-2 in Vero cells, activity value is EC50 = 2.7 uM||Anti-HSV-2 acyclovir-resistant strain :inhibition of cytopathic effet of HSV-2 in Vero cells, activity value is EC50 = 5.1 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin S4) N/A hRBC(LC50= 0.5 ± 0.1 uM) 10660589|||Ref.23161023|||J Med Virol. 2013 Feb;85(2):272-81. 28 FPDB13965 Brevinin-2HS1|||DRAMP01985|||Brevinin-2HS1|||DRAMP01985 GLWDTIKQAGKKIFLSVLDKIRCKVAGGC Antibacterial||Antifungal||Antiviral||Antimicrobial Huia schmackeri [Chinese piebald odorous frog]|||Huia schmackeri (Chinese piebald odorous frog)|||Huia schmackeri [Chinese piebald odorous frog]|||Huia schmackeri (Chinese piebald odorous frog)|||Huia schmackeri (Chinese piebald odorous frog)|||Huia schmackeri N/A No hemolysis information or data found in the reference(s) presented in this entry 18423796|||Peptides. 2008 Aug;29(8):1456-1460.|||18423796|||Peptides. 2008 Aug;29(8):1456-1460.|||Peptides. 2008 Aug;29(8):1456-1460.|||https://pubmed.ncbi.nlm.nih.gov/18423796 29 FPDB13980 Dermaseptin-S1|||DRAMP30686|||Dermaseptin-S1|||DRAMP30686 ALWKTMLKKLGTMALHAGKAALGAAADTI Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 2.7 uM||Anti-Escherichia coli HB101, activity value is MIC = 2.7 uM||Anti-Escherichia coli HB101, activity value is LD50 = 2.2 uM||Anti-Leishmania major MHOM/IL/67/JERICHO-II, activity value is MIC = 6.1 uM||Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 1.7 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S1) N/A Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 20 uM|||[Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM, Vero cells (50% Cytotoxicity at 20 uM|||[Ref.20718719]human red cells:HC50>100 uM. 18676150, 20718719|||Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/18676150,|||APMIS. 2010 Sep 1;118(9):674-80. 29 FPDB14020 Neutrophil defensin1|||DRAMP02669|||Neutrophil defensin1|||DRAMP02669 ACYCRIPACLAGERRYGTCIYQGRLWAFCC Antibacterial||Antifungal||Antiviral||Antimicrobial Pan troglodytes [Chimpanzee]|||Pan troglodytes (chimpanzee)|||Pan troglodytes [Chimpanzee]|||Pan troglodytes (chimpanzee)|||Pan troglodytes (chimpanzee)|||Pan troglodytes|||Cavia porcellus Bridge No hemolysis information or data found in the reference(s) presented in this entry Physiol Genomics. 2004 Dec 15;20(1):1-11. Epub 2004 Oct 19.|||Q5G863|||Physiol Genomics. 2004 Dec 15;20(1):1-11. Epub 2004 Oct 19.|||Physiol Genomics. 2004 Dec 15;20(1):1-11. Epub 2004 Oct 19.|||https://pubmed.ncbi.nlm.nih.gov/15824119 30 FPDB14271 Pom-1|||DRAMP32323 KCAGSIAWAIGSGLFGGAKLIKIKKYIAELGGLQ Antibacterial||Antiviral||Antifungal||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 5 ug/ml||Anti-Listeria monocytogenes ATCC BAA-679, activity value is MIC > 5 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC > 20 ug/ml||Anti-Human adenocarcinoma TZM-bl, activity value is IC50 = 40.16 ug/ml||Antimicrobial||Anticancer Synthetic construct|||Synthetic N/A Vero E6 cells (50% Cytotoxicity at 438 ug/ml 33113998|||Biomolecules. 2020 Oct 23;10(11):1473.|||https://pubmed.ncbi.nlm.nih.gov/33113998 34 FPDB14451 Beta-amyloid peptide|||Beta-amyloid peptide|||AP01675|||AP01675 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV Antibacterial||Antifungal||Anti-Candida albicans ATCC 10231, activity value is MIC = 0.78 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1.56 ug/ml||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae ATCC 49619, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 25 ug/ml||Anti-Listeria monocytogenes, activity value is MIC = 25 ug/ml||Anti-Enterococcus faecalis, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 12.5 ug/ml||Anti-Streptococcus agalactiae, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa, activity value is MIC > 50 ug/ml||Anti-S. pyogenes, activity value is MIC > 50 ug/ml||Anti-S. mitis, activity value is MIC = 50 ug/ml||Anti-S. salivarius, activity value is MIC > 50 ug/ml||The discovery of antimicrobial property of this peptide adds a new avenue to understanding the mechanism of the Alzhermer's disease. It also inhibits Herpes simplex virus 1 (HSV-1) . Although less effective than the 42mer||it also inhibits influenza A virus (White et al. 2014 ).||Anti-Gram+ & Gram-||Antiviral||Synergistic AMPs Homo sapiens [Humans]|||Homo sapiens [Humans]|||Homo sapiens|||Homo sapiens Helix N/A 20209079|||20209079|||PLoS One. 2010 Mar 3;5(3):e9505||Bourgade K et al., 2014|||PLoS One. 2010 Mar 3;5(3):e9505 40 FPDB14720 Hedefensin|||DRAMP18423|||AP02751|||DRAMP18423 EEESEVAHLRVRRGFGCPLNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN Anti-Micrococcus luteus ATCC9341, activity value is MIC = 12.5 uM||No MICs found in DRAMP database||Antiviral||Antimicrobial Haemaphysalis longicornis [Hard tick]|||hemolymph, Haemaphysalis longicornis Bridge No hemolysis information or data found in the reference(s) presented in this entry 30003919|||Dev Comp Immunol. 2017 Mar;68:98-107. PubMed|||Dev Comp Immunol. 2017 Mar;68:98-107 51 FPDB15136 EC-hepcidin1|||DRAMP31350 "MKTFSVAVAVAIVLAFICTQESSALPVTGVEELVELVSSDDPVADHQELPVELGERLFNI RKKRASPKCTPYCYPTRDGVFCGVRCDF" Antibacterial ; Vibrio vulnificus||Staphylococcus aureus||Antimicrobial||Antiviral Epinephelus coioides [Orange-spotted grouper]|||Epinephelus coioides N/A N/A 21145974|||Fish Shellfish Immunol. 2011 Feb;30(2):559-68. 88 FPDB15505 DRAMP03465 NEYHGFVDKANNENKRKKQQGRDDFVVKPNNFANRRRKDDYNENYYDDVDAADVV Anti-Botrytis cinerea, activity value is MIC = 0.1 uM||Anti-Mycosphaerella arachidicola, activity value is MIC = 0.07 uM||Anti-Fusarium oxysporum, activity value is MIC = 0.18 uM||Anti-Physalospora piricola, activity value is MIC = 0.06 uM||Antimicrobial||Antifungal||Antiviral Cicada flammata N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2002;23:7-11. 55 FPDB15538 DRAMP00272|||Thaumatin-like protein|||DRAMP00272|||Thaumatin-like protein|||DRAMP00272 AKITFTNNHPRTIWP Antimicrobial||Antifungal||Antiviral||Anti-F.oxysporum, activity value is IC50 = 0.5 uM||Anti-HIV-1 reverse transcriptase, activity value is IC50 = 1.6 uM Castanopsis chinensis (Chinese chinquapin) (Kweilin chestnut)|||Castanopsis chinensis [Chinese evergreen chinquapin]|||Castanopsis chinensis (Chinese chinquapin) (Kweilin chestnut)|||Castanopsis chinensis [Chinese evergreen chinquapin]|||Castanopsis chinensis (Chinese chinquapin) (Kweilin chestnut) N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem Biophys Res Commun. 2003 Feb 7;301(2):364-370.|||12565869|||Biochem Biophys Res Commun. 2003 Feb 7;301(2):364-370.|||https://pubmed.ncbi.nlm.nih.gov/12565869|||Biochem Biophys Res Commun. 2003 Feb 7;301(2):364-370. 15 FPDB15575 DRAMP00339|||Alpha-basrubrin|||AP00446|||DRAMP00339|||AP00446|||DRAMP00339|||Alpha-basrubrin GADFQECMKEHSQKQHQHQG Antimicrobial||Antifungal||Antiviral||Antiviral ; B. cinerea||M. arachidicola||F. oxysporum||HIV1 Basella alba (Malabar spinach) (Basella rubra)|||edible Chinese vegetable, Malabar spinach|||Basella alba (Malabar spinach) (Basella rubra)|||edible Chinese vegetable, Malabar spinach|||Basella alba (Malabar spinach) (Basella rubra)|||Basella alba [Malabar spinach] N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770.|||11688973|||Biochem. Biophys. Res. Commun. 2001; 288: 765-770|||Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770.|||Biochem. Biophys. Res. Commun. 2001; 288: 765-770|||Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770.|||11688973 20 FPDB15576 DRAMP00340|||Beta-basrubin|||DRAMP00340|||Beta-basrubin|||DRAMP00340 KIMAKPSKFYEQLRGR Antimicrobial||Antifungal||Antiviral||Antiviral ; B. cinerea||M. arachidicola||F. oxysporum||HIV1 Basella alba (Malabar spinach) (Basella rubra)|||Basella alba [Malabar spinach]|||Basella alba (Malabar spinach) (Basella rubra)|||Basella alba [Malabar spinach]|||Basella alba (Malabar spinach) (Basella rubra) N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770.|||11688973|||Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770.|||https://pubmed.ncbi.nlm.nih.gov/11688973|||Biochem Biophys Res Commun. 2001 Nov 9;288(4):765-770. 16 FPDB15580 DRAMP00361|||PHP|||DRAMP00361 ITCPQVTQSLAPCVPYLISG Antimicrobial||Antifungal||Antiviral||Anti-cancer||Anti-A. alternate, activity value is IC50 = 1.5 uM||Anti-P. degitatum, activity value is IC50 = 37.5 uM||Anti-R. stuolonifer, activity value is IC50 = 8.44 uM||Anti-and M. grisea, activity value is IC50 = 2.19 uM||Anti-HIV-1 reverse transcriptase, activity value is IC50 = 1.26 uM Peganum harmala (Syrian rue) (Harmal peganum)|||Peganum harmala (Syrian rue) (Harmal peganum)|||Peganum harmala N/A Rabbit RBC (Non-hemolytic)|||No hemolysis information or data found in the reference(s) presented in this entry|||Rabbit RBC (Non-hemolytic) Submitted (MAR-2012) to UniProtKB|||23165744|||Submitted (MAR-2012) to UniProtKB 20 FPDB15610 DRAMP00427 AICKKPSKFFKGACGRDADCEKACDQENWPGGVCVPFLRCECQRSC Antimicrobial||Antibacterial||Antifungal||Antiviral Beta vulgaris (Sugar beet) N/A No hemolysis information or data found in the reference(s) presented in this entry Mol Plant Microbe Interact. 1995 May-Jun;8(3):424-434. 46 FPDB15611 DRAMP00428 ATCRKPSMYFSGACFSDTNCQKACNREDWPNGKCLVGFKCECQRPC Antimicrobial||Antibacterial||Antifungal||Antiviral Beta vulgaris (Sugar beet) N/A No hemolysis information or data found in the reference(s) presented in this entry Mol Plant Microbe Interact. 1995 May-Jun;8(3):424-434. 46 FPDB15939 DRAMP01000|||Ascalin|||DRAMP01000|||CAMPSQ497|||DRAMP01000 YQCGQGG Antimicrobial||Antifungal||Antiviral||Antiviral ; N.A Allium cepa var. aggregatum (shallot)|||Allium cepa var. aggregatum|||Allium cepa var. aggregatum (shallot)|||Allium cepa var. aggregatum [Shallot]|||Allium cepa var. aggregatum (shallot) N/A "In the provided PDF document "Ascalin, a new anti-fungal peptide...", information about * * hemolytic (hemolytic activity)* * appears in the "2.6. Assay for lectin (hemagglutinating) activity" section on page 2 * * *, and the test results are clearly given in the "Results" section on page 3 * *: > **Section 2.6 on page 2** describes the detection method: > “A serial two- fold dilution of the ascalin solution in microtiter U- plates \((50\mu \mathrm{l})\) was mixed with \(50\mu \mathrm{l}\) of a \(2\%\) suspension of rabbit red blood cells ..." > **Page 3, Section Results** Explicit results: > “It did not exhibit any hemagglutinating activity ." This means that **Ascalin (Alliarin) does not exhibit any hemagglutinating activity** under the conditions tested, I .e. **does not cause agglutination of rabbit red blood cells**, indirectly indicating **no hemolytic activity** or at least no significant hemolytic effect at the concentrations tested. The results support that Ascalin may have good hemocompatibility as a potential antifungal or antiviral agent.|||No hemolysis information or data found in the reference(s) presented in this entry" Peptides. 2002 Jun;23(6):1025-1029.|||https://pubmed.ncbi.nlm.nih.gov/12126728|||Peptides. 2002 Jun;23(6):1025-1029.|||12126728|||Peptides. 2002 Jun;23(6):1025-1029. 7 FPDB15942 DRAMP01003|||Gymnin|||DRAMP01003|||CAMPSQ519|||DRAMP01003 KTCENLADDY Antimicrobial||Antifungal||Antiviral||Antibacterial||Antifungal ; N.A Gymnocladus chinensis|||Gymnocladus chinensis [Soap tree]|||Gymnocladus chinensis N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2003 Jul;24(7):963-968.|||https://pubmed.ncbi.nlm.nih.gov/14499273|||Peptides. 2003 Jul;24(7):963-968.|||14499273|||Peptides. 2003 Jul;24(7):963-968. 10 FPDB15943 DRAMP01005|||Cicerarin|||DRAMP01005 VKSTGRADDDLAVKTKYLPP Antimicrobial||Antifungal||Antiviral||Antifungal ; B.cinerea||M.arachidicola||P.piricola||HIV-1 reverse transcriptase Cicer arietinum (chickpea) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2003 May;24(5):659-663.|||12895650|||Peptides. 2003 May;24(5):659-663. 20 FPDB15975 DRAMP01067|||Coccinin|||DRAMP01067|||CAMPSQ652|||DRAMP01067 KQTENLADTY Antimicrobial||Antifungal||Antiviral||Antibacterial||Antifungal ; N.A Phaseolus coccineus (Scarlet runner bean) (Phaseolus multiflorus)|||Phaseolus coccineus|||Phaseolus coccineus (Scarlet runner bean) (Phaseolus multiflorus)|||Phaseolus coccineus [Scarlet runner bean]|||Phaseolus coccineus (Scarlet runner bean) (Phaseolus multiflorus) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2004 Dec;25(12):2063-2068.|||https://pubmed.ncbi.nlm.nih.gov/15572193|||Peptides. 2004 Dec;25(12):2063-2068.|||15572193|||Peptides. 2004 Dec;25(12):2063-2068. 10 FPDB15990 DRAMP01559 GLFKVLGSVAKHLLPHVVPVIAEKL Antimicrobial||Antibacterial||Antifungal||Antiviral Litoria chloris (Blue-thighed frog) Alpha helix No hemolysis information or data found in the reference(s) presented in this entry J Pept Res. 1998 Feb;51(2):121-126. 25 FPDB15991 DRAMP01629 GWMSKIASGIGTFLSGVQQG Antimicrobial||Antibacterial||Antifungal||Antiviral Phyllomedusa sauvagii (Waxy Monkey Leaf Frog) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2008 Nov;29(11):2074-2082. 20 FPDB15992 DRAMP01630 AVWKDFLKNIGKAAGKAVLNSVTDMVNE Antimicrobial||Antibacterial||Antifungal||Antiviral Phyllomedusa hypochondrialis (Orange legged leaf frog) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2008 Nov;29(11):2074-2082. 28 FPDB15993 DRAMP01631 GLWKSLLKNVGKAAGKAALNAVTDMVNQ Antimicrobial||Antibacterial||Antifungal||Antiviral Phyllomedusa sauvagei (Sauvage's leaf frog) N/A No hemolysis information or data found in the reference(s) presented in this entry Regul Pept. 2003 Nov 15;116(1-3):139-146. 28 FPDB15994 DRAMP01632 ALWKTMLKKLGTVALHAGKAALGAAADTISQ Antimicrobial||Antibacterial||Antifungal||Antiviral Phyllomedusa sauvagei (Sauvage's leaf frog) Alpha helix No hemolysis information or data found in the reference(s) presented in this entry Regul Pept. 2003 Nov 15;116(1-3):139-146. 31 FPDB15995 DRAMP01654 GLWSKIKEAGKAVLTAAGKAALGAVSDAV Antimicrobial||Antibacterial||Antifungal||Antiviral Phyllomedusa bicolor (Two-colored leaf frog)|||Phyllomedusa bicolor (Two-colored leaf frog) (Rana bicolor) N/A No hemolysis information or data found in the reference(s) presented in this entry FEBS Lett. 1997 Sep 1;414(1):27-32. 29 FPDB15997 DRAMP01713 VHLEEILLLLFFLGTISLSLCEEERDADEEENEVSGYAANVNVKRCGYKHGRANCGRG Antimicrobial||Antibacterial||Antifungal||Antiviral Odorrana grahami (Yunnanfu frog) (Rana grahami) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases 58 FPDB15998 DRAMP01714 MFTMKKSLLLLFFLGTINLSFCQEETNAEEERRDEEVAKMEEIKRGLLSGPRCGEESTMWT Antimicrobial||Antibacterial||Antifungal||Antiviral Odorrana grahami (Yunnanfu frog) (Rana grahami) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases 61 FPDB15999 DRAMP01715 MFTLKKPLLLLFFLGTINLSLCQDETNAEEERRDEEVVKMEEIKRGLLSGILGAGKHIVCGLTGCAKA Antimicrobial||Antibacterial||Antifungal||Antiviral Odorrana grahami (Yunnanfu frog) (Rana grahami) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases 68 FPDB16000 DRAMP01716 MFTLKKSLLLLFFLGTINLSLCQDVTNAEEERRDEEVAKMEEIKRGLLRPPRCGEAYSMWT Antimicrobial||Antibacterial||Antifungal||Antiviral Odorrana grahami (Yunnanfu frog) (Rana grahami) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases 61 FPDB16059 DRAMP03235|||Latarcin 6b|||DRAMP03235 QAFKTFTPDWNKIRNDAKRMQDNLEQMKKRFNLNL Antibacterial||Antimicrobial||Antifungal||Antiviral Lachesana tarabaevi (Spider)|||Lachesana tarabaevi [Spider]|||Lachesana tarabaevi (Spider) N/A No hemolysis information or data found in the reference(s) presented in this entry J Biol Chem. 2006 Jul 28;281(30):20983-20992.|||16735513|||J Biol Chem. 2006 Jul 28;281(30):20983-20992. 35 FPDB16060 DRAMP03258|||Rondonin|||AP02556|||DRAMP03258|||AP02556 IIIQYEGHKH Antimicrobial||Antifungal||Anti-Trichosporon sp IOC 4569, activity value is MIC = 1.1 uM||Anti-Candida albicans MDM8, activity value is MIC = 16.75 uM||Anti-Candida krusei IOC 4559, activity value is MIC = 16.75 uM||Anti-Candida glabrata IOC 4565, activity value is MIC = 8.37 uM||Anti-Candida albicans IOC 4558, activity value is MIC = 8.37 uM||Anti-Candida parapsilosis IOC 4564, activity value is MIC = 16.75 uM||Anti-Candida tropicalis IOC 4560, activity value is MIC = 8.75 uM||Anti-Candida guilliermondii IOC 4557, activity value is MIC = 16.75 uM||Anti-fungi B. bassiana Trichosporon sp IOC4569, activity value is MIC = 1.1 uM||Anti-s C. albicans MDM8 or IOC 4558, activity value is MIC = 8.37||Anti-C. krusei IOC 4559, activity value is MIC = 16.75 uM||Anti-C. glabrata IOC 4565 (MIC, activity value is MIC = 8.37 uM||Anti-C. parapsilosis IOC 4564, activity value is MIC = 16.75 uM||Anti-C. tropicalis IOC 4560, activity value is MIC = 8.75 uM||Anti-and C. guilliermondii IOC 4557, activity value is MIC = 16.75 uM||Antiviral||candidacidal||Synergistic AMPs Acanthoscurria rondoniae (Spider)|||Acanthoscurria rondoniae|||haemolymph, Eurypelma californicum and Acanthoscurria gomesiana;|||Acanthoscurria rondoniae (Spider)|||haemolymph, Eurypelma californicum and Acanthoscurria gomesiana;|||haemolymph, Eurypelma californicum and Acanthoscurria gomesiana; N/A N/A "Results Immunol. 2012;2:66-71.|||http://www.uniprot.org/uniprot/B3EWP8|||Results Immunol . 2012 Apr 2:2:66-71. doi: 10.1016/j.rinim.2012.03.001. eCollection 2012.|||Results Immunol. 2012;2:66-71.|||Results Immunol. 2012 Apr 2;2:66-71. PubMed|||Results Immunol. 2012 Apr 2;2:66-71. PubMed" 10 FPDB16079 DRAMP03596|||AP00181|||DRAMP03596|||AP00181|||DRAMP03596 AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral(SARS-CoV-2)||It had been puzzling regarding the role of this defensin. Recent studies revealed two mechanisms:||t had been puzzling regarding the role of this defensin. Recent studies revealed two mechanisms:||Antiviral(SARS-CoV-6) Homo sapiens (Human)|||Paneth cells, intestine, Homo sapiens|||Homo sapiens (Human)|||Paneth cells, intestine, Homo sapiens|||Homo sapiens (Human) Beta strand (3 strands; 19 residues)||Beta||Beta strand No hemolysis information or data found in the reference(s) presented in this entry Viruses. 2021 Jun 26;13(7):1246.|||FEBS Lett. 1993; 315:187-192|||Viruses. 2021 Jun 26;13(7):1246.FEBS Lett. 1993; 315:187-192.Protein Sci. 2006 Dec;15(12):2749-2760.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.|||FEBS Lett. 1993; 315:187-192|||Viruses. 2021 Jun 26;13(7):1246. 32 FPDB16082 DRAMP03637|||Thaumatin-like protein , Actc2|||DRAMP03637 ATFNFINNCPFTVWAAAVPG Antimicrobial||Antifungal||Antiviral||Antiviral ; B.cinerea||C.comatus||M.arachidicola||P.piricola||C.albicans||S.carlsbergensis||HIV-1 reverse transcriptase Actinidia chinensis (Kiwi) (Yangtao)|||Actinidia chinensis (Kiwi) (Yangtao)|||Actinidia chinensis [Kiwi] N/A No hemolysis information or data found in the reference(s) presented in this entry Phytochemistry. 2002 Sep;61(1):1-6.|||12165295 , 12417892|||Phytochemistry. 2002 Sep;61(1):1-6.J Allergy Clin Immunol. 2002 Nov;110(5):805-810.J Allergy Clin Immunol. 2004 Nov;114(5):1169-1175. 20 FPDB16091 DRAMP03755 QFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antifungal||Antiviral Leiurus quinquestriatus hebraeus (Yellow scorpion) Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-7368.|||Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-7368.Eur J Biochem. 1991 Feb 26;196(1):19-28.Biochemistry. 1997 Apr 1;36(13):3760-3766.Biochemistry. 1992 Sep 1;31(34):7756-7764. 37 FPDB16093 DRAMP03783 QWGYGGMPYGGYGGMGGYGMGGYGMGYRRRMWGSPYGGYGGYGGYGGWG Antimicrobial||Antibacterial||Antifungal||Antiviral Caenorhabditis elegans N/A No hemolysis information or data found in the reference(s) presented in this entry Nat Immunol. 2004 May;5(5):488-494. 49 FPDB16094 DRAMP03784 QWGYGGYGRGYGGYGGYGRGMYGGYGRGMYGGYGRGMYGGWGK Antimicrobial||Antibacterial||Antifungal||Antiviral Caenorhabditis elegans N/A No hemolysis information or data found in the reference(s) presented in this entry Nat Immunol. 2004 May;5(5):488-494. 43 FPDB16307 KP|||DRAMP31421|||CAMPSQ8830|||CAMPSQ11413|||DRAMP31421 AKVTMTCSAS Antibacterial||Antifungal ; N.A||Antimicrobial||Antiviral Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/28704490|||Intervirology. 2018;61(4):166-173.|||18824612|||30654366|||Intervirology. 2018;61(4):166-173. 10 FPDB16412 L12P|||DRAMP31427|||CAMPSQ12477|||DRAMP31427 LCLRNWDQGHRP Antifungal||Antiviral||Antimicrobial Homo sapiens [Humans ]|||Synthetic construct|||Homo sapiens [Humans ]|||Synthetic construct N/A Hemolytic against Human RBC 28883642, 30654366|||Intervirology. 2018;61(4):166-173.|||28883642|||Intervirology. 2018;61(4):166-173. 12 FPDB16459 DRAMP30316 FVPWFSKFlpRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 > 50 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 > 50 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 > 50 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16460 Undecanoic-|||Tridecanoic-|||Pentadecanoic-|||Hexadecenoic-|||DRAMP30317|||DRAMP30324|||DRAMP30325|||DRAMP30330|||DRAMP30331|||DRAMP30332|||DRAMP30333 FVPWFSKFlXRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 7.73 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 9.61 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 6.72 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 11.74 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 11.33 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 0.68 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 0.54 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.65 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 = 33.83 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 0.74 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 0.62 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 2.66 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 0.92 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.53 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 = 32.35 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 2.08 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 0.97 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 34.58 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 2.66 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 < 0.1 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 < 0.1 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 10.01 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 < 0.1 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 1.39 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.39 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 33.36 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 3.39 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 2.48 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.48 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 37.77 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 3.48 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 3.13 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.77 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 39.4 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 4.77 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM.|||[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 12.5 uM.|||[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060. 13 FPDB16461 DRAMP30318|||DRAMP30319 FVPWFSKFlxRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 > 50 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 > 50 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 3.65 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 3.13 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 1 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 6.21 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 8.55 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16462 DRAMP30320 FVPWFSKFlKRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 2.49 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 1 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.88 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 = 40.69 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 4.39 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 2.9 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]About 20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16463 DRAMP30321 FVPWFSKFlkRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 3.53 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 2.8 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 4.63 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 = 40.64 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 5.39 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 8.29 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A Human RBC (7(±4)% hemolysis at 50 uM)|||[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16464 DRAMP30322 FVPWFSKFlWRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 3.01 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 0.77 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.88 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 0.91 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 0.96 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A Human RBC (37(±1)% hemolysis at 50 uM)|||[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16465 DRAMP30323 FVPWFSKFlwRIL Antibacterial||Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 1.86 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 0.58 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 4.07 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 = 41.18 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 0.92 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 5.1 uM Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]<40% hemolysis against human erythrocytes at concentrations equal or above 25 uM. 28863356, 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB16549 DRAMP30326 FVPWFSKFlXRILC Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 6.4 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 3.18 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 39.1 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 5.55 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A N/A 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060. 14 FPDB16550 CHOL-C-|||DRAMP30328 CFVPWFSKFlXRIL Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 0.89 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 0.76 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 22.3 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 2.55 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A N/A 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060. 14 FPDB16587 DRAMP30327 FVPWFSKFlXRILGGC Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 9.54 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 12.12 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 40.89 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 21.12 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A N/A 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060. 16 FPDB16588 CHOL-CGG-|||DRAMP30329 CGGFVPWFSKFlXRIL Antifungal||Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 2.32 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 1.02 uM||Anti-Measles virus :inhibition of MeV replication in VERO/hSLAM cells, activity value is IC50 = 28.88 uM||Anti-VR-1894):inhibition of replication in MDKC cells, activity value is IC50 = 6.02 uM||Antimicrobial||Antiviral Synthetic construct|||Synthetic construct(derived from Temporin-L) N/A N/A 35216177|||Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060. 16 FPDB16794 TPA_exp: DEFB103-like protein QKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCR Antibacterial||Antifungal||Antiviral||Antiviral ; Mycobacteria Papio anubis [Olive baboon]|||Synthetic construct N/A N/A N/A 36 FPDB16828 Lingual antimicrobial peptide|||DRAMP02824 VRNSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK Antibacterial||Antifungal||Escherichia coli||Staphylococcus aureus||Streptococcus pyogenes||Candida albicans||Rinderpest Virus (RPV) and Newcastle Disease Virus (NDV)||Antimicrobial||Antiviral Bos taurus [Bovine]|||Bubalus bubalis (Domestic water buffalo)|||Holotrichia diomphalia (Korean black chafer)|||Bubalus bubalis (Domestic water buffalo) Bridge No hemolysis information or data found in the reference(s) presented in this entry 7886453|||Biol. Pharm. Bull. 1995; 18:1049-1052.|||Altern Lab Anim. 2008 Sep;36(4):429-440. 40 FPDB16891 DRAMP31250 KPPSKPNNDFHFEVFN Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 16 FPDB16892 DRAMP31251 KQRQNKPPSKPNNDFHFEVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 29 FPDB16893 DRAMP31252 KPPSKPNNDFHFEVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16894 DRAMP31253 KPNNDFHFEVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 20 FPDB16895 DRAMP31254 DFHFEVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 16 FPDB16896 DRAMP31255 EVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 12 FPDB16897 DRAMP31256 FVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 8 FPDB16898 DRAMP31257 KQRQNKPPSKPNNDFHFEVFNFVPB Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 25 FPDB16899 DRAMP31258 KPPSKPNNDFHFEVFNFVPBSIAG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16900 DRAMP31259 KPPSKPNNDFHFEVFNFVPBSABG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16901 DRAMP31260 KPPSKPNNDFHFEVFNFVPBAIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16902 DRAMP31261 KPPSKPNNDFHFEVFNFVPASIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16903 DRAMP31262 KPPSKPNNDFHFEVFNFVABSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16904 DRAMP31263 KPPSKPNNDFHFEVFNFAPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16905 DRAMP31264 KPPSKPNNDFHFEVFNAVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16906 DRAMP31265 KPPSKPNNDFHFEVFAFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16907 DRAMP31266 KPPSKPNNDFHFEVANFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16908 DRAMP31267 KPPSKPNNDFHFEAFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16909 DRAMP31268 KPPSKPNNDFHFAVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16910 DRAMP31269 KPPSKPNNDFHAEVFNFVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 24 FPDB16911 DRAMP31270 KQRQNKPPSKPNNDFHFEVANAVPBSIBG Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 29 FPDB16912 DRAMP31271 DTRACDVIALLCHLNT Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2007 Feb;81(4):2047-55. 16 FPDB16913 DRAMP31272 CDVIALLCHLNT Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2007 Feb;81(4):2047-55. 12 FPDB16914 DRAMP31273 CDVIALLACHLNT Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2007 Feb;81(4):2047-55. 13 FPDB16915 DRAMP31274 CDVIALLCHLNTPSF Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2007 Feb;81(4):2047-55. 15 FPDB16916 DRAMP31275 CDVIALLCHLNTPSFNTTHYRESWY Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2007 Feb;81(4):2047-55. 25 FPDB16917 DRAMP31276 SSCNMGWDTPAAnti-CCVWFPYWV Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2009 Nov;83(22):11902-13. 24 FPDB16918 DRAMP31277 MAVGLVLCDWWLGEYLLEA Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2009 Nov;83(22):11902-13. 19 FPDB16919 DRAMP31278 PVLQPALSLSCGPEPLLLSC Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2009 Nov;83(22):11902-13. 20 FPDB16920 DRAMP31279 IEVTFVNRRGDGAELWYLSA Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2009 Nov;83(22):11902-13. 20 FPDB16921 DRAMP31280|||HCV gp|||DRAMP31280 SFAIKWEYVLLLFLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[90-100% Inhibition = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 15 FPDB16922 DRAMP31281|||HCV gp|||DRAMP31281 FAIKWEYVLLLFLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[90-100% Inhibition = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 14 FPDB16923 DRAMP31282|||D-HCV gp|||DRAMP31282 AIKWEYVLLLFLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[90-100% Inhibition = 50 uM]||Hepatitis C virus (HCV) PsV[IC50 E = 0.3+-0.1 uM]||Hepatitis C virus (HCV) PsV[IC50 E = 6.7+-2.8 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 13 FPDB16924 DRAMP31283|||HCV gp|||DRAMP31283 IKWEYVLLLFLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[80-90% Inhibition = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 12 FPDB16925 DRAMP31284|||CAMPSQ23926|||DRAMP31284 KWEYVLLLFLL Antimicrobial||Antiviral Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||20156485|||Antiviral Res. 2010 May;86(2):172-9. 11 FPDB16926 DRAMP31285|||CAMPSQ23927|||DRAMP31285 WEYVLLLFLL Antimicrobial||Antiviral Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||20156485|||Antiviral Res. 2010 May;86(2):172-9. 10 FPDB16927 DRAMP31286|||HCV gp|||DRAMP31286 VSFAIKWEYVLLLFL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[60-70% Inhibition = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 15 FPDB16928 DRAMP31287|||HCV gp|||DRAMP31287 VSFAIKWEYVLLLF Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 14 FPDB16929 DRAMP31288|||HCV gp|||DRAMP31288 VSFAIKWEYVLLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 13 FPDB16930 DRAMP31289|||HCV gp|||DRAMP31289 VSFAIKWEYVLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[40-50% Inhibition = 50 uM] Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 12 FPDB16931 DRAMP31290|||CAMPSQ23932|||DRAMP31290 VSFAIKWEYVL Antimicrobial||Antiviral Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||20156485|||Antiviral Res. 2010 May;86(2):172-9. 11 FPDB16932 DRAMP31291|||HCV gp|||DRAMP31291 VSFAIKWEYVLLLFLL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[70-80% Inhibition = 50 uM]||Hepatitis C virus (HCV) PsV[IC50 I = 0.3+-0.4 uM]||Hepatitis C virus (HCV) PsV[IC90 I = 14+-12 uM]||Hepatitis C virus (HCV) PsV[IC50 E = 0.3 uM]||Vesicular Stomatitis Virus (VSV) PsV||HIV PsV Synthetic construct(derived from HCV envelope protein)|||Synthetic construct|||Synthetic construct(derived from HCV envelope protein) N/A N/A Antiviral Res. 2010 May;86(2):172-9.|||https://pubmed.ncbi.nlm.nih.gov/20156485|||Antiviral Res. 2010 May;86(2):172-9. 16 FPDB16933 DRAMP31292|||DN57opt|||DRAMP31292 RWMVWRHWFHRLRLPYNPGKNKQNQQWP Antimicrobial||Antiviral||Antiviral ; DENV-2[IC50 E = 8+-1 uM]||DENV-2[90-100% Inhibition = 20 uM] Synthetic construct N/A N/A PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721.|||https://pubmed.ncbi.nlm.nih.gov/20582308|||PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. 28 FPDB16934 DRAMP31293|||DN81opt|||DRAMP31293 RQMRAWGQDYQHGGMGYSC Antimicrobial||Antiviral||Antiviral ; DENV-2[IC50 E = 36+-6 uM]||DENV-2[50-60% Inhibition = 50 uM] Synthetic construct N/A N/A PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721.|||20582308|||PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. 19 FPDB16935 DRAMP31294|||1OAN1|||DRAMP31294 FWFTLIKTQAKQPARYRRFC Antimicrobial||Antiviral||Antiviral ; DENV-2[IC50 E = 7+-4 uM]||DENV-2[90-100% Inhibition = 50 uM] Synthetic construct N/A Monkey kidney epithelial cells LLC-MK2 (- at NA PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721.|||20582308|||PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. 20 FPDB16936 DRAMP31295|||GBV-A1|||DRAMP31295 LLDCWVRLGRYLLRRLKT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 10 uM]||Hepatitis C virus (HCV)[80-90% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16937 DRAMP31296|||GBV-A2|||DRAMP31296 LLDCWVRLGRYLLRRLKTPFTRL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 15 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 23 FPDB16938 DRAMP31297|||GBV-A3|||DRAMP31297 LLDCWVRLGRYLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >20 uM]||Hepatitis C virus (HCV) JFH-1[0-10% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 21 FPDB16939 DRAMP31298|||GBV-A4|||DRAMP31298 LLDCWVRLGRYLLRRLKTP Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 3 uM]||Hepatitis C virus (HCV) JFH-1[90-100% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 19 FPDB16940 DRAMP31299|||GBV-A5|||DRAMP31299 LLDCWVRLGRYLLRRLK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 5 uM]||Hepatitis C virus (HCV) JFH-1[90-100% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||https://pubmed.ncbi.nlm.nih.gov/23175359|||J Virol. 2013 Feb;87(3):1649-57. 17 FPDB16941 DRAMP31300|||GBV-A6|||DRAMP31300 LDCWVRLGRYLLRRLKTPFTRL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >20 uM]||Hepatitis C virus (HCV) JFH-1[0-10% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 22 FPDB16942 DRAMP31301|||GBV-A7|||DRAMP31301 CWVRLGRYLLRRLKTPFTRL Antimicrobial||Antiviral||Anti-Hepatitis C virus JFH-1, activity value is IC50 = 12 uM Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 20 FPDB16943 DRAMP31302|||GBV-A8|||DRAMP31302 LDCWVRLGRYLLRRLKTP Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 4 uM]||Hepatitis C virus (HCV) JFH-1[90-100% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16944 DRAMP31303|||GBV-A9|||DRAMP31303 DCWVRLGRYLLRRLKTPF Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 12 uM]||Hepatitis C virus (HCV) JFH-1[IC90 I = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16945 DRAMP31304|||GBV-A10|||DRAMP31304 CWVRLGRYLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 2 uM]||Hepatitis C virus (HCV) JFH-1[90-100% Inhibition = 20 uM]||Hepatitis C virus (HCV) PsV[IC50 E = 2 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16946 DRAMP31305|||GBV-A11|||DRAMP31305 WVRLGRYLLRRLKTPFTR Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 12 uM]||Hepatitis C virus (HCV) JFH-1[50-60% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16947 DRAMP31306|||GBV-A12|||DRAMP31306 VRLGRYLLRRLKTPFTRL Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >20 uM]||Hepatitis C virus (HCV) JFH-1[0-10% Inhibition = 20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16948 DRAMP31307|||GBV-A10|||DRAMP31307 CWVRLGRYKLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16949 DRAMP31308|||GBV-A10|||DRAMP31308 CWVRLGRYSLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 18 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16950 DRAMP31309|||GBV-A10|||DRAMP31309 CWVRLGRYALRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 2 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16951 DRAMP31310|||GBV-A10|||DRAMP31310 CWVRLGRYVLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 16 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16952 DRAMP31311|||GBV-A10|||DRAMP31311 CWVRLARYLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 2.5 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16953 DRAMP31312|||GBV-A10|||DRAMP31312 CWVRLVRYLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 1.25 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16954 DRAMP31313|||GBV-A10|||DRAMP31313 CWVRLLRYLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 1.25 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||CWVRLLRYLLRRLKTPFT 18 FPDB16955 DRAMP31314|||GBV-A10|||DRAMP31314 CWVRLLRYLLRRLKTLFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 1.25 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16956 DRAMP31315|||GBV-A10|||DRAMP31315 CWVRLGRYLLRRLKTLFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 0.16 uM]||Hepatitis C virus (HCV) JFH-1[IC50 E = 0.1 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 E >1 uM]||Human hepatocellular carcinoma Huh-7.5.1 cells[50% Cell death = 80 uM]||Human hepatocellular carcinoma HepG2[50% Cell death = 85 uM]||Human cervical carcinoma HeLa[50% Cell death = 45 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16957 DRAMP31316|||GBV-A10|||DRAMP31316 CWVRLGRYILRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 10 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16958 DRAMP31317|||GBV-A10|||DRAMP31317 CWVRLGRYILRRIKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E = 0.63 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16959 DRAMP31318|||GBV-A10|||DRAMP31318 CWVRIGRYILRRIKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16960 DRAMP31319|||GBV-A10|||DRAMP31319 KWVRLGRKLLRRLKKPFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16961 DRAMP31320 KWVRLGRKLLRRLKKPFT Antimicrobial||Antiviral Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16962 DRAMP31321 CWVRLGRKLLRRLKKPFT Antimicrobial||Antiviral Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16963 DRAMP31322|||GBV-A10|||DRAMP31322 CWVRLGRKLLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16964 DRAMP31323 EWVRLGRELLRRLKEPFT Antimicrobial||Antiviral Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16965 DRAMP31324|||GBV-A10|||DRAMP31324 EWVRLGRELLRRLKEPFE Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16966 DRAMP31325 CWVRLGRELLRRLKEPFT Antimicrobial||Antiviral Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16967 DRAMP31326|||GBV-A10|||DRAMP31326 CWVRLGRELLRRLKTPFT Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >20 uM] Synthetic construct(derived from GBVA non-structutal protein 5A)|||Synthetic construct|||Synthetic construct(derived from GBVA non-structutal protein 5A) N/A N/A J Virol. 2013 Feb;87(3):1649-57.|||23175359|||J Virol. 2013 Feb;87(3):1649-57. 18 FPDB16968 DRAMP31327 IPESSELTLQELLGEERR Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 18 FPDB16969 DRAMP31328 YKFACPECPKRFMRSDHLTLHILLHENKK Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 29 FPDB16970 DRAMP31329 YKFACPECPKRFMRSDHLSKHITLHELLGEERR Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 33 FPDB16971 DRAMP31330 ALQELLGQWLKDGGPSSGRPPPS Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 23 FPDB16972 DRAMP31331 ALQELLGEYIQWLKDGGPSSGRPPPS Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 26 FPDB16973 DRAMP31332 YLQELLGE Antimicrobial||Antiviral Synthetic construct(derived from E6-associated protein (E6AP)) N/A N/A Biochemistry. 2004 Jun 15;43(23):7421-31. 8 FPDB16974 DRAMP31333 FLKGIVGMLGKLF Antimicrobial||Antiviral Synthetic construct(derived from Temporin-SHa) N/A N/A Viruses. 2019 Jan 18;11(1):77. 13 FPDB16975 DRAMP31334 LLGDLLRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Antimicrobial||Antiviral Synthetic construct(derived from human cathelicidin LL-37) N/A N/A Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 37 FPDB16976 DRAMP31335|||LL-37|||DRAMP31335 LLGDLLRKSKEKIGKEFKRIVQR Antimicrobial||Antiviral||Antiviral ; HIV[IC50 REP >35.4 uM] Synthetic construct(derived from human cathelicidin LL-37)|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37) N/A CEM-SS cells (50% cell death at >35.4 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 23 FPDB16978 DRAMP31338|||DRAMP31337|||DRAMP31338 GFKRIVQRiKDFLRNLV Antimicrobial||Antiviral Synthetic construct(derived from human cathelicidin LL-37) N/A N/A Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 17 FPDB16979 DRAMP31339 GFKRIVQRiKDFlRNLV Antimicrobial||Antiviral Synthetic construct(derived from human cathelicidin LL-37) N/A N/A Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 17 FPDB16980 DRAMP31341|||LL-37|||DRAMP31341 GIKEXKRIVQRIKDFLRNLV Antimicrobial||Antiviral||Antiviral ; HIV[IC50 REP >40.6 uM] Synthetic construct(derived from human cathelicidin LL-37)|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37) N/A CEM-SS cells (50% cell death at 7.3 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 20 FPDB16981 DRAMP31347|||Cathelicidin-6|||DRAMP31347 GRFKRXRKKXKKLFKKIS Antimicrobial||Antiviral||Antiviral ; HIV[IC50 REP = 0.68 uM] Synthetic construct(derived from BMAP-27)|||Synthetic construct|||Synthetic construct(derived from BMAP-27) N/A CEM-SS cells (50% cell death at 10.2 uM ntimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||https://pubmed.ncbi.nlm.nih.gov/18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 18 FPDB16982 DRAMP31348|||Cathelicidin-6|||DRAMP31348 GRFKRIRKKLKKLFKKIS Antimicrobial||Antiviral||Antiviral ; HIV[IC50 REP >44 uM] Synthetic construct(derived from BMAP-27)|||Synthetic construct|||Synthetic construct(derived from BMAP-27) N/A CEM-SS cells (50% cell death at 2.79 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||https://pubmed.ncbi.nlm.nih.gov/18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 18 FPDB16983 DRAMP31349|||Cathelicidin-6|||DRAMP31349 GRFKRFRKKFKKLFK Antimicrobial||Antiviral||Antiviral ; HIV[IC50 REP >49.6 uM] Synthetic construct(derived from BMAP-27)|||Synthetic construct|||Synthetic construct(derived from BMAP-27) N/A CEM-SS cells (50% cell death at >49.6 uM Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||https://pubmed.ncbi.nlm.nih.gov/18591279|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. 15 FPDB16984 DRAMP31358 RRQRPRLSHKGPMPF Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2000 Dec;74(24):11972-6. 15 FPDB16985 DRAMP31359 RRKFRRQRPRLSHKGPMPF Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2000 Dec;74(24):11972-6. 19 FPDB16986 DRAMP31360 RRQRPRLSHKGPM Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2000 Dec;74(24):11972-6. 13 FPDB16987 DRAMP31361 RRQRPRLSHKGPX Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2000 Dec;74(24):11972-6. 13 FPDB16988 DRAMP31362 RRQRPRLSHKGP Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2000 Dec;74(24):11972-6. 12 FPDB16989 DRAMP31363|||CAMPSQ21822|||DRAMP31363 RRKKRRQRRR Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Pept. 2012;2012:349427.|||22319541|||Int J Pept. 2012;2012:349427. 10 FPDB16990 DRAMP31364|||CAMPSQ21823|||DRAMP31364 GRKKRRRRRR Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Pept. 2012;2012:349427.|||22319541|||Int J Pept. 2012;2012:349427. 10 FPDB16991 DRAMP31365|||CAMPSQ21824|||DRAMP31365 RRKKRRRRRR Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Pept. 2012;2012:349427.|||22319541|||Int J Pept. 2012;2012:349427. 10 FPDB16992 DRAMP31366|||Undefined|||DRAMP31366 KGEAMHGQVDCSPGIWQLDC Antimicrobial||Antiviral||Antiviral ; HIV-1[0-10% RT activity = 30 uM]||HIV-1[IC50 RT RDDP = 4 uM]||HIV-1[IC50 RT DDDP = 6.8 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 20 FPDB16993 DRAMP31367|||Undefined|||DRAMP31367 ASCDKCQLKGEAMHG Antimicrobial||Antiviral||Antiviral ; HIV-1[90-100% RT activity = 30 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16994 DRAMP31368|||Undefined|||DRAMP31368 KCQLKGEAMHGQVDC Antimicrobial||Antiviral||Antiviral ; HIV-1[60-70% RT activity = 30 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16995 DRAMP31369|||Undefined|||DRAMP31369 KGEAMHGQVDCSPGI Antimicrobial||Antiviral||Antiviral ; HIV-1[90-100% RT activity = 30 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16996 DRAMP31370|||Undefined|||DRAMP31370 MHGQVDCSPGIWQLD Antimicrobial||Antiviral||Antiviral ; HIV-1[80-90% RT activity = 30 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16997 DRAMP31371|||Undefined|||DRAMP31371 VDCSPGIWQLDCTHL Antimicrobial||Antiviral||Antiviral ; HIV-1[60-70% RT activity = 30 uM] Synthetic construct N/A N/A Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16998 DRAMP31372|||Undefined|||DRAMP31372 PGIWQLDCTHLEGKI Antimicrobial||Antiviral||Antiviral ; HIV-1[60-70% RT activity = 30 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=13.84 uM. Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.|||https://pubmed.ncbi.nlm.nih.gov/17257575|||Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. 15 FPDB16999 DRAMP31373|||NS5A-derived peptide C5A|||DRAMP31373 SWLRDLWDWICEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.40+-0.13 uM]||HIV[IC50 E >5 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=13.84 uM.|||Human erythrocytes (0% Hemolysis at 13.84 uM|||[Ref.21801309]Human erythrocytes:MHC=13.84 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||https://pubmed.ncbi.nlm.nih.gov/21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17000 DRAMP31374|||NS5A-derived peptide C5A|||DRAMP31374 SWLRDIWDWLCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.20+-0.09 uM]||HIV[IC50 E = 1.84+-0.16 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=6.92 uM.|||Human erythrocytes (0% Hemolysis at 6.92 uM|||[Ref.21801309]Human erythrocytes:MHC=6.92 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||https://pubmed.ncbi.nlm.nih.gov/21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17001 DRAMP31375|||NS5A-derived peptide C5A|||DRAMP31375 SWLRDIWDWICELLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.20+-0.11 uM]||HIV[IC50 E = 2.76+-0.19 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=3.44 uM.|||Human erythrocytes (0% Hemolysis at 3.44 uM|||[Ref.21801309]Human erythrocytes:MHC=3.44 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17002 DRAMP31376|||NS5A-derived peptide C5A|||DRAMP31376 SWLRDLWDWLCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.40+-0.15 uM]||HIV[IC50 E >5 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=6.92 uM.|||Human erythrocytes (0% Hemolysis at 6.92 uM|||[Ref.21801309]Human erythrocytes:MHC=6.92 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17003 DRAMP31377|||NS5A-derived peptide C5A|||DRAMP31377 SWLRDLWDWICELLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 0.78+-0.07 uM]||HIV[IC50 E = 3.31+-0.31 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=53.75 uM.|||Human erythrocytes (0% Hemolysis at 53.75 uM|||[Ref.21801309]Human erythrocytes:MHC=53.75 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17004 DRAMP31378|||NS5A-derived peptide C5A|||DRAMP31378 SWLRDIWDWLCELLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 0.82+-0.1 uM]||HIV[IC50 E = 2.58+-0.22 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=3.44 uM.|||Human erythrocytes (0% Hemolysis at 3.44 uM|||[Ref.21801309]Human erythrocytes:MHC=3.44 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17005 DRAMP31379|||NS5A-derived peptide C5A|||DRAMP31379 SWLRDLWDWLCELLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.20+-0.14 uM]||HIV[IC50 E = 0.59+-0.03 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=107.5 uM.|||Human erythrocytes (0% Hemolysis at 107.5 uM|||[Ref.21801309]Human erythrocytes:MHC=107.5 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17006 DRAMP31380|||NS5A-derived peptide C5A|||DRAMP31380 SWLRDIWDWVCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 1.40+-0.17 uM]||HIV[IC50 E = 1.86+-0.25 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=13.93 uM.|||Human erythrocytes (0% Hemolysis at 13.93 uM|||[Ref.21801309]Human erythrocytes:MHC=13.93 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17007 DRAMP31381|||NS5A-derived peptide C5A|||DRAMP31381 SWLRDIWDWACEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 4.00+-0.36 uM]||HIV[IC50 E = 2.21+-0.28 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=14.1 uM.|||Human erythrocytes (0% Hemolysis at 14.1 uM|||[Ref.21801309]Human erythrocytes:MHC=14.1 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17008 DRAMP31382|||NS5A-derived peptide C5A|||DRAMP31382 SWLRDIWDWGCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP >5 uM]||HIV[IC50 E = 3.50+-0.36 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=28.38 uM.|||Human erythrocytes (0% Hemolysis at 28.38 uM|||[Ref.21801309]Human erythrocytes:MHC=28.38 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17009 DRAMP31383|||NS5A-derived peptide C5A|||DRAMP31383 SWLRDIWDWSCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP >5 uM]||HIV[IC50 E >5 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=28 uM.|||Human erythrocytes (0% Hemolysis at 28 uM|||[Ref.21801309]Human erythrocytes:MHC=28 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17010 DRAMP31384|||NS5A-derived peptide C5A|||DRAMP31384 SWLRDIWDWECEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP >5 uM]||HIV[IC50 E >5 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=214.91 uM.|||Human erythrocytes (0% Hemolysis at 214.91 uM|||[Ref.21801309]Human erythrocytes:MHC=214.91 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17011 DRAMP31385|||NS5A-derived peptide C5A|||DRAMP31385 SWLRDIWDWKCEVLSDFK Antimicrobial||Antiviral||Antiviral ; Hepatitis C virus (HCV)[IC50 REP >5 uM]||HIV[IC50 E >5 uM] Synthetic construct N/A [Ref.21801309]Human erythrocytes:MHC=214.81 uM.|||Human erythrocytes (0% Hemolysis at 214.81 uM|||[Ref.21801309]Human erythrocytes:MHC=214.81 uM. Chem Biol Drug Des. 2011 Nov;78(5):835-43.|||21801309|||Chem Biol Drug Des. 2011 Nov;78(5):835-43. 18 FPDB17012 DRAMP31386|||Rev|||DRAMP31386 TRQARRNRRRRWRERQR Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP = 1.7+-0.25 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||https://pubmed.ncbi.nlm.nih.gov/20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 17 FPDB17013 DRAMP31387|||Rev|||DRAMP31387 TRQARRNRRRRWRERQRAAAAC Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP = 0.35+-0.07 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 22 FPDB17014 DRAMP31388|||Rev|||DRAMP31388 TRQARRNRRRRWRERQRAAAACYGRKKRRQRRR Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP = 0.37+-0.09 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||https://pubmed.ncbi.nlm.nih.gov/20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 33 FPDB17015 DRAMP31389|||Rex|||DRAMP31389 MPKTRRRPRRSQRKRPPTPWP Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP >10 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 21 FPDB17016 DRAMP31390|||Rex|||DRAMP31390 MPKTRRRPRRSQRKRPPTPWPYGRKKRRQRRR Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP = 2.5+-0.76 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||https://pubmed.ncbi.nlm.nih.gov/20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 32 FPDB17017 DRAMP31391|||RCG-P2G4|||DRAMP31391 RPRGRRGSRPSGAERRRRRAAAA Antimicrobial||Antiviral||Antiviral ; HIV-1 IIIB[IC50 REP = 2.2+-0.51 uM]||HIV-1 BaL[IC50 REP >10 uM] Synthetic construct N/A N/A Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.|||20580677|||Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. 23 FPDB17018 DRAMP31392|||CCR5 ECL2|||DRAMP31392 RSQKEGLHYTCSSHFPYSQYQFWK Antimicrobial||Antiviral||Antiviral ; HIV-1 YU2[IC50 E = 136+-49 uM]||HIV-1 BaL26[IC50 E = 138+-36 uM]||HIV-1 HxB2[IC50 E = 89+-31 uM]||HIV-1 NL4-3[IC50 E = 103+-37 uM] Synthetic construct N/A N/A J Biol Chem. 2012 Apr 27;287(18):15076-86.|||22403408|||J Biol Chem. 2012 Apr 27;287(18):15076-86. 24 FPDB17019 DRAMP31393|||CCR5 ECL2|||DRAMP31393 CSSHFPYSQYQFWK Antimicrobial||Antiviral||Antiviral ; HIV-1 YU2[IC50 E = 28+-7 uM]||HIV-1 BaL26[IC50 E = 65+-3 uM]||HIV-1 HxB2[IC50 E = 54+-2 uM]||HIV-1 NL4-3[IC50 E = 53+-2 uM] Synthetic construct N/A N/A J Biol Chem. 2012 Apr 27;287(18):15076-86.|||https://pubmed.ncbi.nlm.nih.gov/22403408|||J Biol Chem. 2012 Apr 27;287(18):15076-86. 14 FPDB17020 DRAMP31394|||CCR5 ECL2|||DRAMP31394 QKEGLHYTCSSHFPYSQYQF Antimicrobial||Antiviral||Antiviral ; HIV-1 YU2[IC50 E = 237+-31 uM]||HIV-1 BaL26[IC50 E = 612+-21 uM]||HIV-1 HxB2[IC50 E = 374+-28 uM]||HIV-1 NL4-3[IC50 E = 600+-24 uM] Synthetic construct N/A N/A J Biol Chem. 2012 Apr 27;287(18):15076-86.|||22403408|||J Biol Chem. 2012 Apr 27;287(18):15076-86. 20 FPDB17021 DRAMP31395 RRWYRWW Antimicrobial||Antiviral Synthetic construct N/A N/A FEBS J. 2007 Sep;274(17):4511-25. 7 FPDB17022 DRAMP31405 HCKFWW Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17023 DRAMP31406 HCKFWI Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17024 DRAMP31407 HCKFWF Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17025 DRAMP31408 HCKFAW Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17026 DRAMP31409 HCKFWA Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17027 DRAMP31410 HCKAWW Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17028 DRAMP31411 ACKFWW Antimicrobial||Antiviral Synthetic construct N/A N/A Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. 6 FPDB17029 DRAMP31412|||AP03045|||DRAMP31412 GWINEKKMQQKIDEKIGKNIIGGMAKAVIHKMAKNEFQCVANVDTLGNCKKHCAKTTGEKGYCHGTKCKCGIELSY Antimicrobial||Antiviral Scorpio maurus palmatu|||venom, Scorpio maurus palmatu, Africa, Asia|||Scorpio maurus palmatu Bridge [Ref.32435168]human red blood cells:HC50>10 ug/ml. Int J Pept Res Ther. 2020;26(2):811-821.|||Virol Sin. 2018 Dec 19. 33: 545–556. doi: 10.1007/s12250-018-0068-4. PubMed|||Int J Pept Res Ther. 2020;26(2):811-821. 76 FPDB17030 DRAMP31414 LLMVNEATRFQTVSGFV Antimicrobial||Antiviral Synthetic construct N/A [Ref.35896605]BRIP is not hemolytic at 0.5 uM and slightly hemolytic at 50 uM. Sci Rep. 2022 Jul 27;12(1):12802 17 FPDB17031 DRAMP31415 KFFRKKSVKK Antimicrobial||Antiviral Bungarus fasciatus N/A N/A Peptides. 2019 Feb;112:14-22. 10 FPDB17032 DRAMP31417 MRRKVELFTYMRFD Antimicrobial||Antiviral Synthetic construct N/A N/A Virus Res. 2021 Oct 2;303:198456. 14 FPDB17033 DRAMP31418 RRKVELFTYMRFD Antimicrobial||Antiviral Synthetic construct N/A N/A Virus Res. 2021 Oct 2;303:198456. 13 FPDB17034 DRAMP31419 RKVELFTYMRFD Antimicrobial||Antiviral Synthetic construct N/A N/A Virus Res. 2021 Oct 2;303:198456. 12 FPDB17035 DRAMP31420 QMRRKVELFTYMRF Antimicrobial||Antiviral Synthetic construct N/A N/A Virus Res. 2021 Oct 2;303:198456. 14 FPDB17036 DRAMP31422|||CAMPSQ11414|||DRAMP31422 KKVTMTCSAS Antimicrobial||Antiviral Synthetic construct N/A N/A Intervirology. 2018;61(4):166-173.|||30654366|||Intervirology. 2018;61(4):166-173. 10 FPDB17037 DRAMP31423|||K13000 ml|||DRAMP31423 KKLVAASQAALGL Antimicrobial||Antiviral||Antiviral ; Coxsackievirus B5 Synthetic construct N/A N/A Intervirology. 2018;61(4):166-173.|||https://pubmed.ncbi.nlm.nih.gov/30654366|||Intervirology. 2018;61(4):166-173. 13 FPDB17038 DRAMP31424|||D15R|||DRAMP31424 DSGEGDFLAEGGGVR Antimicrobial||Antiviral||Antiviral ; Coxsackievirus B5 Synthetic construct N/A N/A Intervirology. 2018;61(4):166-173.|||https://pubmed.ncbi.nlm.nih.gov/30654366|||Intervirology. 2018;61(4):166-173. 15 FPDB17039 DRAMP31425|||G17K|||DRAMP31425 GLEEELQFSLGSKINVK Antimicrobial||Antiviral||Antiviral ; Coxsackievirus B5 Synthetic construct N/A N/A Intervirology. 2018;61(4):166-173.|||https://pubmed.ncbi.nlm.nih.gov/30654366|||Intervirology. 2018;61(4):166-173. 17 FPDB17040 DRAMP31426|||S17K|||DRAMP31426 SEETKENEGFTVTAEGK Antimicrobial||Antiviral||Antiviral ; Adenovirus Synthetic construct N/A N/A Intervirology. 2018;61(4):166-173.|||https://pubmed.ncbi.nlm.nih.gov/30654366|||Intervirology. 2018;61(4):166-173. 17 FPDB17041 DRAMP31428 GKRKSGCA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17042 DRAMP31429 GKRKSGAA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17043 DRAMP31430|||DRAMP31432 GKRKSXCA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17044 DRAMP31431 GKRKSFCA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17045 DRAMP31433 GKRKSxCA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17046 DRAMP31434 GKRKSXAA Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17047 DRAMP31435|||DRAMP31439 GKRKSXAX Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17048 DRAMP31436|||DRAMP31440 GKRKSXAx Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17049 DRAMP31437 GKRKSXAF Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17050 DRAMP31438 GKRKSXAf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17051 DRAMP31441 GKRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17052 DRAMP31442 AKRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17053 DRAMP31443 aKRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17054 DRAMP31444 PKRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17055 DRAMP31445|||DRAMP31446|||DRAMP31447 pKRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17056 DRAMP31448 pRRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17057 DRAMP31449 rRRKSXSf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17058 DRAMP31450 rRRKSXSr Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17059 DRAMP31451|||DRAMP31453 rRRKSXXf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17060 DRAMP31452 rRRKAXXf Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17061 DRAMP31454 rRRKfXFx Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17062 DRAMP31455 rRRKxXFx Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590. 8 FPDB17063 DRAMP31456 CGGGGGSLTEINTELLDLEYEMKKLEEVVKKLEESYIDLKEL Antimicrobial||Antiviral Synthetic construct N/A N/A ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19799-19807. 42 FPDB17064 DRAMP31457 PWLKPGDLDL Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Med Sci. 2013 Apr 16;10(6):719-29. 10 FPDB17065 DRAMP31458 AGVKDGKLDF Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Med Sci. 2013 Apr 16;10(6):719-29. 10 FPDB17066 DRAMP31459 WLVFFVIFYFFR Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 12 FPDB17067 DRAMP31460 WLVFFVIAYFAR Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 12 FPDB17068 DRAMP31461 WLVFFVIFYFFRRRKK Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 16 FPDB17069 DRAMP31462 RRKKWLVFFVIFYFFR Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 16 FPDB17070 DRAMP31463 RRKKIFYFFR Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 10 FPDB17071 DRAMP31464 WLVFFVRRKK Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 10 FPDB17072 DRAMP31465 FFVIFYRRKK Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2012 May;93(Pt 5):980-986. 10 FPDB17073 DRAMP31466 GYRARPKFKAGKR Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Virol. 2004 Jul;73(3):474-80. 13 FPDB17074 DRAMP31467 TTTPAKRKKTKK Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Virol. 2004 Jul;73(3):474-80. 12 FPDB17075 DRAMP31468 MLRKRRKRL Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Virol. 2004 Jul;73(3):474-80. 9 FPDB17076 DRAMP31470|||Undefined|||DRAMP31470 GKKYRRFRWKFKFGKWFWFG Antimicrobial||Antiviral||Antiviral ; HIV-1 BaL[IC50 E = 22 ug/ml]||HIV-1 NL4-3[IC50 E = 10 ug/ml]||HSV-1[IC50 E = 1.8 ug/ml]||Hepatitis C virus (HCV)[IC50 E = 37 ug/ml] Synthetic construct N/A N/A J Infect Dis. 2012 Jun;205(11):1654-64.|||22457281|||J Infect Dis. 2012 Jun;205(11):1654-64. 20 FPDB17077 DRAMP31471 ATSSANSKA Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2012 May;94(2):179-83. 9 FPDB17078 DRAMP31472 SISNALNKLEESNRNLDKVNVKLT Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20. 24 FPDB17079 DRAMP31473 KQNAANILRLKESIAATNEAVAnti-HeV Antimicrobial||Antiviral Synthetic construct N/A N/A Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20. 28 FPDB17080 DRAMP31475 FKCRRWQWRMKKLGAPSITCVRRAFA Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2007 Sep;75(3):258-65. 26 FPDB17081 DRAMP31476|||LF C-lobe peptide 2|||DRAMP31476 AGDDQGLDKCVPNSKEK Antimicrobial||Antiviral||Antiviral ; Viral strain (A/Roma-ISS/2/08) Subtype (H1N1); Viral strain (A/Parma/24/09) Subtype (H1N1); Viral strain (A/Parma/05/06) Subtype (H3N2) Synthetic construct N/A N/A Pathog Glob Health. 2012 Mar;106(1):12-9.|||https://pubmed.ncbi.nlm.nih.gov/26492266,|||Pathog Glob Health. 2012 Mar;106(1):12-9. 17 FPDB17082 DRAMP31477|||CAMPSQ8828|||DRAMP31477 NGESSADWAKN Antimicrobial||Antiviral Synthetic construct N/A N/A Pathog Glob Health. 2012 Mar;106(1):12-9.|||26492266|||Pathog Glob Health. 2012 Mar;106(1):12-9. 11 FPDB17083 DRAMP31478 AVSKVLHLEGEVNKISALLSTNKAVVSLSNGAnti-VSVLTSKVLDLDNYIDKQLLPIVNK Antimicrobial||Antiviral Synthetic construct N/A N/A Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. 60 FPDB17084 DRAMP31479 NFYDPLVFPSDEFDASISQVNEKINQSLASIRKSDELLHNVNAGK Antimicrobial||Antiviral Synthetic construct N/A N/A Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. 45 FPDB17085 DRAMP31480 NKGCATCSIGAACLVDGPIPDFEIAGAtGLfGLWG Antimicrobial||Antiviral Bacillus subtilis N/A N/A J Appl Microbiol. 2014 Nov;117(5):1253-9. 35 FPDB17086 DRAMP31481|||CAMPSQ24027|||DRAMP31481 EF Antimicrobial||Antiviral Synthetic construct N/A Vero cells (0% Cytotoxicity at 500 uM Chem Biol Drug Des. 2014 Aug;84(2):148-57.|||24612829|||Chem Biol Drug Des. 2014 Aug;84(2):148-57. 2 FPDB17087 DRAMP31482 KEN Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2014 Aug;84(2):148-57. 3 FPDB17088 DRAMP31483 SVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPG Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2015 Nov;86(5):1093-104. 41 FPDB17089 DRAMP31484 GLLYFAIFFVAAWHIRGR Antimicrobial||Antiviral Synthetic construct N/A [Ref.26251517]<10% hemolysis even at 400 uM against human erythrocytes. J Biol Chem. 2015 Sep 18;290(38):23254-63. 18 FPDB17090 DRAMP31485 HGLLYFAIFFVAAWHIRGR Antimicrobial||Antiviral Synthetic construct N/A [Ref.26251517]<10% hemolysis even at 400 uM against human erythrocytes. J Biol Chem. 2015 Sep 18;290(38):23254-63. 19 FPDB17091 DRAMP31486 WPFCLLLMAL Antimicrobial||Antiviral Synthetic construct N/A [Ref.26251517]<10% hemolysis even at 400 uM against human erythrocytes. J Biol Chem. 2015 Sep 18;290(38):23254-63. 10 FPDB17092 DRAMP31487 LYGNEGCGWAGWLLSPRG Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2009 Jun;90(Pt 6):1319-1328. 18 FPDB17093 DRAMP31488 GWAGWLLSPRGSRPSWGP Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2009 Jun;90(Pt 6):1319-1328. 18 FPDB17094 DRAMP31489 GWAGWLLSPRGSRPS Antimicrobial||Antiviral Synthetic construct N/A N/A J Gen Virol. 2009 Jun;90(Pt 6):1319-1328. 15 FPDB17095 DRAMP31490 MDVNP Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 5 FPDB17096 DRAMP31491|||DRAMP30967|||DRAMP30967|||DRAMP31491 MDVNPTLLFL KVPAQNAIST TFPYT Antimicrobial||Antiviral||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.0018 Synthetic construct|||Synthetic construct(derived from INFV A polymerase (PB1))|||Synthetic construct(derived from INFV A polymerase (PB1))|||Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10.|||Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517.|||Antiviral Res. 2015 Jan;113:4-10. 25 FPDB17097 DRAMP31492 TLLFLKVPAQ NAISTTFPYT Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 20 FPDB17098 DRAMP31493 AQNAISTTFPYT Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 12 FPDB17099 DRAMP31494 Anti-MeVVQQTRMD KLTQGRQTYD Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 24 FPDB17100 DRAMP31495 LPVGGNEKKA KLANVVRKMM Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 20 FPDB17101 DRAMP31496 FNESTR Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 6 FPDB17102 DRAMP31497 FNESTRKKIE Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 10 FPDB17103 DRAMP31498 FNESTRKKIE KIRPLLVEGT Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 20 FPDB17104 DRAMP31499 KIRPLLVEGT Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 10 FPDB17105 DRAMP31500 MFNMLSTVLG Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 10 FPDB17106 DRAMP31501 IGVTVI Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 6 FPDB17107 DRAMP31502 IGVTVIKNNMI Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 11 FPDB17108 DRAMP31503|||DRAMP31504|||DRAMP31505|||DRAMP31506 TLLFLKVP Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 8 FPDB17109 DRAMP31507|||DRAMP31508|||DRAMP31509|||DRAMP31510 TLLFLKVPA Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 9 FPDB17110 DRAMP31511|||DRAMP31512|||DRAMP31513|||DRAMP31514 GDPPY Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 5 FPDB17111 DRAMP31515|||DRAMP31516|||DRAMP31517|||DRAMP31518 LLVEGT Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 6 FPDB17112 DRAMP31519|||DRAMP31520|||DRAMP31521|||DRAMP31522 KNNMINNDLG Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2015 Jan;113:4-10. 10 FPDB17113 DRAMP31523 LNLFKKTINGLISDSLVIR Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol. 2014 Aug;88(15):8556-64. 19 FPDB17114 DRAMP31524 GREERRQRRRC Antimicrobial||Antiviral Synthetic construct N/A N/A J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. 11 FPDB17115 DRAMP31525 NDSRGIDAEEELETKAELVITKLKTPLMRGKVVVGAAGA Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol Methods. 2014 Apr;199:11-6. 39 FPDB17116 DRAMP31526 NADIIKSLIRKTIINASKNTASLSILQHLYVLRS Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol Methods. 2014 Apr;199:11-6. 34 FPDB17117 DRAMP31527 LGNVNNSISNALDKLEESNSKLDKVNVKLTGTSAL Antimicrobial||Antiviral Synthetic construct N/A N/A J Virol Methods. 2014 Apr;199:11-6. 35 FPDB17118 DRAMP31528 TIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFV Antimicrobial||Antiviral Synthetic construct N/A N/A Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. 43 FPDB17119 DRAMP31529 AKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKN Antimicrobial||Antiviral Synthetic construct N/A N/A Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. 48 FPDB17120 DRAMP31530 LESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRE Antimicrobial||Antiviral Synthetic construct N/A N/A Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. 35 FPDB17121 DRAMP31531 FNVALDQVFESIENSQALVDQSNRILSSAEKGNTG Antimicrobial||Antiviral Synthetic construct N/A N/A Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. 35 FPDB17122 DRAMP31532 PEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTG Antimicrobial||Antiviral Synthetic construct N/A N/A Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. 39 FPDB17123 DRAMP31533 SWLVNRDWFHDLNLPWTGSSAGTWQ Antimicrobial||Antiviral Synthetic construct N/A N/A Vet Microbiol. 2020 Jun;245:108708. 25 FPDB17124 DRAMP31534 MVALGDTAWDFGSVGGVLTSIGKGIHQVFGSAFKSL Antimicrobial||Antiviral Synthetic construct N/A N/A Vet Microbiol. 2020 Jun;245:108708. 36 FPDB17125 DRAMP31535 RRRQRRKKRGYGFVNLLFLVVE Antimicrobial||Antiviral Synthetic construct N/A N/A Sci Rep. 2017 Jul 7;7(1):4875. 22 FPDB17126 DRAMP31537 DHVTPDIAYNPRTYM Antimicrobial||Antiviral Acacia catechu N/A N/A Viruses. 2020 Nov 6;12(11):1267. 15 FPDB17127 DRAMP31538 DHVTPDIAYNPWAYF Antimicrobial||Antiviral Acacia catechu N/A N/A Viruses. 2020 Nov 6;12(11):1267. 15 FPDB17128 DRAMP31539 DHVTPDIAYNP Antimicrobial||Antiviral Acacia catechu N/A N/A Viruses. 2020 Nov 6;12(11):1267. 11 FPDB17129 DRAMP31540|||DRAMP31541 KKR Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem. 2022 Mar 1;57:116631. 3 FPDB17130 DRAMP31542|||DRAMP31543 GKR Antimicrobial||Antiviral Synthetic construct N/A N/A Bioorg Med Chem. 2022 Mar 1;57:116631. 3 FPDB17131 DRAMP31545 GIGDPVTCLKSGAICAnti-HPVFCPRRYKQIGTCGLPGTKCCKKP Antimicrobial||Antiviral Homo sapiens N/A N/A J Virol. 2005 Nov;79(22):14318-29. 45 FPDB17132 DRAMP31548 AKKAAKKAKKAAKKIEKAAKK Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17133 DRAMP31549 AKKAKKKAKKAAKKIKKKAKK Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17134 DRAMP31550 ARRARRRARRAARRARRGARR Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17135 DRAMP31551 ARRARRRARRAARRARRWARR Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17136 DRAMP31552 KAAKKAAKWAKKAAKWAKKAA Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17137 DRAMP31553 KYAKKAAKYAKKAAKYAKKAA Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17138 DRAMP31554 AAKAWKKAKAWKKAKWWKKAA Antimicrobial||Antiviral Synthetic construct N/A N/A Chem Biol Drug Des. 2006 Jul;68(1):58-66. 21 FPDB17139 DRAMP31555 WNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2007 Mar 30;282(13):9612-9620. 36 FPDB17140 DRAMP31556 REINNYTSLIHSLIEESQNQQEKNEQELLELDKWAS Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2007 Mar 30;282(13):9612-9620. 36 FPDB17141 DRAMP31557 HSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW Antimicrobial||Antiviral Synthetic construct N/A N/A J Biol Chem. 2007 Mar 30;282(13):9612-9620. 36 FPDB17142 DRAMP31558 STSQKAnti-SIVAYTM Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2006 Feb;69(2):70-6. 16 FPDB17143 DRAMP31559 GFLYVYKGYQPI Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2006 Feb;69(2):70-6. 12 FPDB17144 DRAMP31560 FYTTTGIGYQPY Antimicrobial||Antiviral Synthetic construct N/A N/A Antiviral Res. 2006 Feb;69(2):70-6. 12 FPDB17145 DRAMP31561 IHAEIKNSLKIDNLDVNRCIEAL Antimicrobial||Antiviral Synthetic construct N/A N/A FEBS Lett. 2008 Apr 30;582(10):1425-30. 23 FPDB17146 DRAMP31562 IEEQAKTFLDKFQAnti-HeVEEIYWQS Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 27 FPDB17147 DRAMP31563 QDKHEEDYQMYNKGDKED Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 18 FPDB17148 DRAMP31564 DKFNHEAEDLFYQSSLASWNYNT Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 23 FPDB17149 DRAMP31565 IDENARSYIDKFQHDAEEMWYQ Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 22 FPDB17150 DRAMP31566 IYALLENAEDYNLVN Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 15 FPDB17151 DRAMP31567 SRDKHEEHEKENDRGQ Antimicrobial||Antiviral Synthetic construct N/A N/A J Med Chem. 2022 Feb 24;65(4):2836-2847. 16 FPDB17300 DRAMP31984|||CAMPSQ24148 XXXVXAaXXXX Antimicrobial||Anticancer||Antiviral Tolypocladium inflatum N/A Vero E6 cells (<10% Killing at 5 uM, Vero E6 cells (50% Cytotoxicity at >20 uM Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.|||22046132 11 FPDB17368 DRAMP32156|||LP-83 WEQKIEELLKKAEEQQKKNEEELKKLEKC Antimicrobial||Anticancer||Antiviral ; HIV-1 NL4-3[IC50 I = 0 uM]||HIV-1 JRCSF[IC50 I = 0.000005 uM]||HIV-1 PsV[IC50 I = 0.000003 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.000002 uM]||HIV-1 NL4-3[IC50 I = 0.000002 uM]||HIV-1 NL4-3[IC50 I = 0.000002-0.000041 uM]||HIV-2 ROD[IC50 I = 0.000032 uM]||HIV-2[IC50 I = 0.00002 uM]||HIV-1[IC50 F = 0.000009 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 19.65 uM]||Human T-cell leukemia C8166[50-60% Cytotoxicity = 19.19 uM]||Human histiocytic lymphoma U-937[50-60% Cytotoxicity = 9.97 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 12.34 uM]||Simian immunodeficiency virus (SIV)[IC50 I = 0.000004-0.000006 uM] Synthetic|||Synthetic construct N/A Human PBMC (50% Cytotoxicity at 40.27 uM J Virol. 2019 May 15;93(11):e02312-18.|||https://pubmed.ncbi.nlm.nih.gov/30867304 29 FPDB17970 DRAMP35120|||CAMPSQ23791 Xaix Antimicrobial||Anticancer||Antiviral Fungi|||Aspergillus terreus SCSGAF0162 N/A N/A J Nat Prod. 2013 Jun 28;76(6):1182-6.|||23806112 4 FPDB18498 DRAMP02833 SALYALYDFSPPARKMRAYTVRAYVHGSYSRRGPWYDFEPVPGASMDGL No MICs found in DRAMP database||Antimicrobial||Antiviral Bos taurus (Bovine) N/A No hemolysis information or data found in the reference(s) presented in this entry EMBO J. 1983;2(7):1159-1163.Biol Chem Hoppe Seyler. 1990 Feb;371(2):111-116.Proc Natl Acad Sci U S A. 1985 Oct;82(19):6490-6491.|||Biochem Biophys Res Commun. 1999 Sep 16;263(1):187-191. 49 FPDB18520 DRAMP31150|||C-apoE|||DRAMP31150 CEELRVRLASHLRKLRKRLLRDADDLQKRLAVY Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 = 0.5 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||CEELRVRLASHLRKLRKRLLRDADDLQKRLAVY 33 FPDB18521 DRAMP31151|||ApoE|||DRAMP31151 EELRVRLASHLRKLRKRLLRDADDLQKRLAVY Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Anti-Hepatitis C virus JFH-1, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 32 FPDB18522 DRAMP31152|||C-MapoE|||DRAMP31152 CEEIRARLSTHLRKMRKRLMRDADDLQKRLAVY Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 33 FPDB18523 DRAMP31153|||C-apoE|||DRAMP31153 CEEQAQQIRLQAEAFQARLKSWFEPLVEDM Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 30 FPDB18524 DRAMP31154|||C-apoE|||DRAMP31154 CVRLASHLRKLRKRLLRDADDL Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||22334503|||Hepatology. 2012 Aug;56(2):484-91. 22 FPDB18525 DRAMP31155|||C-apoE|||DRAMP31155 CIRLQAEAFQARLKSWFEPLV Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||22334503|||Hepatology. 2012 Aug;56(2):484-91. 21 FPDB18526 DRAMP31156 VRLASHLRKLRKRLLRDADDLIRLQAEAFQARLKSWFEPLV Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||Hepatology. 2012 Aug;56(2):484-91. 41 FPDB18527 DRAMP31158|||ApoE|||DRAMP31158 EELRVRLASHLRKLRKRLLRDADDL Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||22334503|||Hepatology. 2012 Aug;56(2):484-91. 25 FPDB18528 DRAMP31159|||ApoE|||DRAMP31159 VRLASHLRKLRKRLLRDADDLQKRLAVY Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 28 FPDB18529 DRAMP31160|||C-apoE|||DRAMP31160 CVRLASHLRKLRKRLLRDADDLQKRLAVY Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 = 0.8 uM||Antiviral ; Hepatitis C virus (HCV)[IC50 I = 0.8 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 29 FPDB18530 DRAMP31161|||C-apoE|||DRAMP31161 CLRVRLASHLRKLRKRLLRDADDL Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 = 4 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||22334503|||Hepatology. 2012 Aug;56(2):484-91. 24 FPDB18531 DRAMP31162|||C-apoE|||DRAMP31162 CLRKLRKRLLRC Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 > 10 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >10 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E)|||Synthetic construct|||Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||https://pubmed.ncbi.nlm.nih.gov/22334503|||Hepatology. 2012 Aug;56(2):484-91. 12 FPDB18532 DRAMP31163|||DRAMP31168|||DRAMP31169|||DRAMP31170 YAGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 36||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 20 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 190 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 76 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)|||Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18533 DRAMP31164 AGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 283 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV ribonucleotide reductase subunit 2) N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 8 FPDB18534 DRAMP31165 GAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 225 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV ribonucleotide reductase subunit 2) N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 7 FPDB18535 DRAMP31166 AVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 190 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV ribonucleotide reductase subunit 2) N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 6 FPDB18536 DRAMP31167|||DRAMP31171 VVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 760 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 400 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)|||Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 5 FPDB18537 DRAMP31172|||DRAMP31173 YAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 340 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 330 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 7 FPDB18538 DRAMP31174|||DRAMP31175 YGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 330 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 150 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 8 FPDB18539 DRAMP31176 AAGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 280 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18540 DRAMP31177|||DRAMP31178 yAGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 200 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 165 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18541 DRAMP31179|||DRAMP31180|||DRAMP31181 XAGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 88 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 40 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 33 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18542 DRAMP31182|||DRAMP31183 YaGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 200 uM||Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 230 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18543 DRAMP31184 YXGAVVNDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 100 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18544 DRAMP31185 YAGAVANDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 760 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18545 DRAMP31186 YTMLVVDDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 110 uM||Antimicrobial||Antiviral Synthetic construct(derived from EBV ribonucleotide reductase subunit 2) N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18546 DRAMP31187 YAGTVINDL Anti-Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity, activity value is IC50 = 15 uM||Antimicrobial||Antiviral Synthetic construct(derived from VZV ribonucleotide reductase subunit 2) N/A N/A Ref.3040743|||J Biol Chem. 1987 Sep 15;262(26):12413-6. 9 FPDB18547 DRAMP31188 FAVAVKAVAVKAVAVKAVKKAVKKVKKAVKKAVKKKK Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 0.75 uM||Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 0.78 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||J Virol. 2002 Oct;76(19):9952-61. 37 FPDB18548 DRAMP31189|||D1D6|||DRAMP31189 FLAAARIAKRVAKKARKLAKRAARKRK Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 0.94 uM||Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 1.47 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 0.94 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 27 FPDB18549 DRAMP31190|||D4C3|||DRAMP31190 FRFKIKFRLKFRFKARFKFRAKFRA Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 1.32 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 1.32 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||12208971|||J Virol. 2002 Oct;76(19):9952-61. 25 FPDB18550 DRAMP31192 KRKRAVKRVGRRLKKLARKIARLGVAKLAGLRAVKLF Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 3.38 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||J Virol. 2002 Oct;76(19):9952-61. 37 FPDB18551 DRAMP31193|||D2B15|||DRAMP31193 GAKKGAKKGKKGAKKGAKGAGAKGAGAFKKKK Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 4.07 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 4.07 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 32 FPDB18552 DRAMP31194|||D2A3|||DRAMP31194 KKKKFVKKVAKKVKKVAKKVAKVAVAV Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 3 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 3 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 27 FPDB18553 DRAMP31195|||D1A22|||DRAMP31195 FLFAFRIFKRVFKKFRKLFKRAF Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 10.51 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 10.51 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||12208971|||J Virol. 2002 Oct;76(19):9952-61. 23 FPDB18554 DRAMP31196|||D5C|||DRAMP31196 KRKRAVKRVGRRLKKKLARKIARLGVAF Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 7.82 uM||Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 6.84 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 7.82 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 28 FPDB18555 DRAMP31197|||D3A15|||DRAMP31197 KRKRFAKKFLRFLRKVIRFLKRFIRRF Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 3.69 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 3.69 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||https://pubmed.ncbi.nlm.nih.gov/12208971|||J Virol. 2002 Oct;76(19):9952-61. 27 FPDB18556 DRAMP31198|||D1D2|||DRAMP31198 FAIAIKAIKKAIKKIKKAIKKAI Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 8.71 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 8.71 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||12208971|||J Virol. 2002 Oct;76(19):9952-61. 23 FPDB18557 DRAMP31199|||D4B|||DRAMP31199 FKVKAKVKAKVKAKVKAKKKK Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 2.85 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 2.85 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||12208971|||J Virol. 2002 Oct;76(19):9952-61. 21 FPDB18558 DRAMP31200|||D5D|||DRAMP31200 AVKRVGRRLKKLARKIARLGVAF Anti-Feline immunodeficiency virus :inhibition of reverse transcriptase activity in CrFK cells, activity value is IC50 = 3.37 uM||Anti-Feline immunodeficiency virus, activity value is IC50 = 3.37 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12208971|||12208971|||J Virol. 2002 Oct;76(19):9952-61. 23 FPDB18559 DRAMP31201 LPRRLHLEPAFLPYSVKAHECC Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 = 11 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 22 FPDB18560 DRAMP31202 PGGETARKDKFLHMVLPRRL Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18561 DRAMP31203 EQVLKAVTNVLSPVFPGGET Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 = 280 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18562 DRAMP31204 YVREHGVPIHADKYFEQVLK Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18563 DRAMP31205 PPSAVCNYEVAEDPSYVREH Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)|||Synthetic construct(derived from human cytomegalovirus(HCMV) UL55 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18564 DRAMP31206 RRLHLEPAFLPYSVKAHECC Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 = 20 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18565 DRAMP31207 LPRRLHLEPAFLPYSVKAHEC Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 = 75 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 21 FPDB18566 DRAMP31208 LPRRLHLEPAFLPYSVKAHE Anti-human cytomegalovirus :inhibition of phyical interaction between UL54 and UL44, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein) N/A N/A Ref.12857903|||J Virol. 2003 Aug;77(15):8336-44. 20 FPDB18567 DRAMP31209|||DRAMP31210 ACFPWGNTWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 13 uM||Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 > 150 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18568 DRAMP31211|||DRAMP31212 ACFPWGKEYCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 22 uM||Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 > 150 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18569 DRAMP31213|||DRAMP31214 ACFPWGNQWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 6 uM||Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 37 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18570 DRAMP31215|||DRAMP31216 CFPWGC Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 50 uM||Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 > 150 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 6 FPDB18571 DRAMP31217 ACAPWGNTWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 > 200 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18572 DRAMP31218 ACFAWGNTWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 39 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18573 DRAMP31219 ACFPAGNTWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 43 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18574 DRAMP31220 ACFPWANTWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 7.4 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18575 DRAMP31221 ACFPWGATWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 40 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18576 DRAMP31222 ACFPWGNAWCGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 11 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18577 DRAMP31223 ACFPWGNTACGGK Anti-Hepatitis C virus :inhibition of polymerase activity, activity value is IC50 = 80 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.12951030|||Virology. 2003 Aug 15;313(1):158-69. 13 FPDB18578 DRAMP31224|||Fp1|||DRAMP31224 MWKTPTLKYFGGFNFSQI SARS-CoV:inhibition of plaque information on Vero E6 cells(58% inhibition at ~30 uM).||Antiviral ; SARS-CoV-2||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.16616792|||https://pubmed.ncbi.nlm.nih.gov/34591335|||Virus Res. 2006 Sep;120(1-2):146-55. 18 FPDB18579 DRAMP31225|||DRAMP29998|||DRAMP29998|||Fp2|||DRAMP31225 ATAGWTFGAGAALQIPFAMQMAY SARS-CoV:inhibition of plaque information on Vero E6 cells(39% inhibition at ~30 uM).||SARS-CoV: inhibition of virus infection in Vero-E6 cells(39% inhibition at 30 uM).||Antiviral ; SARS-CoV-2||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.16616792|||Ref.16616792|||34591335|||Virus Res. 2006 Sep;120(1-2):146-55. 23 FPDB18580 DRAMP31226|||Fp3|||DRAMP31226 GYHLMSFPQAAPHGVVFLHVTW activity value is IC50 = 2 uM||Antiviral ; SARS-CoV-2||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.16616792|||34591335|||Virus Res. 2006 Sep;120(1-2):146-55. 22 FPDB18581 DRAMP31227|||DRAMP29996|||DRAMP29996|||Fp4|||DRAMP31227 GVFVFNGTSWFITQRNFFS activity value is IC50 = 2 uM||SARS-CoV: inhibition of virus infection in Vero-E6 cells(83% inhibition at 30 uM||IC50~2 uM).||Antiviral ; SARS-CoV-2||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.16616792|||Ref.16616792|||34591335|||Virus Res. 2006 Sep;120(1-2):146-55. 19 FPDB18582 DRAMP31228|||DRAMP29995|||DRAMP29995|||Fp6|||DRAMP31228 AACEVAKNLNESLIDLQELGKYEQYIKW SARS-CoV:inhibition of plaque information on Vero E6 cells(42% inhibition at ~30 uM).||SARS-CoV: inhibition of virus infection in Vero-E6 cells(42% inhibition at 30 uM).||Antiviral ; SARS-CoV-2||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.16616792|||Ref.16616792|||https://pubmed.ncbi.nlm.nih.gov/34591335|||Virus Res. 2006 Sep;120(1-2):146-55. 28 FPDB18583 DRAMP31229|||DRAMP29994|||DRAMP29994|||MHV|||DRAMP31229 GYFVQDDGEWKFTGSSYYY Anti-SARS-CoV:inhibition of plaque information on Vero E6 cells, activity value is IC50 = 4 uM||activity value is IC50 = 4 uM||Antiviral ; Murine Hepatitis Virus (MHV/M-CoV)[90-100% Inhibition = 30 uM]||Murine Hepatitis Virus (MHV/M-CoV)[IC50 I = 4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from MHV spike protein)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from MHV spike protein) N/A Rat epithelial cells L2 (0% Cytotoxicity at 30 uM Ref.16616792|||Ref.16616792|||16616792|||Virus Res. 2006 Sep;120(1-2):146-55. 19 FPDB18584 DRAMP31230 AAHLIDALYAEFLGGRVLTTPVVHRALFYASAVLRQPFLAGVPSA Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250 uM-500 uM).||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 H glycoprotein (gH)) N/A N/A Ref.18572274|||Peptides. 2008 Sep;29(9):1461-71. 45 FPDB18585 DRAMP31231 AAHLIDALYAEFLGGRVLTT Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(60% inhibition at 250 uM).||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 H glycoprotein (gH)) N/A N/A Ref.18572274|||Peptides. 2008 Sep;29(9):1461-71. 20 FPDB18586 DRAMP31232 GLASTLTRWAHYNALIRAF Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250 uM-500 uM).||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 H glycoprotein (gH)) N/A N/A Ref.18572274|||Peptides. 2008 Sep;29(9):1461-71. 19 FPDB18587 DRAMP31233|||HTLV-1 gp|||DRAMP31233 CCFLNITNSHVSILQERPPLENRVLTGWGL Anti-Human T cell leukemia virus type 1 :inhibition of mambrane fusion in 293T cells, activity value is IC50 = 0.18||Antiviral ; Human T-cell leukaemia virus 1 (HTLV-1)[IC50 F = 0.28+-0.01 uM]||Bovine leukaemia virus (BLV)||Antimicrobial||Antiviral Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))|||Synthetic construct|||Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)) N/A N/A Ref.19114713|||https://pubmed.ncbi.nlm.nih.gov/18680566|||J Biol Chem. 2009 Mar 6;284(10):6575-84. 30 FPDB18588 DRAMP31234 LNITNSHVSILQERPPLENRVL Anti-Human T cell leukemia virus type 1 :inhibition of mambrane fusion in 293T cells, activity value is IC50 = 5.8 uM||Antimicrobial||Antiviral Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)) N/A N/A Ref.19114713|||J Biol Chem. 2009 Mar 6;284(10):6575-84. 22 FPDB18589 DRAMP31235 CFLNITNSHVSILQERPPLENRV Anti-Human T cell leukemia virus type 1 :inhibition of mambrane fusion in 293T cells, activity value is IC50 = 0.19||Antimicrobial||Antiviral Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)) N/A N/A Ref.19114713|||J Biol Chem. 2009 Mar 6;284(10):6575-84. 23 FPDB18590 DRAMP31236 CFLNITNSHVSILQEAPPLENRV Anti-Human T cell leukemia virus type 1 :inhibition of mambrane fusion in 293T cells, activity value is IC50 = 1.55||Antimicrobial||Antiviral Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)) N/A N/A Ref.19114713|||J Biol Chem. 2009 Mar 6;284(10):6575-84. 23 FPDB18591 DRAMP31237 CFLNITNSHVSILQEAPPLENAV Anti-Human T cell leukemia virus type 1 :inhibition of mambrane fusion in 293T cells, activity value is IC50 = 8.5 uM||Antimicrobial||Antiviral Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)) N/A N/A Ref.19114713|||J Biol Chem. 2009 Mar 6;284(10):6575-84. 23 FPDB18593 DRAMP31239 FHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 80 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 35 FPDB18594 DRAMP31240 VPCSICSNNPTCWAICKRIPNKKPGKK Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 > 165 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 27 FPDB18595 DRAMP31241 CSICSNNPTCWAICKRIPNKKPGKK Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 > 177 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 25 FPDB18596 DRAMP31242 KQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 12 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 41 FPDB18597 DRAMP31243 KPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 12 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 36 FPDB18598 DRAMP31244 KPNNDFHFEVFNFVPCSICSNNPTCWAICKRI Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 25 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 32 FPDB18599 DRAMP31245 KQRQNKPPSKPNNDFHFEVFN Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 > 190 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 21 FPDB18600 DRAMP31246 KQRQNKPPSKPNNDFHF Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 > 240 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 17 FPDB18601 DRAMP31247 KPPSKPNNDFHFEVFNFVP KPPSKPNNDFHFEVFNFVP||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 19 FPDB18602 DRAMP31248 KPPSKPNNDFHFEVFNFV Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 14 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 18 FPDB18603 DRAMP31249 KPPSKPNNDFHFEVFNF Anti-Respiratory syncytial virus :inhibition of the cytopathic effect of RSV in HEp-2 cells, activity value is IC50 = 7 uM||Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A Ref.11487583|||J Biol Chem. 2001 Oct 19;276(42):38988-94. 17 FPDB18633 DRAMP00279 AQIVKLGGDDGSLAFVPSKISVAAGEAIEFVNNAGFPHNIVFDEDAVPAGVDADAISYDDYLNSKGETVVRKLSTPGVYGVYCEPHAGAGMKMTITVQ Antimicrobial||Antiviral Ulva pertusa (Sea lettuce) Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry J Biol Chem. 1999 Feb 12;274(7):4225-4230.Submitted (JUN-2003) to UniProtKB.|||J Biol Chem. 1999 Feb 12;274(7):4225-4230. 98 FPDB18634 DRAMP00299 DADIAVWAPPVNAQN Antimicrobial||Antiviral Thelephora ganbajun (Mushroom) N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem Biophys Res Commun. 2004 Nov 12;324(2):855-859. 15 FPDB18636 DRAMP00333 AVKTITLNLVSPSANRYATFLTEIRDNVRXRSLDYSHSGIDVIGAPSSRDSXLNINFQSP Antimicrobial||Antiviral Dianthus caryophyllus (Carnation) (Clove pink) N/A No hemolysis information or data found in the reference(s) presented in this entry FEBS Lett. 1991 Oct 7;291(1):139-144. 60 FPDB18637 DRAMP00334 GLDTVSFSTKGATYITYVNFLNELRVKTKPEGNSHGIPSLRKSSDDPGSSFVVAG Antimicrobial||Antiviral Suregada multiflora (False lime) (Gelonium multiflorum) N/A No hemolysis information or data found in the reference(s) presented in this entry FEBS Lett. 1991 Oct 7;291(1):139-144. 55 FPDB18649 DRAMP00831 GLPVCGETCFGGTCNTPGCICDPWPVCTRN Antimicrobial||Antiviral Staphylococcus warneri RK|||Viola hederacea (Australian violet) Bridge No hemolysis information or data found in the reference(s) presented in this entry Peptides. 2008 Jun;29(6):978-84.Biophys J. 2009 Oct 7;97(7):1933-40.|||J Mol Biol. 1999 Dec 17;294(5):1327-1336. 30 FPDB18650 DRAMP00832 GIPCAESCVWIPCTVTALLGCSCSNNVCYN Antimicrobial||Antiviral hemolymph, tobacco hornworm, Manduca sexta|||Viola hederacea (Australian violet) Bridge [Ref.16441062] HD50=5.5 uM against human type A red blood cells. Dev Comp Immunol.61:258-68(2016)|||J Mol Biol. 1999 Dec 17;294(5):1327-1336. 30 FPDB18651 DRAMP00834|||DRAMP00834|||Cycloviolacin Y2 GGTIFDCGESCFLGTCYTAGCSCGNWGLCYGTN Antimicrobial||Antiviral||Antiviral ; HIV Viola hederacea (Australian violet)|||Viola yedoensis (Chinese herb)|||Viola philippica Bridge No hemolysis information or data found in the reference(s) presented in this entry J Mol Biol. 1999 Dec 17;294(5):1327-1336.|||J Nat Prod. 2008 Jan;71(1):47-52.|||https://pubmed.ncbi.nlm.nih.gov/18081258 33 FPDB18652 DRAMP00835|||DRAMP00835|||Cycloviolacin Y3 GGTIFDCGETCFLGTCYTAGCSCGNWGLCYGTN Antimicrobial||Antiviral||Antiviral ; HIV Viola hederacea (Australian violet)|||Viola yedoensis (Chinese herb)|||Viola philippica Bridge No hemolysis information or data found in the reference(s) presented in this entry J Mol Biol. 1999 Dec 17;294(5):1327-1336.|||J Nat Prod. 2008 Jan;71(1):47-52|||https://pubmed.ncbi.nlm.nih.gov/18081258 33 FPDB18655 DRAMP00876|||DRAMP00876|||Vhl-2 GLPVCGETCFTGTCYTNGCTCDPWPVCTRN Antimicrobial||Antiviral Viola hederacea (Australian violet)|||Viola hederacea (Australian violet)|||Viola hederacea Beta strand (5 strands; 6 residues) [Ref:15824119]Has hemolytic activity Biopolymers. 2008;90(1):51-60.J Biol Chem. 2005 Jun 10;280(23):22395-22405.|||J Biol Chem. 2005 Jun 10;280(23):22395-22405.Aust. J. Chem. 2010;63:771-778.|||https://pubmed.ncbi.nlm.nih.gov/15824119 30 FPDB18659 DRAMP00936 DVSFRLSGATSKKKVYFISNLRKALPNEKKLYDIPLVRSSXSGSK Antiviral||Cytotoxic||Antimicrobial Vitis vinifera (Berry)|||Trichosanthes kirilowii (Chinese snake gourd) (Chinese cucumber) N/A No hemolysis information or data found in the reference(s) presented in this entry BMC Plant Biol. 2008 Jul 8;8:75.|||Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6570-4. 45 FPDB18985 DRAMP02523 MLHLVVYDISDDGSRARLAKLLEKFGLQRVQYSAFRGELNPNDREVLARQVGKFVRDDRDCIFIIPLCQRCSSTAIVISNTGVELVKEKGVEFV Antimicrobial||Antiviral Archaeoglobus fulgidus (strain ATCC 49558 / VC-16 / DSM 4304 / JCM9628 / NBRC 100126) N/A No hemolysis information or data found in the reference(s) presented in this entry Nature. 1997 Nov 27;390(6658):364-370. J Biol Chem. 2008 Jul 18;283(29):20361-71.|||Nature. 1997 Nov 27;390(6658):364-370.J Biol Chem. 2008 Jul 18;283(29):20361-71. 94 FPDB18986 DRAMP02524 MFYLISYDISVDQRRLKIAKLLEGYGQRVLESVFECDLELPAYRQLRQKLNRLIKDEEGDRLRIYRLCASCREQIEIIGDGPPPETSQDIYII Antimicrobial||Antiviral Chloroflexus aurantiacus (strain ATCC 29366 / DSM 635 / J-10-fl) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases 93 FPDB18987 DRAMP02525 MTVKHLIVCYDVEKTKDRNKVIKVLEYYGLIRVQYSVFMGSLTETRLHQMNARIKREFTKPSIKILVIEVCNACMERALLVHEELPKVNRQFEVI Antimicrobial||Antiviral Methanospirillum hungatei JF-1 (strain ATCC 27890 / DSM 864 / NBRC100397 / JF-1) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases 95 FPDB18988 DRAMP02526 MIWLAVYDIEDDGERAKASAILQAWGFVRVQRSFYVGRMPRGKAADLLKILQRHVKSGHIALIPITDELLAKALELGRPPYAPLKPPKYAQIYVV Antimicrobial||Antiviral Pyrobaculum aerophilum (strain ATCC 51768 / IM2 / DSM 7523 / JCM 9630/ NBRC 100827) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):984-989. 95 FPDB18989 DRAMP02527 MLYLIIYDVPATKAGNKRRTRLFDLLSGYGKWRQFSVFECFLSVKQFAKLQTAMEKLIKLDEDAVCIYVLDENTVQRTITYGTPQPEKPGSIII Antimicrobial||Antiviral Synechocystis sp. (strain PCC 6803 / Kazusa) N/A No hemolysis information or data found in the reference(s) presented in this entry DNA Res. 2003 Oct 31;10(5):221-228. 94 FPDB18990 DRAMP02528 MRELYLVIAYDTPDDRRRARLAKLLKGFGERRQYSVFEARLTREQWAHLKGKLEALVNKEEDVLAVYFLPPEAVGRTWRIGHEGLKRLEDPDFV Antimicrobial||Antiviral Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039) N/A No hemolysis information or data found in the reference(s) presented in this entry Nat Biotechnol. 2004 May;22(5):547-553. 94 FPDB18991 DRAMP02529 MRVLYIIAYDITDARRLGQIRYFLKGYSTGGQKSVYECFLEREELKFIISKIKRLINPNEDRVHIFRIDGRSKVITLGIAVPPIDPEYFYIG Antimicrobial||Antiviral Thermodesulfovibrio yellowstonii (strain ATCC 51303 / DSM 11347 /YP87) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases 92 FPDB18992 DRAMP02530 MVVIVYVIVAYDVNVERVNRVKKFLRRYLNWVQNSLFEGELSSADLEEVKMGLREIINEDEDMVVIYRFRSADAFKREVMGIEKGLGGEEVI Antimicrobial||Antiviral Archaeoglobus fulgidus (strain ATCC 49558 / VC-16 / DSM 4304 / JCM9628 / NBRC 100126) N/A No hemolysis information or data found in the reference(s) presented in this entry Nature. 1997 Nov 27;390(6658):364-370. 92 FPDB18993 DRAMP02531 MQCLVIYDIPNDRARQRVADACLDYGLQRIQYSAFAGNLSRTHQRALFGEITRRVKGHTANVQLFVFDSKTWSDRRILEQQYDDA Antimicrobial||Antiviral Chloroflexus aurantiacus (strain ATCC 29366 / DSM 635 / J-10-fl) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases 85 FPDB18994 DRAMP02532 MVRLVITYDIRKDKIRNKLFRLLERYGAWKQYSVFELEINPVHKVELFHSIADLIEDTDRVRIYDLCERCQGKITELGEVSPDKMQVVI Antimicrobial||Antiviral Methanospirillum hungatei JF-1 (strain ATCC 27890 / DSM 864 / NBRC100397 / JF-1) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases 89 FPDB18995 DRAMP02533 MILIYDINTEDNDGKRRLVKIMKTSRKYLSHVQKSVFEGDITEGQISLLKKEIMAIVNMKKDFVIIYSLRDGVKLNREILTDTPDPTDNFL Antimicrobial||Antiviral Moorella thermoacetica (strain ATCC 39073) N/A No hemolysis information or data found in the reference(s) presented in this entry Environ Microbiol. 2008 Oct;10(10):2550-2573. 91 FPDB18996 DRAMP02534 MYVVVAYDITEDEVRNKVADALKAYGLERIQRSVFVGRINPALLKDLVERLKRITKGANADITIFKVDRRAIDTAIRIGPPPPARKNVDLY Antimicrobial||Antiviral Pyrobaculum aerophilum (strain ATCC 51768 / IM2 / DSM 7523 / JCM 9630/ NBRC 100827) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):984-989. 91 FPDB18997 DRAMP02535 MKLLVVYDVSDDSKRNKLANNLKKLGLERIQRSAFEGDIDSQRVKDLVRVVKLIVDTNTDIVHIIPLGIRDWERRIVIGREGLEEWLV Antimicrobial||Antiviral Sulfolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 /P2) Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7835-7840. J Biol Chem. 2008 Jul 18;283(29):20361-71. To be Published|||Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7835-7840.J Biol Chem. 2008 Jul 18;283(29):20361-71.To be Published 88 FPDB18998 DRAMP02536 MDFWLVCYDVRDDKRRRKLAKLLEQRCQRVQYSVFECPLPEKVLTDLLHRRWLKELNLKEDSLRAYPLQRQSRSQAKIFGSPDLYEPPDFLIL Antimicrobial||Antiviral Synechocystis sp. (strain PCC 6803 / Kazusa) N/A No hemolysis information or data found in the reference(s) presented in this entry DNA Res. 2003 Oct 31;10(5):221-228. 93 FPDB18999 DRAMP02537 MGKRLYAVAYDIPDDTRRVKLANLLKSYGERVQLSVFECYLDERLLEDLRRRARRLLDLGQDALRIYPVAGQVEVLGVGPLPELREVQVL Antimicrobial||Antiviral Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039) Combine helix and strand structure No hemolysis information or data found in the reference(s) presented in this entry Nat Biotechnol. 2004 May;22(5):547-553. J Biol Chem. 2012 Oct 19;287(43):35943-52. To be Published|||Nat Biotechnol. 2004 May;22(5):547-553.J Biol Chem. 2012 Oct 19;287(43):35943-52.To be Published 90 FPDB19000 DRAMP02538 MRLPYLVCYDISDEGRLNRVYRFMKGKGFHIQYSVFYCILTDVELKEMKAEILKLIHSRYDDVRIYPLPNNSLVAVLGVGDRIPDGVEVFY Antimicrobial||Antiviral Thermodesulfovibrio yellowstonii (strain ATCC 51303 / DSM 11347 /YP87) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases 91 FPDB19001 DRAMP02539 MKMFTVISYDIVDDQRRTSVMKVLKGYGVRVQYSVFEAILDAREFHDLSNQLRKIIDPGQDSIRCYRLDQVAAQRTVIYGIGLTTTDPTHYMV Antimicrobial||Antiviral Chloroflexus aurantiacus (strain ATCC 29366 / DSM 635 / J-10-fl) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases 93 FPDB19002 DRAMP02540 MLIIVTYDVSTETRAGRKRLRRVAKLCESIGQRVQKSVFECRINLMQYEELERRLLSEIDEQEDNLRLYRLTEPAELHVKEYGNFKAIDFEGPLTI Antimicrobial||Antiviral Nitrosomonas europaea (strain ATCC 19718 / NBRC 14298) N/A No hemolysis information or data found in the reference(s) presented in this entry J Bacteriol. 2003 May;185(9):2759-2773. J Biol Chem. 2008 Jul 18;283(29):20361-71.|||J Bacteriol. 2003 May;185(9):2759-2773.J Biol Chem. 2008 Jul 18;283(29):20361-71. 96 FPDB19003 DRAMP02541 MILVTYDVNTVEPGGRRRLRQVAKACQDYGQRVQNSVFEVEVDPARWVALKARLEAIIDPALDSLRYYDLGANWQRRVDHVGAKPAVDLHGPLIL Antimicrobial||Antiviral Rhodospirillum rubrum (strain ATCC 11170 / NCIB 8255) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2005) to the EMBL/GenBank/DDBJ database 95 FPDB19004 DRAMP02542 MFLYVIAYDIPDDRRRKKMADLLEGYGQRVQYSVFECTLSKSKFNELQKRLRKIYQSEEDSLRFYPLSGHTLTQVDIWGEPPLTKPPGSVIV Antimicrobial||Antiviral Synechocystis sp. (strain PCC 6803 / Kazusa) N/A No hemolysis information or data found in the reference(s) presented in this entry DNA Res. 2003 Oct 31;10(5):221-228. 92 FPDB19005 DRAMP02543 MPYLIVTYDIAEERVNKVRKILKKYFMWVQNSVFEGEITEGKLLKCKLELEKVIDKEVDSVYFYSLENRLNYRKTVLGIEKEITGNIL Antimicrobial||Antiviral Thermodesulfovibrio yellowstonii (strain ATCC 51303 / DSM 11347 /YP87) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases 88 FPDB19006 DRAMP02544 MVYVLIAYDISNDSKRLKAAQKLLQMGFARVQKSVYIAKGGRSLAKEAYRALQRLADSGKDKIMVMVIPGDSVRDAYGLGGSLEDGKRVVVV Antimicrobial||Antiviral Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC100138 / K1) N/A No hemolysis information or data found in the reference(s) presented in this entry DNA Res. 1999 Apr 30;6(2):83-101, 145-152. 92 FPDB19007 DRAMP02545 MSSRLAVFAYDIRDDRVRRHALKTLREWRLDGQLSVHECQVDAIQARRLFEQLGDELDPATDAWLFTWVEGHRAVLARGKGRTTALQDGLLLAA Antimicrobial||Antiviral Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / D)(Chromatium vinosum) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (FEB-2010) to the EMBL/GenBank/DDBJ databases 94 FPDB19008 DRAMP02546 MLVLITYDVQTSSMGGTKRLRKVAKACQNYGQRVQNSVFECIVDSTQLTSLKLELTSLIDEEKDSLRIYRLGNNYKTKVEHIGAKPSIDLEDPLIF Antimicrobial||Antiviral Bacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM9153 / C-125) N/A No hemolysis information or data found in the reference(s) presented in this entry Nucleic Acids Res. 2000 Nov 1;28(21):4317-4331. J Biol Chem. 2012 Oct 19;287(43):35943-52. To be Published|||Nucleic Acids Res. 2000 Nov 1;28(21):4317-4331. J Biol Chem. 2012 Oct 19;287(43):35943-52.To be Published 96 FPDB19009 DRAMP02547 MLVLVTYDVNTETPAGRRRLRRIAKTCQNYGQRVQFSVFECNVDPAQWVKLRSKLLNEMDPKLDSLRFYFLGSNWQGRVEHEGAKEPRDLEGTLIL Antimicrobial||Antiviral Chlorobium tepidum (strain ATCC 49652 / DSM 12025 / TLS) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9509-9514. 96 FPDB19010 DRAMP02548 MYVIMVYDVNQRRINKVLNTARKYLEWIQNSVLEGEITEAKFEMLKREIEIIINEEEDSVIFYIMRTTKYSERQILGIEKNKREQIL Antimicrobial||Antiviral Dictyoglomus turgidum (strain Z-1310 / DSM 6724) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases 87 FPDB19011 DRAMP02549 MSMLVVVTENVPPRLRGRLAIWLLEVRAGVYVGDVSAKIREMIWEQIAGLAEEGNVVMAWATNTETGFEFQTFGLNRRTPVDLDGLRLVSFLPV Antimicrobial||Antiviral Escherichia coli (strain K12) N/A No hemolysis information or data found in the reference(s) presented in this entry J Bacteriol. 1989 Jun;171(6):3553-6. Science. 1997 Sep 5;277(5331):1453-1462. Mol Syst Biol. 2006;2:2006.0007.|||J Bacteriol. 1989 Jun;171(6):3553-6. Science. 1997 Sep 5;277(5331):1453-1462.Mol Syst Biol. 2006;2:2006.0007. 94 FPDB19012 DRAMP02550 MFVVLVYDTAAERNPNALRTCRKYLHWVQRSVFEGELSAAQYRALMTTLRDQLDLTYDSIRVYRTRSPALVETEWLGVPLGNQDSVL Antimicrobial||Antiviral Frankia alni (strain ACN14a) N/A No hemolysis information or data found in the reference(s) presented in this entry Genome Res. 2007 Jan;17(1):7-15. 87 FPDB19013 DRAMP02551 MEHLYIVSYDIRNQRRWRRLFKTMHGFGCWLQLSVFQCRLDRIRIIKMEAAINEIVNHAEDHVLILDLGPAENVKPKVSSIGKTFDPILRQAVIV Antimicrobial||Antiviral Geobacter sulfurreducens (strain ATCC 51573 / DSM 12127 / PCA) N/A No hemolysis information or data found in the reference(s) presented in this entry Science. 2003 Dec 12;302(5652):1967-1969. 95 FPDB19014 DRAMP02552 MPYVVVFYDVSDNKRRDLLAKTLQSLGLVRVQRSVFMGRGGYTKAKEAIRAASRIVDARTDSVVALVVPEDYARRMLVYGGIMSDPKQKQAVRVV Antimicrobial||Antiviral Hyperthermus butylicus (strain DSM 5456 / JCM 9403) N/A No hemolysis information or data found in the reference(s) presented in this entry Archaea. 2007 May;2(2):127-135. 95 FPDB19015 DRAMP02553 MRGGNLKVLVVYDITDDSLRLKVAEILKDLGLFRIQKSAFIGEMTSQERENMEEILRRQNLGPSDRIDVFPICDRDLKMHSQIGRGKFGRGPP Antimicrobial||Antiviral Korarchaeum cryptofilum (strain OPF8) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8102-8107. 93 FPDB19016 DRAMP02554 MKHWRLVSYDIREPKRLRRVAKIMEGFGERIQYSVFRIYSTDKELEKLRWKLAKVTEEEDNIFYLTLCTKCASGAHTQEKKSAWPEAPKTLKIL Antimicrobial||Antiviral Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai(strain 56601) N/A No hemolysis information or data found in the reference(s) presented in this entry Nature. 2003 Apr 24;422(6934):888-893. 94 FPDB19017 DRAMP02555 MYVVIVYDVGVERVNKVRSFLREYMNWVQNSVFEGELTKAEFLKIKSRLKELIQESSDHIIFYSSRDRKYLGIEDLGTPKADTSNII Antimicrobial||Antiviral Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 /C2A) N/A No hemolysis information or data found in the reference(s) presented in this entry Genome Res. 2002 Apr;12(4):532-542. 87 FPDB19018 DRAMP02556 MAVFLIAYDLVNERRGTHDYQPLWDELKRLGAHRTQFSLWLVSANNTTAEVRQHFQQFVDSNDRIWVTRLRKSQYDYANAIGGTNNWLSNNPPEA Antimicrobial||Antiviral Methylobacterium extorquens (strain CM4 / NCIMB 13688)(Methylobacterium chloromethanicum) N/A No hemolysis information or data found in the reference(s) presented in this entry Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases 95 FPDB19019 DRAMP02558 MKVLVSFEIKFKTNKEKIISILKHFGFRRMQENLYFGDVEYDELYAMQSDIMENIREYDSILTIPICKSCYLKLNVFGRNLSFKDELYKIF Antimicrobial||Antiviral Methanobrevibacter ruminantium (strain ATCC 35063 / DSM 1093 / JCM13430 / M1) (Methanobacterium rumi N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS One. 2010 Jan 28;5(1):e8926. 91 FPDB19020 DRAMP02559 MVVTVYLLIVYDVGVERVNRVKSYLRTELHWVQNSVFEGEVTESQFRRIETNLERIIDRERDSVIIYSFRSERAMNRNVLGLEKSPLDVIL Antimicrobial||Antiviral Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 /JCM 10044 / NBRC 100330 / Delt N/A No hemolysis information or data found in the reference(s) presented in this entry J Bacteriol. 1997 Nov;179(22):7135-7155. J Biol Chem. 2008 Jul 18;283(29):20361-71.|||J Bacteriol. 1997 Nov;179(22):7135-7155. 91 FPDB19021 DRAMP02560 MAEPRRWYLITYDIRDPKRWRKVHALLKGYGEWLQLSVFRCSLTDRDREKLRWELSRRMDAVDTLLVIGLCGGCVERVRAINAKEDWPEEPAPFKVL Antimicrobial||Antiviral Myxococcus xanthus (strain DK 1622) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15200-5.J Bacteriol. 2007 May;189(10):3738-3750.|||Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15200-5. 97 FPDB19022 DRAMP02561 MQYKINMYAIVVYDVNVSRQNQIREFLRKYLYHVQRSVFEGEISPSSLYYMKKILQSYIGETDSLIIYVLRDKSCLMDKIVLGEDKDLQIY Antimicrobial||Antiviral Nanoarchaeum equitans (strain Kin4-M) N/A No hemolysis information or data found in the reference(s) presented in this entry Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12984-8. 91 FPDB19023 DRAMP02562 MYIVVVYDVGVERVNKVKKFLRMHLNWVQNSVFEGEVTLAEFERIKEGLKKIIDENSDSVIIYKLRSMPPRETLGIEKNPIEEII Antimicrobial||Antiviral Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) N/A No hemolysis information or data found in the reference(s) presented in this entry Genetics. 1999 Aug;152(4):1299-1305.Submitted (AUG-2006) to the PDB data bank.|||Genetics. 1999 Aug;152(4):1299-1305. 85 FPDB19024 DRAMP02563 MYIIVVYDVSVERVNRVKKFLRQHLHWVQNSVFEGEVTLAEFERIKAGIGELIDGDEDSVVIYKLRSMPKREVMGVEKNPIEDII Antimicrobial||Antiviral Pyrococcus kodakaraensis (strain ATCC BAA-918 / JCM 12380 / KOD1)(Thermococcus kodakaraensis (strain N/A No hemolysis information or data found in the reference(s) presented in this entry Genome Res. 2005 Mar;15(3):352-363. 85 FPDB19025 DRAMP02564 MYVIMVYDVNEKRVAKILKIARKYLKWVQNSVLEGELSPGKYEKLKLEVSRLIDEKEDSVRFYVMDSQKVFNLETLGVEKGEDGFIF Antimicrobial||Antiviral Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099) N/A No hemolysis information or data found in the reference(s) presented in this entry Nature. 1999 May 27;399(6734):323-329. 87 FPDB19026 DRAMP02565 MIVIVAYDISDEDRRGRLRRYLRRLGLARVNRSVYAGPGTATTAELVAERAKEIVEEGDSVFVIVVREDEYQRAHVFDGRDYYIVSERKYEVY Antimicrobial||Antiviral Thermofilum pendens (strain Hrk 5) N/A No hemolysis information or data found in the reference(s) presented in this entry J Bacteriol. 2008 Apr;190(8):2957-2965. 93 FPDB19028 DRAMP02567 MYILITYDVSTETEAGKKRLRKVAQVCKDFGQRVQKSVFECSVNEAQFEQLKHRLLQCIDEKSDSLRIYRLREPAKKYIQEYGVNLTIDFDAPLVL Antimicrobial||Antiviral Moorella thermoacetica (strain ATCC 39073) N/A No hemolysis information or data found in the reference(s) presented in this entry Environ Microbiol. 2008 Oct;10(10):2550-2573. 96 FPDB19046 DRAMP02644 RCICTRGFCRCICTRGFC Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral Macaca mulatta (Rhesus macaque) Bridge No hemolysis information or data found in the reference(s) presented in this entry Science. 1999 Oct 15;286(5439):498-502.J Leukoc Biol. 2001 Sep;70(3):461-464.J Biol Chem. 2002 Feb 1;277(5):3079-3084.|||Science. 1999 Oct 15;286(5439):498-502. 18 FPDB19078 DRAMP02739|||DRAMP02739|||Reptilian Defensin EKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral||Antiviral ; E. coli||S. typhimurium||enveloped rhabdovirus||Chandipura virus||Vesicular stomatitis virus Caretta caretta (Loggerhead turtle)|||Caretta caretta (Loggerhead turtle)|||Synthetic construct Bridge No hemolysis information or data found in the reference(s) presented in this entry Proteins. 2006 Aug 1;64(2):524-531.|||Proteins. 2006 Aug 1;64(2):524-531.|||https://pubmed.ncbi.nlm.nih.gov/16700051 36 FPDB19171 DRAMP18205|||AP02525|||DRAMP18205 SDWSLWECCSTGSLFACC Antimicrobial||Antiviral Actinomadura namibiensis DSM 6313|||Actinomadura namibiensis|||Actinomadura namibiensis DSM 6313 N/A No hemolysis information or data found in the reference(s) presented in this entry Angew Chem Int Ed Engl. 2010 Mar 22;49(13):2436-40.|||Angew Chem Int Ed Engl. 2010 Mar 22;49(13):2436-40. PubMed|||Angew Chem Int Ed Engl. 2010 Mar 22;49(13):2436-40. 18 FPDB19434 DRAMP04674|||DRAMP04674|||Antiviral protein Y3 - Pleurotus citrinopileatus VYINKLTPPCGTMYYACEAV No MICs found in DRAMP database||Antimicrobial||Antiviral||Anticancer ; Tobacco mosaic virus Pleurotus citrinopileatus (Golden oyster mushroom)|||Pleurotus citrinopileatus (Golden oyster mushroom)|||Pleurotus citrinopileatus [Golden oyster mushroom] N/A No hemolysis information or data found in the reference(s) presented in this entry Chinese J Biochem Mol Biol 2008; 24(7):597-603. 20 FPDB19435 DRAMP04681 VIAGGXAAIIG No MICs found in DRAMP database||Antimicrobial||Antiviral Eisenia foetida (Common brandling worm) (Common dung-worm) N/A No hemolysis information or data found in the reference(s) presented in this entry Comp Biochem Physiol B Biochem Mol Biol. 2008 Dec;151(4):381-385. 11 FPDB19436 DRAMP04682 QGRMYQRFLRQHVDPDETGGNDHYLNLSRRNIQCPNRHEGVRFNTDIHEDLTNRRPIDEHEGVVRVTDKTEEG No MICs found in DRAMP database||Antimicrobial||Antiviral Bos taurus (Bovine) N/A No hemolysis information or data found in the reference(s) presented in this entry Biochem Biophys Res Commun. 1999 Sep 16;263(1):187-191. 73 FPDB19437 DRAMP04683|||CAMPSQ10849|||DRAMP04683 SMIGGVMSKG No MICs found in DRAMP database||Antiviral||Antimicrobial Bombyx mori (Silk moth)|||Bombyx mori [Silk moth]|||Bombyx mori (Silk moth) N/A No hemolysis information or data found in the reference(s) presented in this entry Biosci Biotechnol Biochem. 2007 Jan;71(1):200-205.|||17213661|||Biosci Biotechnol Biochem. 2007 Jan;71(1):200-205. 10 FPDB19443 DRAMP04693 GSPRTEYEACRVRCQVAEHGVERQRRCQQVCEKRLREREGRRE No MICs found in DRAMP database||Antimicrobial||Antiviral||Toxin Luffa aegyptiaca (Sponge gourd) (Luffa cylindrica) Alpha helix No hemolysis information or data found in the reference(s) presented in this entry Biosci Biotechnol Biochem. 1997 Jun;61(6):984-988.##J Struct Biol. 2011 Apr;174(1):164-172. 43 FPDB19474 DRAMP18680 GIADILKGLL The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antimicrobial||Antiviral Chaerilus tryznai (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 10 FPDB19475 DRAMP18681|||CAMPSQ8161|||DRAMP18681 LLGGLLQSLL The HCV RNA level is screened that between 1.E-01% and 1.E+00% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral||Antimicrobial Chaerilus tryznai (Scorpion)|||Chaerilus tryznai [Scorpion]|||Chaerilus tryznai (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 10 FPDB19476 DRAMP18682|||CAMPSQ8168|||DRAMP18682 GILDAITGLL The HCV RNA level is screened that between 1.E-03% and 1.E-02% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral||Antimicrobial Chaerilus tryznai (Scorpion)|||Chaerilus tryznai [Scorpion]|||Chaerilus tryznai (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 10 FPDB19477 DRAMP18683|||Peptide Ctri9194|||DRAMP18683 YIRDFITRRPPFGNI The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral ; HCV||Antimicrobial||Antiviral Chaerilus tricostatus (Scorpion)|||Chaerilus tricostatus [Scorpion]|||Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||https://pubmed.ncbi.nlm.nih.gov/23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 15 FPDB19478 DRAMP18684|||CAMPSQ8172|||DRAMP18684 GILDALTGIL The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral||Antimicrobial Chaerilus tricostatus (Scorpion)|||Chaerilus tricostatus [Scorpion]|||Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 10 FPDB19479 DRAMP18686 FLFNVIPHAINATASLIKK The HCV RNA level is screened that between 1.E-01% and 1.E+00% of control(IFNα.2a) in Huh7.5.1 cells.||Antimicrobial||Antiviral Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 19 FPDB19480 DRAMP18687 FLVGILPRMRGFITPFLKKVR The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antimicrobial||Antiviral Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 21 FPDB19481 DRAMP18688 FLWSLIPSAISAVTSLIKK The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antimicrobial||Antiviral Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 19 FPDB19482 DRAMP18689|||Peptide Ctri10261|||DRAMP18689 FDLGGLIKGVVDLF The HCV RNA level is screened that between 1.E+00% and 1.E+01% of control(IFNα.2a) in Huh7.5.1 cells.||Antiviral ; HCV||Antimicrobial||Antiviral Chaerilus tricostatus (Scorpion)|||Chaerilus tricostatus|||Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||https://pubmed.ncbi.nlm.nih.gov/23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 14 FPDB19507 DRAMP20908|||AP04146|||CAMPSQ8165|||DRAMP20908 FLHFLHHLF Anti-Hepatitis C virus, activity value is EC50 = 0.85 ug/ml||Antiviral||Antimicrobial Synthetic construct(from a scorpion venom peptide library)|||amino acid substitution, scorpion, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(from a scorpion venom peptide library) Helix "[Ref.23415044] HC50 = 416.4 ug/ml against human red blood cells.|||The document mentions hemolytic-related data for Ctry2459 and its histidine-rich mutants (Ctry2459-H2, Ctry2459-H3), as follows: - Ctry2459 (WT): 50% hemolytic concentration (HC_{50}) is 137.9 µg/ml. - Ctry2459-H2 (H2): 50% hemolytic concentration (HC_{50}) is 203.3 µg/ml, approximately 1.5 times that of the wild type. - Ctry2459-H3 (H3): 50% hemolytic concentration (HC_{50}) is 416.4 µg/ml, approximately 3 times that of the wild type. Note: HC_{50} refers to the peptide concentration that causes 50% lysis of human red blood cells; the higher the value, the lower the hemolytic activity. In the experiment, peptide concentrations ranged from 0 to 1000 µg/ml, and hemolysis was assessed by measuring the release of hemoglobin (absorbance at 570 nm), with 0.9% saline as a negative control and 0.1% Triton X-100 as a positive control.|||Human RBC ( HC50 = 416.4 ug/ml ) [HC50 (50% hemolysis concentration)]|||[Ref.23415044] HC50 = 416.4 ug/ml against human red blood cells." Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. PubMed|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 9 FPDB19508 DRAMP20909|||AP04145|||CAMPSQ8166|||DRAMP20909 FLGFLHHLF Anti-Hepatitis C virus, activity value is EC50 = 1.08 ug/ml||Antiviral||Antimicrobial Synthetic construct( from a scorpion venom peptide library)|||amino acid substitution, scorpion, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct( from a scorpion venom peptide library) Helix "[Ref.23415044] HC50 = 203.3 ug/ml against human red blood cells.|||The document mentions hemolytic-related data for Ctry2459 and its histidine-rich mutants (Ctry2459-H2, Ctry2459-H3), as follows: - Ctry2459 (WT): 50% hemolytic concentration (HC_{50}) is 137.9 µg/ml. - Ctry2459-H2 (H2): 50% hemolytic concentration (HC_{50}) is 203.3 µg/ml, approximately 1.5 times that of the wild type. - Ctry2459-H3 (H3): 50% hemolytic concentration (HC_{50}) is 416.4 µg/ml, approximately 3 times that of the wild type. Note: HC_{50} refers to the peptide concentration that causes 50% lysis of human red blood cells; the higher the value, the lower the hemolytic activity. In the experiment, peptide concentrations ranged from 0 to 1000 µg/ml, and hemolysis was assessed by measuring the release of hemoglobin (absorbance at 570 nm), with 0.9% saline as a negative control and 0.1% Triton X-100 as a positive control.|||Human RBC ( HC50 = 203.3 ug/ml ) [HC50 (50% hemolysis concentration)]|||[Ref.23415044] HC50 = 203.3 ug/ml against human red blood cells." Biomaterials. 2013 Apr;34(13):3511-22.||Ref.23415044|||Biomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. PubMed|||23415044|||Biomaterials. 2013 Apr;34(13):3511-22. 9 FPDB19634 DRAMP29209 SALEEQYKTFLDKFMHELEDLLYQLAL Anti-ion of replication in Calu-3 cells, activity value is IC50 = 0.042 uM||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.33580154|||Commun Biol. 2021 Feb 12;4(1):197. 27 FPDB19635 DRAMP29210|||FBP|||DRAMP29210 RGAHIKGRWKSRCHRF Anti-A, activity value is IC50 = 3.9 ug/ml||Anti-A, activity value is IC50 = 1.6 ug/ml||Anti-FluB, activity value is IC50 = 7.1 ug/ml||Anti-SARS-CoV-2 :inhibition of infection in Vero-E6 cells, activity value is IC50 = 2.9 ug/ml||Anti-D614G):inhibition of infection in Vero-E6 cells, activity value is IC50 = 3 ug/ml||Anti-SARS-CoV-2 :inhibition of infection in Vera-E6 cells, activity value is IC50 = 3.9 ug/ml||Antiviral ; H1N1||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A [Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC). Ref.35259078|||https://pubmed.ncbi.nlm.nih.gov/35259078|||Emerg Microbes Infect. 2022 Dec;11(1):926-937. 16 FPDB19636 DRAMP29211|||DRAMP29212|||DRAMP29213|||DRAMP29214|||DRAMP29157|||DRAMP29158|||DRAMP29159|||DRAMP29160|||DRAMP29163|||DRAMP29211|||DRAMP29212|||DRAMP29213|||DRAMP29214 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG Anti-SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.8 uM||Anti-SARS-CoV-2 B.1.1.7 :inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 2.28 uM||Anti-SARS-CoV-2 B.1.351 :inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.62 uM||Anti-SARS-CoV-2 P.1 :inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.48 uM||Anti-SARS-CoV-2 B.1.617.2 :inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.11 uM||Anti-HCoV-229E :inhibition of infection in Caco2 cells, activity value is IC50 = 0.48 uM||Anti-HCoV-OC43 :inhibition of infection in Caco2 cells, activity value is IC50 = 0.41 uM||Anti-SARS-CoV:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.35 uM||Anti-MERS-CoV:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 0.1 uM||Anti-SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 3.7 uM||Anti-SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 5.2 uM||Anti-SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells, activity value is IC50 = 10.3 uM||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.34769299|||Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.|||Cell Res. 2020 Apr;30(4):343-355.|||Viruses. 2022 Mar 6;14(3):549.|||Int J Mol Sci. 2021 Nov 1;22(21):11869. 41 FPDB19637 DRAMP29215|||DRAMP29216|||DRAMP29217|||DRAMP29218|||DRAMP29219|||DRAMP29220|||DRAMP29221|||DRAMP29222 SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00136 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.05052 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.03385 uM||Anti-SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.10317 uM||Anti-SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.12887 uM||Anti-SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.11141 uM||Anti-SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.07909 uM||Anti-SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.08849 uM||Anti-SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.09216 uM||Anti-SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.07386 uM||Anti-MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.2284 uM||Anti-HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.81721 uM||Anti-HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.47154 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0075 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.1914 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.12665 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00623 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.17995 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.08633 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.03907 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 1.23638 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.50732 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00033 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.00377 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00289 uM||Anti-ion of live SARS-CoV-2 infection in Vero cells, activity value is IC50 = 0.00897 uM||Anti-SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00629 uM||Anti-SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.0065 uM||Anti-SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00742 uM||Anti-SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00697 uM||Anti-SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00622 uM||Anti-SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00606 uM||Anti-SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.02164 uM||Anti-MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.0699 uM||Anti-HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.37556 uM||Anti-HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.42148 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00029 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.00213 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00143 uM||Anti-ion of live SARS-CoV-2 infection in Vero cells, activity value is IC50 = 0.02571 uM||Anti-SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.0068 uM||Anti-SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00652 uM||Anti-SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00656 uM||Anti-SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00671 uM||Anti-SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00587 uM||Anti-SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00676 uM||Anti-SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.01769 uM||Anti-MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.0485 uM||Anti-HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.35322 uM||Anti-HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.33614 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00026 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.00305 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00182 uM||Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.00032 uM||Anti-ion of pseudovirus infections in 293T/ACE2 cells, activity value is IC50 = 0.00277 uM||Anti-ion of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00154 uM||Anti-ion of live SARS-CoV-2 infection in Vero cells, activity value is IC50 = 0.02985 uM||Anti-SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00675 uM||Anti-SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00787 uM||Anti-SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00756 uM||Anti-SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00755 uM||Anti-SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00718 uM||Anti-SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.00825 uM||Anti-SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.02495 uM||Anti-MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.06008 uM||Anti-HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.17953 uM||Anti-HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells, activity value is IC50 = 0.23118 uM||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 48% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C||16% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C||18% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C||12% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34057039|||Emerg Microbes Infect. 2021 Dec;10(1):1227-1240. 37 FPDB19638 DRAMP29223|||DRAMP29232|||DRAMP29179|||DRAMP29223|||DRAMP29232|||SARS-CoV-S ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0011||Anti-ion of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0178 uM||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0143 uM||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0006||Anti-ion of pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.05 uM||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0215 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0336||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0669||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0625||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.2039||Anti-HCoV-19:inhibition of HCoV-19 S mediated cell–cell fusion, activity value is EC50 = 0.72 uM||Anti-neutralizing activities against pseudotype HCoV-19 virus, activity value is EC50 = 0.32 uM||Anti-ion of authentic HCoV-19 virus infection in Vero E6 cells, activity value is EC50 = 0.58 uM||Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV[IC50 E = 0.005 uM]||SARS-CoV PsV[IC50 E = 0.34 uM]||SARS-CoV-2[IC50 F = 0.022+-0.005 uM]||SARS-CoV-2 PsV[IC50 I = 33.74+-11.827 uM]||SARS-CoV PsV[IC50 I >50 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct Alpha helix||0% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Ref.32482145|||J Virol. 2008 Jan;82(1):588-92.##J Cell Biochem. 2008 Aug 15;104(6):2335-47.##J Virol. 2020 Jul 1;94(14):e00635-20.|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294.|||Emerg Microbes Infect. 2020 Dec;9(1):1238-1241.|||https://pubmed.ncbi.nlm.nih.gov/17942557, 35 FPDB19639 DRAMP29224|||DRAMP29175|||DRAMP29224 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0006||Anti-ion of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0201 uM||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0181 uM||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0004||Anti-ion of pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0193 uM||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0208 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0565||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0553||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0675||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.5357||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct Alpha helix||22% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767.|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 36 FPDB19640 DRAMP29225 EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0004||Anti-ion of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0141 uM||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0175 uM||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0002||Anti-ion of pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0402 uM||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0144 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.048||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0385||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0758||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.5457||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 48% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 36 FPDB19641 DRAMP29226 ELSGINASVVNLQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0003||Anti-ion of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0186 uM||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0152 uM||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0001||Anti-ion of pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0292 uM||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0263 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.063||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0224||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0663||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.502||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 59% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 36 FPDB19642 DRAMP29227 SLTQINASVVNIQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0021||Anti-ion of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.021 uM||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0235 uM||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0013||Anti-ion of pseudovirus infection in 293T/ACE2 cells, activity value is IC50 = 0.0988 uM||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0275 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0659||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0684||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0708||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 1.1284||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 16% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 36 FPDB19643 DRAMP29228|||DRAMP29228|||MERS-HR2P SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.1029||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 5.046||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0791||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 > 25 uM||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 > 25 uM||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0829||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 > 25 uM||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 > 25 uM||Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; MERS-CoV Synthetic construct 8% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294.|||https://pubmed.ncbi.nlm.nih.gov/30646495 36 FPDB19644 DRAMP29229 SLDYINVTFLDLQDEMNRLQEAIKVLNQSYINLKDI Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0041||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0828||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0024||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0975||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.2504||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0052||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.4165||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 2.0088||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 22% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 36 FPDB19645 DRAMP29230 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELK Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.2735||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 2.6721||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.2145||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 1.7908||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 4.3703||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.4998||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.4872||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 1.2556||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct 39% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37 °C No hemolysis information or data found in the reference(s) presented in this entry Ref.34344868|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294. 37 FPDB19646 DRAMP29231|||DRAMP29151|||DRAMP29152|||DRAMP29153|||DRAMP29154|||DRAMP29231|||EK1 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL Anti-SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion, activity value is IC50 = 0.0009||Anti-ion of SARS-CoV-2 pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0872||Anti-SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion, activity value is IC50 = 0.0005||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.1065||Anti-SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.252||Anti-MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0011||Anti-HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.0594||Anti-HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.5033||Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral Synthetic construct 68% α-helicity in phosphate-buffered saline (PBS; pH 7.2) with a final concentration of 10 uM and incubated at 37°C No hemolysis information or data found in the reference(s) presented in this entry|||SARS-CoV-2 Ref.34344868|||Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.##Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767.|||Cell Res. 2020 Apr;30(4):343-355.|||Signal Transduct Target Ther. 2021 Aug 3;6(1):294.|||https://pubmed.ncbi.nlm.nih.gov/34591335 36 FPDB19647 DRAMP29233 XxXVXAaXXXX Anti-SARS-CoV-2:Inhibition of infection in Vero E6 cells, activity value is EC50 = 0.46||Anti-E90=3.1±1.4 uM). Virus: SARS-CoV-2:Inhibition of infection in Vero E6 cells, activity value is EC50 = 4.9||Anti-SARS-CoV:Inhibition of infection in Vero E6 cells, activity value is EC50 = 4.3||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.32376613||Ref.32568027|||Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. ##J Gen Virol. 2020 Sep;101(9):925-940. 11 FPDB19648 DRAMP29234 PxTXXLPX Anti-SARS-CoV-2:inhibition of replication In Vero E6 cells, activity value is IC50 = 0.0007 uM||Anti-ion of replication In hACE2-HEK293T cells, activity value is IC50 = 0.00073 uM||Anti-ion of replication In pneumocyte-like cells, activity value is IC50 = 0.00162 uM||Anti-IC90=0.00314 uM). Virus: SARS-CoV-2 D614G:inhibition of replication in Vero E6 cells, activity value is IC50 = 0.0052 uM||Anti-SARS-CoV-2 Delta:inhibition of replication in Vero E6 cells, activity value is IC50 = 0.0039 uM||Anti-SARS-CoV-2 Omicron:inhibition of replication in Vero E6 cells, activity value is IC50 = 0.0043 uM||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.33495306||Ref.35231500|||Antiviral Res. 2022 Apr;200:105270.##Science. 2021 Feb 26;371(6532):926-931. 8 FPDB19649 DRAMP29242|||CAMPSQ8826|||CAMPSQ14234|||DRAMP29242 SKHSSLDCVLRP Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000004||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000003||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000006||Antiviral||Antimicrobial Synthetic construct|||Synthetic construct|||Bos taurus N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||26492266|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 12 FPDB19650 DRAMP29243|||Peptide 4|||DRAMP29243 KANEGLTWNSLKDK Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000001||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.00005||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000001||Anti-A/Roma-ISS/02/08 H1N1, activity value is EC50 = 1||Anti-A/Parma/24/09 H1N1, activity value is EC50 = 50||Anti-A/Parma/05/06 H3N3, activity value is EC50 = 1||Antimicrobial||Antiviral Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||https://pubmed.ncbi.nlm.nih.gov/28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 14 FPDB19651 DRAMP29244|||CAMPSQ14236|||DRAMP29244 TNGESTADWAKN Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.0004||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.00005||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.00001||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 12 FPDB19652 DRAMP29245|||CAMPSQ14237|||DRAMP29245 KSETKN Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.0005||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.0004||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 6 FPDB19653 DRAMP29246|||CAMPSQ14238|||DRAMP29246 SLDCVLRP Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000002||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.0003||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 8 FPDB19654 DRAMP29247|||CAMPSQ14239|||DRAMP29247 VLRP Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000001||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.00025||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 4 FPDB19655 DRAMP29248|||CAMPSQ14240|||DRAMP29248 SKHSSLDC Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.00008||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000005||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593. 8 FPDB19656 DRAMP29249|||CAMPSQ14232|||DRAMP29249 SLDC Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000005||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000004||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. 4 FPDB19657 DRAMP29250|||CAMPSQ14231|||DRAMP29250 SKHS Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000003||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 0||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 0.000005||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.28878220|||28878220|||Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. 4 FPDB19658 DRAMP29251|||CAMPSQ14233|||DRAMP29251 SAHS Anti-A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 5.77||Anti-A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells, activity value is EC50 = 4.3||Anti-A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells, activity value is EC50 = 9.36||Antiviral||Antimicrobial Synthetic construct|||Bos taurus|||Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.34681184|||34681184|||Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. 4 FPDB19659 DRAMP29252|||DRAMP29253|||DRAMP29254|||CAMPSQ14365|||CAMPSQ14366|||CAMPSQ14367|||DRAMP29252|||DRAMP29253|||DRAMP29254 GGVLVQPG Anti-SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus AD-169 Strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus Davis strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Anti-varicella-zoster virus TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 50.05 uM||Anti-varicella-zoster virus TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 48.42 uM||Anti-SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus Davis strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 100 uM||Anti-varicella-zoster virus TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 58.09 uM||Anti-varicella-zoster virus TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 81.09 uM||Anti-cytomegalovirus Davis strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 100 uM||Anti-varicella-zoster virus TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 78.2 uM||Anti-varicella-zoster virus TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 100 uM||Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.34502335|||34502335|||Int J Mol Sci. 2021 Aug 30;22(17):9427. 8 FPDB19660 DRAMP29255|||CAMPSQ14368|||DRAMP29255 GVLVQ Anti-SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus AD-169 Strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus Davis strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 100 uM||Anti-varicella-zoster virus TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung cells, activity value is EC50 = 59.8 uM||Anti-varicella-zoster virus TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 100 uM||Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.34502335|||34502335|||Int J Mol Sci. 2021 Aug 30;22(17):9427. 5 FPDB19661 DRAMP29256|||CAMPSQ14369|||DRAMP29256 GVLV Anti-SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells, activity value is EC50 > 20 uM||Anti-cytomegalovirus AD-169 Strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 4 uM||Anti-cytomegalovirus Davis strain:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Anti-varicella-zoster virus TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Anti-varicella-zoster virus TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung cells, activity value is EC50 > 20 uM||Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.34502335|||34502335|||Int J Mol Sci. 2021 Aug 30;22(17):9427. 4 FPDB19662 DRAMP29257|||CAMPSQ11292|||DRAMP29257 YWKIXNTLVNIC Anti-Zika Virus :inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 1.5||Anti-Dengue virus serotype 2:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 10 uM||Anti-West Nile virus:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 10 uM||Antiviral||Antimicrobial Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19663 DRAMP29258 YXKXKXXKXXKC Anti-Zika Virus :inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 0.25||Anti-Dengue virus serotype 2:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 1.7||Anti-West Nile virus:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 3.9||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19664 DRAMP29259|||CAMPSQ11294|||DRAMP29259 YTNFYLYPYXFC Anti-Zika Virus :inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 2.2||Anti-Dengue virus serotype 2:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 20 uM||Anti-West Nile virus:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 20 uM||Antiviral||Antimicrobial Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19665 DRAMP29260 YXIAKYNXXIPC Anti-Zika Virus :inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 4.6||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19666 DRAMP29261 YTLPFHNXTFFC Anti-Dengue virus serotype 2:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 10 uM||Anti-West Nile virus:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19667 DRAMP29262 yAIIXYNKYXNC Anti-Zika Virus :inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 = 3.2||Anti-Dengue virus serotype 2:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 20 uM||Anti-West Nile virus:inhibition of flaviviral Protease activity in Huh-7 cells, activity value is IC50 > 20 uM||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.30783498|||ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. 12 FPDB19668 DRAMP29263|||E1P37|||DRAMP29263 PVPNLTCAVACELKWESE Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 41||Anti-HIV-1 NL4-3, activity value is IC50 = 41||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19669 DRAMP29264|||E1P37-1|||DRAMP29264 VPNLTCAVACELKWESEF Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 80||Anti-HIV-1 NL4-3, activity value is IC50 = 80||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19670 DRAMP29265|||E1P37-2|||DRAMP29265 PNLTCAVACELKWESEFR Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 99||Anti-HIV-1 NL4-3, activity value is IC50 = 99||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19671 DRAMP29266|||E1P38|||DRAMP29266 NLTCAVACELKWESEFWR Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM)||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19672 DRAMP29267|||E1P38-1|||DRAMP29267 LTCAVACELKWESEFWRW Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM)||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19673 DRAMP29268|||E1P38-2|||DRAMP29268 TCAVACELKWESEFWRWT Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM)||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19674 DRAMP29269|||E1P39|||DRAMP29269 CAVACELKWESEFWRWTE Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 11.3||Anti-HIV-1 NL4-3, activity value is IC50 = 11.3||Antimicrobial||Antiviral Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. 18 FPDB19675 DRAMP29270|||E1P39-1|||DRAMP29270 AVACELKWESEFWRWTEQ Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 44||Anti-HIV-1 NL4-3, activity value is IC50 = 44 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19676 DRAMP29271|||E1P39-2|||DRAMP29271 VACELKWESEFWRWTEQL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 37.7||Anti-HIV-1 NL4-3, activity value is IC50 = 37.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19677 DRAMP29272|||E1P40|||DRAMP29272 ACELKWESEFWRWTEQLA Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19678 DRAMP29273|||E1P40-1|||DRAMP29273 CELKWESEFWRWTEQLAS Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 34||Anti-HIV-1 NL4-3, activity value is IC50 = 34 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19679 DRAMP29274|||E1P40-2|||DRAMP29274 ELKWESEFWRWTEQLASN Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19680 DRAMP29275|||E1P41|||DRAMP29275 LKWESEFWRWTEQLASNY Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19681 DRAMP29276|||E1P41-1|||DRAMP29276 KWESEFWRWTEQLASNYW Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 66.7||Anti-HIV-1 NL4-3, activity value is IC50 = 66.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19682 DRAMP29277|||E1P41-2|||DRAMP29277 WESEFWRWTEQLASNYWI Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 22||Anti-HIV-1 NL4-3, activity value is IC50 = 22 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19683 DRAMP29278|||E1P42|||DRAMP29278 ESEFWRWTEQLASNYWIL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 50||Anti-HIV-1 NL4-3, activity value is IC50 = 50 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19684 DRAMP29279|||E1P42-1|||DRAMP29279 SEFWRWTEQLASNYWILE Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 31||Anti-HIV-1 NL4-3, activity value is IC50 = 31 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19685 DRAMP29280|||E1P42-2|||DRAMP29280 EFWRWTEQLASNYWILEY Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19686 DRAMP29281|||E1P43|||DRAMP29281 FWRWTEQLASNYWILEYL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 43||Anti-HIV-1 NL4-3, activity value is IC50 = 43 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19687 DRAMP29282|||E1P43-1|||DRAMP29282 WRWTEQLASNYWILEYLW Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 6.8||Anti-HIV-1 NL4-3, activity value is IC50 = 6.8 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19688 DRAMP29283|||E1P43-2|||DRAMP29283 RWTEQLASNYWILEYLWK Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 19.7||Anti-HIV-1 NL4-3, activity value is IC50 = 19.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19689 DRAMP29284|||E1P44|||DRAMP29284 WTEQLASNYWILEYLWKV Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19690 DRAMP29285|||E1P44-1|||DRAMP29285 TEQLASNYWILEYLWKVP Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19691 DRAMP29286|||E1P44-2|||DRAMP29286 EQLASNYWILEYLWKVPF Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 90.3||Anti-HIV-1 NL4-3, activity value is IC50 = 90.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19692 DRAMP29287|||E1P45|||DRAMP29287 QLASNYWILEYLWKVPFD Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 27.7||Anti-HIV-1 NL4-3, activity value is IC50 = 27.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19693 DRAMP29288|||E1P45-1|||DRAMP29288 LASNYWILEYLWKVPFDF Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 12.7||Anti-HIV-1 NL4-3, activity value is IC50 = 12.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19694 DRAMP29289|||E1P45-2|||DRAMP29289 ASNYWILEYLWKVPFDFW Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 11.3||Anti-HIV-1 NL4-3, activity value is IC50 = 11.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19695 DRAMP29290|||E1P46|||DRAMP29290 SNYWILEYLWKVPFDFWR Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 19.7||Anti-HIV-1 NL4-3, activity value is IC50 = 19.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19696 DRAMP29291|||E1P46-1|||DRAMP29291 NYWILEYLWKVPFDFWRG Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 12.3||Anti-HIV-1 NL4-3, activity value is IC50 = 12.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19697 DRAMP29292|||E1P46-2|||DRAMP29292 YWILEYLWKVPFDFWRGV Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 32.3||Anti-HIV-1 NL4-3, activity value is IC50 = 32.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19698 DRAMP29293|||E1P47|||DRAMP29293 WILEYLWKVPFDFWRGVI Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 2.7||Anti-HIV-1 NL4-3, activity value is IC50 = 2.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19699 DRAMP29294|||E1P47-1|||DRAMP29294 ILEYLWKVPFDFWRGVIS Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 5.4||Anti-HIV-1 NL4-3, activity value is IC50 = 5.4 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19700 DRAMP29295|||E1P47-2|||DRAMP29295 LEYLWKVPFDFWRGVISL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 6.6||Anti-HIV-1 NL4-3, activity value is IC50 = 6.6 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19701 DRAMP29296|||E1P48|||DRAMP29296 EYLWKVPFDFWRGVISLT Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 44.7||Anti-HIV-1 NL4-3, activity value is IC50 = 44.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19702 DRAMP29297|||E1P48-1|||DRAMP29297 YLWKVPFDFWRGVISLTP Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 70.7||Anti-HIV-1 NL4-3, activity value is IC50 = 70.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19703 DRAMP29298|||E1P48-2|||DRAMP29298 LWKVPFDFWRGVISLTPL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 14.7||Anti-HIV-1 NL4-3, activity value is IC50 = 14.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19704 DRAMP29299|||E1P49|||DRAMP29299 WKVPFDFWRGVISLTPLL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 17.3||Anti-HIV-1 NL4-3, activity value is IC50 = 17.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19705 DRAMP29300|||E1P49-1|||DRAMP29300 KVPFDFWRGVISLTPLLV Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 63.3||Anti-HIV-1 NL4-3, activity value is IC50 = 63.3 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19706 DRAMP29301|||E1P49-2|||DRAMP29301 VPFDFWRGVISLTPLLVC Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19707 DRAMP29302|||E1P50|||DRAMP29302 PFDFWRGVISLTPLLVCV Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19708 DRAMP29303|||E1P50-1|||DRAMP29303 FDFWRGVISLTPLLVCVA Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19709 DRAMP29304|||E1P50-2|||DRAMP29304 DFWRGVISLTPLLVCVAA Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19710 DRAMP29305|||E1P51|||DRAMP29305 FWRGVISLTPLLVCVAAL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19711 DRAMP29306|||E1P51-1|||DRAMP29306 WRGVISLTPLLVCVAALL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19712 DRAMP29307|||E1P51-2|||DRAMP29307 RGVISLTPLLVCVAALLL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19713 DRAMP29308|||E1P52|||DRAMP29308 GVISLTPLLVCVAALLLL Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 55.7||Anti-HIV-1 NL4-3, activity value is IC50 = 55.7 Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19714 DRAMP29309|||E1P52-1|||DRAMP29309 VISLTPLLVCVAALLLLE Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19715 DRAMP29310|||E1P52-2|||DRAMP29310 ISLTPLLVCVAALLLLEQ Anti-HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 125 uM||Antiviral ; HIV-1 NL4-3 ( IC50 = >125 uM) Synthetic construct N/A N/A Ref.26905802|||https://pubmed.ncbi.nlm.nih.gov/26905802|||Ref.26905802 18 FPDB19716 DRAMP29311 GPNFAEISKINTTLLDLSDEMAMLLQEVVKQLNDSYI Anti-MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells, activity value is IC50 = 1.09 uM||Anti-MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 2.15 uM||Anti-MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 2.72 uM Synthetic construct α-helix N/A Ref.30646495 37 FPDB19717 DRAMP29312 EISKINTTLLDLSDEMAMLLQEVVKQLNDSYIDLKEL Anti-MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells, activity value is IC50 = 0.38 uM||Anti-MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 0.34 uM||Anti-MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 0.44 uM Synthetic construct α-helix N/A Ref.30646495 37 FPDB19718 DRAMP29313 LDLSDEMAMLLQEVVKQLNDSYIDLKELGNYTYYNKW Anti-MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells, activity value is IC50 = 0.55 uM||Anti-MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 0.48 uM||Anti-MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 0.52 uM Synthetic construct α-helix α-helix Ref.30646495 37 FPDB19719 DRAMP29314 GGGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL Anti-MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells, activity value is IC50 = 1.07 uM||Anti-MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 1.14 uM||Anti-MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells, activity value is IC50 = 1.71 uM Synthetic construct α-helix N/A Ref.30646495 39 FPDB19720 DRAMP29949 GFGCPFNQGKCHRHCRSIRRRGGYCDGFLKQRCVCYRK Anti-Hepatitis C virus : inhibition of viral replication in Huh7.5.1 cells, activity value is IC50 = 3.35 Mesobuthus martensii Karsch N/A N/A Ref.31963532 38 FPDB19721 DRAMP29950 MITHGCYTRTRHKHKLKKTL Respiratory syncytial virus (RSV):SA-35 caused a significant decrease of the RSV infectivity by 33 times at concentrations 1000 ug/ml. Synthetic construct N/A N/A Ref.32124885 20 FPDB19722 DRAMP29951 KRRGGGKLLKLLLKLLLKLLKC Anti-Respiratory syncytial virus :inhibition of viral infection in the MA-104 cell, activity value is IC50 = 40 ug/ml Synthetic construct N/A N/A Ref.32124885 22 FPDB19723 DRAMP29952 gikefkrivqrikdflrnlv Anti-Ebola Virus :inhibition of viral infection in Hela cells, activity value is IC50 = 0.99 uM||Anti-ion of viral infection in primary macrophages, activity value is IC50 = 2.2 uM Synthetic construct(derived from LL-37) N/A N/A Ref.32252021 20 FPDB19724 DRAMP29954|||FBP1|||DRAMP29954 RGAHINGRWDSRCHRF influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 100 ug/ml).||Antiviral ; H1N1 Synthetic construct N/A N/A Ref.35259078|||https://pubmed.ncbi.nlm.nih.gov/35259078|||Ref.35259078 16 FPDB19725 DRAMP29955|||FBP2|||DRAMP29955 RGAHIKGRWDSRCHRF influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 50 ug/ml).||Antiviral ; H1N1 Synthetic construct N/A N/A Ref.35259078|||https://pubmed.ncbi.nlm.nih.gov/35259078|||Ref.35259078 16 FPDB19726 DRAMP29956|||DRAMP29956|||U5 IPLRGAFINGRWDSQCHRFS Anti-influenza A virus : inhibition of viral replication in MDCK cells, activity value is IC50 = 12.9 ug/ml||Antiviral ; H1N1 Synthetic construct N/A N/A Ref.35259078|||Ref.35259078|||35259078 20 FPDB19727 DRAMP29957|||DRAMP29957|||U4 FINGRWDSQCHRFSNGAIACA Anti-influenza A virus : inhibition of viral replication in MDCK cells, activity value is IC50 = 6.6 ug/ml||Antiviral ; H1N1 Synthetic construct N/A N/A Ref.35259078|||Ref.35259078|||35259078 21 FPDB19728 DRAMP29958|||DRAMP31024 WEDWVR Anti-Feline immunodeficiency virus : inhibition of virus replication in lymphoid cells, activity value is IC50 > 50 ug/ml||Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from gp36 membrane proximal external region of FIV)|||Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.30240422|||Ref.12610147|||Ref.30240422|||J Virol. 2003 Mar;77(6):3724-33. 6 FPDB19729 DRAMP29959|||DRAMP31023 DWVRWI Anti-Feline immunodeficiency virus : inhibition of virus replication in lymphoid cells, activity value is IC50 = 0.06||Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.15 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.07 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from gp36 membrane proximal external region of FIV)|||Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.30240422|||Ref.12610147|||Ref.30240422|||J Virol. 2003 Mar;77(6):3724-33. 6 FPDB19730 DRAMP29960|||DRAMP31022 WEDWVRWI Anti-Feline immunodeficiency virus : inhibition of virus replication in lymphoid cells, activity value is IC50 = 0.05||Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.07||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.46||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.05||Antimicrobial||Antiviral Synthetic construct(derived from gp36 membrane proximal external region of FIV)|||Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.30240422|||Ref.12610147|||Ref.30240422|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB19731 DRAMP29961|||DRAMP29962 XGSGSGVALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSI activity value is IC50 < 0.000001 uM||activity value is IC50 = 0.00006 Synthetic construct N/A N/A Ref.28344321 46 FPDB19732 DRAMP29963|||DRAMP29964|||DRAMP29965 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX activity value is IC50 = 0.000007||activity value is IC50 = 0.000015||activity value is IC50 = 0.00003 Synthetic construct N/A N/A Ref.28344321 46 FPDB19733 DRAMP29966 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGC activity value is IC50 = 0.001 uM Synthetic construct N/A N/A Ref.28344321 46 FPDB19734 DRAMP29967 SKVNGQSGRMEFFWTIAK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19735 DRAMP29968 SKVNGQSGRMEFFWTALK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>10% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19736 DRAMP29969 SKVNGQSGRMAFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19737 DRAMP29970 SKVNGQSGRMEFAWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19738 DRAMP29971 SKVNGQSGRAEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19739 DRAMP29972 SKVNGQAGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~60% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19740 DRAMP29973 SKVNGASGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19741 DRAMP29974 SKVAGQSGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>70% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19742 DRAMP29975 SKANGQSGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19743 DRAMP29976 SAVNGQSGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~20% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19744 DRAMP29977 AKVNGQSGRMEFFWTILK Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>20% inhibition at 30 uM). Synthetic construct(derived from influenza viral HA) N/A N/A Ref.27623031 18 FPDB19745 DRAMP29978|||DRAMP31091|||DRAMP29978|||DENV2 Ep|||DRAMP31091 AWDFGSLGGVFTSIGKALHQVFGAIYGAA "DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~250 uM)||Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 uM); Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=0.3 uM); Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=2 uM); Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=0.7 uM).||Antiviral ; DENV-1[IC90 I = 0.1 uM]||DENV-2[IC90 I = 0.25 uM]||DENV-3[IC90 I = 2 uM]||DENV-4[IC90 I = 0.7 uM]||Antimicrobial||Antiviral" Synthetic construct|||Synthetic construct(derived from DENV2 E protein stem) N/A N/A Ref.20881042|||Ref.20881042|||https://pubmed.ncbi.nlm.nih.gov/20881042|||J Virol. 2010 Dec;84(24):12549-54. 29 FPDB19746 DRAMP29979 GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG Anti-SARS-CoV: inhibition of SARS-CoV cytopathic effect in Vero E6 cells ( synthetic HR2-38, activity value is IC50 = 0.0005||Anti-GST-HR2-38, activity value is IC50 = 0.0662 uM Synthetic construct N/A N/A Ref.15158473 38 FPDB19747 DRAMP29980|||DRAMP29980|||DENV2 Ep AWDFGSLGGVFTSIGKALHQVFGGAFGAA DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~2 uM)||Antiviral ; DENV-2[IC90 I = 2 uM] Synthetic construct N/A N/A Ref.20881042|||Ref.20881042|||https://pubmed.ncbi.nlm.nih.gov/20881042 29 FPDB19748 DRAMP29981|||DRAMP29981|||SARS-CoV Sgp ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL Anti-SARS-CoV : inhibition of SARS-CoV infction in Vero cells, activity value is EC50 = 41.6 uM||Antiviral ; SARS-CoV[IC50 I = 41.6 uM]||Human Influenza A Virus H1N1||Poliovirus Synthetic construct N/A N/A Ref.16153058|||Ref.16153058|||https://pubmed.ncbi.nlm.nih.gov/16153058 33 FPDB19749 DRAMP29982 SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL Anti-MERS-COV : inhibition of cell–cell fusion infection in Huh-7 and 293T/MERS/EGFP cells, activity value is IC50 = 0.93||Anti-ion of MERS-CoV infection in Vero cells, activity value is IC50 = 0.6 uM||Anti-ion of MERS-CoV infection in Calu-3 cells, activity value is IC50 = 0.6 uM||Anti-ion of MERS-CoV infection in HFL cells, activity value is IC50 = 13.9 uM Synthetic construct N/A N/A Ref.24473083 36 FPDB19750 DRAMP29983|||DRAMP29983|||MERS-S LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of MERS-CoV PsV infection in 293T/Huh7 cells (EC50~3.013 uM).||Antiviral ; MERS-CoV PsV[IC50 F = 3.013 uM] Synthetic construct N/A N/A Ref.24067982|||Ref.24067982|||https://pubmed.ncbi.nlm.nih.gov/24067982 35 FPDB19751 DRAMP29984 RIQQIEQKIHHIEQRIQQIEQRISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL Anti-HIV-1 : inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells, activity value is IC50 = 0.0818 Synthetic construct N/A N/A Ref.31932193 59 FPDB19752 DRAMP29985 RIQQIEQKIHHIEQRIQQIEQRAIEAQQHLLQLTVWGIKQLQARIL Anti-HIV-1 : inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells, activity value is IC50 = 0.0389 Synthetic construct N/A N/A Ref.31932193 46 FPDB19753 DRAMP29986 RIQQIEQKIHHIEQRIQQIEQLLQLTVWGIKQLQARIL Anti-HIV-1 : inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells, activity value is IC50 = 0.251 Synthetic construct N/A N/A Ref.31932193 38 FPDB19754 DRAMP29987|||HCV gp|||DRAMP29987 LHQNIVDVQYMYGLS Anti-HCV : inhibition of HCVcc infection in Huh7.5/CD81 cells, activity value is IC50 = 1||Antiviral ; Hepatitis C virus (HCV)[IC50 I = 0.007 uM]||Human hepatocellular carcinoma Huh7.5/CD81[50% Cell death >0.1 uM] Synthetic construct N/A N/A Ref.28638089|||https://pubmed.ncbi.nlm.nih.gov/28638089|||Ref.28638089 15 FPDB19755 DRAMP29988|||HCV gp|||DRAMP29988 GLLHLHQNIVDVQYM Anti-HCV : inhibition of HCVcc infection in Huh7.5/CD81 cells, activity value is IC50 = 1||Antiviral ; Hepatitis C virus (HCV)[IC50 I = 0.006 uM]||Human hepatocellular carcinoma Huh7.5/CD81[50% Cell death >0.1 uM] Synthetic construct N/A N/A Ref.28638089|||https://pubmed.ncbi.nlm.nih.gov/28638089|||Ref.28638089 15 FPDB19756 DRAMP29989|||HCV gp|||DRAMP29989 FGCTWMNSTGFTKTC Anti-HCV : inhibition of HCVcc infection in Huh7.5/CD81 cells, activity value is IC50 = 1||Antiviral ; Hepatitis C virus (HCV)[IC50 I = 0.005 uM]||Human hepatocellular carcinoma Huh7.5/CD81[50% Cell death >0.1 uM] Synthetic construct N/A N/A Ref.28638089|||https://pubmed.ncbi.nlm.nih.gov/28638089|||Ref.28638089 15 FPDB19757 DRAMP29990|||HCV gp|||DRAMP29990 QGSWFGCTWMNSTGF Anti-HCV : inhibition of HCVcc infection in Huh7.5/CD81 cells, activity value is IC50 = 1||Antiviral ; Hepatitis C virus (HCV)[IC50 I = 0.005 uM]||Human hepatocellular carcinoma Huh7.5/CD81[50% Cell death >0.1 uM] Synthetic construct N/A N/A Ref.28638089|||https://pubmed.ncbi.nlm.nih.gov/28638089|||Ref.28638089 15 FPDB19758 DRAMP29991|||DENV-2 gp|||DRAMP29991 VEPGQLKLNWFKK activity value is IC50 = 12.86||Antiviral ; DENV-2[60-70% Inhibition = 40 uM]||DENV-2[50-60% Inhibition = 20 uM]||DENV-2[40-50% Inhibition = 10 uM]||DENV-2[IC50 E = 12.86+-5.96 uM]||DENV-1[60-70% Inhibition = 40 uM] Synthetic construct N/A Human umbilical vein endothelial cells HUVEC (- at NA Ref.29709564|||https://pubmed.ncbi.nlm.nih.gov/29709564|||Ref.29709564 13 FPDB19759 DRAMP29992|||DENV-2 gp|||DRAMP29992 CKIPFEIMDLEKRHV activity value is IC50 = 19.08||Antiviral ; DENV-2[70-80% Inhibition = 40 uM]||DENV-2[40-50% Inhibition = 20 uM]||DENV-2[40-50% Inhibition = 10 uM]||DENV-2[IC50 E = 19.08+-2.52 uM]||DENV-1 Synthetic construct N/A Human umbilical vein endothelial cells HUVEC ( at NA Ref.29709564|||https://pubmed.ncbi.nlm.nih.gov/29709564|||Ref.29709564 15 FPDB19760 DRAMP29993|||DRAMP29993|||MHV GNHILSLVQNAPYGLYFIHFSW MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(22% inhibition at 30 uM).||Antiviral ; Murine Hepatitis Virus (MHV/M-CoV)[20-30% Inhibition = 30 uM] Synthetic construct N/A N/A Ref.16616792|||Ref.16616792|||16616792 22 FPDB19761 DRAMP29997 GYHLMSFPQAAP-HGVVFLHVTW SARS-CoV: inhibition of virus infection in Vero-E6 cells(90% inhibition at 30 uM||IC50~2 uM). Synthetic construct N/A N/A Ref.16616792 22 FPDB19762 DRAMP29999|||DRAMP29999|||SARS-CoV-S TLKPIFKLPLGINITNFR Anti-SARS-COV: inhibition of SARS-CoV/HIV PsV virus infection in 293T/ACE2 cells, activity value is IC50 = 11 uM||Antiviral ; SARS-CoV PsV[IC50 E = 11 uM] Synthetic construct N/A N/A Ref.19853613|||Ref.19853613|||19853613 18 FPDB19763 DRAMP30000|||DRAMP30000|||SARS-CoV MWKTPTLKYFGGFNFSQIL SARS-CoV: inhibition of virus infection in Vero-E6 cells(58% inhibition at 30 uM).||Antiviral ; SARS-CoV[50-60% Inhibition = 30 uM] Synthetic construct N/A Vero E6 cells (0% Cytotoxicity at 30 uM Ref.16616792|||Ref.16616792|||16616792 19 FPDB19764 DRAMP30001 QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE Anti-SARS-CoV:inhibition of cell fusion in Hela cells, activity value is IC50 = 5.07 Synthetic construct N/A N/A Ref.18983873 46 FPDB19765 DRAMP30002 QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ Anti-SARS-CoV:inhibition of cell fusion in Hela cells, activity value is IC50 = 3.97 Synthetic construct N/A N/A Ref.18983873 46 FPDB19766 DRAMP30003|||DRAMP30003|||SARS-CoV GINASVVNIQKEIDRLNEVAKNLNESLIDL Anti-SARS-CoV:inhibition of cell fusion in Hela cells, activity value is IC50 = 0.8||Anti-ion of SARS-CoV infection in Vero-E6 cells, activity value is IC50 = 3.17||Antiviral ; SARS-CoV[IC50 F = 0.8 uM]||SARS-CoV[IC50 I = 3.17 uM] Synthetic construct N/A Vero E6 cells (50% Cytotoxicity at >300 ug/ml Ref.18983873|||Ref.18983873|||https://pubmed.ncbi.nlm.nih.gov/18983873 30 FPDB19767 DRAMP30004|||DRAMP30004|||SARS-CoV GINASVVNIQKEIDRLNEVAKNL Anti-SARS-CoV:inhibition of cell fusion in Hela cells, activity value is IC50 = 1.04||Anti-ion of SARS-CoV infection in Vero-E6 cells, activity value is IC50 = 2.28||Antiviral ; SARS-CoV[IC50 F = 1.04 uM]||SARS-CoV[IC50 I = 2.28 uM] Synthetic construct N/A N/A Ref.18983873|||Ref.18983873|||18983873 23 FPDB19768 DRAMP30005 GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of cell fusion in Hela cells, activity value is IC50 = 0.62||Anti-ion of SARS-CoV infection in Vero-E6 cells, activity value is IC50 = 3.04 Synthetic construct N/A N/A Ref.18983873||Ref.15043961 37 FPDB19769 DRAMP30006|||DRAMP30006|||ZIKV Ep AWDFGSVGGVFNSLGKGIHQIFGAAFKSL Anti-Zika virus :inhibition of Zika virus infection in Vero cells, activity value is IC50 = 1.32 uM||Antiviral ; Zika virus (ZIKV)[IC50 I = 1.32 uM]||Zika virus (ZIKV) H/PF[IC50 I = 0.55 uM]||Zika virus (ZIKV) MRS[IC50 I = 0.07 uM]||Zika virus (ZIKV) MRS[IC50 I = 0.13 uM] Synthetic construct N/A N/A Ref.28232248|||Ref.28232248|||https://pubmed.ncbi.nlm.nih.gov/28232248 29 FPDB19770 DRAMP30007|||DRAMP30007|||JEV Ep AWDFGSIGGVFNSIGRAVHQVFGGAFRTL Anti-Japanese encephalitis virus :inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 0.00766 uM||Antiviral ; Japanese encephalitis virus (JEV)[IC50 I = 0.00766 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 (25% Cell death at 10 uM Ref.28232248|||Ref.28232248|||https://pubmed.ncbi.nlm.nih.gov/28232248 29 FPDB19771 DRAMP30008|||DRAMP30008|||JEV Ep AWDFGSIGGVFNSIGRAVHQVF Anti-Japanese encephalitis virus :inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 0.00393 uM||Anti-Zika virus :inhibition of Zika virus infection in Vero cells, activity value is IC50 = 3.27 uM||Antiviral ; Japanese encephalitis virus (JEV)[IC50 I = 0.00393 uM]||Japanese encephalitis virus (JEV) AT31[IC50 I = 0.00148 uM]||Japanese encephalitis virus (JEV) SA14[IC50 I = 0.0186 uM]||Japanese encephalitis virus (JEV) SA14[IC50 I = 0.00157 uM]||Zika virus (ZIKV)[IC50 I = 3.27 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 (25% Cell death at 10 uM Ref.28232248|||Ref.28232248|||28232248 22 FPDB19772 DRAMP30009|||DRAMP30009|||JEV Ep AALGDTAWDFGSIGGVFNSIGRAVHQVFGGAFRTL Anti-Japanese encephalitis virus :inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 0.05807 uM||Antiviral ; Japanese encephalitis virus (JEV)[IC50 I = 0.05807 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 (25% Cell death at 10 uM Ref.28232248|||Ref.28232248|||https://pubmed.ncbi.nlm.nih.gov/28232248 35 FPDB19773 DRAMP30010|||DRAMP30010|||JEV Ep SIGGVFNSIGRAVHQVFGGAFRTL Anti-Japanese encephalitis virus :inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 0.0941 uM||Antiviral ; Japanese encephalitis virus (JEV)[IC50 I = 0.0941 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 (25% Cell death at 10 uM Ref.28232248|||Ref.28232248|||28232248 24 FPDB19774 DRAMP30011|||DRAMP30011|||JEV Ep STLGKAFSTTLKGAQRLAALGDTAWDFG Anti-Japanese encephalitis virus :inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 3.79071 uM||Antiviral ; Japanese encephalitis virus (JEV)[IC50 I = 3.79 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 (25% Cell death at 10 uM Ref.28232248|||Ref.28232248|||https://pubmed.ncbi.nlm.nih.gov/28232248 28 FPDB19775 DRAMP30012|||Alloferon-1|||DRAMP30012 AGVSGHGQHGVHG Anti-Coxsackie virus 971 PT :inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 358 ug/ml||Antiviral ; HSV-1||HSV-1 McIntyre strain||Coxsackie virus 971 PT B2 [IC50 REP = 358 ug/ml]||Coxsackie virus B2||Coxsackie virus 971 PT B2||Human epidermoid cancer Hep2 Synthetic construct N/A Vero cells (- at NA Ref.21766388|||https://pubmed.ncbi.nlm.nih.gov/21766388|||Ref.21766388 13 FPDB19776 DRAMP30013|||Alloferon-1|||DRAMP30013 RGVSGHGQHGVHG Anti-HHV-1 McIntyre strain:inhibition of virus replication in Vero cells, activity value is IC50 = 321.1 ug/ml||Anti-HHV-1:inhibition of virus replication in Vero cells, activity value is IC50 = 277.5 ug/ml||Anti-ion of virus replication in HEp-2 cells, activity value is IC50 = 602.18 ug/ml||Anti-Coxsackie virus 971 PT :inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 577.73 ug/ml||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 167.71 ug/ml||Anti-CVB2:inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 355.18 ug/ml||Antiviral ; HSV-1[IC50 REP = 277.5 ug/ml]||HSV-1 McIntyre strain[IC50 REP = 321.1 ug/ml]||HSV-1[IC50 REP = 602.18 ug/ml]||HSV-1 McIntyre strain||Coxsackie virus 971 PT B2 [IC50 REP = 577.73 ug/ml]||Coxsackie virus B2[IC50 REP = 355.18 ug/ml]||Coxsackie virus 971 PT B2 [IC50 REP = 167.71 ug/ml]||Coxsackie virus B2||Human epidermoid cancer Hep2 Synthetic construct N/A Vero cells (- at NA Ref.21766388|||https://pubmed.ncbi.nlm.nih.gov/21766388|||Ref.21766388 13 FPDB19777 DRAMP30014|||Alloferon-1|||DRAMP30014 KGVSGHGQHGVHG Anti-HHV-1 McIntyre strain:inhibition of virus replication in Vero cells, activity value is IC50 = 147.09 ug/ml||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 241.9 ug/ml||Anti-HHV-1:inhibition of virus replication in Vero cells, activity value is IC50 = 9.19 ug/ml||Anti-ion of virus replication in HEp-2 cells, activity value is IC50 = 12.98 ug/ml||Anti-Coxsackie virus 971 PT :inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 157.73 ug/ml||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 107.04 ug/ml||Anti-CVB2:inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 190.67 ug/ml||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 74 ug/ml||Antiviral ; HSV-1[IC50 REP = 9.19 ug/ml]||HSV-1 McIntyre strain[IC50 REP = 147.09 ug/ml]||HSV-1[IC50 REP = 12.98 ug/ml]||HSV-1 McIntyre strain[IC50 REP = 241.9 ug/ml]||Coxsackie virus 971 PT B2 [IC50 REP = 157.73 ug/ml]||Coxsackie virus B2[IC50 REP = 190.67 ug/ml]||Coxsackie virus 971 PT B2 [IC50 REP = 107.04 ug/ml]||Coxsackie virus B2[IC50 REP = 74 ug/ml]||Human epidermoid cancer Hep2 Synthetic construct N/A Vero cells (- at NA Ref.21766388|||https://pubmed.ncbi.nlm.nih.gov/21766388|||Ref.21766388 13 FPDB19778 DRAMP30015|||Pep 3|||DRAMP30015 GQGKAHNGRLITANP activity value is IC50 = 33 uM||Anti-DENV-2:inhibition of virus infection in Vero cells, activity value is IC50 = 10 uM||Antiviral ; Active against DENV-1||DENV-2||DENV-3||DENV-6 Synthetic construct(derived from DENV Envelope glycoprotein)|||Dengue virus (DENV)|||Synthetic construct(derived from DENV Envelope glycoprotein) N/A N/A Ref.30508603|||https://pubmed.ncbi.nlm.nih.gov/30508603|||Ref.30508603 15 FPDB19779 DRAMP30016|||CAMPSQ11687|||DRAMP30016 DRGWGNGCGLFG activity value is IC50 = 10 uM||Anti-DENV-2:inhibition of virus infection in Vero cells, activity value is IC50 = 10 uM||Antiviral Synthetic construct(derived from DENV Envelope glycoprotein)|||Dengue virus (DENV)Â|||Synthetic construct(derived from DENV Envelope glycoprotein) N/A N/A Ref.30508603|||30508603|||Ref.30508603 12 FPDB19780 DRAMP30017|||Pep 1|||DRAMP30017 LEHGSCVTTMAKDKPTL activity value is IC50 = 10 uM||Anti-DENV-2:inhibition of virus infection in Vero cells, activity value is IC50 = 10 uM||Antiviral ; Active against DENV-1||DENV-2||DENV-3||DENV-4 Synthetic construct(derived from DENV Envelope glycoprotein)|||Dengue virus (DENV)|||Synthetic construct(derived from DENV Envelope glycoprotein) N/A N/A Ref.30508603|||https://pubmed.ncbi.nlm.nih.gov/30508603|||Ref.30508603 17 FPDB19781 DRAMP30018|||DRAMP30018|||7R-Ahx-HBV Large envelope protein RRRRRRRXPLSPPLRNTHPQAMQWNSTTF Anti-HBV:inhibition of cell proliferation in HepG2.2.15 cells, activity value is EC50 = 6.5||Anti-Hepatitis B virus, activity value is EC50 = 6.5||Anti-Hepatitis B virus, activity value is EC50 = 41.4||Anti-Human hepatocellular carcinoma HepG2, activity value is IC50 = 152.2 Synthetic construct N/A N/A Ref.21144865|||Ref.21144865|||https://pubmed.ncbi.nlm.nih.gov/21144865 29 FPDB19782 DRAMP30019|||7R-Ahx-HBV Large envelope protein|||DRAMP30019 RRRRRRRXLDPAFR Anti-HBV:inhibition of cell proliferation in HepG2.2.15 cells, activity value is EC50 = 3||Anti-Hepatitis B virus, activity value is EC50 = 3.0||Anti-Human hepatocellular carcinoma HepG2.2.15, activity value is IC50 = 556.8 Synthetic construct N/A N/A Ref.21144865|||https://pubmed.ncbi.nlm.nih.gov/21144865|||Ref.21144865 14 FPDB19783 DRAMP30020|||DRAMP30020|||7R-Ahx-HBV Large envelope protein RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF Anti-HBV:inhibition of cell proliferation in HepG2.2.15 cells, activity value is EC50 = 12.8||Anti-Hepatitis B virus, activity value is EC50 = 12.8||Anti-Human hepatocellular carcinoma HepG2.2.15, activity value is IC50 = 135.4 Synthetic construct N/A N/A Ref.21144865|||Ref.21144865|||https://pubmed.ncbi.nlm.nih.gov/21144865 33 FPDB19784 DRAMP30021|||DRAMP30021|||7R-Ahx-P3 RRRRRRRXGSLLGRMKGA Anti-HBV:inhibition of cell proliferation in HepG2.2.15 cells, activity value is EC50 = 2.5||Anti-Hepatitis B virus, activity value is EC50 = 2.5||Anti-Human hepatocellular carcinoma HepG2.2.15, activity value is IC50 = 287.5 Synthetic construct N/A N/A Ref.21144865|||Ref.21144865|||21144865 18 FPDB19785 DRAMP30022|||DRAMP30022|||ACE2 EEQAKTFLDKFNHEAEDLFYQSSGLGKGDFR Anti-SARS-CoV:inhibition of pseudovirus infection in HeLa cells, activity value is IC50 = 0.1 uM||Antiviral ; SARS-CoV PsV[IC50 I = 0.1 uM]||SARS-CoV PsV[IC50 I = 0.3 uM]||Vesicular Stomatitis Virus (VSV) PsV Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct N/A N/A Ref.16510163|||Ref.16510163|||https://pubmed.ncbi.nlm.nih.gov/16510163 31 FPDB19786 DRAMP30023 EEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEE Anti-SARS-CoV:inhibition of pseudovirus infection in HeLa cells, activity value is IC50 = 6 uM Synthetic construct(derived from angiotensin-converting enzyme 2) N/A N/A Ref.16510163 36 FPDB19787 DRAMP30024|||DRAMP30024|||ACE2 EEQAKTFLDKFNHEAEDLFYQSS Anti-SARS-CoV:inhibition of pseudovirus infection in HeLa cells, activity value is IC50 = 50 uM||Antiviral ; SARS-CoV PsV[IC50 I = 50 uM]||Vesicular Stomatitis Virus (VSV) PsV Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct N/A N/A Ref.16510163|||Ref.16510163|||16510163 23 FPDB19788 DRAMP30025|||CAMPSQ23917|||DRAMP30025 NHEAEDLFY SARS-CoV:inhibition of pseudovirus infection in HeLa cells(30% inhibition at 100 uM).||Antiviral Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct|||Synthetic construct(derived from angiotensin-converting enzyme 2) N/A N/A Ref.16510163|||16510163|||Ref.16510163 9 FPDB19789 DRAMP30026|||CAMPSQ23916|||DRAMP30026 DKFNHEAED SARS-CoV:inhibition of pseudovirus infection in HeLa cells(40% inhibition at 100 uM).||Antiviral Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct|||Synthetic construct(derived from angiotensin-converting enzyme 2) N/A N/A Ref.16510163|||16510163|||Ref.16510163 9 FPDB19790 DRAMP30027|||CAMPSQ23915|||DRAMP30027 EEQAKTFLDK SARS-CoV:inhibition of pseudovirus infection in HeLa cells(25% inhibition at 100 uM).||Antiviral Synthetic construct(derived from angiotensin-converting enzyme 2)|||Synthetic construct|||Synthetic construct(derived from angiotensin-converting enzyme 2) N/A N/A Ref.16510163|||16510163|||Ref.16510163 10 FPDB19791 DRAMP30028 HAKFWW Anti-HIV-1:inhibition of integrase-mediated 3'-processing and integration, activity value is IC50 = 30 uM Synthetic construct N/A N/A Ref.8524782 6 FPDB19792 DRAMP30029 HCAFWW Anti-HIV-1:inhibition of integrase-mediated 3'-processing and integration, activity value is IC50 = 49 uM Synthetic construct N/A N/A Ref.8524782 6 FPDB19793 DRAMP30030 EEHEKYHSNW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19794 DRAMP30031 ASCDKCQLKG Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19795 DRAMP30032 HGQVDCSPGIWQLDCTH Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 17 FPDB19796 DRAMP30033 VHVASGY Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 7 FPDB19797 DRAMP30034 PAETGQET Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 8 FPDB19798 DRAMP30035 TAYFLLKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 21||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 2.7 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 12 FPDB19799 DRAMP30036 GRWPVKT Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 7 FPDB19800 DRAMP30037 HTDNGSNF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 8 FPDB19801 DRAMP30038 ACWWAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 95||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 56 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 11 FPDB19802 DRAMP30039 FGIPYNPQSQ Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19803 DRAMP30040 ESMNKELKKI Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19804 DRAMP30041 VRDQAEHLKT Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19805 DRAMP30042 FIHNFKRK Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 8 FPDB19806 DRAMP30043 GYSAGERIVD Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 2000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 2000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053 10 FPDB19807 DRAMP30044 WKGPAKLLWK Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 10 FPDB19808 DRAMP30045 VPRRKAKI Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 8 FPDB19809 DRAMP30046 AAYFLLKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 100||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 47 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19810 DRAMP30047 TAAFLLKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 193||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 119 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19811 DRAMP30048 TAYALLKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19812 DRAMP30049 TAYFALKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 115||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 51 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19813 DRAMP30050 TAYFLAKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19814 DRAMP30051 TAYFLLALAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 113||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 56 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19815 DRAMP30052 TAYFLLKAAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 106 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19816 DRAMP30053 TAYFLLKLAARW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 118||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 19 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19817 DRAMP30054 TAYFLLKLAGAW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 83||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 80 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19818 DRAMP30055 TAYFLLKLAGRA Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19819 DRAMP30056 AAWWAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 277||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 311 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19820 DRAMP30057 ACAWAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 33||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 34 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19821 DRAMP30058 ACWAAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19822 DRAMP30059 ACWWAAIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 90||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 43 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19823 DRAMP30060 ACWWAGAKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19824 DRAMP30061 ACWWAGIAQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 62||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 55 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19825 DRAMP30062 ACWWAGIKAEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19826 DRAMP30063 ACWWAGIKQAF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19827 DRAMP30064 ACWWAGIKQEA Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 245||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 206 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19828 DRAMP30065 TASFLLKLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 186||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 11 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19829 DRAMP30066 TAYFLLILAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 4.1||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 3 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19830 DRAMP30067 TAYFLLKLAGRL Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 315||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 38 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19831 DRAMP30068 ASWWAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 294||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 163 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19832 DRAMP30069 ACGWAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 46||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 16 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19833 DRAMP30070 ACWGAGIKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19834 DRAMP30071 ACWWAGIRQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19835 DRAMP30072 TAYFLL Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 500 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 500 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 6 FPDB19836 DRAMP30073 YFLLKL Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 20 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 20 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 6 FPDB19837 DRAMP30074 KLAGRW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 100 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 100 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 6 FPDB19838 DRAMP30075 ACWWAG Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 100 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 100 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 6 FPDB19839 DRAMP30076 WAGIKQ Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 100 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 100 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 6 FPDB19840 DRAMP30077 IKQEF Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 100 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 100 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 5 FPDB19841 DRAMP30078 tayfllklagrw Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 65||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 13 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19842 DRAMP30079 WRGALKLLFYAT Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 96||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 16 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19843 DRAMP30080 wrgalkllfyat Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 3.5||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 4 Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 12 FPDB19844 DRAMP30081 acwwagikqef Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19845 DRAMP30082 FEQKIGAWWCA Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19846 DRAMP30083 feqkigawwca Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 1000 uM Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.16854053|||J Med Chem. 2006 Jul 27;49(15):4477-86.||Ref.16854053 11 FPDB19847 DRAMP30084 DFRELNKRTQDFWEVQLGIP HIV-1:the level of peptide binding to HIV integrase is very low. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19848 DRAMP30085 SPAIFQSSMTKILEPFRKQN Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 35 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 270 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 100 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19849 DRAMP30086 FRKQNPDIVIYQYMD Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 119 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 97 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 270 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 15 FPDB19850 DRAMP30087 KILEPFRKQNPDIVIYQYMD Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 4.8 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 4.5 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 9.4 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19851 DRAMP30088 PDIVIYQYMDDLYVGSDLEI Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 22 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 54 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 120 uM||Anti-HIV-1:the level of peptide binding to HIV integrase is high. HIV:inhibition of 3′-processing catalyzed by wild-type integrase, activity value is IC50 = 6||Anti-ion of strand transfer catalyzed by wild-type integrase, activity value is IC50 = 10||Anti-ion of 3′-processing catalyzed by soluble mutant integrase, activity value is IC50 = 28||Anti-ion of strand transfer catalyzed by soluble mutant integrase, activity value is IC50 = 23||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 41||Anti-ion of strand transfer catalyzed by C130S integrase, activity value is IC50 = 2||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 20 uM||Anti-ion of strand transfer catalyzed by C130A integrase, activity value is IC50 = 5 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559||Ref.16879966|||J Biol Chem. 2005 Jun 10;280(23):21987-96.Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.||Ref.15790559||Ref.16879966 20 FPDB19852 DRAMP30089 DIQKLVGKLNWASQIYPGIK HIV-1:the level of peptide binding to HIV integrase is low. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19853 DRAMP30090 IAEIQKQGQGQWTYQIYQEP HIV-1:the level of peptide binding to HIV integrase is high. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19854 DRAMP30091 KQLTEAVQKITTEAnti-SIVIWGK Anti-HIV-1:the level of peptide binding to HIV integrase is high. HIV:inhibition of 3′-processing catalyzed by wild-type integrase, activity value is IC50 = 7||Anti-ion of strand transfer catalyzed by wild-type integrase, activity value is IC50 = 4||Anti-ion of 3′-processing catalyzed by soluble mutant integrase, activity value is IC50 = 51||Anti-ion of strand transfer catalyzed by soluble mutant integrase, activity value is IC50 = 31||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 29||Anti-ion of strand transfer catalyzed by C130S integrase, activity value is IC50 = 2||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 15 uM||Anti-ion of strand transfer catalyzed by C130A integrase, activity value is IC50 = 10 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559||Ref.16879966|||J Biol Chem. 2005 Jun 10;280(23):21987-96.Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.||Ref.15790559||Ref.16879966 24 FPDB19855 DRAMP30092 TPKFKLPIQKETWETWWTEY HIV-1:the level of peptide binding to HIV integrase is high. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19856 DRAMP30093 ETWETWWTEYWQATWIPEWE Anti-HIV:inhibition of 3′-processing catalyzed by wild-type integrase, activity value is IC50 = 6||Anti-ion of strand transfer catalyzed by wild-type integrase, activity value is IC50 = 2||Anti-ion of 3′-processing catalyzed by soluble mutant integrase, activity value is IC50 = 13||Anti-ion of strand transfer catalyzed by soluble mutant integrase, activity value is IC50 = 9||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 126||Anti-ion of strand transfer catalyzed by C130S integrase, activity value is IC50 = 27||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 25 uM||Anti-ion of strand transfer catalyzed by C130A integrase, activity value is IC50 = 5 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.16879966|||J Biol Chem. 2005 Jun 10;280(23):21987-96.Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.||Ref.16879966 20 FPDB19857 DRAMP30094 GYVTNRGRQKVVTLTDTTNQ HIV-1:the level of peptide binding to HIV integrase is very low||HIV-1:the level of peptide binding to HIV integrase is very low. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19858 DRAMP30095 VVTLTDTTNQKTELQAIYLA HIV-1:the level of peptide binding to HIV integrase is high. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19859 DRAMP30096 KTELQAIYLALQDSGLEVNI HIV-1:the level of peptide binding to HIV integrase is low. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19860 DRAMP30097 LQDSGLEVNIVTDSQYALGI Anti-HIV:inhibition of 3′-processing catalyzed by wild-type integrase, activity value is IC50 = 11||Anti-ion of strand transfer catalyzed by wild-type integrase, activity value is IC50 = 2||Anti-ion of 3′-processing catalyzed by soluble mutant integrase, activity value is IC50 > 167 uM||Anti-ion of strand transfer catalyzed by soluble mutant integrase, activity value is IC50 = 36||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 18||Anti-ion of strand transfer catalyzed by C130S integrase, activity value is IC50 = 4||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 > 167 uM||Anti-ion of strand transfer catalyzed by C130A integrase, activity value is IC50 = 20 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.16879966|||J Biol Chem. 2005 Jun 10;280(23):21987-96.Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.||Ref.16879966 20 FPDB19861 DRAMP30098 VTDSQYALGIIQAQPDQSES HIV-1:the level of peptide binding to HIV integrase is low. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19862 DRAMP30099 IQAQPDQSESELVNQIIEQL Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 120 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 120 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 120 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19863 DRAMP30100 ELVNQIIEQLIKKEKVYLAW Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 6.9 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 5 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 100 uM||Anti-HIV-1:the level of peptide binding to HIV integrase is high. HIV:inhibition of 3′-processing catalyzed by wild-type integrase, activity value is IC50 = 15||Anti-ion of strand transfer catalyzed by wild-type integrase, activity value is IC50 = 14||Anti-ion of 3′-processing catalyzed by soluble mutant integrase, activity value is IC50 = 113||Anti-ion of strand transfer catalyzed by soluble mutant integrase, activity value is IC50 = 83||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 136||Anti-ion of strand transfer catalyzed by C130S integrase, activity value is IC50 = 7||Anti-ion of 3′-processing catalyzed by C130S integrase, activity value is IC50 = 45 uM||Anti-ion of strand transfer catalyzed by C130A integrase, activity value is IC50 = 15 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559||Ref.16879966|||J Biol Chem. 2005 Jun 10;280(23):21987-96.Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.||Ref.15790559||Ref.16879966 20 FPDB19864 DRAMP30101 NQIIEQLIKKEKVY Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 240 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 240 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 120 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 14 FPDB19865 DRAMP30102 IKKEKVYLAWVPAHKGIGN Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 120 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 120 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 120 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 19 FPDB19866 DRAMP30103 EQVDKLVSAGIRKVLFLDGI HIV-1:the level of peptide binding to HIV integrase is high. Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 20 FPDB19867 DRAMP30104 ESELVSQIIEQLIKK Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 120 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 60 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 > 120 uM Synthetic construct(derived from HIV-1 Reverse Transcriptase) N/A N/A Ref.15790559|||J Biol Chem. 2005 Jun 10;280(23):21987-96.||Ref.15790559 15 FPDB19868 DRAMP30105 LQQLLFIHFRIGCQH Anti-HIV-1:inhibition of strand transfer catalyzed by integrase, activity value is IC50 = 5.5 uM Synthetic construct(HIV-1 gene product) N/A N/A Ref.20586421|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421 15 FPDB19869 DRAMP30106 TNWLWYIKIFIMIV Anti-HIV-1:inhibition of strand transfer catalyzed by integrase, activity value is IC50 = 1.9 uM Synthetic construct N/A N/A Ref.20586421|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421 14 FPDB19870 DRAMP30107 LQQLLF Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 > 11 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 68 Synthetic construct(derived from HIV-1 gene products(Vpr)) N/A N/A Ref.20586421|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421 6 FPDB19871 DRAMP30108 LQQLLFRRRRRRRR Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 6.1||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 11 uM Synthetic construct(derived from HIV-1 gene products(Vpr)) N/A N/A Ref.20586421|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421 14 FPDB19872 DRAMP30109 IHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 0.7||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.83 Synthetic construct(derived from HIV-1 gene products(Vpr)) N/A N/A Ref.20586421|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421 14 FPDB19873 DRAMP30110|||DRAMP30389 LQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 0.004||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.008||Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.13||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 gene products(Vpr))|||Synthetic construct N/A N/A Ref.20586421|||Ref.20708407|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB19874 DRAMP30111|||DRAMP30390 EAIIRILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 0.005||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.006||Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.09||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.04||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 gene products(Vpr))|||Synthetic construct N/A N/A Ref.20586421|||Ref.20708407|||J Med Chem. 2010 Jul 22;53(14):5356-60.||Ref.20586421|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB19875 DRAMP30112|||Vpr|||DRAMP30112 TYGDTWAGVEAIIRI HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>150 uM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>150 uM);inhibit the activity of Rnase H(IC50>>200 uM).||Antiviral ; HIV-1[IC50 RT RDDP >>150 uM]||HIV-1[IC50 RT DDDP >>150 uM]||HIV-1[IC50 RT RH >>200 uM] Synthetic construct(derived from HIV-1 viral protein R (Vpr))|||Synthetic construct|||Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||https://pubmed.ncbi.nlm.nih.gov/17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19876 DRAMP30113 TWAGVEAIIRILQQL Anti-HIV-1:inhibit the activity of RNA-dependent DNA polymerase, activity value is IC50 = 0.88 uM||Anti-the activity of DNA-dependent DNA polymerase, activity value is IC50 = 0.88 uM||Anti-the activity of Rnase H, activity value is IC50 = 6.9 uM||Anti-ion of 3′-end processing catalyzed by integrase, activity value is IC50 > 200 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 144 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 27 uM Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19877 DRAMP30114 VEAIIRILQQLLFIH Anti-HIV-1:inhibit the activity of RNA-dependent DNA polymerase, activity value is IC50 = 0.22 uM||Anti-the activity of DNA-dependent DNA polymerase, activity value is IC50 = 0.22 uM||Anti-the activity of Rnase H, activity value is IC50 = 2 uM||Anti-ion of 3′-end processing catalyzed by integrase, activity value is IC50 = 7.8 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 16 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 3 uM Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19878 DRAMP30115 IRILQQLLFIHFRIG Anti-HIV-1:inhibit the activity of RNA-dependent DNA polymerase, activity value is IC50 = 0.7 uM||Anti-the activity of DNA-dependent DNA polymerase, activity value is IC50 = 1.3 uM||Anti-the activity of Rnase H, activity value is IC50 = 5.25 uM||Anti-ion of 3′-end processing catalyzed by integrase, activity value is IC50 = 1.3 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 1 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 10 uM Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19879 DRAMP30116 QQLLFIHFRIGCQHS Anti-HIV-1:inhibit the activity of RNA-dependent DNA polymerase, activity value is IC50 = 33 uM||Anti-the activity of DNA-dependent DNA polymerase, activity value is IC50 = 43 uM||Anti-the activity of Rnase H, activity value is IC50 = 16.5 uM||Anti-ion of 3′-end processing catalyzed by integrase, activity value is IC50 = 76 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 14 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 10 uM Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19880 DRAMP30117 FIHFRIGCQHSRIGI "HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>200 uM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>200 uM);inhibit the activity of Rnase H(IC50>>200 uM); Inhibition of 3′-end processing catalyzed by integrase(IC50>>200 uM);inhibition of strand transfer catalyzed by integrase(IC50>>200 uM);inhibition of disintegration catalyzed by integrase(IC50>>200 uM)." Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19881 DRAMP30118 HFPRIWLHSLGQHIY Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 187 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 41 uM||Anti-ion of disintegration catalyzed by integrase, activity value is IC50 = 73 uM Synthetic construct(derived from HIV-1 viral protein R (Vpr)) N/A N/A Ref.17490682|||J Mol Biol. 2007 Jun 22;369(5):1230-43.||Ref.17490682 15 FPDB19882 DRAMP30119 QLLIRMIYKNILFYLVPGPGHGAEPERRNIKYL Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 9 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 33 FPDB19883 DRAMP30120 RMIYKNILFYLVPGPGHGAEPERRNIKYL Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 85 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 29 FPDB19884 DRAMP30121 QLLIRMI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 > 200 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 7 FPDB19885 DRAMP30122 AEPERRNIKYL Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 50 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 11 FPDB19886 DRAMP30123 LFYLVPGPGH Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 > 200 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 10 FPDB19887 DRAMP30124 YQLLIRMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 5 uM||Anti-ion of HIV-1 infection in HeLa CD4-β-Gal cells, activity value is IC50 = 40 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19888 DRAMP30125 YALLIRMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 8 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19889 DRAMP30126 YQALIRMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 165 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19890 DRAMP30127 YQLAIRMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 14 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19891 DRAMP30128 YQLLARMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 45 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19892 DRAMP30129 YQLLIAMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 34 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19893 DRAMP30130 YQLLIRAIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 70 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19894 DRAMP30131 YQLLIRMAYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 35 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19895 DRAMP30132 YQLLIRMIAKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 40 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19896 DRAMP30133 YQLLIRMIYANI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 11 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19897 DRAMP30134 YQLLIRMIYKAI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 7 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19898 DRAMP30135 YQLLIRMIYKNA Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 11 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19899 DRAMP30136 YQLLIRMIY Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 5 uM||Anti-ion of HIV-1 infection in HeLa CD4-β-Gal cells, activity value is IC50 = 55 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 9 FPDB19900 DRAMP30137 YQLLIRMI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 120 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 8 FPDB19901 DRAMP30138 QLLIRMIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 = 21 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 11 FPDB19902 DRAMP30139 YQLLIRPIYKNI Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 > 200 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 12 FPDB19903 DRAMP30140 LSELDDRADALQAGASQFETSAAKLKRKYWWKN Anti-HIV-1:Inhibition of 3′-end processing catalyzed by integrase, activity value is IC50 > 200 uM Synthetic construct N/A N/A Ref.12054767|||J Mol Biol. 2002 Apr 19;318(1):45-58.||Ref.12054767 33 FPDB19904 DRAMP30141|||P11, GBV-C E2|||DRAMP30141 TGEKVWDRGNVTLLCDCP Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 439.7 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 162.1 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 484.5 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 208.8 uM||Antiviral ; HIV-1[IC50 F = 439.7 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19905 DRAMP30142|||P19, GBV-C E2|||DRAMP30142 LPAFCQAIGWGDPITHWS Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 369.5 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 46 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 194.3 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 71.4 uM||Antiviral ; HIV-1[IC50 F = 369.5 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19906 DRAMP30143|||P20, GBV-C E2|||DRAMP30143 FCQAIGWGDPITHWSHGQ Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 347.6 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 70.1 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 125.5 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 111.1 uM||Antiviral ; HIV-1[IC50 F = 347.6 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19907 DRAMP30144|||P21, GBV-C E2|||DRAMP30144 AIGWGDPITHWSHGQNRW Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 832.9 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 44.9 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 529.1 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 371.1 uM||Antiviral ; HIV-1[IC50 F = 832.9 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19908 DRAMP30145|||P23, GBV-C E2|||DRAMP30145 PITHWSHGQNRWPLSCPQ Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 508.8 uM||Antiviral ; HIV-1[IC50 F = 508.8 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19909 DRAMP30146|||P25, GBV-C E2|||DRAMP30146 HGQNRWPLSCPQYVYGSV Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 304.4 uM||Antiviral ; HIV-1[IC50 F = 304.4 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19910 DRAMP30147 SWFASTGGRDSKIDVWSL Anti-HIV-1:inhibition of HIV infection in TZM-bl Cells, activity value is IC50 = 237.4 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 411.2 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 118.6 uM Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19911 DRAMP30148|||P45, GBV-C E2|||DRAMP30148 SDRDTVVELSEWGVPCAT Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 141.2 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 48.8 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 505.5 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 43.7 uM||Antiviral ; HIV-1[IC50 F = 141.2 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19912 DRAMP30149|||P46, GBV-C E2|||DRAMP30149 DTVVELSEWGVPCATCIL Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 428.8 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 39.9 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 462.8 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 24.1 uM||Antiviral ; HIV-1[IC50 F = 428.8 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19913 DRAMP30150|||P47, GBV-C E2|||DRAMP30150 VELSEWGVPCATCILDRR Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 330.8 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 58.6 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 140.3 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 20.1 uM||Antiviral ; HIV-1[IC50 F = 330.8 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19914 DRAMP30151|||P59, GBV-C E2|||DRAMP30151 RFPFHRCGAGPKLTKDLE Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 529.6 uM||Antiviral ; HIV-1[IC50 F = 529.6 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19915 DRAMP30152|||P97, GBV-C E2|||DRAMP30152 LVRRRSELMGRRNPVCPG Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 537.6 uM||Antiviral ; HIV-1[IC50 F = 537.6 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19916 DRAMP30153|||P109, GBV-C E2|||DRAMP30153 LQEVDAGNFIPPPRWLLL Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 687.1 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 37.5 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 294.8 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 60.8 uM||Antiviral ; HIV-1[IC50 F = 687.1 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19917 DRAMP30154|||P124, GBV-C E2|||DRAMP30154 WVNQLAVLGLPAVDAAVA Anti-HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells, activity value is IC50 = 332.7 uM||Anti-ion of HIV infection in TZM-bl Cells, activity value is IC50 = 94.7 uM||Antiviral ; HIV-1[IC50 F = 332.7 uM] Synthetic construct(derived from E2 envelope protein of GB virus C)|||Synthetic construct|||Synthetic construct(derived from E2 envelope protein of GB virus C) N/A N/A Ref.20718496|||20718496|||J Med Chem. 2010 Aug 26;53(16):6054-63.||Ref.20718496 18 FPDB19918 DRAMP30155 SAnti-VSVGMKPSPRP HIV-1:binding with vif proteins. Synthetic construct(phage display) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 16 FPDB19919 DRAMP30156|||VMI 7|||DRAMP30156 SNQGGSPLPRSV Anti-HIV-1:inhibition of Vif-Vif bingding, activity value is IC50 = 7.43 uM||Anti-HIV-1, activity value is IC50 = 7.43 uM Synthetic construct(phage display)|||Synthetic construct|||Synthetic construct(phage display) N/A N/A Ref.12480936|||https://pubmed.ncbi.nlm.nih.gov/12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 12 FPDB19920 DRAMP30157|||VMI 9|||DRAMP30157 LPLPAPSFHRTT Anti-HIV-1:inhibition of Vif-Vif bingding, activity value is IC50 = 4.84 uM||Anti-HIV-1, activity value is IC50 = 4.84 uM Synthetic construct(phage display)|||Synthetic construct|||Synthetic construct(phage display) N/A N/A Ref.12480936|||https://pubmed.ncbi.nlm.nih.gov/12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 12 FPDB19921 DRAMP30158 SPYPSWSTPAGR HIV-1:binding with vif proteins. Synthetic construct(phage display) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 12 FPDB19922 DRAMP30159|||Vif|||DRAMP30159 KPKQIKPPLPSV Anti-HIV-1:inhibition of Vif-Vif bingding, activity value is IC50 = 17.39 uM||Anti-HIV-1, activity value is IC50 = 17.39 uM Synthetic construct(derived from the proline-enriched C terminus of Vif)|||Synthetic construct|||Synthetic construct(derived from the proline-enriched C terminus of Vif) N/A N/A Ref.12480936|||https://pubmed.ncbi.nlm.nih.gov/12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 12 FPDB19923 DRAMP30160 WQVMIVWQVDRMRIR HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19924 DRAMP30161 RHHYESTHPRISSEV HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19925 DRAMP30162 ESTHPRISSEVHIPL HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19926 DRAMP30163 HTGERDWHLGQGVSI HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19927 DRAMP30164 RDWHLGQGVSIEWRK HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19928 DRAMP30165 LGQGVSIEWRKKRYS HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19929 DRAMP30166 RYSTQVDPDLADQLI HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19930 DRAMP30167 QVDPDLADQLIHLYY HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19931 DRAMP30168 DLADQLIHLYYFDCF HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19932 DRAMP30169 QLIHLYYFDCFSESA HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19933 DRAMP30170 LYYFDCFSESAIRKA HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19934 DRAMP30171 ESAIRKAILGHIVSP HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19935 DRAMP30172 RKAILGHIVSPRCEY HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19936 DRAMP30173 VSPRCEYQAGHNKVG HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19937 DRAMP30174 CEYQAGHNKVGSLQY HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19938 DRAMP30175 AGHNKVGSLQYLALA HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19939 DRAMP30176 KVGSLQYLALAALIT HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19940 DRAMP30177 LQYLALAALITPKKI HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19941 DRAMP30178 ALAALITPKKIKPPL HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19942 DRAMP30179 LITPKKIKPPLPSVT HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19943 DRAMP30180 KKIKPPLPSVTKLTE HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19944 DRAMP30181 PPLPSVTKLTEDRWN HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19945 DRAMP30182 SVTKLTEDRWNKPQK HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19946 DRAMP30183 LTEDRWNKPQKTKGH HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19947 DRAMP30184 RWNKPQKTKGHRGSH HIV-1:inhibit vif-vif binding. Synthetic construct(derived from HIV-1 Vif protein) N/A N/A Ref.12480936|||J Biol Chem. 2003 Feb 21;278(8):6596-602.||Ref.12480936 15 FPDB19948 DRAMP30185 PTGERVWDRGNVTLLCDCPN Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 15.07 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 18.28 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19949 DRAMP30186|||DRAMP30187 WDRGNVTLLCDCPNGPWVWV Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 2.59 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 2.66 uM||Anti-HIV-1 :inhibition of HIV replication, activity value is IC50 = 3 uM||Anti-HIV-1 :inhibition of HIV replication, activity value is IC50 = 5.2 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19950 DRAMP30188 GPWVWVPAFCQAVGWGDPIT Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 16.8 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 3.57 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19951 DRAMP30189 TLLCDCPNGPWVWVPAFCQA Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 2.36 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 1.29 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19952 DRAMP30190|||DRAMP30191 LCDCPNGPWVWVPAFCQAVG Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 3.33 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 1.32 uM||Anti-HIV-1 :inhibition of HIV replication, activity value is IC50 = 2.3 uM||Anti-HIV-1 :inhibition of HIV replication, activity value is IC50 = 2.4 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19953 DRAMP30192 DCPNGPWVWVPAFCQAVGWG Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 4 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 2 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19954 DRAMP30193 PNGPWVWVPAFCQAVGWGDP Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 11.88 uM||Anti-HIV-1 :inhibition of HIV replication in TZM-bl cells, activity value is IC50 = 8.04 uM Synthetic construct(derived from region of GB virus C glycoprotein E2) N/A N/A Ref.21543477|||J Virol. 2011 Jul;85(14):7037-47.||Ref.21543477 20 FPDB19955 DRAMP30194 RGTKALTEVIPLTEEAEC "HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 5 uM). NOTE:Ki: inhibition constants" Synthetic construct N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 18 FPDB19956 DRAMP30195 GTKALTEVIPLTEEAEC Anti-ion of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.0782 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19957 DRAMP30196 ATKALTEVIPLTEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =28 ±11 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19958 DRAMP30197 GAKALTEVIPLTEEAEC "HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =10.3 ± 2.1 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19959 DRAMP30198 GTAALTEVIPLTEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ± 2.9 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19960 DRAMP30199 GTKGLTEVIPLTEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =20 ± 3.7 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19961 DRAMP30200 GTKAATEVIPLTEEAEC Anti-ion of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.17 uM Synthetic construct(derived from Pep-A)|||ynthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19962 DRAMP30201 GTKALAEVIPLTEEAEC "HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =13.5 ± 2.1 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19963 DRAMP30202 GTKALTAVIPLTEEAEC Anti-ion of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.29 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19964 DRAMP30203 GTKALTEAIPLTEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ±7.3 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19965 DRAMP30204 GTKALTEVAPLTEEAEC Anti-ion of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.14 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19966 DRAMP30205 GTKALTEVIALTEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7 ± 1.4 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19967 DRAMP30206 GTKALTEVIPATEEAEC "HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =22 ± 3 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19968 DRAMP30207 GTKALTEVIPLAEEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =10.2 ± 2.5 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19969 DRAMP30208 GTKALTEVIPLTAEAEC "HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 3 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19970 DRAMP30209 GTKALTEVIPLTEAAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 2.2 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19971 DRAMP30210 GTKWLTEVWPLC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 4 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 12 FPDB19972 DRAMP30211 GTKAWTEVWPLC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 11 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 12 FPDB19973 DRAMP30212 GTKALTEVIPLTC Anti-HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 > 1 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 13 FPDB19974 DRAMP30213 GTKAATEVIPLTC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =49 ± 9 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 13 FPDB19975 DRAMP30214 GTKWLTEWIPLC Anti-HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.0023 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 12 FPDB19976 DRAMP30215 KWLTEWIPLTAEAEC Anti-HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 > 1 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 15 FPDB19977 DRAMP30216 GTKWLTEWIPLTAEC Anti-HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 < 0.00032 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 15 FPDB19978 DRAMP30217 GTKWATEWAPLTAEAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =2 ± 0.6 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19979 DRAMP30218 KWLTEWIPLTAEC "HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =1 ± 0.4 uM). NOTE:Ki: inhibition constants" Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 13 FPDB19980 DRAMP30219 GTKWLTEWIPLTAEAEC Anti-ion of PHA-P-activated PBMCs infected with HIV-1-LAI, activity value is EC50 = 0.0018 uM Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19981 DRAMP30220 GAKTETLVIPETELEAC HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =61 ± 12 uM). Synthetic construct(derived from Pep-A) N/A N/A Ref.18952602|||J Biol Chem. 2009 Jan 2;284(1):254-264.||Ref.18952602 17 FPDB19982 DRAMP30221|||DRAMP30240|||DRAMP30241|||DRAMP30242 LEAIPMSIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 14.79||Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19983 DRAMP30222 AEAIPMSIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19984 DRAMP30223 LAAIPMSIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19985 DRAMP30224 LEAAPMSIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19986 DRAMP30225 LEAIAMSIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 23.5 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19987 DRAMP30226 LEAIPASIPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 13 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19988 DRAMP30227 LEAIPMSAPPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 23.46 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19989 DRAMP30228 LEAIPMSIAPEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 16.33 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19990 DRAMP30229 LEAIPMSIPAEVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 9.72 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19991 DRAMP30230 LEAIPMSIPPAVKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 11 Synthetic construct(derived from α1-antitrypsin)|||Synthetic construct(derived from α1-antitrypsin N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19992 DRAMP30231 LEAIPMSIPPEAKFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 10.64 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19993 DRAMP30232 LEAIPMSIPPEVAFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 4.73 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19994 DRAMP30233 LEAIPMSIPPEVKANKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 4.62 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19995 DRAMP30234 LEAIPMSIPPEVKFAKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 17.41 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19996 DRAMP30235 LEAIPMSIPPEVKFNAPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 10.81 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19997 DRAMP30236 LEAIPMSIPPEVKFNKAFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 12.72 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19998 DRAMP30237 LEAIPMSIPPEVKFNKPAVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB19999 DRAMP30238 LEAIPMSIPPEVKFNKPFAF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20000 DRAMP30239 LEAIPMSIPPEVKFNKPFVA Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20001 DRAMP30243 LEAIPMSIPPEVAFAKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 3.45 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20002 DRAMP30244 LEAIPMSIPPEVFFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.66 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20003 DRAMP30245 LEAIPMCIPPECAFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 1 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20004 DRAMP30246 LEAIPCSIPPCVAFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.18 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20005 DRAMP30247 LEAIPCSIPpCVAFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.94 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20006 DRAMP30248 LEAIPCSIPPCVGFGKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.73 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20007 DRAMP30249 LEAIPCSIPPCVLFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.84 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20008 DRAMP30250 LEAIPCSIPPCVFFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.93 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20009 DRAMP30251|||VIR165|||DRAMP30251 LEAIPCSIPPCFAFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.27||Anti-HIV-1 LAI, activity value is IC50 = 1.31 ug/ml||Anti-HIV-1 LAI I515F, activity value is IC50 = 14.05 ug/ml||Anti-HIV-1 LAI I515T, activity value is IC50 = 0.39 ug/ml||Anti-HIV-1 LAI L536F, activity value is IC50 = 0.15 ug/ml Synthetic construct(derived from α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||30696772|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20010 DRAMP30252 LEAIPMSIPPEFLFGKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 1.34 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20011 DRAMP30253 LEAIPCSIPPCVFFGKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.28 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20012 DRAMP30254 LEAIPCSIPPCFLFGKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.39 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20013 DRAMP30255 LEAIPCSIPpCVFFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.33 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20014 DRAMP30256 LEAIPCSIPpCFLFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.2 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20015 DRAMP30257 LEAIPMGIPpEVXFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.28 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20016 DRAMP30258 LEKIPMSIPpEVXFNKPFVF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 = 0.41 Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20017 DRAMP30259 KVINPEPIVEPFMSKPFALF Anti-HIV-1:inhibition of virus infection in P4-CCR5 clls, activity value is IC50 > 100 uM Synthetic construct(derived from α1-antitrypsin) N/A N/A Ref.17448989|||Cell. 2007 Apr 20;129(2):263-75.||Ref.17448989 20 FPDB20018 DRAMP30260 YTSLIHSLIEEGQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0013||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.065||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.141||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.185 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20019 DRAMP30261 YTSLIHSLIEEAQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0006||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0036||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0035||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0032 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20020 DRAMP30262 YTSLIHSLIEEVQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0004||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.031||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.022||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.023 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20021 DRAMP30263 YTSLIHSLIEELQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0007||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.013||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0029||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0022 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20022 DRAMP30264 YTSLIHSLIEEIQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0005||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0049||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0029||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0024 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20023 DRAMP30265 YTSLIHSLIEEMQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0007||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0044||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0017||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0012 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20024 DRAMP30266 YTSLIHSLIEEPQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.446||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20025 DRAMP30267 YTSLIHSLIEETQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0009||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.039||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.161||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.124 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20026 DRAMP30268 YTSLIHSLIEEFQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0094||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.203||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.393||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.478 Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20027 DRAMP30269 YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.025||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.516||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20028 DRAMP30270 YTSLIHSLIEEWQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.029||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20029 DRAMP30271 YTSLIHSLIEENQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.019||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20030 DRAMP30272 YTSLIHSLIEEQQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.034||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20031 DRAMP30273 YTSLIHSLIEEDQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.21||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20032 DRAMP30274 YTSLIHSLIEEEQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.283||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20033 DRAMP30275 YTSLIHSLIEEHQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.21||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20034 DRAMP30276 YTSLIHSLIEEKQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.708||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20035 DRAMP30277 YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF Anti-HIV-1WT:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.362||Anti-HIV-1V38A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1N43D/S138A:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from Enfuvirtide) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 36 FPDB20036 DRAMP30278 WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL Anti-HIV-1 NL4-3:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.002||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0017||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.002||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0013 Synthetic construct(derived from C34) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 34 FPDB20037 DRAMP30279 WMEWDREINNYTSLIHSLIEELQNQQEKNEQELL Anti-HIV-1 NL4-3:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0015||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0012||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0005||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0004 Synthetic construct(derived from C34) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 34 FPDB20038 DRAMP30280 WMEWDREINNYTSLIHSLIEETQNQQEKNEQELL Anti-HIV-1 NL4-3:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0026||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.0048||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.032||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.024 Synthetic construct(derived from C34) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 34 FPDB20039 DRAMP30281 WMEWDREINNYTSLIHSLIEEWQNQQEKNEQELL Anti-HIV-1 NL4-3:inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 > 1 uM Synthetic construct(derived from C34) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 34 FPDB20040 DRAMP30282 WMEWDREINNYTSLIHSLIEEPQNQQEKNEQELL Anti-HIV-1 NL4-3:inhibition of virus replication in HeLa cells, activity value is EC50 = 0.046||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.436||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.25||Anti-HIV-1 :inhibition of virus replication in HeLa cells, activity value is EC50 = 0.176 Synthetic construct(derived from C34) N/A N/A Ref.19073606|||J Biol Chem. 2009 Feb 20;284(8):4914-20.||Ref.19073606 34 FPDB20041 DRAMP30283 TTWEEWDREINEYTSRIESLIRESQEQQEKNEQELREL Anti-HIV IIIB:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.012 ug/ml||Anti-HIV 098:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.021 ug/ml||Anti-HIV 098-T20:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.056 ug/ml||Anti-HIV 098-T1249:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.037 ug/ml||Anti-HIV 098-T651:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.167 ug/ml Synthetic construct N/A N/A Ref.17640899|||Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.||Ref.17640899 38 FPDB20042 DRAMP30284 MTWMAWDRAIANYAALIHALIEAAQNQQEKNEAALLEL Anti-HIV IIIB:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.061 ug/ml||Anti-HIV 098:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.079 ug/ml||Anti-HIV 098-T20:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.079 ug/ml||Anti-HIV 098-T1249:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.12 ug/ml||Anti-HIV 098-T651:inhibition of virus infection on CEM4 cells, activity value is IC50 = 0.25 ug/ml Synthetic construct N/A N/A Ref.17640899|||Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.||Ref.17640899 38 FPDB20043 DRAMP30285|||CAMPSQ21474|||DRAMP30285 AEAMSQVTN Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 5 uM||Antiviral Synthetic construct N/A N/A Ref.15113844|||15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 9 FPDB20044 DRAMP30286|||CAMPSQ21475|||DRAMP30286 AAAMSQVTN Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 100 uM||Antiviral Synthetic construct N/A N/A Ref.15113844|||15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 9 FPDB20045 DRAMP30287|||CAMPSQ21477|||DRAMP30287 AEAMAQVTN Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 124 uM||Antiviral Synthetic construct N/A N/A Ref.15113844|||15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 9 FPDB20046 DRAMP30288|||Undefined|||DRAMP30288 AEAMSQVTNTATIM Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 10 uM||Antiviral ; HIV-1[IC50 PR = 10 uM] Synthetic construct N/A N/A Ref.15113844|||https://pubmed.ncbi.nlm.nih.gov/15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 14 FPDB20047 DRAMP30289|||Undefined|||DRAMP30289 AEAASQVTNTATIM Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 142 uM||Antiviral ; HIV-1[IC50 PR = 142 uM] Synthetic construct N/A N/A Ref.15113844|||https://pubmed.ncbi.nlm.nih.gov/15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 14 FPDB20048 DRAMP30290|||Undefined|||DRAMP30290 AEASQVTNTATIM Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 126 uM||Antiviral ; HIV-1[IC50 PR = 126 uM] Synthetic construct N/A N/A Ref.15113844|||https://pubmed.ncbi.nlm.nih.gov/15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 13 FPDB20049 DRAMP30291|||Undefined|||DRAMP30291 AEAMSQVANTATIM Anti-HIV:inhibition of protease activity in CEM/LAV-1 cells, activity value is IC50 = 110 uM||Antiviral ; HIV-1[IC50 PR = 110 uM] Synthetic construct N/A N/A Ref.15113844|||https://pubmed.ncbi.nlm.nih.gov/15113844|||J Biochem. 2004 Mar;135(3):447-53.||Ref.15113844 14 FPDB20050 DRAMP30292|||Circulin-D|||DRAMP30292 KIPCGESCVWIPCVTSIFNCKCENKVCYHD Anti-HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.05||Anti-HIV-1, activity value is EC50 = 0.05 Chassalia parviflora N/A N/A Ref.18008336|||https://pubmed.ncbi.nlm.nih.gov/10691702|||Biopolymers. 2008;90(1):51-60.||Ref.18008336 30 FPDB20051 DRAMP30293|||Circulin-F|||DRAMP30293 AIPCGESCVWIPCISAAIGCSCKNKVCYR Anti-HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast cells, activity value is EC50 = 0.05||Anti-HIV-1, activity value is EC50 = 0.05 Chassalia parviflora N/A N/A Ref.18008336|||https://pubmed.ncbi.nlm.nih.gov/10691702|||Biopolymers. 2008;90(1):51-60.||Ref.18008336 29 FPDB20052 DRAMP30294 CGESCAXISFCFTEVIGCSCKNKVCYLNSIS Anti-HIV-1:inhibition of cytopathic effect, activity value is EC50 = 0.87 uM Viola hederacea N/A N/A Ref.15824119|||J Biol Chem. 2005 Jun 10;280(23):22395-405.||Ref.15824119 31 FPDB20053 DRAMP30295 VFQFLGRIIAnti-HHVGNFVHGFSHVF Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 = 7.1 uM Styela clava (Sea squirt) N/A N/A Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159 27 FPDB20054 DRAMP30296 GLWEKIDKFASII Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 > 65.8 uM Synthetic construct(derived from Caerin 3.2) N/A N/A Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159 13 FPDB20055 DRAMP30299 GIFDKLAKEISIW Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 > 65.8 uM Synthetic construct(derived from Brevinin-2DYd) N/A N/A Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159 13 FPDB20056 DRAMP30304 GFNEIVQDIEDFLQNLV Anti-HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells, activity value is EC50 > 25.1 uM Synthetic construct(derived from LL-37) N/A N/A Ref.20086159|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.||Ref.20086159 17 FPDB20057 DRAMP30307|||Caerin 1.1|||DRAMP30307 GLLSVLGSVAKHVLPHVVPVIAAAL Anti-Human immunodeficiency virus : inhibition of HIV Pseudovirus infection in CD4+ T cells, activity value is IC50 = 2.5 uM||Antiviral ; HIV PsV[IC50 I = 2.5 uM] Sythetic construct(derived from Caerin 1.1)|||Synthetic construct|||Sythetic construct(derived from Caerin 1.1) N/A N/A Ref.26026377|||26026377|||Peptides. 2015 Sep;71:296-303.Antibiotics (Basel). 2020 Sep 30;9(10):661.||Ref.26026377 25 FPDB20058 DRAMP30308|||Caerin 1.1|||DRAMP30308 GLLSVLGSVAKHVLPHVVPVIAKLH Anti-Human immunodeficiency virus : inhibition of HIV Pseudovirus infection in CD4+ T cells, activity value is IC50 = 2.5 uM||Antiviral ; HIV PsV[IC50 I = 2.5 uM] Sythetic construct(derived from Caerin 1.1)|||Synthetic construct|||Sythetic construct(derived from Caerin 1.1) N/A CD4+ T Lymphocytes (50% Cell death at 17 uM Ref.26026377|||26026377|||Peptides. 2015 Sep;71:296-303.||Ref.26026377 25 FPDB20059 DRAMP30309|||Caerin 1.1|||DRAMP30309 GLLKVLGSVAKKVLPKVVPVIAEKL Anti-Human immunodeficiency virus : inhibition of HIV Pseudovirus infection in CD4+ T cells, activity value is IC50 = 4 uM||Antiviral ; HIV PsV[IC50 I = 4 uM] Sythetic construct(derived from Caerin 1.1)|||Synthetic construct|||Sythetic construct(derived from Caerin 1.1) N/A N/A Ref.26026377|||26026377|||Peptides. 2015 Sep;71:296-303.||Ref.26026377 25 FPDB20060 DRAMP30310|||Caerin 1.9|||DRAMP30310 GLFGVLGSIAKHLLPHVVPVIAEKL Anti-Human immunodeficiency virus : inhibition of HIV Pseudovirus infection in CD4+ T cells, activity value is IC50 = 3 uM||Antiviral ; HIV PsV[IC50 I = 3 uM] Sythetic construct(derived from Caerin 1.9)|||Synthetic construct|||Sythetic construct(derived from Caerin 1.9) N/A CD4+ T Lymphocytes (50% Cell death at 17.5 uM Ref.26026377|||26026377|||Peptides. 2015 Sep;71:296-303.Antibiotics (Basel). 2020 Sep 30;9(10):661.||Ref.26026377 25 FPDB20061 DRAMP30313 GFLSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC "Frog Virus 3: inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 uM); Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells( 90% inhibition at 50 uM)." Rana pipiens (northern leopard frog) N/A N/A Ref.11601906|||Virology. 2001 Sep 30;288(2):351-7.||Ref.11601906 37 FPDB20062 DRAMP30315 FVPWFSKFlPRIL Anti-HSV-1:inhibition of HSV-1 replication in Vero cells, activity value is IC50 = 7.7 uM||Anti-HSV-2:inhibition of HSV-2 replication in Vero cells, activity value is IC50 = 9.83 uM||Anti-SARS-CoV-2:inhibition of replication in Vero cells, activity value is IC50 = 4.82 uM||Anti-HPIV-3:inhibition of replication in Vero cells, activity value is IC50 > 50 uM||Anti-HCoV-229E:inhibition of replication in Vero cells, activity value is IC50 = 10.56 uM||Anti-HCoV-OC43:inhibition of replication in Vero cells, activity value is IC50 = 11.31 uM Synthetic construct(derived from Temporin-L) N/A [Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 uM. Ref.35216177|||Int J Mol Sci. 2022 Feb 13;23(4):2060.||Ref.35216177 13 FPDB20063 DRAMP30338 RLFFKCIYRFFEHGLKRG Anti-H1N1 :inhibition of infection in Madin-Darby canine kidney epithelial cells, activity value is IC50 = 0.87 uM||Antimicrobial||Antiviral Synthetic construct(derived from influenza virus M2 protein) N/A N/A Ref.31375212|||Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512. 18 FPDB20064 DRAMP30339 RKFFKKIYRFFRKLLKRL Anti-H1N1 :inhibition of infection in Madin-Darby canine kidney epithelial cells, activity value is IC50 = 0.053 uM||Anti-H3N2 :inhibition of infection in Madin-Darby canine kidney epithelial cells, activity value is IC50 = 0.058 uM||Anti-H3N2 :inhibition of infection in Madin-Darby canine kidney epithelial cells, activity value is IC50 = 0.016 uM||Anti-H5N2 :inhibition of infection in Madin-Darby canine kidney epithelial cells, activity value is IC50 = 0.066 uM||Antimicrobial||Antiviral Synthetic construct(derived from influenza virus M2 protein) N/A N/A Ref.31375212|||Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512. 18 FPDB20065 DRAMP30340 RLAAKCAARFAEHGLKRG H1N1:did not exhibit any inhibitory effect.||Antimicrobial||Antiviral Synthetic construct(derived from influenza virus M2 protein) N/A N/A Ref.31375212|||Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512. 18 FPDB20066 DRAMP30342 FLPLILPAnti-SIVTALSSFLKQG "DENV2:reduced the number of lysis plaques by 100% at 125 ug/ml; by 60% at 7.81 ug/ml; DENV3:reduced the number of lysis plaques by 100% at 125 ug/ml; by 50% at 7.81 ug/ml||Antimicrobial||Antiviral" Hypsiboas semilineatus N/A N/A Ref.29153860|||Virology. 2018 Jan 15;514:79-87. 24 FPDB20067 DRAMP30343 GGARDAGKAEWW Anti-dengue virus serotype 2 :inhibition the cytopathic effect and plaque formation in Vero cells, activity value is IC50 = 77||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.26248692|||J Appl Microbiol. 2015 Oct;119(4):1170-80. 12 FPDB20068 DRAMP30344 QEGISRFKICPYHWYKQHMSLLFRRYYHKLDSII "Herpes simplex virus-1(HSV-1):inhibition of HSV-1 infection in MelJuSo(MJS) cells(75.9 ± 5.7% inhibition at 150 ug/ml); Hepatitis B virus(HBV): decrease of HBeAg and viral DNA infected with HBV-1 in HepRG cells(84.0 ± 3.0% of HBeAg and 73.6 ± 2.3% of viral DNA at 100 ug/ml); HIV-1:inhibition of virus infection in LC5-RIC reporter cells(82.7 ± 4.9% inhibition at 100 ug/ml);inhibition of virus replication in LC5-RIC reporter cells(62.2 ± 2.4% inhibition at 100 ug/ml); Rift Valley fever virus(RVFV): inhibition of virus infection in MJS cells(65.5 ± 2.3% inhibition at 160 ug/ml).||Antimicrobial||Antiviral" Synthetic construct(derived from the cowpox virus protein) N/A N/A Ref.32872420|||Cells. 2020 Aug 29;9(9):1989. 34 FPDB20069 DRAMP30345 TEPSTRGSWKFW Japanese encephalitis virus (JEV): inhibition of JEV infection in BHK-21 cells(IC50~100 uM).||Antimicrobial||Antiviral Synthetic construct(phage display) N/A N/A Ref.24468276|||Antiviral Res. 2014 Apr;104:7-14. 12 FPDB20070 DRAMP30346 SENRKVPFYSHS Anti-Japanese encephalitis virus : inhibition of JEV infection in BHK-21 cells, activity value is IC50 = 1.42||activity value is IC50 = 1.12||Antimicrobial||Antiviral Synthetic construct(phage display) N/A N/A Ref.24468276|||Antiviral Res. 2014 Apr;104:7-14. 12 FPDB20071 DRAMP30347 MVDRGWGNHAGLFGKGAnti-SIV Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(17±10% inhibition at 49.9 uM).||Antimicrobial||Antiviral Synthetic construct(derived from the E polyprotein of DENV) N/A N/A Ref.31351847|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 23 FPDB20072 DRAMP30348|||DN57wt|||DRAMP30348 AWLVHTQWFLDLPLPWLPGADTQGSNWI Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(7±4% inhibition at 30.6 uM).||Antiviral||Antimicrobial Synthetic construct(derived from the E polyprotein of DENV)|||Synthetic construct|||Synthetic construct(derived from the E polyprotein of DENV) N/A N/A Ref.31351847|||https://pubmed.ncbi.nlm.nih.gov/20582308|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 28 FPDB20073 DRAMP30349|||DN81wt|||DRAMP30349 AWLVHRQWFLDLPLPWLPG Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(25±8% inhibition at 42.6 uM).||Antiviral ; DENV-2||Antimicrobial||Antiviral Synthetic construct(derived from the E polyprotein of DENV)|||Synthetic construct|||Synthetic construct(derived from the E polyprotein of DENV) N/A N/A Ref.31351847|||20582308|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 19 FPDB20074 DRAMP30350|||DENV-2 gp|||DRAMP30350 MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY "Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10 uM||100.0±0.5% inhibition at 20 uM); West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(>99% inhibition at <25 uM).||Antiviral ; DENV-2[IC50 I = 5 uM]||DENV-1[IC50 I = 2 uM]||DENV-3[IC50 I = 2 uM]||DENV-4[IC50 I = 5 uM]||Yellow fever virus (YFV)[IC50 I = 20 uM]||Russian spring-summer encephalitis virus (RSSEV)[IC50 I = 27 uM]||Central European encephalitis virus (CEEV)[IC50 I = 29 uM]||Vesicular Stomatitis Virus (VSV)||Aedes albopictus C6/36 cells||DENV-2[IC50 I = 1 uM]||Antimicrobial||Antiviral" Synthetic construct(derived from the E polyprotein of DENV)|||Synthetic construct|||Synthetic construct(derived from the E polyprotein of DENV) N/A Monkey kidney epithelial cells LLC-MK2 ( at NA Ref.31351847|||https://pubmed.ncbi.nlm.nih.gov/23226444|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 33 FPDB20075 DRAMP30351 VVDRGWGNGAGLFGKGSID West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(4±13% inhibition at 52.5 uM).||Antimicrobial||Antiviral Synthetic construct(derived from the E polyprotein of WNV) N/A N/A Ref.31351847|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 19 FPDB20076 DRAMP30352 TFLVHREWFMDLNLPWSSAGSTVWR West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10 uM||56.0±3.0% inhibition at 99 uM).||Antimicrobial||Antiviral Synthetic construct(derived from the E polyprotein of WNV) N/A N/A Ref.31351847|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 25 FPDB20077 DRAMP30353 TFLVHREWFMDLNLPWSSA West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10 uM||70.0±3.0% inhibition at 128 uM).||Antimicrobial||Antiviral Synthetic construct(derived from the E polyprotein of WNV) N/A N/A Ref.31351847|||Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. 19 FPDB20078 DRAMP30354 GYIEAEVI Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 8 FPDB20079 DRAMP30355 QETAYFLLKLAGRWP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 3.5 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 15 FPDB20080 DRAMP30356 STTVKAASWWA Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 1000 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 11 FPDB20081 DRAMP30357 HLKTAVQMAVFIHNFKR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 17 FPDB20082 DRAMP30358 AGERIVDIIATDIQ Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 2 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 14 FPDB20083 DRAMP30359 QETAYFLLKLAGR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 150 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 13 FPDB20084 DRAMP30360 AGERIVDIIA Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 30 uM||Antimicrobial||Antiviral Synthetic construct(derived from HIV-1 integrase) N/A N/A Ref.12643937|||Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7. 10 FPDB20085 DRAMP30361|||CAMPSQ21593|||DRAMP30361 WNSLKIDNLDV HIV-1:inhibition of integrase catalytic activity(81% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. 11 FPDB20086 DRAMP30362|||CAMPSQ21594|||DRAMP30362 WASLKIDNLDV HIV-1:inhibition of integrase catalytic activity(76% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. 11 FPDB20087 DRAMP30363|||CAMPSQ21595|||DRAMP30363 WNALKIDNLDV HIV-1:inhibition of integrase catalytic activity(79% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. 11 FPDB20088 DRAMP30364|||CAMPSQ21596|||DRAMP30364 WNSAKIDNLDV HIV-1:inhibition of integrase catalytic activity(71% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20089 DRAMP30365|||CAMPSQ21597|||DRAMP30365 WNSLAIDNLDV HIV-1:inhibition of integrase catalytic activity(68% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20090 DRAMP30366|||CAMPSQ21598|||DRAMP30366 WNSLKADNLDV HIV-1:inhibition of integrase catalytic activity(65% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20091 DRAMP30367|||CAMPSQ21599|||DRAMP30367 WNSLKIANLDV HIV-1:inhibition of integrase catalytic activity(58% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20092 DRAMP30368|||CAMPSQ21600|||DRAMP30368 WNSLKIDALDV HIV-1:inhibition of integrase catalytic activity(75% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20093 DRAMP30369|||CAMPSQ21601|||DRAMP30369 WNSLKIDNADV HIV-1:inhibition of integrase catalytic activity(75% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20094 DRAMP30370|||CAMPSQ21602|||DRAMP30370 WNSLKIDNLAV HIV-1:inhibition of integrase catalytic activity(73% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20095 DRAMP30371|||CAMPSQ21603|||DRAMP30371 WNSLKIDNLDA HIV-1:inhibition of integrase catalytic activity(68% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20096 DRAMP30372|||CAMPSQ21604|||DRAMP30372 WNSLKIANLAV HIV-1:inhibition of integrase catalytic activity(43% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 11 FPDB20097 DRAMP30373|||CAMPSQ21605|||DRAMP30373 WIDNLD HIV-1:inhibition of integrase catalytic activity(30% inhibition at 0.1 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.20171172|||20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 6 FPDB20098 DRAMP30374|||HRP2|||DRAMP30374 WKFALKVDSPDV HIV-1:inhibition of integrase catalytic activity(25% inhibition at 0.1 uM).||Antiviral ; HIV-1[20-30% IN activity = 19.5 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20171172|||https://pubmed.ncbi.nlm.nih.gov/20171172|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.|||Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5.||Ref.20171172 12 FPDB20099 DRAMP30375|||WQ|||DRAMP30375 WEEWDKKIEEYTKKIEELIKKSQNQQ Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.1234||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.1595||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.1262||Anti-HIV-1 clinical isolates :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0812||Anti-HIV-1 pseudoviruses :inhibition of pseudoviruses infection in MT-2 cells, activity value is IC50 = 0.0135||Anti-HIV-1 T20-resistant strains :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0348||Anti-HIV-1 T2635-resistant strain :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.1951||Antiviral ; HIV-1 IIIB[IC50 I = 0.1234 uM]||HIV-1 IIIB[IC50 F = 0.1595 uM]||HIV-1 BaL[IC50 I = 0.1262 uM]||HIV-1[IC50 I = 0.0812-0.3833 uM]||HIV-1 PsV[IC50 I = 0.0135-0.0568 uM]||HIV-1 9489[IC50 I = 0.1608 uM]||HIV-1 NL4-3 V38A[IC50 I = 0.4331 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 26 FPDB20100 DRAMP30376|||MT-WQ|||DRAMP30376 MTWEEWDKKIEEYTKKIEELIKKSQNQQ Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0088||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0148||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0067||Antiviral ; HIV-1 IIIB[IC50 I = 0.0088 uM]||HIV-1 IIIB[IC50 F = 0.0148 uM]||HIV-1 BaL[IC50 I = 0.0067 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 28 FPDB20101 DRAMP30377|||WQ-SM|||DRAMP30377 WEEWDKKIEEYTKKIEELIKKSQNQQSM Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0604 uM||Antiviral ; HIV-1 IIIB[IC50 I = 0.0604 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 28 FPDB20102 DRAMP30378|||WQ-SW|||DRAMP30378 WEEWDKKIEEYTKKIEELIKKSQNQQSW Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0477 uM||Antiviral ; HIV-1 IIIB[IC50 I = 0.0477 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 28 FPDB20103 DRAMP30379|||WQ-SY|||DRAMP30379 WEEWDKKIEEYTKKIEELIKKSQNQQSY Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0548 uM||Antiviral ; HIV-1 IIIB[IC50 I = 0.0548 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 28 FPDB20104 DRAMP30380|||WQ-SDLD|||DRAMP30380 WEEWDKKIEEYTKKIEELIKKSQNQQSDLD Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0441 uM||Antiviral ; HIV-1 IIIB[IC50 I = 0.0441 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 30 FPDB20105 DRAMP30381|||WQ-LDL|||DRAMP30381 WEEWDKKIEEYTKKIEELIKKSQNQQLDL Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0037||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0064||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0036||Antiviral ; HIV-1 IIIB[IC50 I = 0.0036 uM]||HIV-1 IIIB[IC50 F = 0.0064 uM]||HIV-1 BaL[IC50 I = 0.0036 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 29 FPDB20106 DRAMP30382|||WQ-IDI|||DRAMP30382 WEEWDKKIEEYTKKIEELIKKSQNQQIDI Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0037||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0064||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0032||Antiviral ; Antiviral||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 29 FPDB20107 DRAMP30383|||WQ-LDI|||DRAMP30383 WEEWDKKIEEYTKKIEELIKKSQNQQLDI Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0036||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0072||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0031||Antiviral ; HIV-1 IIIB[IC50 I = 0.0036 uM]||HIV-1 IIIB[IC50 F = 0.0072 uM]||HIV-1 BaL[IC50 I = 0.0031 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 29 FPDB20108 DRAMP30384|||WQ-IDL|||DRAMP30384 WEEWDKKIEEYTKKIEELIKKSQNQQIDL Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0016||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0056||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0025||Anti-HIV-1 clinical isolates :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.002||Anti-HIV-1 pseudoviruses :inhibition of pseudoviruses infection in MT-2 cells, activity value is IC50 = 0.0008||Anti-HIV-1 T20-resistant strains :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0016||Anti-HIV-1 T2635-resistant strain :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0085||Antiviral ; HIV-1 IIIB[IC50 I = 0.0016 uM]||HIV-1 IIIB[IC50 F = 0.0056 uM]||HIV-1 BaL[IC50 I = 0.0025 uM]||HIV-1[IC50 I = 0.002-0.0206 uM]||HIV-1 PsV[IC50 I = 0.0008-0.007 uM]||HIV-1 9489[IC50 I = 0.0068 uM]||HIV-1 NL4-3 V38A[IC50 I = 0.022 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0015 uM]||HIV-1 HxB2[IC50 F = 0.0011 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416,|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 29 FPDB20109 DRAMP30385|||MT-WQ-IDL|||DRAMP30385 MTWEEWDKKIEEYTKKIEELIKKSQNQQIDL Anti-HIV-1 IIIB:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0006||Anti-ion of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 = 0.0012||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0006||Anti-HIV-1 clinical isolates :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0005||Anti-HIV-1 pseudoviruses :inhibition of pseudoviruses infection in MT-2 cells, activity value is IC50 = 0.0001||Anti-HIV-1 T20-resistant strains :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0001||Anti-HIV-1 T2635-resistant strain :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.0011||Antiviral ; HIV-1 IIIB[IC50 I = 0.0006 uM]||HIV-1 IIIB[IC50 F = 0.0012 uM]||HIV-1 BaL[IC50 I = 0.0006 uM]||HIV-1[IC50 I = 0.0005-0.0041 uM]||HIV-1 PsV[IC50 I = 0.0001-0.0009 uM]||HIV-1 9489[IC50 I = 0.0022 uM]||HIV-1 NL4-3 V38A[IC50 I = 0.0044 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0009 uM]||HIV-1 HxB2[IC50 F = 0.0007 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416,|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 31 FPDB20110 DRAMP30386|||MT-WQ-IDL-scrambled|||DRAMP30386 EEQKTQLKNKIEIDWTKMELEQDWSKIYKEI Anti-HIV-1 IIIB:inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells, activity value is IC50 > 0.5 uM||Anti-HIV-1 Bal:inhibition of virus infection in MT-2 cells, activity value is IC50 > 0.5 uM||Antiviral ; HIV-1 IIIB[IC50 F >0.5 uM]||HIV-1 BaL[IC50 I >0.5 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 31 FPDB20111 DRAMP30387|||MERS-S|||DRAMP30387 TTLLDLTYEMLSLQQVVKALNESYIDLKEL Anti-MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells, activity value is IC50 = 4.5 uM||Anti-ion of pseudovirus infection in MT-2 cells, activity value is IC50 = 17.8 uM||Antiviral ; MERS-CoV[IC50 F = 4.5 uM]||MERS-CoV PsV[IC50 I = 17.8 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 30 FPDB20112 DRAMP30388|||MERS-S|||DRAMP30388 EANTTLLDLTYEMLSLQQVVKALNESYIDLKEL Anti-MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells, activity value is IC50 = 0.9 uM||Anti-ion of pseudovirus infection in MT-2 cells, activity value is IC50 = 2.3 uM||Antiviral ; MERS-CoV[IC50 F = 0.9 uM]||MERS-CoV PsV[IC50 I = 2.3 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.27795416|||https://pubmed.ncbi.nlm.nih.gov/27795416|||J Virol. 2016 Dec 16;91(1):e01445-16.|||J Virol. 2016 Dec 16;91(1):e01445-16.||Ref.27795416 33 FPDB20113 DRAMP30391 ILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.1||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.07||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 21 FPDB20114 DRAMP30392 RILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.13||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.11||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 22 FPDB20115 DRAMP30393 IRILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.26||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.11||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 23 FPDB20116 DRAMP30394 IIRILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.11||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.07||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 24 FPDB20117 DRAMP30395 AIIRILQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.08||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.05||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 25 FPDB20118 DRAMP30396 EAIIRILQQLLFIEFRIKRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.05||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.01||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20119 DRAMP30397 EEIIRKLQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.12||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.047||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20120 DRAMP30398 EAIIRILQELLFKHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.14||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.065||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20121 DRAMP30399 EAIERILKQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.23||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.15||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20122 DRAMP30400 EAEIRIKQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.04||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.031||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20123 DRAMP30401 EAIIRILQQLEFIHKRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.71||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20124 DRAMP30402 EEIIRKLQQLLFIEFRIKRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.18||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.08||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 26 FPDB20125 DRAMP30403 AQQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.12||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.08||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20126 DRAMP30404 LAQLLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.13||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20127 DRAMP30405 LQALLFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.1||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20128 DRAMP30406 LQQALFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.12||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.07||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20129 DRAMP30407 LQQLAFIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.13||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20130 DRAMP30408 LQQLLAIHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.34||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.18||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20131 DRAMP30409 LQQLLFAHFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.33||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.22||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20132 DRAMP30410 LQQLLFIAFRIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.13||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.06||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20133 DRAMP30411 LQQLLFIHARIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.25||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.12||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20134 DRAMP30412 LQQLLFIHFAIGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.11||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.05||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20135 DRAMP30413 LQQLLFIHFRAGRRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.2||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.16||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20136 DRAMP30414 LQQLLFIHFRIARRRRRRRR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 0.09||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 0.09||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20708407|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.|||Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.||Ref.20708407 20 FPDB20137 DRAMP30415|||DRAMP30416|||DRAMP30417|||N27 -C16|||DRAMP30415|||DRAMP30416|||DRAMP30417 RQLLSGIVQQQNNLLRAIEAQQHLLQK Anti-HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells, activity value is IC50 = 1.075||Anti-ion of peptide against virus-cell fusion on CD4-expressing cells, activity value is IC50 = 0.293||Anti-HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells, activity value is IC50 = 0.473||Anti-ion of peptide against virus-cell fusion on CD4-expressing cells, activity value is IC50 = 0.182||Anti-HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells, activity value is IC50 = 0.148||Anti-ion of peptide against virus-cell fusion on CD4-expressing cells, activity value is IC50 = 0.01||Antiviral ; HIV-1||HIV-1[IC50 F = 1.075+-0.09 uM]||HIV-1[IC50 F = 0.473+-0.074 uM]||HIV-1[IC50 F = 0.148+-0.004 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20605950|||https://pubmed.ncbi.nlm.nih.gov/20605950|||FASEB J. 2010 Nov;24(11):4196-202.|||FASEB J. 2010 Nov;24(11):4196-202.||Ref.20605950 27 FPDB20138 DRAMP30418|||C16- N25|||DRAMP30418 RQLLSGIVQQQNNLLRAIEAQQHLL Anti-HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells, activity value is IC50 = 0.484||Antiviral ; HIV-1||HIV-1[IC50 F = 0.484+-0.06 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20605950|||20605950|||FASEB J. 2010 Nov;24(11):4196-202.|||FASEB J. 2010 Nov;24(11):4196-202.||Ref.20605950 25 FPDB20139 DRAMP30419|||C16- N23|||DRAMP30419 RQLLSGIVQQQNNLLRAIEAQQH Anti-HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells, activity value is IC50 = 1.931||Antiviral ; HIV-1||HIV-1[IC50 F = 1.931+-0.187 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20605950|||20605950|||FASEB J. 2010 Nov;24(11):4196-202.|||FASEB J. 2010 Nov;24(11):4196-202.||Ref.20605950 23 FPDB20140 DRAMP30420|||MERS-S|||DRAMP30420 XDLTXEMLSLQQVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 > 50 uM||Antiviral ; MERS-CoV[IC50 F >50 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20141 DRAMP30421|||DRAMP30430|||MERS-S|||DRAMP30421|||DRAMP30430 LXLTYXMLSLQQVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 3.9||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 10.9||Antiviral ; MERS-CoV[IC50 F = 3.9+-1.1 uM]||MERS-CoV[IC50 F = 10.9+-1.1 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20142 DRAMP30422|||MERS-S|||DRAMP30422 LDLXYEMXSLQQVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 > 50 uM||Antiviral ; MERS-CoV[IC50 F >50 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20143 DRAMP30423|||DRAMP30431|||MERS-S|||DRAMP30423|||DRAMP30431 LDLTXEMLXLQQVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 7.14||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 8.21||Antiviral ; MERS-CoV[IC50 F = 7.14+-0.7 uM]||MERS-CoV[IC50 F = 8.21+-0.9 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20144 DRAMP30424|||DRAMP30432|||MERS-S|||DRAMP30424|||DRAMP30432 LDLTYEMXSLQXVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 10.7||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 4.49||Antiviral ; MERS-CoV[IC50 F = 10.7+-2.6 uM]||MERS-CoV[IC50 F = 4.49+-0.6 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20145 DRAMP30425|||MERS-S|||DRAMP30425 LDLTYEMLXLQQXVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 > 50 uM||Antiviral ; MERS-CoV[IC50 F >50 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20146 DRAMP30426|||MERS-S|||DRAMP30426 LDLTYEMLSLXQVVXALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 > 50 uM||Antiviral ; MERS-CoV[IC50 F >50 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20147 DRAMP30427|||DRAMP30433|||DRAMP30436|||MERS-S|||DRAMP30427|||DRAMP30433|||DRAMP30436 LDLTYEMLSLQXVVKXLNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 0.26||Anti-WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 3.03||Anti-Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 4.06||Anti-Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 1.98||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 20.6||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 16.3||Antiviral ; MERS-CoV[IC50 F = 0.26+-0.05 uM]||MERS-CoV PsV[IC50 I = 3.03+-0.29 uM]||Cov-Q1020H PsV[IC50 I = 4.06+-0.34 uM]||Cov-Q1020R PsV[IC50 I = 1.98+-0.28 uM]||MERS-CoV PsV[IC50 I = 2.21+-0.62 uM]||Human hepatocellular carcinoma Huh7[50-60% Cytotoxicity >100 uM]||Human lung carcinoma Calu-3[50-60% Cytotoxicity >100 uM]||MERS-CoV[IC50 F = 20.6+-3.3 uM]||MERS-CoV[IC50 F = 16.3+-1.1 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20148 DRAMP30428|||DRAMP30434|||MERS-S|||DRAMP30428|||DRAMP30434 LDLTYEMLSLQQVVXALNXSY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 14.1||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 10.9||Antiviral ; MERS-CoV[IC50 F = 14.1+-2.3 uM]||MERS-CoV[IC50 F = 10.9+-1 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20149 DRAMP30429|||DRAMP30435|||MERS-S|||DRAMP30429|||DRAMP30435 LDLTYEMLSLQQVVKXLNEXY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 0.33||Anti-WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 0.97||Anti-Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 1.82||Anti-Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 0.89||Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 3.55||Antiviral ; MERS-CoV[IC50 F = 0.33+-0.04 uM]||MERS-CoV PsV[IC50 I = 0.97+-0.08 uM]||Cov-Q1020H PsV[IC50 I = 1.82+-0.28 uM]||Cov-Q1020R PsV[IC50 I = 0.89+-0.07 uM]||MERS-CoV PsV[IC50 I = 1.58+-0.16 uM]||Human hepatocellular carcinoma Huh7[50-60% Cytotoxicity >100 uM]||Human lung carcinoma Calu-3[50-60% Cytotoxicity >100 uM]||MERS-CoV[IC50 F = 3.55+-0.2 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20150 DRAMP30437 LDLTYEZLSLQXVVKXLNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 0.63||Anti-WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 2.8||Anti-Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 4.15||Anti-Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 2.49||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20151 DRAMP30438|||MERS-S|||DRAMP30438 LDLTYEMLSLQXVVKXLNESF Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 2.16||Antiviral ; MERS-CoV[IC50 F = 2.16+-1.1 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20152 DRAMP30439 LDLTYEZLSLQXVVKXLNESF Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 3.89||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20153 DRAMP30440|||MERS-S|||DRAMP30440 LDLTYEMLSLQQVVKALNESY Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 > 50 uM||Antiviral ; MERS-CoV[IC50 F >50 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 21 FPDB20154 DRAMP30441 SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL Anti-MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells, activity value is EC50 = 0.75||Anti-WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 1.07||Anti-Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 1.25||Anti-Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells, activity value is EC50 = 0.64||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.29442512|||J Med Chem. 2018 Mar 8;61(5):2018-2026.|||J Med Chem. 2018 Mar 8;61(5):2018-2026.||Ref.29442512 36 FPDB20155 DRAMP30442 FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNI Anti-feline coronavirus :inhibition of virus replication in Fcwf-4 cells, activity value is IC50 = 14.21 uM||Antimicrobial||Antiviral Synthetic construct(derived from S protein of FCoV) N/A N/A Ref.24312629|||PLoS One. 2013 Dec 3;8(12):e82081.|||PLoS One. 2013 Dec 3;8(12):e82081.||Ref.24312629 36 FPDB20156 DRAMP30443 FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNL Anti-feline coronavirus :inhibition of virus replication in Fcwf-4 cells, activity value is IC50 = 1.8 uM||Antimicrobial||Antiviral Synthetic construct(derived from S protein of FCoV) N/A N/A Ref.24312629|||PLoS One. 2013 Dec 3;8(12):e82081.|||PLoS One. 2013 Dec 3;8(12):e82081.||Ref.24312629 43 FPDB20157 DRAMP30444 FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNLEWLNRIE Anti-feline coronavirus :inhibition of virus replication in Fcwf-4 cells, activity value is IC50 = 1.33 uM||Antimicrobial||Antiviral Synthetic construct(derived from S protein of FCoV) N/A N/A Ref.24312629|||PLoS One. 2013 Dec 3;8(12):e82081.|||PLoS One. 2013 Dec 3;8(12):e82081.||Ref.24312629 50 FPDB20158 DRAMP30445|||SC34EK|||DRAMP30445 WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0009||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0007||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0009 uM]||HIV-1 HxB2[IC50 F = 0.0007 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 34 FPDB20159 DRAMP30446|||SC33EK|||DRAMP30446 WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0011||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0007||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0011 uM]||HIV-1 HxB2[IC50 F = 0.0007 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 33 FPDB20160 DRAMP30447|||SC32EK|||DRAMP30447 WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0011||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0008||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0011 uM]||HIV-1 HxB2[IC50 F = 0.0008 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 32 FPDB20161 DRAMP30448|||SC31EK|||DRAMP30448 WEEWDKKIEEYTKKIEELIKKSEEQQKKNEK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0013||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0009||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0013 uM]||HIV-1 HxB2[IC50 F = 0.0009 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 31 FPDB20162 DRAMP30449|||SC30EK|||DRAMP30449 WEEWDKKIEEYTKKIEELIKKSEEQQKKNE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.001||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0009||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.001 uM]||HIV-1 HxB2[IC50 F = 0.0009 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 30 FPDB20163 DRAMP30450|||SC29EK|||DRAMP30450 WEEWDKKIEEYTKKIEELIKKSEEQQKKN Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0012||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.001||Antiviral ; HIV-1 NL4-3[IC50 REP = 0.0024+-0.0001 uM]||HIV-1 NL4-3 D36G[IC50 REP = 0.0019+-0 uM]||HIV-1 NL4-3 D36G/V38A[IC50 REP = 0.003+-0.0006 uM]||HIV-1 NL4-3 D36G/N43D[IC50 REP = 0.0041+-0.0006 uM]||HIV-1 NL4-3 D36G/N43D/S138A[IC50 REP = 0.0034+-0.0009 uM]||HIV-1 NL4-3 D36G/N126K[IC50 REP = 0.0027+-0.0001 uM]||HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I[IC50 REP = 0.05+-0.011 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0012 uM]||HIV-1 HxB2[IC50 F = 0.001 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/19114674,|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 29 FPDB20164 DRAMP30451|||SC28EK|||DRAMP30451 WEEWDKKIEEYTKKIEELIKKSEEQQKK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.018||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.013||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.018 uM]||HIV-1 HxB2[IC50 F = 0.013 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 28 FPDB20165 DRAMP30452|||SC27EK|||DRAMP30452 WEEWDKKIEEYTKKIEELIKKSEEQQK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.029||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0214||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.029 uM]||HIV-1 HxB2[IC50 F = 0.0214 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 27 FPDB20166 DRAMP30453|||SC26EK|||DRAMP30453 WEEWDKKIEEYTKKIEELIKKSEEQQ Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0449||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0362||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0449 uM]||HIV-1 HxB2[IC50 F = 0.0362 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 26 FPDB20167 DRAMP30454|||SC25EK|||DRAMP30454 WEEWDKKIEEYTKKIEELIKKSEEQ Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0798||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0415||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0798 uM]||HIV-1 HxB2[IC50 F = 0.0415 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 25 FPDB20168 DRAMP30455|||SC24EK|||DRAMP30455 WEEWDKKIEEYTKKIEELIKKSEE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.1076||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0757||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.1076 uM]||HIV-1 HxB2[IC50 F = 0.0757 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 24 FPDB20169 DRAMP30456|||SC23EK|||DRAMP30456 WEEWDKKIEEYTKKIEELIKKSE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.1051||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0942||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.1051 uM]||HIV-1 HxB2[IC50 F = 0.0942 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 23 FPDB20170 DRAMP30457|||SC22EK|||DRAMP30457 WEEWDKKIEEYTKKIEELIKKS Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0669||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0986||Antiviral ; HIV-1 NL4-3[IC50 REP = 0.217+-0.041 uM]||HIV-1 NL4-3 D36G[IC50 REP = 0.686+-0.094 uM]||HIV-1 NL4-3 D36G/V38A[IC50 REP = 0.289+-0.084 uM]||HIV-1 NL4-3 D36G/N43D[IC50 REP = 0.114+-0.036 uM]||HIV-1 NL4-3 D36G/N43D/S138A[IC50 REP >1 uM]||HIV-1 NL4-3 D36G/N126K[IC50 REP >1 uM]||HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I[IC50 REP = 0.252+-0.071 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0669 uM]||HIV-1 HxB2[IC50 F = 0.0986 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||19114674, 31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 22 FPDB20171 DRAMP30458|||SC21EK|||DRAMP30458 WEEWDKKIEEYTKKIEELIKK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.1132||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.1054||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.1132 uM]||HIV-1 HxB2[IC50 F = 0.1054 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 21 FPDB20172 DRAMP30459|||SC20EK|||DRAMP30459 WEEWDKKIEEYTKKIEELIK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.1266||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.2024||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.1266 uM]||HIV-1 HxB2[IC50 F = 0.2024 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 20 FPDB20173 DRAMP30460|||SC19EK|||DRAMP30460 WEEWDKKIEEYTKKIEELI Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0707||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.2172||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0707 uM]||HIV-1 HxB2[IC50 F = 0.2172 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 19 FPDB20174 DRAMP30461|||SC18EK|||DRAMP30461 WEEWDKKIEEYTKKIEEL Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 > 2 uM||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 2 uM||Antiviral ; HIV-1 NL4-3 PsV[IC50 E >2 uM]||HIV-1 HxB2[IC50 F >2 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 18 FPDB20175 DRAMP30462 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.001||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0007||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 36 FPDB20176 DRAMP30463|||MTSC33EK|||DRAMP30463 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0012||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0008||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0012 uM]||HIV-1 HxB2[IC50 F = 0.0008 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353 35 FPDB20177 DRAMP30464|||MTSC32EK|||DRAMP30464 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0013||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0011||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0013 uM]||HIV-1 HxB2[IC50 F = 0.0011 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 34 FPDB20178 DRAMP30465|||MTSC31EK|||DRAMP30465 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0013||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0009||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0013 uM]||HIV-1 HxB2[IC50 F = 0.0009 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 33 FPDB20179 DRAMP30466|||MTSC30EK|||DRAMP30466 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0008||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0008||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0008 uM]||HIV-1 HxB2[IC50 F = 0.0008 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 32 FPDB20180 DRAMP30467|||MTSC29EK|||DRAMP30467 MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0009||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0011||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0009 uM]||HIV-1 HxB2[IC50 F = 0.0011 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 31 FPDB20181 DRAMP30468|||MTSC28EK|||DRAMP30468 MTWEEWDKKIEEYTKKIEELIKKSEEQQKK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0013||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0012||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0013 uM]||HIV-1 HxB2[IC50 F = 0.0012 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 30 FPDB20182 DRAMP30469|||MTSC27EK|||DRAMP30469 MTWEEWDKKIEEYTKKIEELIKKSEEQQK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0011||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0014||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0011 uM]||HIV-1 HxB2[IC50 F = 0.0014 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 29 FPDB20183 DRAMP30470|||MTSC26EK|||DRAMP30470 MTWEEWDKKIEEYTKKIEELIKKSEEQQ Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0016||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0011||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0016 uM]||HIV-1 HxB2[IC50 F = 0.0011 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 28 FPDB20184 DRAMP30471|||MTSC25EK|||DRAMP30471 MTWEEWDKKIEEYTKKIEELIKKSEEQ Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0019||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.002||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0019 uM]||HIV-1 HxB2[IC50 F = 0.002 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 27 FPDB20185 DRAMP30472|||MTSC24EK|||DRAMP30472 MTWEEWDKKIEEYTKKIEELIKKSEE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0028||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0023||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0028 uM]||HIV-1 HxB2[IC50 F = 0.0023 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 26 FPDB20186 DRAMP30473|||MTSC23EK|||DRAMP30473 MTWEEWDKKIEEYTKKIEELIKKSE Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0021||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0019||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0021 uM]||HIV-1 HxB2[IC50 F = 0.0019 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 25 FPDB20187 DRAMP30474|||MTSC22EK|||DRAMP30474 MTWEEWDKKIEEYTKKIEELIKKS Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0024||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0022||Antiviral ; HIV-1 IIIB[IC50 I = 0.0195 uM]||HIV-1 IIIB[IC50 F = 0.02332 uM]||HIV-1 BaL[IC50 I = 0.0101 uM]||HIV-1 JRCSF[IC50 I = 0.01385 uM]||HIV-1[IC50 I = 0.0008-0.0082 uM]||HIV-1 PsV[IC50 I = 0.0007-0.0091 uM]||HIV-1 NL4-3 V38A[IC50 I = 0.0381 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.0506 uM]||Human T cell leukemia MT-2||Acute myeloid leukemia AML-M7||HIV-1 NL4-3 PsV[IC50 E = 0.0024 uM]||HIV-1 HxB2[IC50 F = 0.0022 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31805154, 31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 24 FPDB20188 DRAMP30475|||MTSC21EK|||DRAMP30475 MTWEEWDKKIEEYTKKIEELIKK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0038||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0031||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0038 uM]||HIV-1 HxB2[IC50 F = 0.0031 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 23 FPDB20189 DRAMP30476|||MTSC20EK|||DRAMP30476 MTWEEWDKKIEEYTKKIEELIK Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0037||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0033||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0037 uM]||HIV-1 HxB2[IC50 F = 0.0033 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 22 FPDB20190 DRAMP30477|||MTSC19EK|||DRAMP30477 MTWEEWDKKIEEYTKKIEELI Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.005||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0049||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.005 uM]||HIV-1 HxB2[IC50 F = 0.0049 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 21 FPDB20191 DRAMP30478|||MTSC18EK|||DRAMP30478 MTWEEWDKKIEEYTKKIEEL Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 > 2 uM||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 2 uM||Antiviral ; HIV-1 NL4-3 PsV[IC50 E >2 uM]||HIV-1 HxB2[IC50 F >2 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 20 FPDB20192 DRAMP30479|||MT-WQ-ENK|||DRAMP30479 MTWEEWDKKIEEYTKKIEELIKKSQNQQEKN Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0011||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0008||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0011 uM]||HIV-1 HxB2[IC50 F = 0.0008 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 31 FPDB20193 DRAMP30480|||WQ-ENK|||DRAMP30480 WEEWDKKIEEYTKKIEELIKKSQNQQEKN Anti-HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells, activity value is IC50 = 0.0014||Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0008||Antiviral ; HIV-1 NL4-3 PsV[IC50 E = 0.0014 uM]||HIV-1 HxB2[IC50 F = 0.0012 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.31277353|||https://pubmed.ncbi.nlm.nih.gov/31277353|||Viruses. 2019 Jul 3;11(7):609.||Ref.31277353|||Viruses. 2019 Jul 3;11(7):609. 29 FPDB20194 DRAMP30481 YTSLIREILVESRIQQEKNERELRDIDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.06 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.1 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.06 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.17 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.12 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.06 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.29 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20195 DRAMP30482 YTSLIHSIIEESRNRQEKNEQALLELDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.06 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.06 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.03 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.17 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.09 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.03 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.05 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20196 DRAMP30483 YTSLLRSIIEEGRNQQEKNEQALLELDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.13 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.08 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.03 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.19 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.08 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.03 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.34 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20197 DRAMP30484 YTSLIRSIIEESRNQQEKNEQKLLEVDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.15 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.12 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.04 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.22 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.5 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.03 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.8 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20198 DRAMP30485 YTSLLRSLIEESRNLQEKNEQALLEVDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.17 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.15 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.14 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.5 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.29 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.13 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 5.69 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T21) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20199 DRAMP30486 YTSLLWSIIEEGRNLQEKNEQKLLELDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.16 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.14 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.21 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.62 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.59 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.1 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 5.68 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T22) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20200 DRAMP30487 YTSLIWKVLNDAREQQENNQETLVEIDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.37 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.16 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.45 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.12 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.23 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.07 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 5.1 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T23) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20201 DRAMP30488 YTSLIREIMNKSWGQQRRNEGTLAEIDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 0.4 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.24 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.31 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.53 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.11 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.24 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 10.2 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T24) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20202 DRAMP30489 YTSLIRELISNARTQQTDNEESLRNVDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 1.2 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.34 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.41 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.82 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 1.09 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.35 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 16.8 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T25) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20203 DRAMP30490 YTSLIWSIIIDGREQQRDNEGVLADLDKWASLWNWF Anti-HIV-1 N43:inhibition of virus infection in U87 cells, activity value is IC50 = 23.3 ug/ml||Anti-HIV-1 JRCSF:inhibition of virus infection in U87 cells, activity value is IC50 = 0.5 ug/ml||Anti-HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 3.35 ug/ml||Anti-HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 12 ug/ml||Anti-HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.45 ug/ml||Anti-HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 0.11 ug/ml||Anti-HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells, activity value is IC50 = 24.4 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from T20)|||Synthetic construct(derived from T20)|||Synthetic construct(derived from T26) N/A N/A Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.31228294|||Protein Sci. 2019 Aug;28(8):1501-1512. 36 FPDB20204 DRAMP30491|||RSV Fgp|||DRAMP30491 EKINQSLAFIRKSDELLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 > 50 uM||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I >50 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Protein Sci. 2019 Aug;28(8):1501-1512.||Ref.28137809|||Protein Sci. 2019 Aug;28(8):1501-1512. 20 FPDB20205 DRAMP30492|||RSV Fgp|||DRAMP30492 EKINQSLXFIRXSDXLLHXV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1.82||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.82+-0.42 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20206 DRAMP30493|||RSV Fgp|||DRAMP30493 EKIXQSLXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.74||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.74+-0.27 uM]||Human hepatocellular carcinoma HepG2[10-20% Cytotoxicity = 12 uM]||Human hepatocellular carcinoma HepG2[40-50% Cytotoxicity = 25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20207 DRAMP30494|||RSV Fgp|||DRAMP30494 EXINXSLXFIRXSDELLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.59||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.59+-0.13 uM]||Human hepatocellular carcinoma HepG2[0-10% Cytotoxicity = 12 uM]||Human hepatocellular carcinoma HepG2[0-10% Cytotoxicity = 25 uM]||Respiratory syncytial virus (RSV)[IC50 REP = 8.3 uM]||Respiratory syncytial virus (RSV)[IC50 REP = 0.86 uM]||Respiratory syncytial virus (RSV)[IC50 REP = 0.47 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20208 DRAMP30495|||RSV Fgp|||DRAMP30495 XKINQSLXFIRXSDELLHXV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 3.07||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 3.07+-1.45 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20209 DRAMP30496|||RSV Fgp|||DRAMP30496 EKIXQSLXFIRXSDELLHXV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 2.49||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 2.49+-0.09 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RSV fusion protein)|||Synthetic construct|||Synthetic construct(derived from RSV fusion protein) N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20210 DRAMP30497|||RSV Fgp|||DRAMP30497 EKIAQSLXFIRXSDXLLHXV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 20.41||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 20.41+-2.4 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20211 DRAMP30498|||RSV Fgp|||DRAMP30498 EKINQSLXFIAXSDXLLHXV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 175||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 175.45 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20212 DRAMP30499|||RSV Fgp|||DRAMP30499 AKIXQSLXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1.16||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.16+-0.08 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A "Ref.28137809|||28137809|||--Structure Information --Physicochemical Information --Comments Information --Literature Information General Information DRAMP ID DRAMP30499 Peptide Name peptide 4bb[E497A] Source Synthetic construct Family Paramyxoviridae Gene Not found Sequence AKIXQSLXFIXKSDXLLHNV Sequence Length 20 UniProt Entry No entry found Protein Existence Not found Activity Information Biological Activity Antimicrobial, Antiviral Target Organism [Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.16±0.08 uM). Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry Cytotoxicity No cytotoxicity information or data found in the reference(s) presented in this entry Binding Target membrane Structure Information Linear/Cyclic Cyclic N-terminal Modification Acetylation C-terminal Modification Free Nonterminal Modifications and Unusual Amino Acids The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling. Stereochemistry L Structure Not found Structure Description Not found Helical Wheel Diagram DRAMP30499 helical wheel diagram PDB ID None Predicted Structure There is no predicted structure for DRAMP30499. Physicochemical Information Formula C84H132N22O19 Absent Amino Acids CEGMPRTWY Common Amino Acids X Mass 2271.49 PI 8.64 Basic Residues 3 Acidic Residues 1 Hydrophobic Residues 8 Net Charge +2 Boman Index -1003 Hydrophobicity 0.305 Aliphatic Index 117 Half Life Mammalian:4.4 h Yeast:>20 h E.coli:>10 h Extinction Coefficient Cystines 0 Absorbance 280nm 0 Polar Residues 3 DRAMP30499 DRAMP30499 chydropathy plot Comments Information Mechanism The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry. Literature Information ·Literature 1 Title A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading. Pubmed ID 28137809 Reference||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." 20 FPDB20213 DRAMP30500|||RSV Fgp|||DRAMP30500 EAIXQSLXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.6||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.60+-0.02 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20214 DRAMP30501|||RSV Fgp|||DRAMP30501 EKAXQSLXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1.3||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.30+-0.89 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20215 DRAMP30502|||RSV Fgp|||DRAMP30502 EKIXASLXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.28||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.28+-0.43 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20216 DRAMP30503|||RSV Fgp|||DRAMP30503 EKIXQALXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.66||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.66+-0.26 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20217 DRAMP30504|||RSV Fgp|||DRAMP30504 EKIXQSAXFIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.95||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.95+-0.53 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20218 DRAMP30505|||RSV Fgp|||DRAMP30505 EKIXQSLXAIXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1.39||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.39+-0.1 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20219 DRAMP30506|||RSV Fgp|||DRAMP30506 EKIXQSLXFAXKSDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 10.44||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 10.44+-2.97 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20220 DRAMP30507|||RSV Fgp|||DRAMP30507 EKIXQSLXFIXASDXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 10.93||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 10.93+-13.9 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20221 DRAMP30508|||RSV Fgp|||DRAMP30508 EKIXQSLXFIXKADXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 82.04||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 82.04+-1.56 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20222 DRAMP30509|||RSV Fgp|||DRAMP30509 EKIXQSLXFIXKSAXLLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1.1||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.10+-0.08 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20223 DRAMP30510|||RSV Fgp|||DRAMP30510 EKIXQSLXFIXKSDXALHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.88||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.88+-0.06 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20224 DRAMP30511|||RSV Fgp|||DRAMP30511 EKIXQSLXFIXKSDXLLANV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.52||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.52+-0.07 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20225 DRAMP30512|||RSV Fgp|||DRAMP30512 EKIXQSLXFIXKSDXLLHAV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 2.71||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 2.71+-2.93 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20226 DRAMP30513|||RSV Fgp|||DRAMP30513 EKIXQSLXFIXKSDXLLHNA Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 0.6||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 0.60+-0.03 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20227 DRAMP30514|||RSV Fgp|||DRAMP30514 EXINXSLXFIRXSDALLHNV Anti-Respiratory syncytial virus :inhibition of virus infection in Hep-2 cells, activity value is EC50 = 1||Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 1.00+-0.03 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.28137809|||28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.||Ref.28137809|||Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16. 20 FPDB20228 DRAMP30515|||LP-53|||DRAMP30515 YTSLIHSLIEESQNQQEKNEQELLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.002949||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.009968||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.021352||Antiviral ; HIV-1 HxB2[IC50 F = 0.002949 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.009968 uM]||HIV-1 JRCSF[IC50 I = 0.021352 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20229 DRAMP30516|||LP-54|||DRAMP30516 YTSLIEELIKKSEEQQKKNEEELKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000149||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000301||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.001796||Antiviral ; HIV-1 HxB2[IC50 F = 0.000149 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000301 uM]||HIV-1 JRCSF[IC50 I = 0.001796 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 25 FPDB20230 DRAMP30517|||LP-55|||DRAMP30517 WEQKIEELLKKAEEQQKKNEEELKKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000014||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000008||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000012||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 < 0.00001 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00011||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.01067||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00019||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000034 uM||Antiviral ; HIV-1 HxB2[IC50 F = 0.000014 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000008 uM]||HIV-1 JRCSF[IC50 I = 0.000012 uM]||HIV-1 PsV[IC50 I = 0.000034 uM]||HIV-1 NL4-3 D36G[IC50 I = <0.00001 uM]||HIV-1 NL4-3[IC50 I = 0.00011 uM]||HIV-1 NL4-3[IC50 I = 0.00118-0.18934 uM]||HIV-2 ROD[IC50 I = 0.13777 uM]||HIV-2[IC50 I = 0.01067 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00019-0.01061 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20231 DRAMP30518 WEQKIEELLKKAEEQQKKNEEELKXX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000012||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000009||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000011||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20232 DRAMP30519|||LP-57|||DRAMP30519 WEQKIEELLKKAEEQQKKNEEEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000213||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000178||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.001917||Antiviral ; HIV-1 HxB2[IC50 F = 0.000213 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000178 uM]||HIV-1 JRCSF[IC50 I = 0.001917 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 23 FPDB20233 DRAMP30520|||LP-58|||DRAMP30520 WEQKIEELLKKAEEQQKKNEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.143||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.1109||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.107033||Antiviral ; HIV-1 HxB2[IC50 F = 0.143 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.1109 uM]||HIV-1 JRCSF[IC50 I = 0.107033 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 21 FPDB20234 DRAMP30521|||LP-59|||DRAMP30521 WEQKIEELLKKAEEQQKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.9 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.2408||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.210477||Antiviral ; HIV-1 HxB2[IC50 F >9 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.2408 uM]||HIV-1 JRCSF[IC50 I = 0.210477 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 18 FPDB20235 DRAMP30522|||LP-60|||DRAMP30522 SLIEELIKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000055||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000048||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000062||Antiviral ; HIV-1 HxB2[IC50 F = 0.000055 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000048 uM]||HIV-1 JRCSF[IC50 I = 0.000062 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20236 DRAMP30523|||LP-61|||DRAMP30523 IEELIKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000085||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000043||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000126||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000144 uM||Antiviral ; HIV-1 HxB2[IC50 F = 0.000085 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000043 uM]||HIV-1 JRCSF[IC50 I = 0.000126 uM]||HIV-1 PsV[IC50 I = 0.000144 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 193.63+-13.92 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 164.47+-37.69 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 140.43+-10.7 uM Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 24 FPDB20237 DRAMP30524|||LP-62|||DRAMP30524 EQKIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000015||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000005||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000012||Antiviral ; HIV-1 HxB2[IC50 F = 0.000014 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000004 uM]||HIV-1 JRCSF[IC50 I = 0.000004 uM]||HIV-1 HxB2[IC50 F = 0.000015 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000005 uM]||HIV-1 JRCSF[IC50 I = 0.000012 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 27 FPDB20238 DRAMP30525|||LP-63|||DRAMP30525 QKIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000017||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000006||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000013||Antiviral ; HIV-1 HxB2[IC50 F = 0.000017 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000006 uM]||HIV-1 JRCSF[IC50 I = 0.000013 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20239 DRAMP30526|||LP-64|||DRAMP30526 KIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000128||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000036||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000025||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00004 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00008||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00023||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0001||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000058 uM||Antiviral ; HIV-1 HxB2[IC50 F = 0.000073 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000011 uM]||HIV-1 JRCSF[IC50 I = 0.000012 uM]||HIV-1 HxB2[IC50 F = 0.000128 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000036 uM]||HIV-1 JRCSF[IC50 I = 0.000025 uM]||HIV-1 PsV[IC50 I = 0.000058 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.00004 uM]||HIV-1 NL4-3[IC50 I = 0.00008 uM]||HIV-1 NL4-3[IC50 I = 0.00143-0.115 uM]||HIV-2 ROD[IC50 I = 0.00023 uM]||HIV-2[IC50 I = 0.00075 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.0001-0.00011 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 25 FPDB20240 DRAMP30527|||DRAMP30659|||LP-65|||DRAMP30527|||DRAMP30659 IEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000014||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000008||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000007||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 < 0.00001 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00015||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00023||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00007||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000035 uM||Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000002||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000006||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000016||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000007 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000004||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000004||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000019||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000011||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.000027 uM||Antiviral ; HIV-1 HxB2[IC50 F = 0.000016 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000004 uM]||HIV-1 JRCSF[IC50 I = 0.000005 uM]||HIV-1 NL4-3[IC50 I = 0.000077 uM]||HIV-1 JRCSF[IC50 I = 0.000009 uM]||HIV-1[IC50 I = 0.000002-0.000057 uM]||HIV-1[IC50 I = 0.000013 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.000003 uM]||HIV-1 NL4-3[IC50 I = 0.00003 uM]||HIV-1 NL4-3[IC50 I = 0.00051-0.04919 uM]||HIV-1 HxB2[IC50 F = 0.000014 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000008 uM]||HIV-1 JRCSF[IC50 I = 0.000007 uM]||HIV-1 PsV[IC50 I = 0.000035 uM]||HIV-1 NL4-3 D36G[IC50 I = <0.00001 uM]||HIV-1 NL4-3[IC50 I = 0.00015 uM]||HIV-1 NL4-3[IC50 I = 0.00104-0.08863 uM]||HIV-2 ROD[IC50 I = 0.00011 uM]||HIV-2[IC50 I = 0.00043 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00004-0.00007 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 256.23+-14.58 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 213.4+-59.59 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 208.43+-22.9 uM Ref.30089693|||Ref.30867304|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.|||J Virol. 2019 May 15;93(11):e02312-18. 24 FPDB20241 DRAMP30528|||LP-66|||DRAMP30528 EELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.001008||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000434||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.001109||Antiviral ; HIV-1 HxB2[IC50 F = 0.001008 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000434 uM]||HIV-1 JRCSF[IC50 I = 0.001109 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 23 FPDB20242 DRAMP30529|||LP-67|||DRAMP30529 LLEQAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.003417||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000627||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.001527||Antiviral ; HIV-1 HxB2[IC50 F = 0.003417 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000627 uM]||HIV-1 JRCSF[IC50 I = 0.001527 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 21 FPDB20243 DRAMP30530 AEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.25 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.25 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.25 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 17 FPDB20244 DRAMP30531|||DRAMP30660|||LP-69|||DRAMP30531|||DRAMP30660 IEELLKKAEEQQKKNEEELKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000239||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000125||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000157||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00031 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00201||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00983||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00056||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.001391 uM||Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.0002||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000024||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.004781||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000149 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000067||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00039||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.002857||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000556||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.00003 uM||Antiviral ; HIV-1 HxB2[IC50 F = 0.000189 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000168 uM]||HIV-1 JRCSF[IC50 I = 0.000229 uM]||HIV-1 HxB2[IC50 F = 0.000239 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000125 uM]||HIV-1 JRCSF[IC50 I = 0.000157 uM]||HIV-1 PsV[IC50 I = 0.001391 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.00031 uM]||HIV-1 NL4-3[IC50 I = 0.00201 uM]||HIV-1 NL4-3[IC50 I = 0.02257-1.81567 uM]||HIV-2 ROD[IC50 I = 0.15228 uM]||HIV-2[IC50 I = 0.00983 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00056-0.01191 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||Ref.30867304|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.|||J Virol. 2019 May 15;93(11):e02312-18. 21 FPDB20245 DRAMP30532|||LP-70|||DRAMP30532 INNYTSLIEELIKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000025||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000021||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00003||Antiviral ; HIV-1 HxB2[IC50 F = 0.000025 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000021 uM]||HIV-1 JRCSF[IC50 I = 0.00003 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20246 DRAMP30533|||LP-71|||DRAMP30533 IEEYTKKIEEILKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000027||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000025||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000055||Antiviral ; HIV-1 HxB2[IC50 F = 0.000027 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000025 uM]||HIV-1 JRCSF[IC50 I = 0.000055 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20247 DRAMP30534|||LP-72|||DRAMP30534 VRYLEANIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000023||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000028||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000024||Antiviral ; HIV-1 HxB2[IC50 F = 0.000023 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000028 uM]||HIV-1 JRCSF[IC50 I = 0.000024 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20248 DRAMP30535|||LP-73|||DRAMP30535 VEELEKKIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000033||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000019||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000042||Antiviral ; HIV-1 HxB2[IC50 F = 0.000033 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000019 uM]||HIV-1 JRCSF[IC50 I = 0.000042 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20249 DRAMP30536 WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.00011||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000059||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000059||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 38 FPDB20250 DRAMP30537 EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0001||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000065||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000086||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 41 FPDB20251 DRAMP30538|||LP-46|||DRAMP30538 WQEWEQKITALLEQAQIQQEKNEYELQKLDKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000088||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.00005||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000044||Antiviral ; HIV-1 HxB2[IC50 F = 0.000088 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.00005 uM]||HIV-1 JRCSF[IC50 I = 0.000044 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 32 FPDB20252 DRAMP30539|||LP-48|||DRAMP30539 WEQKITALLEQAQIQQEKNEYELQKLDKX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000083||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000047||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000037||Antiviral ; HIV-1 HxB2[IC50 F = 0.000083 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000047 uM]||HIV-1 JRCSF[IC50 I = 0.000037 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 29 FPDB20253 DRAMP30540|||C34-C16|||DRAMP30540 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000247||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000065||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000109||Antiviral ; HIV-1 HxB2[IC50 F = 0.000247 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000065 uM]||HIV-1 JRCSF[IC50 I = 0.000109 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 35 FPDB20254 DRAMP30541 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLGSGX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000316||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000024||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000037||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 38 FPDB20255 DRAMP30542|||P-50|||DRAMP30542 YTSLIEELIKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0356||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.1911||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0218||Antiviral ; HIV-1 HxB2[IC50 F = 0.0356 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.1912 uM]||HIV-1 JRCSF[IC50 I = 0.0218 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20256 DRAMP30543|||P-51|||DRAMP30543 LEANIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0102||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0249||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0454||Antiviral ; HIV-1 HxB2[IC50 F = 0.0102 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0249 uM]||HIV-1 JRCSF[IC50 I = 0.0454 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20257 DRAMP30544|||P-52|||LP-52|||LP-77|||LP-78|||LP-79|||LP-80|||LP-81|||LP-82|||DRAMP30544 WEQKIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0009||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0019||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0019||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.020541 uM||Antiviral||Anti-NL4-3, activity value is IC50 = 4.5||Anti-LAI, activity value is IC50 = 12.22||Anti-SG3, activity value is IC50 = 5.22||Anti-JR-CSF, activity value is IC50 = 8.02||Anti-WITO.c/2474, activity value is IC50 = 5.29||Anti-RHPA.c/2635, activity value is IC50 = 9.42||Anti-THRO.c/2626, activity value is IC50 = 27.12||Anti-CH040.c/2625, activity value is IC50 = 66.67||Anti-89.6, activity value is IC50 = 17.49||Anti-R3A, activity value is IC50 = 13.58||Anti-NL4-3, activity value is IC50 = 2.45||Anti-LAI, activity value is IC50 = 5.85||Anti-SG3, activity value is IC50 = 1.8||Anti-JR-CSF, activity value is IC50 = 4.02||Anti-WITO.c/2474, activity value is IC50 = 3.38||Anti-RHPA.c/2635, activity value is IC50 = 4.81||Anti-THRO.c/2626, activity value is IC50 = 14.93||Anti-CH040.c/2625, activity value is IC50 = 22.67||Anti-89.6, activity value is IC50 = 5.27||Anti-R3A, activity value is IC50 = 5.67||Antimicrobial Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20258 DRAMP30545 YTSLIEELIKKSEEQQKKNEEELKK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 25 FPDB20259 DRAMP30546|||LP-91|||DRAMP30546 WEQKIEELLKKAEEQQKKNEEELKK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0142||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0169||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0323||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.30089693|||30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 25 FPDB20260 DRAMP30547 WEQKIEELLKKAEEQQKKNEEEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 23 FPDB20261 DRAMP30548 WEQKIEELLKKAEEQQKKNEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 21 FPDB20262 DRAMP30549 WEQKIEELLKKAEEQQKK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 18 FPDB20263 DRAMP30550|||P-60|||DRAMP30550|||DRAMP30551 SLIEELIKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.5914||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antiviral ; HIV-1 HxB2[IC50 F >0.75 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.5914 uM]||HIV-1 JRCSF[IC50 I >0.75 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20264 DRAMP30551|||LP-88|||DRAMP30551 EQKIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0253||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0442||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0221||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693 27 FPDB20265 DRAMP30552|||P-63|||DRAMP30552 QKIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0161||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.024||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0244||Antiviral ; HIV-1 HxB2[IC50 F = 0.0161 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.024 uM]||HIV-1 JRCSF[IC50 I = 0.0244 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 26 FPDB20266 DRAMP30553|||LP-89|||DRAMP30553 KIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0076||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0093||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0104||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.30089693|||30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 25 FPDB20267 DRAMP30554|||LP-90|||DRAMP30554|||DRAMP30555 IEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0179||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0257||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0258||Anti-NL4-3, activity value is IC50 = 76.78||Anti-LAI, activity value is IC50 = 8.34||Anti-SG3, activity value is IC50 = 1.67||Anti-JR-CSF, activity value is IC50 = 9.33||Anti-WITO.c/2474, activity value is IC50 = 4.06||Anti-RHPA.c/2635, activity value is IC50 = 5.36||Anti-THRO.c/2626, activity value is IC50 = 14.59||Anti-CH040.c/2625, activity value is IC50 = 50.18||Anti-89.6, activity value is IC50 = 57.44||Anti-R3A, activity value is IC50 = 9.32||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 24 FPDB20268 DRAMP30555|||LP-92|||DRAMP30555 IEELLKKAEEQQKKNEEELKK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 > 7.508 uM||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 > 0.75 uM||Antiviral Synthetic construct N/A N/A Ref.30089693|||30716118|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693 21 FPDB20269 DRAMP30556|||P-70|||DRAMP30556 INNYTSLIEELIKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0085||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0365||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0497||Antiviral ; HIV-1 HxB2[IC50 F = 0.0085 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0365 uM]||HIV-1 JRCSF[IC50 I = 0.0497 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20270 DRAMP30557|||P-71|||DRAMP30557 IEEYTKKIEEILKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0021||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0091||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0387||Antiviral ; HIV-1 HxB2[IC50 F = 0.0021 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0091 uM]||HIV-1 JRCSF[IC50 I = 0.0387 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20271 DRAMP30558|||P-72|||DRAMP30558 VRYLEANIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0041||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0162||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0159||Antiviral ; HIV-1 HxB2[IC50 F = 0.0041 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0162 uM]||HIV-1 JRCSF[IC50 I = 0.0159 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20272 DRAMP30559|||P-73|||DRAMP30559 VEELEKKIEELLKKAEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.002||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0056||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0082||Antiviral ; HIV-1 HxB2[IC50 F = 0.002 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.0056 uM]||HIV-1 JRCSF[IC50 I = 0.0082 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 31 FPDB20273 DRAMP30560 WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0004||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0008||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0014||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 38 FPDB20274 DRAMP30561 EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.0004||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.0009||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.0006||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18.||Ref.30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 41 FPDB20275 DRAMP30562 ILPWKWPWWPWPP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 16 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 13 uM||Antimicrobial||Antiviral Synthetic construct(derived from Indolicidin) N/A N/A Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.||Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. 13 FPDB20276 DRAMP30563 LPWKWPWWPWPP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 185 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 215 uM||Antimicrobial||Antiviral Synthetic construct(derived from Indolicidin) N/A N/A Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.||Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. 12 FPDB20277 DRAMP30564 ILPWKWPWWPWP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 180 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 80 uM||Antimicrobial||Antiviral Synthetic construct(derived from Indolicidin) N/A N/A Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. 12 FPDB20278 DRAMP30565 ILPWGWPWWPWPP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 > 333 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 > 333 uM||Antimicrobial||Antiviral Synthetic construct(derived from Indolicidin) N/A N/A Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. 13 FPDB20279 DRAMP30566 ILAWKWAWWAWPP Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 54 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 41 uM||Antimicrobial||Antiviral Synthetic construct(derived from Indolicidin) N/A N/A Ref.15482931|||Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8. 13 FPDB20280 DRAMP30567|||CAMPSQ21699|||DRAMP30567 LLEYSI Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 0.02 uM||Antiviral||Antimicrobial Crassostrea gigas(hydrolysate of oyster)|||Synthetic construct|||Crassostrea gigas(hydrolysate of oyster) N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 6 FPDB20281 DRAMP30568|||CAMPSQ21700|||DRAMP30568 LLEYSL Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 0.015 uM||Antiviral||Antimicrobial Crassostrea gigas(hydrolysate of oyster)|||Synthetic construct|||Crassostrea gigas(hydrolysate of oyster) N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 6 FPDB20282 DRAMP30569|||CAMPSQ21701|||DRAMP30569 LLEYS Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 0.12 uM||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 5 FPDB20283 DRAMP30570|||CAMPSQ21702|||DRAMP30570 LEYSI Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 0.55 uM||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 5 FPDB20284 DRAMP30571|||CAMPSQ21703|||DRAMP30571 LLEY Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 5.1 uM||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 4 FPDB20285 DRAMP30572|||CAMPSQ21704|||DRAMP30572 LEYS Anti-HIV-1:inhibition of HIV-1 protease, activity value is IC50 = 4.8 uM||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.9918775|||9918775|||Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8. 4 FPDB20286 DRAMP30573|||CAMPSQ21761|||DRAMP30573 FVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 5 FPDB20287 DRAMP30574|||CAMPSQ21762|||DRAMP30574 PFVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 > 200 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20288 DRAMP30575|||CAMPSQ21763|||DRAMP30575 KPFVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 7 FPDB20289 DRAMP30576|||CAMPSQ21764|||DRAMP30576 NKPFVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 8 FPDB20290 DRAMP30577|||CAMPSQ21765|||DRAMP30577 PFVYLI Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20291 DRAMP30578|||CAMPSQ21766|||DRAMP30578 PFVFLE Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 > 200 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20292 DRAMP30579|||CAMPSQ21767|||DRAMP30579 EFVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20293 DRAMP30580|||CAMPSQ21768|||DRAMP30580 PEVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 > 200 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20294 DRAMP30581|||CAMPSQ21769|||DRAMP30581 PFVFLR Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 > 200 uM||Antiviral||Antimicrobial Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)|||Synthetic construct|||Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 6 FPDB20295 DRAMP30582 CPFVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 = 8.96||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 = 67.2||Anti-HIV-1:inhibition of pseudovirus infection, activity value is IC50 = 5.95 uM||Antimicrobial||Antiviral Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 7 FPDB20296 DRAMP30583 CPFVFLE Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 = 55.84||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 = 115.58||Antimicrobial||Antiviral Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 7 FPDB20297 DRAMP30584 CPFVFLR Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 = 74.07||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 = 73.98||Antimicrobial||Antiviral Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 7 FPDB20298 DRAMP30585 CPEVFLM Anti-HIV-1 IIIB:inhibition of virus replication, activity value is IC50 > 100 uM||Anti-ion of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells, activity value is IC50 > 200 uM||Antimicrobial||Antiviral Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin) N/A N/A Ref.22406118|||Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. 7 FPDB20299 DRAMP30586|||FIV Egp|||DRAMP30586 IWNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNV Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.318 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.318 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 1.236 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20300 DRAMP30587|||FIV Egp|||DRAMP30587 WNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQ Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.259 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.259 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.971 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20301 DRAMP30588|||FIV Egp|||DRAMP30588 GNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQG Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 2.454 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 = 2.053 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 2.454 uM]||Feline immunodeficiency virus (FIV)[IC90 F >2.518 uM]||HIV-1[IC50 F = 2.053 uM]||HIV-1[IC90 F >2.518 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 33 FPDB20302 DRAMP30589|||FIV Egp|||DRAMP30589 NITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGK Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.586 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.473 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.586 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 2.067 uM]||HIV-1[IC50 F >2.473 uM]||HIV-1[IC90 F >2.473 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 33 FPDB20303 DRAMP30590|||FIV Egp|||DRAMP30590 ITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGI Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.026 uM||Anti-ion of virus infection in FCD4-E cells, activity value is EC50 = 0.055 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.356 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.026 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.117 uM]||Feline immunodeficiency virus (FIV)[50-60% RT activity = 0.055 uM]||Feline immunodeficiency virus (FIV)[90-100% RT activity = 0.106 uM]||HIV-1[IC50 F >2.365 uM]||HIV-1[IC90 F >2.365 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20304 DRAMP30591|||FIV Egp|||DRAMP30591 TLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKG Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.435 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.435 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 1.413 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 33 FPDB20305 DRAMP30592|||FIV Egp|||DRAMP30592 LGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQ Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.05 uM||Anti-ion of virus infection in FCD4-E cells, activity value is EC50 = 0.098 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 = 1.933 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.05 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.162 uM]||Feline immunodeficiency virus (FIV)[50-60% RT activity = 0.098 uM]||Feline immunodeficiency virus (FIV)[90-100% RT activity = 0.177 uM]||HIV-1[IC50 F = 1.933 uM]||HIV-1[IC90 F >2.342 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20306 DRAMP30593|||FIV Egp|||DRAMP30593 GEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQL Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.012 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.342 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.012 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.033 uM]||HIV-1[IC50 F >2.342 uM]||HIV-1[IC90 F >2.342 uM]||Human cervical carcinoma HeLa[0-10% Cytotoxicity = 23 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20307 DRAMP30594|||FIV Egp|||DRAMP30594 EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.012 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.304 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.012 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.054 uM]||HIV-1[IC50 F >2.304 uM]||HIV-1[IC90 F >2.304 uM]||Human cervical carcinoma HeLa[0-10% Cytotoxicity = 23 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20308 DRAMP30595|||FIV Egp|||DRAMP30595 WYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQK Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.02 uM||Anti-ion of virus infection in FCD4-E cells, activity value is EC50 = 0.053 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.02 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.09 uM]||Feline immunodeficiency virus (FIV)[50-60% RT activity = 0.053 uM]||Feline immunodeficiency virus (FIV)[90-100% RT activity = 0.157 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20309 DRAMP30596|||FIV Egp|||DRAMP30596 YNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKW Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 0.03 uM||Anti-ion of virus infection in FCD4-E cells, activity value is EC50 = 0.168 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 0.03 uM]||Feline immunodeficiency virus (FIV)[IC90 F = 0.125 uM]||Feline immunodeficiency virus (FIV)[50-60% RT activity = 0.168 uM]||Feline immunodeficiency virus (FIV)[90-100% RT activity = 0.423 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20310 DRAMP30597|||FIV Egp|||DRAMP30597 NQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWE Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 1.99 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.322 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 1.99 uM]||Feline immunodeficiency virus (FIV)[IC90 F >2.322 uM]||HIV-1[IC50 F >2.322 uM]||HIV-1[IC90 F >2.322 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20311 DRAMP30598|||FIV Egp|||DRAMP30598 QTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWED Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 > 2.321 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F >2.321 uM]||Feline immunodeficiency virus (FIV)[IC90 F >2.321 uM]||HIV-1[IC50 F >2.321 uM]||HIV-1[IC90 F >2.321 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20312 DRAMP30599|||FIV Egp|||DRAMP30599 TKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWEDW Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 = 1.145 uM||Anti-HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells, activity value is EC50 > 2.321 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F = 1.145 uM]||Feline immunodeficiency virus (FIV)[IC90 F >2.29 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20313 DRAMP30600|||FIV Egp|||DRAMP30600 FYEIIMDIEQNNVQGKKGIQQLQKWEDWVGWIGNI Anti-Feline immunodeficiency virus :inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells, activity value is EC50 > 2.346 uM||Antiviral ; Feline immunodeficiency virus (FIV)[IC50 F >2.346 uM]||Feline immunodeficiency virus (FIV)[IC90 F >2.346 uM]||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope protein)|||Synthetic construct|||Synthetic construct(derived from FIV envelope protein) N/A N/A Ref.12186891|||https://pubmed.ncbi.nlm.nih.gov/12186891|||J Virol. 2002 Sep;76(18):9079-86. 35 FPDB20314 DRAMP30601 XTWXEWDREINNYTSLIHSLIEESQNQQEKNEQELLE Anti-HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0029||Anti-HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells, activity value is IC50 > 3 uM||Anti-HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0158||Anti-HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0444||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20660316|||Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8. 37 FPDB20315 DRAMP30602 XTWXEWDXEINNYTSLIHSLIEESQNQQEKNEQELLE Anti-HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0021||Anti-HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells, activity value is IC50 = 0.339||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20660316|||Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8. 37 FPDB20316 DRAMP30603 XTWMEWDREINNYTSLIHSLIEESQNQXEKNXQELLE Anti-HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0045||Anti-HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells, activity value is IC50 = 1.958||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20660316|||Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8. 37 FPDB20317 DRAMP30604 XTWXEWDXEINNYTSLIHSLIEESQNQXEKNXQELLE Anti-HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0025||Anti-HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells, activity value is IC50 = 0.087||Anti-HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0107||Anti-HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells, activity value is IC50 = 0.0161||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.20660316|||Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8. 37 FPDB20318 DRAMP30605 AEEASKKAEEASKKAEEASKKAEEASKKAEEASKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 4.47||Synthetic construct Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20319 DRAMP30606 VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20320 DRAMP30607 FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 3.11||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20321 DRAMP30608 YEEYSKKYEEYSKKYEEYSKKYEEYSKKYEEYSKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 6.26||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20322 DRAMP30609 LEELSKKLEELSKKLEELSKKLEELSKKLEELSKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 0.24||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20323 DRAMP30610 IEEISKKIEEISKKIEEISKKIEEISKKIEEISKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 0.1||Anti-A/Puerto Rico/8/34 :inhibition of virus infection in MDCK cells, activity value is EC50 = 1.96||Anti-A/Hong Kong/8/68 :inhibition of virus infection in MDCK cells, activity value is EC50 = 6.38||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20324 DRAMP30611 IEEIYKKIEEIYKKIEEIYKKIEEIYKKIEEIYKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 0.52||Anti-A/Puerto Rico/8/34 :inhibition of virus infection in MDCK cells, activity value is EC50 = 3.15||Anti-A/Hong Kong/8/68 :inhibition of virus infection in MDCK cells, activity value is EC50 = 12.9||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20325 DRAMP30612 IEEIWKKIEEIWKKIEEIWKKIEEIWKKIEEIWKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 10.6||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20326 DRAMP30613 IEEIHKKIEEIHKKIEEIHKKIEEIHKKIEEIHKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 1.68||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20327 DRAMP30614 IEEIQKKIEEIQKKIEEIQKKIEEIQKKIEEIQKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 0.11||Anti-ion of pseudovirus infection in Huh-7 cells, activity value is IC50 = 0.13||Anti-A/Puerto Rico/8/34 :inhibition of virus infection in MDCK cells, activity value is EC50 = 1.73||Anti-A/Hong Kong/8/68 :inhibition of virus infection in MDCK cells, activity value is EC50 = 0.7||Anti-HIV-1 inhibition of cell-cell fusion in TZM-bl cells, activity value is EC50 = 3.63||Anti-Ebola virus :inhibition of pseudovirus infection in TZM-bl cells, activity value is EC50 = 1.02||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20328 DRAMP30615 IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 0.45||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20329 DRAMP30616 IEEIEKKIEEIEKKIEEIEKKIEEIEKKIEEIEKKXX Anti-MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells, activity value is EC50 = 2.93||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30192544|||J Med Chem. 2018 Oct 11;61(19):8734-8745. 37 FPDB20330 DRAMP30617|||DRAMP30622|||Eval418|||DRAMP30617|||DRAMP30622 LWGEIWNTVKGLI Anti-HSV-1:inhibition of viral inactivation in Vero cells, activity value is IC50 = 2.48 ug/ml||Anti-ion of viral attachment in Vero cells, activity value is IC50 = 3.7 ug/ml||Anti-ion of viral entry in Vero cells, activity value is IC50 = 31.71 ug/ml||Anti-Herpes simplex virus type 1 : inhibition of viral inactivation in Vero cells, activity value is IC50 = 2.48 ug/ml||Anti-Herpes simplex virus type I, activity value is IC50 = 2.48 ug/ml||Antimicrobial||Antiviral Synthetic construct N/A [Ref.29290802]the cell viability of erythrocytes was also more than 95% at concentrations of Eval418 of 10 ug/ml or less.|||[Ref.29290802]The hemolysis rate of human erythrocytes was less than 50% when the concentration of Eval418 was as high as 200 ug/ml.|||Hemolytic activity ( <50%hemolysis, 200 ug/ml), Human RBC|||[Ref.29290802]the cell viability of erythrocytes was also more than 95% at concentrations of Eval418 of 10 ug/ml or less.|||[Ref.29290802]The hemolysis rate of human erythrocytes was less than 50% when the concentration of Eval418 was as high as 200 ug/ml. Ref.29290802|||https://pubmed.ncbi.nlm.nih.gov/29290802|||Theranostics. 2018 Jan 1;8(1):199-211. 13 FPDB20331 DRAMP30618|||DRAMP30623|||Eval418-FH2|||DRAMP30618|||DRAMP30623 LWGHIWNFVHGLI Anti-HSV-1:inhibition of viral inactivation in Vero cells, activity value is IC50 = 1.5 ug/ml||Anti-ion of viral attachment in Vero cells, activity value is IC50 = 1.43 ug/ml||Anti-ion of viral entry in Vero cells, activity value is IC50 = 8.63 ug/ml||Anti-Herpes simplex virus type 1 : inhibition of viral inactivation in Vero cells, activity value is IC50 = 1.5 ug/ml||Anti-Herpes simplex virus type I, activity value is IC50 = 1.5 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Eval418)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from Eval418) N/A [Ref.29290802]the cell viability of erythrocytes was also more than 95% at concentrations of Eval418 of 11 ug/ml or less. Ref.29290802|||https://pubmed.ncbi.nlm.nih.gov/29290802|||Theranostics. 2018 Jan 1;8(1):199-211. 13 FPDB20332 DRAMP30619|||DRAMP30624|||Eval418-FH3|||DRAMP30619|||DRAMP30624 LWHHIWNFVHGLI Anti-HSV-1:inhibition of viral inactivation in Vero cells, activity value is IC50 = 1.01 ug/ml||Anti-ion of viral attachment in Vero cells, activity value is IC50 = 0.86 ug/ml||Anti-ion of viral entry in Vero cells, activity value is IC50 = 4.23 ug/ml||Anti-Herpes simplex virus type 1 : inhibition of viral inactivation in Vero cells, activity value is IC50 = 1.01 ug/ml||Anti-Herpes simplex virus type I, activity value is IC50 = 1.01 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Eval418)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from Eval418) N/A N/A Ref.29290802|||https://pubmed.ncbi.nlm.nih.gov/29290802|||Theranostics. 2018 Jan 1;8(1):199-211. 13 FPDB20333 DRAMP30620|||DRAMP30625 LWHHIWNTVHHLI Anti-HSV-1:inhibition of viral inactivation in Vero cells, activity value is IC50 = 0.87 ug/ml||Anti-ion of viral attachment in Vero cells, activity value is IC50 = 0.63 ug/ml||Anti-ion of viral entry in Vero cells, activity value is IC50 = 4.37 ug/ml||Anti-Herpes simplex virus type 1 : inhibition of viral inactivation in Vero cells, activity value is IC50 = 0.87 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Eval418)|||Synthetic construct N/A N/A Ref.29290802|||Theranostics. 2018 Jan 1;8(1):199-211. 13 FPDB20334 DRAMP30621|||DRAMP30626 LWHHIWHTVHHLI Anti-HSV-1:inhibition of viral inactivation in Vero cells, activity value is IC50 = 0.86 ug/ml||Anti-ion of viral attachment in Vero cells, activity value is IC50 = 0.67 ug/ml||Anti-ion of viral entry in Vero cells, activity value is IC50 = 2.88 ug/ml||Anti-Herpes simplex virus type 1 : inhibition of viral inactivation in Vero cells, activity value is IC50 = 0.86 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Eval418)|||Synthetic construct N/A N/A Ref.29290802|||Theranostics. 2018 Jan 1;8(1):199-211. 13 FPDB20335 DRAMP30627 WQCLTLTHRGFVLLTITVLR Anti-HIV-1:Inhibition of 3′-processing catalyzed by integrase, activity value is IC50 = 38 uM||Anti-ion of strand transfer catalyzed by integrase, activity value is IC50 = 12 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.18201721||Ref.19850483|||Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. 20 FPDB20336 DRAMP30628|||CAMPSQ21707|||DRAMP30628 WQCLTLTHRG HIV-1:inhibition of integrase catalytic activity(73% inhibition at 62.5 uM);inhibition of virus replication in TZM-bl cells(68% inhibition at 62.5 uM);inhibition of intergration(64% inhibition at 62.5 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.19850483|||19850483|||Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. 10 FPDB20337 DRAMP30629|||CAMPSQ21708|||DRAMP30629 WFVLLTITVLR HIV-1:inhibition of integrase catalytic activity(24% inhibition at 62.5 uM);inhibition of virus replication in TZM-bl cells(29% inhibition at 62.5 uM);inhibition of intergration(23% inhibition at 62.5 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.19850483|||19850483|||Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. 11 FPDB20338 DRAMP30630|||CAMPSQ21709|||DRAMP30630 WQSLTLTHRG HIV-1:inhibition of integrase catalytic activity(62% inhibition at 62.5 uM);inhibition of virus replication in TZM-bl cells(60% inhibition at 62.5 uM);inhibition of intergration(51% inhibition at 62.5 uM).||Antiviral||Antimicrobial Synthetic construct N/A N/A Ref.19850483|||19850483|||Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. 10 FPDB20339 DRAMP30631|||CAMPSQ24045|||DRAMP30631 VSGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 500 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells, activity value is IC50 = 117 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 38 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 250 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 93 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 11 FPDB20340 DRAMP30632|||CAMPSQ24046|||DRAMP30632 SGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 186 uM||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 310 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 173 uM||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 450 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 170 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 170 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 210 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 180 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 10 FPDB20341 DRAMP30633|||CAMPSQ24047|||DRAMP30633 GHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 360 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells, activity value is IC50 = 290 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 170 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in LLC-MK2 cells, activity value is IC50 = 230 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 9 FPDB20342 DRAMP30634|||CAMPSQ24048|||DRAMP30634 HGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 179 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 117 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 78 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 170 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 190 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 410 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 8 FPDB20343 DRAMP30635|||CAMPSQ24049|||DRAMP30635 GQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 215 uM||Anti-ion of virus replication in HEp-2 cells, activity value is IC50 = 840 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 168 uM||Anti-ion of virus replication in Vero cells, activity value is IC50 = 280 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 170 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 190 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 870 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 170 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 7 FPDB20344 DRAMP30636|||CAMPSQ24050|||DRAMP30636 QHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 1300 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 950 uM||Anti-ion of virus replication in Hep-2 cells, activity value is IC50 = 280 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 170 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 500 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 210 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 6 FPDB20345 DRAMP30637|||CAMPSQ24051|||DRAMP30637 HGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 300 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 400 uM||Anti-Coxsackie virus B2 :inhibition of virus replication in Hep-2 cells, activity value is IC50 = 350 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 290 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 350 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 180 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 5 FPDB20346 DRAMP30638|||CAMPSQ24052|||DRAMP30638 GVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 500 uM||Anti-HHV-1 clinical strain:inhibition of virus replication in Vero cells, activity value is IC50 = 1500 uM||Anti-Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells, activity value is IC50 = 1040 uM||Anti-ion of virus replication in LLC-MK2 cells, activity value is IC50 = 540 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 4 FPDB20347 DRAMP30639|||CAMPSQ24053|||DRAMP30639 HGVSGHGQHGV Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 178 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 11 FPDB20348 DRAMP30640|||CAMPSQ24054|||DRAMP30640 HGVSGHGQHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 520 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 10 FPDB20349 DRAMP30641|||CAMPSQ24055|||DRAMP30641 HGVSGHGQ Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 310 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 8 FPDB20350 DRAMP30642|||CAMPSQ24056|||DRAMP30642 HGVSGHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 550 uM||Antiviral||Antimicrobial Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 7 FPDB20351 DRAMP30643|||Alloferon|||DRAMP30643 FGVSGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 160 uM||Antiviral ; HSV-1[IC50 REP = 160 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||https://pubmed.ncbi.nlm.nih.gov/22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 13 FPDB20352 DRAMP30644|||Alloferon|||DRAMP30644 YGVSGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 190 uM||Antiviral ; HSV-1 McIntyre strain[IC50 REP = 190 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||https://pubmed.ncbi.nlm.nih.gov/22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 13 FPDB20353 DRAMP30645|||Alloferon|||DRAMP30645 WGVSGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 190 uM||Antiviral ; HSV-1 McIntyre strain[IC50 REP = 190 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA Ref.22883213|||https://pubmed.ncbi.nlm.nih.gov/22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 13 FPDB20354 DRAMP30646|||DRAMP30647|||DRAMP30648|||Alloferon|||DRAMP30646|||DRAMP30647|||DRAMP30648 XGVSGHGQHGVHG Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 190 uM||Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 110 uM||Anti-Herpesvirus 1 McIntire :inhibition of virus replication in Vero cells, activity value is IC50 = 220 uM||Antiviral ; HSV-1 McIntyre strain[IC50 REP = 190 uM]||HSV-1 McIntyre strain[IC50 REP = 110 uM]||HSV-1 McIntyre strain[IC50 REP = 200 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Alloferon-1)|||Synthetic construct|||Synthetic construct(derived from Alloferon-1) N/A Vero cells (- at NA , Vero cells (- at NA Ref.22883213|||https://pubmed.ncbi.nlm.nih.gov/22883213|||Chem Biol Drug Des. 2013 Feb;81(2):302-9. 13 FPDB20355 DRAMP30649|||LP-11|||DRAMP30649 EMTWEEWEKKIEEYTKKIEEILXX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000931||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000201||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000253||Antiviral ; HIV-1 HxB2[IC50 F = 0.000931 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000201 uM]||HIV-1 JRCSF[IC50 I = 0.000253 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 24 FPDB20356 DRAMP30650|||LP-19|||DRAMP30650 EMTWEEWEKKVEELEKKIEELLXX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000296||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000095||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000092||Antiviral ; HIV-1 HxB2[IC50 F = 0.000296 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000095 uM]||HIV-1 JRCSF[IC50 I = 0.000092 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30089693|||30089693|||J Virol. 2018 Sep 26;92(20):e01088-18. 24 FPDB20357 DRAMP30651|||LP-40|||DRAMP30651 YTSLIHSLIEESQNQQEKNEQELLELDX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000361||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000392||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000384||Antiviral ; HIV-1 NL4-3[IC50 I = 0.020153 uM]||HIV-1 JRCSF[IC50 I = 0.001815 uM]||HIV-1 HxB2[IC50 F = 0.000361 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000392 uM]||HIV-1[IC50 I = 0.000182-0.029186 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 800.8+-62.29 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 366.3+-119.08 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 408+-40.1 uM, Human PBMC (50% Cytotoxicity at 212.6+-25.71 uM Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30867304,|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20358 DRAMP30652|||LP-50|||DRAMP30652 YTSLIEELIKKSEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000021||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000007||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000023||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 < 0.00001 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00006||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00009||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00006 uM||Antiviral ; HIV-1 NL4-3[IC50 I = 0.000067 uM]||HIV-1 JRCSF[IC50 I = 0.000023 uM]||HIV-1 HxB2[IC50 F = 0.000021 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000007 uM]||HIV-1[IC50 I = 0.000012-0.000078 uM]||HIV-1 NL4-3 D36G[IC50 I = <0.00001 uM]||HIV-1 NL4-3[IC50 I = 0.00106-0.13612 uM]||HIV-2 ROD[IC50 I = 0.00009 uM]||HIV-2[IC50 I = 0.00581 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00006 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 106.4+-2.72 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 138.37+-6.55 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 166.77+-35.33 uM, Human PBMC (50% Cytotoxicity at 40.01+-4.63 uM Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30867304,|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20359 DRAMP30653|||LP-51|||DRAMP30653 LEANIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000021||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000006||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000027||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 < 0.00001 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00002||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00009||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00003||Antiviral ; HIV-1 NL4-3[IC50 I = 0.000025 uM]||HIV-1 JRCSF[IC50 I = 0.000023 uM]||HIV-1 HxB2[IC50 F = 0.000021 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000006 uM]||HIV-1[IC50 I = 0.000013-0.000072 uM]||HIV-1 NL4-3 D36G[IC50 I = <0.00001 uM]||HIV-1 NL4-3[IC50 I = 0.0004-0.01207 uM]||HIV-2 ROD[IC50 I = 0.00009 uM]||HIV-2[IC50 I = 0.00084 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00003-0.00006 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 434.03+-90.38 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 135.07+-32.3 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 130.07+-15.27 uM, Human PBMC (50% Cytotoxicity at 46.83+-4.65 uM Ref.30089693|||https://pubmed.ncbi.nlm.nih.gov/30867304,|||J Virol. 2018 Sep 26;92(20):e01088-18. 28 FPDB20360 DRAMP30654|||DRAMP30655|||LP-80|||DRAMP30654|||DRAMP30655 WEQKIEELLKKAEEQQKKNEEELKKLEX Anti-HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells, activity value is IC50 = 0.000013||Anti-HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000004||Anti-HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000005||Anti-6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000017 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 < 0.00001 uM||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00001||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00006||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00001||Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000003||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000007||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000013||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000005 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000003||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000007||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000288||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000034||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.000013 uM||Antiviral ; HIV-1 NL4-3[IC50 I = 0.000003 uM]||HIV-1 JRCSF[IC50 I = 0.000007-0.000009 uM]||HIV-1 PsV[IC50 I = 0.000017 uM]||HIV-1[IC50 F = 0.000057 uM]||HIV-1 HxB2[IC50 F = 0.000019 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000006 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000004 uM]||HIV-1[IC50 I = 0.000004-0.000016 uM]||HIV-1 NL4-3 D36G[IC50 I = <0.00001 uM]||HIV-1 NL4-3[IC50 I = 0.00001-0.00186 uM]||HIV-2 ROD[IC50 I = 0.00006 uM]||HIV-2[IC50 I = 0.00034 uM]||Simian immunodeficiency virus (SIV) PsV[IC50 I = 0.00001-0.00004 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 112.9+-2.21 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 94.06+-4.97 uM]||HIV-1 NL4-3[IC50 I = 0.000005 uM]||HIV-1 JRCSF[IC50 I = 0.000008 uM]||HIV-1[IC50 I = 0.000005-0.000067 uM]||HIV-1[IC50 I = 0.000017 uM]||HIV-1 NL4-3[IC50 I = 0.000002-0.000003 uM]||HIV-1 JRCSF[IC50 I = 0.000007 uM]||HIV-1 PsV[IC50 I = 0.000005 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.000003 uM]||HIV-1 NL4-3[IC50 I = 0.000007 uM]||HIV-1 NL4-3[IC50 I = 0.000121-0.004006 uM]||HIV-2 ROD[IC50 I = 0.000288 uM]||HIV-2[IC50 I = 0.000299 uM]||HIV-1[IC50 F = 0.000013 uM]||Simian immunodeficiency virus (SIV)[IC50 I = 0.000034-0.000155 uM]||HIV-1 HxB2[IC50 F = 0.000013 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000002 uM]||HIV-1 NL4-3[IC50 I = 0.000002 uM]||HIV-1 JRCSF[IC50 I = 0.000004 uM]||HIV-1[IC50 I = 0.000002-0.000023 uM]||HIV-1[IC50 I = 0.000006 uM]||Human adenocarcinoma TZM-bl[50-60% Cytotoxicity = 62.33 uM]||Human T cell leukemia MT-4[50-60% Cytotoxicity = 218.37 uM]||HIV-1 HxB2[IC50 F = 0.000161 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000008 uM]||HIV-1 JRCSF[IC50 I = 0.000012 uM]||HIV-1 HxB2[IC50 F = 0.000054 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000004 uM]||HIV-1 HxB2[IC50 F = 0.000039 uM]||HIV-1 JRCSF[IC50 I = 0.000006 uM]||HIV-1 HxB2[IC50 F = 0.000353 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.000111 uM]||HIV-1 JRCSF[IC50 I = 0.000183 uM]||HIV-1 HxB2[IC50 F = 0.003205 uM]||HIV-1 NL4-3 D36G PsV[IC50 E = 0.001012 uM]||HIV-1 JRCSF[IC50 I = 0.003713 uM]||Antimicrobial||Antiviral Synthetic construct N/A Human embryonic kidney HEK293T cells (50% Cytotoxicity at 88.86+-6.68 uM, Human embryonic kidney HEK293T cells (50% Cytotoxicity at 80.45 uM, Human embryonic kidney HEK293T cells (50% Cytotoxicity at 72.23 uM Ref.30089693|||Ref.30867304|||https://pubmed.ncbi.nlm.nih.gov/30867304,|||J Virol. 2018 Sep 26;92(20):e01088-18.|||J Virol. 2019 May 15;93(11):e02312-18. 28 FPDB20361 DRAMP30656 WEQKIEELLKKAEEQQKKNEEELKKLEKX Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000005||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000005||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000003 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000002||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000002||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.00002||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000004||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.000009 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30867304|||J Virol. 2019 May 15;93(11):e02312-18. 29 FPDB20362 DRAMP30657|||T-20-based lipopeptide fusion inhibitor|||DRAMP30657 LEANIEELLKKAEEQQKKNEEELKKLEKX Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000005||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000007||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.000005 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000003||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000003||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000014||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000005||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.000012 uM||Anti-HIV-1 NL4-3 subtype B, activity value is IC50 = 23||Anti-HIV-1 LAI subtype B, activity value is IC50 = 17||Anti-Hiv-1 SG3 subtype B, activity value is IC50 = 9||Anti-HIV-1 JR-CSF subtype B, activity value is IC50 = 28||Anti-HIV-1 89.6 subtype B, activity value is IC50 = 56||Anti-HIV-1 R3A subtye B, activity value is IC50 = 17||Anti-HIV-2 ROD, activity value is IC50 = 0.00008 uM||Anti-HIV-2 ST, activity value is IC50 = 0.0017 uM||Anti-SIV 239, activity value is IC50 = 0.00004 uM||Anti-SIV PBJ, activity value is IC50 = 0.00007 uM||Anti-SHIV SF162P3, activity value is IC50 = 0.00009 uM||Anti-SHIV 1157, activity value is IC50 = 0.00004 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30867304|||https://pubmed.ncbi.nlm.nih.gov/29899103|||J Virol. 2019 May 15;93(11):e02312-18. 29 FPDB20363 DRAMP30658 WEQKIEELLKKAEEQQKKNEEELKX Anti-HIV-1 NL4-3 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000006||Anti-HIV-1 JR-CSF :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000007||Anti-HIV-1 89.6 :inhibition of virus replication in TZM-bl cells, activity value is IC50 = 0.000008||Anti-HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells, activity value is IC50 = 0.00001 uM||Anti-T-20 sensitive HIV-1 :inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000006||Anti-V38A/N42T):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000012||Anti-ST):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.001244||Anti-PBJ):inhibition of virus infection in TZM-bl cells, activity value is IC50 = 0.000013||Anti-1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells, activity value is IC50 = 0.000015 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30867304|||J Virol. 2019 May 15;93(11):e02312-18. 25 FPDB20364 DRAMP30661 EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0015||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20365 DRAMP30662|||DRAMP30663 XEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0072||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0112||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 42 FPDB20366 DRAMP30664|||DRAMP30665 EWDXEINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0051||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0087||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20367 DRAMP30666|||DRAMP30667 EWDREINNYTXLIHSLIEESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0044||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0049||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20368 DRAMP30668|||DRAMP30669 EWDREINNYTSLIHXLIEESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0041||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.005||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20369 DRAMP30670|||DRAMP30671 EWDREINNYTSLIHSLIXESQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0045||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0049||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20370 DRAMP30672|||DRAMP30673 EWDREINNYTSLIHSLIEESQXQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0042||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0051||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20371 DRAMP30674|||DRAMP30675 EWDREINNYTSLIHSLIEESQNQQEKNEXELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0052||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0055||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20372 DRAMP30676|||DRAMP30677 EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWX Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0109||Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 = 0.0433||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 42 FPDB20373 DRAMP30678|||DRAMP30679 EWDREINNYTSLIHSLIEEXQNQQEKNEQELLELDKWASLW Anti-HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells, activity value is IC50 > 0.4 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22770564|||Bioconjug Chem. 2012 Aug 15;23(8):1648-60. 41 FPDB20374 DRAMP30680 RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWDIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 15||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 45 FPDB20375 DRAMP30681 RMKQIEDKIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 0.14||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 45 FPDB20376 DRAMP30682 KIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 1.4||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 38 FPDB20377 DRAMP30683 KIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 0.16||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 38 FPDB20378 DRAMP30684|||Undefined|||DRAMP30684 KQKKIENEIARIKKLLQLTVWGIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 5.5||Antiviral ; HIV-1[IC50 E = 5.5+-1.5 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||https://pubmed.ncbi.nlm.nih.gov/11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 31 FPDB20379 DRAMP30685|||Undefined|||DRAMP30685 KIKKIENEIARIKKLLQLTVWGIKQLQARIL Anti-HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells, activity value is IC50 = 2.1||Antiviral ; HIV-1[IC50 E = 2.1+-0.8 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.11572974|||https://pubmed.ncbi.nlm.nih.gov/11572974|||Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. 31 FPDB20380 DRAMP30687|||Dermaseptin-S1|||DRAMP30687 ALWTTMLKKLGKMALHAGKAALGAAADTI Anti-HSV-1:inhibition of virus infection in Vero cells, activity value is IC50 = 1.3 uM||Antiviral||Antiparasitic ; Trichomonas vaginalis SS22[LC50 = 18 uM]||HSV-1[IC50 I = 1.3 uM]||Human papillomavirus (HPV) PsV[60-70% Inhibition = 5 uM]||Antimicrobial Synthetic construct(derived from Dermaseptin-S1)|||Synthetic construct|||Synthetic construct(derived from Dermaseptin-S2) N/A [Ref.20718719]human red cells:HC50>100 uM.|||Human erythrocytes (50% Hemolysis at >100 uM|||[Ref.20718719]human red cells:HC50>101 uM. Ref.20718719|||https://pubmed.ncbi.nlm.nih.gov/20718719|||APMIS. 2010 Sep 1;118(9):674-80. 29 FPDB20381 DRAMP30695|||Undefined|||DRAMP30695 EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL Anti-HIV-1IIIB :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000338 uM||Anti-ion of cell-cell fusion between H9/IIIB cells and MT-2 cells, activity value is IC50 = 0.00114 uM||Anti-HIV-1Bal :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000813 uM||Anti-N42T/N43K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000748||Anti-K90E/N126K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000349||Anti-L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000699||Antiviral ; HIV-1 IIIB[IC50 I = 0.000338 uM]||HIV-1 BaL[IC50 I = 0.000813 uM]||HIV-1 NL4-3[IC50 I = 0.000912 uM]||HIV-1 NL4-3 D36G/V38A[IC50 I = 0.000647 uM]||HIV-1 NL4-3[IC50 I = 0.000699 uM]||HIV-1 IIIB[IC50 F = 0.00114 uM]||Human T cell leukemia MT-2||Acute myeloid leukemia AML-M7||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30901967|||https://pubmed.ncbi.nlm.nih.gov/30901967|||Molecules. 2019 Mar 21;24(6):1134. 32 FPDB20382 DRAMP30696|||Undefined|||DRAMP30696 EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDL Anti-HIV-1IIIB :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000275 uM||Anti-ion of cell-cell fusion between H9/IIIB cells and MT-2 cells, activity value is IC50 = 0.00112 uM||Anti-HIV-1Bal :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.00064 uM||Anti-N42T/N43K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000627||Anti-K90E/N126K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.00046||Anti-L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000856||Antiviral ; HIV-1 IIIB[IC50 I = 0.000275 uM]||HIV-1 BaL[IC50 I = 0.00064 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.000784 uM]||HIV-1 NL4-3 D36G/V38A[IC50 I = 0.000627 uM]||HIV-1 NL4-3[IC50 I = 0.000856 uM]||HIV-1 IIIB[IC50 F = 0.00112 uM]||Human T cell leukemia MT-2||Acute myeloid leukemia AML-M7||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30901967|||https://pubmed.ncbi.nlm.nih.gov/30901967|||Molecules. 2019 Mar 21;24(6):1134. 32 FPDB20383 DRAMP30697 EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDLGSGX Anti-HIV-1IIIB :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000076 uM||Anti-ion of cell-cell fusion between H9/IIIB cells and MT-2 cells, activity value is IC50 = 0.00055 uM||Anti-HIV-1Bal :inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000061 uM||Anti-N42T/N43K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.00004||Anti-K90E/N126K):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000065||Anti-L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells, activity value is IC50 = 0.000065||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.30901967|||Molecules. 2019 Mar 21;24(6):1134. 36 FPDB20384 DRAMP30698 PACQDFLGAMIHLKAKTNISIR Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(28% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20385 DRAMP30699 LKAKTNISIREGPTLGNWAR Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20386 DRAMP30700 EGPTLGNWAREIWATLFKKA Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20387 DRAMP30701 EIWATLFKKATRQCRRGRIW Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20388 DRAMP30702 TRQCRRGRIWKRWNETITGP Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(94% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20389 DRAMP30703 SGCANNTCYNVSVIVPDYQC Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20390 DRAMP30704 YLDRVDTWLQGKINISLCLT Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20391 DRAMP30705 GKINISLCLTGGKMLYNKVT Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20392 DRAMP30706 GGKMLYNKVTKQLSYCTDPL Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20393 DRAMP30707 KQLSYCTDPLQIPLINYTFG Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20394 DRAMP30708 PNQTCMWNTSQIQDPEIPKC Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20395 DRAMP30709 QIQDPEIPKCGWWNQMAYYN Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20396 DRAMP30710 FHCQRTQSQPGSWFRAISSWKQ Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378 22 FPDB20397 DRAMP30711 GSWFRAISSWKQRNRWEWRPDF Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20398 DRAMP30712 KQRNRWEWRPDFKSKKVKISLPC Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378 23 FPDB20399 DRAMP30713 KSKKVKISLPCNSTKNLTFA Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20400 DRAMP30714 CNSTKNLTFAMRSSGDYGEV Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20401 DRAMP30715 MRSSGDYGEVTGAWIEFGCH Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(27% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20402 DRAMP30716 TGAWIEFGCHRNKSNLHTEA Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20403 DRAMP30717 RNKSNLHTEARFRIRCRWNV Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20404 DRAMP30718 RFRIRCRWNVGSDTSLIDTC Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(40% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20405 DRAMP30719 GSDTSLIDTCGNTPNVSGAN Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(12% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20406 DRAMP30720 PVDCTMYSNKMYNCSLQNGF Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20407 DRAMP30721 MYNCSLQNGFTMKVDDLIVH Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(33% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-85. 20 FPDB20408 DRAMP30722 TMKVDDLIVHFNMTKAVEMV Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20409 DRAMP30723 FNMTKAVEMVNIAGNWSCTS Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20410 DRAMP30724 NIAGNWSCTSDLPSSWGYMN Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(22% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20411 DRAMP30725 CTSDLPSSWGYMNCNCTNSSSS Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20412 DRAMP30726 CNCTNSSSSYSGTKMACPSNRG Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20413 DRAMP30727 SGTKMACPSNRGILRNWYNP Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20414 DRAMP30728 RGILRNWYNPFAGLRQSLEQ Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20415 DRAMP30729 VAGLRQSLEQYQVVKQPDYL Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(48% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20416 DRAMP30730 YQVVKQPDYLLVPEEVMEYK Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(38% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20417 DRAMP30731 PDYLLVPEEVMEYKPRRKRAAI Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(54% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20418 DRAMP30732 YKPRRKRAAIHVMLALATVLSI Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20419 DRAMP30733 HVMLALATVLSIAGAGTGATAI Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(58% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 22 FPDB20420 DRAMP30734 AGAGTGATAIGMVTQYHQVL Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20421 DRAMP30735 GMVTQYHQVLATHQEAIEKV Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(43% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20422 DRAMP30736 ATHQEAIEKVTGALKINNLR Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(44% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||ATHQEAIEKVTGALKINNLR 20 FPDB20423 DRAMP30737 TGALKINNLRLVTLEHQVLV Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(73% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20424 DRAMP30738 LVTLEHQVLVIGLKVEAMEK Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(45% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20425 DRAMP30739 IGLKVEAMEKFLYTAFAMQE Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(74% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20426 DRAMP30740 FLYTAFAMQELGCNQNQFFC Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(18% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20427 DRAMP30741 LGCNQNQFFCKIPLELWTRY Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(21% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20428 DRAMP30742 NMTINQTIWNHGNITLGEWY Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20429 DRAMP30743 HGNITLGEWYNQTKDLQQKF Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(35% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20430 DRAMP30744 NQTKDLQQKFYEIIMDIEQN Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(68% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20431 DRAMP30745 YEIIMDIEQNNVQGKTGIQQ Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(37% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20432 DRAMP30746 NVQGKTGIQQLQKWEDWVRW Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(96% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20433 DRAMP30747 LQKWEDWVRWIGNIPQYLKG Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(98% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20434 DRAMP30748 IGNIPQYLKGLLGGILGIGL Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20435 DRAMP30749 LLGGILGIGLGVLLLILCLP Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(88% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20436 DRAMP30750 GVLLLILCLPTLVDCIRNCI Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(32% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20437 DRAMP30751 TLVDCIRNCIHKILGYTVIA Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20438 DRAMP30752 HKILGYTVIAMPEVEGEEIQ Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20439 DRAMP30753 MPEVEGEEIQPQMELRRNGR Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(7% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20440 DRAMP30754 PQMELRRNGRQCGMSEKEEE Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 ug/ml).||Antimicrobial||Antiviral Synthetic construct(derived from FIV envelope glycoprotein (gE)) N/A N/A Ref.8661378|||Virology. 1996 Jun 15;220(2):274-84. 20 FPDB20441 DRAMP30755 NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD Anti-Respiratory syncytial virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20442 DRAMP30756 YTPNDITLNNSVALDPIDISIELNKAKSDLEESKE Anti-Human parainfluenza virus type 3 :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20443 DRAMP30757 TPNDITLNNSVALDPIDISIELNKAKSDLEESKEW Anti-Human parainfluenza virus type 3 :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20444 DRAMP30758 PNDITLNNSVALDPIDISIELNKAKSDLEESKEWI Anti-Human parainfluenza virus type 3 :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20445 DRAMP30759 NDITLNNSVALDPIDISIELNKAKSDLEESKEWIR Anti-Human parainfluenza virus type 3 :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20446 DRAMP30760 DITLNNSVALDPIDISIELNKAKSDLEESKEWIRR Anti-Human parainfluenza virus type 3 :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20447 DRAMP30761 DAVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDA Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20448 DRAMP30762 AVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAK Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 > 100 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20449 DRAMP30763 VYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAKE Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 85.3 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20450 DRAMP30764 YLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKEL Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 90.7 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20451 DRAMP30765 LHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELL Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 1.5 ug/ml||Anti-ion of cell-cell fusion in HEp2 cell, activity value is EC50 = 0.068 ug/ml||Anti-Human parainfluenza virus type 3 :inhibition of cell-cell fusion in HEp2 cell, activity value is EC50 > 25 ug/ml||Anti-Respiratory syncytial virus :inhibition of cell-cell fusion in HEp2 cell, activity value is EC50 > 25 ug/ml||Anti-HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell, activity value is EC50 > 50 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20452 DRAMP30766 HRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLE Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 2.2 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20453 DRAMP30767 RIDLGPPISLERLDVGTNLGNAIAKLEDAKELLES Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 1.7 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20454 DRAMP30768 IDLGPPISLERLDVGTNLGNAIAKLEDAKELLESS Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 4.9 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20455 DRAMP30769 DLGPPISLERLDVGTNLGNAIAKLEDAKELLESSD Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 5.7 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20456 DRAMP30770 LGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQ Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 6.5 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20457 DRAMP30771 GPPISLERLDVGTNLGNAIAKLEDAKELLESSDQI Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 10.1 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20458 DRAMP30772 PPISLERLDVGTNLGNAIAKLEDAKELLESSDQIL Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 1.1 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20459 DRAMP30773 PISLERLDVGTNLGNAIAKLEDAKELLESSDQILR Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 3.1 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20460 DRAMP30774 ISLERLDVGTNLGNAIAKLEDAKELLESSDQILRS Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 13 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20461 DRAMP30775 SLERLDVGTNLGNAIAKLEDAKELLESSDQILRSM Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 12.3 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20462 DRAMP30776 LERLDVGTNLGNAIAKLEDAKELLESSDQILRSMK Anti-measles virus :protection of HEp2 cell from viral cytopathic effect, activity value is EC50 = 7.3 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from measles virus(MV) fusion (F) protein) N/A N/A Ref.8700906|||Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91. 35 FPDB20463 DRAMP30777 DDSVVCAAMSYSYA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(22% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20464 DRAMP30778 DDSVVCAAMSYSFA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(29% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20465 DRAMP30779 DDSVVCAAMSYSHA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(26% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20466 DRAMP30780|||Undefined|||DRAMP30780 DDSVVSAAMSYSYA activity value is IC50 = 3.5 uM||Antiviral ; Hepatitis C virus (HCV)[80-90% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 3.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20467 DRAMP30781 DDSVVSAAMSYSFA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20468 DRAMP30782 DDSVVAAMSYSYA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(9% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20469 DRAMP30783 DDSVVAAMSYSFA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20470 DRAMP30784 DDSVVAAMSYSHA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(22% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20471 DRAMP30785|||Undefined|||DRAMP30785 ADLEVVAATYVLVA activity value is IC50 = 6.3 uM||Antiviral ; Hepatitis C virus (HCV)[70-80% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 6.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20472 DRAMP30786|||Undefined|||DRAMP30786 ADLEVVAATFVLVA activity value is IC50 = 5.72 uM||Antiviral ; Hepatitis C virus (HCV)[80-90% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 5.72 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20473 DRAMP30787|||Undefined|||DRAMP30787 ADLEVVAATHVLVA activity value is IC50 = 2.2 uM||Antiviral ; Hepatitis C virus (HCV)[90-100% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 2.2 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20474 DRAMP30788 ADLEVVAATYV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(15% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 11 FPDB20475 DRAMP30789 KKKKVVAATYVLVA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(30% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20476 DRAMP30790 DDDEVVAATYVLVA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(1% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20477 DRAMP30791 ADLEVVAATYVDDD Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(9% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20478 DRAMP30792|||Undefined|||DRAMP30792 ADLEVVAATYVDVA activity value is IC50 = 2.1 uM||Antiviral ; Hepatitis C virus (HCV)[90-100% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 2.1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20479 DRAMP30793 ADLEVVAATYVLDA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(22% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20480 DRAMP30794 ADLEVVAATYVLVD Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(38% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20481 DRAMP30795 ADLEVVAATYVDDA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(20% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20482 DRAMP30796|||Undefined|||DRAMP30796 ADLEVVAATYVLDD activity value is IC50 = 7.4 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7.4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20483 DRAMP30797 ADLEVVAATYVDVD Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(19% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20484 DRAMP30798 KKKKVVAATYVKKA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(13% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20485 DRAMP30799 KKKKVVAATYFFFA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(5% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20486 DRAMP30800 KKKKVVAATYFLVA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20487 DRAMP30801 KKKKVVAATYVLVF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(12% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20488 DRAMP30802 KKKKVVAATYVLFA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(12% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20489 DRAMP30803 KKKKVVAATYKKVA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20490 DRAMP30804 AKLKVVAATYVLKK Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(5% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20491 DRAMP30805 KKKKVVAATYKKKK Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20492 DRAMP30806 ADLEVVAATYVKKK Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20493 DRAMP30807 ADLEVVAATYKKKK Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(7% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20494 DRAMP30808 ADLEVVAATYAAAA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20495 DRAMP30809 KDLKVVAATYVKKK Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(21% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20496 DRAMP30810 KKKKAVAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(59% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20497 DRAMP30811|||Undefined|||DRAMP30811 KKKKVAAATYVLV activity value is IC50 = 3 uM||Antiviral ; Hepatitis C virus (HCV)[70-80% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20498 DRAMP30812 KKKKVVAAAYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(19% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20499 DRAMP30813 KKKKVVAATAVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(13% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20500 DRAMP30814 KKKKVVAATYVAV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(21% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20501 DRAMP30815 KKKKVVAATYVLA Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(19% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20502 DRAMP30816 KKKKVLAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(12% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20503 DRAMP30817|||Undefined|||DRAMP30817 KKKKVVLATYVLV activity value is IC50 = 7.5 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20504 DRAMP30818 KKKKVVAALYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(7% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20505 DRAMP30819 KKKKVVAATYLLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(26% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20506 DRAMP30820 KKKKVVAATYVLL Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(25% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20507 DRAMP30821|||Undefined|||DRAMP30821 KKKKFVAATYVLV activity value is IC50 = 7 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20508 DRAMP30822 KKKKVFAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(26% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20509 DRAMP30823 KKKKVVFATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(34% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20510 DRAMP30824 KKKKVVAFTYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(23% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20511 DRAMP30825 KKKKVVAAFYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20512 DRAMP30826 KKKKVVAATFVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(28% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20513 DRAMP30827 KKKKVVAATYFLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20514 DRAMP30828 KKKKVVAATYVFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(15% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20515 DRAMP30829 KKKKVVAATYVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(1% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20516 DRAMP30830 KKKKEVAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20517 DRAMP30831 KKKKVVAETYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(19% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20518 DRAMP30832 KKKKVVAAEYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(5% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20519 DRAMP30833 KKKKVVAATEVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20520 DRAMP30834 KKKKVKAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(25% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20521 DRAMP30835|||Undefined|||DRAMP30835 KKKKVVKATYVLV activity value is IC50 = 6.5 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 6.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20522 DRAMP30836 KKKKVVAKTYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(12% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20523 DRAMP30837 KKKKTVAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(27% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20524 DRAMP30838|||Undefined|||DRAMP30838 KKKKVTAATYVLV activity value is IC50 = 4.3 uM||Antiviral ; Hepatitis C virus (HCV)[70-80% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 4.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20525 DRAMP30839 KKKKVVTATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(1% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20526 DRAMP30840 KKKKVVATTYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(16% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20527 DRAMP30841 KKKKVVAATTVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2223% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20528 DRAMP30842 KKKKVVAATYVLT Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20529 DRAMP30843 KKKKVVGATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20530 DRAMP30844 KKKKVVAGTYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(30% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20531 DRAMP30845 KKKKVVAAGYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20532 DRAMP30846 KKKKVVAATGVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(26% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20533 DRAMP30847 KKKKVVAATYVGV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20534 DRAMP30848 KKKKVVAATYVLG Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(13% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20535 DRAMP30849 KKKKVVAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(17% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20536 DRAMP30850 KKKKPVAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(24% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20537 DRAMP30851 KKKKVPAATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20538 DRAMP30852 KKKKVVAATYVPV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(10% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20539 DRAMP30853 KKKKVVLATLVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(5% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20540 DRAMP30854 KKKKLVLPFLFFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(6% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20541 DRAMP30855 KKKKLLAPFLFFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20542 DRAMP30856 KKKKLLLAFLFFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20543 DRAMP30857 KKKKLLLPTLFFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20544 DRAMP30858 KKKKLVLATYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20545 DRAMP30859 KKKKLVAAFYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(18% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20546 DRAMP30860 KKKKLVAATYVFV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20547 DRAMP30861 KKKKLVAATYVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20548 DRAMP30862 KKKKVLAPTYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(1% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20549 DRAMP30863 KKKKVVLAFYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(10% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20550 DRAMP30864 KKKKVVAPFYVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20551 DRAMP30865 KKKKVVAPTLVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20552 DRAMP30866 KKKKVVAPTYFLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(15% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20553 DRAMP30867 KKKKVVAPTYVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(15% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20554 DRAMP30868 KKKKVVAAFLVLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(20% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20555 DRAMP30869 KKKKVVAAFYFLV Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(7% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20556 DRAMP30870 KKKKVVAAFYVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20557 DRAMP30871 KKKKVVAATLVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(9% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20558 DRAMP30872 KKKKVLLPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(2% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20559 DRAMP30873 KKKKLVLPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(12% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20560 DRAMP30874 KKKKLLAPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20561 DRAMP30875 KKKKLLLAFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(16% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20562 DRAMP30876 KKKKLLLPFYFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(24% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20563 DRAMP30877 KKKKLLLPFLFLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20564 DRAMP30878 KKKKLLLPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(19% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20565 DRAMP30879|||Undefined|||DRAMP30879 KKKKVVLPFLFFF activity value is IC50 = 7 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20566 DRAMP30880 KKKKLVAPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(15% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20567 DRAMP30881|||Undefined|||DRAMP30881 KKKKLLAAFLFFF activity value is IC50 = 7.6 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7.6 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20568 DRAMP30882 KKKKLLLATLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(16% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20569 DRAMP30883 KKKKLLLPTYFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20570 DRAMP30884 KKKKLLLPFLVLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(4% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20571 DRAMP30885 KKKKVLAPFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20572 DRAMP30886 KKKKVLLPFYFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(27% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20573 DRAMP30887 KKKKLVLAFLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(18% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20574 DRAMP30888 KKKKLVLPTLFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(29% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20575 DRAMP30889 KKKKLVLPFYFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(14% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20576 DRAMP30890 KKKKLVLPFLLFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(18% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20577 DRAMP30891|||Undefined|||DRAMP30891 KKKKLVLPFLFVF activity value is IC50 = 8.3 uM||Antiviral ; Hepatitis C virus (HCV)[50-60% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 8.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20578 DRAMP30892 KKKKLLAPFLVFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(9% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20579 DRAMP30893 KKKKLLLAFYFFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20580 DRAMP30894 KKKKLLLAFLFLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(8% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20581 DRAMP30895 KKKKLLLPTLVFF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(3% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20582 DRAMP30896 KKKKLLLPFYFLF Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(0.05 uM)(22% inhibition at 3 uM).||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 13 FPDB20583 DRAMP30897|||Undefined|||DRAMP30897 AKDLEVVTSTYVLVEA activity value is IC50 = 2.3 uM||Antiviral ; Hepatitis C virus (HCV)[90-100% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 2.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 16 FPDB20584 DRAMP30898|||Undefined|||DRAMP30898 AKDLEVVCSTYVLVEA activity value is IC50 = 1.8 uM||Antiviral ; Hepatitis C virus (HCV)[90-100% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 1.8 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 16 FPDB20585 DRAMP30899|||Undefined|||DRAMP30899 AECVVSCSMSYTKA activity value is IC50 = 7 uM||Antiviral ; Hepatitis C virus (HCV)[60-70% PR activity = 10 uM]||Hepatitis C virus (HCV)[IC50 PR = 7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)|||Synthetic construct|||Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein) N/A N/A Ref.14694985|||https://pubmed.ncbi.nlm.nih.gov/14694985|||Antivir Chem Chemother. 2003 Sep;14(5):225-33. 14 FPDB20586 DRAMP30900 swlrdiwdwicevlsdfk Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.32 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20587 DRAMP30901|||HCV|||DRAMP30901 SWLRDIWDWICEVLSD Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.98 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.98 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 16 FPDB20588 DRAMP30902|||HCV|||DRAMP30902 SWLRDIWDWICEV Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >27 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 13 FPDB20589 DRAMP30903 SWLRDIWDWICE Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 12 FPDB20590 DRAMP30904 SWLRDIWDWI Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 10 FPDB20591 DRAMP30905 SWLRDIWD Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 8 FPDB20592 DRAMP30906|||HCV|||DRAMP30906 LRDIWDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >27 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 16 FPDB20593 DRAMP30907 DIWDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 14 FPDB20594 DRAMP30908 WDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 12 FPDB20595 DRAMP30909 WICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 10 FPDB20596 DRAMP30910 CEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 27 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 8 FPDB20597 DRAMP30911|||HCV|||DRAMP30911 SGSWLRDIWDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 1.7 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 1.7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 20 FPDB20598 DRAMP30912|||HCV|||DRAMP30912 GSWLRDIWDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.51 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.51 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 19 FPDB20599 DRAMP30913|||HCV|||DRAMP30913 SWLRDIWDWICEVLSDFKT Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 1.7 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 1.7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 19 FPDB20600 DRAMP30914|||HCV|||DRAMP30914 SWLRDIWDWICEVLSDFKTW Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.51 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.51 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 20 FPDB20601 DRAMP30915|||HCV|||DRAMP30915 SWRLIDWDWICEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 4 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20602 DRAMP30916|||HCV|||DRAMP30916 SWRLDIWDWICESVLDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 30 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >30 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20603 DRAMP30917|||BVDV|||DRAMP30917 VLDLIYSLHKQINRGLKKIVL Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 > 36 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I >36 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 21 FPDB20604 DRAMP30918|||D-Retro-HCV|||DRAMP30918 KFDSLVECIWDWIDRLWS Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.85 uM||Anti-Hepatitis C virus JFH-1, activity value is IC50 = 0.48 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20605 DRAMP30919|||HCV|||DRAMP30919 KWLCRIWSWISDVLDDFE Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.5 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20606 DRAMP30920|||HCV|||DRAMP30920 SIWRDWVDLICEFLSDWK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.4 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20607 DRAMP30921|||HCV|||DRAMP30921 SWLRDVWDWICTVLTDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 3.9 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 3.9 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20608 DRAMP30922|||HCV|||DRAMP30922 SWLRDVWDWVCTILTDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 2.1 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 2.1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20609 DRAMP30923|||HCV|||DRAMP30923 DWLRIIWDWVCSVVSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.55 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.55 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20610 DRAMP30924|||HCV|||DRAMP30924 SWLWEVWDWVLHVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 7 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20611 DRAMP30925|||HCV|||DRAMP30925 TWLRAIWDWVCTALTDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 7.1 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 7.1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20612 DRAMP30926|||HCV|||DRAMP30926 SWLRDVWDWVCTVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 3.5 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 3.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20613 DRAMP30927|||HCV|||DRAMP30927 SWLRDIWDWISEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 13.5 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 13.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20614 DRAMP30928|||HCV|||DRAMP30928 SWLRDIWDWIREVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 12.5 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 12.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20615 DRAMP30929|||HCV|||DRAMP30929 SWLRDIWDWIEEVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 13 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 13 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20616 DRAMP30930|||HCV|||DRAMP30930 SWLDDIWDWICEVLSDFE Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 4.7 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 4.7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20617 DRAMP30931|||HCV|||DRAMP30931 SWLRDIWDWICKVLSDFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 6.8 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 6.8 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20618 DRAMP30932|||HCV|||DRAMP30932 SWLDRIWRWICKVLSRFE Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 1.7 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 1.7 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20619 DRAMP30933|||HCV|||DRAMP30933 SWLRDIWRWICKVLSRFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.84 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.84 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20620 DRAMP30934|||HCV|||DRAMP30934 SWLRRIWRWICKVLSRFK Anti-Hepatitis C virus :inhibition of HCV infection in Huh-7.5.1 cells, activity value is IC50 = 0.89 uM||Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 0.89 uM]||Antimicrobial||Antiviral Synthetic construct(derived from HCV non-structural protein 5A)|||Synthetic construct|||Synthetic construct(derived from HCV non-structural protein 5A) N/A N/A Ref.18287023|||https://pubmed.ncbi.nlm.nih.gov/18287023|||Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93. 18 FPDB20621 DRAMP30935 RTQRRGRTGRGKPGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 27.1||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 37.1||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 49.8||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 17 FPDB20622 DRAMP30936 STQRRGRTGRGRRGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 24.3||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 33.6||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 47.2||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 17 FPDB20623 DRAMP30937 RRGRTGRGRRGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 0.2||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 2.7||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 21.1||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 14 FPDB20624 DRAMP30938 RTGRGRRGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 34.6||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 106||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 322||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 11 FPDB20625 DRAMP30939 RGRRGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 313||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 397||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 8 FPDB20626 DRAMP30940 RGIYR Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 > 500 uM||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from HCV NS3 helicase protein) N/A N/A Ref.18479669 5 FPDB20627 DRAMP30941 SQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 > 500 uM||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from WNV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 5 FPDB20628 DRAMP30942 RNPSQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 > 500 uM||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 383||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 437||Antimicrobial||Antiviral Synthetic construct(derived from WNV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 8 FPDB20629 DRAMP30943 RIGRNPSQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 417||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 285||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 334||Antimicrobial||Antiviral Synthetic construct(derived from WNV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 11 FPDB20630 DRAMP30944 RRGRIGRNPSQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 169||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 156||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 191||Antimicrobial||Antiviral Synthetic construct(derived from WNV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 14 FPDB20631 DRAMP30945 AAQRRGRIGRNPSQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 358||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from WNV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 17 FPDB20632 DRAMP30946 NQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 > 500 uM||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from JEV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 5 FPDB20633 DRAMP30947 RNPNQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 > 500 uM||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from JEV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 8 FPDB20634 DRAMP30948 RVGRNPNQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 374||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 448||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from JEV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 11 FPDB20635 DRAMP30949 RRGRVGRNPNQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 196||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 = 215||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 = 253||Antimicrobial||Antiviral Synthetic construct(derived from JEV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 14 FPDB20636 DRAMP30950 AAQRRGRVGRNPNQVGD Anti-Hepatitis C virus : inhibition of HCV helicase activity, activity value is IC50 = 442||Anti-West Nile virus : inhibition of WNV helicase activity, activity value is IC50 > 500 uM||Anti-Japanese encephalitis virus :inhibition of JEV helicase activity, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct(derived from JEV NS3 helicase protein) N/A N/A Ref.18479669|||Biochem Pharmacol. 2008 Jul 1;76(1):28-38. 17 FPDB20637 DRAMP30951 TTPKFTVAWDWVPKR Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 85 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20638 DRAMP30952 KTTSSIEFARLQFTY Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 6.5||Anti-ion of virus entry in Vero cells, activity value is EC50 > 200 uM||Anti-ion of virus infection in Vero cells, activity value is EC50 = 165||Anti-ability of inactive virus, activity value is EC50 = 125||Anti-ion of virus attachment on Vero cells, activity value is EC50 > 200 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20639 DRAMP30953 GHRRYFTFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 15||Anti-ion of virus entry in Vero cells, activity value is EC50 = 17.6||Anti-ion of virus infection in Vero cells, activity value is EC50 = 71.5||Anti-ability of inactive virus, activity value is EC50 = 118||Anti-ion of virus attachment on Vero cells, activity value is EC50 > 200 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20640 DRAMP30954 Anti-HeVVPLEVYTRHEIK Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 18.7||Anti-ion of virus entry in Vero cells, activity value is EC50 = 12.2||Anti-ion of virus infection in Vero cells, activity value is EC50 > 200 uM||Anti-ability of inactive virus, activity value is EC50 > 200 uM||Anti-ion of virus attachment on Vero cells, activity value is EC50 > 200 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 19 FPDB20641 DRAMP30955 HRRYFTFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 31.2||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 14 FPDB20642 DRAMP30956 GHRAYFTFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 26.4||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20643 DRAMP30957 GHRRAFTFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 119.2||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20644 DRAMP30958 GHRRYATFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 67.6||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20645 DRAMP30959 GHRRYFTAGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 37.5||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20646 DRAMP30960 GHRRYFTFGAGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 25.1||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20647 DRAMP30961 GHRRYFTFGGGYVAF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 58||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20648 DRAMP30962 GHRRYFTFGGGYVYA Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 48.6||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 15 FPDB20649 DRAMP30963 RYFTFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 34.9||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 12 FPDB20650 DRAMP30964 TFGGGYVYF Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 > 100 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 9 FPDB20651 DRAMP30965 GHRRYFTFGGGY Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 = 91.4||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 12 FPDB20652 DRAMP30966 GHRRYFTFG Anti-Herpes simplex virus type 1 :comprehensive antiviral activity, activity value is EC50 > 100 uM||Antimicrobial||Antiviral Synthetic construct(derived from HSV-1 B glycoprotein (gB)) N/A N/A Ref.19104014|||Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. 9 FPDB20653 DRAMP30968 VNPTLLFLKVPAQNAISTTFPYT Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.66177||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 23 FPDB20654 DRAMP30969 PTLLFLKVPAQNAISTTFPYT Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.4832||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 21 FPDB20655 DRAMP30970 LLFLKVPAQNAISTTFPYT Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 19 FPDB20656 DRAMP30971|||DRAMP30971|||DRAMP30972 FLKVPAQNAISTTFPYT Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 17 FPDB20658 DRAMP30973 MDVNPTLLFLKVPAQNAIST Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.0338||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 20 FPDB20660 DRAMP30975|||DRAMP30974|||DRAMP30975 MDVNPTLLFLKVPAQN Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.04586||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 16 FPDB20661 DRAMP30976 MDVNPTLLFLKVPA Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.03453||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 14 FPDB20662 DRAMP30977 MDVNPTLLFLKVP Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.13817||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 13 FPDB20663 DRAMP30978 MDVNPTLLFLKV Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.64393||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 12 FPDB20664 DRAMP30979 MDVNPTLLFLK Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.89953||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 11 FPDB20665 DRAMP30980 MDVNPTLLFL Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 10 FPDB20666 DRAMP30981 MDVNPTLLF Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 9 FPDB20667 DRAMP30982 MDVNPTLL Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 8 FPDB20668 DRAMP30983 MDVNPTL Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 7 FPDB20669 DRAMP30984 MDVNPT Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 6 FPDB20670 DRAMP30985 MDVNPTLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.04332||Anti-Influenza B :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20671 DRAMP30986 MNINPYPLFIDVPIQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.045||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20672 DRAMP30987 MNINPTLLFLKVPIQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.00669||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20673 DRAMP30988 MDVNPTLLFIDVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20674 DRAMP30989 MNINPTLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.01296||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20675 DRAMP30990 MDVNPYFLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.00751||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.345||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20676 DRAMP30991 MDVNPTFLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20678 DRAMP30993|||DRAMP30992|||DRAMP30993 MDVNPFLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.00284||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.7504||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20679 DRAMP30994 MDVNPWLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.0034||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.6283||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20680 DRAMP30995 MDVNPHLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.29216||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20681 DRAMP30996 MDVNPCLLFLKVPAQ Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 = 0.04358||Anti-Influenza A :inhibition of PA-binding activity and virus replication, activity value is IC50 > 3 uM||Antimicrobial||Antiviral Synthetic construct(derived from INFV A polymerase (PB1)) N/A N/A Ref.19841738|||PLoS One. 2009 Oct 20;4(10):e7517. 15 FPDB20682 DRAMP30997|||DRAMP31004 GWWYKGRARPVSAVA Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 3.2 uM||Anti-H3N2 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 > 10 uM||Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20683 DRAMP30998|||DRAMP31005 RAVWRHSVATPSHSV Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 6.5 uM||Anti-H3N2 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 68 uM||Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 > 500 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20684 DRAMP30999 GAWYKGRARPVSAVA Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 53 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20685 DRAMP31000 GWWYKGRARAVSAVA Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 89 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20686 DRAMP31001 AVASVPRARGKYWWG Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 44 uM||Anti-H3N2 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 17 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20687 DRAMP31002 DFRRLPGAFWQLRQP Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 52 uM||Anti-H3N2 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 19 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20688 DRAMP31003 AETVESCLAKPHTEN Anti-H1N1 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 = 66 uM||Anti-H3N2 :inhibition of virus infection in Madin-Darby canine kidney cells, activity value is IC50 > 100 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.19558186|||J Med Chem. 2009 Jul 23;52(14):4247-56. 15 FPDB20689 DRAMP31006 RRKKAVLLALLAP Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(97 ± 2% inhibition at 10 uM).||Antimicrobial||Antiviral Synthetic construct(derived from FGF-4 signal sequence) N/A N/A Ref.21220525|||Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3. 13 FPDB20690 DRAMP31007 RRKKVALLAVLLALLA Anti-Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells, activity value is EC50 = 0.3||Antimicrobial||Antiviral Synthetic construct(derived from FGF-4 signal sequence) N/A [Ref.21220525]>50% hemolysis agaisnt human red blood cells at 30 uM. Ref.21220525|||Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3. 16 FPDB20691 DRAMP31008 RRKKALLAVLLALLA Anti-Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells, activity value is EC50 = 0.4||Antimicrobial||Antiviral Synthetic construct(derived from FGF-4 signal sequence) N/A N/A Ref.21220525|||Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3. 15 FPDB20692 DRAMP31010 KAKAKAKAKAKAKAKAKAKAK Anti-herpes simplex virus 2 :inhibition of HSV-2 infection in MRC-5 cells, activity value is IC50 = 53.2 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20693 DRAMP31011 KAAKKAAKAAKKAAKWAKKAA Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 117 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20694 DRAMP31012 AKKAAKKAKKAAKKAKKAAKK Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 41 uM||Anti-herpes simplex virus 2 :inhibition of HSV-2 infection in MRC-5 cells, activity value is IC50 = 14.3 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20695 DRAMP31013 AKKAAKKAKKAAKKAKKWAKK Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 47.3 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20696 DRAMP31014 AKKAWKKAKKAAKKAKKWAKK Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 40.8 uM||Anti-herpes simplex virus 2 :inhibition of HSV-2 infection in MRC-5 cells, activity value is IC50 = 44.9 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20697 DRAMP31015 ARRAWRRARRAARRARRAARR Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 18.2 uM||Anti-herpes simplex virus 2 :inhibition of HSV-2 infection in MRC-5 cells, activity value is IC50 = 22.2 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20699 DRAMP31017 ARRAKRRARRAKRRARRKKRR Anti-herpes simplex virus 1 :inhibition of HSV-1 infection in MRC-5 cells, activity value is IC50 = 24.6 uM||Anti-herpes simplex virus 2 :inhibition of HSV-2 infection in MRC-5 cells, activity value is IC50 = 54.7 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15498607|||Antiviral Res. 2004 Nov;64(2):119-26. 21 FPDB20700 DRAMP31018 QLQKWEDWVRWIGNIPQYLKG Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.03 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.01 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 21 FPDB20701 DRAMP31019|||DRAMP31016|||DRAMP31019 QKWEDWVRWIGN Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.25 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.18 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 12 FPDB20702 DRAMP31020 WEDWVRWIGNIP Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.04 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.09 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 12 FPDB20703 DRAMP31021 QLQKWEDWVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.03 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.04 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 12 FPDB20704 DRAMP31025 WVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.2 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.11 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 5 FPDB20705 DRAMP31026 WVRW Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 36 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 24 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 4 FPDB20706 DRAMP31027 VRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 7.8 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 4.06 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 4 FPDB20707 DRAMP31028 AEDWVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 4.3||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 2.1||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20708 DRAMP31029 WADWVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.16||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.22||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.12||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20709 DRAMP31030 WEAWVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.1||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.4||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.03||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20710 DRAMP31031 WEDAVRWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20711 DRAMP31032 WEDWARWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.07||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.54||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.15||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20712 DRAMP31033 WEDWVAWI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.09||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.38||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.25||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20713 DRAMP31034 WEDWVRAI Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 > 50||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 > 50 ug/ml||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20714 DRAMP31035 WEDWVRWA Anti-FIV-M2 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.15||Anti-FIV-GL8 :inhibition of virus replication in MBM cells, activity value is IC50 = 0.64||Anti-FIV-Pet :inhibition of virus replication in MBM cells, activity value is IC50 = 0.13||Antimicrobial||Antiviral Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus) N/A N/A Ref.12610147|||J Virol. 2003 Mar;77(6):3724-33. 8 FPDB20715 DRAMP31036|||RhoA 77-95|||DRAMP31036 TDVILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 7.6 uM||Antiviral ; HIV-1[IC50 E = 7.8 uM]||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein)|||Synthetic construct|||Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||21198428|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20716 DRAMP31037 CSIELSDIPLSVDFNTMID Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20717 DRAMP31038 ADVILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 2.56 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20718 DRAMP31039 TAVILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 1.37 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20719 DRAMP31040 TDAILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 6.6 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20720 DRAMP31041 TDVALMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 11.6 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20721 DRAMP31042 TDVIAMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 5.42 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20722 DRAMP31043 TDVILACFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 1.43 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20723 DRAMP31044 TDVILMAFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20724 DRAMP31045 TDVILMCASIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 6.29 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20725 DRAMP31046 TDVILMCFAIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 6.82 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20726 DRAMP31047 TDVILMCFSADSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 3.52 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20727 DRAMP31048 TDVILMCFSIASPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 4.36 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20728 DRAMP31049 TDVILMCFSIDAPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 2.26 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20729 DRAMP31050 TDVILMCFSIDSADSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 15.32 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20730 DRAMP31051 TDVILMCFSIDSPASLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 2.61 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20731 DRAMP31052 TDVILMCFSIDSPDALENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 1.19 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20732 DRAMP31053 TDVILMCFSIDSPDSAENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 2.27 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20733 DRAMP31054 TDVILMCFSIDSPDSLANI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 9.83 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20734 DRAMP31055 TDVILMCFSIDSPDSLEAI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 18.47 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20735 DRAMP31056 TDVILMCFSIDSPDSLENA Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 4.89 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 19 FPDB20736 DRAMP31057 TDVILMCFSI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 10 FPDB20737 DRAMP31058 TDVILMCFSIDSP Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 13 FPDB20738 DRAMP31059 TDVILMCFSIDSPDSL Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 10.86 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 16 FPDB20739 DRAMP31060 DVILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 1.23 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 18 FPDB20740 DRAMP31061 VILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 16.95 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 17 FPDB20741 DRAMP31062 ILMCFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 7.17 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 16 FPDB20742 DRAMP31063 CFSIDSPDSLENI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 13 FPDB20743 DRAMP31064 ILMCFSIDSPDSLEN Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 1.75 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 15 FPDB20744 DRAMP31065 ILMCFSIDSPDSLE Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 3.5 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 14 FPDB20745 DRAMP31066 ILMCFSIDSPDSL Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 12.4 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 13 FPDB20746 DRAMP31067 ILMCFSIDSPDS Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 6.36 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 12 FPDB20747 DRAMP31068 ILMCFSIDSPD Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 4.61 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 11 FPDB20748 DRAMP31069 ILMCFSIDSP Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 = 35.77 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 10 FPDB20749 DRAMP31070 ILMCFSIDS Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 9 FPDB20750 DRAMP31071 ILMCFSID Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 8 FPDB20751 DRAMP31072 ILMCFSI Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 7 FPDB20752 DRAMP31073 ILMCFS Anti-respiratory syncytial virus :inhibition of RSV replication in HEp-2 cells, activity value is IC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from RhoA protein) N/A N/A Ref.14576104|||Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7. 6 FPDB20753 DRAMP31074 NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA Anti-HIV-luc/SARS pseudotyped virus:inhibition of virus infection in 293T cells, activity value is EC50 = 0.14 uM||Anti-SARS-CoV :inhibition of virus infection in 293T cells, activity value is EC50 = 3.68 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.15184046|||Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52. 38 FPDB20754 DRAMP31075|||Undefined|||DRAMP31075 HRILMRIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 56.47 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 56.47 uM]||Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 16.12 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at 473 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20755 DRAMP31076|||Undefined|||DRAMP31076 ARILMRIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 56.12263 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 56.12 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20756 DRAMP31077|||Undefined|||DRAMP31077 HRALMRIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 34.18095 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 34.18 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20757 DRAMP31078|||Undefined|||DRAMP31078 HRIAMRIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 54.5872 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 54.58 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20758 DRAMP31079|||Undefined|||DRAMP31079 HRILARIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 435.4996 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 435.49 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20759 DRAMP31080|||Undefined|||DRAMP31080 HRILMRARQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 150.1405 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 150.14 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20760 DRAMP31081|||Undefined|||DRAMP31081 HRILMRIAQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 60.60846 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 60.6 uM]||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20761 DRAMP31082|||Undefined|||DRAMP31082 HRILMRIRAMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 34.13563 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 34.13 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20762 DRAMP31083|||Undefined|||DRAMP31083 HRILMRIRQAMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 57.98146 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 57.98 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20763 DRAMP31084|||Undefined|||DRAMP31084 HRILMRIRQMAT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 120.5239 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 120.52 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20764 DRAMP31085|||Undefined|||DRAMP31085 HRILMRIRQMMA Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 89.41235 uM||Antiviral ; Porcine reproductive and respiratory syndrome virus (PRRSV)[IC50 REP = 89.41 uM]||Antimicrobial||Antiviral Synthetic construct N/A MARC-145 cells (50% Cell death at 186.25 uM Ref.22743126|||https://pubmed.ncbi.nlm.nih.gov/22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20765 DRAMP31086|||CAMPSQ22215|||DRAMP31086 LMRIRQMMT Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 263.8101 uM||Antiviral||Antimicrobial Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||22743126|||Virology. 2012 Oct 10;432(1):73-80. 9 FPDB20766 DRAMP31087|||CAMPSQ22216|||DRAMP31087 HRILMRIR Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 43.50202 uM||Antiviral||Antimicrobial Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||22743126|||Virology. 2012 Oct 10;432(1):73-80. 8 FPDB20767 DRAMP31088|||CAMPSQ22217|||DRAMP31088 LMRIR Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 716.4193 uM||Antiviral||Antimicrobial Synthetic construct N/A MARC-145 cells (50% Cell death at >500 uM Ref.22743126|||22743126|||Virology. 2012 Oct 10;432(1):73-80. 5 FPDB20768 DRAMP31089 hrilmrirqmmt Anti-Porcine reproductive and respiratory syndrome virus :inhibition of PRRSV replication in MARC-145 cells, activity value is IC50 = 16.12312 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.22743126|||Virology. 2012 Oct 10;432(1):73-80. 12 FPDB20769 DRAMP31090|||DENV1 Ep|||DRAMP31090 AWDFGSIGGVFTSVGKLVHQVFGTAYGVL "Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=1.5 uM); Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 uM); Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 uM); Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90>6 uM).||Antiviral ; DENV-1[IC90 I = 1.5 uM]||DENV-2[IC90 I = 2 uM]||DENV-3[IC90 I >6 uM]||DENV-4[IC90 I >6 uM]||Antimicrobial||Antiviral" Synthetic construct(derived from DENV1 E protein stem)|||Synthetic construct|||Synthetic construct(derived from DENV1 E protein stem) N/A N/A Ref.20881042|||https://pubmed.ncbi.nlm.nih.gov/20881042|||J Virol. 2010 Dec;84(24):12549-54. 29 FPDB20770 DRAMP31092|||DENV3 Ep|||DRAMP31092 AWDFGSVGGVLNSLGKMVHQIFGSAYTAL "Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 uM); Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 uM); Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=4 uM); Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=1.5 uM).||Antiviral ; DENV-1[IC90 I = 0.1 uM]||DENV-2[IC90 I = 2 uM]||DENV-3[IC90 I = 4 uM]||DENV-4[IC90 I = 1.5 uM]||Antimicrobial||Antiviral" Synthetic construct(derived from DENV3 E protein stem)|||Synthetic construct|||Synthetic construct(derived from DENV3 E protein stem) N/A N/A Ref.20881042|||https://pubmed.ncbi.nlm.nih.gov/20881042|||J Virol. 2010 Dec;84(24):12549-54. 29 FPDB20771 DRAMP31093|||DENV4 Ep|||DRAMP31093 AWDFGSVGGLFTSLGKAVHQVFGSVYTTM "Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=5 uM); Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=6 uM); Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 uM); Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=6 uM).||Antiviral ; DENV-1[IC90 I = 5 uM]||DENV-2[IC90 I = 6 uM]||DENV-3[IC90 I >6 uM]||DENV-4[IC90 I = 6 uM]||Antimicrobial||Antiviral" Synthetic construct(derived from DENV4 E protein stem)|||Synthetic construct|||Synthetic construct(derived from DENV4 E protein stem) N/A N/A Ref.20881042|||https://pubmed.ncbi.nlm.nih.gov/20881042|||J Virol. 2010 Dec;84(24):12549-54. 29 FPDB20772 DRAMP31094|||DRAMP31097|||SARS-Cov-S|||DRAMP31094|||DRAMP31097 YENQKQIANQFNKAISQIQESLTTTSTA Anti-HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells, activity value is EC50 = 1.16 uM||Anti-SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells, activity value is EC50 = 1.16 uM||Antiviral ; SARS-CoV PsV[IC50 E = 1.16 uM]||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct|||Synthetic construct|||Synthetic construct(derived from SARS-CoV spike protein) N/A N/A Ref.18442051|||https://pubmed.ncbi.nlm.nih.gov/18442051|||J Cell Biochem. 2008 Aug 15;104(6):2335-47. 28 FPDB20773 DRAMP31095|||DRAMP31096 DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI Anti-HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells, activity value is EC50 = 2.15 uM||Anti-SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells, activity value is EC50 = 2.15 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein)|||Synthetic construct N/A N/A Ref.18442051|||J Cell Biochem. 2008 Aug 15;104(6):2335-47. 48 FPDB20774 DRAMP31098|||DRAMP31115 ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 = 43||Anti-murine coronavirus:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 = 43||Anti-MHV : inhibition of MHV infection in Vero 118 cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 64 FPDB20775 DRAMP31099 PKEELDKYFKNHTSPDVDLGLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 = 24||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat) N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 62 FPDB20776 DRAMP31100|||DRAMP31114 LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 56 FPDB20777 DRAMP31101 FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat) N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 52 FPDB20778 DRAMP31102 TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat) N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 48 FPDB20779 DRAMP31103 VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat) N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 44 FPDB20780 DRAMP31104|||DRAMP31113 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 40 FPDB20781 DRAMP31105|||DRAMP31112 ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 = 17||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 = 17||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 68 FPDB20782 DRAMP31106|||DRAMP31110 ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 = 34||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 = 34||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 60 FPDB20783 DRAMP31107 ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat) N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 56 FPDB20784 DRAMP31108|||DRAMP31109 DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE Anti-SARS-CoV:inhibition of virus infection in Vero cells, activity value is EC50 > 50 uM||Anti-murine coronavirus:inhibition of virus infection in Vero cells, activity value is EC50 = 0.9||Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 > 50 uM||Anti-MHV : inhibition of MHV infection in Vero 118 cells, activity value is EC50 = 0.9||Antimicrobial||Antiviral Synthetic construct(derived from SARS-CoV spike protein heptad repeat)|||Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 39 FPDB20785 DRAMP31111 NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 > 50 uM||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 46 FPDB20786 DRAMP31116 PKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE Anti-SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells, activity value is EC50 = 24||Antimicrobial||Antiviral Synthetic construct N/A N/A Ref.15150417|||Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. 60 FPDB20787 DRAMP31117|||Human Defensin-5/HD5|||DRAMP31117 ATCYCRTGRCATRESLSGVCRISGRLYRLCCR Anti-neutralization activity against HSV-2 during the preinfection stage, activity value is IC50 = 25 ug/ml||Anti-HIV-1:inhibition of virus infection in JLTRG cells, activity value is IC50 = 3.53 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is LD50 = 1.3||Anti-Staphylococcus aureus ATCC 25923, activity value is LD50 = 0.6||Antimicrobial||Antiviral Synthetic construct(derived from human alpha defensin(HD5))|||Synthetic construct|||Synthetic construct(derived from human alpha defensin(HD5)) N/A Mouse erythrocytes (0.5% Hemolysis at 100 ug/ml, Human cervical epithelial cells CaSki ( at NA Ref.23269800|||https://pubmed.ncbi.nlm.nih.gov/23269800,|||J Virol. 2013 Mar;87(5):2835-45. 32 FPDB20788 DRAMP31118|||Human Defensin-5, HD5|||DRAMP31118 ATCYCRTGRCATRESLSGVCEIRGRLYRLCCR Anti-Herpes simplex virus2 :neutralization activity against HSV-2 during the preinfection stage, activity value is IC50 = 36 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is LD50 = 1.7||Anti-Escherichia coli ATCC 25922, activity value is LD50 = 6.0||Anti-Staphylococcus aureus ATCC 25923, activity value is LD50 = 1.5||Antimicrobial||Antiviral Synthetic construct(derived from human alpha defensin(HD5))|||Synthetic construct|||Synthetic construct(derived from human alpha defensin(HD5)) N/A Human cervical epithelial cells CaSki ( at NA Ref.23269800|||https://pubmed.ncbi.nlm.nih.gov/23269800,|||J Virol. 2013 Mar;87(5):2835-45. 32 FPDB20789 DRAMP31119|||Human Defensin-5/HD5|||DRAMP31119 ATCYCRRGRCATRESLSGVCEISGRLYRLCCR Anti-Herpes simplex virus2 :neutralization activity against HSV-2 during the preinfection stage, activity value is IC50 = 40 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is LD50 = 1.4||Anti-Staphylococcus aureus ATCC 25923, activity value is LD50 = 1.3||Antimicrobial||Antiviral Synthetic construct(derived from human alpha defensin(HD5))|||Synthetic construct|||Synthetic construct(derived from human alpha defensin(HD5)) N/A Human cervical epithelial cells CaSki ( at NA Ref.23269800|||https://pubmed.ncbi.nlm.nih.gov/23269800,|||J Virol. 2013 Mar;87(5):2835-45. 32 FPDB20790 DRAMP31120|||HD5|||DRAMP31120 ATCYCRTGRCATRESRSGVCEISGRLYRLCCR Anti-neutralization activity against HSV-2 during the preinfection stage, activity value is IC50 = 67 ug/ml||Antiviral ; HSV-2[IC50 E = 67 ug/ml]||Antimicrobial||Antiviral Synthetic construct(derived from human alpha defensin(HD5))|||Synthetic construct|||Synthetic construct(derived from human alpha defensin(HD5)) N/A Human cervical epithelial cells CaSki (- at NA Ref.23269800|||https://pubmed.ncbi.nlm.nih.gov/23269800|||J Virol. 2013 Mar;87(5):2835-46. 32 FPDB20791 DRAMP31121 PPVYTKDVDISSQISSMNQSLQQSKDYIKEAQKILDTVNPSL Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.075 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.04 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from HeV fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 42 FPDB20792 DRAMP31122 VYTDKVDISSQISSMNQSLQQSKDYIKEAQKILDTV Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.075 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.04 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from HeV fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 36 FPDB20793 DRAMP31123 DITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.02 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.0075 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.5 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.5 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 45 FPDB20794 DRAMP31124 VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.02 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.0075 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.5 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.5 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 36 FPDB20795 DRAMP31125 VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.1 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 3 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 = 1.1 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.75 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 36 FPDB20796 DRAMP31126 VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.1 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 8 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 = 0.5 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.35 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 36 FPDB20797 DRAMP31127 VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 1 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 = 1.1 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 = 0.75 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 36 FPDB20798 DRAMP31128 VALDPIDISIELNKAKSDLEESKEWIRR Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 1 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 28 FPDB20799 DRAMP31129 SIELNKAKSDLEESKEWIRRSNQKLDSI Anti-Henda virus :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 1 uM||Anti-human parainfluenza virus 3 :inhibition of virus infection in HeLa cells, activity value is IC50 > 10 uM||Anti-ion of fusion in HeLa cells, activity value is IC50 > 10 uM||Antimicrobial||Antiviral Synthetic construct(derived from HPIV3 fusion (F) protein) N/A N/A Ref.16973588|||J Virol. 2006 Oct;80(19):9837-49. 28 FPDB20800 DRAMP31130|||D-Claudin-1|||DRAMP31130 MANAGLQLLGFILAFLGW Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 2.1||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 2.1+-0.5 uM]||Hepatitis C virus (HCV) JFH-1[IC50 I = 2 uM]||Human hepatocellular carcinoma Huh-7.5.1 cells||Vesicular Stomatitis Virus (VSV) PsV||Coxsackie virus||Hepatitis C virus (HCV) PsV[90-100% Inhibition = 20 uM]||Hepatitis C virus (HCV)[IC50 I = 1.8+-0.4 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-15. 18 FPDB20801 DRAMP31131|||Claudin-1|||DRAMP31131 GLQLLGFILAFLGWIGAI Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-16. 18 FPDB20802 DRAMP31132|||Claudin-1|||DRAMP31132 LLGFILAFLGWIGAIVST Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 4.3||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 4.3+-0.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-17. 18 FPDB20803 DRAMP31133|||Claudin-1|||DRAMP31133 FILAFLGWIGAIVSTALP Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 8.9||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 8.9+-1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-18. 18 FPDB20804 DRAMP31134|||Claudin-1|||DRAMP31134 AFLGWIGAIVSTALPQWR Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 12.5||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 12.5+-1.5 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-19. 18 FPDB20805 DRAMP31135|||Claudin-1|||DRAMP31135 GWIGAIVSTALPQWRIYS Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 21.5||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 21.5+-1.9 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-20. 18 FPDB20806 DRAMP31136|||Claudin-1|||DRAMP31136 GAIVSTALPQWRIYSYAG Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 23.8||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 23.8+-2.1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-21. 18 FPDB20807 DRAMP31137|||Claudin-1|||DRAMP31137 VSTALPQWRIYSYAGDNI Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-22. 18 FPDB20808 DRAMP31138|||Claudin-1|||DRAMP31138 ALPQWRIYSYAGDNIVTA Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-23. 18 FPDB20809 DRAMP31139|||Claudin-1|||DRAMP31139 MANAGLQLLGFILA Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||https://pubmed.ncbi.nlm.nih.gov/22378192|||Hepatology. 2012 Aug;56(2):507-24. 14 FPDB20810 DRAMP31140|||Claudin-1|||DRAMP31140 MANAGLQLLGFILAFL Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 7.6||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 7.6+-0.9 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||https://pubmed.ncbi.nlm.nih.gov/22378192|||Hepatology. 2012 Aug;56(2):507-25. 16 FPDB20811 DRAMP31141|||Claudin-1|||DRAMP31141 MANAGLQLLGFILAFLGWIG Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 17.8||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 17.8+-1.1 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-26. 20 FPDB20812 DRAMP31142|||Claudin-1|||DRAMP31142 MANAGLQLLGFILAFLGWIGAI Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 4||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 4.0+-0.3 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-27. 22 FPDB20813 DRAMP31143|||Claudin-1|||DRAMP31143 MANAGLQLLGFILAFLGWIGAIVS Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 5.1||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I = 5.1+-0.6 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-28. 24 FPDB20814 DRAMP31144 managlqllgfilaflgw Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 = 1.8||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||Hepatology. 2012 Aug;56(2):507-29. 18 FPDB20815 DRAMP31145|||Scrambled Claudin-1|||DRAMP31145 AGALMFAWLLLGLQGIFN Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-29. 18 FPDB20816 DRAMP31146|||Claudin-6|||DRAMP31146 MASAGMQILGVVLTLLGW Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-30. 18 FPDB20817 DRAMP31147|||Claudin-7|||DRAMP31147 MANSGLQLLGFSMALLGW Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV)[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-31. 18 FPDB20818 DRAMP31148|||Claudin-9|||DRAMP31148 MASTGLELLGMTLAVLGW Anti-Hepatitis C virus :inhibition of viral-entry in Huh7.5.1 cells, activity value is IC50 > 25 uM||Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM]||Antimicrobial||Antiviral Synthetic construct(derived from human claudin-1)|||Synthetic construct|||Synthetic construct(derived from human claudin-1) N/A N/A Ref.22378192|||22378192|||Hepatology. 2012 Aug;56(2):507-32. 18 FPDB20819 DRAMP31149 EELRVRLASHLRKLRKRLLRDADDLQKRLAVYEEQAQQIRLQAEAFQARLKSWFEPLVEDM Anti-hepatitis C virus :inhibition of infection in Huh7.5.1 cells, activity value is IC50 = 0.67 uM||Antimicrobial||Antiviral Synthetic construct(derived from human apolipoprotein E) N/A N/A Ref.22334503|||Hepatology. 2012 Aug;56(2):484-91. 61 FPDB20820 AP00223 AACARFIDDFCDTLTPNIYRPRDNGQRCYAVNGHRCDFTVFNTNNGGNPIRASTPNCKTVLRTAANRCPTGGRGKINPNAPFLFAIDPNDGDCST Antiviral protein Y3: at 2 ug/ml achieved 50.0% inhibition of tobacco mosaic virus (TMV||20 ug/ml) lesions in Nicotiana glutinosa leaves. (provided by Chunfeng Wang). Submitted OCT-2002 to the SWISS-PROT data bank. It shows antiviral activity against Tobacco mosaic virus and antitumor activity against stomach cancer cells in vitro. Golden oyster mushroom, Pleurotus citrinopileatus N/A N/A 2008, Vol. 24 ›› Issue (07) : 597-603. 95 FPDB20821 AP00741 PITYLDAILAAVRLLNQRISGPCILRLREAQPRPGWVGTLQRRREVSFLVEDGPCPPGVDCRSCEPGALQHCVGTVSIEQQPTAELRCR Anti-Gram+ & Gram-||Antiviral the epithelium of the bursa of Fabricius, Gallus gallus N/A N/A Proc Natl Acad Sci USA 2007; 104: 15063-15068 89 FPDB20822 AP01702 MKTFSVAVAVAVVLAFICTQESSALPVTGIEELVEPVSSDNNDNHQGLPVELRERLVNIRKKRAPTDCIPYCYPTGDGFHCGVTCR Anti-Gram-||Antiviral Orange-spotted liver, grouper, Epinephelus coioides Bridge N/A Fish Shellfish Immunol. 2011 Feb;30(2):559-68 86 FPDB20823 AP02073 KPKGMTSSQWFKIQHMQPSPQACNSAMKNINKHTKRCKDLNTFLHEPFSSVAATCQTPKIACKNGDKNCHQSHGAVSLTMCKLTS Anti-Gram+ & Gram-||Antiviral||Antifungal||anti-TB keratinocytes, Skin (e.g. hair follicle), urinary tract, Homo sapiens, including pre-term and term infants Combine Helix and Beta structure N/A J Biol Chem. 2002 Nov 29;277(48):46779-84. Pub-Med. GenBank:NP_115961.2. 85 FPDB20824 AP02075 Skin, Homo sapiens Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Anti-HIV||Chemotactic||Antibiofilm Skin, Homo sapiens Combine Helix and Beta structure N/A J Leukoc Biol. 2003 Sep;74(3):448-55. Pub-Med. GenBank:NP_001123518.1. 15 FPDB20825 AP02095 SGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPGKKRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYGQCLMLNPPNFCEMDG Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-inflammatory||Enzyme inhibitor tears, saliva, airway, gastrointestines, genital tracts, Homo sapiens Beta N/A J Bacteriol. 1989 Apr;171(4):2166-72. Pub-Med. GenBank:CAA28187.1 84 FPDB20826 AP02099 RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWRCKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNNCHRSRFRVPLLHCDLIN Anti-Gram+ & Gram-||Antiviral||Antiparasitic||anti-sepsis||bacteria-agglutinating AMPs eosinophilic leukocytes, Homo sapiens Combine Helix and Beta structure N/A J Immunol. 1990 Apr 15;144(8):3166-73. Pub-Med. GenBank:NP_002926.2 87 FPDB20827 AP02130 GSGPTYCWNEANNPGGPNRCSNNKQCDGARTCSSSGFCQGTSRKPDPGPKGPTYCWDEAKNPGGPNRCSNSKQCDGARTCSSS Antiviral||Anti-HIV cyanobacterium, Scytonema varium Combine Helix and Beta structure N/A Biochemistry. 2003 Mar 11;42(9):2578-84.Pub-Med. 83 FPDB20828 AP02131 LGKFSQTCYNSAIQGSVLTSTCERTNGGYNTSSIDLNSVIENVDGSLKWQPSNFIETCRNTQLAGSSELAAECKTRAQQFVSTKINLDD Antiviral||Anti-HIV cyanobacterium (blue-green alga), Nostoc ellipsosporum Beta N/A Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.Pub-Med. 89 FPDB20829 AP02132 MASYKVNIPAGPLWSNAEAQQVGPKIAAAHQGNFTGQWTTVVESAMSVVEVELQVENTGIHEFKTDVLAGPLWSNDEAQKLGPQI Antiviral||Anti-HIV blue-green algae, Microcystis viridis Combine Helix and Beta structure N/A N/A 85 FPDB20830 AP02133 SLTHRKFGGSGGSPFSGLSSIAVRSGSYLDAIIIDGVHHGGSGGNLSPTFTFGSGEYISNMTIRSGDYIDNISFETNMGRRFGPYGGSG Antiviral||Anti-HIV the red alga Griffithsia sp Beta N/A J Biol Chem. 2005 Mar 11;280(10):9345-53.Pub-Med. 89 FPDB20831 AP02144 YETLIASVLGKLTGLWHNNSVDFMGHTCHFRRRPKVRKFKLYHEGKFWCPGWAPFEGRSRTKSRSGSSREAIKDFVRKALQNGLITQ Anti-Gram+ & Gram-||Antiviral hemocyte, most common mud crabs in Asia, Scylla paramamosain N/A N/A Fish Shellfish Immunol. 2012 Jul;33(1):1-10.Pub-Med. 87 FPDB20832 AP02145 YEALVASILGKLSGLWHSDTVDFMGHTCHIRRRPKFRKFKLYHEGKFWCPGWTHLEGNSRTKSRSGSARDAIKDFVYKALQNKLITEN Anti-Gram+ & Gram-||Antiviral hemocyte, most common mud crabs in Asia, Scylla paramamosain N/A N/A Fish Shellfish Immunol. 2012 Jul;33(1):1-10.Pub-Med. 88 FPDB20833 AP02146 QGWEAVAAAVASKIVGLWRNEKTELLGHECKFTVKPYLKRFQVYYKGRMWCPGWTAIRGEASTRSQSGVAGKTAKDFVRKAFQKG Anti-Gram+ & Gram-||Antiviral||Antifungal the black tiger shrimp, Penaeus monodon Combine Helix and Beta structure "The document mentions the hemolytic values of recombinant ALFPm3 (rALFPm3) and its derived synthetic peptide (ALFPm3#35–51) as follows: - rALFPm3: In the concentration range of 1.95–250 μM, the hemolysis rate of human red blood cells was 0–3% (specific data: 2% at 250 μM, 3% at 125 μM, 2% at 62.5 μM, 2% at 31.3 μM, 2% at 15.6 μM, 2% at 7.8 μM, 0% at 3.9 μM, and 0% at 1.95 μM). - Synthetic peptide ALFPm3#35–51: In the concentration range of 1.95–250 μM, the hemolysis rate decreased with decreasing concentration (specific data: 22% at 250 μM, 20% at 125 μM, 9% at 62.5 μM, 8% at 31.3 μM, 7% at 15.6 μM, 6% at 7.8 μM, 4% at 3.9 μM, and 0% at 1.95 μM). These data indicate that rALFPm3 has almost no hemolytic activity, while the synthetic peptide exhibits weak hemolytic activity at high concentrations." Dev Comp Immunol. 2005;29(10):841-51.Pub-Med. 85 FPDB20834 AP02156 MQLSTIFCFAVLIACARAQVFVKPGHKDEDLAWMRSMGKGHVFGTLGSTDGSLIGKLGYKQNIYNDQRGNLGGTAYGSRVINEYGGT Antiviral hemocytes, Trichoplusia ni N/A N/A J Invertebr Pathol. 2012 May;110(1):92-101. Pub-Med. 87 FPDB20835 AP02157 MQSSILLIFAAFVACTYAQVSLPPGYAQKYPQYKYSKVARHPRDTTWEHNVGRGKIFGTLGSNDDSVFGRGGYKQDIFNDHRGRLSG Antiviral hemocytes, Trichoplusia ni N/A N/A J Invertebr Pathol. 2012 May;110(1):92-101. Pub-Med. 87 FPDB20836 AP02230 PKRKAEGDAKGDKAKVKDEPQRRSARLSAKPAPPKPEPKPKKAPAKKGEKVPKGKKGKADAGKEGNNPAENGDAKTDQAQKAEGA Anti-Gram-||Antiviral||Antifungal||candidacidal human mononuclear leukocyte, Homo sapiens N/A N/A J Leukoc Biol. 2005 Nov;78(5):1136-41. Pub-Med. 85 FPDB20837 AP02256 HRPYCGSKGGIGGGHGGGSGGFGGGGGFGGGGLGGGKPIGIGGGGGFGGGSGFGGGVGLKPNVGGGGGFGGGGGGFGGGIGLKP Antiviral ovaries, antennal gland, intestine, gill, hepatopancreas, heart, haemocytes, red swamp crayfish, Procambarus clarkii N/A N/A Fish & Shellfish Immunology 2013; 35: 407-412. Sci Direct 84 FPDB20838 AP02334|||Peptide Hp1036|||DRAMP18139 ILGKIWEGIKSIF Antiviral||Anti-HSV-1, activity value is EC50 = 0.43||Antimicrobial||Antibacterial venom, Heterometrus petersii, Asia|||Heterometrus petersii [Asian forest scorpion]|||Heterometrus petersii (Asian forest scorpion) N/A Human RBC ( HC50 = 34.91 +/- 0.47 uM ) [HC50 (50% hemolysis concentration)]|||No hemolysis information or data found in the reference(s) presented in this entry Antiviral Res. 2013 Dec 4;102C:1-10.PubMed|||https://pubmed.ncbi.nlm.nih.gov/24315793|||Proteomics 10:2471-2485 (2010).##Antiviral ReS. 102:1-10 (2014). 13 FPDB20839 AP02335|||Peptide Hp1239|||DRAMP18137 ILSYLWNGIKSIF Antiviral||Anti-HSV-1, activity value is EC50 = 0.41||Antimicrobial||Antibacterial venom, Heterometrus petersii, Asia|||Heterometrus petersii [Asian forest scorpion]|||Heterometrus petersii (Asian forest scorpion) N/A Human RBC ( HC50 = 33.32 +/- 0.96 uM ) [HC50 (50% hemolysis concentration)]|||No hemolysis information or data found in the reference(s) presented in this entry Antiviral Res. 2013 Dec 4;102C:1-10. PubMed|||https://pubmed.ncbi.nlm.nih.gov/24315793|||Proteomics 10:2471-2485 (2010).##Antiviral ReS. 102:1-10 (2014). 13 FPDB20840 AP02337 KPPQFTWAQWFETQHINMTSQQCTNAMQVINNYQRRCKNQNTFLLTTFANVVNVCGNPNMTCPSNKTRKNCHHSGSQVPLIH Antiviral||Antiparasitic||Chemotactic liver, lung, spleen, eosinophilic leukocytes; neutrophils, and monocytes, Homo sapiens Combine Helix and Beta structure N/A J Immunol. 1990 Apr 15;144(8):3166-73.PubMed; Gene Bank; 82 FPDB20841 AP02338 LGQTPSQWFAIQHINNNANLQCNVEMQRINRFRRTCKGLNTFLHTSFANAVGVCGNPSGLCSDNISRNCHNSSSRVRITVCNITSRR Antiviral||Chemotactic Mus musculus N/A N/A Antiviral Res. 2003 Aug;59(3):181-91.PubMed; Gene Bank; 87 FPDB20842 AP02571 CGESCVFIPCITTVLGCSCSIKVCYKNGSIP Antiviral Viola yedoensis Bridge N/A Yao Xue Xue Bao. 2014 Jun;49(6):905-12. PubMed 31 FPDB20843 AP02695 SSFSPAAPLPPGTKHPCLPLSCPPCPDEECPTCEILPPCELCPEIHIGCDCPFHHSCLCDQPACPPCDFPFGSLINKGGYRG Antiviral mainly gills and hemocytes; Marsupenaeus japonicus Bridge N/A Fish Shellfish Immunol. 2015 Dec;47(2):817-23. PubMed 82 FPDB20844 AP02846|||Urumin IPLRGAFINGRWDSQCHRFSNGAIACA Antiviral||Antiviral ; H1N1 Hydrophylax bahuvistara, India, Asia|||Synthetic construct N/A "The provided document contains experimental data related to hemolysis, as detailed below: - Hemolytic activity of urumin: - In PBS, urumin showed no toxicity (hemolysis) at concentrations up to 320 µM. - Only at a concentration of 1430 µM did it cause 20% hemolysis. - Its median toxic dose (TD₅₀) is 2450 µM. - Hemolytic activity of alanine scan mutants: - Except for the mutant with a substitution at the 3rd residue, which showed 20% hemolysis at 160 µM, the other 22 mutants were non-toxic to human red blood cells. - Hemolytic activity of D-form urumin: - Similar to the L-form urumin, the D-form was non-toxic to human red blood cells. The above data were measured using human red blood cell hemolysis experiments. Hemolysis induced by 0.1% Triton X-100 was used as a 100% control, PBS as a 0% control, and the amount of hemoglobin released (degree of hemolysis) was assessed by measuring absorbance at 450 nm." Immunity. 2017 Apr 18;46(4):587-595. PubMed|||https://pubmed.ncbi.nlm.nih.gov/35259078 27 FPDB20845 AP03266|||An1a GFGCPLDQMQCHNHCQSVRYRGGYCTNFLKMTCKCY Antiviral||Antiviral ; Dengue serotype-2 virus venom gland, female Alopecosa nagpag , Yunnan, China, Asia|||Synthetic construct Bridge "The document only mentions that An1a did not show hemolytic activity at a concentration of 20 uM (""An1a did not show any cytotoxicity and hemolytic activity under 20 uM""), but does not provide specific hemolytic values (such as half-hemolysis concentration HC₅₀ or hemolysis rates at different concentrations). Note: The hemolysis experiment used the hemolytic effect induced by 1% Triton X-100 as a control, and no hemolysis was observed for An1a at the tested concentration of 20 uM.|||Human red blood cells (<50% hemolysis at 640 uM)" Toxins (Basel). 2019 Oct 10;11(10):584. doi: 10.3390/toxins11100584. PubMed|||https://pubmed.ncbi.nlm.nih.gov/31658707 36 FPDB20846 AP03332 SMLLLFFLGTISLSLCQDDQERC Antiviral Indosylvirana aurantiaca, Sri Lanka and South India, Asia N/A "The document mentions hemolysis-related data for Yodha peptide, as follows: - Non-toxic concentration: it is non-toxic to human red blood cells at a concentration of 1000 uM and only shows toxicity at 2000 uM. - Hemolysis at different concentrations: the specific hemolysis rate values are not directly given in the text, but experiments indicate that at the effective concentrations used for antiviral experiments (such as 20 uM, 50 uM, 160 uM, etc.), Yodha peptide shows no hemolytic toxicity. Note: In the hemolysis experiments, the hemolytic effect produced by 0.1% Triton X-100 is taken as the 100% hemolysis standard, and PBS treatment is used as the 0% hemolysis control. In addition, both alanine scanning mutants and natural variants of Yodha showed no toxicity to human red blood cells." Sci Rep. 2021 Jan 12;11(1):602. doi: 10.1038/s41598-020-80596-4. PubMed 23 FPDB20847 AP03939 GLINEKKVQQYLDEKLPNGVVKGALKSLVHKAAKNQNLCAFNVDTVGMCDADCKRQGKAKGVCHGTKCKCDVELSYKK Antiviral||Channel inhibitors Venom, Euscorpiops validus, China, Asia Bridge "The document mentions the hemolytic-related results of the novel scorpion venom peptide Ev37 and its truncated peptides, specifically as follows: - rEv37, Ev37-N, Ev37-C: At concentrations of 5 μM and 10 μM, they showed no hemolytic activity on human red blood cells, with a hemolysis rate of 0%. Note: In the hemolysis assay, the buffer-treated group was used as the 0% hemolysis control, and the 1% Triton X-100-treated group was used as the 100% hemolysis control. Hemolysis was evaluated by measuring the absorbance at 490 nm." Protein Expr Purif. 2013 Mar;88(1):127-33. doi: 10.1016/j.pep.2012.12.004. PubMed 78 FPDB20848 AP03940 GLIDVKCYATSQCWAPCKKETGSGQSKCQNNQCRCY Antiviral Venom, Androctonus amoreuxi , North Africa Bridge N/A Peptides. 2024 Mar;173:171139. doi: 10.1016/j.peptides.2023.171139. PubMed 36 FPDB20849 AP04147 GFKRIVQRIKDFLRNLVKL Antiviral amino acid appending, Derivative of GF-17, animal-derived, natural derivative N/A N/A Sci Rep. 2024 Feb 19;14(1):4096. doi: 10.1038/s41598-024-53662-4. PubMed 19 FPDB20850 AP04153 FVVWGCADYRGSCRTACFAYEYSLGAKGCADGYICCVPNTFRLM Antiviral European fire salamander, Salamandra salamandra Bridge N/A Pharmaceutics. 2024 Jan 29;16(2):190. doi: 10.3390/pharmaceutics16020190. PubMed 44 FPDB20851 AP04700 ALWKTLLKKVLKAAAKAALKAVLVGAKA Antiviral amino acid substitution, AMPHIBIAN, animal-derived, natural derivative N/A N/A Biochem Biophys Rep. 2024 Jun 7;39:101747. doi: 10.1016/j.bbrep.2024.101747. PubMed 28 FPDB20852 AP04774 GWKRIKQRIKDKLRNL Antiviral amino acid substitution, human cathelicidin analog, animal-derived, natural derivative N/A N/A Front Microbiol. 2023 Jun 5;14:1201505. doi: 10.3389/fmicb.2023.1201505. PubMed 16 FPDB20853 AP05016 LQRYYCKIRRGRCAVLGCLPKEEQIGSCSVSGRKCCRK Antiviral pigs, Sus scofa Bridge N/A Viral Immunol. 2009 Jul;22(4):235-42. doi: 10.1089/vim.2009.0005. PubMed 38 FPDB20854 AP05554 FIFHVIKGLFHAGKMIHGLVTRRRH Anti-Gram+ & Gram-||Antiviral largemouth bass, Micropterus salmoides Helix "The document mentions the hemolytic results of the new antimicrobial peptides MSPiscidin-2 and MSPiscidin-3 from largemouth bass, as follows: - Hemolytic activity on human red blood cells: - At a concentration of 200 μg/ml, MSPiscidin-2 caused only 10.33% hemolysis; - At the same concentration, MSPiscidin-3 caused almost 100% hemolysis. - Hemolytic activity on largemouth bass red blood cells: - At a concentration of 200 μg/ml, MSPiscidin-2 induced 11.53% hemolysis; - At the same concentration, MSPiscidin-3 caused 54.33% hemolysis. In summary, MSPiscidin-2 has weak hemolytic activity, whereas MSPiscidin-3 has strong hemolytic activity at high concentrations and exhibits stronger hemolytic effects on human red blood cells than on largemouth bass red blood cells." Microbiol Res. 2022 Mar;256:126953. doi: 10.1016/j.micres.2021.126953. PubMed 25 FPDB20855 AP05555 FLKHIKSFWRGAKAIFRGARQGWREHR Anti-Gram+ & Gram-||Antiviral largemouth bass, Micropterus salmoides Helix "The document mentions the hemolytic results of the new antimicrobial peptides MSPiscidin-2 and MSPiscidin-3 from largemouth bass, as follows: - Hemolytic activity on human red blood cells: - At a concentration of 200 μg/ml, MSPiscidin-2 caused only 10.33% hemolysis; - At the same concentration, MSPiscidin-3 caused almost 100% hemolysis. - Hemolytic activity on largemouth bass red blood cells: - At a concentration of 200 μg/ml, MSPiscidin-2 induced 11.53% hemolysis; - At the same concentration, MSPiscidin-3 caused 54.33% hemolysis. In summary, MSPiscidin-2 has weak hemolytic activity, whereas MSPiscidin-3 has strong hemolytic activity at high concentrations and exhibits stronger hemolytic effects on human red blood cells than on largemouth bass red blood cells." Microbiol Res. 2022 Mar;256:126953. doi: 10.1016/j.micres.2021.126953. PubMed 27 FPDB20856 AP05556 FLGTLLHGAVHVSKILHGIMGGDH Antiviral largemouth bass, Micropterus salmoides Helix N/A Front Immunol. 2025 Jun 23;16:1629256. doi: 10.3389/fimmu.2025.1629256. PubMed 24 FPDB20857 AP05621 RRIRGLRKFFRKSKEKLKKV Antiviral sequence truncation, elephant cathelicidin analogs, animal-derived, natural derivative N/A N/A Antibiotics. 2025; 14(7):655. https://doi.org/10.3390/antibiotics14070655. MDPI 20 FPDB20858 AP05622 GRRVKGFFRDVLRRVPYLPGPR Antiviral sequence truncation, elephant cathelicidin analogs, animal-derived, natural derivative N/A N/A Antibiotics. 2025; 14(7):655. https://doi.org/10.3390/antibiotics14070655. MDPI 22 FPDB20859 CAMPSQ17080 LRKRLLLRKLRKRL Antiviral Synthetic construct N/A N/A 17681018 14 FPDB20860 CAMPSQ17081 RLLLRKLRKRL Antiviral Synthetic construct N/A N/A 17681018 11 FPDB20861 CAMPSQ17082 LRKLRKRLLLRKLRK Antiviral Synthetic construct N/A N/A 17681018 15 FPDB20862 CAMPSQ17083 LRKLRKRLLLRK Antiviral Synthetic construct N/A N/A 17681018 12 FPDB20863 CAMPSQ17084 LRKLRKRLL Antiviral Synthetic construct N/A N/A 17681018 9 FPDB20864 CAMPSQ17085 LRKLRKRLLRLRKLRKRLLR Antiviral Synthetic construct N/A N/A 17681018 20 FPDB20865 CAMPSQ17086 ERKERKREEERKERKREE Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20866 CAMPSQ17087 ARKARKRAAARKARKRAA Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20867 CAMPSQ17088 DRKDRKRDDDRKDRKRDD Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20868 CAMPSQ17090 MRKMRKRMMMRKMRKRMM Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20869 CAMPSQ17091 YRKYRKRYYYRKYRKRYY Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20870 CAMPSQ17092 FRKFRKRFFFRKFRKRFF Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20871 CAMPSQ17093 IRKIRKRIIIRKIRKRII Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20872 CAMPSQ17094 QRKQRKRQQQRKQRKRQQ Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20873 CAMPSQ17095 NRKNRKRNNNRKNRKRNN Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20874 CAMPSQ17096 CRKCRKRCCCRKCRKRCC Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20875 CAMPSQ17097 SRKSRKRSSSRKSRKRSS Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20876 CAMPSQ17098 VRKVRKRVVVRKVRKRVV Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20877 CAMPSQ17099 TRKTRKRTTTRKTRKRTT Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20878 CAMPSQ17100 GRKGRKRGGGRKGRKRGG Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20879 CAMPSQ17101 HRKHRKRHHHRKHRKRHH Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20880 CAMPSQ17102 PRKPRKRPPPRKPRKRPP Antiviral Synthetic construct N/A N/A 17681018 18 FPDB20881 CAMPSQ16223 AD Antiviral Trachipteridae [Ribbonfish] N/A N/A 34877713 2 FPDB20882 CAMPSQ16222 PTR Antiviral Trachipteridae [Ribbonfish] N/A N/A 34877713 3 FPDB20883 CAMPSQ21483 VTN Antiviral Synthetic construct N/A N/A 15113844 3 FPDB20884 CAMPSQ21705 LLE Antiviral Synthetic construct N/A N/A 9918775 3 FPDB20885 CAMPSQ16221 APDG Antiviral Trachipteridae [Ribbonfish] N/A N/A 34877713 4 FPDB20886 CAMPSQ17600|||DRAMP29203 RVKR Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A Vero cells (50% Cell death at 712.9 , Vero E6 cells (50% Cytotoxicity at 318.2|||No hemolysis information or data found in the reference(s) presented in this entry 23617302|||Liver Int. 2013 Sep;33(8):1230-8. ##Viruses. 2019 Oct 31;11(11):1011.##Cell Rep. 2020 Oct 13;33(2):108254. 4 FPDB20887 CAMPSQ21482 AEAM Antiviral Synthetic construct N/A N/A 15113844 4 FPDB20888 CAMPSQ23725 KKWK Antiviral Synthetic construct N/A , Madin-Darby canine kidney cells (50% Cytotoxicity at 43.37+-0.53 ug/ml, Madin-Darby canine kidney cells (50% Cytotoxicity at 62.49+-0.4 uM, Madin-Darby canine kidney cells (50% Cytotoxicity at 56.50+-0.68 uM 24946217 4 FPDB20889 CAMPSQ23903 EVll Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 12.9+-0.2 ug/ml 30973929 4 FPDB20890 CAMPSQ24061 XXWX Antiviral Synthetic construct N/A Madin-Darby canine kidney cells (50% Cytotoxicity at 41.38+-0.04 uM 28774731 4 FPDB20891 CAMPSQ24062 NKKN Antiviral Synthetic construct N/A N/A 28774731 4 FPDB20892 CAMPSQ4610 CPFVC Antiviral Synthetic construct N/A N/A 17441904 5 FPDB20893 CAMPSQ12360 GRLVF Antiviral Hepatitis B virus (HBV) N/A N/A 29752938 5 FPDB20894 CAMPSQ15118 SELFP Antiviral Synthetic construct N/A N/A 35257734 5 FPDB20895 CAMPSQ15133 VXLfP Antiviral Synthetic construct N/A N/A 35236909 5 FPDB20896 CAMPSQ23902 EVlDl Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 69.7+-2.6 ug/ml, Pig erythrocytes (50% Hemolysis at 847.2+-124.9 ug/ml, Pig erythrocytes (50% Hemolysis at 274.1+-21 ug/ml, Pig erythrocytes (50% Hemolysis at 82.8+-3.4 ug/ml 30973929 5 FPDB20897 CAMPSQ23904 KVlKl Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 12.6+-0.4 ug/ml 30973929 5 FPDB20898 CAMPSQ23905 EVllD Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 217.5+-18.9 ug/ml 30973929 5 FPDB20899 CAMPSQ23906 EDVll Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 52.2+-2 ug/ml 30973929 5 FPDB20900 CAMPSQ24589|||DRAMP29202 PHSCN Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry 33102950|||JACC Basic Transl Sci. 2021 Jan;6(1):1-8. 5 FPDB20901 CAMPSQ11785 XFLFLF Antiviral Synthetic construct N/A N/A 28483551 6 FPDB20902 CAMPSQ12361 GRLVFQ Antiviral Hepatitis B virus (HBV) N/A N/A 29752938 6 FPDB20903 CAMPSQ17665|||DRAMP29197 EDLFYQ Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry 33356169|||Bioconjug Chem. 2021 Jan 20;32(1):215-223. 6 FPDB20904 CAMPSQ21481 AEAMSQ Antiviral Synthetic construct N/A N/A 15113844 6 FPDB20905 CAMPSQ23901 EVlDlV Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 33.0+-1.6 ug/ml 30973929 6 FPDB20906 CAMPSQ12362 GRLVFQT Antiviral Hepatitis B virus (HBV) N/A N/A 29752938 7 FPDB20907 CAMPSQ21480 AEAMSQV Antiviral Synthetic construct N/A N/A 15113844 7 FPDB20908 CAMPSQ23900 EVlADlV Antiviral Synthetic construct N/A Pig erythrocytes (50% Hemolysis at 52.6+-2.3 ug/ml 30973929 7 FPDB20909 CAMPSQ12087 CGWIYWNV Antiviral Synthetic construct N/A N/A 30068652 8 FPDB20910 CAMPSQ14392 DYKDDDDK Antiviral Synthetic construct N/A N/A 34834377 8 FPDB20911 CAMPSQ16979 IYWNVSGW Antiviral Synthetic construct N/A N/A 19099395 8 FPDB20912 CAMPSQ21417 MENRWQVM Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20913 CAMPSQ21418 IVWQVDRM Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20914 CAMPSQ21428 YVSGKARG Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20915 CAMPSQ21429 GKARGWFY Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20916 CAMPSQ21430 GWFYRHHY Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20917 CAMPSQ21432 VHIPLGDA Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20918 CAMPSQ21433 PLGDARLV Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20919 CAMPSQ21434 DWHLGQGV Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20920 CAMPSQ21435 LGQGVSIE Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20921 CAMPSQ21436 VSIEWRKK Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20922 CAMPSQ21437 EWRKKRYS Antiviral Synthetic construct N/A N/A 10074409 8 FPDB20923 CAMPSQ21479 AEAMSQVT Antiviral Synthetic construct N/A N/A 15113844 8 FPDB20924 CAMPSQ21484 VTNTATIM Antiviral Synthetic construct N/A N/A 15113844 8 FPDB20925 CAMPSQ11516 SRARIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20926 CAMPSQ11517 SRARIDERI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20927 CAMPSQ11518 SRARIRARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20928 CAMPSQ11519 SRARIDRRI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20929 CAMPSQ11520 SRASIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20930 CAMPSQ11521 SDARIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20931 CAMPSQ11522 SHARIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20932 CAMPSQ11523 SRAKIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20933 CAMPSQ11524 SQARIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20934 CAMPSQ11525 SRARIDYRI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20935 CAMPSQ11526 SRAMIDARI Antiviral Synthetic construct N/A N/A 30597438 9 FPDB20936 CAMPSQ14393 LFNELMLWL Antiviral Synthetic construct N/A N/A 34835083 9 FPDB20937 CAMPSQ14394 NKLVYTGRL Antiviral Synthetic construct N/A N/A 34835083 9 FPDB20938 CAMPSQ15115 LDAPPSYSE Antiviral Synthetic construct N/A N/A 35257734 9 FPDB20939 CAMPSQ17663|||DRAMP29193 EDLFYQSSL Antiviral||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry 33356169|||Bioconjug Chem. 2021 Jan 20;32(1):215-223. 9 FPDB20940 CAMPSQ21431 ISSEVHIPL Antiviral Synthetic construct N/A N/A 10074409 9 FPDB20941 CAMPSQ21476 AEAASQVTN Antiviral Synthetic construct N/A N/A 15113844 9 FPDB20942 CAMPSQ21478 AEAMSQVAN Antiviral Synthetic construct N/A N/A 15113844 9 FPDB20943 CAMPSQ24038 WDFGSLGGV Antiviral Synthetic construct N/A Human umbilical vein endothelial cells HUVEC ( at NA 29709564 9 FPDB20944 CAMPSQ24474 wrrrrrrrG Antiviral Synthetic construct N/A N/A 23173037 9 FPDB20945 CAMPSQ24477 rrrrkkkkG Antiviral Synthetic construct N/A N/A 23173037 9 FPDB20946 CAMPSQ11415 NQVSATCSVK Antiviral Synthetic construct N/A N/A 30654366 10 FPDB20947 CAMPSQ21825 RRRRRRRRRR Antibacterial||Antiviral Synthetic construct N/A N/A 22319541 10 FPDB20948 CAMPSQ24473 wrrrrrrrrG Antiviral Synthetic construct N/A , Primary duck hepatocytes (PDH) (15% Killing at 4 uM 23173037 10 FPDB20949 CAMPSQ8157 GIADILKGLLG Antiviral Chaerilus tryznai [Scorpion] N/A N/A 23415044 11 FPDB20950 CAMPSQ8158|||DRAMP18133 NRILPTLIGPL Antiviral||Antimicrobial Chaerilus tricostatus [Scorpion]|||Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry 23415044|||Biomaterials 34:3511-3522 (2013). 11 FPDB20951 CAMPSQ11356 XTLTTTQTLLL Antiviral Synthetic construct N/A N/A 30721034 11 FPDB20952 CAMPSQ11783 XQRLFQVKGRR Antiviral Synthetic construct N/A N/A 28483551 11 FPDB20953 CAMPSQ14395 KCLARIQERCK Antiviral Synthetic construct N/A N/A 34835083 11 FPDB20954 CAMPSQ14396 MCLSFDSNYCR Antiviral Synthetic construct N/A N/A 34835083 11 FPDB20955 CAMPSQ15121 TAPPPAYATLG Antiviral Synthetic construct N/A N/A 35257734 11 FPDB20956 CAMPSQ15122 TGLPSYDEALH Antiviral Synthetic construct N/A N/A 35257734 11 FPDB20957 CAMPSQ15124 ILPTAPPEYME Antiviral Synthetic construct N/A N/A 35257734 11 FPDB20958 CAMPSQ19724 VCSCRLVFCRR Antiviral Synthetic construct N/A Human retinal epithelial cells ARPE-19 (50% Cytotoxicity at 42 uM, Human retinal epithelial cells ARPE-19 (50% Cytotoxicity at 31 uM 32209394 11 FPDB20959 CAMPSQ20827 SLIGGLVSAFK Antiviral Synthetic construct N/A N/A 22536342 11 FPDB20960 CAMPSQ21427 EWRKKRYSTQV Antiviral Synthetic construct N/A N/A 10074409 11 FPDB20961 CAMPSQ21466 PRLSHKGPMPF Antiviral Synthetic construct N/A N/A 10802050 11 FPDB20962 CAMPSQ24475 wrrrrrrrrrG Antiviral Synthetic construct N/A N/A 23173037 11 FPDB20963 CAMPSQ9618 IAKTALKVLPQL Antiviral Synthetic construct N/A N/A 29290802 12 FPDB20964 CAMPSQ11293 YXKZKBXKXXKC Antiviral Synthetic construct N/A N/A 30783498 12 FPDB20965 CAMPSQ11295 YJIAKYNXXIPC Antiviral Synthetic construct N/A N/A 30783498 12 FPDB20966 CAMPSQ11296 YTLPFHNJTFFC Antiviral Synthetic construct N/A N/A 30783498 12 FPDB20967 CAMPSQ11658 LHWDFQSWVPLL Antiviral Epinephelus coioides [Orange-spotted grouper] N/A N/A 30521966 12 FPDB20968 CAMPSQ12137 HTKQIPRHIYSA Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20969 CAMPSQ12138 VSRHQSWHPHDL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20970 CAMPSQ12139 HTLHRQVPKHWL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20971 CAMPSQ12140 HSSQWHPMAVHR Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20972 CAMPSQ12141 KHLPHANMQLYG Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20973 CAMPSQ12142 SPHVNHRHWSGS Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20974 CAMPSQ12143 AHGWNPHKTHSR Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20975 CAMPSQ12144 HPVKPLFAHPVL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20976 CAMPSQ12145 NHVHRMHATPAY Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20977 CAMPSQ12146 HHRLHSAPAPQA Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20978 CAMPSQ12147 WPMPHKHQHTAL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20979 CAMPSQ12148 LQAKPHGHRLLP Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20980 CAMPSQ12149 KHMHWHPPALNT Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20981 CAMPSQ12150 HYSRYNPGPHPL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20982 CAMPSQ12151 GHIHSMRHHRPT Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20983 CAMPSQ12152 HSLHVHKGLSEL Antiviral Synthetic construct N/A N/A 30041713 12 FPDB20984 CAMPSQ15113 LDAPPSYSELFP Antiviral Synthetic construct N/A N/A 35257734 12 FPDB20985 CAMPSQ15114 LDSLPSYSELFP Antiviral Synthetic construct N/A N/A 35257734 12 FPDB20986 CAMPSQ15116 LDAPPSYSSLFP Antiviral Synthetic construct N/A N/A 35257734 12 FPDB20987 CAMPSQ15117 LDAPPSYSELYG Antiviral Synthetic construct N/A N/A 35257734 12 FPDB20988 HTLV1 SDPQIPPPYVEP Antiviral ; M13 phage Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35257734 12 FPDB20989 12p1 RINNIPWSEAMM Antiviral ; HIV-1 YU2(IC50 E = 1.1 uM) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/14967033 12 FPDB20990 CCR5 ECL2 RSQKEGLHYTCS Antiviral ; HIV-1 YU2||HIV-1 BaL26||HIV-1 HxB2||HIV-1 NL4-3 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/22403408 12 FPDB20991 Undefined KKKKYRNIRRPG Antiviral ; SARS-CoV[IC50 E = 45 ug/ml] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18383098 12 FPDB20992 Undefined HVTTTFAPPPPR Anti-Transmissible gastroenteritis coronavirus, activity value is EC50 = 11 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/21176936 12 FPDB20993 Undefined SVVPSKATWGFA Anti-Transmissible gastroenteritis coronavirus, activity value is EC50 = 15 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/21176936 12 FPDB20994 Undefined FKPSSPPSITLW Antiviral ; Transmissible gastroenteritis coronavirus (TGEV/PCoV)[40-50% Inhibition = 20 ug/ml] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/21176936 12 FPDB20995 NYAD-1 ITFXDLLXYYGP Antiviral ; HIV-1 IIIB[IC50 I = 6.22+-0.75 uM]||HIV-1 IIIB[IC90 I = 23.83+-1.74 uM]||HIV-1 RF[IC50 I = 4.29+-0.42 uM]||HIV-1 RF[IC90 I = 9.86+-2.08 uM]||HIV-1 BaL[IC50 I = 6.47+-0.85 uM]||HIV-1 BaL[IC50 I = 15.46+-3.71 uM]||HIV-1 A17[IC50 I = 10.55+-1.56 uM]||HIV-1 A17[IC90 I = 38.46+-0.62 uM]||HIV-1 92UG029[IC50 I = 13.85+-1.34 uM]||HIV-1 92UG029[IC90 I = 36.51+-19.39 uM]||HIV-1 93BR020[IC90 I = 6.60+-1.6 uM]||HIV-1 93BR020[IC90 I = 17.27+-2.72 uM]||HIV-1 RU570[IC50 I = 9.79+-2.49 uM]||HIV-1 RU570[IC50 I = 39.97+-9.65 uM] Synthetic construct N/A Human PBMC (50% Cytotoxicity at >300 uM https://pubmed.ncbi.nlm.nih.gov/18374356 12 FPDB20996 Deca- wrrrrrrrrrrG Antiviral ; Duck Hepatitis B Virus (DHBV)[IC50 REP = 1.4 uM]||Duck Hepatitis B Virus (DHBV)[IC50 REP = 0.7 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/23173037 12 FPDB20997 Peptide Hp1412 IFKAIWSGIKRLC Antiviral Heterometrus petersii [Asian forest scorpion] N/A N/A https://pubmed.ncbi.nlm.nih.gov/24315793 13 FPDB20998 Peptide Hp1478 ILGKFCDEIKRIV Antiviral Heterometrus petersii [Asian forest scorpion] N/A N/A https://pubmed.ncbi.nlm.nih.gov/24315793 13 FPDB20999 Eval151 QDYNHDRDIVPPR Antiviral ; Herpes simplex virus type I (HSV-1) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29290802 13 FPDB21000 Eval655 IWGALLSGVADLL Antiviral||Anticancer ; Herpes simplex virus type I (HSV-1) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29290802 13 FPDB21001 Eval418-FH4 LWHHIWNFVHHLI Anti-Herpes simplex virus type I, activity value is IC50 = 0.87 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29290802 13 FPDB21002 Eval418-FH5 LWHHIWHFVHHLI Anti-Herpes simplex virus type I, activity value is IC50 = 0.86 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29290802 13 FPDB21003 CXCL9 KKKQKNGKKHQKK Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 > 100 uM||Anti-Herpes simplex virus type 1, activity value is EC50 > 100 uM||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 > 100 uM||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26551597 13 FPDB21004 Compound 6 DYAIIXYNKYUNC Anti-Zika virus NS2B-NS3 protease, activity value is IC50 = 3.2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/30783498 13 FPDB21005 13-amino acid PI FLDKFNHNFKDLF Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34924897 13 FPDB21006 Mod13AApi YADKYQKQYKDAY Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34924897 13 FPDB21007 U1 IPLRGAFINGRWD Antiviral ; H1N1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35259078 13 FPDB21008 P53BP2 EYPPYPPPPYPSG Antiviral ; M13 phage Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35257734 13 FPDB21009 ACE2|||DRAMP29196 QAKTFLDKFNHEA Antiviral ; SARS-CoV-2 PsV( = NA )||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry https://pubmed.ncbi.nlm.nih.gov/33356169|||Bioconjug Chem. 2021 Jan 20;32(1):215-223. 13 FPDB21010 Vif RIRTWKSLVKHHM Antiviral ; HIV-1[90-100% PR activity = 1 uM]||Rous sarcoma virus[40-50% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 13 FPDB21011 IBP DCAWHLGELVWCT Antiviral ; HIV-1 IIIB[IC50 I >0.5 uM]||HIV-1 IIIB[IC50 F >0.5 uM]||HIV-1 BaL[IC50 I >0.5 uM]||HIV-1[IC50 I >1 uM]||HIV-1 PsV[IC50 I >1 uM]||HIV-1 NL4-3 V38A[IC50 I >1 uM]||HIV-1 NL4-3 D36G[IC50 I >1 uM]||Human T cell leukemia MT-2||Acute myeloid leukemia AML-M7 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/31805154 13 FPDB21012 D-Retro-HCV gp LLFLLLVYEWKIA Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >30 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20156485 13 FPDB21013 HCV gp LKLFEVYLILWLA Antiviral ; Hepatitis C virus (HCV) PsV[IC50 E >3 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20156485 13 FPDB21014 DENV-2 gp MVDRGWGNGCGLF Antiviral ; DENV-2[40-50% Inhibition = 40 uM]||DENV-1[40-50% Inhibition = 40 uM] Synthetic construct N/A Human umbilical vein endothelial cells HUVEC ( at NA https://pubmed.ncbi.nlm.nih.gov/29709564 13 FPDB21015 Peptide Ctri9677|||DRAMP18134 INWDILIDTIKDKL Antiviral ; HCV||Antimicrobial||Antiviral Chaerilus tricostatus|||Chaerilus tricostatus (Scorpion) N/A No hemolysis information or data found in the reference(s) presented in this entry https://pubmed.ncbi.nlm.nih.gov/23415044|||Biomaterials 34:3511-3522 (2013). 14 FPDB21016 Eval36 GFLGNLWEGIKTAL Antiviral ; Herpes simplex virus type I (HSV-1) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29290802 14 FPDB21017 U2 FINGRWDSQCHRFS Antiviral ; H1N1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35259078 14 FPDB21018 HCV SWLRDIWDWICEVL Antiviral ; Hepatitis C virus (HCV) JFH-1[IC50 I = 11.3 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18287023 14 FPDB21019 RSV peptide M209-223 NKGAFKYIKPQSQFI Antiviral ; Respiratory syncytial virus Respiratory syncytial virus N/A N/A https://pubmed.ncbi.nlm.nih.gov/29990516 15 FPDB21020 L-SP40 QMRRKVELFTYMRFD Antiviral ; Poliovirus type 1||Coxsackievirus A 16 (CV-A16)||EV-A71 BrCr (A)||EV-A71 SHA66/97 (B3)||EV-A71 5865/SIN/000009 (B4)||EV-A71 SHA52 (C2) Enterovirus 71 (Capsid Protein VP1) N/A N/A https://pubmed.ncbi.nlm.nih.gov/34715144, 15 FPDB21021 ARRDC3 ERPEAPPSYAEVVTE Antiviral ; M13 phage Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35257734 15 FPDB21022 Ebola-long ILPTAPPEYMEAIYP Antiviral ; M13 phage Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35257734 15 FPDB21023 Chain W, ACE-DTY-LEU-GLN-TYR-ALA-VAL-LEU-ARG-HIS-LYS-ARG-ARG-GLU-SEC|||Chain Z, ACE-DTY-LEU-GLN-TYR-ALA-VAL-LEU-ARG-HIS-LYS-ARG-ARG-GLU-SEC|||Chain Y, ACE-DTY-LEU-GLN-TYR-ALA-VAL-LEU-ARG-HIS-LYS-ARG-ARG-GLU-SEC|||Chain X, ACE-DTY-LEU-GLN-TYR-ALA-VAL-LEU-ARG-HIS-LYS-ARG-ARG-GLU-SEC XXLQYAVLRHKRREX Antiviral ; SARS-CoV-2||Antiviral ; SARS-CoV-3||Antiviral ; SARS-CoV-4||Antiviral ; SARS-CoV-5 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/unpublished 15 FPDB21024 Vif YVSGKARGWFYRHHY Antiviral ; HIV-1[60-70% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 15 FPDB21025 Vif RHHYESPHPRISSEV Antiviral ; Rous sarcoma virus[90-100% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 15 FPDB21026 Vif ISSEVHIPLGDARLV Antiviral ; HIV-1[60-70% PR activity = 1 uM]||Rous sarcoma virus[90-100% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 15 FPDB21027 Vif DWHLGQGVSIEWRKK Antiviral ; HIV-1[10-20% PR activity = 1 uM]||Rous sarcoma virus[70-80% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 15 FPDB21028 HCV gp PRPISYLKGSSGGPL Antiviral ; Hepatitis C virus (HCV)[IC50 REP = 5 uM]||Hepatitis C virus (HCV)[IC50 REP = 60-80 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/22910295 15 FPDB21029 AmPep1 SVGRKWRMKWAQMRQQ Antiviral ; Tomato yellow leaf curl virus (TYLCV-IL) Amaranthus hypochondriacus N/A N/A https://pubmed.ncbi.nlm.nih.gov/31369258 16 FPDB21030 U3 WDSQCHRFSNGAIACA Antiviral ; H1N1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35259078 16 FPDB21031 FBP3 RGAHIKGRWDSRCHRK Antiviral ; H1N1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/35259078 16 FPDB21032 ACE2|||DRAMP29192 TFLDKFNHEAEDLFYQ Antiviral ; SARS-CoV-2 PsV(IC50 I = 2390 +- 200 uM)||Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry https://pubmed.ncbi.nlm.nih.gov/33356169|||Bioconjug Chem. 2021 Jan 20;32(1):215-223. 16 FPDB21033 Vif LGDARLVITTYWGLHT Antiviral ; HIV-1[80-90% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 16 FPDB21034 Vif ITTYWGLHTGERDWHL Antiviral ; HIV-1[90-100% PR activity = 1 uM]||Rous sarcoma virus[40-50% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 16 FPDB21035 CCR5 ECL2 EGLHYTCSSHFPYSQY Antiviral ; HIV-1 YU2||HIV-1 BaL26||HIV-1 HxB2||HIV-1 NL4-3 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/22403408 16 FPDB21036 K-HCV KGSVVIVGRIILSGRK Antiviral ; Hepatitis C virus (HCV)[IC50 PR = 5.7 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10574908 16 FPDB21037 Undefined LLQLTVWGIKQLQARIL Antiviral ; HIV-1[IC50 E = 13+-4 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/11572974 17 FPDB21038 RG-HCV RGGSVVIVGRIILSGRK Antiviral ; Hepatitis C virus (HCV)[IC50 PR = 3.4 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10574908 17 FPDB21039 C5A SWLRDIWDWICEVLSDFK Antiviral ; Simian Human Immunodeficiency Virus (SHIV-162P3)||Hepatitis C virus (HCV)||Herpes simplex virus 1 (HSV-1)||HSV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26552985 18 FPDB21040 CXCL9 KKVLKVRKSQRSRQKKTT Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 > 100 uM||Anti-Herpes simplex virus type 1, activity value is EC50 > 100 uM||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 > 100 uM||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26551597 18 FPDB21041 P18 TVAAPSVFIFPPSDEQLK Anti-Influenza virus A/FM/1/47, activity value is MIC = 12.5 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/28416546 18 FPDB21042 T22, Polyphemusin II RRWCYRKCYKGYCYRKCR Anti-HIV-1 HTLV-IIIB, activity value is EC50 = 0.008||Anti-HIV-1 HTLV-IIIB, activity value is EC50 = 0.063||Anti-HIV-1 A012B, activity value is EC50 = 0.006||Anti-HIV-1 A012D, activity value is EC50 = 0.006||Anti-HIV-1 A018A, activity value is EC50 = 0.014||Anti-HIV-1 A018C, activity value is EC50 = 0.024||Anti-HIV-2 ROD, activity value is EC50 = 0.031||Anti-HIV-2 EHO, activity value is EC50 = 0.071 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/1384424 18 FPDB21043 DRAMP18119 ADCVGDGQRCADWAGPYCCSGYYCSCRSMPYCRCRSDS Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) N/A No hemolysis information or data found in the reference(s) presented in this entry Toxicon 43:509-525 (2004).J. Biol. CheM. 264:2150-2155 (1989). 38 FPDB21044 DRAMP18121 ADCVGDGQKCADWFGPYCCSGYYCSCRSMPYCRCRSDS Insecticidal Hololena curta (Funnel-web spider) (Agelena curta) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 265:2054-2059 (1990).Toxicon 43:509-525 (2004). 38 FPDB21045 DRAMP18122 SCVGEYGRCRSAYEDCCDGYYCNCSQPPYCLCRNNN Insecticidal Hololena curta (Funnel-web spider) (Agelena curta) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 265:2054-2059 (1990).Toxicon 43:509-525 (2004). 36 FPDB21046 DRAMP18123 DCVGESQQCADWAGPHCCDGYYCTCRYFPKCICVNNN Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 264:2150-2155 (1989).Toxicon 43:509-525 (2004). 37 FPDB21047 DRAMP18124 ACVGENKQCADWAGPHCCDGYYCTCRYFPKCICRNNN Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 264:2150-2155 (1989).Toxicon 43:509-525 (2004). 37 FPDB21048 DRAMP18125 ACVGENQQCADWAGPHCCDGYYCTCRYFPKCICRNNN Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 264:2150-2155 (1989). Toxicon 43:509-525 (2004).Biochemistry 35:2836-2844 (1996). 37 FPDB21049 DRAMP18126 ECATKNKRCADWAGPWCCDGLYCSCRSYPGCMCRPSS Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) N/A No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 264:2150-2155 (1989).Toxicon 43:509-525 (2004). 37 FPDB21050 DRAMP18127 ECVPENGHCRDWYDECCEGFYCSCRQPPKCICRNNN Insecticidal Agelenopsis aperta (North American funnel-web spider) (Agelenopsisgertschi) beta sheet No hemolysis information or data found in the reference(s) presented in this entry J. Biol. CheM. 264:2150-2155 (1989).Toxicon 43:509-525 (2004).Biochemistry 35:2836-2844 (1996). 36 FPDB21051 DRAMP18141 PSPPGFSPFR Insecticidal Nephila clavipes (Golden silk orbweaver) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides 27:690-697 (2006). 10 FPDB21052 DRAMP18142 EAPPGFSPFR Insecticidal Nephila clavipes (Golden silk orbweaver) N/A No hemolysis information or data found in the reference(s) presented in this entry Peptides 27:690-697 (2006). 10 FPDB21053 DRAMP18143 EELEAKDVIESKALATLDEER Insecticidal Selenotypus plumipes (Australian featherleg tarantula) N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS ONE 8:E66279-E66279 (2013) 21 FPDB21054 DRAMP18144 YCQKWMWTCDAERKCCEDMACELWCKKRL Insecticidal Selenotypus plumipes (Australian featherleg tarantula) N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS ONE 8:E66279-E66279 (2013) 29 FPDB21055 DRAMP18145 ECGGLMTRCDGKTTFCCSGMNCSPTWKWCVYAP Insecticidal Selenotypus plumipes (Australian featherleg tarantula) N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS ONE 8:E66279-E66279 (2013) 33 FPDB21056 DRAMP18146 DCLGQWASCEPKNSKCCPNYACTWKYPWCRYRA Insecticidal Selenotypus plumipes (Australian featherleg tarantula) N/A No hemolysis information or data found in the reference(s) presented in this entry PLoS ONE 8:E66279-E66279 (2013) 33 FPDB21057 DRAMP18148 ATCAGQDQTCKVTCDCCGERGECVCGGPCICRQGNFLIAWYKLASCKK Insecticidal Phoneutria nigriventer (Brazilian armed spider) (Ctenus nigriventer) N/A No hemolysis information or data found in the reference(s) presented in this entry Toxicon 36:1843-1850 (1998). FEBS Lett. 310:153-156 (1992).Biochemistry 48:3078-3088 (2009).Comp. BiocheM. Physiol. 142:173-187 (2006).Toxicon 29:1225-1233 (1991). 48 FPDB21058 DRAMP18149 DCGHLHDPCPNDRPGHRTCCIGLQCRYGKCLVRV Insecticidal Selenotypus plumipes (Australian featherleg tarantula) beta sheet (7 strands; 13 residues) N/A PLoS ONE 8:E66279-E66279 (2013).PLoS ONE 8:E73136-E73136 (2013). 34 FPDB21059 DRAMP01272 ATCAGQDQPCKETCDCCGERGECVCGGPCICRQGYFWIAWYKLANCKK Insecticidal Phoneutria nigriventer (Brazilian armed spider) (Ctenus nigriventer) N/A No hemolysis information or data found in the reference(s) presented in this entry FEBS Lett. 523:219-223 (2002).FEBS Lett. 310:153-156 (1992).Comp. BiocheM. Physiol. 142:173-187 (2006).Biochemistry 48:3078-3088 (2009).Toxicon 51:1197-1206 (2008). 48 FPDB21060 DRAMP18345|||DRAMP18344 CLGIGSCNNFAGCGYAVVCFW Antiviral||Anti-HIV||Antimicrobial Streptomyces sp. (strain SP9440) Beta strand No hemolysis information or data found in the reference(s) presented in this entry J Antibiot (Tokyo). 1993 Nov;46(11):1756-7. 21 FPDB21061 DRAMP29155|||DRAMP29156 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Cell Res. 2020 Apr;30(4):343-355. 39 FPDB21062 DRAMP29161 LKVLLYEEFKLLESLIMEILEYQKDSDIKENAEDTK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Cell Res. 2020 Apr;30(4):343-355. 36 FPDB21063 DRAMP29162 NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Cell Res. 2022 Apr;32(4):404-406.##Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21064 DRAMP29164 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 45 FPDB21065 DRAMP29165 NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEY Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 36 FPDB21066 DRAMP29166 TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYV Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 36 FPDB21067 DRAMP29167 LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 36 FPDB21068 DRAMP29168 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 49 FPDB21069 DRAMP29169 TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21070 DRAMP29170 LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21071 DRAMP29171 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 49 FPDB21072 DRAMP29172 NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21073 DRAMP29173 TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21074 DRAMP29174 LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Acta Pharm Sin B. 2021 Aug 2. 40 FPDB21075 DRAMP29176|||P9 NGAICWGPCPTAFRQIGNCGHFKVRCCKIR Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; Influenza A virus H1N1||H3N2||H5N1||and H7N7 Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Sci Rep. 2016 Feb 25;6:22008. ##Nat Commun. 2020 Aug 25;11(1):4252.|||https://pubmed.ncbi.nlm.nih.gov/29907765 30 FPDB21076 DRAMP29177|||DRAMP29178|||MBD-4 NGAICWGPCPTAFRQIGNCGRFRVRCCRIR Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 I = 0.9 ug/ml]||MERS-CoV[IC50 I = 2.2 ug/ml]||SARS-CoV[IC50 I = 4.2 ug/ml]||Human Influenza A Virus H1N1[IC50 I = 0.6 ug/ml]||Human Influenza A Virus H7N9[IC50 I = 0.9 ug/ml]||Human rhinovirus (HRV)[IC50 I = 5.7 ug/ml]||Human parain uenza virus 3[IC50 I >25 ug/ml]||Human lung carcinoma A549[50-60% Cytotoxicity >300 ug/ml] Synthetic construct N/A [Ref.32843628]P9R did not cause the hemolysis of Chicken red blood cells.|||[Ref.33750821]no obvious hemolysis was observed when turkey red blood cells were treated at 200 ug/ml. Nat Commun. 2020 Aug 25;11(1):4252.|||Nat Commun. 2021 Mar 9;12(1):1517.|||https://pubmed.ncbi.nlm.nih.gov/32843628 30 FPDB21077 DRAMP29180 ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct Alpha helix No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20. 36 FPDB21078 DRAMP29181|||SARS-CoV-2-S INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F = 0.015+-0.002 uM]||SARS-CoV-2 PsV[IC50 I = 0.947+-0.179 uM]||SARS-CoV PsV[IC50 I = 1.315+-0.463 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct Alpha helix No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||https://pubmed.ncbi.nlm.nih.gov/32376627 34 FPDB21079 DRAMP29182|||SARS-CoV-2-S SVVNIQKEIDRLNEVAKNLNESLIDLQELGK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F = 0.033+-0.013 uM]||SARS-CoV-2 PsV[IC50 I = 0.218+-0.063 uM]||SARS-CoV PsV[IC50 I = 1.053+-0.444 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct Alpha helix No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||https://pubmed.ncbi.nlm.nih.gov/32376627 31 FPDB21080 DRAMP29183|||SARS-CoV-2-S IQKEIDRLNEVAKNLNESLIDLQELGK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV[IC50 I = 5.22 uM]||SARS-CoV PsV[IC50 E = 1.19 uM]||SARS-CoV-2[IC50 F >5 uM]||SARS-CoV-2 PsV[IC50 I >25 uM]||SARS-CoV PsV[IC50 I >25 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >25 uM] Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||https://pubmed.ncbi.nlm.nih.gov/32376627, 27 FPDB21081 DRAMP29184|||SARS-CoV-2-S IDRLNEVAKNLNESLIDLQELGK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F >5 uM]||SARS-CoV-2 PsV[IC50 I >25 uM]||SARS-CoV PsV[IC50 I >25 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||32376627 23 FPDB21082 DRAMP29185|||SARS-CoV-2-S IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F = 0.017+-0.001 uM]||SARS-CoV-2 PsV[IC50 I = 0.993+-0.08 uM]||SARS-CoV PsV[IC50 I = 1.037+-0.836 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct Alpha helix No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||https://pubmed.ncbi.nlm.nih.gov/32376627 33 FPDB21083 DRAMP29186|||SARS-CoV-2-S ISGINASVVNIQKEIDRLNEVAKNLNESLIK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F = 4.66+-1.565 uM]||SARS-CoV-2 PsV[IC50 I = 1.738+-0.898 uM]||SARS-CoV PsV[IC50 I = 1.13+-0.472 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||https://pubmed.ncbi.nlm.nih.gov/32376627 31 FPDB21084 DRAMP29187|||SARS-CoV-2-S SVVNIQKEIDRLNEVAKNLNESLIK Antimicrobial||Antiviral(SARS-CoV-2)||Antiviral ; SARS-CoV-2[IC50 F >5 uM]||SARS-CoV-2 PsV[IC50 I >25 uM]||SARS-CoV PsV[IC50 I >25 uM]||Vesicular Stomatitis Virus (VSV) PsV[IC50 I >50 uM] Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Virol. 2020 Jul 1;94(14):e00635-20.|||32376627 25 FPDB21085 DRAMP29188 DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Science. 2020 Oct 23;370(6515):426-431. 85 FPDB21086 DRAMP29189 ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Science. 2020 Oct 23;370(6515):426-431. 75 FPDB21087 DRAMP29190 DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Science. 2020 Oct 23;370(6515):426-431. 56 FPDB21088 DRAMP29191 NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Science. 2020 Oct 23;370(6515):426-431. 64 FPDB21089 DRAMP29194 LAQMYPL Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Bioconjug Chem. 2021 Jan 20;32(1):215-223. 7 FPDB21090 DRAMP29195 GKGDFRIL Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Bioconjug Chem. 2021 Jan 20;32(1):215-223. 8 FPDB21091 DRAMP29198 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry mBio. 2020 Oct 20;11(5):e01935-20.##Science. 2021 Mar 26;371(6536):1379-1382. 42 FPDB21092 DRAMP29199 SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry mBio. 2020 Oct 20;11(5):e01935-20. 42 FPDB21093 DRAMP29200 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry mBio. 2020 Oct 20;11(5):e01935-20. 42 FPDB21094 DRAMP29201 ANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Cell Mol Immunol. 2020 Jul;17(7):765-767. 42 FPDB21095 DRAMP29204 LQTALYALMEEIHIAALEKTWTALRHQYT Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Med Chem. 2021 Oct 28;64(20):14955-14967. 29 FPDB21096 DRAMP29205 RFDGKGLGIYQYMEEIEHAASRFAYFFYQHLA Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry J Med Chem. 2021 Oct 28;64(20):14955-14967. 32 FPDB21097 DRAMP29206 SALEEQYKTFLDKFLHELEDLLYQLALAL Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Commun Biol. 2021 Feb 12;4(1):197. 29 FPDB21098 DRAMP29207 SALEEQLKTFLDKFMHELEDLLYQLAL Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct Alpha helix No hemolysis information or data found in the reference(s) presented in this entry Commun Biol. 2021 Feb 12;4(1):197. 27 FPDB21099 DRAMP29208 SALEEQYKTFLDKFMHELEDLLYQLSL Antimicrobial||Antiviral(SARS-CoV-2) Synthetic construct N/A No hemolysis information or data found in the reference(s) presented in this entry Commun Biol. 2021 Feb 12;4(1):197. 27 FPDB21100 WNV-GP1 AKGSRAIWFMWLGARFLE Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21101 DENV-1 gp KREKKLGEFGKAKGSRAI Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21102 YFV gp WVLNNPHMKDKTTVKEWR Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21103 HPgV gp LLDWCVRLGRYLLRRLKT Antiviral ; Hepatitis C virus (HCV)[IC50 I = 10 uM]||Hepatitis C virus (HCV)[80-90% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21104 GBV-B gp IWQYVCNFFVICFNVLKA Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21105 GBV-C gp LWEWIMRQVRMVMSRLRA Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[10-20% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21106 BVDV gp VLDLIYSLHKQINRGLKK Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21107 CSFV gp ILELLYKFRDNIKSSVRE Antiviral ; Hepatitis C virus (HCV)[IC50 I >20 uM]||Hepatitis C virus (HCV)[0-10% Inhibition = 20 uM] Synthetic construct N/A N/A 23175359 18 FPDB21108 Peptide 6 CATCEQIADSQHRSHRQMV Antiviral ; Influenza A/PR/8/34 and A/Victoria/3/75 (H3N2)||H1N1 Synthetic construct N/A N/A 26492266, 9056014 19 FPDB21109 Defensin MGD1 CGGYCGGWKRKRCTSYRCG Anti-Micrococcus luteus ATCC 4698, activity value is MIC = 8 uM||Anti-Leishmania major, activity value is LD50 = 45 uM Synthetic construct N/A N/A 12823551, 15480442 19 FPDB21110 RhoA scrmbl DDMSVISELICTSPLDFIN Antiviral ; HIV-1[IC50 E = 27 uM] Synthetic construct N/A N/A 21198428 19 FPDB21111 DN80wt MVDRGWGNHAGLFGKGSIV Antiviral ; DENV-2 Synthetic construct N/A N/A 20582308 19 FPDB21112 Chain C, D, Co-Complex Structure Of Ns3-4a Protease With The Optimized Inhibitory Peptide Cp5-46a-4d5e. GELDELVYLLDGPGYDPIHS Antiviral ; HCV Synthetic construct N/A N/A 22965230 20 FPDB21113 CXCL9 KKKQKNGKKHQKKKVLKVRK Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 = 43||Anti-Herpes simplex virus type 1, activity value is EC50 = 14||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 = 50||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A 26551597 20 FPDB21114 SARS-CoV Sgp FKLPLGIKITNFRAILTAFL Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21115 SARS-CoV Sgp PTKFMLKYDENGTITDAVDC Antiviral ; SARS-CoV[IC90 = 112.5 +-26.3 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21116 SARS-CoV Sgp VLYNSTSFSTFKCYGVSATK Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21117 SARS-CoV Sgp PALNCYWPLKDYGFYTTSGI Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21118 SARS-CoV Sgp RDVSDITDSVRDPKTSEILD Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21119 SARS-CoV Sgp YQDVNCTDVPTAIHADQLTP Antiviral ; SARS-CoV[IC90 = 113.0 +-27.6 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 (- at NA 15918330 20 FPDB21120 SARS-CoV Sgp SNNTIAIPTNFLISITTEVM Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21121 SARS-CoV Sgp QYGSFCAQLNRALSGIAVEQ Antiviral ; SARS-CoV[IC90 = 24.9+-6.2 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21122 SARS-CoV Sgp GIGVAQNVLYENQKQIANQF Antiviral ; SARS-CoV[IC90 >500 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21123 SARS-CoV Sgp IQEEIDRLNEVAKNLNESLI Antiviral ; SARS-CoV[IC90 = 73.5+-15.7 ug/ml] Synthetic construct N/A Monkey kidney cells FRhK-4 ( at NA 15918330 20 FPDB21124 Chain C, D, Co-Complex Of The Of Ns3-4a Protease With The Inhibitory Peptide Cp5-46-A GELGRLVYLLDGPGYDPIHCD Antiviral ; HCV Synthetic construct N/A N/A 22965230 21 FPDB21125 MERS-S LDLTYEXLSLQXVVKXLNESY Antiviral ; MERS-CoV[IC50 F = 0.63+-0.05 uM]||MERS-CoV PsV[IC50 I = 2.8+-0.74 uM]||Cov-Q1020H PsV[IC50 I = 4.15+-0.25 uM]||Cov-Q1020R PsV[IC50 I = 2.49+-0.18 uM]||MERS-CoV PsV[IC50 I = 2.57+-0.24 uM]||Human hepatocellular carcinoma Huh7[50-60% Cytotoxicity >100 uM]||Human lung carcinoma Calu-3[50-60% Cytotoxicity >100 uM] Synthetic construct N/A N/A 29442512 21 FPDB21126 MERS-S LDLTYEXLSLQXVVKXLNESF Antiviral ; MERS-CoV[IC50 F = 3.89+-0.8 uM] Synthetic construct N/A N/A 29442512 21 FPDB21127 CXCL12y KKEKIGKKKRQKKRKAAQKRKN Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 = 48||Anti-Herpes simplex virus type 1, activity value is EC50 = 59||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 = 109||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A 26551597 22 FPDB21128 Envelope glycoprotein gp160 SGIVQQQNNLLRAIEAQQHLLQ Antiviral ; HIV-1 Synthetic construct N/A N/A 20605950 22 FPDB21129 FCoV Sgp FNATYLNLTGEIDDLEFRSEKL Antiviral ; Feline Coronavirus (FCoV)[20-30% REP = 20 uM] Synthetic construct N/A Fcwf-4 cells (50% Cell death at >=200 uM 24312629 22 FPDB21130 SARS-CoV Sgp TDVSTAIHADQLTPAWRIYSTG Antiviral ; SARS-CoV Synthetic construct N/A N/A 16153058 22 FPDB21131 Chain A, E6-Bind Trp-Cage XLQELLGQWLKDGGPSSGRPPPS Antiviral ; Human Papillomavirus Synthetic construct N/A N/A 15182185 23 FPDB21132 Dermaseptin S4 LLKKVLKAAAKAALNAVLVGANA Antiviral ; Rabies virus (RABV)[IC50 I >>10 uM] Synthetic construct N/A Baby Hamster Kidney cells BHK-21 BSR (0% Cytotoxicity at 10 uM 29439871 23 FPDB21133 Ncap-MT APKEWMAWAREIAAYAKLIAALI Antiviral ; HIV-1[IC50 F = 1.7 uM] Synthetic construct N/A N/A 11118065 23 FPDB21134 Undefined IEAQQHLLQLTVWGIKQLQARIL Antiviral ; HIV-1[IC50 E = 29+-10 uM] Synthetic construct N/A N/A 11572974 23 FPDB21135 2P23 EMTWEEWEKKVEELEKKIEELLK Antiviral ; HIV-1 NL4-3[IC50 I = 0.00059 uM]||HIV-1 NL4-3 PsV[IC50 I = 0.00071-0.00278 uM] Synthetic construct N/A N/A 29929981 23 FPDB21136 LP-19 EMTWEEWEKKVEELEKKIEELLX Antiviral ; HIV-1 NL4-3[IC50 I = 0.00009 uM]||HIV-1 NL4-3 PsV[IC50 I = 0.00007-0.00034 uM] Synthetic construct N/A N/A 29929981 23 FPDB21137 Pa-MAP 1.6, Antifreeze peptide analogue KTAATLADTLADTAATLAKAAAA Antiviral ; HSV-1||Aichi virus Synthetic construct N/A Vero cells (50% Cell death at 256 ug/ml 27161201 23 FPDB21138 CXCL9 NGKKHQKKKVLKVRKSQRSRQKKTT Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 > 100 uM||Anti-Herpes simplex virus type 1, activity value is EC50 = 33.5||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 = 100 uM||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A 26551597 25 FPDB21139 P1 CWGPCPTAFRQIGNCGRFRVRCCRIR Anti-A/Hong Kong/415742Md/2009 H1N1, activity value is IC50 = 1.6 ug/ml||Anti-A/Netherlands/219/2003 H7N7, activity value is IC50 = 1.56 ug/ml Synthetic construct N/A N/A 29907765 26 FPDB21140 Undefined RGGLSGIVQQQNNLLRAIEAQQHLLQ Antiviral ; HIV-1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20605950 26 FPDB21141 Pa-MAP3, Antifreeze peptide analogue LAAKLTKAAKLTAALTKLAAALTAAAT Antiviral ; HSV-1||Aichi virus[30-40% Inhibition = 250 ug/ml] Synthetic construct N/A Vero cells (50% Cell death at >250 ug/ml https://pubmed.ncbi.nlm.nih.gov/27161201 27 FPDB21142 Caps-WT APKEWMEWDREINNYTSLIHSLIKQGI Antiviral ; HIV-1[IC50 F = 5.8 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/11118065 27 FPDB21143 Caps-MT APKEWMAWAREIAAYAKLIAALIKQGI Antiviral ; HIV-1[IC50 F = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/11118065 27 FPDB21144 Undefined HQTLSGIDQEQNNLTRLIEAQIHELQK Antiviral ; HIV-1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20605950 27 FPDB21145 Undefined RQLLSGIDQEQNNLTRLIEAQIHELQK Antiviral ; HIV-1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20605950 27 FPDB21146 Pa-MAP 1.7, Antifreeze peptide analogue LKAALTAAKTALTAALTALKAALTAAKT Antiviral ; HSV-1||Aichi virus Synthetic construct N/A Vero cells (50% Cell death at 256 ug/ml https://pubmed.ncbi.nlm.nih.gov/27161201 28 FPDB21147 Pa-MAP 1.8, Antifreeze peptide analogue LAAALTAKATALTAKLTALAAALTAKAT Antiviral ; HSV-1||Aichi virus Synthetic construct N/A Vero cells (50% Cell death at 64 ug/ml https://pubmed.ncbi.nlm.nih.gov/27161201 28 FPDB21148 Claudin-1 SCVSQSTGQIQCKVFDSLLNLSSTLQAT Antiviral ; Hepatitis C virus (HCV) PsV[IC50 I >25 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/22378192 28 FPDB21149 Chain A, E6-Binding Zinc Finger XKFACPECPKRFMRSDHLTLHILLHENKK Antiviral ; Human Papillomavirus Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/15182185 29 FPDB21150 T-20-based lipopeptide fusion inhibitor YTSLIHSLIEESQNQQEKNDQELLELDKX Anti-HIV-1 NL4-3 subtype B, activity value is IC50 = 26054||Anti-HIV-1 LAI subtype B, activity value is IC50 = 286||Anti-Hiv-1 SG3 subtype B, activity value is IC50 = 425||Anti-HIV-1 JR-CSF subtype B, activity value is IC50 = 1304||Anti-HIV-1 89.6 subtype B, activity value is IC50 = 11986||Anti-HIV-1 R3A subtye B, activity value is IC50 = 499||Anti-HIV-2 ROD, activity value is IC50 = 1.58233 uM||Anti-SIV 239, activity value is IC50 = 0.43533 uM||Anti-SIV PBJ, activity value is IC50 = 1.69533 uM||Anti-SHIV SF162P3, activity value is IC50 = 0.00123 uM||Anti-SHIV 1157, activity value is IC50 = 0.02368 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29899103 29 FPDB21151 T-20-based lipopeptide fusion inhibitor YTSLIEELIKKSEEQQKKNEEELKKLEKX Anti-HIV-1 NL4-3 subtype B, activity value is IC50 = 71||Anti-HIV-1 LAI subtype B, activity value is IC50 = 25||Anti-Hiv-1 SG3 subtype B, activity value is IC50 = 9||Anti-HIV-1 JR-CSF subtype B, activity value is IC50 = 19||Anti-HIV-1 89.6 subtype B, activity value is IC50 = 57||Anti-HIV-1 R3A subtye B, activity value is IC50 = 26||Anti-HIV-2 ROD, activity value is IC50 = 0.00009 uM||Anti-HIV-2 ST, activity value is IC50 = 0.00701 uM||Anti-SIV 239, activity value is IC50 = 0.00005 uM||Anti-SIV PBJ, activity value is IC50 = 0.00006 uM||Anti-SHIV SF162P3, activity value is IC50 = 0.00007 uM||Anti-SHIV 1157, activity value is IC50 = 0.00004 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29899103 29 FPDB21152 C29 WMEWDREINNYTSLIHSLIEESQNQQEKN Antiviral ; HIV-1 NL4-3[IC50 REP = 0.245+-0.042 uM]||HIV-1 NL4-3 D36G[IC50 REP = 0.052+-0.018 uM]||HIV-1 NL4-3 D36G/V38A[IC50 REP = 0.504+-0.193 uM]||HIV-1 NL4-3 D36G/N43D[IC50 REP >1 uM]||HIV-1 NL4-3 D36G/N43D/S138A[IC50 REP >1 uM]||HIV-1 NL4-3 D36G/N126K[IC50 REP = 0.192+-0.022 uM]||HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I[IC50 REP >1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/19114674 29 FPDB21153 LP-86 LEANIEELLKKAEEQQKKNEEELKKLEKC Antiviral ; HIV-1 NL4-3[IC50 I = 0 uM]||HIV-1 JRCSF[IC50 I = 0.000005 uM]||HIV-1 PsV[IC50 I = 0.000005 uM]||HIV-1 NL4-3 D36G[IC50 I = 0.000003 uM]||HIV-1 NL4-3[IC50 I = 0.000003 uM]||HIV-1 NL4-3[IC50 I = 0.000004-0.00017 uM]||HIV-2 ROD[IC50 I = 0.000026 uM]||HIV-2[IC50 I = 0.000014 uM]||HIV-1[IC50 F = 0.000012 uM]||Simian immunodeficiency virus (SIV)[IC50 I = 0.000005-0.000006 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/30867304 29 FPDB21154 FCoV Sgp FNATYLNLTGEIDDLEFRSEKLHNTTVEL Antiviral ; Feline Coronavirus (FCoV)[20-30% REP = 20 uM] Synthetic construct N/A Fcwf-4 cells (50% Cell death at >=200 uM https://pubmed.ncbi.nlm.nih.gov/24312629 29 FPDB21155 BLV gp CCFLRIQNDSIIRLGDLQPLSQRVSTDWQ Antiviral ; Bovine leukaemia virus (BLV)[IC50 F = 3.49+-0.03 uM]||Human T-cell leukaemia virus 1 (HTLV-1) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18680566 29 FPDB21156 BLV gp CCFLRIQNDSIIALGDLQPLSQRVSTDWQ Antiviral ; Bovine leukaemia virus (BLV)[IC50 F = 1.56+-0.05 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18680566 29 FPDB21157 WNV gp AWDFGSVGGVFTSVGKAVHQVFGGAFRSL Antiviral ; DENV-2[IC90 I = 0.25 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20881042 29 FPDB21158 WNV gp AWDFGSVGGVFTSVGKAVHQVFGWWWRSL Antiviral ; DENV-2[IC90 I = 0.025 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/20881042 29 FPDB21159 Circulin-C CGESCVFIPCITSVAGCSCKSKVCYRNGIP Anti-HIV-1, activity value is EC50 = 0.05 Chassalia parviflora N/A N/A https://pubmed.ncbi.nlm.nih.gov/10691702 30 FPDB21160 Cycloviolacin Y5 GIPCAESCVWIPCTVTAIVGCSCSDKVCYN Anti-HIV ( MIC =, activity value is EC50 = 0.04 uM Viola philippica N/A N/A https://pubmed.ncbi.nlm.nih.gov/18081258 30 FPDB21161 CXCL9|||Acetyl-CXCL9 KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 = 11||Anti-Herpes simplex virus type 1, activity value is EC50 = 15||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 = 23||Anti-Vaccinia virus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 = 21||Anti-Herpes simplex virus type 1, activity value is EC50 = 9||Anti-Respiratory syncytial virus, activity value is EC50 = 31 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26551597 30 FPDB21162 LP-56 WEQKIEELLKKAEEQQKKNEEELKKAEEAX Antiviral ; HIV-1 HxB2[IC50 F = 0.000012 uM]||HIV-1 NL4-3 PsV[IC50 E = 0.000009 uM]||HIV-1 JRCSF[IC50 I = 0.000011 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/30089693 30 FPDB21163 Alstotide S1 CRPYGYRCDGVINQCCDPYHCTPPLIGICL Antiviral ; DENV-2[IC50 REP = 90 uM]||Respiratory syncytial virus (RSV)||Infectious bronchitis virus (IBV/ACoV)[IC50 REP = 35 uM] Alstonia scholaris N/A N/A https://pubmed.ncbi.nlm.nih.gov/26546678 30 FPDB21164 Vhl-1 CGESCAMISFCFTEVIGCSCKNKVCYLNSIS Antiviral Viola hederacea N/A N/A https://pubmed.ncbi.nlm.nih.gov/15824119 31 FPDB21165 CXCL12y KGRREEKVGKKEKIGKKKRQKKRKAAQKRKN Anti-Adenovirus, activity value is EC50 > 100 uM||Anti-Dengue virus, activity value is EC50 = 22||Anti-Herpes simplex virus type 1, activity value is EC50 = 39||Anti-Herpes simplex virus type 2, activity value is EC50 > 100 uM||Anti-Respiratory syncytial virus, activity value is EC50 = 115||Anti-Vaccinia virus, activity value is EC50 > 100 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26551597 31 FPDB21166 P5 gggyskggkgggkggkgggkggkgggkggkg Anti-Human cytomegalovirus TB40/E, activity value is IC50 = 9.98 uM||Anti-murine cytomegalovirus K181, activity value is IC50 = 22.6 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/30760613 31 FPDB21167 Fp5 NEVAKNLNESLIDLQELGKYEQYIKWPWYVW Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34591335 31 FPDB21168 Undefined YGGIKKEIEAIKKEQEAIKKKIEAIEKEIEA Antiviral ; HIV-1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/11572974 31 FPDB21169 T-32 SGEWVMKDYRGWKHWVYYTCCPDTPYLDITYH Antiviral ; Rabies virus (RABV) Torpedo N/A N/A https://pubmed.ncbi.nlm.nih.gov/28587964 32 FPDB21170 H-32 SGEWVIKESRGWKHWVFYACCPSTPYLDITYH Antiviral ; Rabies virus (RABV) Homo sapiens N/A N/A https://pubmed.ncbi.nlm.nih.gov/28587964 32 FPDB21171 C-32 SGEWVIKESRGWKHSVTYSCCPDTPYLDITYH Antiviral ; Rabies virus (RABV) Bos taurus N/A N/A https://pubmed.ncbi.nlm.nih.gov/28587964 32 FPDB21172 Undefined VNKKIEEIDKKIEELNKKLEELEKKLEEVNKK Antiviral ; Newcastle Disease Virus (NDV)[IC90 I = 5 uM]||Infectious bronchitis virus (IBV/ACoV)[IC90 I = 5 uM]||Newcastle Disease Virus (NDV)[IC50 F = 0.0102 uM]||Newcastle Disease Virus (NDV)[IC50 F = 0.0081 uM] Synthetic construct N/A Chicken Embryonic Fibroblasts (CEF) ( at NA , Chicken Embryonic Fibroblasts (CEF) (- at NA https://pubmed.ncbi.nlm.nih.gov/21601229, 32 FPDB21173 Chain A, E6-Binding Zinc Finger XKFACPECPKRFMRSDHLSKHITLHELLGEERR Antiviral ; Human Papillomavirus Homo sapiens N/A N/A https://pubmed.ncbi.nlm.nih.gov/15182185 33 FPDB21174 GA763 CGETCVGGTCNTPGCTCWPVCGSFLRFLTKGPV Antiviral ; HIV Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26517259 33 FPDB21175 GA190 CGETCVGGTCNTPGCTCWPVCGSFLTGQGSFPV Antiviral ; HIV Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/26517259 33 FPDB21176 Peptides Z2 MAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAF Antiviral ; Zika virus (ZIKV) SZ01/2016||ZIKV MR766 (#VR1838)||ZIKV FLR (#VR1844) Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/31611865 33 FPDB21177 TAT-P3 YGRKKRRQRRRCWRPCPSFRQLCGRFRIRCRIR Anti-A/Hong Kong/415742Md/2009 H1N1, activity value is IC50 = 0.68 ug/ml||Anti-A/Netherlands/219/2003 H7N7, activity value is IC50 = 0.78 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29907765 33 FPDB21178 Fp13 LTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFG Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34591335 34 FPDB21179 Fp15 GRLQSLQTYVTQQLIRAAEIRASANLAATKMSEC Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34591335 34 FPDB21180 C34 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL Antiviral ; HIV-1[IC50 REP = 0.00068+-0.00012 uM]||HIV-1 NL4-3[IC50 REP = 0.0023+-0.0001 uM]||HIV-1 NL4-3 D36G[IC50 REP = 0.0023+-0.0006 uM]||HIV-1 NL4-3 D36G/V38A[IC50 REP = 0.0044+-0.0014 uM]||HIV-1 NL4-3 D36G/N43D[IC50 REP = 0.0079+-0.0009 uM]||HIV-1 NL4-3 D36G/N43D/S138A[IC50 REP = 0.015+-0.002 uM]||HIV-1 NL4-3 D36G/N126K[IC50 REP = 0.007+-0.002 uM]||HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I[IC50 REP = 0.171+-0.015 uM]||HIV-1 IIIB[IC50 I = 0.0072 uM]||HIV-1 IIIB[IC50 F = 0.0188 uM]||HIV-1 BaL[IC50 I = 0.0076 uM]||HIV-1 JRCSF[IC50 I = 0.03094 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/19114674, 34 FPDB21181 SC34EK WXEWDRKIEEYTKKIEELIKKSQEQQEKNEKELK Antiviral ; HIV-1[IC50 REP = 0.00023+-0.00011 uM]||HIV-1 NL4-3[IC50 REP = 0.0016+-0.0002 uM]||HIV-1 NL4-3 D36G[IC50 REP = 0.0024+-0.001 uM]||HIV-1 NL4-3 D36G/V38A[IC50 REP = 0.0022+-0.0004 uM]||HIV-1 NL4-3 D36G/N43D[IC50 REP = 0.0016+-0.0004 uM]||HIV-1 NL4-3 D36G/N43D/S138A[IC50 REP = 0.0015+-0.0003 uM]||HIV-1 NL4-3 D36G/N126K[IC50 REP = 0.012+-0.001 uM]||HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I[IC50 REP = 0.003+-0.002 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/19114674, 34 FPDB21182 Undefined RMKQIEDKIEEIESKQKKIENEIARIKKLIGERY Antiviral ; HIV-1 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/11572974 34 FPDB21183 Undefined WXEWDRKIEEYTKKIKKLIEESQEQQEKNEKELK Antiviral ; HIV-1[IC50 REP = 0.00064+-0.0002 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/12203417 34 FPDB21184 Undefined WMEWDRKIEEYTKKIKKLIEESQEQQEKNEKELK Antiviral ; HIV-1[IC50 REP = 0.00073+-0.00012 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/12203417 34 FPDB21185 Undefined WMEWDRKIEEYTKKIEELIKKSQEQQEKNEKELK Antiviral ; HIV-1[IC50 REP = 0.00042+-0.00006 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/12203417 34 FPDB21186 TEWP KKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK Anti-Escherichia coli, activity value is IC50 = 3.3 uM||Anti-Salmonella typhimurium, activity value is IC50 = 2.8 uM||Anti-Staphylococcus aureus, activity value is IC50 = 5 Caretta caretta N/A N/A https://pubmed.ncbi.nlm.nih.gov/16700051 35 FPDB21187 Undefined WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK Antiviral ; HIV-1[IC50 REP = 0.00039+-0.00011 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/12203417 35 FPDB21188 Undefined EEYTKKIEEYTKKIEEYTKKIEEYTKKIEEYTKKI Antiviral ; HIV-1[IC50 F = 156.27+-8.33 ug/ml] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18662985 35 FPDB21189 SR9EK13 ISGINASVVNIQEEIKKLNEEAKKLNESLIDLQEL Antiviral ; SARS-CoV[IC50 E = 0.004 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/17942557 35 FPDB21190 SR9EK1 IEEINKKVEEIQKKIEELNKKAEELNKKLEELQKK Antiviral ; SARS-CoV[IC50 E >100 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/17942557 35 FPDB21191 SARS-Cov-S IQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSS Antiviral ; SARS-CoV PsV Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/18442051 35 FPDB21192 RSV Fgp FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 6.33 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/28137809 35 FPDB21193 RSV Fgp FDXSISQVNXKINQSLAFIXKSDELLXNVNAGKST Antiviral ; Respiratory syncytial virus (RSV)[IC50 I = 3.5 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/28137809 35 FPDB21194 CT105 MTWCDWRDEIERYTKKIEELIRAAQEKNEAALKEL Antiviral ; HIV-1 PsV[IC50 I = 0.00101_x0013_0.02604 uM]||HIV-1 R3A[IC50 REP = 0.00026 uM]||HIV-1 JRCSF[IC50 REP = 0.00217 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29433929 35 FPDB21195 T-20 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF Anti-NL4-3, activity value is IC50 = 47386.67||Anti-LAI, activity value is IC50 = 1163.33||Anti-SG3, activity value is IC50 = 2851.32||Anti-JR-CSF, activity value is IC50 = 2968.33||Anti-WITO.c/2474, activity value is IC50 = 7810.56||Anti-RHPA.c/2635, activity value is IC50 = 6517.44||Anti-THRO.c/2626, activity value is IC50 = 31310||Anti-CH040.c/2625, activity value is IC50 = 30883.33||Anti-89.6, activity value is IC50 = 15431.01||Anti-R3A, activity value is IC50 = 6731.67 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/30716118 36 FPDB21196 T-20 peptide YTSLIHSLIEESQNQQEKNDQELLELDKWASLWNWF Anti-HIV-1 NL4-3 subtype B, activity value is IC50 = 53097||Anti-HIV-1 LAI subtype B, activity value is IC50 = 2437||Anti-Hiv-1 SG3 subtype B, activity value is IC50 = 1919||Anti-HIV-1 JR-CSF subtype B, activity value is IC50 = 6601||Anti-HIV-1 89.6 subtype B, activity value is IC50 = 11549||Anti-HIV-1 R3A subtye B, activity value is IC50 = 7605||Anti-HIV-2 ROD, activity value is IC50 = 0.49673 uM||Anti-HIV-2 ST, activity value is IC50 = 1.39544 uM||Anti-SIV 239, activity value is IC50 = 0.35313 uM||Anti-SIV PBJ, activity value is IC50 = 0.93983 uM||Anti-SHIV SF162P3, activity value is IC50 = 0.00494 uM||Anti-SHIV 1157, activity value is IC50 = 0.01148 uM Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29899103 36 FPDB21197 TAT-P2 YGRKKRRQRRRCWRPCPRAFRKRNCGRFRIRCCRIR Anti-A/Hong Kong/415742Md/2009 H1N1, activity value is IC50 = 0.76 ug/ml||Anti-A/Netherlands/219/2003 H7N7, activity value is IC50 = 0.97 ug/ml Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/29907765 36 FPDB21198 Fp14 KQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITG Antiviral ; SARS-CoV-2 Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/34591335 36 FPDB21199 Vif YVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLV Antiviral ; HIV-1[20-30% PR activity = 1 uM]||Rous sarcoma virus[80-90% PR activity = 1 uM] Synthetic construct N/A N/A https://pubmed.ncbi.nlm.nih.gov/10074409 36 FPDB21200 DRAMP31238 Synthetic construct(derived from RSV attachment glycoprotein) Antimicrobial||Antiviral Synthetic construct(derived from RSV attachment glycoprotein) N/A N/A J Biol Chem. 2001 Oct 19;276(42):38988-94. 54